https://evidence-hub.com/study/10001-suzetrigine-for-the-treatment-of-acute-pain-reply2026-10-01 https://evidence-hub.com/study/10003-suzetrigine-a-novel-non-opioid-for-acute-postoperative-pasin-relief2026-10-06 https://evidence-hub.com/study/10006-suzetrigine-in-moderate-to-severe-acute-pain-a-profile-of-its-use2026-10-01 https://evidence-hub.com/study/10007-prevalence-of-halogens-in-2025-fda-approved-drugs-highlight-on2026-10-01 https://evidence-hub.com/study/10008-suzetrigine-a-first-in-class-na-v-1-8-inhibitor-for-opioid-free-pain2026-10-01 https://evidence-hub.com/study/10009-does-preoperative-suzetrigine-impact-asc-opioid-consumption-for-total2026-10-01 https://evidence-hub.com/study/10010-087-use-of-suzetrigine-for-post-operative-pain-management-protocol2026-09-27 https://evidence-hub.com/study/10011-a-phase-2-randomized-double-blind-placebo-controlled-dose-ranging2026-09-27 https://evidence-hub.com/study/10012-a-phase-1-open-label-study-to-evaluate-the-pharmacokinetics-and2026-09-27 https://evidence-hub.com/study/10013-a-phase-2-randomized-double-blind-placebo-controlled-parallel-design2026-09-27 https://evidence-hub.com/study/10014-a-phase-2-randomized-double-blind-active-controlled-dose-ranging2026-09-27 https://evidence-hub.com/study/10015-a-phase-3-randomized-double-blind-placebo-controlled-study-evaluating2026-09-27 https://evidence-hub.com/study/10016-a-phase-1-open-label-study-to-evaluate-the-pharmacokinetics-and2026-09-27 https://evidence-hub.com/study/10017-a-phase-1-open-label-randomized-crossover-study-to-evaluate-the2026-09-27 https://evidence-hub.com/study/10018-a-phase-4-open-label-single-arm-study-evaluating-the-effectiveness2026-09-27 https://evidence-hub.com/study/10019-a-phase-1-randomized-open-label-crossover-study-evaluating-the2026-09-27 https://evidence-hub.com/study/10020-a-phase-1-open-label-single-dose-study-evaluating-the-excretion-of2026-09-27 https://evidence-hub.com/study/10021-a-phase-1-open-label-study-to-evaluate-the-effect-of-suzetrigine-on2026-09-27 https://evidence-hub.com/study/10022-a-phase-4-open-label-single-arm-study-evaluating-the-effectiveness2026-09-27 https://evidence-hub.com/study/10023-a-phase-3-single-arm-study-evaluating-the-safety-and-effectiveness-of2026-09-27 https://evidence-hub.com/study/10024-the-role-of-nav1-8-in-human-pain-models-a-randomized-placebo2026-09-27 https://evidence-hub.com/study/10025-a-phase-1-open-label-taste-assessment-study-of-suzetrigine-spray2026-09-27 https://evidence-hub.com/study/10026-a-randomized-double-blind-placebo-controlled-crossover-study-to2026-09-27 https://evidence-hub.com/study/10027-a-phase-1-open-label-drug-drug-interaction-study-to-evaluate-the2026-09-27 https://evidence-hub.com/study/10028-a-phase-1-open-label-drug-drug-interaction-study-to-evaluate-the2026-09-27 https://evidence-hub.com/study/10029-a-phase-1-open-label-randomized-crossover-study-to-evaluate-the2026-09-27 https://evidence-hub.com/study/10030-a-phase-2-randomized-double-blind-placebo-controlled-multi-dose-study2026-09-27 https://evidence-hub.com/study/10031-a-phase-1-randomized-double-blind-placebo-and-active-controlled2026-09-27 https://evidence-hub.com/study/10032-a-phase-3-randomized-double-blind-placebo-controlled-study-evaluating2026-09-27 https://evidence-hub.com/study/10033-opioid-avoidance-in-surgery-through-integrating-suzetrigine-post2026-09-27 https://evidence-hub.com/study/10034-a-phase-1-open-label-study-to-evaluate-pharmacokinetic-drug-drug2026-09-27 https://evidence-hub.com/study/10035-a-phase-2-randomized-double-blind-placebo-controlled-dose-ranging2026-09-27 https://evidence-hub.com/study/10046-a-review-article-on-suzetrigine2026-09-27 https://evidence-hub.com/study/10047-interpreting-heterogeneity-and-effect-size-in-meta-analysis-of2026-10-01 https://evidence-hub.com/study/10049-non-opioid-analgesics-in-adults-after-major-surgery-a-comprehensive2026-10-01 https://evidence-hub.com/study/10050-suzetrigine-in-the-management-of-pain-review-of-the-first-in-class-na2026-10-01 https://evidence-hub.com/study/10052-the-global-prevalence-of-antibiotic-self-medication-among-the-adult2026-10-19 https://evidence-hub.com/study/10053-falls-prevention-interventions-for-community-dwelling-older-adults2026-10-19 https://evidence-hub.com/study/10054-the-association-of-social-networks-and-depression-in-community2026-10-19 https://evidence-hub.com/study/10055-the-global-economic-burden-of-covid-19-disease-a-comprehensive2026-10-19 https://evidence-hub.com/study/10056-a-systematic-review-and-meta-analysis-of-balance-training-in-patients2026-10-19 https://evidence-hub.com/study/10057-the-impact-of-sports-participation-on-mental-health-and-social2026-10-19 https://evidence-hub.com/study/10058-physical-exercise-for-people-with-parkinson-s-disease-a-systematic2026-10-19 https://evidence-hub.com/study/10059-how-to-do-a-systematic-review-a-best-practice-guide-for-conducting2026-10-19 https://evidence-hub.com/study/10060-are-chatgpt-and-large-language-models-the-answer-to-bringing-us2026-10-19 https://evidence-hub.com/study/10061-effectiveness-of-training-programs-based-on-mindfulness-in-reducing2026-10-19 https://evidence-hub.com/study/10062-non-adherence-and-non-persistence-to-intravitreal-anti-vascular2026-10-19 https://evidence-hub.com/study/10063-keloid-treatments-an-evidence-based-systematic-review-of-recent2026-10-19 https://evidence-hub.com/study/10064-effectiveness-of-worksite-wellness-programs-based-on-physical2026-10-19 https://evidence-hub.com/study/10065-functional-social-support-and-cognitive-function-in-middle-and-older2026-10-19 https://evidence-hub.com/study/10066-efficacy-of-homoeopathic-treatment-systematic-review-of-meta-analyses2026-10-19 https://evidence-hub.com/study/10067-a-systematic-review-of-risk-factors-for-mortality-among-tuberculosis2026-10-19 https://evidence-hub.com/study/10068-the-effects-of-flipped-classrooms-to-improve-learning-outcomes-in2026-10-19 https://evidence-hub.com/study/10069-global-prevalence-of-rett-syndrome-systematic-review-and-meta-analysis2026-10-19 https://evidence-hub.com/study/10070-a-systematic-review-and-meta-analysis-of-long-covid-symptoms2026-10-19 https://evidence-hub.com/study/10071-the-psychological-subtype-of-intimate-partner-violence-and-its-effect2026-10-19 https://evidence-hub.com/study/10072-where-to-prospectively-register-a-systematic-review2026-10-19 https://evidence-hub.com/study/10073-interventions-for-myopia-control-in-children-a-living-systematic2026-10-19 https://evidence-hub.com/study/10074-barriers-and-facilitators-to-clinical-behaviour-change-by-primary2026-10-19 https://evidence-hub.com/study/10075-policies-and-interventions-to-remove-gender-related-barriers-to-girls2026-10-19 https://evidence-hub.com/study/10076-an-updated-systematic-review-of-interventions-to-increase-awareness2026-10-19 https://evidence-hub.com/study/10077-acceptance-and-use-of-complementary-and-alternative-medicine-among2026-10-19 https://evidence-hub.com/study/10078-reducing-systematic-review-burden-using-deduklick-a-novel-automated2026-10-19 https://evidence-hub.com/study/10079-safety-interventions-for-the-prevention-of-accidents-at-work-a2026-10-19 https://evidence-hub.com/study/10080-effect-of-the-precede-proceed-model-on-health-programs-a-systematic2026-10-19 https://evidence-hub.com/study/10081-systematic-review-of-the-utility-of-the-frailty-index-and-frailty2026-10-19 https://evidence-hub.com/study/10082-barriers-and-facilitators-to-access-mental-health-services-among2026-10-19 https://evidence-hub.com/study/10083-automation-of-literature-screening-using-machine-learning-in-medical2026-10-19 https://evidence-hub.com/study/10084-systematic-review-of-lifestyle-interventions-to-improve-weight2026-10-19 https://evidence-hub.com/study/10085-vitamin-d-supplementation-for-the-treatment-of-covid-19-a-living2026-10-19 https://evidence-hub.com/study/10086-the-impacts-of-agroforestry-interventions-on-agricultural2026-10-19 https://evidence-hub.com/study/10087-prevalence-and-incidence-of-carbapenem-resistant-k-pneumoniae2026-10-19 https://evidence-hub.com/study/10088-health-outcomes-of-sexual-and-gender-minorities-after-cancer-a2026-10-19 https://evidence-hub.com/study/10089-the-score-after-10-years-of-registration-of-systematic-review2026-10-19 https://evidence-hub.com/study/10090-prevalence-of-hypertension-in-ghanaian-society-a-systematic-review2026-10-19 https://evidence-hub.com/study/10091-effectiveness-of-school-based-programs-to-reduce-bullying2026-10-19 https://evidence-hub.com/study/10092-interventions-for-improving-outcomes-in-patients-with-multimorbidity2026-10-19 https://evidence-hub.com/study/10093-strengthening-women-s-empowerment-and-gender-equality-in-fragile2026-10-19 https://evidence-hub.com/study/10094-cognitive-and-behavioral-radicalization-a-systematic-review-of-the2026-10-19 https://evidence-hub.com/study/10095-progress-in-the-treatment-of-knee-osteoarthritis-with-high-tibial2026-10-19 https://evidence-hub.com/study/10096-interleukin-6-blocking-agents-for-treating-covid-19-a-living2026-10-19 https://evidence-hub.com/study/10097-proactive-psychological-programs-designed-to-mitigate-posttraumatic2026-10-19 https://evidence-hub.com/study/10098-court-mandated-interventions-for-individuals-convicted-of-domestic2026-10-19 https://evidence-hub.com/study/10099-toward-systematic-review-automation-a-practical-guide-to-using2026-10-19 https://evidence-hub.com/study/10100-interventions-to-support-the-resilience-and-mental-health-of2026-10-19 https://evidence-hub.com/study/10101-effects-of-walking-speed-on-gait-biomechanics-in-healthy-participants2026-10-19 https://evidence-hub.com/study/10102-psychotropic-medication-non-adherence-and-its-associated-factors2026-10-19 https://evidence-hub.com/study/10103-srbert-automatic-article-classification-model-for-systematic-review2026-10-19 https://evidence-hub.com/study/10104-role-of-preoperative-intravenous-iron-therapy-to-correct-anemia2026-10-19 https://evidence-hub.com/study/10105-understanding-the-mental-health-of-doctoral-researchers-a-mixed2026-10-19 https://evidence-hub.com/study/10106-problem-oriented-policing-for-reducing-crime-and-disorder-an-updated2026-10-19 https://evidence-hub.com/study/10107-effectiveness-of-exergames-for-improving-mobility-and-balance-in2026-10-19 https://evidence-hub.com/study/10108-traditional-chinese-herbal-medicine-for-treating-novel-coronavirus2026-10-19 https://evidence-hub.com/study/10109-e-health-interventions-for-healthy-aging-a-systematic-review2026-10-19 https://evidence-hub.com/study/10110-strategies-to-overcome-vaccine-hesitancy-a-systematic-review2026-10-19 https://evidence-hub.com/study/10111-under-detection-of-depression-in-primary-care-settings-in-low-and2026-10-19 https://evidence-hub.com/study/10112-the-impact-of-social-activities-social-networks-social-support-and2026-10-19 https://evidence-hub.com/study/10113-the-effectiveness-of-peer-and-community-health-worker-led-self2026-10-19 https://evidence-hub.com/study/10114-impact-of-financial-inclusion-in-low-and-middle-income-countries-a2026-10-19 https://evidence-hub.com/study/10115-impacts-of-school-feeding-on-educational-and-health-outcomes-of2026-10-19 https://evidence-hub.com/study/10116-the-experiences-of-family-caregivers-living-with-breast-cancer2026-10-19 https://evidence-hub.com/study/10117-automation-of-systematic-reviews-of-biomedical-literature-a-scoping2026-10-19 https://evidence-hub.com/study/10118-medical-cannabis-for-the-reduction-of-opioid-dosage-in-the-treatment2026-10-19 https://evidence-hub.com/study/10119-under-five-anemia-and-its-associated-factors-with-dietary-diversity2026-10-19 https://evidence-hub.com/study/10120-effects-of-exercise-therapy-in-patients-with-acute-low-back-pain-a2026-10-19 https://evidence-hub.com/study/10121-the-psychological-subtype-of-intimate-partner-violence-and-its-effect2026-10-19 https://evidence-hub.com/study/10122-usability-and-acceptability-of-four-systematic-review-automation2026-10-19 https://evidence-hub.com/study/10123-loneliness-and-social-isolation-causal-association-with-health2026-10-19 https://evidence-hub.com/study/10124-machine-learning-algorithms-for-systematic-review-reducing-workload2026-10-19 https://evidence-hub.com/study/10125-use-of-powered-air-purifying-respirator-papr-by-healthcare-workers2026-10-19 https://evidence-hub.com/study/10126-a-systematic-review-and-taxonomy-of-tools-for-evaluating-evidence2026-10-19 https://evidence-hub.com/study/10127-negative-pressure-wound-therapy-in-patients-with-wounds-healing-by2026-10-19 https://evidence-hub.com/study/10128-open-defecation-free-slippage-and-its-associated-factors-in-ethiopia2026-10-19 https://evidence-hub.com/study/10129-interventions-for-treatment-of-covid-19-a-protocol-for-a-living2026-10-19 https://evidence-hub.com/study/10130-prevalence-of-metabolic-syndrome-among-hiv-positive-and-hiv-negative2026-10-19 https://evidence-hub.com/study/10131-still-moving-toward-automation-of-the-systematic-review-process-a2026-10-19 https://evidence-hub.com/study/10132-population-segmentation-based-on-healthcare-needs-a-systematic-review2026-10-19 https://evidence-hub.com/study/10133-a-question-of-trust-can-we-build-an-evidence-base-to-gain-trust-in2026-10-19 https://evidence-hub.com/study/10134-effectiveness-of-interventions-to-prevent-pre-frailty-and-frailty2026-10-19 https://evidence-hub.com/study/10135-factors-associated-with-antiretroviral-treatment-failure-among-people2026-10-19 https://evidence-hub.com/study/10136-effects-of-bystander-programs-on-the-prevention-of-sexual-assault2026-10-19 https://evidence-hub.com/study/10137-body-worn-cameras-effects-on-police-officers-and-citizen-behavior-a2026-10-19 https://evidence-hub.com/study/10138-the-humanistic-and-economic-burden-of-chronic-wounds-a-protocol-for-a2026-10-19 https://evidence-hub.com/study/10139-effects-of-selective-sphingosine-1-phosphate-receptor-1-agonist2026-10-01 https://evidence-hub.com/study/10140-human-cold-pain-a-randomized-crossover-trial2026-10-06 https://evidence-hub.com/study/10141-risks-and-benefits-of-estrogen-plus-progestin-in-healthy2026-10-19 https://evidence-hub.com/study/10142-effects-of-a-personalized-nutrition-program-on-cardiometabolic-health2026-10-06 https://evidence-hub.com/study/10143-efficacy-and-safety-of-the-oral-pcsk9-inhibitor-mk-0616-a-phase-2b2026-10-06 https://evidence-hub.com/study/10144-evaluation-of-mechanical-thrombectomy-in-acute-ischemic-stroke2026-10-06 https://evidence-hub.com/study/10145-clinical-gut-microbial-and-neural-effects-of-a-probiotic-add-on2026-10-06 https://evidence-hub.com/study/10146-effect-of-helicobacter-pylori-eradication-on-gastric-cancer2026-10-06 https://evidence-hub.com/study/10147-effect-of-therapeutic-drug-monitoring-based-dose-optimization-of2026-10-06 https://evidence-hub.com/study/10148-endovascular-treatment-for-acute-basilar-artery-occlusion-a2026-10-06 https://evidence-hub.com/study/10149-cognitive-effects-of-aerobic-exercise-in-alzheimer-s-disease-a-pilot2026-10-06 https://evidence-hub.com/study/10150-efficacy-and-safety-of-lianhuaqingwen-capsules-a-repurposed-chinese2026-10-08 https://evidence-hub.com/study/10151-total-neoadjuvant-folfirinox-versus-neoadjuvant-gemcitabine-based2026-10-06 https://evidence-hub.com/study/10152-repetitive-transcranial-magnetic-stimulation-for-smoking-cessation-a2026-10-06 https://evidence-hub.com/study/10153-short-term-postpartum-blood-pressure-self-management-and-long-term2026-10-06 https://evidence-hub.com/study/10155-ruxolitinib-in-treatment-of-severe-coronavirus-disease-2019-covid-192026-10-13 https://evidence-hub.com/study/10157-phase-iii-randomized-controlled-trial-of-erapid-ehealth-intervention2026-10-16 https://evidence-hub.com/study/10158-exenatide-adjunct-to-nicotine-patch-facilitates-smoking-cessation-and2026-10-06 https://evidence-hub.com/study/10159-efficacy-and-safety-of-lopinavir-ritonavir-or-arbidol-in-adult2026-10-08 https://evidence-hub.com/study/10160-randomized-controlled-intervention-trial-of-male-circumcision-for2026-10-16 https://evidence-hub.com/study/10161-using-psychological-artificial-intelligence-tess-to-relieve-symptoms2026-10-13 https://evidence-hub.com/study/10162-a-novel-self-assembling-peptide-for-hemostasis-during-endoscopic2026-10-06 https://evidence-hub.com/study/10163-randomized-controlled-trial-of-a-12-week-digital-care-program-in2026-10-13 https://evidence-hub.com/study/10164-rationale-and-protocol-of-the-dapagliflozin-and-prevention-of-adverse2026-10-19 https://evidence-hub.com/study/10165-adipose-derived-mesenchymal-stem-cell-therapy-in-the-treatment-of2026-10-13 https://evidence-hub.com/study/10166-a-randomized-controlled-trial-of-surgical-rib-fixation-in-polytrauma2026-10-06 https://evidence-hub.com/study/10168-cytokine-clearance-with-cytosorb-during-cardiac-surgery-a-pilot2026-10-06 https://evidence-hub.com/study/10169-comparison-of-the-duration-of-hospital-stay-after-laparoscopic-or2026-10-13 https://evidence-hub.com/study/10170-treatment-of-keloid-scars-with-intralesional-triamcinolone-and-52026-10-06 https://evidence-hub.com/study/10171-dexmedetomidine-improved-renal-function-in-patients-with-severe2026-10-08 https://evidence-hub.com/study/10172-a-randomized-controlled-trial-with-everolimus-for-iq-and-autism-in2026-10-06 https://evidence-hub.com/study/10173-ards-subphenotypes-and-differential-response-to-simvastatin-secondary2026-10-19 https://evidence-hub.com/study/10174-intravenous-pegylated-liposomal-prednisolone-outperforms2026-10-19 https://evidence-hub.com/study/10175-liraglutide-3-0-mg-and-intensive-behavioral-therapy-ibt-for-obesity2026-10-06 https://evidence-hub.com/study/10176-effects-of-hydroxychloroquine-on-proteinuria-in-iga-nephropathy-a2026-10-06 https://evidence-hub.com/study/10178-nursing-students-knowledge-attitude-self-efficacy-in-blended-learning2026-10-06 https://evidence-hub.com/study/10179-efficacy-of-platelet-rich-plasma-for-the-treatment-of-interstitial2026-10-06 https://evidence-hub.com/study/10180-fecal-microbiota-transplantation-for-treatment-of-recurrent-c2026-10-06 https://evidence-hub.com/study/10181-treatment-of-middle-east-respiratory-syndrome-with-a-combination-of2026-10-10 https://evidence-hub.com/study/10182-analysis-of-plasma-epstein-barr-virus-dna-in-nasopharyngeal-cancer2026-10-06 https://evidence-hub.com/study/10183-colorectal-liver-metastases-surgery-versus-thermal-ablation-collision2026-10-19 https://evidence-hub.com/study/10184-does-feedback-from-activity-trackers-influence-physical-activity2026-10-19 https://evidence-hub.com/study/10185-minimally-invasive-versus-open-distal-pancreatectomy-leopard-study2026-10-08 https://evidence-hub.com/study/10186-seven-versus-fourteen-days-of-antibiotic-therapy-for-uncomplicated2026-10-08 https://evidence-hub.com/study/10187-a-mediterranean-diet-with-additional-extra-virgin-olive-oil-and2026-10-06 https://evidence-hub.com/study/10191-randomized-controlled-trial-of-a-positive-affect-intervention-for2026-10-06 https://evidence-hub.com/study/10192-semaglutide-added-to-basal-insulin-in-type-2-diabetes-sustain-5-a2026-10-08 https://evidence-hub.com/study/10193-secukinumab-shows-significant-efficacy-in-palmoplantar-psoriasis2026-10-13 https://evidence-hub.com/study/10194-intravenous-tramadol-is-effective-in-the-management-of-postoperative2026-10-06 https://evidence-hub.com/study/10197-safety-of-vaginal-mesh-surgery-versus-laparoscopic-mesh-sacropexy-for2026-10-06 https://evidence-hub.com/study/10200-therapist-guided-internet-delivered-cognitive-behavioral-therapy-for2026-10-06 https://evidence-hub.com/study/10201-walnut-consumption-alters-the-gastrointestinal-microbiota-microbially2026-10-06 https://evidence-hub.com/study/10202-a-randomized-controlled-trial-of-exercise-during-pregnancy-on2026-10-06 https://evidence-hub.com/study/10203-a-walnut-enriched-diet-affects-gut-microbiome-in-healthy-caucasian2026-10-06 https://evidence-hub.com/study/10204-ad-libitum-mediterranean-and-low-fat-diets-both-significantly-reduce2026-10-06 https://evidence-hub.com/study/10209-airway-pressure-release-ventilation-in-pediatric-acute-respiratory2026-10-06 https://evidence-hub.com/study/10213-cement-augmentation-of-the-proximal-femoral-nail-antirotation-pfna-a2026-10-06 https://evidence-hub.com/study/10218-a-randomized-controlled-trial-of-zmapp-for-ebola-virus-infection2026-10-10 https://evidence-hub.com/study/10219-bevacizumab-monotherapy-reduces-radiation-induced-brain-necrosis-in2026-10-06 https://evidence-hub.com/study/10220-promoting-resilience-in-adolescents-and-young-adults-with-cancer2026-10-06 https://evidence-hub.com/study/10221-international-ballroom-dancing-against-neurodegeneration-a-randomized2026-10-06 https://evidence-hub.com/study/10226-a-randomized-controlled-trial-of-eicosapentaenoic-acid-in-patients2026-10-06 https://evidence-hub.com/study/10229-effects-of-dyadic-planning-on-physical-activity-in-couples-a2026-10-06 https://evidence-hub.com/study/10232-internet-cognitive-behavioral-therapy-for-women-with-postnatal2026-10-06 https://evidence-hub.com/study/10235-the-stepwise-approach-to-diabetes-prevention-results-from-the-d-clip2026-10-06 https://evidence-hub.com/study/10239-erlotinib-plus-gemcitabine-compared-with-gemcitabine-alone-in2026-10-19 https://evidence-hub.com/study/10240-lenvatinib-combined-with-transarterial-chemoembolization-as-first2026-10-16 https://evidence-hub.com/study/10241-prediction-of-clinical-trials-outcomes-based-on-target-choice-and2026-10-19 https://evidence-hub.com/study/10242-clinical-trial-landscape-in-nash2026-10-19 https://evidence-hub.com/study/10243-the-gut-microbiome-mild-cognitive-impairment-and-probiotics-a2026-10-19 https://evidence-hub.com/study/10244-early-local-therapy-for-the-primary-site-in-de-novo-stage-iv-breast2026-10-19 https://evidence-hub.com/study/10245-efficacy-and-safety-of-axs-05-dextromethorphan-bupropion-in-patients2026-10-19 https://evidence-hub.com/study/10246-phase-ii-clinical-trial-of-neoadjuvant-and-adjuvant-pembrolizumab-in2026-10-19 https://evidence-hub.com/study/10247-breast-cancers-are-immunogenic-immunologic-analyses-and-a-phase-ii2026-10-19 https://evidence-hub.com/study/10248-phase-i-ib-clinical-trial-of-sabatolimab-an-anti-tim-3-antibody-alone2026-10-19 https://evidence-hub.com/study/10249-updated-overall-survival-of-ribociclib-plus-endocrine-therapy-versus2026-10-19 https://evidence-hub.com/study/10250-efficacy-safety-and-correlative-biomarkers-of-toripalimab-in2026-10-19 https://evidence-hub.com/study/10251-adjuvant-trastuzumab-emtansine-versus-paclitaxel-in-combination-with2026-10-19 https://evidence-hub.com/study/10252-laparoscopic-versus-open-gastrectomy-for-gastric-cancer-logica-a2026-10-19 https://evidence-hub.com/study/10253-primary-tumor-resection-plus-chemotherapy-versus-chemotherapy-alone2026-10-19 https://evidence-hub.com/study/10254-use-of-real-world-evidence-to-drive-drug-development-strategy-and2026-10-19 https://evidence-hub.com/study/10255-phase-2a-randomized-clinical-trial-of-dupilumab-anti-il-4r-for2026-10-19 https://evidence-hub.com/study/10256-effect-of-probiotic-and-prebiotic-vs-placebo-on-psychological2026-10-19 https://evidence-hub.com/study/10257-avifavir-for-treatment-of-patients-with-moderate-coronavirus-disease2026-10-19 https://evidence-hub.com/study/10258-daptomycin-plus-fosfomycin-versus-daptomycin-alone-for-methicillin2026-10-19 https://evidence-hub.com/study/10259-long-term-outcomes-of-laparoscopic-distal-gastrectomy-for-locally2026-10-19 https://evidence-hub.com/study/10260-molecular-landscape-and-actionable-alterations-in-a-genomically2026-10-19 https://evidence-hub.com/study/10261-children-s-oncology-group-aall0434-a-phase-iii-randomized-clinical2026-10-19 https://evidence-hub.com/study/10262-improvement-in-inner-retinal-function-in-glaucoma-with-nicotinamide2026-10-19 https://evidence-hub.com/study/10263-esaxerenone-cs-3150-in-patients-with-type-2-diabetes-and2026-10-19 https://evidence-hub.com/study/10264-clinical-trial-generalizability-assessment-in-the-big-data-era-a2026-10-19 https://evidence-hub.com/study/10265-overcoming-barriers-to-clinical-trial-enrollment2026-10-19 https://evidence-hub.com/study/10266-efficacy-of-cinnamon-in-patients-with-type-ii-diabetes-mellitus-a2026-10-19 https://evidence-hub.com/study/10267-neoadjuvant-chemoradiotherapy-followed-by-surgery-versus-surgery2026-10-19 https://evidence-hub.com/study/10268-phase-i-clinical-trial-of-combination-propranolol-and-pembrolizumab2026-10-19 https://evidence-hub.com/study/10269-a-frameshift-peptide-neoantigen-based-vaccine-for-mismatch-repair2026-10-06 https://evidence-hub.com/study/10270-randomized-clinical-trial-representativeness-and-outcomes-in-real2026-10-19 https://evidence-hub.com/study/10271-positive-affect-treatment-for-depression-and-anxiety-a-randomized2026-10-19 https://evidence-hub.com/study/10273-dietary-supplement-use-during-chemotherapy-and-survival-outcomes-of2026-10-19 https://evidence-hub.com/study/10274-efficacy-and-safety-analysis-of-nelipepimut-s-vaccine-to-prevent2026-10-19 https://evidence-hub.com/study/10275-a-5-day-course-of-oral-antibiotics-followed-by-faecal-transplantation2026-10-06 https://evidence-hub.com/study/10276-first-in-human-randomized-double-blind-clinical-trial-of2026-10-19 https://evidence-hub.com/study/10277-a-randomized-placebo-controlled-clinical-trial-of-nicotinamide2026-10-19 https://evidence-hub.com/study/10278-comparative-evaluation-of-retention-cariostatic-effect-and2026-10-16 https://evidence-hub.com/study/10279-guadecitabine-plus-ipilimumab-in-unresectable-melanoma-the-nibit-m42026-10-19 https://evidence-hub.com/study/10280-effects-of-bifidobacterium-probiotic-on-the-treatment-of-chronic2026-10-19 https://evidence-hub.com/study/10283-human-intrabony-defect-regeneration-with-micrografts-containing2026-10-19 https://evidence-hub.com/study/10284-adoptive-transfer-of-invariant-nkt-cells-as-immunotherapy-for2026-10-19 https://evidence-hub.com/study/10287-parents-perceived-obstacles-to-pediatric-clinical-trial-participation2026-10-19 https://evidence-hub.com/study/10289-immediate-versus-delayed-implant-placement-after-anterior-single2026-10-19 https://evidence-hub.com/study/10290-first-in-human-clinical-trial-of-oral-onc201-in-patients-with2026-10-19 https://evidence-hub.com/study/10293-design-of-the-women-s-health-initiative-clinical-trial-and2026-10-19 https://evidence-hub.com/study/10297-readmission-and-mortality-in-malnourished-older-hospitalized-adults2026-10-19 https://evidence-hub.com/study/10298-suzetrigine-and-the-future-of-analgesia-a-new-non-opioid-approach-to2026-10-01 https://evidence-hub.com/study/10299-suzetrigine-and-targeted-nav1-8-inhibition-for-acute-pain-management2026-10-01 https://evidence-hub.com/study/10300-advances-in-the-pathophysiology-and-management-of-cancer-pain-a2026-10-01 https://evidence-hub.com/study/10301-obesity-driven-low-grade-chronic-inflammation-as-a-mechanistic-bridge2026-10-06 https://evidence-hub.com/study/10302-therapeutic-targets-pharmacological-mechanisms-and-delivery2026-10-06 https://evidence-hub.com/study/10303-recent-advances-in-the-pharmacology-of-voltage-gated-ion-channels2026-10-06 https://evidence-hub.com/study/10304-pharmacological-and-behavioral-pain-treatment-strategies-for-patients2026-10-06 https://evidence-hub.com/study/10305-breaking-through-cancer-pain-from-single-drug-management-to2026-10-01 https://evidence-hub.com/study/10306-a-neurocutaneous-nav1-8-channelopathy-underlies-a-genetic-subtype-of2026-10-06 https://evidence-hub.com/study/10307-identification-of-alkaline-phosphatase-as-a-putative-biomarker-of2026-10-06 https://evidence-hub.com/study/10308-new-pharmacological-agents-and-emerging-therapeutic-targets-for2026-10-01 https://evidence-hub.com/study/10309-changing-profiles-of-cancer-burden-worldwide-and-in-china-a-secondary2026-10-19 https://evidence-hub.com/study/10310-vegan-diet-processed-foods-and-body-weight-a-secondary-analysis-of-a2026-10-19 https://evidence-hub.com/study/10311-cognitive-benefits-of-hearing-intervention-vary-by-risk-of-cognitive2026-10-19 https://evidence-hub.com/study/10312-effects-of-tirzepatide-on-circulatory-overload-and-end-organ-damage2026-10-19 https://evidence-hub.com/study/10313-prostate-specific-antigen-screening-and-15-year-prostate-cancer2026-10-19 https://evidence-hub.com/study/10314-the-impact-of-alternate-defibrillation-strategies-on-shock-refractory2026-10-19 https://evidence-hub.com/study/10315-clinical-practice-and-effect-of-carbon-dioxide-on-outcomes-in2026-10-19 https://evidence-hub.com/study/10316-dapagliflozin-and-right-ventricular-pulmonary-vascular-interaction-in2026-10-19 https://evidence-hub.com/study/10317-perinatal-outcomes-in-early-and-late-gestational-diabetes-mellitus2026-10-19 https://evidence-hub.com/study/10318-azithromycin-induced-asthma-remission-in-adults-with-persistent2026-10-19 https://evidence-hub.com/study/10319-amino-acid-infusion-for-kidney-protection-in-cardiac-surgery-patients2026-10-19 https://evidence-hub.com/study/10320-impact-of-high-dose-early-mobilization-on-outcomes-for-patients-with2026-10-19 https://evidence-hub.com/study/10321-frailty-and-effects-of-a-multidomain-physical-rehabilitation2026-10-19 https://evidence-hub.com/study/10322-the-prevalence-of-sepsis-induced-coagulopathy-in-patients-with-sepsis2026-10-19 https://evidence-hub.com/study/10324-effect-of-bypassing-the-closest-stroke-center-in-patients-with2026-10-19 https://evidence-hub.com/study/10325-the-relationship-between-perineal-trauma-and-postpartum-psychological2026-10-19 https://evidence-hub.com/study/10326-effect-of-total-cholesterol-and-statin-therapy-on-mortality-in-ards2026-10-19 https://evidence-hub.com/study/10327-prevalence-and-factors-associated-with-non-use-of-health-services-in2026-10-19 https://evidence-hub.com/study/10328-longitudinal-changes-in-choroidal-structure-following-repeated-low2026-10-19 https://evidence-hub.com/study/10329-device-related-complications-in-subcutaneous-versus-transvenous-icd-a2026-10-19 https://evidence-hub.com/study/10330-extracorporeal-versus-conventional-cardiopulmonary-resuscitation-for2026-10-19 https://evidence-hub.com/study/10331-admission-serum-albumin-concentrations-and-response-to-nutritional2026-10-19 https://evidence-hub.com/study/10332-adverse-effects-of-delayed-antimicrobial-treatment-and-surgical2026-10-19 https://evidence-hub.com/study/10333-how-well-do-cognitive-behavioural-therapy-and-behavioural-activation2026-10-19 https://evidence-hub.com/study/10335-co-infection-and-icu-acquired-infection-in-covid-19-icu-patients-a2026-10-19 https://evidence-hub.com/study/10336-long-term-mortality-following-complications-after-elective-surgery-a2026-10-19 https://evidence-hub.com/study/10337-peripheral-intravenous-catheter-failure-a-secondary-analysis-of-risks2026-10-19 https://evidence-hub.com/study/10338-nutritional-support-during-the-hospital-stay-reduces-mortality-in2026-10-19 https://evidence-hub.com/study/10339-do-not-attempt-cardiopulmonary-resuscitation-dnacpr-decisions-in2026-10-19 https://evidence-hub.com/study/10340-is-indonesia-achieving-universal-health-coverage-secondary-analysis2026-10-19 https://evidence-hub.com/study/10341-an-investigation-of-virtual-reality-nature-experiences-in-patients2026-10-19 https://evidence-hub.com/study/10342-prenatal-repair-and-physical-functioning-among-children-with2026-10-19 https://evidence-hub.com/study/10343-association-of-effective-regurgitation-orifice-area-to-left2026-10-19 https://evidence-hub.com/study/10344-validation-of-modified-glim-criteria-to-predict-adverse-clinical2026-10-19 https://evidence-hub.com/study/10345-a-secondary-analysis-of-the-belimumab-international-study-in-lupus2026-10-19 https://evidence-hub.com/study/10346-assessing-the-effects-of-alternative-plant-based-meats-v-animal-meats2026-10-19 https://evidence-hub.com/study/10347-individualized-versus-fixed-positive-end-expiratory-pressure-for2026-10-19 https://evidence-hub.com/study/10348-venous-thromboembolism-risk-after-spinal-cord-injury-a-secondary2026-10-19 https://evidence-hub.com/study/10350-sickle-cell-anaemia-and-severe-plasmodium-falciparum-malaria-a2026-10-19 https://evidence-hub.com/study/10351-sodium-bicarbonate-use-during-pediatric-cardiopulmonary-resuscitation2026-10-19 https://evidence-hub.com/study/10352-six-month-outcomes-of-the-codes-randomised-controlled-trial-of2026-10-19 https://evidence-hub.com/study/10353-association-of-immunophenotype-with-pathologic-complete-response-to2026-10-19 https://evidence-hub.com/study/10354-presymptomatic-transmission-of-sars-cov-2-infection-a-secondary2026-10-19 https://evidence-hub.com/study/10355-higher-radiation-dose-to-the-immune-cells-correlates-with-worse-tumor2026-10-19 https://evidence-hub.com/study/10356-early-prehospital-tranexamic-acid-following-injury-is-associated-with2026-10-19 https://evidence-hub.com/study/10357-value-of-handgrip-strength-to-predict-clinical-outcomes-and2026-10-19 https://evidence-hub.com/study/10358-association-of-circulating-tumor-dna-and-circulating-tumor-cells2026-10-19 https://evidence-hub.com/study/10359-taking-a-critical-stance-towards-mixed-methods-research-a-cross2026-10-19 https://evidence-hub.com/study/10360-the-roles-of-men-and-women-in-maternal-and-child-nutrition-in-urban2026-10-19 https://evidence-hub.com/study/10361-working-at-a-remove-continuous-collective-and-configurative2026-10-19 https://evidence-hub.com/study/10362-clinical-outcomes-in-early-breast-cancer-with-a-high-21-gene2026-10-19 https://evidence-hub.com/study/10363-association-of-sex-with-severity-of-coronary-artery-disease-ischemia2026-10-19 https://evidence-hub.com/study/10364-risk-factors-associated-with-adverse-fetal-outcomes-in-pregnancies2026-10-19 https://evidence-hub.com/study/10365-assessment-of-limitations-to-optimization-of-guideline-directed2026-10-19 https://evidence-hub.com/study/10366-c-reactive-protein-procalcitonin-and-white-blood-count-to-rule-out2026-10-19 https://evidence-hub.com/study/10367-defining-persistent-staphylococcus-aureus-bacteraemia-secondary2026-10-19 https://evidence-hub.com/study/10368-secondary-analysis-of-loot-box-data-are-high-spending-whales-wealthy2026-10-19 https://evidence-hub.com/study/10370-efficacy-of-evolocumab-on-cardiovascular-outcomes-in-patients-with2026-10-19 https://evidence-hub.com/study/10371-intravenous-iron-dosing-and-infection-risk-in-patients-on2026-10-19 https://evidence-hub.com/study/10372-association-between-low-dose-rivaroxaban-with-or-without-aspirin-and2026-10-19 https://evidence-hub.com/study/10373-prehospital-blood-product-and-crystalloid-resuscitation-in-the2026-10-19 https://evidence-hub.com/study/10374-nutritional-risk-screening-nrs-2002-is-a-strong-and-modifiable2026-10-19 https://evidence-hub.com/study/10375-effect-of-long-term-omega-3-supplementation-and-a-lifestyle2026-10-19 https://evidence-hub.com/study/10376-effect-of-c-reactive-protein-on-lipoprotein-a-associated2026-10-19 https://evidence-hub.com/study/10377-association-of-germline-variant-status-with-therapy-response-in-high2026-10-19 https://evidence-hub.com/study/10378-intratrial-exposure-to-vitamin-d-and-new-onset-diabetes-among-adults2026-10-19 https://evidence-hub.com/study/10379-a-secondary-analysis-of-the-childhood-obesity-prevention-cochrane2026-10-19 https://evidence-hub.com/study/10380-effect-of-simvastatin-ezetimibe-compared-with-simvastatin-monotherapy2026-10-19 https://evidence-hub.com/study/10381-gender-variations-in-neonatal-and-early-infant-mortality-in-india-and2026-10-19 https://evidence-hub.com/study/10382-renal-cardiovascular-and-safety-outcomes-of-canagliflozin-by-baseline2026-10-19 https://evidence-hub.com/study/10383-balanced-crystalloids-versus-saline-in-sepsis-a-secondary-analysis-of2026-10-19 https://evidence-hub.com/study/10384-association-of-initial-and-serial-c-reactive-protein-levels-with2026-10-19 https://evidence-hub.com/study/10385-does-facility-birth-reduce-maternal-and-perinatal-mortality-in-brong2026-10-19 https://evidence-hub.com/study/10386-previous-radiotherapy-and-the-clinical-activity-and-toxicity-of2026-10-19 https://evidence-hub.com/study/10387-comparative-effectiveness-of-exercise-interventions-for-preventing2026-10-19 https://evidence-hub.com/study/10388-postoperative-anaemia-might-be-a-risk-factor-for-postoperative2026-10-19 https://evidence-hub.com/study/10389-clinical-efficacy-and-safety-of-achieving-very-low-ldl-cholesterol2026-10-19 https://evidence-hub.com/study/10390-estimating-pre-symptomatic-transmission-of-covid-19-a-secondary2026-10-19 https://evidence-hub.com/study/10391-incidence-of-eclampsia-and-related-complications-across-10-low-and2026-10-19 https://evidence-hub.com/study/10392-assessing-the-impact-of-physical-exercise-on-cognitive-function-in2026-10-19 https://evidence-hub.com/study/10393-outcomes-of-premature-ventricular-contraction-cardiomyopathy-in-the2026-10-19 https://evidence-hub.com/study/10394-improving-empathy-in-healthcare-consultations-a-secondary-analysis-of2026-10-19 https://evidence-hub.com/study/10395-intratrial-exposure-to-vitamin-d-and-new-onset-diabetes-among-adults2026-10-19 https://evidence-hub.com/study/10396-the-association-between-postoperative-cognitive-dysfunction-and2026-10-19 https://evidence-hub.com/study/10397-association-of-the-youth-nominated-support-team-intervention-for2026-10-19 https://evidence-hub.com/study/10398-patterns-of-recurrence-after-resection-of-pancreatic-ductal2026-10-19 https://evidence-hub.com/study/10399-a-suzetrigine-based-multimodal-analgesic-protocol-in-spine-surgery-a2026-10-01 https://evidence-hub.com/study/10400-the-effectiveness-of-covid-19-vaccines-to-prevent-long-covid-symptoms2026-10-08 https://evidence-hub.com/study/10401-impact-of-long-covid-on-health-related-quality-of-life-an-opensafely2026-10-06 https://evidence-hub.com/study/10402-6-month-neurological-and-psychiatric-outcomes-in-236-379-survivors-of2026-10-19 https://evidence-hub.com/study/10403-global-epidemiology-and-clinical-outcomes-of-carbapenem-resistant2026-10-06 https://evidence-hub.com/study/10404-sleep-regularity-is-a-stronger-predictor-of-mortality-risk-than-sleep2026-10-06 https://evidence-hub.com/study/10405-prenatal-parental-exposure-to-metals-and-birth-defects-a-prospective2026-10-19 https://evidence-hub.com/study/10406-metabolic-dysfunction-associated-steatotic-liver-disease-increases2026-10-08 https://evidence-hub.com/study/10407-racial-ethnic-and-sex-disparities-in-mental-health-among-u-s-service2026-10-19 https://evidence-hub.com/study/10408-clinical-impact-of-covid-19-on-patients-with-cancer-ccc19-a-cohort2026-10-13 https://evidence-hub.com/study/10409-hyperkalemia-related-discontinuation-of-renin-angiotensin-aldosterone2026-10-06 https://evidence-hub.com/study/10410-bnt162b2-covid-19-vaccine-and-correlates-of-humoral-immune-responses2026-10-06 https://evidence-hub.com/study/10411-effectiveness-of-a-third-dose-of-bnt162b2-mrna-covid-19-vaccine-in-a2026-10-06 https://evidence-hub.com/study/10412-viral-suppression-and-hiv-1-drug-resistance-1-year-after-pragmatic2026-10-06 https://evidence-hub.com/study/10413-association-between-ultraprocessed-food-consumption-and-risk-of2026-10-06 https://evidence-hub.com/study/10414-sex-differences-in-sepsis-hospitalisations-and-outcomes-in-older2026-10-06 https://evidence-hub.com/study/10415-benefits-of-pulmonary-rehabilitation-in-covid-19-a-prospective2026-10-08 https://evidence-hub.com/study/10416-covid-19-in-children-and-adolescents-in-europe-a-multinational2026-10-19 https://evidence-hub.com/study/10417-characteristics-and-outcomes-of-pregnant-women-admitted-to-hospital2026-10-08 https://evidence-hub.com/study/10418-prevalence-of-sarcopenic-obesity-and-sarcopenic-overweight-in-the2026-10-06 https://evidence-hub.com/study/10419-biomarkers-of-dairy-fat-intake-incident-cardiovascular-disease-and2026-10-06 https://evidence-hub.com/study/10420-donor-derived-cell-free-dna-accurately-detects-acute-rejection-in2026-10-06 https://evidence-hub.com/study/10421-cardiometabolic-multimorbidity-genetic-risk-and-dementia-a2026-10-08 https://evidence-hub.com/study/10422-predictors-of-relapse-in-mog-antibody-associated-disease-a-cohort2026-10-08 https://evidence-hub.com/study/10423-preterm-birth-and-stillbirth-during-the-covid-19-pandemic-in-sweden-a2026-10-06 https://evidence-hub.com/study/10424-physical-activity-and-the-risk-of-sars-cov-2-infection-severe-covid2026-10-06 https://evidence-hub.com/study/10425-comparison-of-risk-factor-associations-in-uk-biobank-against2026-10-13 https://evidence-hub.com/study/10426-clinical-characteristics-and-day-90-outcomes-of-4244-critically-ill2026-10-19 https://evidence-hub.com/study/10427-clinical-characteristics-outcomes-and-risk-factors-for-mortality-in2026-10-08 https://evidence-hub.com/study/10428-variations-in-common-diseases-hospital-admissions-and-deaths-in2026-10-06 https://evidence-hub.com/study/10429-meat-consumption-and-risk-of-incident-dementia-cohort-study-of-4932026-10-06 https://evidence-hub.com/study/10432-cumulative-triglyceride-glucose-index-is-a-risk-for-cvd-a-prospective2026-10-06 https://evidence-hub.com/study/10433-covid-19-mortality-in-patients-with-cancer-on-chemotherapy-or-other2026-10-13 https://evidence-hub.com/study/10434-obesity-without-metabolic-abnormality-and-incident-ckd-a-population2026-10-06 https://evidence-hub.com/study/10435-the-millennium-cohort-study-the-first-20-years-of-research-dedicated2026-10-19 https://evidence-hub.com/study/10436-ultra-processed-food-intake-and-risk-of-cardiovascular-disease2026-10-13 https://evidence-hub.com/study/10437-fremanezumab-in-the-prevention-of-high-frequency-episodic-and-chronic2026-10-08 https://evidence-hub.com/study/10438-clinical-outcomes-and-toxic-effects-of-single-agent-immune-checkpoint2026-10-06 https://evidence-hub.com/study/10439-clinical-and-epidemiological-features-of-36-children-with-coronavirus2026-10-06 https://evidence-hub.com/study/10440-safety-and-efficacy-of-rituximab-as-first-and-second-line-treatment2026-10-06 https://evidence-hub.com/study/10441-social-determinants-of-health-and-cancer-mortality-in-the-reasons-for2026-10-06 https://evidence-hub.com/study/10442-the-association-of-covid-19-infection-in-pregnancy-with-preterm-birth2026-10-06 https://evidence-hub.com/study/10444-respiratory-pathophysiology-of-mechanically-ventilated-patients-with2026-10-08 https://evidence-hub.com/study/10446-factors-affecting-drug-retention-of-janus-kinase-inhibitors-in2026-10-06 https://evidence-hub.com/study/10447-jejunoileal-atresia-a-national-cohort-study2026-10-06 https://evidence-hub.com/study/10448-grey-matter-brain-healthcare-quotient-and-cognitive-function-a-large2026-10-19 https://evidence-hub.com/study/10449-case-mix-care-pathways-and-outcomes-in-patients-with-traumatic-brain2026-10-08 https://evidence-hub.com/study/10450-clinical-outcomes-in-patients-with-chronic-hepatitis-c-after-direct2026-10-08 https://evidence-hub.com/study/10451-associations-of-fats-and-carbohydrate-intake-with-cardiovascular2026-10-16 https://evidence-hub.com/study/10452-association-of-frailty-with-mortality-in-older-inpatients-with-covid2026-10-06 https://evidence-hub.com/study/10453-ethnicity-and-outcomes-from-covid-19-the-isaric-ccp-uk-prospective2026-10-19 https://evidence-hub.com/study/10455-physical-activity-trajectories-and-mortality-population-based-cohort2026-10-08 https://evidence-hub.com/study/10456-sleep-and-nighttime-energy-consumption-in-early-childhood-a2026-10-19 https://evidence-hub.com/study/10458-magnetic-resonance-spectroscopy-assessment-of-brain-injury-after2026-10-06 https://evidence-hub.com/study/10459-maternal-and-fetal-outcomes-following-exposure-to-duloxetine-in2026-10-06 https://evidence-hub.com/study/10460-patient-outcomes-associated-with-post-tuberculosis-lung-damage-in2026-10-06 https://evidence-hub.com/study/10461-disease-characteristics-of-mct8-deficiency-an-international2026-10-06 https://evidence-hub.com/study/10462-direct-oral-anticoagulants-in-patients-with-inherited-thrombophilia2026-10-06 https://evidence-hub.com/study/10463-metabolic-syndrome-and-risk-of-pancreatic-cancer-a-population-based2026-10-06 https://evidence-hub.com/study/10464-long-term-outcomes-of-laparoscopic-versus-open-surgery-for-clinical2026-10-06 https://evidence-hub.com/study/10465-cluster-analysis-of-phenotypes-of-patients-with-behcet-s-syndrome-a2026-10-06 https://evidence-hub.com/study/10466-prenatal-phthalate-exposure-oxidative-stress-related-genetic2026-10-06 https://evidence-hub.com/study/10467-intraocular-pressure-lowering-effects-of-ripasudil-in-uveitic2026-10-19 https://evidence-hub.com/study/10468-real-world-evidence-from-a-european-cohort-study-of-patients-with2026-10-06 https://evidence-hub.com/study/10469-hyperthermic-intraperitoneal-chemotherapy-for-gastric-cancer-with2026-10-19 https://evidence-hub.com/study/10473-regular-use-of-vka-prior-to-covid-19-associated-with-lower-7-day2026-10-13 https://evidence-hub.com/study/10474-metabolic-obesity-phenotypes-and-thyroid-cancer-risk-a-cohort-study2026-10-06 https://evidence-hub.com/study/10475-opioid-use-in-knee-or-hip-osteoarthritis-a-region-wide-population2026-10-06 https://evidence-hub.com/study/10477-outcomes-of-patients-with-systemic-sclerosis-treated-with-rituximab2026-10-08 https://evidence-hub.com/study/10478-surgical-site-infection-after-gastrointestinal-surgery-in-high-income2026-10-08 https://evidence-hub.com/study/10480-the-university-of-zimbabwe-college-of-health-sciences-uz-chs-birth2026-10-19 https://evidence-hub.com/study/10481-mortality-and-mesothelioma-incidence-among-chrysotile-asbestos-miners2026-10-06 https://evidence-hub.com/study/10482-participation-in-school-and-physical-education-in-juvenile-idiopathic2026-10-13 https://evidence-hub.com/study/10483-severity-of-hypertension-mediates-the-association-of-hyperuricemia2026-10-06 https://evidence-hub.com/study/10484-active-and-passive-case-finding-in-tuberculosis-affected-households2026-10-06 https://evidence-hub.com/study/10485-solid-cancer-development-in-solid-organ-transplant-recipients-within2026-10-13 https://evidence-hub.com/study/10486-mediterranean-diet-during-pregnancy-and-childhood-respiratory-and2026-10-06 https://evidence-hub.com/study/10487-different-contributions-of-dyslipidemia-and-obesity-to-the-natural2026-10-13 https://evidence-hub.com/study/10489-ambient-polycyclic-aromatic-hydrocarbon-exposure-and-breast-cancer2026-10-19 https://evidence-hub.com/study/10490-vancomycin-resistant-enterococcus-risk-factors-for-hospital2026-10-19 https://evidence-hub.com/study/10492-risk-factors-for-nosocomial-rectal-colonization-with-carbapenem2026-10-19 https://evidence-hub.com/study/10493-infectious-complications-of-probiotic-use-a-matched-case-control-study2026-10-19 https://evidence-hub.com/study/10494-risk-factors-for-nosocomial-methicillin-resistant-staphylococcus2026-10-19 https://evidence-hub.com/study/10495-occupational-exposure-to-pesticides-and-central-nervous-system-tumors2026-10-19 https://evidence-hub.com/study/10496-birth-characteristics-and-childhood-leukemia-in-switzerland-a2026-10-19 https://evidence-hub.com/study/10497-infection-control-and-risk-factors-for-acquisition-of-carbapenemase2026-10-19 https://evidence-hub.com/study/10498-assessing-coronavirus-disease-2019-covid-19-transmission-to2026-10-19 https://evidence-hub.com/study/10499-the-role-of-calcium-and-vitamin-d-dietary-intake-on-risk-of2026-10-19 https://evidence-hub.com/study/10500-risk-factors-for-hepatocellular-carcinoma-hcc-in-the-northeast-of-the2026-10-19 https://evidence-hub.com/study/10501-predictive-factors-for-sepsis-by-carbapenem-resistant-gram-negative2026-10-19 https://evidence-hub.com/study/10502-risk-factors-for-surgical-site-infection-after-cesarean-delivery-a2026-10-19 https://evidence-hub.com/study/10503-active-lifestyle-patterns-reduce-the-risk-of-colorectal-cancer-in-the2026-10-19 https://evidence-hub.com/study/10504-a-multi-center-nested-case-control-study-on-hospitalization-costs-and2026-10-19 https://evidence-hub.com/study/10505-vim-positive-pseudomonas-aeruginosa-in-a-large-tertiary-care-hospital2026-10-19 https://evidence-hub.com/study/10506-benign-gynecologic-conditions-are-associated-with-ovarian-cancer-risk2026-10-19 https://evidence-hub.com/study/10507-the-impact-of-methicillin-resistant-s-aureus-on-length-of-stay2026-10-19 https://evidence-hub.com/study/10508-risk-factors-for-relapse-or-persistence-of-bacteraemia-caused-by2026-10-19 https://evidence-hub.com/study/10509-residential-magnetic-fields-exposure-and-childhood-leukemia-a2026-10-19 https://evidence-hub.com/study/10511-dietary-inflammatory-index-and-non-hodgkin-lymphoma-risk-in-an2026-10-19 https://evidence-hub.com/study/10513-dietary-inflammatory-index-and-ovarian-cancer-risk-in-a-large-italian2026-10-19 https://evidence-hub.com/study/10514-inflammatory-potential-of-diet-and-risk-of-laryngeal-cancer-in-a-case2026-10-19 https://evidence-hub.com/study/10515-plasma-lipopolysaccharide-binding-protein-and-colorectal-cancer-risk2026-10-19 https://evidence-hub.com/study/10517-unique-risks-and-clinical-outcomes-associated-with-extended-spectrum2026-10-19 https://evidence-hub.com/study/10518-a-case-control-study-of-prevalence-of-anemia-among-patients-with-type2026-10-19 https://evidence-hub.com/study/10519-polycystic-ovarian-syndrome-pcos-related-symptoms-sequelae-and-breast2026-10-19 https://evidence-hub.com/study/10523-serum-b6-vitamers-pyridoxal-5-phosphate-pyridoxal-and-4-pyridoxic2026-10-19 https://evidence-hub.com/study/10526-blood-fatty-acid-patterns-are-associated-with-prostate-cancer-risk-in2026-10-19 https://evidence-hub.com/study/10529-the-costs-of-nosocomial-resistant-gram-negative-intensive-care-unit2026-10-19 https://evidence-hub.com/study/10534-breast-cancer-risk-after-exposure-to-perfluorinated-compounds-in2026-10-19 https://evidence-hub.com/study/10536-risk-factors-for-the-acquisition-of-carbapenem-resistant-escherichia2026-10-19 https://evidence-hub.com/study/10537-associations-of-vitamin-d-pathway-genes-with-circulating-252026-10-19 https://evidence-hub.com/study/10546-risk-of-death-for-hematological-malignancies-for-residents-close-to2026-10-19 https://evidence-hub.com/study/10549-cigarette-smoking-and-risk-of-ovarian-cancer-a-pooled-analysis-of-212026-10-19 https://evidence-hub.com/study/10554-asbestos-a-hidden-player-behind-the-cholangiocarcinoma-increase2026-10-19 https://evidence-hub.com/study/10559-androgenetic-alopecia-at-various-ages-and-prostate-cancer-risk-in-an2026-10-19 https://evidence-hub.com/study/10565-subtype-of-dietary-fat-in-relation-to-risk-of-hodgkin-lymphoma-a2026-10-19 https://evidence-hub.com/study/10569-personal-hair-dye-use-and-the-risk-of-bladder-cancer-a-case-control2026-10-19 https://evidence-hub.com/study/10571-erythrocyte-membrane-fatty-acid-composition-serum-lipids-and-non2026-10-19 https://evidence-hub.com/study/10572-total-and-individual-antioxidant-intake-and-endometrial-cancer-risk2026-10-19 https://evidence-hub.com/study/10577-a-multi-ethnic-breast-cancer-case-control-study-in-new-zealand2026-10-19 https://evidence-hub.com/study/10578-body-size-and-risk-of-hodgkin-lymphoma-by-age-and-gender-a-population2026-10-19 https://evidence-hub.com/study/10580-plasma-folate-methylenetetrahydrofolate-reductase-mthfr-and2026-10-19 https://evidence-hub.com/study/10582-a-cross-sectional-study2026-10-19 https://evidence-hub.com/study/10584-barriers-to-physical-activity-in-older-adults-in-germany-a-cross2026-10-19 https://evidence-hub.com/study/10585-investigating-nutrient-intake-during-use-of-glucagon-like-peptide-12026-10-19 https://evidence-hub.com/study/10586-metabolic-non-communicable-disease-health-report-of-india-the-icmr2026-10-19 https://evidence-hub.com/study/10587-knowledge-and-attitudes-toward-artificial-intelligence-in-nursing2026-10-08 https://evidence-hub.com/study/10588-prevalence-risk-factors-and-management-of-dementia-and-mild-cognitive2026-10-19 https://evidence-hub.com/study/10589-prevalence-of-diabetes-recorded-in-mainland-china-using-20182026-10-19 https://evidence-hub.com/study/10591-non-linear-association-of-atherogenic-index-of-plasma-with-insulin2026-10-19 https://evidence-hub.com/study/10593-impact-on-mental-health-and-perceptions-of-psychological-care-among2026-10-19 https://evidence-hub.com/study/10594-risk-of-bias-evaluation-of-cross-sectional-studies-adaptation-of-the2026-10-19 https://evidence-hub.com/study/10595-impact-of-the-covid-19-pandemic-on-mental-health-and-quality-of-life2026-10-06 https://evidence-hub.com/study/10596-variable-generalization-performance-of-a-deep-learning-model-to2026-10-19 https://evidence-hub.com/study/10597-association-between-the-weight-adjusted-waist-index-and-stroke-a2026-10-19 https://evidence-hub.com/study/10598-exposure-to-air-pollution-and-covid-19-mortality-in-the-united-states2026-10-19 https://evidence-hub.com/study/10600-association-between-systemic-immune-inflammation-index-and-low-muscle2026-10-12 https://evidence-hub.com/study/10601-public-knowledge-attitudes-and-practices-towards-covid-19-a-cross2026-10-19 https://evidence-hub.com/study/10602-a-cross-sectional-study-of-smoking-and-depression-among-us-adults2026-10-19 https://evidence-hub.com/study/10605-the-revised-jbi-critical-appraisal-tool-for-the-assessment-of-risk-of2026-10-19 https://evidence-hub.com/study/10606-endotheliopathy-in-covid-19-associated-coagulopathy-evidence-from-a2026-10-19 https://evidence-hub.com/study/10607-the-association-between-the-body-roundness-index-and-the-risk-of2026-10-19 https://evidence-hub.com/study/10608-frontline-nurses-burnout-anxiety-depression-and-fear-statuses-and2026-10-19 https://evidence-hub.com/study/10609-tyg-bmi-and-hypertension-in-normoglycemia-subjects-in-japan-a-cross2026-10-19 https://evidence-hub.com/study/10610-knowledge-attitude-and-practice-toward-covid-19-among-the-public-in2026-10-19 https://evidence-hub.com/study/10611-post-covid-19-syndrome-low-grade-inflammation-and-inflammatory2026-10-10 https://evidence-hub.com/study/10612-knowledge-attitude-and-practice-assessment-toward-covid-19-among2026-10-19 https://evidence-hub.com/study/10613-long-covid-symptoms-in-sars-cov-2-positive-adolescents-and-matched2026-10-19 https://evidence-hub.com/study/10614-psychological-status-of-medical-workforce-during-the-covid-192026-10-19 https://evidence-hub.com/study/10615-prevalence-risk-factors-and-management-of-asthma-in-china-a-national2026-10-19 https://evidence-hub.com/study/10617-long-covid-symptoms-in-sars-cov-2-positive-children-aged-0-14-years2026-10-19 https://evidence-hub.com/study/10618-the-relationship-between-dyslipidemia-and-inflammation-among-adults2026-10-19 https://evidence-hub.com/study/10619-seroprevalence-and-humoral-immune-durability-of-anti-sars-cov-22026-10-13 https://evidence-hub.com/study/10620-acceptance-of-a-covid-19-vaccine-in-southeast-asia-a-cross-sectional2026-10-19 https://evidence-hub.com/study/10621-mask-wearing-and-control-of-sars-cov-2-transmission-in-the-usa-a2026-10-19 https://evidence-hub.com/study/10622-monkeypox-outbreak-in-spain-clinical-and-epidemiological-findings-in2026-10-19 https://evidence-hub.com/study/10623-increased-generalized-anxiety-depression-and-distress-during-the2026-10-19 https://evidence-hub.com/study/10624-association-between-physical-exercise-and-mental-health-in-1-22026-10-19 https://evidence-hub.com/study/10625-clinical-placement-experience-of-nursing-students-during-the-covid-192026-10-19 https://evidence-hub.com/study/10626-global-perspective-of-familial-hypercholesterolaemia-a-cross2026-10-19 https://evidence-hub.com/study/10627-prevalence-and-determinants-of-healthcare-avoidance-during-the-covid2026-10-19 https://evidence-hub.com/study/10628-self-reported-olfactory-and-taste-disorders-in-patients-with-severe2026-10-19 https://evidence-hub.com/study/10629-mobile-health-and-privacy-cross-sectional-study2026-10-19 https://evidence-hub.com/study/10630-physical-activity-in-relation-to-urban-environments-in-14-cities2026-10-19 https://evidence-hub.com/study/10631-knowledge-and-perceptions-of-covid-19-among-health-care-workers-cross2026-10-19 https://evidence-hub.com/study/10632-association-between-sleep-duration-and-depression-in-us-adults-a2026-10-19 https://evidence-hub.com/study/10633-urbanization-ambient-air-pollution-and-prevalence-of-chronic-kidney2026-10-19 https://evidence-hub.com/study/10634-prevalence-of-anxiety-and-depression-among-medical-students-during2026-10-19 https://evidence-hub.com/study/10635-the-association-between-smartphone-addiction-and-sleep-a-uk-cross2026-10-19 https://evidence-hub.com/study/10636-alcohol-consumption-during-the-covid-19-pandemic-in-europe-a-large2026-10-19 https://evidence-hub.com/study/10637-assessment-of-knowledge-attitudes-and-perception-of-health-care2026-10-19 https://evidence-hub.com/study/10638-psychological-impact-of-the-covid-19-pandemic-on-healthcare-workers-a2026-10-19 https://evidence-hub.com/study/10639-alcohol-consumption-during-the-covid-19-pandemic-in-europe-a-large2026-10-19 https://evidence-hub.com/study/10640-global-effect-of-the-covid-19-pandemic-on-paediatric-cancer-care-a2026-10-19 https://evidence-hub.com/study/10641-depression-and-anxiety-in-patients-with-cancer-a-cross-sectional-study2026-10-19 https://evidence-hub.com/study/10642-capture-a-multinational-cross-sectional-study-of-cardiovascular2026-10-19 https://evidence-hub.com/study/10643-mental-health-status-of-pregnant-and-breastfeeding-women-during-the2026-10-19 https://evidence-hub.com/study/10645-a-cross-sectional-study-of-persisting-symptoms-biomarker-and-imaging2026-10-19 https://evidence-hub.com/study/10646-revised-strengthening-the-reporting-of-cohort-cross-sectional-and2026-10-19 https://evidence-hub.com/study/10647-sars-cov-2-seroprevalence-and-asymptomatic-viral-carriage-in2026-10-19 https://evidence-hub.com/study/10648-clinical-and-biomarker-changes-of-alzheimer-s-disease-in-adults-with2026-10-19 https://evidence-hub.com/study/10649-use-of-personal-protective-equipment-against-coronavirus-disease-20192026-10-19 https://evidence-hub.com/study/10650-eating-habits-and-lifestyle-during-covid-19-lockdown-in-the-united2026-10-19 https://evidence-hub.com/study/10651-assessing-acceptability-of-covid-19-vaccine-booster-dose-among-adult2026-10-19 https://evidence-hub.com/study/10652-coronavirus-related-health-literacy-a-cross-sectional-study-in-adults2026-10-19 https://evidence-hub.com/study/10653-burnout-among-healthcare-professionals-during-covid-19-pandemic-a2026-10-19 https://evidence-hub.com/study/10654-age-related-changes-in-gut-microbiota-composition-from-newborn-to2026-10-19 https://evidence-hub.com/study/10655-the-psychological-impact-of-the-covid-19-outbreak-on-health2026-10-19 https://evidence-hub.com/study/10656-a-cross-sectional-study-of-functional-and-metabolic-changes-during2026-10-13 https://evidence-hub.com/study/10657-dentists-awareness-perception-and-attitude-regarding-covid-19-and2026-10-19 https://evidence-hub.com/study/10658-factors-associated-with-covid-19-vaccine-intentions-in-eastern2026-10-19 https://evidence-hub.com/study/10659-headaches-associated-with-personal-protective-equipment-a-cross2026-10-19 https://evidence-hub.com/study/10660-impact-of-online-information-on-self-isolation-intention-during-the2026-10-19 https://evidence-hub.com/study/10661-gut-metagenomic-and-short-chain-fatty-acids-signature-in-hypertension2026-10-19 https://evidence-hub.com/study/10662-covid-19-in-health-care-workers-in-three-hospitals-in-the-south-of2026-10-19 https://evidence-hub.com/study/10663-the-gut-microbiota-in-prediabetes-and-diabetes-a-population-based2026-10-19 https://evidence-hub.com/study/10664-variations-in-use-of-childbirth-interventions-in-13-high-income2026-10-19 https://evidence-hub.com/study/10665-knowledge-of-human-monkeypox-viral-infection-among-general2026-10-19 https://evidence-hub.com/study/10666-burnout-and-resilience-among-frontline-nurses-during-covid-192026-10-19 https://evidence-hub.com/study/10667-prevalence-and-risk-factors-of-chronic-kidney-disease-among-type-22026-10-19 https://evidence-hub.com/study/10668-reporting-of-workplace-violence-towards-nurses-in-5-european2026-10-19 https://evidence-hub.com/study/10669-a-cross-sectional-study-of-nemaline-myopathy2026-10-19 https://evidence-hub.com/study/10670-immediate-psychological-impact-on-nurses-working-at-42-government2026-10-19 https://evidence-hub.com/study/10671-prevalence-of-sleep-disturbances-during-covid-19-outbreak-in-an-urban2026-10-19 https://evidence-hub.com/study/10673-determinants-of-burnout-and-other-aspects-of-psychological-well-being2026-10-06 https://evidence-hub.com/study/10674-association-between-dietary-pattern-and-periodontitis-a-cross2026-10-19 https://evidence-hub.com/study/10675-the-association-between-purine-rich-food-intake-and-hyperuricemia-a2026-10-19 https://evidence-hub.com/study/10676-exercise-levels-and-preferences-in-cancer-patients-a-cross-sectional2026-10-19 https://evidence-hub.com/study/10677-gender-differences-in-factors-associated-with-smartphone-addiction-a2026-10-19 https://evidence-hub.com/study/10678-the-influence-of-spirituality-on-decision-making-in-palliative-care2026-10-19 https://evidence-hub.com/study/10679-influenza-vaccination-rate-and-its-association-with-chronic-diseases2026-10-19 https://evidence-hub.com/study/10680-associations-between-the-neutrophil-to-lymphocyte-ratio-and-diabetic2026-10-19 https://evidence-hub.com/study/10681-headache-as-an-extraocular-manifestation-of-birdshot2026-10-06 https://evidence-hub.com/study/10682-prevention-of-gastrointestinal-bleeding-in-patients-receiving-direct2026-10-01 https://evidence-hub.com/study/10683-myofascial-pain-in-older-adults-a-geroscience-informed-framework2026-10-06 https://evidence-hub.com/study/10684-immunomodulators-for-steroid-dependent-recurrent-acute-pancreatitis2026-10-19 https://evidence-hub.com/study/10685-surgical-technique-challenges-in-adult-aortic-coarctation-patients-a2026-10-19 https://evidence-hub.com/study/10686-a-case-series-on-parathyroid-carcinoma-diagnostic-challenges-and2026-10-19 https://evidence-hub.com/study/10687-management-of-nontraumatic-spontaneous-renal-hemorrhage-wunderlich2026-10-19 https://evidence-hub.com/study/10689-pulmonary-light-chain-deposition-disease-case-series-and-review-of2026-10-19 https://evidence-hub.com/study/10690-image-guided-preoperative-abdominal-wall-botox-injection-for-large2026-10-19 https://evidence-hub.com/study/10691-differential-diagnoses-of-inguinal-swellings-a-case-series-of2026-10-19 https://evidence-hub.com/study/10692-rapid-osteoarthritis-and-femoral-head-collapse-a-case-series2026-10-19 https://evidence-hub.com/study/10693-severe-cutaneous-ulcerations-secondary-to-xylazine-tranq-a-case-series2026-10-19 https://evidence-hub.com/study/10694-migrated-intrauterine-device-case-series-report2026-10-19 https://evidence-hub.com/study/10695-primary-breast-lymphoma-a-case-series-and-review-of-the-literature2026-10-19 https://evidence-hub.com/study/10696-the-role-of-vitamin-d-on-the-wound-healing-process-a-case-series2026-10-19 https://evidence-hub.com/study/10697-impella-as-a-bridge-to-closure-in-post-infarction-ventricular-septal2026-10-19 https://evidence-hub.com/study/10698-functional-regeneration-of-dilated-cardiomyopathy-by-transcatheter2026-10-19 https://evidence-hub.com/study/10699-janus-kinase-inhibition-for-the-treatment-of-refractory-frontal2026-10-19 https://evidence-hub.com/study/10700-bone-defect-filling-with-a-novel-rattan-wood-based-not-sintered2026-10-19 https://evidence-hub.com/study/10701-safety-and-utility-of-cardiomems-device-for-remote-pulmonary-artery2026-10-19 https://evidence-hub.com/study/10702-peripheral-nerve-stimulation-for-the-treatment-of-phantom-limb-pain-a2026-10-19 https://evidence-hub.com/study/10703-guillain-barre-syndrome-associated-with-covid-19-infection-a-case2026-10-19 https://evidence-hub.com/study/10704-distinctive-cutaneous-features-of-dermatomyositis-in-black-adults-a2026-10-19 https://evidence-hub.com/study/10705-dupilumab-as-a-treatment-for-cutaneous-immune-related-adverse-events2026-10-19 https://evidence-hub.com/study/10706-treatment-of-erosive-vulvovaginal-lichen-planus-with-tofacitinib-a2026-10-19 https://evidence-hub.com/study/10707-rasmussen-aneurysm-case-series-of-a-rare-complication-of-pulmonary2026-10-19 https://evidence-hub.com/study/10708-targeted-therapy-with-ixekizumab-in-pyoderma-gangrenosum-a-case2026-10-19 https://evidence-hub.com/study/10709-airbag-related-penetrating-injuries-a-case-series-from-a-level-12026-10-19 https://evidence-hub.com/study/10710-amyloidosis-a-case-series-and-review-of-the-literature2026-10-19 https://evidence-hub.com/study/10711-ehrlichiosis-associated-hemophagocytic-lymphohistiocytosis-a-case2026-10-19 https://evidence-hub.com/study/10712-blood-transfusion-in-severe-dengue-infection-a-case-series2026-10-19 https://evidence-hub.com/study/10713-benign-osteonecrosis-of-the-external-ear-canal-case-series2026-10-19 https://evidence-hub.com/study/10714-major-complications-of-sigmoid-vaginoplasty-a-case-series2026-10-19 https://evidence-hub.com/study/10715-apremilast-for-the-treatment-of-generalized-granuloma-annulare-a-case2026-10-19 https://evidence-hub.com/study/10716-cardiac-resynchronization-therapy-in-patients-with-a-coronary-sinus2026-10-19 https://evidence-hub.com/study/10717-opacification-of-a-scleral-sutured-akreos-ao60-intraocular-lens-in2026-10-19 https://evidence-hub.com/study/10718-thyroid-storm-induced-refractory-multiorgan-failure-managed-by-veno2026-10-19 https://evidence-hub.com/study/10719-surgical-management-of-odontogenic-myxomas-a-case-series2026-10-19 https://evidence-hub.com/study/10720-pimavanserin-treatment-for-psychosis-in-patients-with-dementia-with2026-10-19 https://evidence-hub.com/study/10721-encephalitis-as-a-clinical-manifestation-of-covid-19-a-case-series2026-10-19 https://evidence-hub.com/study/10722-evaluation-of-diode-laser-efficacy-in-treating-benign-oral-soft2026-10-19 https://evidence-hub.com/study/10723-successful-use-of-dupilumab-in-recalcitrant-pediatric-atopic2026-10-19 https://evidence-hub.com/study/10724-retroperitoneal-ganglioneuroma-a-five-case-series-from-a-single2026-10-19 https://evidence-hub.com/study/10725-the-c-cat-sign-may-predict-coronary-artery-perforation-in-severe2026-10-19 https://evidence-hub.com/study/10726-vein-of-galen-malformations-in-the-newborn-case-series2026-10-19 https://evidence-hub.com/study/10727-jak-inhibitors-as-rescue-therapy-in-dupilumab-refractory-severe2026-10-19 https://evidence-hub.com/study/10728-sarcoidosis-following-covid-infection-a-case-series2026-10-19 https://evidence-hub.com/study/10729-intracardiac-echocardiography-probe-via-oesophageal-to-guide2026-10-19 https://evidence-hub.com/study/10730-utilization-of-watchman-flx-for-surgically-incomplete-left-atrial2026-10-19 https://evidence-hub.com/study/10731-clinicopathological-features-of-dysembryoplastic-neuroepithelial2026-10-19 https://evidence-hub.com/study/10732-hidradenitis-suppurativa-flares-following-covid-19-vaccination-a-case2026-10-19 https://evidence-hub.com/study/10733-alleviation-of-post-covid-19-cognitive-deficits-by-treatment-with-egb2026-10-19 https://evidence-hub.com/study/10734-use-of-a-smartphone-electrocardiogram-to-diagnose-arrhythmias-during2026-10-19 https://evidence-hub.com/study/10735-cardiac-manifestations-of-igg4-related-disease-a-case-series2026-10-19 https://evidence-hub.com/study/10736-secondary-osteonecrosis-of-the-knee-as-a-part-of-long-covid-192026-10-19 https://evidence-hub.com/study/10737-acute-pericarditis-leading-to-a-diagnosis-of-sle-a-case-series-of-32026-10-19 https://evidence-hub.com/study/10738-the-multifaceted-presentation-of-syphilitic-chorioretinitis-examined2026-10-19 https://evidence-hub.com/study/10739-may-thurner-syndrome-in-patients-with-postural-orthostatic2026-10-19 https://evidence-hub.com/study/10740-implantation-of-diffractive-extended-depth-of-focus-intraocular2026-10-19 https://evidence-hub.com/study/10741-topical-human-recombinant-nerve-growth-factor-for-stage-12026-10-19 https://evidence-hub.com/study/10742-catheter-ablation-induced-phrenic-nerve-palsy-by-pulsed-field2026-10-19 https://evidence-hub.com/study/10743-ibrutinib-related-uveitis-a-case-series2026-10-19 https://evidence-hub.com/study/10744-malignancies-in-patients-with-cystic-fibrosis-a-case-series2026-10-19 https://evidence-hub.com/study/10745-vernix-caseosa-peritonitis-causing-acute-abdomen-after-cesarean2026-10-19 https://evidence-hub.com/study/10746-anaplastic-multiple-myeloma-case-series-and-literature-review2026-10-19 https://evidence-hub.com/study/10747-autologous-conditioned-serum-orthokine-injection-for-treatment-of2026-10-19 https://evidence-hub.com/study/10748-a-case-series-of-acne-following-janus-kinase-inhibitors-in-patients2026-10-19 https://evidence-hub.com/study/10749-a-case-series-of-desmoplakin-cardiomyopathy-a-mimic-of-viral2026-10-19 https://evidence-hub.com/study/10750-putting-drug-resistant-epithelial-herpes-keratitis-in-the-spotlight-a2026-10-19 https://evidence-hub.com/study/10751-malignant-complications-of-celiac-disease-a-case-series-and-review-of2026-10-19 https://evidence-hub.com/study/10752-case-series-of-transcatherter-edge-to-edge-repair-using-mitracliptm2026-10-19 https://evidence-hub.com/study/10753-methanol-poisoning-outbreak-in-saudi-arabia-a-case-series2026-10-19 https://evidence-hub.com/study/10754-chest-pain-and-coronary-endothelial-dysfunction-after-recovery-from2026-10-19 https://evidence-hub.com/study/10755-musculoskeletal-manifestations-of-lymphoma-a-case-series2026-10-19 https://evidence-hub.com/study/10757-ruptured-middle-cerebral-artery-aneurysm-in-an-infant-case-report-and2026-10-19 https://evidence-hub.com/study/10758-a-case-of-refractory-erythromelalgia-treated-successfully-with2026-10-01 https://evidence-hub.com/study/10759-clinicopathological-and-genomic-features-of-pediatric-intracranial2026-10-19 https://evidence-hub.com/study/10760-usefulness-of-a-curved-multiple-reconstruction-image-for2026-10-19 https://evidence-hub.com/study/10761-a-ruptured-aneurysm-in-aplastic-or-twig-like-middle-cerebral-artery-a2026-10-19 https://evidence-hub.com/study/10762-orbital-tuberculosis-in-childhood-with-intracranial-extension-a-case2026-10-06 https://evidence-hub.com/study/10763-persistence-of-primitive-lateral-basilovertebral-anastomosis-with-a2026-10-19 https://evidence-hub.com/study/10764-double-crush-syndrome-of-the-lower-limb-in-l5-radiculopathy-and2026-10-19 https://evidence-hub.com/study/10765-a-ruptured-anterior-communicating-artery-aneurysm-with-infra-optic2026-10-19 https://evidence-hub.com/study/10766-metastasis-of-renal-cell-carcinoma-to-spinal-hemangioblastoma-in-a2026-10-19 https://evidence-hub.com/study/10767-efficacy-of-intra-arterial-indocyanine-green-videoangiography-in2026-10-19 https://evidence-hub.com/study/10768-a-dorsal-arachnoid-web-of-the-cervical-spine-a-case-report2026-10-19 https://evidence-hub.com/study/10769-successful-endovascular-thrombectomy-for-acute-m1-occlusion-in-a2026-10-19 https://evidence-hub.com/study/10770-primary-meningeal-melanocytoma-located-in-the-craniovertebral2026-10-19 https://evidence-hub.com/study/10771-relapse-of-herpes-simplex-encephalitis-by-epilepsy-surgery-35-years2026-10-19 https://evidence-hub.com/study/10772-delayed-occlusion-of-the-anterior-choroidal-artery-following-flow2026-10-19 https://evidence-hub.com/study/10773-ruptured-basilar-artery-perforator-aneurysm-a-case-report-and-review2026-10-19 https://evidence-hub.com/study/10774-intracranial-subdural-abscess-caused-by-actinomyces-meyeri-related-to2026-10-19 https://evidence-hub.com/study/10775-recurrent-cervical-spinal-epidural-hematoma-case-report-and2026-10-19 https://evidence-hub.com/study/10776-intracranial-intra-parenchymal-capillary-hemangioma-case-report2026-10-19 https://evidence-hub.com/study/10777-supraclinoid-internal-carotid-artery-fenestration-with-associated2026-10-19 https://evidence-hub.com/study/10778-primary-central-nervous-system-methotrexate-associated2026-10-19 https://evidence-hub.com/study/10779-who-grade-i-meningioma-metastasis-to-the-lung-26-years-after-initial2026-10-19 https://evidence-hub.com/study/10780-spontaneous-bilateral-cervical-internal-carotid-artery-dissection2026-10-19 https://evidence-hub.com/study/10781-spontaneous-development-of-encapsulated-subdural-hematoma-in-the2026-10-19 https://evidence-hub.com/study/10782-traumatic-pseudoaneurysm-of-the-distal-anterior-cerebral-artery2026-10-19 https://evidence-hub.com/study/10783-mechanical-thrombectomy-for-acute-ischemic-stroke-arising-from2026-10-19 https://evidence-hub.com/study/10784-non-contiguous-meningeal-recurrence-of-olfactory-neuroblastoma-a-case2026-10-19 https://evidence-hub.com/study/10785-nervus-intermedius-neuralgia-treated-with-microvascular-decompression2026-10-19 https://evidence-hub.com/study/10786-incidental-idiopathic-bilateral-pedicle-fracture-case-report-and2026-10-19 https://evidence-hub.com/study/10787-double-crush-of-l5-spinal-nerve-root-due-to-l4-5-lateral-recess2026-10-19 https://evidence-hub.com/study/10788-surgical-treatment-of-rotational-vertebral-artery-syndrome-induced-by2026-10-19 https://evidence-hub.com/study/10789-tiny-falx-meningioma-causing-massive-interhemispheric-subdural2026-10-19 https://evidence-hub.com/study/10790-rapid-recanalization-using-trevoprovue-through-a-4-2-fr-catheter2026-10-19 https://evidence-hub.com/study/10791-chiari-type-1-malformation-induced-intracranial-hypertension-with2026-10-19 https://evidence-hub.com/study/10792-anastomotic-aneurysm-formation-after-high-flow-bypass-surgery-a-case2026-10-19 https://evidence-hub.com/study/10793-heterotopic-gastric-mucosa-in-the-anus-and-rectum-first-case-report2026-10-19 https://evidence-hub.com/study/10794-nontraumatic-pure-acute-subdural-hematoma-caused-by-a-ruptured2026-10-19 https://evidence-hub.com/study/10795-lemierre-syndrome-associated-with-ipsilateral-recurrent-laryngeal2026-10-19 https://evidence-hub.com/study/10796-budd-chiari-syndrome-associated-with-coeliac-disease-case-report-and2026-10-19 https://evidence-hub.com/study/10797-orbital-abducens-nerve-schwannoma-a-case-report-and-review-of-the2026-10-19 https://evidence-hub.com/study/10798-carotid-endarterectomy-for-atherosclerotic-stenosis-associated-with2026-10-19 https://evidence-hub.com/study/10799-central-hypoventilation-syndrome-complicated-with-lateral-medullary2026-10-19 https://evidence-hub.com/study/10800-super-selective-balloon-test-occlusion-of-the-posterior-communicating2026-10-19 https://evidence-hub.com/study/10801-spontaneous-regression-of-inflammatory-pseudotumor-in-the-cauda2026-10-19 https://evidence-hub.com/study/10802-cerebral-infarction-arising-from-takotsubo-cardiomyopathy-case-report2026-10-19 https://evidence-hub.com/study/10803-post-traumatic-unilateral-avulsion-of-the-abducens-nerve-with-damage2026-10-19 https://evidence-hub.com/study/10804-spontaneous-hemorrhage-of-a-spinal-ependymoma-in-the-filum-terminale2026-10-19 https://evidence-hub.com/study/10805-a-case-of-dural-arteriovenous-fistula-in-the-falx-cerebri-case-report2026-10-19 https://evidence-hub.com/study/10806-abdominal-flank-bulging-after-lateral-retroperitoneal-approach-a-case2026-10-19 https://evidence-hub.com/study/10807-neuroendoscopy-via-an-extremely-narrow-foramen-of-monro-a-case-report2026-10-19 https://evidence-hub.com/study/10808-coexistence-of-quasi-moyamoya-disease-and-poems-syndrome-in-a-patient2026-10-19 https://evidence-hub.com/study/10809-surveillance-for-lyme-disease-after-implementation-of-a-revised-case2026-10-19 https://evidence-hub.com/study/10810-malignant-transformation-of-a-neurenteric-cyst-in-the-posterior-fossa2026-10-19 https://evidence-hub.com/study/10811-repetitive-plantar-flexion-provocation-test-for-the-diagnosis-of2026-10-19 https://evidence-hub.com/study/10812-carotid-artery-stenting-in-right-sided-aortic-arch-a-case-report2026-10-19 https://evidence-hub.com/study/10813-remote-cerebellar-hemorrhage-after-supratentorial-burr-hole2026-10-19 https://evidence-hub.com/study/10814-cardiopulmonary-resuscitation-induced-thoracic-vertebral-fracture-a2026-10-19 https://evidence-hub.com/study/10815-a-purely-endoscopic-and-simultaneous-transsphenoidal-and-transcranial2026-10-19 https://evidence-hub.com/study/10816-estimated-effectiveness-of-jynneos-vaccine-in-preventing-mpox-a2026-10-19 https://evidence-hub.com/study/10817-surgical-treatment-of-gorham-s-disease-with-massive-osteolysis-of-the2026-10-19 https://evidence-hub.com/study/10818-esophageal-intramural-pseudodiverticulosis-a-rare-cause-of-food2026-10-19 https://evidence-hub.com/study/10819-double-edged-sword-in-the-placement-of-carmustine-bcnu-wafers-along2026-10-19 https://evidence-hub.com/study/10820-bilateral-paratesticular-liposarcoma-a-rare-case-report2026-10-19 https://evidence-hub.com/study/10821-thrombus-removal-by-acute-phase-endovascular-reperfusion-therapy-to2026-10-19 https://evidence-hub.com/study/10822-bow-hunter-s-stroke-due-to-stretching-of-the-vertebral-artery2026-10-19 https://evidence-hub.com/study/10823-primary-sellar-neuroblastoma-in-an-elderly-patient-case-report2026-10-19 https://evidence-hub.com/study/10824-primary-intracerebral-alveolar-soft-part-sarcoma-in-an-11-year-old2026-10-19 https://evidence-hub.com/study/10825-coronavirus-disease-2019-case-surveillance-united-states-january-222026-10-19 https://evidence-hub.com/study/10826-case-series-of-multisystem-inflammatory-syndrome-in-adults-associated2026-10-19 https://evidence-hub.com/study/10827-follicular-thyroid-carcinoma-presenting-as-massive-skull-metastasis-a2026-10-19 https://evidence-hub.com/study/10828-spontaneous-epidural-haematoma-in-sickle-cell-anaemia-case-report-and2026-10-19 https://evidence-hub.com/study/10829-urinary-and-genital-tract-obstruction-as-a-complication-of-female2026-10-19 https://evidence-hub.com/study/10830-encysted-hydrocele-of-canal-of-nuck-a-case-report-with-review-of2026-10-19 https://evidence-hub.com/study/10831-public-health-response-to-a-case-of-paralytic-poliomyelitis-in-an2026-10-19 https://evidence-hub.com/study/10832-the-care-guidelines-consensus-based-clinical-case-reporting-guideline2026-10-19 https://evidence-hub.com/study/10833-wastewater-testing-and-detection-of-poliovirus-type-2-genetically2026-10-19 https://evidence-hub.com/study/10839-locally-infiltrative-inflammatory-fibroid-polyp-of-the-ileum-report2026-10-19 https://evidence-hub.com/study/10840-covid-19-case-investigation-and-contact-tracing-efforts-from-health2026-10-19 https://evidence-hub.com/study/10841-case-of-a-pregnant-woman-with-capillary-hemangioma-of-the-parasellar2026-10-19 https://evidence-hub.com/study/10842-pediatric-thymoma-with-a-difference-report-of-a-case-and-review-of2026-10-19 https://evidence-hub.com/study/10843-measles-update-united-states-january-1-april-17-20252026-10-19 https://evidence-hub.com/study/10844-a-case-of-dermoid-cyst-arising-in-the-temporal-lobe2026-10-19 https://evidence-hub.com/study/10845-the-prisma-2020-statement-an-updated-guideline-for-reporting2026-10-19 https://evidence-hub.com/study/10846-revised-surgical-case-report-scare-guideline-an-update-for-the-age-of2026-10-19 https://evidence-hub.com/study/10848-2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of2026-10-19 https://evidence-hub.com/study/10849-the-prisma-2020-statement-an-updated-guideline-for-reporting2026-10-19 https://evidence-hub.com/study/10850-2022-aha-acc-hfsa-guideline-for-the-management-of-heart-failure-a2026-10-19 https://evidence-hub.com/study/10851-consort-2025-statement-updated-guideline-for-reporting-randomised2026-10-19 https://evidence-hub.com/study/10852-the-tripod-llm-reporting-guideline-for-studies-using-large-language2026-10-19 https://evidence-hub.com/study/10854-the-scare-2020-guideline-updating-consensus-surgical-case-report2026-10-19 https://evidence-hub.com/study/10855-the-scare-2023-guideline-updating-consensus-surgical-case-report2026-10-19 https://evidence-hub.com/study/10856-espen-guideline-on-clinical-nutrition-in-surgery-update-20252026-10-19 https://evidence-hub.com/study/10857-global-guideline-for-the-diagnosis-and-management-of-candidiasis-an2026-10-19 https://evidence-hub.com/study/10858-spirit-2025-statement-updated-guideline-for-protocols-of-randomised2026-10-19 https://evidence-hub.com/study/10860-consort-2025-statement-updated-guideline-for-reporting-randomized2026-10-19 https://evidence-hub.com/study/10861-the-2024-uk-clinical-guideline-for-the-prevention-and-treatment-of2026-10-19 https://evidence-hub.com/study/10862-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of2026-10-19 https://evidence-hub.com/study/10863-cosmin-guideline-for-systematic-reviews-of-patient-reported-outcome2026-10-19 https://evidence-hub.com/study/10865-2018-guidelines-for-the-early-management-of-patients-with-acute2026-10-19 https://evidence-hub.com/study/10866-spirit-2025-explanation-and-elaboration-updated-guideline-for2026-10-19 https://evidence-hub.com/study/10867-2018-aha-acc-aacvpr-aapa-abc-acpm-ada-ags-apha-aspc-nla-pcna2026-10-19 https://evidence-hub.com/study/10868-2019-acc-aha-guideline-on-the-primary-prevention-of-cardiovascular2026-10-19 https://evidence-hub.com/study/10869-evidence-based-guideline-for-the-diagnosis-and-treatment-of2026-10-19 https://evidence-hub.com/study/10870-global-guideline-for-the-diagnosis-and-management-of-cryptococcosis2026-10-19 https://evidence-hub.com/study/10871-2024-guideline-for-the-primary-prevention-of-stroke-a-guideline-from2026-10-19 https://evidence-hub.com/study/10872-palliative-care-for-patients-with-cancer-asco-guideline-update2026-10-19 https://evidence-hub.com/study/10873-2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for2026-10-19 https://evidence-hub.com/study/10874-idiopathic-pulmonary-fibrosis-an-update-and-progressive-pulmonary2026-10-19 https://evidence-hub.com/study/10875-cdc-clinical-practice-guideline-for-prescribing-opioids-for-pain2026-10-19 https://evidence-hub.com/study/10876-2023-aha-acc-accp-aspc-nla-pcna-guideline-for-the-management-of2026-10-19 https://evidence-hub.com/study/10879-the-strocss-2024-guideline-strengthening-the-reporting-of-cohort2026-10-19 https://evidence-hub.com/study/10881-2023-guideline-for-the-management-of-patients-with-aneurysmal2026-10-19 https://evidence-hub.com/study/10882-press-peer-review-of-electronic-search-strategies-2015-guideline2026-10-19 https://evidence-hub.com/study/10883-espen-practical-and-partially-revised-guideline-clinical-nutrition-in2026-10-19 https://evidence-hub.com/study/10884-recommendations-from-the-2023-international-evidence-based-guideline2026-10-19 https://evidence-hub.com/study/10885-the-european-guideline-on-management-of-major-bleeding-and2026-10-19 https://evidence-hub.com/study/10886-espen-guideline-on-clinical-nutrition-in-inflammatory-bowel-disease2026-10-19 https://evidence-hub.com/study/10887-2019-american-college-of-rheumatology-arthritis-foundation-guideline2026-10-19 https://evidence-hub.com/study/10888-diagnosis-of-idiopathic-pulmonary-fibrosis-an-official-ats-ers-jrs2026-10-19 https://evidence-hub.com/study/10889-2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of2026-10-19 https://evidence-hub.com/study/10890-2023-chinese-guideline-for-lipid-management2026-10-19 https://evidence-hub.com/study/10891-eshre-guideline-endometriosis2026-10-19 https://evidence-hub.com/study/10892-the-european-insomnia-guideline-an-update-on-the-diagnosis-and2026-10-19 https://evidence-hub.com/study/10893-future-ai-international-consensus-guideline-for-trustworthy-and2026-10-19 https://evidence-hub.com/study/10894-cdc-guideline-for-prescribing-opioids-for-chronic-pain-united-states2026-10-19 https://evidence-hub.com/study/10895-evidence-based-guideline-premature-ovarian-insufficiency2026-10-19 https://evidence-hub.com/study/10897-s2k-guideline-lipedema2026-10-19 https://evidence-hub.com/study/10899-kdoqi-clinical-practice-guideline-for-vascular-access-2019-update2026-10-19 https://evidence-hub.com/study/10900-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic2026-10-19 https://evidence-hub.com/study/10902-biological-drivers-of-imid-induced-peripheral-neuropathy-in-multiple2026-10-06 https://evidence-hub.com/study/10903-a-year-in-pharmacology-new-drugs-approved-by-the-us-food-and-drug2026-10-01 https://evidence-hub.com/study/10904-neuropharmacology-and-physiology-of-human-dorsal-root-ganglion2026-10-01 https://evidence-hub.com/study/10905-latest-developments-in-small-molecule-analgesics-heterocyclic2026-10-01 https://evidence-hub.com/study/10906-opioid-use-following-spine-surgery-strategies-for-a-multimodal2026-10-06 https://evidence-hub.com/study/10907-nanomedicine-against-oxaliplatin-induced-peripheral-neuropathy2026-10-01 https://evidence-hub.com/study/10908-the-economic-burden-of-opioid-related-serious-adverse-events-and2026-10-06 https://evidence-hub.com/study/10909-pain-medication-in-chronic-low-back-pain2026-10-01 https://evidence-hub.com/study/10910-fda-approved-drugs-containing-amide-functionality-in-the-last-five2026-10-06 https://evidence-hub.com/study/10911-the-pharmaceutical-industry-in-2025-an-analysis-of-fda-drug-approvals2026-10-06 https://evidence-hub.com/study/10912-centrally-acting-skeletal-muscle-relaxants-sharing-molecular-targets2026-10-01 https://evidence-hub.com/study/10913-decoding-chemotherapy-induced-peripheral-neuropathy-ion-channels2026-10-01 https://evidence-hub.com/study/10914-opiophobia-misinformation-misconceptions-misrepresentations2026-10-06 https://evidence-hub.com/study/10915-mechanisms-of-pain-occurrence-in-osteoarthritis-peripheral-triggers2026-10-01 https://evidence-hub.com/study/10916-dezocine-and-addiction-friend-or-foe2026-10-06 https://evidence-hub.com/study/10917-engineering-nanoscale-drug-delivery-systems-for-pain2026-10-06 https://evidence-hub.com/study/10918-cellular-and-molecular-basis-of-neuropathic-pain2026-10-06 https://evidence-hub.com/study/10919-single-cell-and-single-nucleus-transcriptomics-of-the-dorsal-root2026-10-01 https://evidence-hub.com/study/10920-personalizing-treatment-of-pancreatitis-associated-chronic-pain-the2026-10-01 https://evidence-hub.com/study/10921-medicinal-chemistry-perspectives-on-pfas-in-drug-design-fluorinated2026-10-06 https://evidence-hub.com/study/10922-mechanism-based-nonopioid-analgesic-targets2026-10-06 https://evidence-hub.com/study/10923-decoding-orofacial-pain-a-translational-review-of-mechanisms-and2026-10-01 https://evidence-hub.com/study/10924-vinpocetine-an-old-drug-with-a-new-face-moving-toward-a-better2026-10-01 https://evidence-hub.com/study/10925-trigeminal-neuralgia-from-clinical-challenges-to-molecular-insights2026-10-06 https://evidence-hub.com/study/10926-current-and-developing-therapeutics-for-dry-eye-disease-targeting-ion2026-10-01 https://evidence-hub.com/study/10927-management-of-patients-with-opioid-use-disorder-oud2026-10-06 https://evidence-hub.com/study/10928-chronic-pain-epidemiology-pathophysiology-and-clinical-management2026-10-08 https://evidence-hub.com/study/10929-stinging-salvation-harnessing-scorpion-venom-peptides-for2026-10-01 https://evidence-hub.com/study/10930-mechanisms-for-reducing-eliminating-chronic-neuropathic-pain-with-a2026-10-01 https://evidence-hub.com/study/10931-neural-tumor-crosstalk-and-molecular-targeting-mechanisms-and2026-10-06 https://evidence-hub.com/study/10932-ectopic-nociceptor-sprouting-as-a-key-peripheral-driver-of-pain-in2026-10-01 https://evidence-hub.com/study/10933-effectiveness-of-physical-therapy-techniques-for-cancer-related-pain2026-10-01 https://evidence-hub.com/study/10934-sensory-neuroimmunology-bidirectional-neuro-immune-circuits-governing2026-10-01 https://evidence-hub.com/study/10935-modulation-of-ion-channels-as-emerging-therapeutic-targets-in-the2026-10-06 https://evidence-hub.com/study/10936-innovative-strategies-for-diabetic-peripheral-neuropathy-from2026-10-06 https://evidence-hub.com/study/10937-human-pain-transcriptomics-lessons-learned-so-far2026-10-06 https://evidence-hub.com/study/10938-voltage-gated-sodium-channels-in-excitable-cells-as-drug-targets2026-10-06 https://evidence-hub.com/study/10939-sodium-channels-as-a-new-target-for-pain-treatment2026-10-06 https://evidence-hub.com/study/10940-narrative-review-on-postoperative-pain-management-following-spine2026-10-01 https://evidence-hub.com/study/10941-exploring-novel-non-opioid-pathways-and-therapeutics-for-pain2026-10-06 https://evidence-hub.com/study/10942-suzetrigine-mechanism-efficacy-and-clinical-implications-a-narrative2026-09-27 https://evidence-hub.com/study/10944-review-of-physiology-pathology-and-pharmacology-of-voltage-gated2026-10-01 https://evidence-hub.com/study/10945-recent-advances-and-practical-strategies-in-opioid-free-multimodal2026-10-01 https://evidence-hub.com/study/10946-neurobiology-of-cancer-pain-a-narrative-review2026-09-27 https://evidence-hub.com/study/10947-innovative-strategies-to-pelvic-trauma-pain-management-a-systematic2026-10-01 https://evidence-hub.com/study/10948-structural-and-functional-basis-of-antinociceptive-action-of2026-10-01 https://evidence-hub.com/study/10949-enhancing-chemical-stability-and-bioavailability-of-aneratrigine2026-10-06 https://evidence-hub.com/study/10950-two-pore-domain-thik2-potassium-channels-regulate-acute-and-chronic2026-10-06 https://evidence-hub.com/study/10951-human-1-antitrypsin-inhibits-nociceptor-excitability-and-relieves2026-10-06 https://evidence-hub.com/study/10952-discovery-of-a-peripherally-restricted-2aar-agonist-as-a-safe-and2026-10-06 https://evidence-hub.com/study/10953-paeoniflorin-as-a-candidate-disease-modifying-therapy-for-diabetic2026-10-06 https://evidence-hub.com/study/10954-targeting-supramolecular-active-complexes-of-nav1-7-nav1-8-to-relieve2026-10-06 https://evidence-hub.com/study/10955-reducing-postoperative-opioids-after-minimally-invasive-hysterectomy2026-10-06 https://evidence-hub.com/study/10956-suzetrigine-vx-548-for-postoperative-pain2026-10-01 https://evidence-hub.com/study/10957-a-quality-improvement-initiative-evaluating-suzetrigine-as-a-strategy2026-10-01 https://evidence-hub.com/study/10958-suzetrigine-journavx-first-in-class-nav1-8-sodium-channel-blocker2026-10-06 https://evidence-hub.com/study/10959-inhibiting-nav1-8-for-pain-lessons-from-patients-and-from-neurons2026-10-06 https://evidence-hub.com/study/10960-pilot-study-to-evaluate-the-efficacy-of-autogenic-training-in2026-10-06 https://evidence-hub.com/study/10961-oral-mucosal-lesions-in-patients-with-sars-cov-2-infection-report-of2026-10-19 https://evidence-hub.com/study/10962-oral-health-care-for-patients-with-alzheimer-s-disease-an-update2026-10-19 https://evidence-hub.com/study/10963-radiotherapy-induced-oral-morbidities-in-head-and-neck-cancer-patients2026-10-19 https://evidence-hub.com/study/10964-exploring-the-attitude-of-patients-with-hiv-about-using-telehealth2026-10-19 https://evidence-hub.com/study/10965-hiv-risk-and-pre-exposure-prophylaxis-eligibility-among-emergency2026-10-19 https://evidence-hub.com/study/10966-why-are-patients-switching-from-tenofovir-disoproxil-fumarate2026-10-19 https://evidence-hub.com/study/10968-metabolic-syndrome-among-antiretroviral-therapy-naive-versus2026-10-19 https://evidence-hub.com/study/10969-effect-of-tenofovir-disoproxil-fumarate-on-incidence-of-chronic2026-10-19 https://evidence-hub.com/study/10970-halitosis-in-covid-19-patients2026-10-19 https://evidence-hub.com/study/10971-patients-with-head-and-neck-cancers-oral-health-knowledge-oral-health2026-10-19 https://evidence-hub.com/study/10972-predicting-the-need-for-third-line-antiretroviral-therapy-by2026-10-19 https://evidence-hub.com/study/10973-barriers-to-hiv-treatment-adherence-a-qualitative-study-of2026-10-19 https://evidence-hub.com/study/10975-a-health-related-quality-of-life-measure-for-use-in-patients-with-hiv2026-10-19 https://evidence-hub.com/study/10977-oral-health-status-in-pediatric-patients-with-cerebral-palsy-fed-by2026-10-19 https://evidence-hub.com/study/10978-oral-health-in-end-of-life-patients-a-rapid-review2026-10-19 https://evidence-hub.com/study/10979-oral-health-care-for-patients-with-developmental-disabilities-a2026-10-19 https://evidence-hub.com/study/10984-prevalence-and-predictors-of-hepatic-steatosis-in-patients-with-hiv2026-10-19 https://evidence-hub.com/study/10985-using-hiv-risk-prediction-tools-to-identify-candidates-for-pre2026-10-19 https://evidence-hub.com/study/10986-a-mixed-methods-approach-to-understanding-antiretroviral-treatment2026-10-19 https://evidence-hub.com/study/10987-virological-outcome-after-choice-of-antiretroviral-regimen-guided-by2026-10-19 https://evidence-hub.com/study/10993-long-acting-injectable-antiretrovirals-for-hiv-treatment-a-multi-site2026-10-19 https://evidence-hub.com/study/10994-implementation-of-a-pharmacist-led-long-acting-injectable2026-10-19 https://evidence-hub.com/study/11001-nav1-8-and-chronic-pain-from-laboratory-animals-to-clinical-patients2026-10-01 https://evidence-hub.com/study/11002-novel-drug-approvals-20242026-10-01 https://evidence-hub.com/study/11003-is-an-opioid-prescription-necessary-after-joint-replacement-in-20262026-09-27 https://evidence-hub.com/study/11004-post-discharge-opioid-consumption-in-tka-and-tha-patients-receiving2026-10-06 https://evidence-hub.com/study/11005-suzetrigine-is-it-the-new-weapon-of-multimodal-analgesia2026-10-01 https://evidence-hub.com/study/11006-suzetrigine-as-a-novel-non-opioid-analgesic-reducing-postoperative2026-09-27 https://evidence-hub.com/study/11007-suzetrigine-for-pediatric-sickle-cell-disease-vaso-occlusive-crisis2026-09-27 https://evidence-hub.com/study/11008-suzetrigine-in-acute-pain-treatment-a-review-of-current-evidence-and2026-10-01 https://evidence-hub.com/study/11009-characterizing-the-role-of-suzetrigine-drug-as-a-non-opioid-analgesic2026-09-27 https://evidence-hub.com/study/11010-sheep-as-a-large-animal-model-for-hearing-research-comparison-to2026-10-19 https://evidence-hub.com/study/11013-assessing-animal-welfare-impact-of-fourteen-control-and-dispatch2026-10-06 https://evidence-hub.com/study/11015-e-cow-an-animal-model-that-predicts-herbage-intake-milk-yield-and2026-10-19 https://evidence-hub.com/study/11016-animal-models-of-stroke2026-10-19 https://evidence-hub.com/study/11018-development-of-a-type-ii-diabetic-mellitus-animal-model-using-micropig2026-10-19 https://evidence-hub.com/study/11019-animal-board-invited-review-meta-analysis-of-genetic-parameters-for2026-10-19 https://evidence-hub.com/study/11020-experimental-animal-models-of-pulmonary-hypertension-development-and2026-10-19 https://evidence-hub.com/study/11021-male-wistar-rats-show-individual-differences-in-an-animal-model-of2026-10-19 https://evidence-hub.com/study/11022-animal-models-zoonotic-reservoirs-and-cross-species-transmission-of2026-10-19 https://evidence-hub.com/study/11023-preclinical-animal-studies-in-ischemic-stroke-challenges-and-some2026-10-06 https://evidence-hub.com/study/11025-energy-based-step-selection-analysis-modelling-the-energetic-drivers2026-10-06 https://evidence-hub.com/study/11028-evaluating-evidence-from-animal-models-of-episodic-memory2026-10-19 https://evidence-hub.com/study/11029-animal-models-to-study-the-neurological-manifestations-of-the-post2026-10-19 https://evidence-hub.com/study/11031-characteristics-of-animal-models-for-covid-192026-10-19 https://evidence-hub.com/study/11033-incorporation-of-genotype-effects-into-animal-model-evaluations-when2026-10-19 https://evidence-hub.com/study/11041-maternal-animal-model-with-correlation-between-maternal-environmental2026-10-19 https://evidence-hub.com/study/11053-threshold-linear-versus-linear-linear-analysis-of-birth-weight-and2026-10-19 https://evidence-hub.com/study/11063-using-the-relational-event-model-rem-to-investigate-the-temporal2026-10-19 https://evidence-hub.com/study/11064-animal-models-of-osteoarthritis-in-small-mammals2026-10-19 https://evidence-hub.com/study/11065-experimental-animal-models-for-diabetes-and-its-related-complications2026-10-19 https://evidence-hub.com/study/11066-animal-models-of-acute-gastric-mucosal-injury-macroscopic-and2026-10-19 https://evidence-hub.com/study/11068-review-animal-health-and-sustainable-global-livestock-systems2026-10-19 https://evidence-hub.com/study/11070-asas-nanp-symposium-mathematical-modeling-in-animal-nutrition2026-10-19 https://evidence-hub.com/study/11071-animal-models-for-cystic-fibrosis-a-systematic-search-and-mapping2026-10-06 https://evidence-hub.com/study/11072-why-are-most-eu-pigs-tail-docked-economic-and-ethical-analysis-of2026-10-19 https://evidence-hub.com/study/11073-animal-models-in-the-study-of-alzheimer-s-disease-and-parkinson-s2026-10-19 https://evidence-hub.com/study/11074-hepatitis-e-virus-animal-models-and-zoonosis2026-10-19 https://evidence-hub.com/study/11075-accounting-for-genetic-differences-among-unknown-parents-in2026-10-19 https://evidence-hub.com/study/11078-biomarkers-of-gastrointestinal-functionality-in-animal-nutrition-and2026-10-19 https://evidence-hub.com/study/11079-preclinical-animal-models-to-investigate-the-role-of-nav1-7-ion2026-10-01 https://evidence-hub.com/study/11080-voltage-gated-ion-channels-in-neuropathic-pain-signaling2026-10-01 https://evidence-hub.com/study/11081-suzetrigine-a-selective-inhibitor-of-the-nav1-8-sodium-channel2026-10-01 https://evidence-hub.com/study/11082-fda-original-new-drug-approvals-in-the-first-quarter-of-20252026-10-01 https://evidence-hub.com/study/11083-nav1-8-intrinsic-limits-on-the-functional-effect-of-abrogation-in-drg2026-10-01 https://evidence-hub.com/study/11084-extended-osteoarthritis-pain-relief-with-neosaxitoxin-using-alginate2026-10-01 https://evidence-hub.com/study/11085-nav1-8-trpv1-and-trpa1-as-possible-targets-of-ambroxol-when-used-for2026-10-01 https://evidence-hub.com/study/11086-voltage-gated-sodium-channels-nav-in-gtopdb-v-2025-42026-10-01 https://evidence-hub.com/study/11088-applications-of-artificial-intelligence-in-drug-discovery-for2026-10-01 https://evidence-hub.com/study/11089-diabetic-peripheral-neuropathy-mechanisms-and-emerging-therapies2026-10-01 https://evidence-hub.com/study/11090-spinal-neuron-glial-crosstalk-and-ion-channel-dysregulation-in2026-10-01 https://evidence-hub.com/study/11091-assessing-nav1-7-during-tonic-firing-in-pig-c-nociceptors2026-10-01 https://evidence-hub.com/study/11092-nav1-8-variant-i206m-as-a-latent-susceptibility-factor-in-postaxotomy2026-10-01 https://evidence-hub.com/study/11093-pain-chronicity-and-relief-from-molecular-basis-to-exercise-based2026-10-01 https://evidence-hub.com/study/11094-biophysical-dissection-of-nociceptor-hyperexcitability-caused-by-a2026-10-01 https://evidence-hub.com/study/11095-roles-of-ion-channels-in-oligodendrocyte-precursor-cells-from2026-10-01 https://evidence-hub.com/study/11096-neuropathic-pain-proposal-of-a-mechanism-based-treatment2026-10-01 https://evidence-hub.com/study/11097-contusive-spinal-cord-injury-causes-nav1-8-dysfunction-to-upregulate2026-10-01 https://evidence-hub.com/study/11098-cost-effectiveness-of-a-high-concentration-179-mg-capsaicin-patch-for2026-10-01 https://evidence-hub.com/study/11099-non-canonical-sodium-channel-isoforms-underlie-chamber-specific2026-10-01 https://evidence-hub.com/study/11101-sodium-channel-isoform-diversity-underlies-chamber-specific-cardiac2026-10-01 https://evidence-hub.com/study/11102-novel-nonopioid-analgesics-for-postoperative-pain2026-10-01 https://evidence-hub.com/study/11103-potential-modulation-of-pain-perception-in-animal-models-of-acute2026-10-01 https://evidence-hub.com/study/11104-functional-expression-of-the-t-type-cav3-2-calcium-channel-in-female2026-10-01 https://evidence-hub.com/study/11105-two-pore-domain-thik2-channel-is-involved-in-acute-and-chronic-pain2026-10-01 https://evidence-hub.com/study/11106-voltage-gated-sodium-channel-1-8-contributes-to-hyperalgesia-induced2026-10-01 https://evidence-hub.com/study/11107-detection-of-probable-neuronal-gene-expression-changes-in-skin2026-10-01 https://evidence-hub.com/study/11108-elife-assessment-modulation-of-human-dorsal-root-ganglion-neuron2026-10-06 https://evidence-hub.com/study/11109-author-response-modulation-of-human-dorsal-root-ganglion-neuron2026-10-06 https://evidence-hub.com/study/11110-reviewer-3-public-review-modulation-of-human-dorsal-root-ganglion2026-10-06 https://evidence-hub.com/study/11111-the-psychoactive-cannabinoid-thc-inhibits-peripheral-nociceptors-by2026-10-01 https://evidence-hub.com/study/11112-in-vitro-inhibition-of-voltage-dependent-sodium-currents-by-the2026-10-01 https://evidence-hub.com/study/11113-janus-nanomotors-for-topical-treatment-of-radiation-induced-dermatitis2026-10-01 https://evidence-hub.com/study/11114-druggable-tumor-nerve-immune-circuits-in-cancer-pain-model-systems2026-10-01 https://evidence-hub.com/study/11115-electrophysiological-characterization-of-the-venom-and-toxins-from2026-10-01 https://evidence-hub.com/study/11116-a-small-lipidated-peptide-targeting-na-v-1-8-channels-attenuates2026-10-01 https://evidence-hub.com/study/11117-myotonic-muscle-activity-drives-a-persistent-pain-state-responsive-to2026-10-01 https://evidence-hub.com/study/11118-journal-related-activities-and-other-special-activities-at-the-20242026-09-27 https://evidence-hub.com/study/11119-modelling-neuropathic-pain-in-vitro-a-multimodal-approach-using2026-10-01 https://evidence-hub.com/study/11121-high-throughput-screening-for-next-generation-analgesics-charting-non2026-10-01 https://evidence-hub.com/study/11123-preferential-innervation-of-endometriosis-by-hyperexcitable-ret-gfr-12026-10-01 https://evidence-hub.com/study/11124-antigen-detected-nmr-for-minimal-epitope-engineering-and-structure2026-10-01 https://evidence-hub.com/study/11125-functional-characterization-of-human-ipsc-derived-sensory-neuron2026-10-01 https://evidence-hub.com/study/11126-the-rise-and-fall-of-trpv1-targeted-analgesia-in-osteoarthritis-a2026-10-01 https://evidence-hub.com/study/11127-genome-wide-association-analysis-of-two-pore-domain-potassium-channel2026-10-01 https://evidence-hub.com/study/11128-g-protein-coupled-receptor-positive-allosteric-modulators-for-chronic2026-10-01 https://evidence-hub.com/study/11129-ethical-challenges-of-acute-pain-management-a-scoping-review2026-10-06 https://evidence-hub.com/study/11130-voltage-gated-sodium-channels-in-the-nervous-system-molecular2026-10-06 https://evidence-hub.com/study/11131-tnf-exacerbates-postoperative-plantar-pain-by-regulating-the2026-10-06 https://evidence-hub.com/study/11132-humanized-nav1-8-rats-overcome-cross-species-potency-shifts-in2026-10-06 https://evidence-hub.com/study/11133-quinoline-based-neuropilin-1-antagonists-exhibit-a-pure-antagonist2026-10-06 https://evidence-hub.com/study/11134-loss-of-glutaminase-1-in-small-sensory-neurons-prevents-nerve-injury2026-10-06 https://evidence-hub.com/study/11135-anacyphrethines-a-and-b-as-potent-analgesics-multiple-ion-channel2026-10-06 https://evidence-hub.com/study/11136-macronutrient-balance-determines-the-human-gut-microbiome-eubiosis2026-10-06 https://evidence-hub.com/study/11137-exploring-the-fate-of-listeria-monocytogenes-in-an-in-vitro-digestion2026-10-06 https://evidence-hub.com/study/11138-effects-of-uv-filters-2-ethylhexyl-4-methoxycinnamate-and2026-10-19 https://evidence-hub.com/study/11140-the-role-of-cacao-powder-in-enhancing-skin-moisture-and-reducing2026-10-19 https://evidence-hub.com/study/11141-in-vitro-cultured-meat-nutritional-aspects-for-the-health-and-safety2026-10-19 https://evidence-hub.com/study/11142-in-vitro-synergistic-inhibitory-effects-of-plant-extract-combinations2026-10-19 https://evidence-hub.com/study/11143-a-narrative-review-of-in-vitro-studies-on-the-role-of-reactive-oxygen2026-10-19 https://evidence-hub.com/study/11144-effects-of-3-3-4-4-5-pentachlorobiphenyl-on-in-vitro-oocyte2026-10-19 https://evidence-hub.com/study/11146-in-vitro-characterization-of-narciclasine-solubility-metabolic2026-10-19 https://evidence-hub.com/study/11150-cheong-sang-bang-pung-san-alleviated-hepatic-lipid-accumulation-by2026-10-19 https://evidence-hub.com/study/11154-an-engineered-probiotic-produces-a-type-iii-interferon-ifnl1-and2026-10-19 https://evidence-hub.com/study/11155-observation-of-curcumin-loaded-hydroxypropyl-methyl-cellulose-hpmc2026-10-19 https://evidence-hub.com/study/11156-advanced-in-vitro-models-microglia-in-action2026-10-19 https://evidence-hub.com/study/11157-antioxidant-effects-of-turmeric-leaf-extract-against-hydrogen2026-10-19 https://evidence-hub.com/study/11158-in-vitro-anti-inflammatory-and-antibiofilm-activities-of-bacterial2026-10-19 https://evidence-hub.com/study/11159-understanding-protein-digestion-in-infants-and-the-elderly-current-in2026-10-19 https://evidence-hub.com/study/11160-edp-938-a-novel-nucleoprotein-inhibitor-of-respiratory-syncytial2026-10-19 https://evidence-hub.com/study/11161-egcg-a-green-tea-polyphenol-inhibits-human-coronavirus-replication-in2026-10-19 https://evidence-hub.com/study/11162-inhibition-of-sars-cov-2-virus-entry-by-the-crude-polysaccharides-of2026-10-19 https://evidence-hub.com/study/11163-robust-three-dimensional-3d-expansion-of-bovine-intestinal-organoids2026-10-19 https://evidence-hub.com/study/11164-blastocyst-development-after-fertilization-with-in-vitro-spermatids2026-10-19 https://evidence-hub.com/study/11165-in-vitro-and-in-vivo-photoprotective-effects-of-loliode-isolated-from2026-10-19 https://evidence-hub.com/study/11166-inhibitory-effects-of-gold-and-silver-nanoparticles-on-the2026-10-19 https://evidence-hub.com/study/11167-in-vitro-synergism-of-azithromycin-combination-with-antibiotics2026-10-19 https://evidence-hub.com/study/11168-comparison-of-the-in-vitro-protein-digestibility-of-protaetia2026-10-19 https://evidence-hub.com/study/11169-in-vitro-screening-of-east-asian-plant-extracts-for-potential-use-in2026-10-19 https://evidence-hub.com/study/11170-assessment-of-metabolic-interaction-between-repaglinide-and-quercetin2026-10-19 https://evidence-hub.com/study/11171-tea-polyphenols-egcg-and-theaflavin-inhibit-the-activity-of-sars-cov2026-10-19 https://evidence-hub.com/study/11172-antioxidant-potential-of-sulfated-polysaccharides-from-padina-boryana2026-10-19 https://evidence-hub.com/study/11173-in-vitro-anticancer-effects-of-ji017-on-two-prostate-cancer-cell2026-10-19 https://evidence-hub.com/study/11174-heme-oxygenase-1-exerts-antiviral-activity-against-hepatitis-a-virus2026-10-19 https://evidence-hub.com/study/11175-in-situ-one-step-fluorescence-labeling-strategy-of-exosomes-via2026-10-19 https://evidence-hub.com/study/11176-increased-protein-digestibility-of-beef-with-aging-in-an-infant-in2026-10-16 https://evidence-hub.com/study/11178-effects-of-lobetyolin-on-xanthine-oxidase-activity-in-vitro-and-in2026-10-19 https://evidence-hub.com/study/11179-in-vitro-synergism-of-rifabutin-with-clarithromycin-imipenem-and2026-10-19 https://evidence-hub.com/study/11180-repeatability-of-intraoral-scanners-for-complete-arch-scan-of2026-10-19 https://evidence-hub.com/study/11181-the-non-saponin-fraction-of-korean-red-ginseng-kgc05p0-decreases2026-10-19 https://evidence-hub.com/study/11182-a-sensitive-hplc-fl-method-to-simultaneously-determine-febuxostat-and2026-10-19 https://evidence-hub.com/study/11183-in-vitro-antidiabetic-effects-and-antioxidant-potential-of-cassia2026-10-19 https://evidence-hub.com/study/11184-a-sensitive-hplc-fld-method-for-the-quantification-of-alpelisib-a2026-10-19 https://evidence-hub.com/study/11186-production-structural-characterization-and-in-vitro-assessment-of-the2026-10-12 https://evidence-hub.com/study/11187-in-vitro-activities-of-carbapenems-in-combination-with-amikacin2026-10-19 https://evidence-hub.com/study/11188-in-vitro-and-in-vivo-anti-cancer-activity-of-silymarin-on-oral-cancer2026-10-19 https://evidence-hub.com/study/11189-viability-of-lactobacillus-plantarum-encapsulated-with-poly-glutamic2026-10-19 https://evidence-hub.com/study/11191-essential-oil-mixture-on-rumen-fermentation-and-microbial-community2026-10-19 https://evidence-hub.com/study/11192-the-postprandial-anti-hyperglycemic-effect-of-pyridoxine-and-its2026-10-19 https://evidence-hub.com/study/11193-melatonin-improves-oocyte-maturation-and-mitochondrial-functions-by2026-10-19 https://evidence-hub.com/study/11194-porcine-reproductive-and-respiratory-syndrome-virus-prrsv-non2026-10-19 https://evidence-hub.com/study/11195-microemulsion-based-hydrogels-for-enhancing-epidermal-dermal2026-10-19 https://evidence-hub.com/study/11196-enamel-anti-demineralization-effect-of-orthodontic-adhesive2026-10-19 https://evidence-hub.com/study/11197-lignans-isolated-from-flower-buds-of-magnolia-fargesii-attenuate2026-10-19 https://evidence-hub.com/study/11198-in-vitro-examination-of-an-oleosome-based-sun-protection-product-on2026-10-19 https://evidence-hub.com/study/11199-original-xpctm-effect-on-salmonella-typhimurium-and-cecal-microbiota2026-10-19 https://evidence-hub.com/study/11201-hif-1-mediated-bmp6-down-regulation-leads-to-hyperproliferation-and2026-10-19 https://evidence-hub.com/study/11204-cmos-biosensors-for-in-vitro-diagnosis-transducing-mechanisms-and2026-10-19 https://evidence-hub.com/study/11206-the-elk3-gata3-axis-orchestrates-invasion-and-metastasis-of-breast2026-10-19 https://evidence-hub.com/study/11208-cryopreservation-of-in-vitro-matured-oocytes-after-ex-vivo-oocyte2026-10-19 https://evidence-hub.com/study/11211-in-vitro-and-in-vivo-anti-allergic-and-anti-inflammatory-effects-of2026-10-19 https://evidence-hub.com/study/11212-an-antioxidant-davallialactone-from-phellinus-baumii-enhances-sperm2026-10-19 https://evidence-hub.com/study/11215-in-vitro-antibacterial-activity-of-selected-medicinal-plants2026-10-06 https://evidence-hub.com/study/11218-evaluation-of-carbonic-anhydrase-ix-as-a-therapeutic-target-for2026-10-19 https://evidence-hub.com/study/11219-an-in-vitro-model-of-latency-and-reactivation-of-varicella-zoster2026-10-19 https://evidence-hub.com/study/11220-in-vitro-interactions-of-antibiotic-combinations-of-colistin2026-10-19 https://evidence-hub.com/study/11222-targeted-ubiquitination-of-na-v-1-8-reduces-sensory-neuronal2026-10-01 https://evidence-hub.com/study/11223-the-iuphar-bps-guide-to-pharmacology-in-20262026-10-01 https://evidence-hub.com/study/11224-recent-advances-in-the-synthesis-of-fluorinated-heterocycles-and-a2026-10-01 https://evidence-hub.com/study/11225-from-a-clinically-relevant-pain-target-to-a-possible-analgesic2026-10-01 https://evidence-hub.com/study/11226-pain-management-beyond-opioids-a-arrestin2-biased-allosteric-gpcr2026-10-01 https://evidence-hub.com/study/11227-combinatorial-logic-of-nav-channels-in-nociceptor-excitability2026-10-01 https://evidence-hub.com/study/11229-biophysical-characterization-of-the-human-nav1-9-sodium-channel-in2026-10-01 https://evidence-hub.com/study/11230-voltage-sensor-trapping-of-cardiac-na-channels-by-mg-protoporphyrin2026-10-01 https://evidence-hub.com/study/11231-impact-of-nav1-8-inhibitor-on-acid-evoked-calcium-dynamics-in-ngf2026-10-01 https://evidence-hub.com/study/11232-exceptionally-selective-voltage-sensor-trapping-of-nav1-5-channels-by2026-10-01 https://evidence-hub.com/study/11233-ligand-based-pharmacophore-modeling-for-the-discovery-of-nav1-72026-10-01 https://evidence-hub.com/study/11234-oral-iron-therapy-for-iron-deficiency-anemia-harmful-and-cold-water2026-10-01 https://evidence-hub.com/study/11235-botulinum-neurotoxin-a1-signaling-in-pain-modulation-within-human2026-10-01 https://evidence-hub.com/study/11236-neuropathic-pain-pathophysiology-current-treatment-and-future2026-10-01 https://evidence-hub.com/study/11238-comparison-of-dose-distribution-in-regional-lymph-nodes-in-whole2026-10-19 https://evidence-hub.com/study/11240-structure-based-in-silico-screening-identifies-a-potent-ebolavirus2026-10-19 https://evidence-hub.com/study/11241-in-silico-identification-and-differential-expressions-of-lepr42026-10-19 https://evidence-hub.com/study/11242-in-silico-identification-and-differential-expression-of-putative2026-10-19 https://evidence-hub.com/study/11243-in-silico-guided-sequence-modifications-of-k-ras-epitopes-improve2026-10-19 https://evidence-hub.com/study/11244-tnf-receptor-type-ii-as-an-emerging-drug-target-for-the-treatment-of2026-10-19 https://evidence-hub.com/study/11246-correction-to-structure-based-in-silico-screening-identifies-a-potent2026-10-19 https://evidence-hub.com/study/11249-in-silico-docking-and-pharmacophoric-analysis-of-3-indolyl-pyridine2026-10-19 https://evidence-hub.com/study/11253-in-silico-development-and-validation-of-est-derived-new-ssr-markers2026-10-19 https://evidence-hub.com/study/11260-genome-scale-metabolic-reconstruction-and-in-silico-analysis-of2026-10-19 https://evidence-hub.com/study/11262-machine-learning-based-sers-chemical-space-for-two-way-prediction-of2026-10-19 https://evidence-hub.com/study/11263-detection-of-polymorphisms-in-the-prion-like-protein-doppel-prnd-gene2026-10-19 https://evidence-hub.com/study/11264-contamination-free-genome-assembly-of-podosphaera-xanthii-reveals2026-10-19 https://evidence-hub.com/study/11265-pathogenic-germline-variants-in-mismatch-repair-genes-in-patients2026-10-19 https://evidence-hub.com/study/11266-forward-predictive-sers-based-chemical-taxonomy-for-untargeted2026-10-09 https://evidence-hub.com/study/11267-first-report-of-novel-single-nucleotide-polymorphisms-and-genetic2026-10-19 https://evidence-hub.com/study/11268-proarrhythmic-risk-assessment-of-sildenafil-under-high-dose-misuse2026-10-19 https://evidence-hub.com/study/11269-therapeutic-osteoinductive-potential-of-saposhnikovia-divaricata2026-10-19 https://evidence-hub.com/study/11270-midgut-damage-triggers-thromboxane-a2-dependent-hemocyte-recruitment2026-10-19 https://evidence-hub.com/study/11271-novel-polymorphisms-and-functional-characterization-of-the-prion2026-10-19 https://evidence-hub.com/study/11272-from-hotspots-to-hotspaces-cascaded-photonic-plasmonic-coupling-for2026-10-19 https://evidence-hub.com/study/11273-exploratory-evaluation-of-peptide-based-immunization-targeting-fusion2026-10-19 https://evidence-hub.com/study/11274-prevalence-of-ctx-m-types-among-esbl-producing-pathogenic-escherichia2026-10-19 https://evidence-hub.com/study/11275-noninvasive-and-point-of-care-surface-enhanced-raman-scattering-sers2026-10-19 https://evidence-hub.com/study/11276-structural-and-biochemical-investigation-into-stable-fgf2-mutants2026-10-19 https://evidence-hub.com/study/11277-tgfb1i1-promotes-cell-proliferation-and-migration-in-urothelial2026-10-09 https://evidence-hub.com/study/11278-novel-insertion-deletion-polymorphisms-and-genetic-studies-of-the2026-10-19 https://evidence-hub.com/study/11279-protracted-neurobehavioral-and-microrna-deficits-by-acute-nicotine2026-10-19 https://evidence-hub.com/study/11281-computational-prediction-of-the-phenotypic-effect-of-flavonoids-on2026-10-19 https://evidence-hub.com/study/11282-upregulation-of-dihydropyrimidinase-like-3-dpysl3-protein-predicts2026-10-19 https://evidence-hub.com/study/11285-genome-wide-identification-and-comprehensive-analysis-of-the-gasa2026-10-19 https://evidence-hub.com/study/11286-protective-effect-of-bojungikki-tang-against-radiation-induced2026-10-19 https://evidence-hub.com/study/11287-inhibition-by-components-of-glycyrrhiza-uralensis-of-3clpro-and-hcov2026-10-19 https://evidence-hub.com/study/11288-extension-of-matrad-with-a-modified-microdosimetric-kinetic-model-for2026-10-19 https://evidence-hub.com/study/11290-rna-seq-based-molecular-classification-analyses-in-colorectal-cancer2026-10-19 https://evidence-hub.com/study/11291-abstract-6433-a-novel-bacterial-strain-cjrb-101-induces-anti-cancer2026-10-19 https://evidence-hub.com/study/11293-ecpas-ecm29-mediated-26s-proteasome-disassembly-is-an-adaptive2026-10-19 https://evidence-hub.com/study/11294-abstract-b142-discovery-of-novel-and-potent-tead-inhibitors-orally2026-10-19 https://evidence-hub.com/study/11295-assembly-of-tight-junction-strands-claudin-10b-and-claudin-3-form2026-10-19 https://evidence-hub.com/study/11297-update-of-the-pompe-variant-database-for-the-prediction-of-clinical2026-10-19 https://evidence-hub.com/study/11298-a-neuropeptide-y-f-like-polypeptide-derived-from-the-transcriptome-of2026-10-19 https://evidence-hub.com/study/11299-molecular-characterization-and-expression-profiling-of-tomato-grf2026-10-19 https://evidence-hub.com/study/11300-de-novo-transcriptome-analysis-and-detection-of-antimicrobial2026-10-19 https://evidence-hub.com/study/11301-the-first-report-of-a-strong-association-between-genetic2026-10-06 https://evidence-hub.com/study/11302-integrated-in-silico-identification-and-molecular-dynamics-validation2026-10-01 https://evidence-hub.com/study/11303-exploring-the-hydrogen-bond-enhanced-halogen-bond-as-a-tool-for2026-10-01 https://evidence-hub.com/study/11305-effect-of-empagliflozin-on-left-ventricular-contractility-and-peak2026-10-06 https://evidence-hub.com/study/11306-empagliflozin-for-patients-with-presumed-resistant-hypertension-a2026-10-01 https://evidence-hub.com/study/11307-the-effects-of-empagliflozin-on-ventricular-arrhythmias-in-heart2026-10-06 https://evidence-hub.com/study/11308-pharmacokinetic-drug-evaluation-of-empagliflozin-plus-linagliptin-for2026-10-06 https://evidence-hub.com/study/11309-heart-failure-and-renal-outcomes-according-to-baseline-and-achieved2026-09-29 https://evidence-hub.com/study/11310-serum-magnesium-outcomes-and-the-effect-of-empagliflozin-in-heart2026-10-06 https://evidence-hub.com/study/11311-serum-magnesium-and-the-effect-of-empagliflozin-in-heart-failure-with2026-10-06 https://evidence-hub.com/study/11312-effects-of-oral-single-dose-empagliflozin-on-urinary-glucose-serum2026-10-06 https://evidence-hub.com/study/11313-urine-extracellular-vesicle-mirna-changes-induced-by-vicadrostat-with2026-10-06 https://evidence-hub.com/study/11314-empagliflozin-reduces-blood-pressure-and-uric-acid-in-patients-with2026-09-27 https://evidence-hub.com/study/11315-sglt2-inhibition-by-empagliflozin-promotes-fat-utilization-and2026-10-04 https://evidence-hub.com/study/11316-efficacy-and-safety-of-empagliflozin-in-patients-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/11317-single-pill-combination-therapy-for-type-2-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/11318-empagliflozin-improves-serum-uric-acid-and-early-cardiometabolic2026-10-06 https://evidence-hub.com/study/11319-empagliflozin-attenuates-the-renal-tubular-ferroptosis-in-diabetic2026-09-27 https://evidence-hub.com/study/11320-sglt2-inhibitor-empagliflozin-and-dpp4-inhibitor-linagliptin2026-10-01 https://evidence-hub.com/study/11321-efficacy-and-safety-of-empagliflozin-added-to-existing-antidiabetes2026-09-29 https://evidence-hub.com/study/11322-effect-of-sglt2-inhibitor-on-cardiomyopathy-in-a-rat-model-of-t2dm2026-10-06 https://evidence-hub.com/study/11323-improved-inflammatory-bowel-disease-wound-healing-and-normal2026-10-06 https://evidence-hub.com/study/11324-impact-of-empagliflozin-in-patients-with-diabetes-and-heart-failure2026-10-06 https://evidence-hub.com/study/11325-empagliflozin-improves-endothelial-and-cardiomyocyte-function-in2026-10-01 https://evidence-hub.com/study/11326-impact-of-empagliflozin-on-blood-pressure-in-patients-with-type-22026-10-01 https://evidence-hub.com/study/11327-effect-of-renal-impairment-on-the-pharmacokinetics-pharmacodynamics2026-10-06 https://evidence-hub.com/study/11328-long-term-treatment-with-empagliflozin-attenuates-renal-damage-in2026-10-06 https://evidence-hub.com/study/11329-empagliflozin-improves-endothelial-function-in-an-ovariectomized-rat2026-10-06 https://evidence-hub.com/study/11330-empagliflozin-mediated-protection-of-heparan-sulfate-rich-endothelial2026-10-06 https://evidence-hub.com/study/11331-immediate-and-short-term-outcomes-of-in-hospital-canagliflozin2026-10-06 https://evidence-hub.com/study/11332-cost-effectiveness-analysis-of-empagliflozin-versus-sitagliptin-as2026-10-06 https://evidence-hub.com/study/11333-antihyperglycemic-and-blood-pressure-effects-of-empagliflozin-in2026-10-01 https://evidence-hub.com/study/11334-cost-effectiveness-of-add-on-empagliflozin-versus-standard-of-care-in2026-10-06 https://evidence-hub.com/study/11335-efficacy-and-safety-of-empagliflozin-at-different-doses-in-patients2026-10-06 https://evidence-hub.com/study/11336-repurposing-empagliflozin-in-individuals-with-glycogen-storage2026-10-06 https://evidence-hub.com/study/11337-empagliflozin-is-associated-with-lower-risk-of-cardiovascular-events2026-10-06 https://evidence-hub.com/study/11338-empagliflozin-attenuates-cardiac-fibrosis-by-suppressing-fibroblast2026-10-06 https://evidence-hub.com/study/11339-current-understanding-on-pathogenesis-and-effective-treatment-of2026-10-06 https://evidence-hub.com/study/11340-efficacy-of-empagliflozin-as-adjunctive-therapy-to-citalopram-in2026-10-06 https://evidence-hub.com/study/11341-comparing-and-contrasting-the-effects-of-the-sglt-inhibitors2026-10-06 https://evidence-hub.com/study/11342-a-european-multinational-cost-effectiveness-analysis-of-empagliflozin2026-10-06 https://evidence-hub.com/study/11343-empagliflozin-and-dulaglutide-are-effective-against-obesity-induced2026-10-01 https://evidence-hub.com/study/11344-clinical-pharmacokinetics-and-pharmacodynamics-of-empagliflozin-in2026-10-06 https://evidence-hub.com/study/11345-empagliflozin-alleviates-hepatic-ischemia-reperfusion-injury-by2026-10-06 https://evidence-hub.com/study/11346-efficacy-and-safety-of-empagliflozin-for-the-acute-myocardial2026-10-01 https://evidence-hub.com/study/11347-evaluation-of-the-effects-of-empagliflozin-on-acute-lung-injury-in2026-10-06 https://evidence-hub.com/study/11348-effects-of-empagliflozin-against-indomethacin-induced-gastric-mucosa2026-10-06 https://evidence-hub.com/study/11349-comparing-the-effects-of-empagliflozin-and-liraglutide-on-lipid2026-10-06 https://evidence-hub.com/study/11350-empagliflozin-alone-and-in-combination-with-metformin-mitigates2026-10-04 https://evidence-hub.com/study/11351-empagliflozin-reduces-diffuse-myocardial-fibrosis-by-extracellular2026-10-04 https://evidence-hub.com/study/11352-empagliflozin-improves-cardiovascular-and-renal-outcomes-in-heart2026-10-06 https://evidence-hub.com/study/11353-sodium-glucose-cotransporter-2-inhibitor-empagliflozin-suppresses-the2026-10-06 https://evidence-hub.com/study/11354-empagliflozin-alleviates-lipid-deposition-and-inflammation-in2026-10-06 https://evidence-hub.com/study/11355-renoprotective-effects-of-empagliflozin-are-linked-to-activation-of2026-10-06 https://evidence-hub.com/study/11357-empagliflozin-attenuates-diabetic-tubulopathy-by-improving2026-10-04 https://evidence-hub.com/study/11358-the-synergy-of-linagliptin-and-empagliflozin-in-catering-to-diabetes2026-10-06 https://evidence-hub.com/study/11359-empagliflozin-in-heart-failure-with-preserved-ejection-fraction-with2026-10-06 https://evidence-hub.com/study/11360-the-comparison-of-the-antidiabetic-effects-of-exenatide-empagliflozin2026-10-06 https://evidence-hub.com/study/11361-liver-tests-cardiovascular-outcomes-and-effects-of-empagliflozin-in2026-10-06 https://evidence-hub.com/study/11362-empagliflozin-significantly-prevents-qtc-prolongation-due-to2026-10-06 https://evidence-hub.com/study/11363-protective-effects-of-empagliflozin-on-testicular-injury-induced-by2026-10-06 https://evidence-hub.com/study/11364-empagliflozin-attenuates-myocardial-sodium-and-calcium-dysregulation2026-10-01 https://evidence-hub.com/study/11365-budget-impact-analysis-of-empagliflozin-in-the-treatment-of-patients2026-10-06 https://evidence-hub.com/study/11366-pharmacokinetics-and-bioequivalence-of-a-generic-empagliflozin-tablet2026-10-06 https://evidence-hub.com/study/11367-the-impact-of-increased-hepatic-glucose-production-caused-by2026-10-06 https://evidence-hub.com/study/11368-empagliflozin-ameliorates-diastolic-dysfunction-and-left-ventricular2026-10-01 https://evidence-hub.com/study/11369-empagliflozin-rescues-diabetic-myocardial-microvascular-injury-via2026-10-01 https://evidence-hub.com/study/11370-the-favorable-effect-of-empagliflozin-on-erectile-function-in-an2026-10-06 https://evidence-hub.com/study/11371-long-term-effectiveness-and-safety-of-quadruple-combination-therapy2026-10-06 https://evidence-hub.com/study/11372-empagliflozin-prohibits-high-fructose-diet-induced-cardiac2026-10-06 https://evidence-hub.com/study/11373-empagliflozin-as-add-on-to-metformin-plus-sulphonylurea-in-patients2026-10-04 https://evidence-hub.com/study/11374-pharmacokinetics-of-empagliflozin-a-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/11375-gliflozins-slow-down-the-progression-of-diabetic-kidney-disease2026-10-06 https://evidence-hub.com/study/11376-empagliflozin-attenuates-neointimal-hyperplasia-after-drug-eluting2026-10-06 https://evidence-hub.com/study/11377-empagliflozin-attenuates-liver-fibrosis-in-high-fat-diet2026-10-06 https://evidence-hub.com/study/11378-empagliflozin-disrupts-a-tnfrsf12a-mediated-feed-forward-loop-that2026-10-06 https://evidence-hub.com/study/11379-nonclinical-safety-of-the-sodium-glucose-cotransporter-2-inhibitor2026-10-06 https://evidence-hub.com/study/11380-empagliflozin-reverses-obesity-and-insulin-resistance-through-fat2026-10-01 https://evidence-hub.com/study/11381-low-dose-empagliflozin-improves-systolic-heart-function-after2026-10-06 https://evidence-hub.com/study/11382-the-antioxidative-effects-of-empagliflozin-on-high-glucose-induced2026-10-06 https://evidence-hub.com/study/11383-a-potential-novel-treatment-for-cirrhosis-related-ascites2026-10-06 https://evidence-hub.com/study/11384-the-effect-of-empagliflozin-on-renal-outcomes-in-patients-with2026-10-01 https://evidence-hub.com/study/11385-pharmacokinetic-and-pharmacodynamic-properties-and-tolerability-of2026-10-06 https://evidence-hub.com/study/11386-impact-of-empagliflozin-on-blood-pressure-in-dipper-and-non-dipper2026-10-06 https://evidence-hub.com/study/11387-empagliflozin-and-kidney-outcomes-in-asian-patients-with-type-22026-10-01 https://evidence-hub.com/study/11388-empagliflozin-ameliorates-olfactory-bulbectomy-induced-depression-by2026-10-04 https://evidence-hub.com/study/11389-effect-of-empagliflozin-on-cardiac-biomarkers-in-a-zebrafish-model-of2026-09-29 https://evidence-hub.com/study/11390-lack-of-drug-drug-interaction-between-empagliflozin-a-sodium-glucose2026-10-06 https://evidence-hub.com/study/11391-distinct-mechanisms-responsible-for-the-increase-in-glucose2026-10-06 https://evidence-hub.com/study/11392-empagliflozin-lessened-cardiac-injury-and-reduced-visceral-adipocyte2026-10-04 https://evidence-hub.com/study/11393-potential-contribution-of-haemoconcentration-to-changes-in-lipid2026-10-06 https://evidence-hub.com/study/11394-correlation-between-myocardial-strain-and-adverse-remodeling-in-a-non2026-10-06 https://evidence-hub.com/study/11395-the-effects-of-empagliflozin-on-cardiometabolic-risk-factors-in2026-10-06 https://evidence-hub.com/study/11396-effects-of-glucagon-like-peptide-1-receptor-agonists-on2026-10-06 https://evidence-hub.com/study/11397-empagliflozin-and-decreased-risk-of-nephrolithiasis-a-potential-new2026-10-06 https://evidence-hub.com/study/11398-sglt2-inhibition-with-empagliflozin-attenuates-myocardial-oxidative2026-10-01 https://evidence-hub.com/study/11399-the-effect-of-empagliflozin-on-echocardiographic-parameters-in2026-10-01 https://evidence-hub.com/study/11400-co-loaded-nanoparticles-of-empagliflozin-and-rutin-for-pancreatitis2026-10-06 https://evidence-hub.com/study/11401-empagliflozin-improves-vascular-insulin-sensitivity-and-muscle2026-10-06 https://evidence-hub.com/study/11402-the-effect-of-empagliflozin-on-the-total-burden-of-cardiovascular-and2026-10-01 https://evidence-hub.com/study/11403-effects-of-empagliflozin-on-erythropoiesis-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/11404-sympathetic-nervous-system-activity-tissue-iron-distribution-and2026-09-27 https://evidence-hub.com/study/11405-smoldering-multiple-myeloma-in-glycogen-storage-disease-type-ib2026-10-06 https://evidence-hub.com/study/11406-real-world-ehr-signals-from-a-cohort-of-blinded-incretin-trial2026-10-06 https://evidence-hub.com/study/11407-on-the-clinical-pharmacokinetics-and-pharmacodynamics-and-drug-level2026-10-06 https://evidence-hub.com/study/11408-copeptin-response-to-empagliflozin-in-patients-with-recent-acute2026-10-06 https://evidence-hub.com/study/11409-personalized-knowledge-based-graph-neural-networks-and-regression2026-10-06 https://evidence-hub.com/study/11410-tirzepatide-attenuates-diabetes-associated-testicular-inflammation2026-10-06 https://evidence-hub.com/study/11411-urinary-frequency-and-polydipsia-mimicking-diabetes-mellitus-obesity2026-10-06 https://evidence-hub.com/study/11412-development-and-validation-of-a-stability-indicating-lc-ms-ms-method2026-10-06 https://evidence-hub.com/study/11413-effect-of-empagliflozin-with-or-without-carvedilol-on-tricuspid2026-10-06 https://evidence-hub.com/study/11414-empagliflozin-improves-gut-microbial-disturbances-and-intestinal2026-10-06 https://evidence-hub.com/study/11415-empagliflozin-protects-against-indomethacin-induced-gastric-injury-in2026-10-06 https://evidence-hub.com/study/11416-effects-of-empagliflozin-on-cardiovascular-outcomes-are-consistent2026-10-06 https://evidence-hub.com/study/11417-head-to-head-comparative-effectiveness-of-empagliflozin-versus2026-10-06 https://evidence-hub.com/study/11418-empagliflozin-and-dapagliflozin-in-improving-ejection-fraction-a2026-10-01 https://evidence-hub.com/study/11419-genetically-nominated-cardiovascular-kidney-metabolic-features-are2026-10-06 https://evidence-hub.com/study/11420-empagliflozin-attenuates-age-bsa-high-glucose-induced-inflammation-in2026-10-06 https://evidence-hub.com/study/11421-dronedarone-hydrochloride-reverses-obesity-related-metabolic-syndrome2026-10-06 https://evidence-hub.com/study/11422-center-composite-design-assisted-optimization-of-rp-hplc-method-for2026-10-06 https://evidence-hub.com/study/11423-therapeutic-repositioning-of-sglt2-inhibitors-using-real-world-data-a2026-10-06 https://evidence-hub.com/study/11424-differential-uptake-of-sglt2-inhibitors-in-england-following-heart2026-10-06 https://evidence-hub.com/study/11425-empagliflozin-preserves-mitochondrial-function-and-reduces-tubular2026-10-01 https://evidence-hub.com/study/11426-neutrophil-to-lymphocyte-ratio-in-patients-with-heart-failure2026-10-06 https://evidence-hub.com/study/11427-a-digital-twin-of-empagliflozin-pharmacokinetics-and-pharmacodynamics2026-09-27 https://evidence-hub.com/study/11428-association-between-different-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/11429-empagliflozin-inhibits-the-apoptosis-of-pancreatic-cells-through2026-10-06 https://evidence-hub.com/study/11430-effects-of-semaglutide-and-empagliflozin-on-markers-of-endothelial2026-10-06 https://evidence-hub.com/study/11431-early-versus-delayed-or-no-empagliflozin-initiation-after2026-10-06 https://evidence-hub.com/study/11432-healthcare-cost-offsets-associated-with-empagliflozin-for-the2026-10-06 https://evidence-hub.com/study/11433-feasibility-of-decentralised-response-guided-albuminuria-monitoring2026-10-06 https://evidence-hub.com/study/11434-real-world-prescribing-patterns-and-clinical-characteristics-of2026-10-04 https://evidence-hub.com/study/11435-empagliflozin-targets-a-renal-neuro-epithelial-immune-axis-in-heart2026-09-27 https://evidence-hub.com/study/11436-long-term-empagliflozin-treatment-50-days-attenuates-protease2026-10-06 https://evidence-hub.com/study/11437-hepatoprotective-effects-of-empagliflozin-in-metabolic-dysfunction2026-10-04 https://evidence-hub.com/study/11438-empagliflozin-in-gsd-ib-long-term-safety-and-sustained-recovery-of2026-10-01 https://evidence-hub.com/study/11439-empagliflozin-ameliorates-experimental-pulmonary-vascular-remodeling2026-10-06 https://evidence-hub.com/study/11440-sglt2-inhibition-attenuates-hippocampal-injury-and-cognitive2026-10-06 https://evidence-hub.com/study/11441-impact-of-empagliflozin-on-serum-calcium-and-phosphate-in-heart2026-10-06 https://evidence-hub.com/study/11442-empagliflozin-therapeutic-area-kidney-disease-nephrology2026-10-06 https://evidence-hub.com/study/11443-hyponatremia-correction-is-associated-with-increased-brain-derived2026-10-06 https://evidence-hub.com/study/11444-bioequivalence-evaluation-of-immediate-release-empagliflozin2026-10-04 https://evidence-hub.com/study/11445-efficacy-and-safety-of-empagliflozin-in-metabolic-dysfunction2026-10-06 https://evidence-hub.com/study/11446-mechanistic-intersections-of-empagliflozin-and-nebivolol-in-aging2026-10-04 https://evidence-hub.com/study/11447-comparative-incidence-of-urinary-tract-infections-in-diabetic-women2026-10-06 https://evidence-hub.com/study/11448-empagliflozin-improves-atherosclerosis-by-promoting-mitophagy-in2026-10-06 https://evidence-hub.com/study/11449-evaluation-of-the-effect-of-empagliflozin-on-prevention-of-atrial2026-10-06 https://evidence-hub.com/study/11450-unexpected-insulinoma-in-type-2-diabetes-during-long-term-dulaglutide2026-10-06 https://evidence-hub.com/study/11451-longitudinal-assessment-of-diastolic-function-and-myocardial-strain2026-10-06 https://evidence-hub.com/study/11452-cardiac-sglt2-expression-and-cell-type-specific-responses-to2026-10-06 https://evidence-hub.com/study/11453-effect-of-empagliflozin-on-copeptin-levels-in-patients-with-recent2026-10-06 https://evidence-hub.com/study/11454-cardioprotective-properties-of-empagliflozin-and-other-sglt22026-10-06 https://evidence-hub.com/study/11455-genitourinary-tract-infections-and-sglt2-inhibitors-in-heart-failure2026-10-06 https://evidence-hub.com/study/11456-cardiovascular-outcomes-of-empagliflozin-glp-1ra-combination-therapy2026-10-06 https://evidence-hub.com/study/11457-empagliflozin-prevents-cardiac-arrest-induced-renal-injury-through2026-10-06 https://evidence-hub.com/study/11458-empagliflozin-linagliptin-and-metformin-differentially-affect-renal2026-10-06 https://evidence-hub.com/study/11459-association-of-sodium-glucose-cotransporter-2-inhibitors-with2026-10-06 https://evidence-hub.com/study/11460-empagliflozin-inhibits-cardiac-hypertrophy-via-a-mechanism-involving2026-10-06 https://evidence-hub.com/study/11461-association-between-empagliflozin-exposure-and-skeletal-muscle2026-10-06 https://evidence-hub.com/study/11462-empagliflozin-attenuates-ptz-induced-neurotoxicity-and-enhances-the2026-10-06 https://evidence-hub.com/study/11463-empagliflozin-reduces-post-myocardial-infarction-inflammation-via2026-10-06 https://evidence-hub.com/study/11464-empagliflozin-in-stemi-patients-a-randomized-controlled-trial-on-left2026-10-06 https://evidence-hub.com/study/11465-empagliflozin-preserves-cardiac-function-and-modulates-metabolism-in2026-10-01 https://evidence-hub.com/study/11466-efficacy-of-empagliflozin-on-liver-enzymes-lipid-profile-and-bmi-in2026-10-04 https://evidence-hub.com/study/11467-tirzepatide-and-sglt2-inhibitors-for-heart-failure-with-preserved2026-10-06 https://evidence-hub.com/study/11468-the-cost-effectiveness-of-second-line-diabetes-medication-added-to2026-10-06 https://evidence-hub.com/study/11469-empagliflozin-alleviates-renal-ischemia-reperfusion-injury-by2026-10-06 https://evidence-hub.com/study/11470-adjunctive-treatments-for-patients-with-type-1-diabetes-using2026-10-06 https://evidence-hub.com/study/11471-pharmacokinetic-interactions-between-three-sglt2-inhibitors-and2026-10-06 https://evidence-hub.com/study/11472-treatment-with-dapagliflozin-and-empagliflozin-reduces-concentrations2026-10-04 https://evidence-hub.com/study/11473-empagliflozin-in-hnf1a-mody-mody3-a-randomized-double-blind-placebo2026-10-06 https://evidence-hub.com/study/11474-comparative-24-month-cardiovascular-outcomes-and-biomarker2026-10-06 https://evidence-hub.com/study/11475-cost-utility-analysis-of-simultaneous-initiation-of-finerenone-and2026-10-06 https://evidence-hub.com/study/11476-effects-of-empagliflozin-combined-with-anaerobic-aerobic-and2026-10-06 https://evidence-hub.com/study/11477-organ-specific-efficacy-of-postischemic-empagliflozin-in-acute-stroke2026-10-06 https://evidence-hub.com/study/11478-comparative-cardiorenal-efficacy-and-safety-of-finerenone-sglt22026-10-06 https://evidence-hub.com/study/11479-distinct-temporal-modulation-of-mesenchymal-stem-cells-and2026-10-06 https://evidence-hub.com/study/11480-mesenchymal-stem-cells-and-empagliflozin-a-potential-therapeutic2026-10-06 https://evidence-hub.com/study/11481-empagliflozin-restores-cardiac-function-in-obese-diabetic-hfpef-mice2026-10-06 https://evidence-hub.com/study/11482-empagliflozin-versus-dapagliflozin-and-urogenital-adverse-events-in2026-10-06 https://evidence-hub.com/study/11483-comparative-effectiveness-of-dapagliflozin-vs-empagliflozin-on-major2026-10-06 https://evidence-hub.com/study/11484-empagliflozin-in-adpkd-with-suspected-iga-nephropathy-antiproteinuric2026-10-06 https://evidence-hub.com/study/11485-implantable-cardioverter-defibrillator-therapy-in-contemporary-heart2026-10-06 https://evidence-hub.com/study/11486-empagliflozin-versus-dapagliflozin-for-kidney-outcomes-in-stage-32026-10-06 https://evidence-hub.com/study/11487-differential-outcomes-with-empagliflozin-and-dapagliflozin-in-heart2026-10-01 https://evidence-hub.com/study/11488-early-onset-euglycemic-diabetic-ketoacidosis-following-empagliflozin2026-10-06 https://evidence-hub.com/study/11489-depot-specific-cardiorenal-adipose-remodeling-with-sglt2i-in-chronic2026-10-06 https://evidence-hub.com/study/11490-targeted-metabolomics-to-assess-positive-effects-of-empagliflozin-in2026-10-06 https://evidence-hub.com/study/11491-a-pharmacovigilance-study-of-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/11492-combination-of-empagliflozin-with-curcumin-attenuates-hepatic2026-10-06 https://evidence-hub.com/study/11493-sex-specific-modulation-of-gut-microbiota-by-empagliflozin2026-10-06 https://evidence-hub.com/study/11494-renal-functional-reserve-predicts-gfr-response-to-empagliflozin-in2026-10-06 https://evidence-hub.com/study/11495-the-effect-of-sodium-glucose-cotransporter-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/11496-empagliflozin-and-renal-histological-changes-in-an-experimental-model2026-10-06 https://evidence-hub.com/study/11497-empagliflozin-s-effects-on-carotid-ultrasound-parameters-in-type-22026-10-06 https://evidence-hub.com/study/11498-association-between-sglt2-inhibitors-and-reporting-of-phimosis2026-10-06 https://evidence-hub.com/study/11499-empagliflozin-in-heart-failure-with-a-preserved-ejection-fraction2026-10-01 https://evidence-hub.com/study/11501-empagliflozin-cardiovascular-outcomes-and-mortality-in-type-2-diabetes2026-10-04 https://evidence-hub.com/study/11502-cardiovascular-and-renal-outcomes-with-empagliflozin-in-heart-failure2026-10-01 https://evidence-hub.com/study/11503-finerenone-with-empagliflozin-in-chronic-kidney-disease-and-type-22026-10-01 https://evidence-hub.com/study/11504-empagliflozin-in-patients-with-chronic-kidney-disease2026-10-01 https://evidence-hub.com/study/11505-empagliflozin-after-acute-myocardial-infarction2026-10-01 https://evidence-hub.com/study/11506-empagliflozin-and-progression-of-kidney-disease-in-type-2-diabetes2026-10-01 https://evidence-hub.com/study/11507-the-effect-of-empagliflozin-on-non-alcoholic-fatty-liver-disease2026-10-08 https://evidence-hub.com/study/11508-combination-effect-of-finerenone-and-empagliflozin-in-participants2026-10-06 https://evidence-hub.com/study/11509-empagliflozin-in-nondiabetic-individuals-with-calcium-and-uric-acid2026-10-06 https://evidence-hub.com/study/11510-effects-of-empagliflozin-on-functional-capacity-lv-filling-pressure2026-10-06 https://evidence-hub.com/study/11511-effect-of-empagliflozin-on-the-mechanisms-driving-erythropoiesis-and2026-10-06 https://evidence-hub.com/study/11512-empagliflozin-in-resistant-hypertension-and-heart-failure-with2026-10-06 https://evidence-hub.com/study/11513-sglt2-inhibitor-empagliflozin-ameliorates-tubulointerstitial-fibrosis2026-10-04 https://evidence-hub.com/study/11514-effectiveness-of-empagliflozin-vs-dapagliflozin-for-kidney-outcomes2026-10-06 https://evidence-hub.com/study/11515-effect-of-empagliflozin-on-heart-failure-outcomes-after-acute2026-10-06 https://evidence-hub.com/study/11516-long-term-effects-of-empagliflozin-in-patients-with-chronic-kidney2026-10-01 https://evidence-hub.com/study/11517-empagliflozin-attenuates-dox-induced-cardiotoxicity-by-inhibiting2026-10-06 https://evidence-hub.com/study/11518-the-sglt2-inhibitor-empagliflozin-in-patients-hospitalized-for-acute2026-10-01 https://evidence-hub.com/study/11519-short-term-effects-of-empagliflozin-on-preventing-contrast-induced2026-10-06 https://evidence-hub.com/study/11520-comparative-outcomes-of-empagliflozin-to-dapagliflozin-in-patients2026-10-01 https://evidence-hub.com/study/11521-empagliflozin-prevents-heart-failure-through-inhibition-of-the-nhe12026-10-01 https://evidence-hub.com/study/11522-effects-of-empagliflozin-on-liver-fat-in-patients-with-metabolic2026-10-06 https://evidence-hub.com/study/11523-uric-acid-and-sglt2-inhibition-with-empagliflozin-in-heart-failure2026-10-06 https://evidence-hub.com/study/11524-empagliflozin-improves-diastolic-function-in-hfpef-by-restabilizing2026-10-06 https://evidence-hub.com/study/11525-cardiorenal-effectiveness-of-empagliflozin-vs-glucagon-like-peptide-12026-10-06 https://evidence-hub.com/study/11526-treatment-effects-of-empagliflozin-in-hospitalized-heart-failure2026-10-06 https://evidence-hub.com/study/11527-empagliflozin-in-acute-myocardial-infarction-the-emmy-trial2026-10-01 https://evidence-hub.com/study/11528-use-of-empagliflozin-in-the-prevention-of-cardiotoxicity-the-empacard2026-10-06 https://evidence-hub.com/study/11529-tailoring-of-an-anti-diabetic-drug-empagliflozin-onto-zinc-oxide2026-10-01 https://evidence-hub.com/study/11530-empagliflozin-reduces-liver-fat-in-individuals-with-and-without2026-10-06 https://evidence-hub.com/study/11531-efficacy-and-safety-of-aldosterone-synthase-inhibition-with-and2026-10-06 https://evidence-hub.com/study/11532-empagliflozin-attenuates-doxorubicin-induced-cardiotoxicity-by2026-10-01 https://evidence-hub.com/study/11533-empagliflozin-lowers-serum-uric-acid-in-chronic-kidney-disease2026-10-06 https://evidence-hub.com/study/11534-randomized-trial-of-empagliflozin-in-non-diabetic-patients-with-heart2026-10-01 https://evidence-hub.com/study/11535-empagliflozin-and-liraglutide-ameliorate-hfpef-in-mice-via-augmenting2026-10-06 https://evidence-hub.com/study/11536-empagliflozin-protects-the-kidney-by-reducing-toxic-alb-albumin2026-10-06 https://evidence-hub.com/study/11537-attenuated-effects-of-topical-empagliflozin-on-imiquimod-induced2026-10-04 https://evidence-hub.com/study/11538-separate-and-combined-effects-of-empagliflozin-and-semaglutide-on2026-10-06 https://evidence-hub.com/study/11539-treatment-recommendations-for-glycogen-storage-disease-type-ib2026-10-06 https://evidence-hub.com/study/11540-effect-of-empagliflozin-on-ventricular-arrhythmias-in-patients-with2026-10-06 https://evidence-hub.com/study/11541-sglt2-inhibitor-empagliflozin-downregulates-mirna-34a-5p-and-targets2026-10-06 https://evidence-hub.com/study/11542-assessment-of-cardiac-energy-metabolism-function-and-physiology-in2026-10-12 https://evidence-hub.com/study/11543-impact-of-primary-kidney-disease-on-the-effects-of-empagliflozin-in2026-10-01 https://evidence-hub.com/study/11544-left-ventricular-function-congestion-and-effect-of-empagliflozin-on2026-10-06 https://evidence-hub.com/study/11545-effects-of-liraglutide-empagliflozin-and-their-combination-on-left2026-10-06 https://evidence-hub.com/study/11546-empagliflozin-attenuates-cardiac-microvascular-ischemia-reperfusion2026-10-01 https://evidence-hub.com/study/11547-the-sglt-2-inhibitor-empagliflozin-improves-myocardial-strain-reduces2026-10-01 https://evidence-hub.com/study/11548-the-sglt2-inhibitor-empagliflozin-inhibits-skeletal-muscle-fibrosis2026-10-06 https://evidence-hub.com/study/11549-effectiveness-and-safety-of-empagliflozin-final-results-from-the2026-10-06 https://evidence-hub.com/study/11550-the-sglt2-inhibitor-empagliflozin-promotes-post-stroke-functional2026-10-04 https://evidence-hub.com/study/11551-effects-of-early-empagliflozin-initiation-on-diuresis-and-kidney2026-10-01 https://evidence-hub.com/study/11552-empagliflozin-alleviates-carfilzomib-induced-cardiotoxicity-in-mice2026-10-06 https://evidence-hub.com/study/11553-impact-of-empagliflozin-on-decongestion-in-acute-heart-failure-the2026-10-01 https://evidence-hub.com/study/11554-empagliflozin-ameliorates-adverse-left-ventricular-remodeling-in2026-10-01 https://evidence-hub.com/study/11555-empagliflozin-alters-lipid-metabolism-in-the-myocardium-and-liver-in2026-10-04 https://evidence-hub.com/study/11556-effect-of-empagliflozin-in-peripheral-diabetic-neuropathy-of-patients2026-10-06 https://evidence-hub.com/study/11557-empagliflozin-and-the-risk-of-retinopathy-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/11558-empagliflozin-attenuates-inflammation-levels-in-autoimmune2026-10-06 https://evidence-hub.com/study/11559-effect-of-empagliflozin-on-left-ventricular-volumes-in-type-22026-10-06 https://evidence-hub.com/study/11560-empagliflozin-in-acute-myocardial-infarction-in-patients-with-and2026-10-06 https://evidence-hub.com/study/11561-effects-of-empagliflozin-on-progression-of-chronic-kidney-disease-a2026-10-06 https://evidence-hub.com/study/11562-dapagliflozin-and-empagliflozin-in-paediatric-indications-a2026-10-04 https://evidence-hub.com/study/11563-comparative-cardiovascular-and-renal-effectiveness-of-empagliflozin2026-10-06 https://evidence-hub.com/study/11564-efficacy-and-safety-of-the-sodium-glucose-co-transporter-2-inhibitor2026-10-06 https://evidence-hub.com/study/11565-effect-of-empagliflozin-on-left-ventricular-mass-in-patients-with2026-10-04 https://evidence-hub.com/study/11566-sglt2-inhibition-via-empagliflozin-improves-endothelial-function-and2026-10-01 https://evidence-hub.com/study/11567-safety-of-empagliflozin-an-individual-participant-level-data-meta2026-10-04 https://evidence-hub.com/study/11568-empagliflozin-ameliorates-the-impaired-osteogenic-differentiation2026-10-06 https://evidence-hub.com/study/11569-empagliflozin-rescues-lifespan-and-liver-senescence-in-naturally-aged2026-10-06 https://evidence-hub.com/study/11570-neutrophil-functions-in-patients-with-neutropenia-due-to-glycogen2026-10-06 https://evidence-hub.com/study/11571-empagliflozin-demonstrates-cytotoxicity-and-synergy-with-tamoxifen-in2026-10-06 https://evidence-hub.com/study/11572-empagliflozin-attenuates-non-alcoholic-fatty-liver-disease-nafld-in2026-10-01 https://evidence-hub.com/study/11573-design-of-the-combination-effect-of-finerenone-and-empagliflozin-in2026-10-06 https://evidence-hub.com/study/11574-randomized-double-blind-placebo-controlled-multicentre-pilot-study-on2026-10-01 https://evidence-hub.com/study/11576-cost-effectiveness-of-empagliflozin-as-add-on-to-standard-of-care-for2026-10-06 https://evidence-hub.com/study/11577-sglt2-inhibitors-empagliflozin-and-canagliflozin-ameliorate-allergic2026-10-06 https://evidence-hub.com/study/11578-efficacy-and-safety-of-the-sglt2-inhibitor-empagliflozin-versus2026-10-08 https://evidence-hub.com/study/11579-blinded-withdrawal-of-long-term-randomized-treatment-with2026-10-01 https://evidence-hub.com/study/11580-empagliflozin-suppresses-mitochondrial-reactive-oxygen-species2026-10-06 https://evidence-hub.com/study/11581-empagliflozin-improves-renal-ischemia-reperfusion-injury-by-reducing2026-10-01 https://evidence-hub.com/study/11582-empagliflozin-attenuates-neointima-formation-after-arterial-injury2026-10-06 https://evidence-hub.com/study/11583-empagliflozin-for-treating-neutropenia-and-neutrophil-dysfunction-in2026-10-06 https://evidence-hub.com/study/11584-cardiac-and-kidney-benefits-of-empagliflozin-in-heart-failure-across2026-10-06 https://evidence-hub.com/study/11585-the-sodium-glucose-cotransporter-2-inhibitor-empagliflozin-inhibits2026-10-01 https://evidence-hub.com/study/11586-mechanistic-insights-of-empagliflozin-in-nondiabetic-patients-with2026-10-01 https://evidence-hub.com/study/11587-effect-of-empagliflozin-on-circulating-proteomics-in-heart-failure2026-10-01 https://evidence-hub.com/study/11588-empagliflozin-effects-on-pulmonary-artery-pressure-in-patients-with2026-10-01 https://evidence-hub.com/study/11589-empagliflozin-improves-cognitive-impairment-in-frail-older-adults2026-10-04 https://evidence-hub.com/study/11590-oral-semaglutide-versus-empagliflozin-in-patients-with-type-22026-10-08 https://evidence-hub.com/study/11591-cardioprotective-effect-of-empagliflozin-and-circulating-ketone2026-09-27 https://evidence-hub.com/study/11592-separate-and-combined-effects-of-semaglutide-and-empagliflozin-on2026-10-06 https://evidence-hub.com/study/11593-uric-acid-and-sodium-glucose-cotransporter-2-inhibition-with2026-10-06 https://evidence-hub.com/study/11594-a-28-day-randomised-placebo-controlled-double-blind-parallel-group2026-09-27 https://evidence-hub.com/study/11595-a-randomized-allocation-concealed-assessor-blinded-parallel-group2026-10-04 https://evidence-hub.com/study/11596-randomised-double-blind-placebo-controlled-and-parallel-dose-group2026-09-27 https://evidence-hub.com/study/11597-empagliflozin-to-elderly-and-obese-patients-with-cardiovascular2026-09-27 https://evidence-hub.com/study/11598-effect-of-empagliflozin-on-cardiac-output-in-patients-with-acute2026-09-29 https://evidence-hub.com/study/11599-investigation-of-the-effect-of-food-on-the-bioavailability-of-a-25-mg2026-09-27 https://evidence-hub.com/study/11600-a-phase-i-study-to-evaluate-the-drug-drug-interaction-of-chiglitazar2026-09-27 https://evidence-hub.com/study/11601-effects-of-the-sglt2-inhibitor-empagliflozin-on-renal-tissue2026-09-29 https://evidence-hub.com/study/11602-the-effect-of-sglt2-inhibition-on-adipose-tissue-inflammation-and2026-09-27 https://evidence-hub.com/study/11603-a-phase-iii-randomised-double-blind-placebo-controlled-parallel-group2026-09-27 https://evidence-hub.com/study/11604-impact-of-sglt2-on-glucosuria-in-hnf1a-mody2026-09-27 https://evidence-hub.com/study/11605-a-phase-iii-multicentre-international-randomised-parallel-group2026-09-29 https://evidence-hub.com/study/11606-effects-of-empagliflozin-and-continuous-positive-airway-pressure-on2026-09-27 https://evidence-hub.com/study/11607-initiation-of-angiotensin-receptor-neprilysin-inhibitor-arni-and2026-09-27 https://evidence-hub.com/study/11608-a-prospective-randomized-open-label-parallel-6-month-study-to-explore2026-10-04 https://evidence-hub.com/study/11609-quadruple-oral-combination-therapy-for-type-2-diabetes-mellitus2026-10-04 https://evidence-hub.com/study/11610-open-label-randomized-two-period-comparative-pharmacokinetics-and2026-10-04 https://evidence-hub.com/study/11611-renal-and-cardiovascular-effect-of-sodium-glucose-co-transporter-22026-09-27 https://evidence-hub.com/study/11612-relative-bioavailability-of-two-different-vicadrostat-empagliflozin2026-09-27 https://evidence-hub.com/study/11613-empagliflozin-after-aortic-valve-replacement-the-empavr-study-a2026-09-27 https://evidence-hub.com/study/11614-canagliflozin-attenuates-cmr-quantified-myocardial-fibrosis-in2026-10-04 https://evidence-hub.com/study/11615-combined-active-treatment-in-type-2-diabetes-with-nash2026-09-27 https://evidence-hub.com/study/11616-clinical-study-to-investigate-the-possible-effect-of-empagliflozin-in2026-10-08 https://evidence-hub.com/study/11617-short-term-effect-of-empagliflozin-on-left-ventricular-relaxation-in2026-09-27 https://evidence-hub.com/study/11618-effects-of-empagliflozin-on-liver-fat-content-energy-metabolism-and2026-09-27 https://evidence-hub.com/study/11619-ameliorating-metabolic-profiling-after-kidney-transplantation-ampkt2026-10-06 https://evidence-hub.com/study/11620-sglt2-inhibitors-after-acute-kidney-injury-with-indications-pilot2026-09-27 https://evidence-hub.com/study/11621-bioequivalence-of-a-fixed-dose-combination-tablet-of-empagliflozin2026-10-04 https://evidence-hub.com/study/11622-bioequivalence-of-a-fixed-dose-combination-tablet-of-empagliflozin2026-10-04 https://evidence-hub.com/study/11623-a-phase-iii-randomised-double-blind-placebo-controlled-parallel-group2026-09-27 https://evidence-hub.com/study/11624-empa-tropism-trial-are-the-cardiac-benefits-of-empagliflozin2026-09-27 https://evidence-hub.com/study/11625-the-effect-of-empagliflozin-versus-metformin-on-hormonal-metabolic2026-10-06 https://evidence-hub.com/study/11626-relative-bioavailability-of-single-dose-bi-10773-co-administered-with2026-09-27 https://evidence-hub.com/study/11627-involvement-of-dipeptidyl-peptidase-4-and-sodium-glucose-co2026-09-27 https://evidence-hub.com/study/11628-a-phase-iii-randomized-double-blind-parallel-group-study-to-evaluate2026-10-04 https://evidence-hub.com/study/11629-clinical-study-to-determine-bioequivalence-between-two-oral2026-10-04 https://evidence-hub.com/study/11630-effects-of-empagliflozin-metformin-sitagliptin-metformin-and2026-10-04 https://evidence-hub.com/study/11631-adiponectin-and-its-role-in-the-treatment-of-patients-with-metabolic2026-09-27 https://evidence-hub.com/study/11632-a-phase-iii-randomised-double-blind-placebo-controlled-parallel-group2026-09-27 https://evidence-hub.com/study/11633-use-of-empagliflozin-to-treat-prediabetes-a-randomized-double-blind2026-09-27 https://evidence-hub.com/study/11634-relative-bioavailability-of-5-mg-bi-10773-administered-twice-daily2026-09-27 https://evidence-hub.com/study/11635-a-prospective-randomized-parallel-group-adaptive-design-phase-iib-iii2026-10-04 https://evidence-hub.com/study/11636-clinical-study-to-determine-bioequivalence-between-two-oral2026-10-04 https://evidence-hub.com/study/11637-efficacy-and-safety-of-oral-semaglutide-versus-empagliflozin-in2026-09-27 https://evidence-hub.com/study/11638-a-phase-ii-randomized-parallel-group-safety-efficacy-and2026-10-04 https://evidence-hub.com/study/11639-relative-bioavailability-of-two-fdc-tablet-strengths-of-empagliflozin2026-10-04 https://evidence-hub.com/study/11640-optimization-of-albuminuria-lowering-therapies-for-individual2026-09-27 https://evidence-hub.com/study/11641-an-open-label-balanced-randomized-single-dose-two-treatment-two2026-09-27 https://evidence-hub.com/study/11642-a-randomized-parallel-arm-double-blind-study-of-efficacy-and-safety2026-10-04 https://evidence-hub.com/study/11643-comparative-effects-of-empagliflozin-versus-glimepiride-after-262026-10-04 https://evidence-hub.com/study/11644-a-phase-iii-double-blind-extension-placebo-controlled-parallel-group2026-10-04 https://evidence-hub.com/study/11645-suppression-with-empagliflozin-as-an-alternative-to-high-fat-low2026-09-27 https://evidence-hub.com/study/11646-comparison-of-the-effects-of-thiazolidinediones-tzd-sodium-glucose2026-09-27 https://evidence-hub.com/study/11647-relative-bioavailability-investigations-of-a-25-mg-bi-10773-5-mg2026-09-27 https://evidence-hub.com/study/11648-investigation-of-the-effect-of-food-on-the-bioavailability-of2026-09-27 https://evidence-hub.com/study/11649-a-multicenter-randomized-placebo-controlled-parallel-group-double2026-10-04 https://evidence-hub.com/study/11650-bioequivalence-of-a-fixed-dose-combination-tablet-of-empagliflozin2026-09-27 https://evidence-hub.com/study/11651-sglt-2-inhibitor-empagliflozin-effects-on-appetite-and-weight2026-09-27 https://evidence-hub.com/study/11652-a-multi-center-randomized-double-blind-parallel-group-dose-finding2026-09-27 https://evidence-hub.com/study/11653-empagliflozin-as-a-modulator-of-systemic-vascular-resistance-and2026-09-27 https://evidence-hub.com/study/11654-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-42026-09-27 https://evidence-hub.com/study/11655-effects-of-the-sglt2-inhibitor-empagliflozin-on-patients-with-chronic2026-09-27 https://evidence-hub.com/study/11656-relative-bioavailability-of-both-bi-10773-and-warfarin-and2026-09-27 https://evidence-hub.com/study/11657-an-open-label-balanced-randomized-single-dose-two-treatment-two2026-10-04 https://evidence-hub.com/study/11658-expanded-combination-of-evolocumab-plus-empagliflozin-on-diabetes2026-09-27 https://evidence-hub.com/study/11659-efficay-and-safety-of-empagliflozin-versus-sitagliptin-for-the-in2026-09-27 https://evidence-hub.com/study/11660-a-randomized-open-label-single-dose-crossover-phase-i-trial-to2026-10-04 https://evidence-hub.com/study/11661-impact-of-empagliflozin-on-cardiac-function-and-biomarkers-of-heart2026-09-27 https://evidence-hub.com/study/11662-bioequivalence-of-empagliflozin-metformin-fixed-dose-combination2026-10-04 https://evidence-hub.com/study/11663-empagliflozin-for-patients-with-acutely-decompensated-congestive2026-09-27 https://evidence-hub.com/study/11664-a-randomised-double-blind-placebo-controlled-parallel-group-efficacy2026-10-04 https://evidence-hub.com/study/11665-effect-of-empagliflozin-on-the-heterogeneity-of-ventricular2026-09-27 https://evidence-hub.com/study/11667-bioequivalence-of-a-fixed-dose-combination-tablet-of-empagliflozin2026-10-04 https://evidence-hub.com/study/11668-comparison-of-effect-of-sitagliptin-and-empagliflozin-in-combination2026-10-04 https://evidence-hub.com/study/11669-relative-bioavailability-of-both-bi-10773-and-sitagliptin-after-co2026-09-27 https://evidence-hub.com/study/11670-effect-of-empagliflozin-on-cardiac-remodeling-in-non-diabetic2026-09-27 https://evidence-hub.com/study/11671-empact-mi-a-streamlined-multicentre-randomised-parallel-group-double2026-09-27 https://evidence-hub.com/study/11672-relative-bioavailability-of-a-12-5-mg-bi-10773-1000-mg-metformin2026-10-08 https://evidence-hub.com/study/11673-a-phase-iii-randomised-double-blind-trial-to-evaluate-the-effect-of2026-09-27 https://evidence-hub.com/study/11674-a-phase-1-open-label-sequential-multiple-dose-drug-drug-interaction2026-09-27 https://evidence-hub.com/study/11675-effects-on-blood-pressure-and-central-sympathetic-nerve-traffic-by2026-09-27 https://evidence-hub.com/study/11676-relative-bioavailability-of-both-bi-10773-50-mg-and-pioglitazone-452026-09-27 https://evidence-hub.com/study/11677-effects-of-the-sglt2-inhibitor-empagliflozin-in-patients-with2026-09-27 https://evidence-hub.com/study/11678-an-open-label-mechanistic-study-to-examine-the-effect-of-oral2026-09-27 https://evidence-hub.com/study/11679-a-multicentre-international-randomized-parallel-group-double-blind2026-09-27 https://evidence-hub.com/study/11680-open-label-double-arm-controlled-randomized-multicentre-clinical2026-10-04 https://evidence-hub.com/study/11681-a-phase-i-randomised-double-blind-placebo-controlled-within-dose2026-09-27 https://evidence-hub.com/study/11682-effects-of-linagliptin-in-addition-to-empagliflozin-on-islet-cell2026-10-04 https://evidence-hub.com/study/11683-a-52-week-randomised-double-blind-placebo-controlled-parallel-group2026-09-27 https://evidence-hub.com/study/11684-effects-of-the-sglt2-inhibitor-empagliflozin-on-patients-with-siadh2026-09-27 https://evidence-hub.com/study/11685-an-open-label-balanced-randomized-two-treatment-two-sequence-two2026-09-27 https://evidence-hub.com/study/11686-effect-of-empagliflozin-10-vs-25-mg-on-lv-remodeling-in-diabetic2026-09-27 https://evidence-hub.com/study/11687-a-phase-iib-randomized-parallel-group-safety-efficacy-and2026-10-04 https://evidence-hub.com/study/11688-relative-bioavailability-of-pioglitazone-after-co-administration-with2026-09-27 https://evidence-hub.com/study/11689-relative-bioavailability-of-bi-10773-given-alone-and-together-with2026-09-27 https://evidence-hub.com/study/11690-empagliflozin-in-heart-failure-diuretic-and-cardiorenal-effects2026-10-01 https://evidence-hub.com/study/11691-heart-failure-outcomes-with-empagliflozin-in-patients-with-type-22026-10-01 https://evidence-hub.com/study/11692-how-does-empagliflozin-reduce-cardiovascular-mortality-insights-from2026-10-01 https://evidence-hub.com/study/11693-empagliflozin-increases-cardiac-energy-production-in-diabetes2026-10-01 https://evidence-hub.com/study/11694-empagliflozin-reduces-blood-pressure-in-patients-with-type-2-diabetes2026-09-29 https://evidence-hub.com/study/11695-empagliflozin-decreases-myocardial-cytoplasmic-na-through-inhibition2026-10-01 https://evidence-hub.com/study/11696-effect-of-empagliflozin-on-the-clinical-stability-of-patients-with2026-10-01 https://evidence-hub.com/study/11697-effects-of-empagliflozin-on-blood-pressure-and-markers-of-arterial2026-10-01 https://evidence-hub.com/study/11698-effect-of-empagliflozin-on-liver-fat-in-patients-with-type-2-diabetes2026-10-19 https://evidence-hub.com/study/11699-empagliflozin-a-novel-selective-sodium-glucose-cotransporter-2-sglt-22026-09-27 https://evidence-hub.com/study/11700-empagliflozin-as-add-on-to-metformin-plus-sulfonylurea-in-patients2026-10-08 https://evidence-hub.com/study/11701-empagliflozin-as-adjunctive-to-insulin-therapy-in-type-1-diabetes-the2026-09-27 https://evidence-hub.com/study/11702-empagliflozin-and-clinical-outcomes-in-patients-with-type-2-diabetes2026-10-01 https://evidence-hub.com/study/11703-the-effect-of-empagliflozin-on-arterial-stiffness-and-heart-rate2026-10-04 https://evidence-hub.com/study/11704-the-sglt2-inhibitor-empagliflozin-improves-the-primary-diabetic2026-10-04 https://evidence-hub.com/study/11705-sglt2-inhibitor-empagliflozin-reduces-renal-growth-and-albuminuria-in2026-09-27 https://evidence-hub.com/study/11706-effect-of-empagliflozin-on-cardiovascular-and-renal-outcomes-in2026-10-01 https://evidence-hub.com/study/11707-glycemic-control-with-empagliflozin-a-novel-selective-sglt2-inhibitor2026-10-04 https://evidence-hub.com/study/11708-cardiac-and-kidney-benefits-of-empagliflozin-in-heart-failure-across2026-10-01 https://evidence-hub.com/study/11709-evaluation-of-glomerular-hemodynamic-function-by-empagliflozin-in2026-10-01 https://evidence-hub.com/study/11710-empagliflozin-as-add-on-to-metformin-in-patients-with-type-2-diabetes2026-10-04 https://evidence-hub.com/study/11711-empagliflozin-directly-improves-diastolic-function-in-human-heart2026-10-01 https://evidence-hub.com/study/11712-empagliflozin-monotherapy-with-sitagliptin-as-an-active-comparator-in2026-09-29 https://evidence-hub.com/study/11714-effect-of-empagliflozin-on-left-ventricular-volumes-in-patients-with2026-10-01 https://evidence-hub.com/study/11715-empagliflozin-and-the-risk-of-heart-failure-hospitalization-in2026-10-01 https://evidence-hub.com/study/11716-empagliflozin-reduced-mortality-and-hospitalization-for-heart-failure2026-10-01 https://evidence-hub.com/study/11717-combination-of-empagliflozin-and-linagliptin-as-second-line-therapy2026-10-04 https://evidence-hub.com/study/11718-empagliflozin-reduces-ca-calmodulin-dependent-kinase-ii-activity-in2026-10-01 https://evidence-hub.com/study/11719-empagliflozin-for-type-2-diabetes-mellitus-an-overview-of-phase-32026-10-01 https://evidence-hub.com/study/11720-effect-of-empagliflozin-in-patients-with-heart-failure-across-the2026-10-01 https://evidence-hub.com/study/11721-effect-of-empagliflozin-on-worsening-heart-failure-events-in-patients2026-10-01 https://evidence-hub.com/study/11722-initial-combination-of-empagliflozin-and-linagliptin-in-subjects-with2026-09-27 https://evidence-hub.com/study/11723-renal-protective-effects-of-empagliflozin-via-inhibition-of-emt-and2026-10-01 https://evidence-hub.com/study/11724-pharmacokinetic-and-pharmacodynamic-profile-of-empagliflozin-a-sodium2026-10-01 https://evidence-hub.com/study/11725-efficacy-and-safety-of-empagliflozin-in-renal-transplant-recipients2026-09-27 https://evidence-hub.com/study/11726-interplay-of-mineralocorticoid-receptor-antagonists-and-empagliflozin2026-10-01 https://evidence-hub.com/study/11727-efficacy-and-safety-of-empagliflozin-for-type-2-diabetes-a-systematic2026-10-04 https://evidence-hub.com/study/11728-comparison-of-empagliflozin-and-glimepiride-as-add-on-to-metformin-in2026-10-04 https://evidence-hub.com/study/11729-cardiac-microvascular-endothelial-enhancement-of-cardiomyocyte2026-10-01 https://evidence-hub.com/study/11730-empagliflozin-a-review-in-type-2-diabetes2026-09-29 https://evidence-hub.com/study/11731-empagliflozin-improves-glycaemic-and-weight-control-as-add-on-therapy2026-10-04 https://evidence-hub.com/study/11732-improvement-in-cardiovascular-outcomes-with-empagliflozin-is2026-10-01 https://evidence-hub.com/study/11733-effect-of-empagliflozin-on-erythropoietin-levels-iron-stores-and-red2026-09-27 https://evidence-hub.com/study/11734-empagliflozin-prevents-doxorubicin-induced-myocardial-dysfunction2026-10-04 https://evidence-hub.com/study/11735-safety-tolerability-pharmacokinetics-and-pharmacodynamics-following-42026-09-27 https://evidence-hub.com/study/11736-empagliflozin-protects-heart-from-inflammation-and-energy-depletion2026-09-27 https://evidence-hub.com/study/11737-a-role-for-tubular-na-h-exchanger-nhe3-in-the-natriuretic-effect-of2026-09-27 https://evidence-hub.com/study/11739-empagliflozin-in-patients-with-heart-failure-reduced-ejection2026-10-01 https://evidence-hub.com/study/11740-improved-glucose-control-with-weight-loss-lower-insulin-doses-and-no2026-09-29 https://evidence-hub.com/study/11741-rationale-design-and-baseline-characteristics-of-a-randomized-placebo2026-10-01 https://evidence-hub.com/study/11742-effect-of-empagliflozin-on-left-ventricular-mass-and-diastolic2026-10-01 https://evidence-hub.com/study/11743-cardiac-late-sodium-channel-current-is-a-molecular-target-for-the2026-10-01 https://evidence-hub.com/study/11744-effects-of-empagliflozin-on-the-urinary-albumin-to-creatinine-ratio2026-09-29 https://evidence-hub.com/study/11745-empagliflozin-a-sodium-glucose-co-transporter-2-inhibitor-alleviates2026-10-01 https://evidence-hub.com/study/11746-sodium-glucose-transporter-2-sglt2-inhibition-with-empagliflozin2026-10-01 https://evidence-hub.com/study/11747-empagliflozin-prevents-worsening-of-cardiac-function-in-an2026-10-01 https://evidence-hub.com/study/11748-the-sodium-glucose-co-transporter-2-inhibitor-empagliflozin-improves2026-10-01 https://evidence-hub.com/study/11749-empagliflozin-blunts-worsening-cardiac-dysfunction-associated-with2026-10-01 https://evidence-hub.com/study/11750-effects-of-empagliflozin-versus-placebo-on-cardiac-sympathetic2026-10-01 https://evidence-hub.com/study/11751-effects-of-empagliflozin-on-renal-sodium-and-glucose-handling-in2026-10-01 https://evidence-hub.com/study/11752-sodium-glucose-co-transporter-2-inhibition-with-empagliflozin2026-10-01 https://evidence-hub.com/study/11753-pooled-analysis-of-phase-iii-trials-indicate-contrasting-influences2026-09-27 https://evidence-hub.com/study/11754-empagliflozin-and-major-renal-outcomes-in-heart-failure2026-10-01 https://evidence-hub.com/study/11755-safety-and-tolerability-of-empagliflozin-in-patients-with-type-22026-10-01 https://evidence-hub.com/study/11756-impact-of-empagliflozin-added-on-to-basal-insulin-in-type-2-diabetes2026-10-04 https://evidence-hub.com/study/11757-effects-of-empagliflozin-on-risk-for-cardiovascular-death-and-heart2026-10-01 https://evidence-hub.com/study/11758-associations-of-empagliflozin-with-left-ventricular-volumes-mass-and2026-10-04 https://evidence-hub.com/study/11759-sglt2-inhibitors-in-patients-with-heart-failure-with-reduced-ejection2026-10-13 https://evidence-hub.com/study/11760-comparative-effectiveness-of-glucose-lowering-drugs-for-type-22026-10-06 https://evidence-hub.com/study/11761-effects-of-anti-diabetic-drugs-on-fracture-risk-a-systematic-review2026-10-04 https://evidence-hub.com/study/11762-canagliflozin-dapagliflozin-and-empagliflozin-monotherapy-for2026-10-04 https://evidence-hub.com/study/11763-efficacy-and-safety-of-sodium-glucose-co-transporter-2-inhibitors-in2026-09-27 https://evidence-hub.com/study/11764-sglt2-inhibitors-for-the-prevention-of-kidney-failure-in-patients2026-10-13 https://evidence-hub.com/study/11765-comparative-cardiovascular-benefits-of-individual-sglt2-inhibitors-in2026-10-01 https://evidence-hub.com/study/11766-empagliflozin-and-other-sglt2-inhibitors-in-patients-with-heart2026-10-04 https://evidence-hub.com/study/11767-sglt2-inhibitors-and-cardiovascular-outcomes-in-heart-failure-with2026-10-06 https://evidence-hub.com/study/11768-evaluation-of-three-mechanisms-of-action-sglt2-inhibitors-glp-12026-10-06 https://evidence-hub.com/study/11769-efficacy-and-safety-of-11-sodium-glucose-cotransporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/11770-effects-of-empagliflozin-on-conventional-and-exploratory-acute-and2026-10-06 https://evidence-hub.com/study/11771-long-term-surrogate-cardiovascular-outcomes-of-sglt2-inhibitor2026-10-04 https://evidence-hub.com/study/11772-comparison-of-the-renal-outcomes-of-novel-antidiabetic-agents-in2026-10-06 https://evidence-hub.com/study/11773-healthcare-resource-utilization-in-patients-treated-with2026-10-06 https://evidence-hub.com/study/11774-comparison-of-effectiveness-among-different-sodium-glucose2026-10-06 https://evidence-hub.com/study/11775-efficacy-and-safety-of-empagliflozin-on-nonalcoholic-fatty-liver2026-10-01 https://evidence-hub.com/study/11776-association-of-glucose-lowering-medications-with-cardiovascular2026-10-06 https://evidence-hub.com/study/11777-efficacy-and-safety-of-empagliflozin-for-type-2-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/11778-efficacy-and-safety-of-empagliflozin-in-acute-heart-failure-a2026-10-06 https://evidence-hub.com/study/11779-differential-acute-kidney-injury-profiles-of-glp-1ras-and-sglt2is-a2026-10-06 https://evidence-hub.com/study/11780-efficacy-and-safety-of-empagliflozin-in-type-2-diabetes-mellitus-a2026-09-27 https://evidence-hub.com/study/11781-meta-analysis-of-the-efficacy-and-impact-on-cardiac-function-of2026-10-01 https://evidence-hub.com/study/11782-safety-and-tolerability-of-empagliflozin-in-patients-with-type-22026-10-01 https://evidence-hub.com/study/11783-systematic-literature-review-and-network-meta-analysis-of-sodium2026-10-04 https://evidence-hub.com/study/11784-comparison-the-effects-of-finerenone-and-sglt2i-on-cardiovascular-and2026-10-06 https://evidence-hub.com/study/11785-a-model-based-meta-analysis-study-of-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/11786-impact-of-sglt2-inhibitors-on-patient-outcomes-a-network-meta-analysis2026-10-06 https://evidence-hub.com/study/11787-admission-hemoglobin-levels-are-associated-with-functional-outcome-in2026-10-06 https://evidence-hub.com/study/11788-comparative-safety-of-different-sodium-glucose-transporter-22026-10-04 https://evidence-hub.com/study/11789-comparative-efficacy-of-glucose-lowering-medications-on-body-weight2026-10-04 https://evidence-hub.com/study/11790-mineralocorticoid-receptor-antagonists-with-sodium-glucose-co2026-10-06 https://evidence-hub.com/study/11791-efficacy-and-safety-of-empagliflozin-as-add-on-to-metformin-for-type2026-10-04 https://evidence-hub.com/study/11792-risk-of-pancreatitis-and-pancreatic-carcinoma-for-anti-diabetic2026-10-06 https://evidence-hub.com/study/11793-serum-uric-acid-lowering-and-effects-of-sodium-glucose-cotransporter2026-10-06 https://evidence-hub.com/study/11794-fixed-dose-combination-of-empagliflozin-and-linagliptin-for-the2026-10-04 https://evidence-hub.com/study/11795-body-mass-index-and-cardiorenal-outcomes-in-the-emperor-preserved2026-10-06 https://evidence-hub.com/study/11796-sglt2-inhibitors-in-patients-with-heart-failure-a-model-based-meta2026-10-06 https://evidence-hub.com/study/11797-sglt-inhibitors-on-weight-and-body-mass-a-meta-analysis-of-1162026-10-06 https://evidence-hub.com/study/11798-sodium-glucose-co-transporter-2-inhibitors-for-the-prevention-of2026-10-06 https://evidence-hub.com/study/11799-sodium-glucose-co-transporter-2-inhibitors-and-all-cause-mortality-a2026-10-06 https://evidence-hub.com/study/11800-sodium-glucose-co-transporter-2-sglt-2-inhibitors-and-cancer-a-meta2026-10-06 https://evidence-hub.com/study/11801-effects-of-sodium-glucose-cotransporter-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/11802-sglt-2i-and-risk-of-malignancy-in-type-2-diabetes-a-meta-analysis-of2026-10-04 https://evidence-hub.com/study/11803-sodium-glucose-co-transporter-2-inhibitors-and-major-adverse-limb2026-10-06 https://evidence-hub.com/study/11804-oral-semaglutide-for-type-2-diabetes-a-systematic-review-and-meta2026-10-06 https://evidence-hub.com/study/11805-sodium-glucose-co-transporter-2-inhibitors-and-the-risk-of-urosepsis2026-10-06 https://evidence-hub.com/study/11806-sodium-glucose-co-transporter-2-inhibitors-and-cardiovascular2026-10-01 https://evidence-hub.com/study/11807-effects-of-dapagliflozin-and-empagliflozin-on-6-min-walk-distance-in2026-10-01 https://evidence-hub.com/study/11808-empagliflozin-for-the-treatment-of-non-alcoholic-fatty-liver-disease2026-10-04 https://evidence-hub.com/study/11809-cardiovascular-outcomes-with-empagliflozin-and-dapagliflozin-in2026-10-06 https://evidence-hub.com/study/11810-effects-of-sglt-2-inhibitors-on-diabetic-ketoacidosis-a-meta-analysis2026-09-27 https://evidence-hub.com/study/11811-different-sodium-glucose-cotransporter-2-inhibitors-can-they-prevent2026-10-06 https://evidence-hub.com/study/11812-microvascular-benefits-of-new-antidiabetic-agents-a-systematic-review2026-10-06 https://evidence-hub.com/study/11813-comparison-of-the-risk-of-sglt2is-and-nonsglt2is-in-leading-to2026-10-06 https://evidence-hub.com/study/11814-influence-of-receptor-selectivity-on-benefits-from-sglt2-inhibitors2026-10-01 https://evidence-hub.com/study/11815-effects-of-sglt2-inhibitors-on-cardiovascular-outcomes-and-mortality2026-10-06 https://evidence-hub.com/study/11816-meta-analysis-of-effects-of-sodium-glucose-cotransporter-2-inhibitors2026-10-01 https://evidence-hub.com/study/11817-efficacy-and-safety-of-oral-semaglutide-in-the-treatment-of-type-22026-10-06 https://evidence-hub.com/study/11818-efficacy-of-once-weekly-semaglutide-vs-empagliflozin-added-to2026-10-04 https://evidence-hub.com/study/11819-the-impact-of-sglt2-inhibitors-on-inflammation-a-systematic-review2026-09-27 https://evidence-hub.com/study/11820-impacts-of-sodium-glucose-cotransporter-2-inhibitors-on-circulating2026-10-01 https://evidence-hub.com/study/11821-comparative-safety-of-the-sodium-glucose-co-transporter-2-sglt22026-10-01 https://evidence-hub.com/study/11822-beneficial-effect-of-sodium-glucose-co-transporter-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/11823-sglt2-inhibitors-and-risk-of-stroke-in-patients-with-type-2-diabetes2026-09-27 https://evidence-hub.com/study/11824-comparative-efficacy-of-sodium-glucose-cotransporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/11825-acute-kidney-injury-with-sodium-glucose-co-transporter-2-inhibitors-a2026-10-06 https://evidence-hub.com/study/11826-effect-of-sodium-glucose-cotransporter-2-inhibitors-on-insulin2026-10-04 https://evidence-hub.com/study/11827-dose-ranging-effects-of-sglt2-inhibitors-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/11828-safety-profile-of-sglt-2-inhibitors-in-older-adults-a-systematic2026-10-06 https://evidence-hub.com/study/11829-safety-outcomes-of-sglt2i-in-the-heart-failure-trials-a-systematic2026-10-06 https://evidence-hub.com/study/11830-sodium-glucose-cotransporter-2-inhibitors-in-patients-with-heart2026-10-06 https://evidence-hub.com/study/11831-model-based-meta-analysis-of-hba1c-reduction-across-sglt2-inhibitors2026-10-06 https://evidence-hub.com/study/11832-effects-of-sodium-glucose-cotransporter-2-inhibitors-on-nervous2026-10-06 https://evidence-hub.com/study/11833-long-term-effect-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/11834-medication-adherence-to-sodium-glucose-cotransporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/11835-sglt-2-inhibitors-and-cardiorenal-outcomes-in-patients-with-or2026-10-01 https://evidence-hub.com/study/11836-effects-of-sglt-2-inhibitors-on-mortality-and-cardiovascular-events-a2026-09-27 https://evidence-hub.com/study/11837-cardiovascular-safety-of-empagliflozin-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/11838-association-of-sglt2-inhibitors-with-risk-of-atrial-fibrillation-and2026-10-04 https://evidence-hub.com/study/11839-dose-dependent-renoprotection-efficacy-of-sglt2-inhibitors-in-type-22026-10-06 https://evidence-hub.com/study/11840-risk-of-amputation-associated-with-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/11841-sodium-glucose-cotransporter-2-inhibitors-and-new-onset-type-22026-10-06 https://evidence-hub.com/study/11842-the-impact-of-pharmacological-and-lifestyle-interventions-on-body2026-10-04 https://evidence-hub.com/study/11843-association-between-sodium-glucose-cotransporter-2-sglt2-inhibitors2026-10-01 https://evidence-hub.com/study/11844-the-efficacy-and-safety-of-empagliflozin-on-outcomes-of-patients-with2026-10-04 https://evidence-hub.com/study/11845-effects-of-sodium-glucose-cotransporter-2-inhibitors-on-24-hour2026-10-06 https://evidence-hub.com/study/11846-impact-of-empagliflozin-and-dapagliflozin-on-sudden-cardiac-death-a2026-10-04 https://evidence-hub.com/study/11847-effects-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-and2026-10-06 https://evidence-hub.com/study/11848-effects-of-sodium-glucose-cotransporter-2-inhibitors-on-serum-uric2026-09-27 https://evidence-hub.com/study/11849-relationship-between-sglt-2i-and-ocular-diseases-in-patients-with2026-10-04 https://evidence-hub.com/study/11850-acute-kidney-injury-and-adverse-renal-events-in-patients-receiving2026-10-01 https://evidence-hub.com/study/11851-comparison-of-new-oral-hypoglycemic-agents-on-risk-of-urinary-tract2026-10-06 https://evidence-hub.com/study/11852-are-sglt2-inhibitors-really-associated-with-increased-urinary-tract2026-10-13 https://evidence-hub.com/study/11853-sglt2-inhibitors-and-secondary-polycythemia-a-systematic-review-and2026-10-06 https://evidence-hub.com/study/11854-impact-of-empagliflozin-on-liver-fat-reduction-in-type-2-diabetes-and2026-10-06 https://evidence-hub.com/study/11855-impact-of-sglt2-inhibitors-on-mortality-across-different-populations2026-10-06 https://evidence-hub.com/study/11856-sglt2-inhibitors-are-associated-with-reductions-in-epicardial-adipose2026-10-06 https://evidence-hub.com/study/11857-comparison-of-effectiveness-and-safety-of-bexagliflozin-and-other2026-10-06 https://evidence-hub.com/study/11858-assessing-the-risk-of-diabetic-retinopathy-progression-with-glp-12026-10-06 https://evidence-hub.com/study/11859-efficacy-and-safety-of-novel-antidiabetic-drugs-in-patients-with-type2026-10-06 https://evidence-hub.com/study/11860-glucose-cotransporter-2-inhibitors-on-mortality-and-hospitalization2026-10-06 https://evidence-hub.com/study/11861-the-primary-preventive-effect-of-sodium-glucose-cotransporter2026-10-06 https://evidence-hub.com/study/11862-cardiorenal-safety-and-efficacy-of-sotagliflozin-a-stratified-meta2026-10-06 https://evidence-hub.com/study/11863-the-effects-of-sglt2-inhibitors-on-muscle-health-in-older-adults-a2026-10-06 https://evidence-hub.com/study/11864-effect-of-sodium-glucose-cotransporter-2-inhibitors-on-haemoglobin2026-10-06 https://evidence-hub.com/study/11865-impact-of-diabetes-on-the-effects-of-sglt2-inhibitors-on-kidney2026-10-06 https://evidence-hub.com/study/11866-effects-of-sodium-glucose-cotransporter-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/11867-effect-of-sodium-glucose-cotransporter-2-inhibitors-on-fracture-risk2026-10-08 https://evidence-hub.com/study/11868-interrelationship-between-baseline-hba1c-sglt-2-inhibitor-use-and2026-10-06 https://evidence-hub.com/study/11869-impact-of-sodium-glucose-cotransporter-2-inhibitors-on-heart-failure2026-10-13 https://evidence-hub.com/study/11870-combination-therapy-with-mineralocorticoid-receptor-antagonists-and2026-10-06 https://evidence-hub.com/study/11871-blood-pressure-effects-of-sglt2-inhibitors-in-kidney-transplant2026-10-06 https://evidence-hub.com/study/11872-cardiovascular-outcomes-of-novel-sglt2-inhibitors-in-patients-with2026-10-06 https://evidence-hub.com/study/11873-comparative-effects-of-sglt2-inhibitors-on-erythropoiesis-a2026-10-06 https://evidence-hub.com/study/11874-cardiopulmonary-remodeling-in-nondiabetic-patients-with-systolic2026-10-06 https://evidence-hub.com/study/11875-the-effects-of-combined-antihypertensive-and-antidiabetic-therapies2026-10-06 https://evidence-hub.com/study/11876-heart-failure-outcomes-with-sglt2-inhibitors-in-adults-with-type-22026-10-06 https://evidence-hub.com/study/11877-risk-of-dementia-in-patients-with-type-2-diabetes-using-sglt22026-10-06 https://evidence-hub.com/study/11878-efficacy-and-safety-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/11879-sodium-glucose-cotransporter-2-inhibitors-and-risk-of-diabetic2026-10-06 https://evidence-hub.com/study/11880-non-antiarrhythmic-pharmacotherapy-in-cardio-renal-metabolic-disease2026-10-06 https://evidence-hub.com/study/11881-comparative-efficacy-and-safety-of-different-sglt2-inhibitor-based2026-10-06 https://evidence-hub.com/study/11882-sglt2-inhibitors-and-the-risk-of-infections-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/11883-safety-of-sglt-2-inhibitors-in-patients-with-glycogen-storage-disease2026-10-06 https://evidence-hub.com/study/11884-effects-of-different-dosages-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/11885-sex-differences-in-trial-representation-and-the-cardiovascular2026-10-06 https://evidence-hub.com/study/11886-sodium-glucose-cotransporter-2-inhibitors-association-with-risk-of2026-10-06 https://evidence-hub.com/study/11887-prevention-of-atrial-fibrillation-with-sglt2-inhibitors-across-the2026-10-06 https://evidence-hub.com/study/11888-sglt-2-inhibitors-after-acute-coronary-syndrome-as-preventive2026-10-06 https://evidence-hub.com/study/11889-efficacy-and-safety-of-sodium-glucose-cotransporter-2-inhibitors-as2026-10-06 https://evidence-hub.com/study/11890-efficacy-of-hypoglycemic-agents-in-metabolic-dysfunction-associated2026-10-04 https://evidence-hub.com/study/11891-time-to-rethink-icd-indications-in-non-ishaemic-cardiomyopathy2026-10-06 https://evidence-hub.com/study/11892-glp-1-receptor-agonists-for-weight-loss-a-systematic-review-and-meta2026-10-06 https://evidence-hub.com/study/11893-effects-of-sodium-glucose-cotransporter-2-inhibitors-on-serum-urate2026-10-06 https://evidence-hub.com/study/11894-tolerability-and-efficacy-of-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/11895-clinical-features-and-outcomes-of-diabetic-ketoacidosis-in-patients2026-10-06 https://evidence-hub.com/study/11896-glp1-receptor-agonists-and-sglt2-inhibitors-for-the-prevention-or2026-10-06 https://evidence-hub.com/study/11897-cardiovascular-limb-and-kidney-effects-of-sglt2-inhibitors-in2026-10-06 https://evidence-hub.com/study/11898-effect-of-sglt2-inhibitors-on-liver-fat-content-a-meta-analysis2026-10-06 https://evidence-hub.com/study/11899-real-world-effectiveness-of-sglt2-inhibitors-across-heart-failure2026-10-06 https://evidence-hub.com/study/11900-hypouricemic-effect-of-sodium-glucose-transporter-2-inhibitors-a2026-10-06 https://evidence-hub.com/study/11901-unlocking-the-power-of-empagliflozin-rescuing-inflammation-in2026-10-01 https://evidence-hub.com/study/11902-effects-of-new-hypoglycemic-drugs-on-patients-with-heart-failure-a2026-10-10 https://evidence-hub.com/study/11903-network-and-pairwise-meta-analysis-of-the-association-between-novel2026-10-06 https://evidence-hub.com/study/11904-renal-protection-at-a-metabolic-cost-a-systematic-review-and-meta2026-10-06 https://evidence-hub.com/study/11905-efficacy-and-safety-of-combination-therapy-using-sglt2-and-dpp42026-10-06 https://evidence-hub.com/study/11906-comparative-effects-of-sglt2-inhibitors-and-incretin-based-therapies2026-10-06 https://evidence-hub.com/study/11907-do-sglt2-inhibitors-improve-cardiovascular-outcomes-after-acute2026-10-06 https://evidence-hub.com/study/11908-redefining-treatment-paradigms-early-use-of-dapagliflozin-and2026-10-01 https://evidence-hub.com/study/11909-sodium-glucose-co-transporter-2-inhibitors-and-new-onset-diabetes-in2026-10-06 https://evidence-hub.com/study/11910-effects-of-glp-1-receptor-agonists-and-dual-gip-glp-1-receptor2026-10-06 https://evidence-hub.com/study/11911-the-different-colorectal-tumor-risk-related-to-glp-1-receptor2026-10-06 https://evidence-hub.com/study/11912-the-impact-of-sglt2-inhibitors-on-renal-outcomes-in-patients-with2026-10-06 https://evidence-hub.com/study/11913-sodium-glucose-cotransporter-2-inhibitors-in-diabetic-solid-organ2026-10-06 https://evidence-hub.com/study/11914-comparative-efficacy-and-safety-of-sglt2-inhibitor-class-members-in2026-10-06 https://evidence-hub.com/study/11915-agent-and-dose-specific-intestinal-obstruction-safety-of-glp-12026-10-06 https://evidence-hub.com/study/11916-impact-of-liraglutide-on-albumin-to-creatinine-ratio-in-type-22026-10-06 https://evidence-hub.com/study/11917-the-impact-of-new-tetralogy-drugs-on-ventricular-remodeling-in-heart2026-10-06 https://evidence-hub.com/study/11918-effect-of-sglt2-inhibitors-on-cardiac-structure-and-function-assessed2026-10-06 https://evidence-hub.com/study/11919-dapagliflozin-improves-hemoglobin-and-anemia-in-chronic-kidney2026-10-06 https://evidence-hub.com/study/11920-effectiveness-of-sglt2-inhibitors-compared-to-sulphonylureas-for-long2026-10-06 https://evidence-hub.com/study/11921-the-influence-of-sodium-glucose-co-transporter-2-inhibitors-on-the2026-10-06 https://evidence-hub.com/study/11922-early-initiation-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/11923-the-impact-of-sodium-glucose-cotransporter-2-inhibitors-on-breast2026-10-06 https://evidence-hub.com/study/11924-comparative-cardiovascular-outcomes-of-dapagliflozin-versus2026-10-04 https://evidence-hub.com/study/11925-empagliflozin-treatment-for-non-alcoholic-fatty-liver-disease-in-type2026-10-04 https://evidence-hub.com/study/11927-the-effect-of-empagliflozin-on-cardiovascular-outcomes-in-patients2026-10-06 https://evidence-hub.com/study/11928-the-effect-of-empagliflozin-on-cardiac-function-and-structure-in2026-10-01 https://evidence-hub.com/study/11929-effect-of-empagliflozin-on-cardiovascular-mortality-and-heart-failure2026-10-04 https://evidence-hub.com/study/11930-efficacy-and-safety-of-empagliflozin-for-treating-neutropenia-and2026-10-06 https://evidence-hub.com/study/11931-3065-effect-of-dapagliflozin-and-empagliflozin-on-phosphate-fgf232026-10-06 https://evidence-hub.com/study/11932-comparative-efficacy-of-dapagliflozin-and-empagliflozin-on2026-10-06 https://evidence-hub.com/study/11933-clinical-outcomes-of-empagliflozin-in-the-treatment-of-acute-heart2026-10-06 https://evidence-hub.com/study/11934-comparative-efficacy-and-safety-of-individual-sglt2-inhibitors2026-10-06 https://evidence-hub.com/study/11936-efficacy-and-safety-comparison-between-empagliflozin-and-linagliptin2026-10-04 https://evidence-hub.com/study/11937-empagliflozin-for-liver-and-lipid-profile-in-metabolic-dysfunction2026-10-04 https://evidence-hub.com/study/11938-efficacy-and-safety-of-sglt2-inhibitor-empagliflozin-in-t2dm-with2026-10-01 https://evidence-hub.com/study/11946-the-comparison-of-the-effectiveness-of-dapagliflozin-and2026-10-06 https://evidence-hub.com/study/11947-abstract-4139688-empagliflozin-versus-placebo-in-patients-with2026-10-06 https://evidence-hub.com/study/11948-abstract-4144695-comparative-cardiovascular-efficacy-of-empagliflozin2026-10-06 https://evidence-hub.com/study/11949-abstract-4136969-empagliflozin-s-role-in-post-myocardial-infarction2026-10-06 https://evidence-hub.com/study/11950-assessing-the-effectiveness-and-safety-of-empagliflozin-in-type-22026-10-06 https://evidence-hub.com/study/11951-abstract-4144446-efficacy-and-safety-of-empagliflozin-after-acute2026-10-06 https://evidence-hub.com/study/11953-empagliflozin-effect-on-left-cardiac-parameters-in-acute-coronary2026-10-04 https://evidence-hub.com/study/11954-abstract-4113561-efficacy-and-outcomes-of-empagliflozin-in-acute2026-10-06 https://evidence-hub.com/study/11955-abstract-4121215-efficacy-and-safety-of-empagliflozin-in-patients2026-10-06 https://evidence-hub.com/study/11956-abstract-4145162-empagliflozin-effect-on-left-cardiac-parameters-in2026-10-06 https://evidence-hub.com/study/11957-effects-of-empagliflozin-on-serum-uric-acid-level-of-patients-with2026-10-04 https://evidence-hub.com/study/11963-abstract-13815-therapeutic-effects-of-empagliflozin-in-diabetic2026-10-06 https://evidence-hub.com/study/11964-efficacy-of-empagliflozin-therapy-in-patient-with-acute-heart-failure2026-10-06 https://evidence-hub.com/study/11965-abstract-12740-efficacy-and-safety-of-empagliflozin-in-acute-heart2026-10-06 https://evidence-hub.com/study/11966-comparative-efficacy-of-tirzepatide-teneligliptin-and-empagliflozin2026-10-04 https://evidence-hub.com/study/11967-empagliflozin-in-patients-with-myocardial-infarction-an-updated-meta2026-10-06 https://evidence-hub.com/study/11969-comparative-efficacy-of-dapagliflozin-and-empagliflozin-of-a-fixed2026-10-06 https://evidence-hub.com/study/11970-comparison-of-cardiovascular-outcomes-between-dapagliflozin-and2026-10-04 https://evidence-hub.com/study/11971-efficacy-of-empagliflozin-in-patients-with-metabolic-dysfunction2026-10-04 https://evidence-hub.com/study/11972-relative-efficacy-and-safety-of-canagliflozin-dapagliflozin2026-10-06 https://evidence-hub.com/study/11973-p150-ece-1744-empagliflozin-for-the-treatment-of-postprandial2026-10-06 https://evidence-hub.com/study/11974-empagliflozin-in-patients-with-heart-failure-a-systematic-review-and2026-10-01 https://evidence-hub.com/study/11975-evaluating-the-comparative-effectiveness-of-sodium-glucose2026-10-06 https://evidence-hub.com/study/11976-sodium-glucose-cotransporter-2-sglt2-inhibitors-and-risk-of-heart2026-10-06 https://evidence-hub.com/study/11977-impact-of-sodium-glucose-cotransporter-2-inhibitors-sglt2i-on2026-10-06 https://evidence-hub.com/study/11980-efficacy-of-acupuncture-in-increasing-quality-of-life-in-hypertension2026-10-06 https://evidence-hub.com/study/11981-2483-hyponatremia-in-elderly-a-systematic-review-and-meta-analysis2026-10-06 https://evidence-hub.com/study/11982-comparative-efficacy-of-empagliflozin-versus-placebo-in-the-treatment2026-10-04 https://evidence-hub.com/study/11983-efficacy-of-transcutaneous-electrical-acupoint-stimulation-teas-in2026-10-06 https://evidence-hub.com/study/11984-efficacy-of-renal-denervation-towards-ambulatory-blood-pressure2026-10-06 https://evidence-hub.com/study/11985-novel-antidiabetic-drugs-and-the-risk-of-diabetic-retinopathy-a2026-10-06 https://evidence-hub.com/study/11987-abstract-4369642-efficacy-of-sodium-glucose-transport-protein-22026-10-06 https://evidence-hub.com/study/11988-body-mass-index-dependent-therapeutic-efficacy-in-hfmref-and-hfpef-a2026-10-06 https://evidence-hub.com/study/11990-anti-diabetic-drugs-and-weight-loss-in-patients-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/11991-clinical-efficacy-and-safety-of-sodium-glucose-cotransporter-protein2026-10-06 https://evidence-hub.com/study/11992-impact-of-heart-failure-medications-on-cognitive-function-a2026-10-06 https://evidence-hub.com/study/11993-a-therapeutic-atlas-of-monogenic-inflammatory-bowel-disease2026-10-06 https://evidence-hub.com/study/11994-a-systematic-critical-review-of-clinical-pharmacokinetics-of2026-10-06 https://evidence-hub.com/study/11995-efficacy-of-peroxisome-proliferator-activated-receptor-agonists2026-09-27 https://evidence-hub.com/study/11996-sacubitril-valsartan-sodium-glucose-cotransporter-2-inhibitors-and2026-10-06 https://evidence-hub.com/study/11997-rationality-efficacy-tolerability-of-empagliflozin-plus-linagliptin2026-10-04 https://evidence-hub.com/study/11998-sodium-glucose-cotransporter-2-inhibitors-and-cardiovascular2026-10-04 https://evidence-hub.com/study/11999-cost-effectiveness-of-empagliflozin-for-the-treatment-of-heart2026-10-01 https://evidence-hub.com/study/12000-sodium-glucose-cotransporter-2-inhibitors-glucose-lowering-against2026-10-06 https://evidence-hub.com/study/12001-pharmacoeconomic-evaluation-of-sodium-glucose-transporter-2-sglt22026-10-06 https://evidence-hub.com/study/12002-sglt2-inhibitors-a-systematic-review-of-diabetic-ketoacidosis-and2026-09-27 https://evidence-hub.com/study/12003-the-role-of-glucagon-in-the-possible-mechanism-of-cardiovascular2026-10-06 https://evidence-hub.com/study/12004-systematic-review-of-sodium-glucose-cotransporter-2-inhibitors-a2026-10-04 https://evidence-hub.com/study/12005-protective-effects-of-sodium-glucose-transporter-2-inhibitors-on2026-10-01 https://evidence-hub.com/study/12006-systematic-review-of-metformin-monotherapy-and-dual-therapy-with2026-10-04 https://evidence-hub.com/study/12007-the-impact-of-sglt2-inhibitors-on-pulmonary-artery-pressures-and2026-10-06 https://evidence-hub.com/study/12008-the-effect-of-sglt-2-inhibitors-on-cardiorespiratory-fitness-capacity2026-10-06 https://evidence-hub.com/study/12009-systematic-review-of-the-economic-evaluation-of-sodium-glucose2026-10-06 https://evidence-hub.com/study/12010-the-gut-heart-axis-effects-of-intestinal-microbiome-modulation-on2026-10-06 https://evidence-hub.com/study/12011-renal-and-cardiac-implications-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/12012-cardiorenal-outcomes-in-the-canvas-declare-timi-58-and-empa-reg2026-09-29 https://evidence-hub.com/study/12013-efficacy-of-sodium-glucose-cotransporter-2-inhibitors-in-patients2026-10-06 https://evidence-hub.com/study/12014-expanding-access-to-sodium-glucose-cotransporter-2-inhibitors-sglt2i2026-10-06 https://evidence-hub.com/study/12015-efficacy-of-sodium-glucose-cotransporter-2-inhibitors-in-heart2026-10-06 https://evidence-hub.com/study/12016-cost-effectiveness-of-dapagliflozin-for-the-treatment-of-heart2026-10-06 https://evidence-hub.com/study/12017-exploring-the-clinical-pharmacokinetics-and-pharmacodynamics-of-sglt22026-10-06 https://evidence-hub.com/study/12018-renal-protective-effect-and-safety-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/12019-sodium-glucose-cotransporter-2-inhibitors-and-risk-of-diabetic2026-10-06 https://evidence-hub.com/study/12020-comparative-efficacy-and-safety-of-glucose-lowering-drugs-as2026-10-04 https://evidence-hub.com/study/12021-efficacy-of-off-label-therapy-for-non-alcoholic-fatty-liver-disease2026-10-06 https://evidence-hub.com/study/12022-combinational-therapy-with-metformin-and-sodium-glucose-cotransporter2026-10-08 https://evidence-hub.com/study/12023-effectiveness-of-sglt2-inhibitors-in-slowing-chronic-kidney-disease2026-10-06 https://evidence-hub.com/study/12024-efficacy-of-combined-sodium-glucose-cotransporter-2-inhibitors-and2026-10-06 https://evidence-hub.com/study/12025-efficacy-of-sglt2-inhibitors-in-preventing-end-stage-kidney-disease2026-10-06 https://evidence-hub.com/study/12026-economic-evaluation-of-sodium-glucose-transporter-2-inhibitors2026-10-04 https://evidence-hub.com/study/12027-chronic-kidney-disease-ckd-systematic-review-of-the-cost2026-10-06 https://evidence-hub.com/study/12028-safety-evaluation-of-sodium-glucose-cotransporter-2-inhibitors-for2026-10-06 https://evidence-hub.com/study/12029-the-impact-of-early-in-hospital-use-of-sglt2-inhibitors-on-outcomes2026-10-06 https://evidence-hub.com/study/12030-application-of-sglt2-inhibitors-in-kidney-diseases-a-bibliometric2026-10-06 https://evidence-hub.com/study/12031-novel-antidiabetic-agents-and-the-risk-of-respiratory-diseases-a2026-10-06 https://evidence-hub.com/study/12032-cost-effectiveness-of-sodium-glucose-co-transporter-2-inhibitors-and2026-10-06 https://evidence-hub.com/study/12033-clinical-advances-in-heart-failure-with-preserved-ejection-fraction-a2026-10-06 https://evidence-hub.com/study/12034-the-efficacy-and-safety-of-sodium-glucose-cotransporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/12035-heart-failure-with-reduced-ejection-fraction-a-systematic-review-of2026-10-06 https://evidence-hub.com/study/12036-sglt2-inhibitors-and-incretin-based-therapies-for-metabolic2026-10-08 https://evidence-hub.com/study/12037-long-term-effects-of-sglt2-inhibitors-on-arrhythmias-a-systematic2026-10-06 https://evidence-hub.com/study/12038-impact-of-sglt2-inhibitors-on-clinical-outcomes-in-patients-with2026-10-06 https://evidence-hub.com/study/12039-from-bench-to-bedside-investigating-sglt2-inhibitors-as-a-novel2026-10-06 https://evidence-hub.com/study/12040-the-preventive-effect-of-sodium-glucose-co-transporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/12041-investigating-the-effect-of-sglt2-inhibitors-on-cardiovascular2026-10-06 https://evidence-hub.com/study/12042-effect-of-hypoglycemic-drugs-on-patients-with-heart-failure-with-or2026-10-06 https://evidence-hub.com/study/12043-peripheral-nerve-complications-from-medications-utilised-for-weight2026-10-06 https://evidence-hub.com/study/12044-efficacy-and-safety-of-sglt2-inhibitors-in-acute-heart-failure-a2026-10-06 https://evidence-hub.com/study/12045-efficacy-and-safety-of-early-initiation-of-sodium-glucose-co2026-10-06 https://evidence-hub.com/study/12046-global-long-term-cost-effectiveness-of-newer-antidiabetic-drugs-for2026-10-06 https://evidence-hub.com/study/12047-the-impact-of-sglt2-inhibitors-on-cardiac-remodeling-after-myocardial2026-10-06 https://evidence-hub.com/study/12048-what-should-the-doctor-prescribe-formula-diet-or-antidiabetics2026-10-06 https://evidence-hub.com/study/12049-association-of-sglt2-inhibitors-with-post-ablation-atrial2026-10-06 https://evidence-hub.com/study/12050-gender-bias-in-clinical-trials-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/12051-role-of-sodium-glucose-cotransporter-2-inhibitors-in-managing2026-10-06 https://evidence-hub.com/study/12052-a-systematic-review-and-expert-evaluation-of-perioperative-sglt22026-10-06 https://evidence-hub.com/study/12053-cardiovascular-outcomes-of-sglt2-inhibitors-versus-glp-1-receptor2026-10-06 https://evidence-hub.com/study/12054-empagliflozin-and-cardiovascular-outcomes-a-systematic-review-of2026-10-01 https://evidence-hub.com/study/12055-evaluating-the-clinical-outcomes-of-empagliflozin-in-heart-failure2026-10-06 https://evidence-hub.com/study/12056-effectiveness-of-empagliflozin-in-treating-patients-with-heart2026-10-06 https://evidence-hub.com/study/12057-the-effects-of-empagliflozin-on-ventricular-arrhythmias-in-heart2026-10-06 https://evidence-hub.com/study/12058-comparative-effects-of-empagliflozin-and-semaglutide-on-left2026-10-06 https://evidence-hub.com/study/12059-efficacy-of-empagliflozin-versus-placebo-in-patients-with-recent2026-10-06 https://evidence-hub.com/study/12060-efficacy-and-safety-of-empagliflozin-to-reduce-atrial-fibrillation2026-10-06 https://evidence-hub.com/study/12061-empagliflozin-and-colchicine-in-patients-with-reduced-left2026-10-06 https://evidence-hub.com/study/12062-evaluating-the-beneficial-effect-of-empagliflozin-in-reducing2026-10-06 https://evidence-hub.com/study/12063-efficacy-of-empagliflozin-as-a-novel-therapeutic-agent-for2026-10-06 https://evidence-hub.com/study/12064-empagliflozin-treatment-for-patients-with-heart-failure-with2026-10-06 https://evidence-hub.com/study/12065-cost-effectiveness-of-empagliflozin-in-patients-with-chronic-heart2026-10-06 https://evidence-hub.com/study/12066-empagliflozin-in-the-absence-of-diabetes-a-systematic-review-of-its2026-10-06 https://evidence-hub.com/study/12067-empagliflozin-ameliorates-progression-from-prediabetes-to-diabetes2026-10-01 https://evidence-hub.com/study/12068-a-systematic-review-exploring-the-cardiovascular-and-renal-effects-of2026-10-01 https://evidence-hub.com/study/12069-efficacy-and-safety-of-empagliflozin-in-type-1-diabetes-mellitus2026-10-01 https://evidence-hub.com/study/12070-sodium-glucose-cotransporter-2-sglt2-inhibitors-in-non-diabetic-heart2026-10-06 https://evidence-hub.com/study/12071-efficacy-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-in-heart2026-10-06 https://evidence-hub.com/study/12072-the-gut-heart-axis-exploring-the-role-of-the-gut-microbiome-in2026-10-06 https://evidence-hub.com/study/12073-efficacy-of-sodium-glucose-cotransporter-2-inhibitors-in-patients2026-10-06 https://evidence-hub.com/study/12074-sodium-glucose-cotransporter-2-sglt2-inhibitors-in-heart-failure-with2026-10-06 https://evidence-hub.com/study/12075-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials2026-10-01 https://evidence-hub.com/study/12076-adverse-drug-events-associated-with-low-dose-10-mg-versus-high-dose2026-10-04 https://evidence-hub.com/study/12077-empagliflozin-use-and-fournier-s-gangrene-case-report-and-systematic2026-10-06 https://evidence-hub.com/study/12078-efficacy-of-sacubitril-valsartan-versus-olmesartan-in-patients-with2026-10-06 https://evidence-hub.com/study/12079-a-systematic-review-on-effect-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/12080-cost-effectiveness-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/12081-effects-of-glucagon-like-peptide-1-receptor-agonists-and-sodium2026-10-06 https://evidence-hub.com/study/12082-effects-of-sglt-2-inhibitors-on-clinical-and-biological2026-10-06 https://evidence-hub.com/study/12083-effect-of-empagliflozin-on-liver-function-in-type-2-diabetes-a2026-10-01 https://evidence-hub.com/study/12084-impact-of-sodium-glucose-cotransporter-2-inhibitors-on-cardiovascular2026-10-06 https://evidence-hub.com/study/12085-sodium-glucose-cotransporter-2-sglt2-inhibitors-for-acute-heart2026-10-06 https://evidence-hub.com/study/12086-intra-myocardial-hemorrhage-and-cardiac-microvascular-injury-in2026-10-06 https://evidence-hub.com/study/12087-spotlight-on-empagliflozin-metformin-fixed-dose-combination-for-the2026-10-04 https://evidence-hub.com/study/12089-a-5-2-intermittent-fasting-meal-replacement-diet-and-glycemic-control2026-10-06 https://evidence-hub.com/study/12090-a-randomized-trial-of-empagliflozin-to-increase-plasma-sodium-levels2026-10-01 https://evidence-hub.com/study/12091-effects-of-empagliflozin-on-fluid-overload-weight-and-blood-pressure2026-10-06 https://evidence-hub.com/study/12092-initial-combination-of-empagliflozin-and-metformin-in-patients-with2026-10-08 https://evidence-hub.com/study/12093-treatment-effect-of-the-sglt2-inhibitor-empagliflozin-on-chronic2026-10-06 https://evidence-hub.com/study/12094-how-do-sglt2-inhibitors-protect-the-kidney-a-mediation-analysis-of2026-10-01 https://evidence-hub.com/study/12095-comparison-of-efficacy-and-safety-profile-of-empagliflozin-versus2026-10-06 https://evidence-hub.com/study/12096-simultaneous-initiation-of-finerenone-and-empagliflozin-across-the2026-10-06 https://evidence-hub.com/study/12097-frailty-multimorbidity-and-polypharmacy-exploratory-analyses-of-the2026-10-06 https://evidence-hub.com/study/12098-empagliflozin-for-heart-failure-with-preserved-left-ventricular2026-10-06 https://evidence-hub.com/study/12099-comparison-of-the-effects-of-empagliflozin-and-sitagliptin-as-an-add2026-10-08 https://evidence-hub.com/study/12100-effects-of-empagliflozin-on-urine-biomarkers-in-empa-kidney2026-10-06 https://evidence-hub.com/study/12101-empagliflozin-in-patients-admitted-to-hospital-with-covid-19-recovery2026-10-01 https://evidence-hub.com/study/12102-sodium-glucose-co-transporter-2-inhibitors-sglt2is-effect-on-erectile2026-10-06 https://evidence-hub.com/study/12103-acute-and-chronic-effects-of-sglt2-inhibitor-empagliflozin-on-renal2026-10-06 https://evidence-hub.com/study/12104-effects-of-vicadrostat-empagliflozin-in-people-with-chronic-kidney2026-10-06 https://evidence-hub.com/study/12105-empagliflozin-after-myocardial-infarction-with-or-without-diabetes2026-10-06 https://evidence-hub.com/study/12106-empagliflozin-improves-insulin-sensitivity-of-the-hypothalamus-in2026-10-06 https://evidence-hub.com/study/12107-effect-of-empagliflozin-on-ectopic-fat-stores-and-myocardial2026-10-04 https://evidence-hub.com/study/12108-pharmacodynamics-of-vicadrostat-for-aldosterone-synthase-inhibition2026-10-06 https://evidence-hub.com/study/12109-efficacy-and-safety-of-pioglitazone-empagliflozin-and-glimepiride-as2026-10-06 https://evidence-hub.com/study/12110-empagliflozin-versus-metformin-for-glucose-variability-and-metabolic2026-10-06 https://evidence-hub.com/study/12111-the-effects-of-sodium-glucose-transporter-2-inhibition-on-cardiac2026-10-06 https://evidence-hub.com/study/12112-the-effect-of-empagliflozin-sodium-glucose-cotransporter-2-inhibitor2026-10-08 https://evidence-hub.com/study/12113-effect-of-hyperglycemia-and-empagliflozin-on-markers-of-cardiorenal2026-10-06 https://evidence-hub.com/study/12114-choice-of-endpoint-in-kidney-outcome-trials-considerations-from-the2026-10-01 https://evidence-hub.com/study/12115-the-effects-of-empagliflozin-on-systemic-haemodynamic-function-three2026-10-06 https://evidence-hub.com/study/12116-effects-of-empagliflozin-in-patients-with-chronic-kidney-disease-from2026-10-06 https://evidence-hub.com/study/12117-baseline-kidney-function-albuminuria-and-urine-albumin-creatinine2026-10-06 https://evidence-hub.com/study/12118-association-between-change-in-ambulatory-pulmonary-artery-pressures2026-10-06 https://evidence-hub.com/study/12119-effect-of-long-term-continuous-cardiac-monitoring-vs-usual-care-on2026-10-06 https://evidence-hub.com/study/12120-effect-of-empagliflozin-on-liver-fibrosis-and-steatosis-in-patients2026-10-06 https://evidence-hub.com/study/12121-empagliflozin-reduces-risk-of-hospitalization-in-patients-with2026-10-06 https://evidence-hub.com/study/12122-comparative-effects-of-empagliflozin-and-metformin-on-metabolic2026-10-06 https://evidence-hub.com/study/12123-empagliflozin-normalizes-fasting-hyperglycemia-and-improves2026-10-06 https://evidence-hub.com/study/12124-empagliflozin-effects-on-iron-metabolism-as-a-possible-mechanism-for2026-10-01 https://evidence-hub.com/study/12125-effects-of-glucagon-like-peptide-1-receptor-agonists-sodium-glucose2026-10-06 https://evidence-hub.com/study/12126-overall-and-inter-individual-effect-of-four-different-drug-classes-on2026-10-06 https://evidence-hub.com/study/12127-empagliflozin-for-the-preservation-of-beta-cell-function-in-women2026-10-06 https://evidence-hub.com/study/12128-glp-1ra-therapy-increases-circulating-vascular-regenerative-cell2026-10-06 https://evidence-hub.com/study/12129-short-and-mid-term-effects-of-empagliflozin-on-sodium-balance-and2026-10-06 https://evidence-hub.com/study/12130-sirtuins-and-regulatory-mirnas-as-epigenetic-determinants-of2026-10-04 https://evidence-hub.com/study/12131-effects-of-semaglutide-empagliflozin-and-their-combination-on-renal2026-10-06 https://evidence-hub.com/study/12132-an-increase-in-plasma-sodium-levels-is-associated-with-an-increase-in2026-10-06 https://evidence-hub.com/study/12133-heart-failure-therapy-in-patients-with-advanced-cancer-receiving2026-10-06 https://evidence-hub.com/study/12134-effects-of-empagliflozin-in-heart-failure-patients-with-type-22026-10-06 https://evidence-hub.com/study/12135-carbohydrate-antigen-125-concentrations-across-the-ejection-fraction2026-10-06 https://evidence-hub.com/study/12136-empagliflozin-to-prevent-worsening-of-left-ventricular-volumes-and2026-10-06 https://evidence-hub.com/study/12137-multi-parametric-magnetic-resonance-imaging-to-assess-empagliflozin2026-10-06 https://evidence-hub.com/study/12138-exercise-metabolic-flexibility-in-type-2-diabetes-treated-with2026-10-06 https://evidence-hub.com/study/12139-the-effect-of-empagliflozin-on-inflammation-and-oxidative-stress-in2026-10-06 https://evidence-hub.com/study/12140-safety-and-synergy-of-finerenone-and-empagliflozin-in-lowering-blood2026-10-06 https://evidence-hub.com/study/12141-distinct-proteomic-signatures-of-urinary-extracellular-vesicles-link2026-10-06 https://evidence-hub.com/study/12142-ldl-subspecies-and-lipidome-change-by-evolocumab-add-on-therapy-to2026-10-06 https://evidence-hub.com/study/12143-impact-of-simultaneous-initiation-of-finerenone-and-empagliflozin-on2026-10-06 https://evidence-hub.com/study/12144-effects-of-empagliflozin-on-right-ventricular-free-wall-strain-in2026-10-06 https://evidence-hub.com/study/12145-limited-impact-of-sodium-glucose-cotransporter-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/12146-effect-of-sglt2-inhibitors-dpp-4-inhibitors-on-urine-microbiota-in2026-10-06 https://evidence-hub.com/study/12147-empagliflozin-and-functional-aerobic-capacity-in-individuals-with2026-10-06 https://evidence-hub.com/study/12148-effects-of-empagliflozin-and-lifestyle-intervention-on-improving-body2026-10-06 https://evidence-hub.com/study/12149-timing-dependent-anti-inflammatory-effects-of-empagliflozin-in2026-10-06 https://evidence-hub.com/study/12150-sglt2-inhibitor-on-infarct-size-and-lv-remodeling-by-cmr-in-patients2026-10-06 https://evidence-hub.com/study/12151-the-effect-of-empagliflozin-on-left-ventricular-mass-and-volumes-in2026-10-06 https://evidence-hub.com/study/12152-empagliflozin-improves-beta-cell-function-independently-of-relief-of2026-10-06 https://evidence-hub.com/study/12153-carbohydrate-antigen-125-ca125-following-acute-myocardial-infarction2026-10-06 https://evidence-hub.com/study/12154-effect-of-empagliflozin-on-urinary-albumin-excretion-and-hypoxic2026-10-06 https://evidence-hub.com/study/12155-the-effect-of-empagliflozin-on-inflammation-in-patients-with2026-10-06 https://evidence-hub.com/study/12156-acute-egfr-changes-and-their-mediation-of-albuminuria-reduction-with2026-10-06 https://evidence-hub.com/study/12157-risk-of-hyperkalemia-with-empagliflozin-finerenone-or-both-secondary2026-10-13 https://evidence-hub.com/study/12158-impact-of-baseline-glp-1-receptor-agonist-use-on-albuminuria2026-10-06 https://evidence-hub.com/study/12159-bioequivalence-evaluation-of-two-metformin-empagliflozin-fixed-dose2026-10-06 https://evidence-hub.com/study/12160-modulation-of-circulating-extracellular-vesicles-by-antihyperglycemic2026-10-06 https://evidence-hub.com/study/12161-empagliflozin-in-de-novo-vs-acute-decompensated-chronic-heart-failure2026-10-06 https://evidence-hub.com/study/12162-comparative-effects-of-empagliflozin-and-vildagliptin-on-inflammation2026-10-06 https://evidence-hub.com/study/12163-emperor-preserved-risk-model-and-outcomes-in-the-finearts-hf-trial-a2026-10-06 https://evidence-hub.com/study/12164-empagliflozin-enhances-hepatic-glucose-production-and-reduces-total2026-10-06 https://evidence-hub.com/study/12165-the-comparison-of-the-effect-of-adding-empagliflozin-to-the2026-10-06 https://evidence-hub.com/study/12166-serum-copeptin-rises-after-tolvaptan-for-hyponatraemia-but-does-not2026-10-06 https://evidence-hub.com/study/12167-the-effect-of-canagliflozin-dose-on-renal-and-cardiovascular-outcomes2026-10-06 https://evidence-hub.com/study/12168-the-effect-of-the-combination-therapy-of-statin-and-dapagliflozin-a2026-10-06 https://evidence-hub.com/study/12169-heart-failure-outcomes-and-empagliflozin-effects-in-patients-with2026-10-06 https://evidence-hub.com/study/12170-effects-of-dapagliflozin-on-the-bone-of-patients-with-ckd-on-dialysis2026-10-08 https://evidence-hub.com/study/12171-effects-of-empagliflozin-on-uric-acid-levels-during-acute-heart2026-10-06 https://evidence-hub.com/study/12172-efficacy-of-levocetirizine-in-reducing-albuminuria-and-inflammatory2026-09-29 https://evidence-hub.com/study/12173-polypill-for-heart-failure-with-reduced-ejection-fraction-the-poly-hf2026-10-06 https://evidence-hub.com/study/12174-semaglutide-treatment-in-young-adults-living-with-type-2-diabetes-a2026-10-06 https://evidence-hub.com/study/12175-evaluating-intensive-insulin-therapy-with-empagliflozin-in-type-22026-10-06 https://evidence-hub.com/study/12176-cardiovascular-outcomes-of-perioperative-sodium-glucose-transporter-22026-10-06 https://evidence-hub.com/study/12177-pharmacokinetics-and-bioequivalence-of-two-empagliflozin-tablet2026-10-06 https://evidence-hub.com/study/12178-effect-of-empagliflozin-on-the-plasma-lipidome-in-patients-with-type2026-10-06 https://evidence-hub.com/study/12179-pharmacokinetics-and-pharmacodynamics-of-empagliflozin-in-paediatric2026-10-06 https://evidence-hub.com/study/12180-rationale-design-and-baseline-characteristics-of-the-polypill-for2026-10-06 https://evidence-hub.com/study/12181-a-phase-2a-b-randomized-trial-of-metabolic-modulators-intranasal2026-10-06 https://evidence-hub.com/study/12182-a-remote-chronic-disease-management-program-to-improve-cardiovascular2026-10-06 https://evidence-hub.com/study/12183-low-blood-pressure-and-the-effect-of-empagliflozin-in-acute-heart2026-10-06 https://evidence-hub.com/study/12184-secondary-analysis-of-the-empact-mi-trial-reveals-cardiovascular2026-10-06 https://evidence-hub.com/study/12185-the-cardio-renal-metabolic-role-of-the-nod-like-receptor-protein-32026-10-06 https://evidence-hub.com/study/12186-the-systemic-and-kidney-hemodynamic-response-to-empagliflozin2026-10-06 https://evidence-hub.com/study/12187-endothelin-receptor-antagonist-ambrisentan-sodium-glucose2026-10-06 https://evidence-hub.com/study/12188-canagliflozin-attenuates-cmr-quantified-myocardial-fibrosis-in2026-10-06 https://evidence-hub.com/study/12189-safety-and-tolerability-of-sotagliflozin-among-kidney-transplant2026-10-06 https://evidence-hub.com/study/12190-semaglutide-central-retinal-thickness-and-continuous-glucose2026-10-06 https://evidence-hub.com/study/12191-acute-effects-of-empagliflozin-on-left-atrial-and-ventricular-filling2026-10-06 https://evidence-hub.com/study/12192-fasting-and-postprandial-kidney-haemodynamic-effects-of-empagliflozin2026-10-06 https://evidence-hub.com/study/12193-sglt2-inhibition-improves-endothelium-independent-vasodilatory2026-10-06 https://evidence-hub.com/study/12194-bioequivalence-study-of-two-empagliflozin-tablets-in-healthy-chinese2026-10-06 https://evidence-hub.com/study/12195-anaemia-predicts-iron-homoeostasis-dysregulation-and-modulates-the2026-10-06 https://evidence-hub.com/study/12196-comparative-effects-of-imeglimin-and-empagliflozin-on-the-redox2026-10-06 https://evidence-hub.com/study/12197-outcomes-of-empagliflozin-in-nondiabetic-fatty-liver-patients-a2026-10-06 https://evidence-hub.com/study/12198-glucometabolic-efficacy-of-the-empagliflozin-metformin-combination-in2026-10-04 https://evidence-hub.com/study/12199-efficacy-and-safety-of-adding-empagliflozin-to-liraglutide-on-renal2026-10-06 https://evidence-hub.com/study/12200-randomized-placebo-controlled-trial-on-the-renal-and-systemic2026-10-06 https://evidence-hub.com/study/12202-participant-experiences-of-low-dose-empagliflozin-use-as-adjunct2026-10-06 https://evidence-hub.com/study/12203-effect-of-sodium-glucose-transporter-2-inhibitor-empagliflozin-on2026-10-06 https://evidence-hub.com/study/12204-the-effect-of-empagliflozin-on-markers-of-inflammation-in-patients2026-10-06 https://evidence-hub.com/study/12206-evaluation-of-the-effect-of-empagliflozin-on-prevention-of-atrial2026-10-01 https://evidence-hub.com/study/12207-the-effect-of-empagliflozin-on-growth-differentiation-factor-15-in2026-10-06 https://evidence-hub.com/study/12208-impact-of-empagliflozin-on-peak-oxygen-uptake-in-hfmref-patients-a2026-10-06 https://evidence-hub.com/study/12209-a-randomized-controlled-trial-of-the-hemodynamic-effects-of2026-10-06 https://evidence-hub.com/study/12210-effects-of-empagliflozin-on-gut-microbiota-in-heart-failure-with-a2026-10-06 https://evidence-hub.com/study/12211-antianginal-effects-of-empagliflozin-in-patients-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/12213-empagliflozin-and-colchicine-in-patients-with-reduced-left2026-10-06 https://evidence-hub.com/study/12214-low-dose-empagliflozin-as-adjunct-to-hybrid-closed-loop-insulin2026-10-06 https://evidence-hub.com/study/12215-synergistic-benefit-of-thiazolidinedione-and-sodium-glucose2026-10-06 https://evidence-hub.com/study/12216-renal-effects-of-empagliflozin-alone-or-in-combination-with2026-10-06 https://evidence-hub.com/study/12218-evolocumab-on-top-of-empagliflozin-improves-endothelial-function-of2026-10-06 https://evidence-hub.com/study/12219-effect-of-empagliflozin-on-liver-steatosis-and-fibrosis-in-patients2026-10-04 https://evidence-hub.com/study/12220-the-effect-of-empagliflozin-on-contractile-reserve-in-heart-failure2026-10-06 https://evidence-hub.com/study/12223-the-effects-of-empagliflozin-dietary-energy-restriction-or-both-on2026-10-06 https://evidence-hub.com/study/12224-study-rationale-and-design-of-a-study-of-empagliflozin-s-effects-in2026-10-04 https://evidence-hub.com/study/12225-empagliflozin-effectively-lowers-liver-fat-content-in-well-controlled2026-10-06 https://evidence-hub.com/study/12226-twelve-weeks-of-treatment-with-empagliflozin-in-patients-with-heart2026-10-04 https://evidence-hub.com/study/12228-abstract-10575-the-effect-of-empagliflozin-on-the-biomarker-growth2026-10-06 https://evidence-hub.com/study/12229-abstract-13062-the-effect-of-empagliflozin-on-contractile-reserve-in2026-10-06 https://evidence-hub.com/study/12231-empagliflozin-ameliorates-the-oxidative-stress-profile-in-type-22026-10-06 https://evidence-hub.com/study/12232-the-effects-of-empagliflozin-in-patients-with-type-1-diabetes-results2026-10-06 https://evidence-hub.com/study/12234-study-design-and-protocol-for-a-randomized-controlled-trial-of2026-10-06 https://evidence-hub.com/study/12235-the-effect-of-empagliflozin-on-non-alcoholic-steatohepatitis-and2026-10-06 https://evidence-hub.com/study/12236-oral-polychemotherapy-to-induce-remission-in-newly-diagnosed-type-22026-10-06 https://evidence-hub.com/study/12237-effects-of-empagliflozin-on-left-ventricular-diastolic-function-in2026-10-06 https://evidence-hub.com/study/12238-differential-effects-of-sglt-2-inhibitors-on-liver-function-and2026-10-06 https://evidence-hub.com/study/12239-1099-p-effects-of-empagliflozin-on-glucose-metabolism-and-body-fat2026-10-06 https://evidence-hub.com/study/12240-empagliflozin-as-add-on-to-linagliptin-in-a-fixed-dose-combination-in2026-10-06 https://evidence-hub.com/study/12241-semaglutide-combined-with-empagliflozin-vs-monotherapy-for-non2026-10-06 https://evidence-hub.com/study/12243-efficacy-and-safety-of-empagliflozin-as-add-on-to-insulin-in-japanese2026-10-06 https://evidence-hub.com/study/12244-efficacy-of-intermittent-empagliflozin-supplementation-on-dietary2026-10-06 https://evidence-hub.com/study/12245-randomized-double-blind-placebo-controlled-crossover-trial-of-once2026-10-19 https://evidence-hub.com/study/12246-the-effects-of-semaglutide-empagliflozin-and-their-combination-on-the2026-10-06 https://evidence-hub.com/study/12247-empagliflozin-improves-liver-steatosis-and-fibrosis-in-patients-with2026-10-12 https://evidence-hub.com/study/12248-the-effect-of-empagliflozin-on-right-ventricular-function-in-heart2026-10-06 https://evidence-hub.com/study/12249-linagliptin-as-add-on-to-empagliflozin-in-a-fixed-dose-combination-in2026-10-06 https://evidence-hub.com/study/12251-empagliflozin-versus-sitagliptin-as-add-on-dual-therapy-in-egyptian2026-10-04 https://evidence-hub.com/study/12252-renal-hemodynamic-effects-differ-between-antidiabetic-combination2026-10-06 https://evidence-hub.com/study/12254-renoprotective-effects-of-the-combination-of-empagliflozin-and2026-10-06 https://evidence-hub.com/study/12255-safety-tolerability-and-effects-on-cardiometabolic-risk-factors-of2026-10-01 https://evidence-hub.com/study/12256-finerenone-added-to-ras-sglt2-blockade-for-ckd-in-alport-syndrome2026-10-06 https://evidence-hub.com/study/12257-reduction-of-estimated-fluid-volumes-following-initiation-of2026-10-06 https://evidence-hub.com/study/12258-effect-of-empagliflozin-and-pioglitazone-on-left-ventricular-function2026-10-06 https://evidence-hub.com/study/12259-or25-08-brain-derived-neurotrophic-factor-levels-bdnf-in-hyponatremia2026-10-06 https://evidence-hub.com/study/12260-efficacy-and-safety-of-fixed-dose-combination-of-empagliflozin2026-10-04 https://evidence-hub.com/study/12261-1719-p-efficacy-and-safety-of-anagliptin-added-to-metformin-and2026-10-06 https://evidence-hub.com/study/12263-empagliflozin-and-cardiovascular-and-kidney-outcomes-across-kdigo2026-10-06 https://evidence-hub.com/study/12264-or27-6-effects-of-the-sglt2-inhibitor-empagliflozin-in-patients-with2026-10-06 https://evidence-hub.com/study/12265-effect-of-empagliflozin-on-endothelial-function-in-patients-with-type2026-10-06 https://evidence-hub.com/study/12266-4534-finerenone-added-to-ras-sglt2-blockade-for-non-diabetic-chronic2026-10-06 https://evidence-hub.com/study/12267-mechanisms-underlying-the-blood-pressure-lowering-effects-of2026-10-06 https://evidence-hub.com/study/12268-automated-insulin-delivery-with-sglt2i-combination-therapy-in-type-12026-10-06 https://evidence-hub.com/study/12269-combined-sodium-glucose-co-transporter-2-inhibitor-and-angiotensin2026-10-06 https://evidence-hub.com/study/12270-empagliflozin-in-combination-with-oral-agents-in-young-and-overweight2026-10-08 https://evidence-hub.com/study/12271-eligibility-of-sodium-glucose-co-transporter-2-inhibitors-among2026-10-06 https://evidence-hub.com/study/12272-effects-of-concomitant-administration-of-a-dipeptidyl-peptidase-42026-10-06 https://evidence-hub.com/study/12273-comparison-of-empagliflozin-and-sitagliptin-therapy-on-myocardial2026-10-06 https://evidence-hub.com/study/12274-sglt2-inhibitors-in-older-adults-with-heart-failure-with-preserved2026-10-06 https://evidence-hub.com/study/12275-optimization-of-albuminuria-lowering-treatment-in-diabetes-by2026-10-06 https://evidence-hub.com/study/12276-renal-and-cardiovascular-effects-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/12277-assessing-pharmacokinetic-interactions-between-the-sodium-glucose2026-10-06 https://evidence-hub.com/study/12278-to-investigate-the-effect-of-a-high-fat-diet-on-pharmacokinetics2026-10-06 https://evidence-hub.com/study/12279-impact-of-empagliflozin-on-insulin-needs-in-patients-with-heart2026-10-06 https://evidence-hub.com/study/12280-influence-of-neprilysin-inhibition-on-the-efficacy-and-safety-of2026-10-01 https://evidence-hub.com/study/12281-combination-of-empagliflozin-and-linagliptin-improves-blood-pressure2026-10-06 https://evidence-hub.com/study/12282-effects-of-empagliflozin-in-women-and-men-with-heart-failure-and2026-10-06 https://evidence-hub.com/study/12283-longitudinal-changes-in-circulating-ketone-body-levels-in-patients2026-10-06 https://evidence-hub.com/study/12284-comparative-analysis-of-the-addition-of-empagliflozin-versus-doubling2026-10-06 https://evidence-hub.com/study/12285-comparison-of-the-effects-of-empagliflozin-and-glimepiride-on2026-10-01 https://evidence-hub.com/study/12286-effect-of-empagliflozin-on-cardiac-remodelling-in-south-asian-and-non2026-10-06 https://evidence-hub.com/study/12287-postprandial-hypoglycemia-in-patients-after-gastric-bypass-surgery-is2026-10-06 https://evidence-hub.com/study/12288-pharmacokinetics-of-empagliflozin-and-pioglitazone-after2026-10-06 https://evidence-hub.com/study/12289-sglt2-inhibition-does-not-affect-myocardial-fatty-acid-oxidation-or2026-10-06 https://evidence-hub.com/study/12290-pharmacokinetics-of-empagliflozin-a-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/12291-how-does-empagliflozin-improve-arterial-stiffness-in-patients-with2026-10-04 https://evidence-hub.com/study/12292-mineralocorticoid-receptor-antagonists-and-empagliflozin-in-patients2026-10-06 https://evidence-hub.com/study/12293-empagliflozin-reduced-long-term-hba1c-variability-and-cardiovascular2026-10-01 https://evidence-hub.com/study/12294-patient-phenotypes-and-sglt-2-inhibition-in-type-2-diabetes-insights2026-10-06 https://evidence-hub.com/study/12296-effects-of-empagliflozin-on-estimated-extracellular-volume-estimated2026-10-06 https://evidence-hub.com/study/12297-empagliflozin-health-status-and-quality-of-life-in-patients-with2026-10-01 https://evidence-hub.com/study/12298-four-weeks-sglt2-inhibition-improves-beta-cell-function-and-glucose2026-10-06 https://evidence-hub.com/study/12299-effects-of-the-sodium-glucose-cotransporter-2-inhibitor-empagliflozin2026-10-06 https://evidence-hub.com/study/12300-empagliflozin-versus-sitagliptin-for-ameliorating-intrahepatic-lipid2026-10-06 https://evidence-hub.com/study/12301-outcomes-with-empagliflozin-in-heart-failure-with-preserved-ejection2026-10-06 https://evidence-hub.com/study/12302-cost-effectiveness-of-empagliflozin-in-patients-with-diabetic-kidney2026-09-29 https://evidence-hub.com/study/12303-pharmacokinetic-evaluation-of-empagliflozin-in-healthy-egyptian2026-10-06 https://evidence-hub.com/study/12304-shift-to-fatty-substrate-utilization-in-response-to-sodium-glucose2026-10-06 https://evidence-hub.com/study/12305-effect-of-empagliflosin-on-renal-filtration-in-patients-with-coronary2026-10-06 https://evidence-hub.com/study/12306-cardiovascular-outcomes-with-canagliflozin-is-it-on-the-canvas2026-10-06 https://evidence-hub.com/study/12307-hemodynamic-determinants-of-activity-measured-by-accelerometer-in2026-10-06 https://evidence-hub.com/study/12308-sglt2-inhibition-and-uric-acid-excretion-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/12309-first-time-usage-of-sglt2-inhibitors-in-patients-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/12310-dipeptidyl-peptidase-4-inhibition-stimulates-distal-tubular2026-10-06 https://evidence-hub.com/study/12311-newly-diagnosed-atrial-fibrillation-after-transient-ischemic-attack2026-10-06 https://evidence-hub.com/study/12312-evaluation-of-the-efficacy-of-empagliflozin-in-patients-with2026-10-06 https://evidence-hub.com/study/12313-a-pharmacokinetic-and-pharmacodynamic-drug-drug-interaction-study-of2026-10-06 https://evidence-hub.com/study/12314-drug-drug-interaction-of-chiglitazar-with-empagliflozin-atorvastatin2026-10-06 https://evidence-hub.com/study/12315-empagliflozin-in-improving-exercise-tolerance-in-hfpef-study-protocol2026-10-06 https://evidence-hub.com/study/12316-design-and-rationale-of-the-empagliflozin-after-aortic-valve2026-10-06 https://evidence-hub.com/study/12317-rationale-and-design-of-the-sota-thrombosis-trial-atru-vi2026-10-06 https://evidence-hub.com/study/12318-safety-and-short-term-effects-of-empagliflozin-in-patients-with-heart2026-10-06 https://evidence-hub.com/study/12319-can-sodium-glucose-cotransporter-2-sglt2-inhibition-preserve-renal2026-10-06 https://evidence-hub.com/study/12320-potential-therapeutic-effects-of-empagliflozin-through-elevated2026-10-06 https://evidence-hub.com/study/12321-evaluating-the-effects-of-liraglutide-empagliflozin-and-linagliptin2026-10-06 https://evidence-hub.com/study/12322-rationale-and-design-of-the-adipose-dysfunction-imaging-physiology2026-10-06 https://evidence-hub.com/study/12323-effect-of-empagliflozin-on-serum-ferritin-and-its-relationship-with2026-10-06 https://evidence-hub.com/study/12324-the-potential-for-improving-cardio-renal-outcomes-in-chronic-kidney2026-10-06 https://evidence-hub.com/study/12325-sglt2-inhibitors-reduce-the-salt-sensitivity-of-blood-pressure-in2026-10-06 https://evidence-hub.com/study/12326-the-effect-of-empagliflozin-on-peripheral-microvascular-dysfunction2026-10-06 https://evidence-hub.com/study/12327-digital-implementation-strategy-to-increase-sglt2-inhibitor-uptake-in2026-10-06 https://evidence-hub.com/study/12328-empagliflozin-in-patients-with-autosomal-dominant-polycystic-kidney2026-10-06 https://evidence-hub.com/study/12329-effect-of-empagliflozin-on-plasma-lipids-and-lipoproteins-in-type-22026-10-06 https://evidence-hub.com/study/12330-randomized-investigation-of-heart-failure-therapy-in-patients-with2026-10-06 https://evidence-hub.com/study/12331-assessing-the-sympatholytic-effects-of-sglt2-inhibitors-in-anuric2026-10-06 https://evidence-hub.com/study/12332-short-term-renal-and-cardiac-outcomes-of-combined-arni-and-sglt22026-10-06 https://evidence-hub.com/study/12333-protocol-and-rationale-for-a-randomized-controlled-sglt2-inhibitor2026-10-06 https://evidence-hub.com/study/12334-dapagliflozin-reduces-epicardial-adipose-tissue-in-patients-with2026-10-06 https://evidence-hub.com/study/12335-delivering-guideline-directed-medical-therapy-for-heart-failure-with2026-10-06 https://evidence-hub.com/study/12336-the-steno-1-study-multifactorial-intervention-to-reduce2026-10-06 https://evidence-hub.com/study/12337-impact-of-empagliflozin-on-cardiac-structure-and-function-assessed-by2026-10-06 https://evidence-hub.com/study/12338-efficacy-and-safety-of-balcinrenone-and-dapagliflozin-for-ckd-design2026-10-06 https://evidence-hub.com/study/12339-empagliflozin-to-prevent-post-operative-atrial-fibrillation-in2026-10-06 https://evidence-hub.com/study/12340-effects-and-safety-of-dapagliflozin-in-paediatric-hereditary-kidney2026-10-06 https://evidence-hub.com/study/12341-a-multicenter-open-label-single-arm-trial-of-the-long-term-safety-of2026-10-06 https://evidence-hub.com/study/12342-efficacy-and-safety-of-as-needed-albuterol-budesonide-versus2026-10-06 https://evidence-hub.com/study/12343-novel-versus-conventional-sequencing-of-blockers-sodium-glucose2026-10-06 https://evidence-hub.com/study/12344-empagliflozin-to-prevent-progressive-adverse-remodelling-after2026-10-06 https://evidence-hub.com/study/12345-sgl-tx-mr-study-protocol-acute-effects-of-sglt2-inhibitor-on-kidney2026-10-06 https://evidence-hub.com/study/12346-empagliflozin-and-risk-of-lower-respiratory-tract-infection-in-heart2026-10-06 https://evidence-hub.com/study/12347-effects-of-sodium-glucose-co-transporter-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/12348-rationale-and-design-of-the-renal-lifecycle-trial-assessing-the2026-10-06 https://evidence-hub.com/study/12349-sodium-glucose-cotransporter-2-inhibitors-but-not-insulin-enhance2026-10-06 https://evidence-hub.com/study/12350-empagliflozin-to-elderly-and-obese-patients-with-increased-risk-of2026-10-06 https://evidence-hub.com/study/12351-sglt2-inhibitor-with-and-without-aldosterone-antagonist-for-heart2026-10-06 https://evidence-hub.com/study/12352-effects-of-empagliflozin-in-type-2-diabetes-with-and-without-chronic2026-10-06 https://evidence-hub.com/study/12353-targeting-epicardial-adipose-tissue-in-heart-failure-with-preserved2026-10-06 https://evidence-hub.com/study/12354-evolution-hf-deallef-a-non-interventional-study-of-patients-with2026-10-06 https://evidence-hub.com/study/12355-effect-of-administration-and-withdrawal-of-the-sodium-glucose2026-10-06 https://evidence-hub.com/study/12356-changes-in-cell-function-and-insulin-sensitivity-during-treatment2026-10-06 https://evidence-hub.com/study/12357-effects-of-sglt2-inhibitors-on-cardiac-autonomic-activity-and2026-10-06 https://evidence-hub.com/study/12358-effects-of-empagliflozin-on-cardiac-structure-function-and-biomarkers2026-10-06 https://evidence-hub.com/study/12359-randomized-controlled-clinical-trial-of-shenzhuo-formula-in-the2026-10-06 https://evidence-hub.com/study/12360-rationale-and-design-of-dapagliflozin-versus-sacubitril-valsartan2026-10-06 https://evidence-hub.com/study/12361-effects-of-dapagliflozin-on-blood-volume-status-and-vascular-outcomes2026-10-06 https://evidence-hub.com/study/12362-effect-of-sodium-glucose-co-transporter-2-inhibitors-on-survival-free2026-10-06 https://evidence-hub.com/study/12363-outcomes-with-finerenone-by-baseline-treatment-goals-in-type-22026-10-06 https://evidence-hub.com/study/12364-improve-dice-a-2-part-open-label-phase-2a-trial-evaluating-the-safety2026-10-06 https://evidence-hub.com/study/12365-recency-of-heart-failure-hospitalization-outcomes-and-the-effect-of2026-10-06 https://evidence-hub.com/study/12366-safety-growth-and-development-after-dapagliflozin-or-saxagliptin-in2026-10-06 https://evidence-hub.com/study/12367-efficacy-and-safety-of-empagliflozin-in-combination-with-insulin-in2026-10-06 https://evidence-hub.com/study/12368-methods-article-for-a-study-protocol-study-design-and-baseline2026-10-06 https://evidence-hub.com/study/12369-the-win-ratio-method-in-heart-failure-trials-lessons-learnt-from2026-10-06 https://evidence-hub.com/study/12370-empagliflozin-irrespective-of-blood-pressure-improves-outcomes-in2026-10-06 https://evidence-hub.com/study/12371-sodium-glucose-co-transporter-2-inhibition-with-empagliflozin-on2026-10-06 https://evidence-hub.com/study/12372-the-spironolactone-initiation-registry-randomized-interventional2026-10-06 https://evidence-hub.com/study/12373-empagliflozin-repurposing-for-lafora-disease-a-pilot-clinical-trial2026-10-04 https://evidence-hub.com/study/12374-empagliflozin-in-children-with-glycogen-storage-disease-associated2026-10-06 https://evidence-hub.com/study/12375-empagliflozin-and-dapagliflozin-improve-endothelial-function-in2026-10-06 https://evidence-hub.com/study/12376-cost-effectiveness-of-empagliflozin-jardiance-in-the-treatment-of2026-10-06 https://evidence-hub.com/study/12377-empagliflozin-add-on-therapy-is-superior-to-metformin-monotherapy-in2026-10-04 https://evidence-hub.com/study/12378-empagliflozin-and-left-atrial-function-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/12379-evaluation-of-urate-lowering-efficacy-of-isolated-and-combined-use-of2026-10-06 https://evidence-hub.com/study/12380-effects-of-semaglutide-and-empagliflozin-on-oxygenation-vascular2026-10-06 https://evidence-hub.com/study/12381-pharmacometrics-enhanced-bayesian-borrowing-approach-to-improve2026-10-06 https://evidence-hub.com/study/12382-public-health-impact-and-cost-effectiveness-of-empagliflozin2026-10-06 https://evidence-hub.com/study/12383-using-real-world-data-for-supporting-regulatory-decision-making2026-10-06 https://evidence-hub.com/study/12384-rationale-and-design-of-the-empa-elderly-trial-a-randomised-double2026-10-06 https://evidence-hub.com/study/12385-safety-and-efficacy-of-empagliflozin-in-pakistani-muslim-patients2026-10-01 https://evidence-hub.com/study/12386-randomized-clinical-trial-on-efficacy-of-empagliflozin-versus2026-10-04 https://evidence-hub.com/study/12387-empagliflozin-and-left-ventricular-remodeling-in-people-without2026-10-06 https://evidence-hub.com/study/12388-comparison-of-effects-of-empagliflozin-and-linagliptin-on-renal2026-10-06 https://evidence-hub.com/study/12389-reduction-of-cardiac-adipose-tissue-volume-with-short-term2026-10-06 https://evidence-hub.com/study/12390-effect-of-empagliflozin-on-blood-volume-redistribution-in-patients2026-10-06 https://evidence-hub.com/study/12391-a-randomized-clinical-trial-evaluating-the-effect-of-empagliflozin-on2026-10-06 https://evidence-hub.com/study/12393-empagliflozin-in-heart-failure-patients-with-reduced-ejection2026-10-06 https://evidence-hub.com/study/12394-differences-between-randomized-clinical-trial-participants-and-real2026-10-06 https://evidence-hub.com/study/12398-oral-semaglutide-versus-empagliflozin-sitagliptin-and-liraglutide-in2026-10-06 https://evidence-hub.com/study/12399-comparison-of-semaglutide-or-dulaglutide-versus-empagliflozin-for2026-10-06 https://evidence-hub.com/study/12401-empagliflozin-leads-to-faster-improvement-in-arterial-stiffness2026-10-06 https://evidence-hub.com/study/12402-effects-of-empagliflozin-treatment-on-glycerol-derived-hepatic2026-10-06 https://evidence-hub.com/study/12403-effect-of-empagliflozin-on-reducing-the-no-reflow-phenomenon-in2026-10-06 https://evidence-hub.com/study/12404-letter-by-tsuda-regarding-article-effect-of-empagliflozin-on-left2026-10-06 https://evidence-hub.com/study/12405-the-effect-of-empagliflozin-on-renal-outcomes-compared-to-sitagliptin2026-10-06 https://evidence-hub.com/study/12407-effects-of-empagliflozin-on-first-and-recurrent-clinical-events-in2026-10-04 https://evidence-hub.com/study/12408-concentration-dependent-clinical-and-prognostic-importance-of-high2026-10-06 https://evidence-hub.com/study/12409-clinical-trial-designs-to-assess-treatment-effects-on-glomerular2026-10-06 https://evidence-hub.com/study/12411-mineralocorticoid-receptor-antagonist-use-and-the-effects-of2026-10-06 https://evidence-hub.com/study/12412-alterations-in-trimethylamine-n-oxide-in-response-to-empagliflozin2026-10-06 https://evidence-hub.com/study/12413-cost-effectiveness-analysis-of-empagliflozin-in-patients-with-heart2026-10-06 https://evidence-hub.com/study/12414-igfbp7-and-left-ventricular-mass-regression-a-sub-analysis-of-the2026-10-06 https://evidence-hub.com/study/12415-effects-of-empagliflozin-on-symptoms-physical-limitations-and-quality2026-10-01 https://evidence-hub.com/study/12416-empagliflozin-improves-quality-of-life-in-nondiabetic-hfref-patients2026-10-06 https://evidence-hub.com/study/12417-renal-effects-of-empagliflozin-in-patients-hospitalized-for-acute2026-10-01 https://evidence-hub.com/study/12418-empagliflozin-and-health-related-quality-of-life-outcomes-in-patients2026-10-01 https://evidence-hub.com/study/12419-cardiovascular-benefit-of-empagliflozin-across-the-spectrum-of2026-10-01 https://evidence-hub.com/study/12420-safety-and-efficacy-of-empagliflozin-in-elderly-japanese-patients2026-10-06 https://evidence-hub.com/study/12421-effects-of-empagliflozin-on-reproductive-system-in-men-without2026-10-06 https://evidence-hub.com/study/12422-reduction-of-cardiovascular-risk-and-improved-estimated-glomerular2026-10-06 https://evidence-hub.com/study/12423-sglt2-inhibitors-and-renal-outcomes-in-type-2-diabetes-with-or2026-10-01 https://evidence-hub.com/study/12424-empagliflozin-in-women-with-type-2-diabetes-and-cardiovascular2026-10-01 https://evidence-hub.com/study/12425-empagliflozin-reduces-the-risk-of-mortality-and-hospitalization-for2026-10-01 https://evidence-hub.com/study/12426-empagliflozin-and-uric-acid-metabolism-in-diabetes-a-post-hoc2026-10-01 https://evidence-hub.com/study/12427-secondary-analyses-to-assess-the-profound-effects-of-empagliflozin-on2026-10-06 https://evidence-hub.com/study/12428-angiotensin-pathways-under-therapy-with-empagliflozin-in-patients2026-10-04 https://evidence-hub.com/study/12429-efficacy-of-empagliflozin-in-patients-with-heart-failure-across2026-10-06 https://evidence-hub.com/study/12430-effect-of-dapagliflozin-versus-empagliflozin-on-cardiovascular-death2026-10-06 https://evidence-hub.com/study/12431-empagliflozin-reduces-cardiovascular-events-mortality-and-renal2026-10-01 https://evidence-hub.com/study/12432-empagliflozin-in-heart-failure-and-previous-coronary2026-10-06 https://evidence-hub.com/study/12433-a-systematic-review-and-meta-analysis-of-the-efficacy-and-safety-of2026-10-06 https://evidence-hub.com/study/12434-comparative-cardiovascular-effectiveness-of-empagliflozin-versus2026-10-06 https://evidence-hub.com/study/12435-empagliflozin-and-risk-of-incident-gout-analysis-from-the2026-10-06 https://evidence-hub.com/study/12436-ketone-production-and-excretion-even-during-mild-hyperglycemia-and2026-10-06 https://evidence-hub.com/study/12437-baseline-cardiovascular-risk-factor-control-in-patients-with-type-22026-10-10 https://evidence-hub.com/study/12438-greater-combined-reductions-of-hba1c-1-0-and-body-weight-loss-5-0-or2026-10-06 https://evidence-hub.com/study/12439-influence-of-angiotensin-receptor-neprilysin-inhibition-on-the2026-10-06 https://evidence-hub.com/study/12440-effects-of-empagliflozin-on-cardiovascular-and-renal-outcomes-in2026-10-06 https://evidence-hub.com/study/12441-twenty-four-hour-blood-pressure-response-to-empagliflozin-and-its2026-10-06 https://evidence-hub.com/study/12442-empagliflozin-in-the-treatment-of-heart-failure-with-reduced-ejection2026-10-06 https://evidence-hub.com/study/12443-design-of-a-prospective-patient-level-pooled-analysis-of-two-parallel2026-10-06 https://evidence-hub.com/study/12444-characterization-and-implications-of-the-initial-estimated-glomerular2026-09-29 https://evidence-hub.com/study/12445-urinary-adenosine-excretion-in-type-1-diabetes2026-10-06 https://evidence-hub.com/study/12446-all-cause-mortality-in-patients-with-diabetes-under-treatment-with2026-10-06 https://evidence-hub.com/study/12447-effect-of-semaglutide-on-measured-vs-estimated-glomerular-filtration2026-10-06 https://evidence-hub.com/study/12448-impact-of-empagliflozin-on-glomerular-hyperfiltration-and-albuminuria2026-10-06 https://evidence-hub.com/study/12449-apelin-and-copeptin-levels-in-patients-with-chronic-siad-treated-with2026-10-06 https://evidence-hub.com/study/12450-ketone-body-levels-and-its-associations-with-cardiac-markers2026-10-06 https://evidence-hub.com/study/12451-effect-of-empagliflozin-with-or-without-the-addition-of-evolocumab-on2026-10-06 https://evidence-hub.com/study/12452-empagliflozin-improves-high-sensitive-cardiac-troponin-i-and-high2026-10-06 https://evidence-hub.com/study/12453-efficacy-and-safety-of-empagliflozin-according-to-background-diuretic2026-10-06 https://evidence-hub.com/study/12454-comparative-effectiveness-of-empagliflozin-in-reducing-the-burden-of2026-10-06 https://evidence-hub.com/study/12455-initiation-of-new-glucose-lowering-therapies-may-act-to-reduce2026-10-06 https://evidence-hub.com/study/12456-sodium-glucose-cotransporter-2-inhibitors-renal-outcomes-according-to2026-10-06 https://evidence-hub.com/study/12457-cardio-kidney-composite-end-points-a-post-hoc-analysis-of-the-empa2026-10-01 https://evidence-hub.com/study/12458-efficacy-and-safety-of-empagliflozin-in-japanese-patients-with-type-22026-10-06 https://evidence-hub.com/study/12459-post-hoc-analysis-on-the-effects-of-vicadrostat-empagliflozin-by-ckd2026-10-06 https://evidence-hub.com/study/12460-effect-of-qualifying-atherosclerotic-cardiovascular-disease-diagnosis2026-10-06 https://evidence-hub.com/study/12461-time-from-admission-to-randomization-and-the-effect-of-empagliflozin2026-10-06 https://evidence-hub.com/study/12462-impact-of-baseline-ecg-characteristics-on-changes-in-cardiac2026-10-06 https://evidence-hub.com/study/12463-empagliflozin-and-rapid-kidney-function-decline-incidence-in-type-22026-10-06 https://evidence-hub.com/study/12464-changes-in-cardiac-and-vascular-haemodynamics-as-potential-mediators2026-10-06 https://evidence-hub.com/study/12465-generalizability-of-reduce-it-eligibility-criteria-in-a-large2026-10-06 https://evidence-hub.com/study/12466-effects-of-empagliflozin-on-erythropoiesis-in-heart-failure-data-from2026-10-06 https://evidence-hub.com/study/12467-association-of-empagliflozin-treatment-with-albuminuria-levels-in2026-10-06 https://evidence-hub.com/study/12468-nephrotic-range-proteinuria-in-type-2-diabetes-effects-of2026-10-06 https://evidence-hub.com/study/12469-impact-of-empagliflozin-on-right-ventricular-parameters-and-function2026-10-06 https://evidence-hub.com/study/12470-impact-of-polyvascular-disease-with-and-without-co-existent-kidney2026-10-01 https://evidence-hub.com/study/12471-short-term-changes-in-albuminuria-and-risk-of-cardiovascular-and2026-10-01 https://evidence-hub.com/study/12472-a-pooled-analysis-of-diffusion-weighted-imaging-lesions-in-patients2026-10-06 https://evidence-hub.com/study/12473-safety-and-tolerability-of-empagliflozin-and-linagliptin-combination2026-10-06 https://evidence-hub.com/study/12474-association-of-black-race-with-early-recurrence-after-minor-ischemic2026-10-06 https://evidence-hub.com/study/12475-the-urinary-albumin-to-creatinine-ratio-can-direct-personalized2026-10-06 https://evidence-hub.com/study/12476-contemporary-medical-therapy-for-heart-failure-with-mildly-reduced-or2026-10-10 https://evidence-hub.com/study/12477-finerenone-in-asian-patients-with-type-2-diabetes-mellitus-and2026-10-06 https://evidence-hub.com/study/12478-egfr-and-potassium-guided-stewardship-of-sglt2-inhibitors-and2026-10-06 https://evidence-hub.com/study/12479-hemoglobin-trajectories-on-sglt2-inhibitor-therapy-in-heart-failure2026-10-06 https://evidence-hub.com/study/12480-sglt2-inhibitors-in-frailty-a-review-of-current-evidence-and-clinical2026-10-06 https://evidence-hub.com/study/12481-sglt2-inhibitors-promote-diabetic-wound-healing-via-ampk-akt-mtorc12026-10-06 https://evidence-hub.com/study/12482-use-of-vericiguat-in-the-victor-trial-a-study-that-is-difficult-to2026-10-06 https://evidence-hub.com/study/12483-finerenone-beyond-diabetic-kidney-disease-emerging-evidence-and2026-10-06 https://evidence-hub.com/study/12484-efficacy-of-sglt2-inhibitors-in-patients-recently-hospitalized-for2026-10-06 https://evidence-hub.com/study/12485-heart-failure-evidence-update-20262026-10-06 https://evidence-hub.com/study/12486-metabolic-dysfunction-associated-steatotic-liver-disease-current2026-10-06 https://evidence-hub.com/study/12487-evidence-on-sglt2-inhibitors-efficacy-in-older-and-frail-patients2026-10-06 https://evidence-hub.com/study/12488-could-sodium-glucose-co-transporter-2-inhibitors-and-glucagon-like2026-10-06 https://evidence-hub.com/study/12489-mineralocorticoid-receptor-antagonists-for-the-treatment-of-heart2026-10-06 https://evidence-hub.com/study/12490-landmark-clinical-trials-shaping-contemporary-guideline-directed2026-10-06 https://evidence-hub.com/study/12491-pro-con-debate-nonsteroidal-versus-steroidal-mineralocorticoid2026-10-06 https://evidence-hub.com/study/12492-benefits-of-sglt2-inhibitors-in-patients-with-diabetes-and-advanced2026-10-06 https://evidence-hub.com/study/12493-sodium-glucose-cotransporter-2-inhibitors-in-diabetic-nephropathy-a2026-10-06 https://evidence-hub.com/study/12494-efficacy-and-safety-of-sglt2-inhibitors-and-sotagliflozin-in-heart2026-10-06 https://evidence-hub.com/study/12495-contemporary-management-of-advanced-chronic-kidney-disease-an2026-10-06 https://evidence-hub.com/study/12496-cardiovascular-implications-of-diabetes-mellitus-a-systematic2026-10-08 https://evidence-hub.com/study/12497-early-administration-of-sglt2-inhibitors-in-hospitalized-patients-a2026-10-06 https://evidence-hub.com/study/12498-fecal-microbiome-predicts-treatment-response-after-the-initiation-of2026-10-06 https://evidence-hub.com/study/12499-mineralocorticoid-receptor-antagonists-efficacy-and-safety-in-chronic2026-10-06 https://evidence-hub.com/study/12500-serum-uric-acid-in-chronic-kidney-disease-as-a-marker-of-risk-or-a2026-10-06 https://evidence-hub.com/study/12501-therapeutic-potential-of-glp-1-receptor-agonists-and-sglt2-inhibitors2026-10-06 https://evidence-hub.com/study/12502-empagliflozin-versus-dapagliflozin-in-patients-with-liver-cirrhosis-a2026-10-06 https://evidence-hub.com/study/12503-risk-factor-obesity-treatment-standard2026-10-06 https://evidence-hub.com/study/12504-effects-of-heart-failure-pharmacotherapy-on-natriuresis-and-diuresis2026-10-06 https://evidence-hub.com/study/12505-practical-guidance-on-implementation-of-guideline-directed-medical2026-10-06 https://evidence-hub.com/study/12506-sodium-glucose-cotransporter-2-inhibitors-following-acute-myocardial2026-10-06 https://evidence-hub.com/study/12507-dual-inhibition-of-the-renin-angiotensin-aldosterone-system-and2026-10-06 https://evidence-hub.com/study/12508-beyond-hyperglycemia-the-role-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/12509-enhancing-evidence-based-care-using-trial-emulation-in-electronic2026-10-06 https://evidence-hub.com/study/12510-addressing-unmet-needs-for-chronic-kidney-disease-treatment-in-type-12026-10-06 https://evidence-hub.com/study/12511-urinary-biomarkers-for-the-risk-assessment-and-management-of-heart2026-10-06 https://evidence-hub.com/study/12512-cardiovascular-protection-by-sglt2-inhibitors-an-integrative-review2026-10-06 https://evidence-hub.com/study/12513-metabolic-shifts-in-plasma-amino-acids-and-related-metabolites-in2026-10-06 https://evidence-hub.com/study/12514-randomized-controlled-trials-in-europe-a-call-to-action-to-protect2026-10-06 https://evidence-hub.com/study/12515-effects-of-sodium-glucose-cotransporter-2-inhibitors-on-anemia-in2026-10-06 https://evidence-hub.com/study/12516-research-progress-of-sglt2-inhibitors-in-the-treatment-of-acute-heart2026-10-06 https://evidence-hub.com/study/12517-dual-sglt1-2-inhibition-with-sotagliflozin-improves-cardiac-function2026-10-06 https://evidence-hub.com/study/12518-cardiometabolic-benefits-and-risks-of-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/12519-treatment-of-youth-onset-type-2-diabetes-focus-on-sglt-2-inhibitor-use2026-10-06 https://evidence-hub.com/study/12520-sodium-glucose-cotransporter-2-inhibitors-in-lupus-nephritis-and-anca2026-10-06 https://evidence-hub.com/study/12521-enhancing-evidence-based-guidelines-using-trial-emulation-in2026-10-06 https://evidence-hub.com/study/12522-sglt2-inhibitors-for-the-prevention-and-treatment-of-heart-failure-a2026-10-06 https://evidence-hub.com/study/12523-impact-of-ertugliflozin-on-cardiac-structure-and-function-in-patients2026-10-06 https://evidence-hub.com/study/12524-sodium-glucose-cotransporter-2-inhibitors-across-the-glycemic2026-10-06 https://evidence-hub.com/study/12525-comparative-effectiveness-of-individual-sodium-glucose-transporter-22026-10-06 https://evidence-hub.com/study/12526-uniform-efficacy-of-sglt2-inhibitors-across-the-ejection-fraction2026-10-06 https://evidence-hub.com/study/12527-finerenone-in-asian-patients-with-diabetic-kidney-disease-evaluating2026-10-06 https://evidence-hub.com/study/12529-dapagliflozin-vs-empagliflozin-in-patients-with-chronic-heart-failure2026-10-06 https://evidence-hub.com/study/12530-abstract-17275-the-sglt2-inhibitor-empagliflozin-ameliorates-left2026-10-06 https://evidence-hub.com/study/12531-abstract-17157-the-sglt2-inhibitor-empagliflozin-ameliorates2026-10-06 https://evidence-hub.com/study/12532-or2805-plasma-sodium-increase-is-associated-with-an-increase-in-bone2026-10-06 https://evidence-hub.com/study/12533-clinical-similarity-economic-divergence-cost-effectiveness-and2026-10-06 https://evidence-hub.com/study/12534-preoperative-empagliflozin-and-ventricular-remodeling-after-coronary2026-10-06 https://evidence-hub.com/study/12535-efficacy-of-empagliflozin-in-heart-failure-with-preserved-versus-mid2026-10-06 https://evidence-hub.com/study/12536-comment-on-neeland-et-al-the-impact-of-empagliflozin-on-obstructive2026-10-01 https://evidence-hub.com/study/12537-empagliflozin-alleviates-type-2-diabetic-renal-fibrosis-by-inhibiting2026-10-06 https://evidence-hub.com/study/12538-effects-of-empagliflozin-on-sarcopenia-risk-body-composition-and2026-10-06 https://evidence-hub.com/study/12539-comparative-effectiveness-and-prescribing-patterns-of-dapagliflozin2026-10-06 https://evidence-hub.com/study/12540-systolic-plood-pressure-response-to-asi-bi-690517-with-and-without2026-10-06 https://evidence-hub.com/study/12541-metabolic-control-in-type-2-diabetic-patients-treated-with2026-10-06 https://evidence-hub.com/study/12542-retinal-and-optic-nerve-measures-after-initiation-of-empagliflozin2026-10-06 https://evidence-hub.com/study/12543-4139-effects-of-empagliflozin-on-fluid-overload-in-chronic-kidney2026-10-06 https://evidence-hub.com/study/12544-long-term-use-of-empagliflozin-vs-dpp4-inhibitors-mitigates-egfr2026-10-06 https://evidence-hub.com/study/12545-abstract-12476-dapagliflozin-versus-empagliflozin-and-the-risk-for2026-10-06 https://evidence-hub.com/study/12546-abstract-4361602-sglt2-inhibitors-in-lvad-patients-a-multi-center2026-10-06 https://evidence-hub.com/study/12549-efficacy-and-safety-of-early-initiation-of-sodium-glucose2026-10-08 https://evidence-hub.com/study/12550-sglt-2-inhibitors-for-ascites-management-in-liver-cirrhosis-a2026-10-06 https://evidence-hub.com/study/12551-impact-of-sodium-glucose-cotransporter-2-inhibitors-on-hemoglobinand2026-10-06 https://evidence-hub.com/study/12552-comparative-efficacy-of-glucose-lowering-drugs-on-liver-steatosis-as2026-10-06 https://evidence-hub.com/study/12553-p1500effects-of-empagliflozin-on-cardiac-function-in-patients-with2026-10-06 https://evidence-hub.com/study/12554-sglt2-inhibitors-in-acute-heart-failure-a-meta-analysis-of-randomized2026-10-06 https://evidence-hub.com/study/12555-benefits-and-harms-of-sodium-glucose-co-transporter-2-inhibitors-in2026-10-04 https://evidence-hub.com/study/12557-sglt2-inhibitors-use-in-kidney-disease-what-did-we-learn2026-10-06 https://evidence-hub.com/study/12558-comparative-cardiovascular-effectiveness-of-glucagon-like-peptide-12026-10-06 https://evidence-hub.com/study/12559-timing-matters-clinical-outcomes-of-early-sodium-glucose2026-10-06 https://evidence-hub.com/study/12560-sglt2-inhibitors-and-outcomes-in-patients-with-diabetes-after-durable2026-10-06 https://evidence-hub.com/study/12561-effects-on-major-adverse-cardiovascular-events-mace-in-persons2026-10-06 https://evidence-hub.com/study/12562-efficacy-of-semaglutide-by-background-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/12563-therapeutic-effects-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/12564-july-2023-at-a-glance-heart-failure-with-preserved-ejection-fraction2026-10-06 https://evidence-hub.com/study/12565-sodium-glucose-co-transporter-2-sglt-2-inhibitors-in-heart-failure-a2026-10-06 https://evidence-hub.com/study/12567-adverse-events-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/12568-perceived-barriers-to-sglt2i-prescription-in-primary-care-vs2026-10-06 https://evidence-hub.com/study/12569-can-treatment-response-to-sglt2-inhibitors-in-syndrome-of2026-09-27 https://evidence-hub.com/study/12571-effects-of-empagliflozin-on-quality-of-life-and-healthcare-use-and2026-10-06 https://evidence-hub.com/study/12572-semaglutide-and-nonarteritic-anterior-ischemic-optic-neuropathy2026-10-06 https://evidence-hub.com/study/12573-efficacy-and-safety-of-sglt2-inhibitors-in-heart-failure2026-10-06 https://evidence-hub.com/study/12574-semaglutide-and-diabetic-retinopathy-an-ohdsi-network-study2026-10-06 https://evidence-hub.com/study/12575-sglt-2-inhibitors-glp-1-receptor-agonists-and-dpp-4-inhibitors-and2026-10-06 https://evidence-hub.com/study/12576-empagliflozin-based-quadruple-oral-therapy-for-type-2-diabetes-a2026-10-06 https://evidence-hub.com/study/12577-comparison-of-ischemic-cardiovascular-events-between-dapagliflozin2026-10-06 https://evidence-hub.com/study/12578-empagliflozin-in-heart-failure-with-preserved-ejection-fraction-from2026-10-06 https://evidence-hub.com/study/12579-empagliflozin-versus-dapagliflozin-in-patients-with-type-2-diabetes2026-10-04 https://evidence-hub.com/study/12580-repurposing-sglt2-inhibitors-treatment-of-renal-proximal-tubulopathy2026-10-06 https://evidence-hub.com/study/12581-kidney-outcomes-associated-with-use-of-sglt2-inhibitors-in-real-world2026-10-08 https://evidence-hub.com/study/12582-relationship-of-concomitant-anti-diabetic-drug-administration-with2026-10-06 https://evidence-hub.com/study/12583-gut-microbiota-predicts-treatment-response-to-empagliflozin-among2026-10-06 https://evidence-hub.com/study/12584-cardiac-mechanics-and-incident-ischemic-stroke-the-cardiovascular2026-10-06 https://evidence-hub.com/study/12585-impact-of-predischarge-nt-probnp-on-treatment-optimisation-in-acute2026-10-06 https://evidence-hub.com/study/12586-association-of-liver-fibrosis-with-cognitive-test-performance-and2026-10-06 https://evidence-hub.com/study/12587-association-of-sodium-glucose-cotransporter-2-inhibitors-with-time-to2026-10-19 https://evidence-hub.com/study/12588-metabolic-profiling-of-the-emdia-cohort-by-lc-ms-reveals2026-10-06 https://evidence-hub.com/study/12589-impact-of-sglt2-inhibitors-use-on-risk-of-postoperative-acute-kidney2026-10-06 https://evidence-hub.com/study/12590-the-position-of-sglt2-inhibitors-in-current-medicine2026-10-06 https://evidence-hub.com/study/12591-empagliflozin-and-dapagliflozin-outcomes-in-heart-failure2026-10-06 https://evidence-hub.com/study/12592-associations-of-semaglutide-with-skeletal-outcomes-in-people-with2026-10-06 https://evidence-hub.com/study/12593-use-of-sglt-2-inhibitors-in-patients-with-type-1-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/12594-effect-of-empagliflozin-as-an-add-on-therapy-on-decongestion-and2026-10-06 https://evidence-hub.com/study/12595-empagliflozin-treatment-is-associated-with-improvements-in-cardiac2026-10-06 https://evidence-hub.com/study/12596-risk-of-amputations-associated-with-sglt2-inhibitors-compared-to-dpp2026-10-06 https://evidence-hub.com/study/12597-solution-is-not-simple-sodium-glucose-cotransporter-2-inhibitor-use2026-10-06 https://evidence-hub.com/study/12598-rationale-and-design-of-the-empyrean-study2026-10-06 https://evidence-hub.com/study/12599-sglt2-inhibitors-decrease-overhydration-and-proteasuria-in-patients2026-10-06 https://evidence-hub.com/study/12600-mechanism-and-reversal-of-drug-induced-nephrotoxicity-on-a-chip2026-10-06 https://evidence-hub.com/study/12601-the-short-term-follow-up-of-patients-with-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/12602-cardioprotective-effects-of-sodium-glucose-cotransporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/12603-loop-diuretic-use-among-patients-with-heart-failure-and-type-22026-10-06 https://evidence-hub.com/study/12604-sodium-glucose-cotransporter-2-inhibitors-dulaglutide-and-risk-for2026-10-06 https://evidence-hub.com/study/12605-empagliflozin-and-hydralazine-isosorbide-dinitrate-combination2026-10-06 https://evidence-hub.com/study/12606-the-evaluation-of-noninferiority-for-renal-composite-outcomes-between2026-10-06 https://evidence-hub.com/study/12607-changes-in-st-segment-elevation-myocardial-infarction2026-10-06 https://evidence-hub.com/study/12608-efficacy-and-safety-of-sglt-2-inhibitors-in-renal-allograft2026-10-06 https://evidence-hub.com/study/12609-optimal-screening-for-predicting-and-preventing-the-risk-of-heart2026-10-06 https://evidence-hub.com/study/12610-dapagliflozin-vs-empagliflozin-for-cardiorenal-risk-reduction-real2026-10-06 https://evidence-hub.com/study/12611-efficacy-of-sodium-glucose-cotransporter-2-inhibitors-as-an-adjunct2026-10-06 https://evidence-hub.com/study/12612-healthy-lifestyle-behaviours-and-all-cause-and-cardiovascular2026-10-06 https://evidence-hub.com/study/12613-discharge-heart-rate-and-1-year-clinical-outcomes-in-heart-failure2026-10-06 https://evidence-hub.com/study/12614-management-of-sodium-glucose-cotransporter-2-inhibitors-during-the2026-10-06 https://evidence-hub.com/study/12615-systolic-blood-pressure-at-admission-and-long-term-clinical-outcomes2026-10-06 https://evidence-hub.com/study/12616-effect-of-empagliflozin-on-brachial-artery-shear-stress-and2026-10-06 https://evidence-hub.com/study/12617-effects-of-sodium-glucose-cotransporter-2-inhibitors-in-diabetic-and2026-10-06 https://evidence-hub.com/study/12618-sodium-glucose-cotransporter-2-inhibitors-erythrocytosis-and2026-10-06 https://evidence-hub.com/study/12619-shifting-towards-empagliflozin-first-line-therapy-in-glycogen-storage2026-10-06 https://evidence-hub.com/study/12620-treatment-outcomes-of-graded-dose-of-empagliflozin-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/12621-efficacy-of-sodium-glucose-cotransporter-2-inhibitors-for-super-aged2026-10-06 https://evidence-hub.com/study/12622-empagliflozin-reduces-markers-of-acute-kidney-injury-in-patients-with2026-10-06 https://evidence-hub.com/study/12623-application-of-eligibility-criteria-from-dapa-hf-emperor-reduced-and2026-10-06 https://evidence-hub.com/study/12624-the-real-world-anti-inflammatory-effect-of-sglt2i-in-patients-with2026-10-06 https://evidence-hub.com/study/12625-effectiveness-of-oral-semaglutide-versus-empagliflozin-for-the2026-10-06 https://evidence-hub.com/study/12626-sglt2-inhibitor-use-and-cardiorenal-outcomes-in-type-2-diabetes-with2026-10-06 https://evidence-hub.com/study/12627-cost-effectiveness-of-second-line-empagliflozin-versus-liraglutide2026-10-06 https://evidence-hub.com/study/12628-effects-of-sodium-glucose-co-transporter-2-inhibitors-on-serum2026-10-06 https://evidence-hub.com/study/12629-reaffirmation-of-mechanistic-proteomic-signatures-accompanying-sglt22026-10-06 https://evidence-hub.com/study/12630-comparative-effectiveness-of-empagliflozin-versus-dapagliflozin-in2026-10-06 https://evidence-hub.com/study/12631-comparison-of-the-effects-of-various-antidiabetic-medication-on-bone2026-10-06 https://evidence-hub.com/study/12632-sglt2-inhibitors-new-option-to-prevent-or-treat-heart-failure2026-10-06 https://evidence-hub.com/study/12633-impact-of-empagliflozin-versus-dapagliflozin-on-left-ventricular2026-10-06 https://evidence-hub.com/study/12634-cardiovascular-outcomes-and-ldl-cholesterol-levels-in-empa-reg-outcome2026-10-01 https://evidence-hub.com/study/12635-sodium-glucose-cotransporter-2-inhibitors-and-the-risk-of-amputation2026-10-06 https://evidence-hub.com/study/12636-mechanisms-of-sodium-glucose-cotransporter-2-inhibition-insights-from2026-10-06 https://evidence-hub.com/study/12637-cognitive-impairment-in-young-and-middle-aged-patients-with-acute2026-10-06 https://evidence-hub.com/study/12638-investigation-of-the-effect-of-empagliflozin-on-cardiac-sympathetic2026-10-06 https://evidence-hub.com/study/12639-use-of-sglt2-inhibitors-versus-dpp-4-inhibitors-and-age-related2026-10-06 https://evidence-hub.com/study/12640-comparison-of-the-efficacy-of-empagliflozin-dapagliflozin-and2026-10-06 https://evidence-hub.com/study/12641-impact-of-empagliflozin-on-cardiovascular-outcomes-and-renal-function2026-10-06 https://evidence-hub.com/study/12642-outcomes-of-empagliflozin-versus-dapagliflozin-treatment-in-patients2026-10-06 https://evidence-hub.com/study/12643-semaglutide-versus-empagliflozin-in-uncontrolled-type-2-diabetes-a2026-10-06 https://evidence-hub.com/study/12644-comparative-long-term-cardiovascular-outcomes-of-empagliflozin-and2026-10-06 https://evidence-hub.com/study/12645-assessing-renoprotective-effects-of-empagliflozin-and-telmisartan2026-10-06 https://evidence-hub.com/study/12650-evaluation-of-rehospitalization-rate-in-heart-failure-patients-with2026-10-06 https://evidence-hub.com/study/12651-comparative-outcomes-between-empagliflozin-and-dapagliflozin-in-heart2026-10-06 https://evidence-hub.com/study/12652-dapagliflozin-versus-empagliflozin-and-major-adverse-cardiovascular2026-10-06 https://evidence-hub.com/study/12653-comparative-cardiovascular-outcomes-in-type-2-diabetes-patients2026-10-06 https://evidence-hub.com/study/12654-safety-and-tolerability-of-empagliflozin-use-during-the-holy-month-of2026-10-06 https://evidence-hub.com/study/12655-comparative-safety-analysis-of-empagliflozin-in-type-2-diabetes2026-10-19 https://evidence-hub.com/study/12656-changes-in-diuretic-medication-prescribing-and-surrogate-laboratory2026-10-06 https://evidence-hub.com/study/12657-association-of-empagliflozin-treatment-with-changes-in-the-metabolic2026-10-06 https://evidence-hub.com/study/12658-comparative-risk-evaluation-for-cardiovascular-events-associated-with2026-10-06 https://evidence-hub.com/study/12659-cardiorenal-outcomes-of-empagliflozin-versus-dapagliflozin-in-primary2026-10-06 https://evidence-hub.com/study/12660-12-month-neurological-and-psychiatric-outcomes-of-semaglutide-use-for2026-10-06 https://evidence-hub.com/study/12663-the-effect-of-empagliflozin-on-the-quality-of-life-in-patients-with2026-10-06 https://evidence-hub.com/study/12664-outcomes-of-patients-with-autosomal-dominant-polycystic-kidney2026-10-06 https://evidence-hub.com/study/12665-personalized-response-to-empagliflozin-in-heart-failure-association2026-10-06 https://evidence-hub.com/study/12666-effects-of-sodium-glucose-cotransporter-2-inhibitors-in-patients-with2026-10-06 https://evidence-hub.com/study/12667-the-role-of-sodium-glucose-cotransporter-2-inhibitors-in-patients2026-10-06 https://evidence-hub.com/study/12668-effectiveness-of-empagliflozin-in-reducing-hypoglycemic-events-as2026-10-06 https://evidence-hub.com/study/12669-the-role-of-sodium-glucose-cotransporter-2-inhibitors-in-adults-with2026-10-06 https://evidence-hub.com/study/12671-type-disparity-in-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/12672-empagliflozin-use-is-associated-with-lower-risk-of-all-cause2026-10-06 https://evidence-hub.com/study/12673-comparing-ischemic-cardiovascular-effectiveness-and-safety-between2026-10-06 https://evidence-hub.com/study/12674-the-impact-of-empagliflozin-on-inflammatory-markers-in-adults-with2026-10-06 https://evidence-hub.com/study/12675-1340-p-the-association-of-sglt2i-vs-dpp4i-on-fracture-cohort-study-of2026-10-06 https://evidence-hub.com/study/12676-impact-of-sglt-2-inhibitors-on-sickle-cell-disease-patients-with-type2026-10-06 https://evidence-hub.com/study/12677-impact-of-empagliflozin-on-the-outcomes-of-thalassemia-major-in2026-10-06 https://evidence-hub.com/study/12678-impact-of-sodium-glucose-co-transporter-type-2-inhibitors-on-alanine2026-10-06 https://evidence-hub.com/study/12681-empagliflozin-cardiovascular-and-renal-effectiveness-and-safety2026-10-06 https://evidence-hub.com/study/12682-risk-of-prostatitis-in-patients-with-type-2-diabetes-mellitus-an2026-10-06 https://evidence-hub.com/study/12683-cost-effectiveness-of-semaglutide-vs-empagliflozin-canagliflozin-and2026-10-06 https://evidence-hub.com/study/12684-cognitive-signs-and-symptoms-in-people-with-a-psychiatric-diagnosis2026-10-06 https://evidence-hub.com/study/12685-patient-and-prescriber-knowledge-of-sglt2i-sick-day-rules-a-single2026-10-06 https://evidence-hub.com/study/12686-wound-healing-outcomes-in-diabetic-kidney-disease-patients-receiving2026-10-06 https://evidence-hub.com/study/12687-sglt2-inhibitors-and-outcomes-in-the-chronic-post-lvad-phase-a2026-10-06 https://evidence-hub.com/study/12688-sex-based-differences-in-clinical-outcomes-among-heart-failure2026-10-06 https://evidence-hub.com/study/12689-real-world-efficacy-and-safety-of-sglt2-inhibitor-add-on-triple2026-10-06 https://evidence-hub.com/study/12690-individual-sglt-2-inhibitors-and-risk-of-new-onset-cancer-in-type-22026-10-06 https://evidence-hub.com/study/12691-empagliflozin-in-paediatric-heart-failure-model-based-optimisation-of2026-10-01 https://evidence-hub.com/study/12692-clinical-and-medication-related-factors-associated-with-adverse-renal2026-10-06 https://evidence-hub.com/study/12693-a-prospective-cohort-study-on-the-impact-of-sglt2-inhibitors-on-the2026-10-06 https://evidence-hub.com/study/12694-269-or-empagliflozin-on-the-risk-of-retinopathy-in-patients-with-type2026-10-06 https://evidence-hub.com/study/12695-870-p-empagliflozin-and-the-risk-of-gout-analysis-from-the2026-10-06 https://evidence-hub.com/study/12696-effect-of-sodium-glucose-cotransporter-2-inhibitors-on-heart-failure2026-10-06 https://evidence-hub.com/study/12697-sodium-glucose-cotransporter-2-inhibitor-treatment-and-risk-of-atrial2026-10-06 https://evidence-hub.com/study/12698-use-of-sodium-glucose-co-transporter-2-inhibitors-and-risk-of-serious2026-10-12 https://evidence-hub.com/study/12699-cardiovascular-events-acute-hospitalizations-and-mortality-in2026-10-06 https://evidence-hub.com/study/12700-healthcare-costs-and-resource-utilization-associated-with-the-use-of2026-10-06 https://evidence-hub.com/study/12701-sodium-glucose-cotransporter-2-inhibitors-and-risk-of-serious-adverse2026-10-06 https://evidence-hub.com/study/12702-abstract-12579-empagliflozin-and-the-risk-of-atherosclerotic-events2026-10-06 https://evidence-hub.com/study/12703-abstract-10855-cardiovascular-effectiveness-of-empagliflozin-compared2026-10-06 https://evidence-hub.com/study/12704-sglt2i-compared-to-other-non-insulin-antidiabetics-in-primary-care2026-10-06 https://evidence-hub.com/study/12706-growth-differentiation-factor-15-a-biomarker-to-guide-empagliflozin2026-10-06 https://evidence-hub.com/study/12707-the-effect-of-empagliflozin-and-sitagliptin-as-an-add-on-therapy-to2026-10-04 https://evidence-hub.com/study/12708-empagliflozin-vs-dapagliflozin-in-heart-failure-a-target-trial2026-10-06 https://evidence-hub.com/study/12709-p5003reduced-healthcare-utilization-in-routine-care-initiators-of2026-10-06 https://evidence-hub.com/study/12710-1193-p-health-care-costs-and-medication-burden-in-routine-care2026-10-06 https://evidence-hub.com/study/12711-empagliflozin-versus-dapagliflozin-in-heart-failure2026-10-06 https://evidence-hub.com/study/12712-dapagliflozin-versus-empagliflozin-in-patients-with-heart-failure2026-10-06 https://evidence-hub.com/study/12713-cost-effectiveness-of-empagliflozin-in-the-treatment-of-malaysian2026-10-06 https://evidence-hub.com/study/12714-cost-effectiveness-of-empagliflozin-in-ckd-with-or-without-albuminuria2026-10-06 https://evidence-hub.com/study/12715-diabetes-mellitus-aggravates-myocardial-inflammation-and-oxidative2026-10-06 https://evidence-hub.com/study/12716-adherence-to-newer-second-line-oral-antidiabetic-drugs-among-people2026-10-06 https://evidence-hub.com/study/12717-efficacy-of-sglt2-inhibitors-as-the-fifth-drug-in-the-management-of2026-10-06 https://evidence-hub.com/study/12718-glycosuria-mediated-urinary-uric-acid-excretion-in-patients-with2026-10-06 https://evidence-hub.com/study/12719-outpatient-medications-associated-with-protection-from-covid-192026-10-04 https://evidence-hub.com/study/12720-progress-of-patients-hospitalized-with-acute-heart-failure-treated2026-10-06 https://evidence-hub.com/study/12721-efficacy-and-safety-of-empagliflozin-a-real-world-experience-from2026-10-06 https://evidence-hub.com/study/12722-pharmacotherapy-of-diabetes-mellitus-in-patients-with-heart-failure-a2026-10-06 https://evidence-hub.com/study/12723-evaluation-of-the-effect-of-sodium-glucose-cotransporter-2-inhibitor2026-10-06 https://evidence-hub.com/study/12724-liver-fibrosis-indices-and-outcomes-after-primary-intracerebral2026-10-06 https://evidence-hub.com/study/12725-rates-of-diabetic-ketoacidosis-with-empagliflozin-use-during2026-10-06 https://evidence-hub.com/study/12726-incidence-and-predictors-of-primary-nonadherence-to-sodium-glucose-co2026-10-06 https://evidence-hub.com/study/12727-exploratory-mediation-informed-analysis-and-dose-response-analysis-of2026-10-06 https://evidence-hub.com/study/12728-clinical-pharmacy-specialist-collaborative-management-and2026-10-06 https://evidence-hub.com/study/12729-use-of-sodium-glucose-cotransporter-2-inhibitors-in-patients-with2026-10-06 https://evidence-hub.com/study/12730-efficacy-and-safety-of-empagliflozin-in-glycogen-storage-disease-type2026-10-06 https://evidence-hub.com/study/12731-sodium-glucose-cotransporter-2-inhibitors-reduce-the-risk-of-incident2026-10-06 https://evidence-hub.com/study/12732-sglt-2-inhibitors-and-the-risk-of-lower-limb-amputation-is-this-a2026-10-06 https://evidence-hub.com/study/12733-efficacy-and-safety-of-empagliflozine-and-semaglutide-once-weekly-in2026-10-06 https://evidence-hub.com/study/12734-comparative-evaluation-of-clinical-outcomes-of-dapagliflozin-and2026-10-06 https://evidence-hub.com/study/12735-real-world-data-on-empagliflozin-and-dapagliflozin-use-in-patients2026-10-06 https://evidence-hub.com/study/12736-the-risk-of-new-onset-atrial-fibrillation-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/12737-effectiveness-and-safety-of-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/12738-can-sodium-glucose-cotransporter-2-inhibitors-be-beneficial-in2026-10-06 https://evidence-hub.com/study/12739-detrimental-effect-of-plasma-from-patients-with-severe-aortic2026-10-06 https://evidence-hub.com/study/12740-comparison-of-cardiovascular-and-renal-outcomes-between-dapagliflozin2026-10-06 https://evidence-hub.com/study/12741-impact-of-inpatient-initiation-of-sglt2-inhibitors-on-diuretic2026-10-06 https://evidence-hub.com/study/12742-efficacy-and-safety-of-sodium-glucose-cotransporter-2-inhibitor-in2026-10-06 https://evidence-hub.com/study/12743-relationship-between-presence-of-visceral-infarction-and-functional2026-10-06 https://evidence-hub.com/study/12744-predictors-of-the-therapeutic-efficacy-and-consideration-of-the-best2026-10-06 https://evidence-hub.com/study/12745-new-onset-diabetes-mellitus-after-adult-heart-transplantation-and-the2026-10-06 https://evidence-hub.com/study/12746-a-5-year-trend-in-the-use-of-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/12747-risk-of-urinary-infections-in-veterans-on-empagliflozin-with2026-10-06 https://evidence-hub.com/study/12748-long-term-empagliflozin-therapy-improves-levels-of-hepatic-fibrosis2026-10-06 https://evidence-hub.com/study/12749-the-safety-of-sodium-glucose-transporter-2-inhibitors-and-trends-in2026-10-06 https://evidence-hub.com/study/12750-sodium-glucose-co-transporter-2-inhibitors-eligibility-in-patients2026-10-06 https://evidence-hub.com/study/12751-effects-of-sglt2-inhibitors-on-circulating-stem-and-progenitor-cells2026-10-06 https://evidence-hub.com/study/12752-assessment-of-the-diagnosis-treatment-and-follow-up-of-a-group-of2026-10-06 https://evidence-hub.com/study/12753-comparative-effectiveness-of-the-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/12754-empagliflozin-in-posttransplantation-diabetes-mellitus-a-prospective2026-10-01 https://evidence-hub.com/study/12755-antihyperglycemic-therapies-with-expansions-of-us-food-and-drug2026-10-06 https://evidence-hub.com/study/12756-inhibition-of-renal-sodium-glucose-cotransport-with-empagliflozin2026-10-06 https://evidence-hub.com/study/12757-empagliflozin-use-in-cardiac-transplant-patients-real-world2026-10-06 https://evidence-hub.com/study/12758-case-report-the-success-of-empagliflozin-therapy-for-glycogen-storage2026-10-06 https://evidence-hub.com/study/12759-low-adoption-of-weight-loss-medications-a-comparison-of-prescribing2026-10-06 https://evidence-hub.com/study/12760-comparative-assessment-of-the-long-term-effectiveness-and-safety-of2026-10-06 https://evidence-hub.com/study/12761-a-retrospective-analysis-of-fixed-combination-of-empagliflozin-and2026-10-06 https://evidence-hub.com/study/12762-clinical-spectrum-and-mechanism-of-acute-kidney-injury-in-patients2026-10-06 https://evidence-hub.com/study/12763-real-world-impact-of-empagliflozin-on-total-cost-of-care-in-adults2026-10-06 https://evidence-hub.com/study/12764-empagliflozin-and-arterial-stiffness-in-patients-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/12766-the-effects-of-sglt2-inhibitors-in-patients-with-preserved-ejection2026-10-06 https://evidence-hub.com/study/12767-case-report-the-long-term-effects-of-the-empagliflozin-therapy-on2026-10-06 https://evidence-hub.com/study/12768-effectiveness-of-sitagliptin-and-empagliflozin-combination-therapy-in2026-10-06 https://evidence-hub.com/study/12769-case-report-high-calorie-glucose-infusion-and-tight-glycemic-control2026-10-06 https://evidence-hub.com/study/12770-efficacy-of-empagliflozin-for-weight-and-glycemic-control-of-a2026-10-06 https://evidence-hub.com/study/12771-management-and-diagnosis-of-empagliflozin-induced-burning-mouth2026-10-06 https://evidence-hub.com/study/12772-sodium-glucose-co-transporter-2-inhibitors-in-intensive-care-unit2026-10-06 https://evidence-hub.com/study/12773-severe-euglycemic-diabetic-ketoacidosis-of-multifactorial-etiology-in2026-10-06 https://evidence-hub.com/study/12774-combination-therapy-with-empagliflozin-and-insulin-results-in2026-10-06 https://evidence-hub.com/study/12776-empagliflozin-role-in-the-treatment-of-type-2-diabetes-with2026-10-06 https://evidence-hub.com/study/12777-diagnostic-and-prognostic-roles-of-inflammatory-biomarkers-in2026-10-06 https://evidence-hub.com/study/12778-characteristic-dysbiosis-in-patients-with-type-2-diabetes-and2026-10-06 https://evidence-hub.com/study/12779-effectiveness-of-empagliflozin-linagliptin-fixed-dose-combination-on2026-10-06 https://evidence-hub.com/study/12780-impact-of-early-administration-of-empagliflozin-in-patients-with2026-10-06 https://evidence-hub.com/study/12781-a-prospective-observational-case-controlled-pilot-study-protocol-on2026-10-06 https://evidence-hub.com/study/12783-mon-648-a-deadly-duo-rapid-onset-lactic-acidosis-and-euglycemic-dka2026-10-06 https://evidence-hub.com/study/12784-the-impact-of-empagliflozin-and-metformin-on-cardiac-parameters-in2026-10-04 https://evidence-hub.com/study/12785-empagliflozin-and-intermittent-fasting-as-a-strategy-to-mitigate2026-10-06 https://evidence-hub.com/study/12786-sat-520-tirzepatide-associated-interstitial-kidney-injury-a-case2026-10-06 https://evidence-hub.com/study/12787-pharmacometrics-enhanced-bayesian-borrowing-for-pediatric2026-10-06 https://evidence-hub.com/study/12788-cardiovascular-and-renal-benefits-of-sglt2-inhibitors-in-chronic2026-10-06 https://evidence-hub.com/study/12789-efficacy-of-sodium-glucose-cotransporter-2-inhibitor-with-glucagon2026-10-06 https://evidence-hub.com/study/12790-8088-connecting-the-dots-semaglutide-constipation-and-diverticulitis2026-10-06 https://evidence-hub.com/study/12791-euglycemic-ketoacidosis-induced-by-sglt2-inhibitor-in-latent2026-10-06 https://evidence-hub.com/study/12792-correction-of-over-dosed-insulin-in-a-type-2-diabetic-led-to-a-better2026-10-06 https://evidence-hub.com/study/12793-use-of-a-sodium-glucose-cotransporter-2-inhibitor-empagliflozin-in-a2026-10-06 https://evidence-hub.com/study/12794-glycemic-efficacy-and-metabolic-consequences-of-an-empagliflozin-add2026-10-04 https://evidence-hub.com/study/12795-correction-of-over-dosed-insulin-in-a-type-2-diabetic-associates-with2026-10-06 https://evidence-hub.com/study/12796-empagliflozin-in-paroxysmal-or-persistent-atrial-fibrillation-a2026-10-06 https://evidence-hub.com/study/12797-an-interesting-experience-with-empagliflozin-unidentified-body-odor2026-10-06 https://evidence-hub.com/study/12798-evaluation-of-the-effect-of-empagliflozin-therapy-on-t-helper-22-cell2026-10-06 https://evidence-hub.com/study/12799-thu380-a-case-of-alpelisib-induced-diabetic-ketoacidosis-dka-in-a2026-10-06 https://evidence-hub.com/study/12800-thu359-a-classical-case-of-sglt-2-inhibitor-euglycemic-ketoacidosis2026-10-06 https://evidence-hub.com/study/12801-euglycemic-diabetic-ketoacidosis-following-sleeve-gastrectomy-in-a2026-10-06 https://evidence-hub.com/study/12802-severe-hypernatraemic-dehydration-and-unconsciousness-in-a-care2026-10-06 https://evidence-hub.com/study/12804-575-emphysematous-kidney-and-pyelonephritis-in-a-diabetic-woman2026-10-06 https://evidence-hub.com/study/12805-euglycemic-diabetic-ketoacidosis-caused-by-sglt2-inhibitors-and-a2026-10-06 https://evidence-hub.com/study/12807-sodium-glucose-cotransporter-2-inhibitor-induced-euglycemic-diabetic2026-10-06 https://evidence-hub.com/study/12808-triple-therapy-with-empagliflozin-linagliptin-and-gliclazide-in-a2026-10-06 https://evidence-hub.com/study/12809-sglt2-inhibitor-promotes-ketogenesis-to-improve-mash-by-suppressing2026-10-06 https://evidence-hub.com/study/12810-risk-of-depression-and-dementia-among-individuals-treated-with-sodium2026-10-06 https://evidence-hub.com/study/12811-bridging-cardiorenal-and-hepatic-disease-the-emerging-role-of-sglt22026-10-06 https://evidence-hub.com/study/12812-use-of-emgliflozin-in-the-prevention-of-cardotoxicity-the-empacard2026-10-06 https://evidence-hub.com/study/12813-evaluation-and-efficacy-of-sglt2-inhibitors-in-diabetes-mellitus-and2026-10-06 https://evidence-hub.com/study/12814-impact-of-sodium-glucose-co-transporter-2-inhibitors-on-bone-mineral2026-10-06 https://evidence-hub.com/study/12815-differing-effects-of-nefecon-and-sparsentan-in-a-patient-with2026-10-06 https://evidence-hub.com/study/12816-creatine-phosphokinase-level-accompanied-with-macro-creatine2026-10-06 https://evidence-hub.com/study/12817-intraoperative-diagnosis-of-sodium-glucose-transporter-2-inhibitor2026-10-06 https://evidence-hub.com/study/12818-judicious-use-of-modern-technology-with-antihyperglycemic-agents-the2026-10-06 https://evidence-hub.com/study/12819-p-31-glp1-receptor-agonist-in-end-stage-kidney-disease-are-they-safe2026-10-06 https://evidence-hub.com/study/12821-sodium-glucose-cotransporter-2-inhibition-prevents-renal-fibrosis-in2026-10-06 https://evidence-hub.com/study/12823-use-of-sodium-glucose-cotransporter-2-inhibitor-for-diabetes2026-10-06 https://evidence-hub.com/study/12825-rapid-onset-clozapine-induced-hyperglycaemia-pathways-of-glycaemic2026-10-06 https://evidence-hub.com/study/12826-dapagliflozin-associated-diabetic-ketoacidosis2026-10-06 https://evidence-hub.com/study/12828-increase-in-glycated-haemoglobin-concentrations-after-unwarranted2026-10-06 https://evidence-hub.com/study/12829-euglycemic-diabetic-ketoacidosis-in-a-neurosurgical-patient-on2026-10-06 https://evidence-hub.com/study/12830-empagliflozin-combined-with-bortezomib-in-the-treatment-of-heavy-and2026-10-06 https://evidence-hub.com/study/12831-long-term-efficacy-of-empagliflozin-as-an-add-on-treatment-for2026-10-06 https://evidence-hub.com/study/12832-crohn-disease-like-enterocolitis-remission-after-empagliflozin2026-10-06 https://evidence-hub.com/study/12833-a-case-of-ureteral-fungal-mass-removal-in-a-patient-taking2026-10-06 https://evidence-hub.com/study/12834-empagliflozin-mediated-lithium-excretion-a-case-study-and-clinical2026-10-08 https://evidence-hub.com/study/12835-glycemic-control-by-the-sglt2-inhibitor-empagliflozin-decreases2026-10-04 https://evidence-hub.com/study/12836-non-carbohydrate-anaplerotic-therapy-counters-empagliflozin-induced2026-10-06 https://evidence-hub.com/study/12837-1491-p-insights-from-1-062-clinicians-evaluating-the-efficacy-and2026-10-06 https://evidence-hub.com/study/12838-efficacy-and-safety-of-empagliflozin-sglt2-inhibitor-in-bangladeshi2026-10-06 https://evidence-hub.com/study/12839-fournier-s-gangrene-in-a-patient-with-type-2-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/12840-sglt2-expression-in-human-vasculature-and-heart-correlates-with-low2026-10-06 https://evidence-hub.com/study/12841-comparative-assessment-of-treatment-outcomes-of-empagliflozin-add-on2026-10-08 https://evidence-hub.com/study/12842-impact-of-cigarette-smoking-and-its-interaction-with-hypertension-and2026-10-06 https://evidence-hub.com/study/12843-severe-hypertension-in-china-results-from-the-china-peace-million2026-10-06 https://evidence-hub.com/study/12844-adherence-to-guideline-recommended-cancer-screening-in-stroke2026-10-06 https://evidence-hub.com/study/12845-the-effect-of-empagliflozin-on-alleviating-c4d-over-activation-in2026-10-06 https://evidence-hub.com/study/12846-association-of-long-term-exposure-to-pm2-5-with-hypertension2026-10-06 https://evidence-hub.com/study/12847-symptoms-of-depression-and-active-smoking-among-survivors-of-stroke2026-10-06 https://evidence-hub.com/study/12848-assessment-of-prevalence-awareness-and-characteristics-of-isolated2026-10-06 https://evidence-hub.com/study/12849-empagliflozin-use-among-patients-with-heart-failure-in-the-outpatient2026-10-06 https://evidence-hub.com/study/12850-type-2-diabetes-patients-requiring-empagliflozin-in-southeast-of-iran2026-10-06 https://evidence-hub.com/study/12851-coverage-formulary-restrictions-and-affordability-of-sodium-glucose2026-10-06 https://evidence-hub.com/study/12852-characteristics-interventions-and-outcomes-of-patients-with-valvular2026-10-06 https://evidence-hub.com/study/12853-real-world-characteristics-modern-antidiabetic-treatment-patterns-and2026-10-06 https://evidence-hub.com/study/12854-investigation-on-the-treatment-of-empagliflozin-in-glycogen-storage2026-10-06 https://evidence-hub.com/study/12855-methodology-of-clinical-trials-on-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/12856-efficacy-and-safety-of-empagliflozin-in-the-treatment-of-glycogen2026-10-06 https://evidence-hub.com/study/12857-the-beneficial-effects-of-empagliflozin-metformin-combination-on2026-10-04 https://evidence-hub.com/study/12858-use-of-antihyperglycemic-medications-in-u-s-adults-an-analysis-of-the2026-10-06 https://evidence-hub.com/study/12859-national-trends-in-use-of-sodium-glucose-cotransporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/12860-prescribing-patterns-and-factors-associated-with-sodium-glucose2026-10-06 https://evidence-hub.com/study/12861-eligibility-of-patients-with-type-2-diabetes-for-sodium-glucose2026-10-06 https://evidence-hub.com/study/12862-early-potential-safety-signals-for-gliptins-and-gliflozins-using-real2026-10-06 https://evidence-hub.com/study/12863-electronic-cigarette-use-and-cigarette-smoking-cessation-attempts2026-10-06 https://evidence-hub.com/study/12864-finerenone-prescriptions-in-the-united-states-2021-2024-by-physician2026-10-06 https://evidence-hub.com/study/12865-influence-of-common-polymorphisms-in-the-slc5a2-gene-on-metabolic2026-10-06 https://evidence-hub.com/study/12866-generalizability-of-cardiovascular-safety-trials-on-sglt2-inhibitors2026-10-06 https://evidence-hub.com/study/12867-a-short-term-follow-up-of-glycemic-and-body-weight-changes-in2026-10-06 https://evidence-hub.com/study/12868-comparative-analysis-of-serious-adverse-effects-of-antidiabetic-drugs2026-10-06 https://evidence-hub.com/study/12869-how-many-patients-with-type-2-diabetes-meet-the-inclusion-criteria-of2026-10-06 https://evidence-hub.com/study/12870-association-between-sglt-2-inhibitor-use-and-retinal-microvascular2026-10-06 https://evidence-hub.com/study/12871-association-of-sglt2-inhibitor-use-with-glycosuria-pyuria-urinary2026-10-06 https://evidence-hub.com/study/12872-urinary-tract-infections-risk-factors-and-antimicrobial-resistance2026-10-06 https://evidence-hub.com/study/12873-a-comparison-of-sodium-glucose-co-transporter-2-inhibitor-kidney2026-10-06 https://evidence-hub.com/study/12874-evaluation-of-oxidative-stress-and-inflammatory-biomarkers-in2026-10-04 https://evidence-hub.com/study/12875-investigation-of-the-effect-of-sglt-2-inhibitors-on-the-triglyceride2026-10-06 https://evidence-hub.com/study/12877-predictors-of-asymptomatic-ketonemia-in-outpatients-with-diabetic2026-10-06 https://evidence-hub.com/study/12878-empagliflozin-perception-mapping-survey2026-10-06 https://evidence-hub.com/study/12879-self-reported-symptoms-of-empagliflozin-discontinuation-an-online2026-10-06 https://evidence-hub.com/study/12880-comparison-of-mean-post-treatment-hba1c-levels-among-patients-using2026-10-04 https://evidence-hub.com/study/12881-comparison-of-metformin-combined-with-empagliflozin-or-sitagliptin-on2026-10-04 https://evidence-hub.com/study/12882-26-pub-real-world-preference-for-triple-fixed-dose-combination-of2026-10-06 https://evidence-hub.com/study/12883-effects-of-empagliflozin-alone-and-in-combination-with-exercise-on2026-10-06 https://evidence-hub.com/study/12884-glycemic-control-and-body-weight-effects-of-sglt2-inhibitors2026-10-06 https://evidence-hub.com/study/12885-comparison-of-inflammatory-markers-in-type-2-diabetic-patients2026-10-04 https://evidence-hub.com/study/12886-full-tablet-and-half-tablet-empagliflozin-prescription-demographic2026-10-06 https://evidence-hub.com/study/12887-cutting-costs-not-quality-a-cost-minimization-analysis-of-diabetes2026-10-06 https://evidence-hub.com/study/12888-effects-of-sglt2-inhibitors-on-circulating-cyclophilin-a-levels-in2026-10-06 https://evidence-hub.com/study/12889-physicians-experience-with-sglt-2-inhibitors-in-type-2-diabetic2026-10-06 https://evidence-hub.com/study/12890-a-comparative-assessment-of-two-antidiabetic-medication-on-glucose2026-10-04 https://evidence-hub.com/study/12891-a64-08-metabolic-reprogramming-in-pulmonary-vascular-disease-insights2026-10-06 https://evidence-hub.com/study/12893-sodium-glucose-cotransporter-2-inhibition-and-urolithiasis-the-effect2026-10-06 https://evidence-hub.com/study/12894-nationwide-trends-in-dispensing-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/12895-need-of-the-hour-pharmacovigilance-study-of-sglt-2-inhibitors2026-10-06 https://evidence-hub.com/study/12896-in-reply-to-letter-regarding-impact-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/12897-occurence-of-urinary-tract-infections-in-type-2-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/12898-prevalence-of-genitourinary-infections-with-sodium-glucose-co2026-10-06 https://evidence-hub.com/study/12901-medical-student-experiences-and-perceptions-of-chatgpt-and-artificial2026-10-19 https://evidence-hub.com/study/12902-the-role-of-empagliflozin-induced-metabolic-changes-for-cardiac2026-10-06 https://evidence-hub.com/study/12903-serum-per-and-polyfluoroalkyl-substances-and-abnormal-lipid2026-10-19 https://evidence-hub.com/study/12904-frequency-and-predictors-of-inappropriate-medication-dosages-for2026-10-06 https://evidence-hub.com/study/12905-indexes-of-ferroptosis-and-iron-metabolism-were-associated-with-the2026-10-06 https://evidence-hub.com/study/12906-factors-influencing-the-professional-identity-of-nursing-interns-a2026-10-19 https://evidence-hub.com/study/12907-stroke-risk-following-takotsubo-cardiomyopathy2026-10-06 https://evidence-hub.com/study/12908-severe-vulvovaginal-candidiasis-associated-with-sodium-glucose2026-10-06 https://evidence-hub.com/study/12909-sodium-glucose-cotransporter-2-sglt2-inhibition-in-kidney-transplant2026-10-06 https://evidence-hub.com/study/12910-clinical-features-treatment-and-prognosis-of-sglt2-inhibitors-induced2026-10-06 https://evidence-hub.com/study/12911-adverse-events-and-drug-drug-interactions-of-sodium-glucose-co2026-10-06 https://evidence-hub.com/study/12912-beware-ketoacidosis-with-sglt2-inhibitors-in-latent-autoimmune2026-10-06 https://evidence-hub.com/study/12913-empagliflozin-a-sodium-glucose-co-transporter-2-inhibitor-overview-of2026-10-06 https://evidence-hub.com/study/12914-a-series-of-diabetic-ketoacidosis-associated-with-the-use-of-sodium2026-10-06 https://evidence-hub.com/study/12915-a-case-series-of-sglt2i-improving-hemoglobin-in-adults-with2026-10-06 https://evidence-hub.com/study/12916-tizanidine-withdrawal-syndrome-clinical-manifestations-and-management2026-10-06 https://evidence-hub.com/study/12917-sglt2-inhibitor-associated-euglycemic-diabetic-ketoacidosis-edka-in2026-10-06 https://evidence-hub.com/study/12918-inpatient-perioperative-euglycemic-diabetic-ketoacidosis-due-to2026-10-06 https://evidence-hub.com/study/12919-sodium-glucose-cotransporter-2-inhibitors-induced-euglycemic-diabetic2026-10-06 https://evidence-hub.com/study/12920-sodium-glucose-cotransporter-2-inhibitors-reduce-albuminuria-in2026-10-06 https://evidence-hub.com/study/12921-sodium-glucose-cotransporter-2-inhibitor-sglt2i-associated-diabetic2026-10-06 https://evidence-hub.com/study/12922-sodium-glucose-cotransporter-2-inhibitors-as-diuretic-adjuvants-in2026-10-06 https://evidence-hub.com/study/12923-diabetic-ketoacidosis-in-patients-with-type-2-diabetes-on-sodium2026-10-06 https://evidence-hub.com/study/12924-sglt2-inhibitors-in-autosomal-dominant-polycystic-kidney-disease-a2026-10-06 https://evidence-hub.com/study/12925-midodrine-to-facilitate-cardioprotective-therapy-in-hypotensive-her22026-10-06 https://evidence-hub.com/study/12926-post-bariatric-hypoglycaemia-from-altered-gut-physiology-to-targeted2026-10-06 https://evidence-hub.com/study/12927-repurposing-sglt2-inhibitors-for-cirrhotic-ascites-from-mechanistic2026-10-06 https://evidence-hub.com/study/12928-clinical-outcomes-and-management-in-late-diagnosed-siblings-affected2026-10-06 https://evidence-hub.com/study/12929-sglt2-inhibitor-therapy-in-overweight-and-obese-patients-with-cystic2026-10-06 https://evidence-hub.com/study/12930-sglt-2-inhibitor-associated-significant-hypernatremia-and-euglycemic2026-10-06 https://evidence-hub.com/study/12931-beneficial-effects-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-08 https://evidence-hub.com/study/12932-early-in-hospital-initiation-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/12933-sglt2-inhibitors-and-liver-cirrhosis-hype-or-hope2026-10-06 https://evidence-hub.com/study/12934-expanding-the-therapeutic-landscape-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/12935-real-world-presentation-of-myocardial-bridging-in-the-cath-lab-a-case2026-10-06 https://evidence-hub.com/study/12936-sglt2-inhibitors-as-a-therapeutic-option-for-both-acute-and-chronic2026-10-08 https://evidence-hub.com/study/12937-real-world-experience-with-dapagliflozin-in-non-diabetic-chronic2026-10-06 https://evidence-hub.com/study/12938-sodium-glucose-cotransporter-2-inhibitors-and-euglycemic-diabetic2026-10-06 https://evidence-hub.com/study/12939-efficacy-and-safety-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-08 https://evidence-hub.com/study/12940-sglt2-inhibition-for-patients-with-adpkd-closing-the-evidence-gap2026-10-06 https://evidence-hub.com/study/12941-active-safety-surveillance-using-real-world-evidence-assure2026-10-06 https://evidence-hub.com/study/12942-empagliflozin-as-treatment-in-glycogen-storage-disease-type-ib2026-10-06 https://evidence-hub.com/study/12943-sglt-2-inhibitors-in-prevention-of-chemotherapy-induced2026-10-06 https://evidence-hub.com/study/12944-sodium-glucose-cotransporter-2-inhibitors-in-underweight-patients2026-10-06 https://evidence-hub.com/study/12945-refractory-heart-failure-in-noncompaction-cardiomyopathy-despite2026-10-06 https://evidence-hub.com/study/12946-new-hope-for-young-hearts-a-systematic-review-of-sodium-glucose2026-10-06 https://evidence-hub.com/study/12947-severe-euglycemic-diabetic-ketoacidosis-requiring-intubation-after2026-10-06 https://evidence-hub.com/study/12948-the-potential-role-of-sglt2-inhibitors-in-cushing-s-disease2026-10-06 https://evidence-hub.com/study/12949-the-sglt2-inhibitor-checklist-a-comprehensive-review-of-perioperative2026-10-06 https://evidence-hub.com/study/12950-pregnancy-outcomes-following-maternal-fenofibrate-exposure2026-10-06 https://evidence-hub.com/study/12951-role-of-sodium-glucose-cotransporter-2-inhibitors-in-liver-diseases2026-10-06 https://evidence-hub.com/study/12952-recognizing-and-mitigating-the-effects-of-medication-on-heat-related2026-10-06 https://evidence-hub.com/study/12953-linagliptin-induced-bullous-pemphigoid-a-case-report-and2026-10-06 https://evidence-hub.com/study/12954-a-comparative-analysis-of-diabetic-ketoacidosis-dka-in-sodium-glucose2026-10-06 https://evidence-hub.com/study/12955-the-use-of-dapagliflozin-in-the-treatment-of-children-with-severe2026-10-06 https://evidence-hub.com/study/12956-the-dual-role-of-sglt2-inhibitors-glycemic-control-and2026-10-06 https://evidence-hub.com/study/12957-comparative-effectiveness-of-sglt2-inhibitors-and-semaglutide-in2026-10-06 https://evidence-hub.com/study/12958-a-case-of-perioperative-euglycemic-ketoacidosis-in-a-patient-without2026-10-06 https://evidence-hub.com/study/12959-secretagogue-laxatives-as-a-potential-strategy-to-overcome-adherence2026-10-06 https://evidence-hub.com/study/12960-role-of-venoarterial-extracorporeal-membrane-oxygenation-as-a2026-10-06 https://evidence-hub.com/study/12961-identification-of-endogenous-hypercortisolism-and-the-effect-of2026-10-06 https://evidence-hub.com/study/12962-temporary-left-ventricular-assist-device-for-peripartum-cardiogenic2026-10-06 https://evidence-hub.com/study/12963-case-report-oral-semaglutide-associated-depression-in-a-patient-with2026-10-06 https://evidence-hub.com/study/12964-a-pitfall-in-diagnosing-type-b-insulin-resistance-syndrome-suspected2026-10-06 https://evidence-hub.com/study/12965-use-of-acetazolamide-in-volume-overload-start-at-the-beginning2026-10-06 https://evidence-hub.com/study/12966-sglt2-inhibitors-and-the-risk-of-arrhythmias-in-heart-failure-a2026-10-06 https://evidence-hub.com/study/12967-adult-annular-pancreas-presenting-with-gastric-outlet-obstruction2026-10-06 https://evidence-hub.com/study/12968-emphysematous-cystitis-in-an-immunocompetent-patient-on-an-sglt22026-10-08 https://evidence-hub.com/study/12969-perioperative-euglycemic-dka-the-yin-and-yang-of-sodium-glucose2026-10-06 https://evidence-hub.com/study/12970-catheter-ablation-of-typical-atrial-flutter-in-a-patient-with-left2026-10-06 https://evidence-hub.com/study/12971-the-role-of-glucagon-like-peptide-1-receptor-modulators-for-the2026-10-06 https://evidence-hub.com/study/12972-the-synergistic-treatment-of-heart-and-kidney-disease2026-10-06 https://evidence-hub.com/study/12973-emerging-therapeutic-strategies-for-the-failing-fontan-circulation2026-10-06 https://evidence-hub.com/study/12974-potential-role-of-sglt-2-inhibitors-in-improving-allograft-function2026-10-06 https://evidence-hub.com/study/12975-genotype-phenotype-spectrum-and-clinical-outcomes-of-glycogen-storage2026-10-06 https://evidence-hub.com/study/12976-facilitating-earlier-diagnosis-of-pulmonary-hypertension-using-a2026-10-06 https://evidence-hub.com/study/12977-baroreflex-activation-therapy-in-hfref-patients-anti-inflammatory2026-10-06 https://evidence-hub.com/study/12978-impact-of-guideline-directed-medical-therapy-on-left-ventricular2026-10-06 https://evidence-hub.com/study/12979-unexpected-cancellation-of-radioactive-iodine-treatment-after-thyroid2026-10-06 https://evidence-hub.com/study/12980-cardiotoxicity-induced-by-multiple-myeloma-therapies-mechanistic2026-10-06 https://evidence-hub.com/study/12981-sglt2-inhibitors-in-cardiac-amyloidosis-mechanistic-insights-and2026-10-06 https://evidence-hub.com/study/12982-efficacy-of-sglt2-inhibitors-on-clinical-outcomes-after-transcatheter2026-10-06 https://evidence-hub.com/study/12983-comparative-risk-of-cancer-associated-with-sglt-inhibitors-and-dpp-42026-10-06 https://evidence-hub.com/study/12985-mon-587-sglt2-inhibitor-related-starvation-ketoacidosis-a-case-series2026-10-06 https://evidence-hub.com/study/12986-metabolic-and-neuropathic-outcomes-following-combined-sodium-glucose2026-10-06 https://evidence-hub.com/study/12987-theuse-of-lcz-696-sacubitril-valsartan-and-sglt2inhibitors-a-real2026-10-06 https://evidence-hub.com/study/12988-mo1034-sodium-glucose-cotransporter-2-inhibitors-in-patients-with2026-10-06 https://evidence-hub.com/study/12989-drug-drug-interactions-of-empagliflozin-and-dapagliflozin2026-10-06 https://evidence-hub.com/study/12990-empagliflozin-ameliorated-neutropenia-in-a-girl-with-glycogen-storage2026-10-06 https://evidence-hub.com/study/12991-empagliflozin-induced-diabetic-ketoacidosis-unmasking-a-type-12026-10-06 https://evidence-hub.com/study/12992-complications-secondary-to-the-use-of-sglt2-inhibitors-in-oncological2026-10-06 https://evidence-hub.com/study/12993-dapagliflozin-ameliorates-lafora-disease-phenotype-in-a-zebrafish2026-10-06 https://evidence-hub.com/study/12994-composite-endpoints-in-health-technology-assessment-part-2-expanding2026-10-06 https://evidence-hub.com/study/12995-sglt2-inhibitor-induced-euglycemic-ketoacidosis-in-acute-surgical2026-10-06 https://evidence-hub.com/study/12996-the-significance-of-precise-diabetes-diagnosis-a-case-of-euglycemic2026-10-06 https://evidence-hub.com/study/12997-8084-euglycemic-diabetic-ketoacidosis-in-vulnerable-populations-a2026-10-06 https://evidence-hub.com/study/12998-a-rare-case-of-incidental-asymptomatic-emphysematous-cystitis-in-a2026-10-06 https://evidence-hub.com/study/12999-empagliflozin-induced-myopathy2026-10-06 https://evidence-hub.com/study/13000-empagliflozin-related-dress-syndrome2026-10-06 https://evidence-hub.com/study/13001-risk-of-euglycemic-diabetic-ketoacidosis-can-persist-after2026-10-06 https://evidence-hub.com/study/13002-euglycemic-diabetic-ketoacidosis-in-the-setting-of-acute2026-10-06 https://evidence-hub.com/study/13003-sodium-glucose-cotransporter-2-inhibitor-associated-severe-epididymo2026-10-13 https://evidence-hub.com/study/13004-acute-pancreatitis-with-normal-amylase-and-lipase-a-diagnostic-dilemma2026-10-06 https://evidence-hub.com/study/13005-improvement-in-serum-magnesium-levels-with-sodium-glucose2026-10-06 https://evidence-hub.com/study/13006-empagliflozin-may-be-a-game-changer-in-managing-pulmonary-embolism-a2026-10-06 https://evidence-hub.com/study/13007-adverse-side-effects-empagliflozin-related-acute-pancreatitis-case2026-10-06 https://evidence-hub.com/study/13008-dapagliflozin-in-the-treatment-of-heart-failure-with-preserved2026-10-06 https://evidence-hub.com/study/13009-late-diagnosis-of-prader-willi-syndrome-in-an-adolescent-with2026-10-06 https://evidence-hub.com/study/13010-slgt2-inhibitor-rescues-myelopoiesis-in-g6pc3-deficiency2026-10-06 https://evidence-hub.com/study/13011-euglycemic-diabetic-ketoacidosis-recurrent-genital-abscess-and2026-10-06 https://evidence-hub.com/study/13012-empagliflozin-induced-pancreatitis-a-case-report-pattern2026-10-06 https://evidence-hub.com/study/13013-empagliflozin-induced-euglycemic-diabetic-ketoacidosis-a-case-reports2026-10-06 https://evidence-hub.com/study/13014-euglycemic-diabetic-ketoacidosis-after-discontinuing-sglt2-inhibitor2026-10-06 https://evidence-hub.com/study/13015-case-report-diabetic-ketoacidosis-after-co-administration-of2026-10-06 https://evidence-hub.com/study/13016-fournier-s-gangrene-in-an-hiv-positive-patient-on-empagliflozin-for2026-10-06 https://evidence-hub.com/study/13017-misleading-presentation-chest-pain-masking-euglycemic-diabetic2026-10-06 https://evidence-hub.com/study/13018-a-rare-case-of-sodium-glucose-cotransporter-2-inhibitor-induced-acute2026-10-06 https://evidence-hub.com/study/13019-clinical-remission-of-severe-crohn-s-disease-with-empagliflozin2026-10-06 https://evidence-hub.com/study/13020-sglt2i-improves-glycemic-control-in-patients-with-congenital-severe2026-10-06 https://evidence-hub.com/study/13021-empagliflozin-associated-pancreatitis-in-the-setting-of-hyperglycemic2026-10-06 https://evidence-hub.com/study/13022-successful-management-of-hfpef-related-pulmonary-hypertension-with2026-10-06 https://evidence-hub.com/study/13023-an-unsuspected-case-of-euglycemic-diabetic-ketoacidosis-with-twists2026-10-06 https://evidence-hub.com/study/13024-empagliflozin-associated-postoperative-mixed-metabolic-acidosis-case2026-10-04 https://evidence-hub.com/study/13025-euglycaemic-diabetic-ketoacidosis-in-patients-using-sodium-glucose-co2026-10-06 https://evidence-hub.com/study/13026-case-of-sodium-glucose-cotransporter-2-inhibitor-associated2026-10-06 https://evidence-hub.com/study/13027-masked-primary-hyperparathyroidism-by-empagliflozin-use2026-10-06 https://evidence-hub.com/study/13028-empagliflozin-associated-euglycemic-diabetic-ketoacidosis-masked-by2026-10-08 https://evidence-hub.com/study/13029-sglt2-inhibitor-induced-euglycemic-diabetic-ketoacidosis-a-case-report2026-10-06 https://evidence-hub.com/study/13031-capivasertib-induced-diabetes-successfully-managed-with-insulin2026-10-06 https://evidence-hub.com/study/13032-a-case-of-euglycemic-diabetic-ketoacidosis-sglt2-inhibitor2026-10-06 https://evidence-hub.com/study/13033-from-glucosuria-to-dialysis-a-case-report-of-osmotic-nephropathy-due2026-10-06 https://evidence-hub.com/study/13034-hypoglycemia-in-a-patient-treated-with-a-sglt2-inhibitor-with-hfref2026-10-06 https://evidence-hub.com/study/13035-postop-complication-with-euglycemic-diabetic-ketoacidosis-in-a2026-10-06 https://evidence-hub.com/study/13036-self-induced-euglycemic-diabetic-ketoacidosis-when-to-stop-the-drip2026-10-06 https://evidence-hub.com/study/13037-extraventricular-neurocytoma-of-the-sellar-region-presenting-with2026-10-06 https://evidence-hub.com/study/13038-sodium-glucose-cotransporter-2-inhibitors-improve-chronic-diabetic2026-10-06 https://evidence-hub.com/study/13039-angioedema-shortly-after-adding-empagliflozin-to-losartan2026-10-06 https://evidence-hub.com/study/13040-empagliflozin-associated-pancreatitis-a-consideration-for-sglt22026-10-06 https://evidence-hub.com/study/13042-case-report-of-empagliflozin-induced-cutaneous-polyarteritis-nodosa2026-10-06 https://evidence-hub.com/study/13043-euglycaemic-diabetic-ketoacidosis-in-a-patient-with-pancreatitis-and2026-10-06 https://evidence-hub.com/study/13044-sodium-glucose-cotransporter-type-2-channel-inhibitor-breakthrough-in2026-10-06 https://evidence-hub.com/study/13045-chronic-kidney-disease-stage-g4-in-a-diabetic-patient-improved-by2026-10-06 https://evidence-hub.com/study/13046-managing-spondylitis-tuberculosis-in-a-patient-with-underlying2026-10-06 https://evidence-hub.com/study/13047-euglycaemic-ketoacidosis-a-potential-new-hazard-to-plastic-surgery2026-10-06 https://evidence-hub.com/study/13048-empagliflozin-in-kidney-transplant-recipients-with-chronic-kidney2026-10-06 https://evidence-hub.com/study/13049-fulminant-emphysematous-pyelonephritis-by-candida-glabrata-in-a2026-10-06 https://evidence-hub.com/study/13050-rapid-onset-of-diabetic-ketoacidosis-after-sglt2-inhibition-in-a2026-10-06 https://evidence-hub.com/study/13051-effect-of-sodium-glucose-co-transporter-2-inhibitor-on-estimated2026-10-06 https://evidence-hub.com/study/13052-empagliflozin-induced-nondiabetic-ketoacidosis-in-advanced-alcoholic2026-10-06 https://evidence-hub.com/study/13053-left-ventricular-noncompaction-with-intractable-heart-failure2026-10-06 https://evidence-hub.com/study/13054-treating-neutropenia-and-neutrophil-dysfunction-in-glycogen-storage2026-10-06 https://evidence-hub.com/study/13055-repurposing-of-empagliflozin-as-a-possible-treatment-for-neutropenia2026-10-06 https://evidence-hub.com/study/13056-immune-checkpoint-inhibitor-induced-takotsubo-syndrome-and-diabetic2026-10-06 https://evidence-hub.com/study/13057-sodium-glucose-cotransporter-2-inhibitors-and-management-of2026-10-06 https://evidence-hub.com/study/13058-hemochromatosis-gene-mutation-in-persons-developing-erythrocytosis-on2026-10-06 https://evidence-hub.com/study/13059-bilateral-gangrene-of-fingers-in-a-patient-on-empagliflozin-first2026-10-06 https://evidence-hub.com/study/13060-sglt2-inhibitors-for-treatment-of-refractory-hypomagnesemia-a-case2026-10-08 https://evidence-hub.com/study/13061-untargeted-metabolomic-profiling-in-a-patient-with-glycogen-storage2026-10-06 https://evidence-hub.com/study/13062-euglycemic-diabetic-ketoacidosis-induced-by-sodium-glucose2026-10-06 https://evidence-hub.com/study/13063-emphysematous-cystitis-and-urinary-retention-in-a-male-patient-with2026-10-06 https://evidence-hub.com/study/13064-a-case-of-severe-metabolic-acidosis-due-to-jardiance-induced2026-10-06 https://evidence-hub.com/study/13065-a-rare-but-life-threatening-case-of-fournier-s-gangrene-caused-by2026-10-06 https://evidence-hub.com/study/13066-fournier-s-gangrene-in-a-man-on-empagliflozin-for-treatment-of-type-22026-10-06 https://evidence-hub.com/study/13067-euglycemic-diabetic-ketoacidosis-associated-with-empagliflozin-use-in2026-10-06 https://evidence-hub.com/study/13068-beyond-glucose-levels-redefining-diabetic-ketoacidosis-a-case-of2026-10-06 https://evidence-hub.com/study/13069-ketoacidosis-due-to-empagliflozin-a-paradigm-shift-case-report-and2026-10-06 https://evidence-hub.com/study/13070-anti-proteinuric-effect-of-glp1-ra-as-add-on-to-sglt2-i-and-ace-i-in2026-10-06 https://evidence-hub.com/study/13071-fournier-s-gangrene-and-diabetic-ketoacidosis-with-lower-than2026-10-06 https://evidence-hub.com/study/13072-long-term-empagliflozin-use-in-chronic-syndrome-of-inappropriate2026-10-06 https://evidence-hub.com/study/13073-euglycemic-diabetic-ketoacidosis-in-a-lung-cancer-patient-using2026-10-06 https://evidence-hub.com/study/13074-resolution-of-severe-gastroparesis-induced-by-parasympathetic-surge2026-10-06 https://evidence-hub.com/study/13075-beneficial-effects-of-empagliflozin-on-hematocrit-levels-in-a-patient2026-10-06 https://evidence-hub.com/study/13076-empagliflozin-associated-euglycemic-diabetic-ketoacidosis-in-a2026-10-06 https://evidence-hub.com/study/13077-euglycemic-diabetic-ketoacidosis-caused-by-empagliflozin-complicated2026-10-06 https://evidence-hub.com/study/13078-a-case-of-sglt2-inhibitor-associated-euglycemic-diabetic-ketoacidosis2026-10-06 https://evidence-hub.com/study/13079-acute-esophageal-necrosis-complicating-diabetic-ketoacidosis-in-a2026-10-06 https://evidence-hub.com/study/13080-renal-pelvis-epidermoid-cyst-mimicking-staghorn-calculus-successful2026-10-06 https://evidence-hub.com/study/13081-sodium-glucose-linked-transporter-2-sglt-2-inhibitor-associated2026-10-06 https://evidence-hub.com/study/13082-sglt-2-inhibitor-induced-euglycemic-diabetic-ketoacidosis-masked-by2026-10-06 https://evidence-hub.com/study/13083-undifferentiated-purpuric-and-desquamative-drug-eruption-after2026-10-06 https://evidence-hub.com/study/13084-post-diphtheritic-myocarditis-with-right-ventricular-thrombus-a-rare2026-10-06 https://evidence-hub.com/study/13085-successful-control-of-late-onset-nephrotic-syndrome-in-fn1-associated2026-10-06 https://evidence-hub.com/study/13086-biventricular-heart-failure-with-reduced-ejection-fraction-in-a-young2026-10-06 https://evidence-hub.com/study/13087-euglycemic-diabetic-ketoacidosis-under-empagliflozin-during2026-10-06 https://evidence-hub.com/study/13088-st-segment-elevation-myocardial-infarction-stemi-with-a-fishy-twist-a2026-10-06 https://evidence-hub.com/study/13089-normal-glycosylated-hemoglobin-masking-glucose-dysregulation-in-a2026-10-06 https://evidence-hub.com/study/13090-berberine-poisoning-with-polymorphic-ventricular-tachycardia-a-case2026-10-06 https://evidence-hub.com/study/13091-treatment-of-refractory-syndrome-of-inappropriate-antidiuresis-with2026-10-06 https://evidence-hub.com/study/13092-ischemic-stroke-after-anticoagulation-discontinuation-following2026-10-06 https://evidence-hub.com/study/13093-smartwatch-detected-atrial-fibrillation-on-the-morning-after-a2026-10-06 https://evidence-hub.com/study/13094-severe-rhabdomyolysis-in-an-elderly-patient-with-diabetes-and2026-10-06 https://evidence-hub.com/study/13095-cardiohepatic-syndrome-presenting-as-large-volume-ascites-in-acute2026-10-06 https://evidence-hub.com/study/13096-euglycemic-diabetic-ketoacidosis-with-gastrointestinal-dysfunction2026-10-06 https://evidence-hub.com/study/13097-late-presenting-fulminant-immune-checkpoint-inhibitor-myocarditis2026-10-06 https://evidence-hub.com/study/13098-severe-euglycemic-diabetic-ketoacidosis-with-mixed-acid-base-disorder2026-10-06 https://evidence-hub.com/study/13099-clinical-and-radiographic-intersection-of-cerebral-amyloid-angiopathy2026-10-06 https://evidence-hub.com/study/13100-single-session-combined-mitral-transcatheter-edge-to-edge-repair-and2026-10-06 https://evidence-hub.com/study/13101-intraoperative-detection-and-management-of-euglycemic-ketonemia2026-10-06 https://evidence-hub.com/study/13102-established-and-emerging-use-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/13103-digenic-hnf1a-and-abcc8-variants-provide-mechanistic-insight-into2026-10-06 https://evidence-hub.com/study/13104-delayed-onset-giant-bleb-formation-and-persistent-intraocular2026-10-06 https://evidence-hub.com/study/13105-autosomal-dominant-tubulointerstitial-kidney-disease-umod-case-report2026-10-06 https://evidence-hub.com/study/13106-dabrafenib-and-trametinib-induced-hyperglycemia-with-decreased2026-10-08 https://evidence-hub.com/study/13107-spontaneous-restoration-of-premature-ovarian-insufficiency-and2026-10-06 https://evidence-hub.com/study/13108-case-report-dual-pathology-of-lmx1b-associated-nephropathy-and-iga2026-10-06 https://evidence-hub.com/study/13109-a-case-of-insulin-edema-syndrome-improved-by-weekly-insulin2026-10-06 https://evidence-hub.com/study/13110-exercise-induced-ventricular-tachycardia-unmasking-high-risk2026-10-06 https://evidence-hub.com/study/13111-cerebral-hemorrhage-after-left-ventricular-assist-device-implantation2026-10-06 https://evidence-hub.com/study/13112-sigmoid-volvulus-as-one-of-the-differential-diagnoses-for-bradycardia2026-10-06 https://evidence-hub.com/study/13113-hydroxychloroquine-cardiotoxicity-confirmed-by-electron-microscopy2026-10-06 https://evidence-hub.com/study/13114-early-hypocortisolism-with-persistent-remission-following2026-10-06 https://evidence-hub.com/study/13115-erythromelalgia-mimicking-diabetic-foot-infection-diagnostic2026-10-06 https://evidence-hub.com/study/13116-severe-left-ventricular-dilation-with-preserved-contractile-reserve2026-10-06 https://evidence-hub.com/study/13117-diabetic-ketoacidosis-associated-with-painless-thyroiditis-in-a2026-10-06 https://evidence-hub.com/study/13118-imaging-signatures-of-eosinophilic-granulomatosis-with-polyangiitis2026-10-06 https://evidence-hub.com/study/13119-atrioventricular-nodal-reentrant-tachycardia-mimicking-a-flutter-and2026-10-06 https://evidence-hub.com/study/13120-acute-small-bowel-obstruction-induced-by-tirzepatide-mounjaro2026-10-06 https://evidence-hub.com/study/13121-syndrome-of-inappropriate-anti-diuretic-hormone-siadh-in-non-small2026-10-06 https://evidence-hub.com/study/13122-bilateral-atrial-appendage-thrombosis-in-light-chain-cardiac2026-10-06 https://evidence-hub.com/study/13123-a-diagnostic-cascade-triggered-by-physical-examination-uncovering2026-10-06 https://evidence-hub.com/study/13124-sglt2-inhibitor-associated-diabetic-ketoacidosis-in-a-pediatric2026-10-06 https://evidence-hub.com/study/13125-atypical-atrial-flutter-unveiling-cor-triatriatum-sinister-in-a2026-10-06 https://evidence-hub.com/study/13126-exercise-stress-cardiomyopathy-a-case-report2026-10-06 https://evidence-hub.com/study/13127-to-be-or-not-to-be-amiodarone-as-both-savior-and-foe-a-therapeutic2026-10-06 https://evidence-hub.com/study/13128-subintimal-excimer-laser-coronary-atherectomy-s-elca-as-a-bail-out2026-10-06 https://evidence-hub.com/study/13129-sacubitril-valsartan-facilitates-recovery-of-cardiac-function-in-a2026-10-06 https://evidence-hub.com/study/13130-a-case-report-of-giant-left-ventricular-outflow-tract-pseudoaneurysm2026-10-06 https://evidence-hub.com/study/13131-diagnostic-challenges-of-clinically-significant-portal-hypertension2026-10-06 https://evidence-hub.com/study/13132-reversible-severe-mitral-regurgitation-during-immunotherapy-in-a2026-10-06 https://evidence-hub.com/study/13133-ai-driven-heart-failure-decision-support-in-skilled-nursing-facilities2026-10-06 https://evidence-hub.com/study/13134-improved-cardiac-structure-and-ventricular-arterial-coupling-after2026-10-06 https://evidence-hub.com/study/13135-when-type-2-diabetes-isn-t-type-2-latent-autoimmune-diabetes-in-a2026-10-06 https://evidence-hub.com/study/13136-fournier-gangrene-in-a-patient-with-corticotrophinoma-and-diabetes2026-10-06 https://evidence-hub.com/study/13137-successful-multidisciplinary-management-of-esophageal-perforation2026-10-06 https://evidence-hub.com/study/13138-pulmonary-artery-pressure-sensor-guided-therapy-for-cardiac-al2026-10-06 https://evidence-hub.com/study/13139-cocaine-induced-cardiomyopathy-as-a-rare-etiology-of-severe-heart2026-10-06 https://evidence-hub.com/study/13140-extensive-cecal-angioectasia-causing-chronic-occult-gastrointestinal2026-10-06 https://evidence-hub.com/study/13141-the-diagnostic-mirage-xanthogranulomatous-cholecystitis-and-the2026-10-06 https://evidence-hub.com/study/13142-dual-antithyroid-drug-induced-agranulocytosis-in-graves-disease-with2026-10-06 https://evidence-hub.com/study/13143-abstract-4363027-paradoxical-renal-protection-after-euglycemic-dka-in2026-10-06 https://evidence-hub.com/study/13145-bradycardia-induced-heart-failure-with-preserved-ejection-fraction2026-10-06 https://evidence-hub.com/study/13146-the-association-of-sglt-2-inhibitors-empagliflozin-with-the2026-10-06 https://evidence-hub.com/study/13149-crohn-like-disease-long-remission-in-a-pediatric-patient-with2026-10-06 https://evidence-hub.com/study/13150-thu371-empagliflozin-associated-pancreatitis-a-case-report2026-10-06 https://evidence-hub.com/study/13153-case-report-euglycemic-diabetic-ketoacidosis-led-by-empagliflozin-a2026-10-06 https://evidence-hub.com/study/13154-extensive-empagliflozin-associated-fournier-s-gangrene-with-complete2026-10-06 https://evidence-hub.com/study/13155-short-term-treatment-with-empagliflozin-resulted-in-dehydration-and2026-10-06 https://evidence-hub.com/study/13156-effect-of-sglt2-inhibitor-empagliflozin-on-the-stabilization-of-heart2026-10-06 https://evidence-hub.com/study/13159-euglycemic-diabetic-ketoacidosis-in-covid-19-patient-caused-by2026-10-06 https://evidence-hub.com/study/13160-early-detection-of-euglycemic-ketoacidosis-during-thoracic-surgery2026-10-06 https://evidence-hub.com/study/13161-mon-645-metabolic-chorea-a-case-report2026-10-06 https://evidence-hub.com/study/13163-fasting-is-not-always-good-perioperative-fasting-leads-to-pronounced2026-10-06 https://evidence-hub.com/study/13164-diagnosis-of-turner-syndrome-after-presenting-with-ischemic2026-10-06 https://evidence-hub.com/study/13165-euglycemic-diabetic-ketoacidosis-associated-with-a-sodium-glucose-co2026-10-06 https://evidence-hub.com/study/13166-how-to-manage-a-severe-form-of-euglycemic-diabetic-ketoacidosis2026-10-06 https://evidence-hub.com/study/13167-euglycemic-diabetic-ketoacidosis-induced-by-sodium-glucose2026-10-06 https://evidence-hub.com/study/13168-risk-of-euglycemic-diabetic-ketoacidosis-due-to-low-carbohydrate-diet2026-10-06 https://evidence-hub.com/study/13169-antiarrhythmic-effect-of-sglt-2-inhibitors-in-high-degree-av-block2026-10-06 https://evidence-hub.com/study/13170-euglycemic-diabetic-ketoacidosis-due-to-small-bowel-perforation-a2026-10-06 https://evidence-hub.com/study/13171-unsuspected-diabetic-ketoacidosis-after-myocardial-infarction-in-a2026-10-06 https://evidence-hub.com/study/13172-rapidly-progressive-hiv-associated-dilated-cardiomyopathy-presenting2026-10-06 https://evidence-hub.com/study/13173-a-rare-case-of-empagliflozin-induced-euglycemic-diabetic-ketoacidosis2026-10-06 https://evidence-hub.com/study/13174-ps11-psychiatric-associations-in-bullous-pemphigoid-review-and-case2026-10-08 https://evidence-hub.com/study/13175-bullous-pemphigoid-in-a-patient-with-a-neuropsychological-disorder2026-10-06 https://evidence-hub.com/study/13176-effective-cholesterol-lowering-after-myocardial-infarction-in2026-10-06 https://evidence-hub.com/study/13177-euglycemic-diabetic-ketoacidosis-in-a-sedated-patient-after-coronary2026-10-06 https://evidence-hub.com/study/13178-a-rare-case-of-drug-induced-liver-injury-secondary-to-empagliflozin2026-10-06 https://evidence-hub.com/study/13179-a-case-report-of-euglycemic-diabetic-ketoacidosis-in-the-setting-of2026-10-06 https://evidence-hub.com/study/13180-a-case-report-euglycemic-diabetic-ketoacidosis-presenting-as-chest2026-10-06 https://evidence-hub.com/study/13181-empagliflozin-associated-acidoketosis-a-sneaky-friend2026-10-06 https://evidence-hub.com/study/13183-sodium-glucose-cotransporter-2-sglt2-inhibitor-induced-euglycemic2026-10-06 https://evidence-hub.com/study/13184-early-presentation-of-a-rare-complication-of-sodium-glucose2026-10-06 https://evidence-hub.com/study/13185-euglycemic-diabetic-ketoacidosis-in-a-patient-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13186-empagliflozin-induced-liver-injury2026-10-06 https://evidence-hub.com/study/13187-sun-181-case-report-rare-complication-of-sglt2-inhibitors-can-occur2026-10-06 https://evidence-hub.com/study/13188-1700-a-rare-case-of-candida-glabrata-hemorrhagic-cystitis-with2026-10-06 https://evidence-hub.com/study/13189-sat-541-empagliflozin-induced-acute-pancreatitis2026-10-06 https://evidence-hub.com/study/13190-diagnosis-management-and-treatment-of-the-alport-syndrome-20242026-10-06 https://evidence-hub.com/study/13191-a-practical-guide-to-the-use-of-glucose-lowering-agents-with2026-10-06 https://evidence-hub.com/study/13192-the-new-esc-guidelines-for-acute-and-chronic-heart-failure-20162026-10-06 https://evidence-hub.com/study/13193-2024-update-of-chinese-guidelines-for-management-of-hyperuricemia-and2026-10-06 https://evidence-hub.com/study/13194-2026-acc-aha-clinical-performance-and-quality-measures-for-patients2026-10-06 https://evidence-hub.com/study/13195-kidney-disease-and-heart-failure-recent-advances-and-current2026-10-06 https://evidence-hub.com/study/13196-guidelines-for-clinical-evaluation-of-chronic-kidney-disease-in-early2026-10-06 https://evidence-hub.com/study/13197-guideline-for-the-use-of-natriuretic-peptides-in-the-early-diagnosis2026-10-06 https://evidence-hub.com/study/13198-the-2024-british-society-for-rheumatology-guideline-for-management-of2026-10-10 https://evidence-hub.com/study/13199-a-european-renal-association-era-synopsis-for-nephrology-practice-of2026-10-06 https://evidence-hub.com/study/13200-2024-acc-aha-aacvpr-apma-abc-scai-svm-svn-svs-sir-vess-guideline-for2026-10-08 https://evidence-hub.com/study/13201-supervised-exercise-training-for-chronic-heart-failure-with-preserved2026-10-06 https://evidence-hub.com/study/13202-mexican-position-paper-for-the-diagnosis-and-treatment-of-cardiac2026-10-06 https://evidence-hub.com/study/13203-guidelines-for-the-management-of-diabetes-in-care-homes-during-the2026-10-06 https://evidence-hub.com/study/13204-management-of-hypertension-and-renin-angiotensin-aldosterone-system2026-10-06 https://evidence-hub.com/study/13205-clinical-management-of-stable-coronary-artery-disease-in-patients2026-10-06 https://evidence-hub.com/study/13206-diabetes-canada-2018-clinical-practice-guidelines-key-messages-for2026-10-06 https://evidence-hub.com/study/13207-antihyperglycemic-agent-therapy-for-adult-patients-with-type-22026-10-06 https://evidence-hub.com/study/13208-treatment-of-diabetes-in-older-adults-an-endocrine-society-clinical2026-10-13 https://evidence-hub.com/study/13209-clinical-care-pathway-for-the-risk-stratification-and-management-of2026-10-06 https://evidence-hub.com/study/13210-spanish-adaptation-of-the-2016-european-guidelines-on-cardiovascular2026-10-06 https://evidence-hub.com/study/13213-development-and-validation-of-new-analytical-method-for-the2026-10-06 https://evidence-hub.com/study/13214-early-efficacy-of-empagliflozin-in-addition-to-optimal-medical2026-10-06 https://evidence-hub.com/study/13215-effects-of-early-empagliflozin-in-acute-decompensated-hfref-on2026-10-06 https://evidence-hub.com/study/13216-abstract-4373610-effect-of-combined-guideline-directed-medical2026-10-06 https://evidence-hub.com/study/13217-impact-of-the-sglt2-inhibitor-empagliflozin-on-inflammatory2026-10-06 https://evidence-hub.com/study/13218-cardioprotection-of-canagliflozin-dapagliflozin-and-empagliflozin2026-10-06 https://evidence-hub.com/study/13219-guideline-summary-ngc-2016-canagliflozin-dapagliflozin-and2026-10-06 https://evidence-hub.com/study/13220-evaluating-the-budget-impact-of-empagliflozin-in-managing-heart2026-10-06 https://evidence-hub.com/study/13221-early-empagliflozin-initiation-after-hospitalization-for-heart2026-10-06 https://evidence-hub.com/study/13222-the-national-financial-burden-of-guideline-directed-medical-therapy2026-10-06 https://evidence-hub.com/study/13223-cost-effectiveness-of-dapagliflozin-vs-empagliflozin-for-treating2026-10-06 https://evidence-hub.com/study/13224-the-implementation-of-modern-guideline-directed-medical-therapy-among2026-10-06 https://evidence-hub.com/study/13225-abstract-14084-empagliflozin-in-hospitalized-patients-with-heart2026-10-06 https://evidence-hub.com/study/13226-effect-of-empagliflozin-on-hemodynamics-in-patients-with-heart2026-10-01 https://evidence-hub.com/study/13227-empagliflozin-and-renal-sodium-handling-an-intriguing-smart-osmotic2026-10-06 https://evidence-hub.com/study/13228-management-of-chronic-heart-failure-state-of-the-art-according-to-the2026-10-06 https://evidence-hub.com/study/13229-effects-of-empagliflozin-on-extracellular-volume-plasma-volume-and2026-10-06 https://evidence-hub.com/study/13230-sglt2-inhibitor-use-in-chronic-kidney-disease-supporting2026-10-06 https://evidence-hub.com/study/13231-sglt2-inhibitors-and-new-frontiers-in-heart-failure-treatment2026-10-06 https://evidence-hub.com/study/13232-medical-treatments-in-ambulatory-heart-failure-patients-first-data2026-10-06 https://evidence-hub.com/study/13233-role-and-molecular-mechanisms-of-sglt2-inhibitors-in-pathological2026-10-06 https://evidence-hub.com/study/13234-cvot-summit-report-2025-advances-along-the-cardiovascular-kidney2026-10-06 https://evidence-hub.com/study/13235-sglt2-inhibitors-are-associated-with-left-ventricular-reverse2026-10-06 https://evidence-hub.com/study/13236-real-world-outcomes-and-safety-of-low-vs-standard-dose-sglt22026-10-06 https://evidence-hub.com/study/13237-discharge-medical-treatment-implementation-in-patients-admitted-for2026-10-06 https://evidence-hub.com/study/13238-sglt2-inhibitor-therapy-in-patients-with-acute-takotsubo-syndrome2026-10-06 https://evidence-hub.com/study/13239-medical-treatment-implementation-in-ambulatory-patients-with-hf2026-10-06 https://evidence-hub.com/study/13240-safety-of-early-and-accelerated-evidence-based-pharmacological2026-10-06 https://evidence-hub.com/study/13241-adoption-and-diffusion-of-sglt2-inhibitors-among-cardiologists-in2026-10-06 https://evidence-hub.com/study/13242-short-term-efficacy-of-early-sodium-glucose-cotransporter-2-inhibitor2026-10-06 https://evidence-hub.com/study/13243-effects-of-sglt2-inhibition-on-cardiac-structure-left-atrial-function2026-10-06 https://evidence-hub.com/study/13244-sodium-glucose-transporter-2-inhibitors-for-heart-failure2026-10-06 https://evidence-hub.com/study/13245-safety-and-short-term-cardiorenal-effects-of-initiating-sglt22026-10-06 https://evidence-hub.com/study/132462026-10-06 https://evidence-hub.com/study/13247-guidelines-for-treating-heart-failure2026-10-06 https://evidence-hub.com/study/13248-sglt2-inhibition-in-heart-failure-clues-to-cardiac-effects2026-10-06 https://evidence-hub.com/study/13249-8494-a-case-of-diabetic-ketoacidosis-in-setting-of-covid-19-infection2026-10-06 https://evidence-hub.com/study/13250-advances-in-contemporary-medical-management-to-treat-patients-with2026-10-06 https://evidence-hub.com/study/13251-evaluation-of-inpatient-sodium-glucose-co-transporter-2-inhibitor-use2026-10-06 https://evidence-hub.com/study/13252-abstract-p3149-effect-of-sglt2-inhibitors-on-atrial-fibrillation2026-10-06 https://evidence-hub.com/study/13253-early-initiation-of-sglt2-inhibitors-is-important-irrespective-of2026-10-06 https://evidence-hub.com/study/13254-the-dawn-of-the-four-drug-era-sglt2-inhibition-in-heart-failure-with2026-10-06 https://evidence-hub.com/study/13255-innovative-tlc-densitometric-method-with-fluorescent-detection-for2026-10-06 https://evidence-hub.com/study/13256-21-or-optimization-of-albuminuria-lowering-treatment-by-crossover2026-10-06 https://evidence-hub.com/study/13257-abstract-15820-the-use-of-sglt-2-inhibitors-during-hospitalization2026-10-06 https://evidence-hub.com/study/13258-renal-function-and-vericiguat-in-heart-failure-patients-light-at-the2026-10-06 https://evidence-hub.com/study/13259-dissolution-or-disintegration-substitution-of-dissolution-by2026-10-06 https://evidence-hub.com/study/13260-sodium-glucose-cotransporter-2-inhibitors-as-a-treatment-for-heart2026-10-06 https://evidence-hub.com/study/13261-sodium-glucose-co-transporter-2-inhibitors-strength-of-evidence-for-a2026-10-06 https://evidence-hub.com/study/13262-dapagliflozin-and-dapa-hf-from-glycaemic-control-to-heart-failure2026-10-06 https://evidence-hub.com/study/13265-targeting-nlrp3-inflammasomes-in-myocarditis-potential-therapeutic2026-10-06 https://evidence-hub.com/study/13266-sodium-glucose-cotransporter-2-inhibitors-and-heart-failure2026-10-06 https://evidence-hub.com/study/13267-neuroprotective-effect-of-sglt2-inhibitors2026-10-06 https://evidence-hub.com/study/13268-exploring-sglt2-inhibitors-activity-in-breast-cancer-an-overview2026-10-06 https://evidence-hub.com/study/13269-update-on-evidence-based-clinical-application-of-sodium-glucose2026-10-06 https://evidence-hub.com/study/13270-cardio-renal-benefits-of-sodium-glucose-co-transporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/13271-pharmacologic-treatments-for-masld-a-review-of-efficacy-and-safety2026-10-06 https://evidence-hub.com/study/13272-cardiovascular-outcome-trial-update-in-diabetes-new-evidence2026-10-06 https://evidence-hub.com/study/13273-promise-of-sodium-glucose-co-transporter-2-inhibitors-in-heart2026-10-06 https://evidence-hub.com/study/13274-improvement-of-renal-outcomes-with-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/13275-dapagliflozin-cardiovascular-safety-and-benefits-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13276-expanding-the-possibilities-of-using-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/13277-sglt2-inhibitors-in-heart-failure-with-reduced-ejection-fraction2026-10-06 https://evidence-hub.com/study/13278-sglt2-inhibitors-and-mechanisms-of-hypertension2026-10-06 https://evidence-hub.com/study/13279-the-treatment-of-type-2-diabetes-in-the-presence-of-renal-impairment2026-10-06 https://evidence-hub.com/study/13280-sglt2-inhibition-and-heart-failure-current-concepts2026-10-06 https://evidence-hub.com/study/13281-cardiologist-and-diabetologist-crosstalk-in-the-era-of-cardiovascular2026-10-06 https://evidence-hub.com/study/13282-drug-drug-interactions-with-sodium-glucose-cotransporters-type-22026-10-06 https://evidence-hub.com/study/13283-pharmacologic-management-of-type-2-diabetes-mellitus-available2026-10-06 https://evidence-hub.com/study/13284-sodium-glucose-co-transporter-2-inhibitors-for-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13285-robustness-of-outcomes-in-trials-evaluating-sodium-glucose-co2026-10-06 https://evidence-hub.com/study/13286-the-efficacy-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/13287-a-clever-evaluation-of-the-antidiabetic-medications-linagliptin-and2026-10-06 https://evidence-hub.com/study/13288-role-of-sodium-glucose-transport-protein-2-sglt2-inhibitors-in2026-10-06 https://evidence-hub.com/study/13289-the-role-of-sglt2-inhibitors-in-atherosclerosis-a-systematic-review2026-10-06 https://evidence-hub.com/study/13290-lupus-nephritis-new-and-emerging-biologic-and-targeted-therapies2026-10-06 https://evidence-hub.com/study/13291-cardiovascular-outcome-trials-with-glucose-lowering-drugs2026-10-06 https://evidence-hub.com/study/13292-sodium-glucose-co-transporter-2-inhibition-in-diabetes-treatment2026-10-06 https://evidence-hub.com/study/13293-sglt2-inhibitors-a-novel-player-in-the-treatment-and-prevention-of2026-10-06 https://evidence-hub.com/study/13294-emerging-role-of-sodium-glucose-cotransporter-2-inhibitors-in-aortic2026-10-06 https://evidence-hub.com/study/13295-resolving-the-kga1c-paradox-in-the-management-of-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13296-highlights-of-cardiovascular-disease-prevention-studies-presented-at2026-10-06 https://evidence-hub.com/study/13297-effect-of-sodium-glucose-cotransporter-2-inhibitors-on-hemoglobin-and2026-09-27 https://evidence-hub.com/study/13298-highlights-of-cardiovascular-disease-studies-presented-at-the-20212026-10-06 https://evidence-hub.com/study/13299-effects-of-heart-failure-therapies-on-atrial-fibrillation-biological2026-10-06 https://evidence-hub.com/study/13300-cardiac-and-renal-effects-of-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/13301-cardioprotective-anti-hyperglycaemic-medications-a-review-of-clinical2026-10-06 https://evidence-hub.com/study/13302-interpreting-cardiovascular-endpoints-in-trials-of-antihyperglycemic2026-10-06 https://evidence-hub.com/study/13303-sodium-glucose-co-transporter-2-inhibitors-and-nephroprotection-in2026-10-06 https://evidence-hub.com/study/13304-are-sglt-2-inhibitors-the-future-of-heart-failure-treatment-the2026-10-06 https://evidence-hub.com/study/13306-cardiovascular-aspects-of-diabetes-treatment-finally-a-reason-for2026-10-06 https://evidence-hub.com/study/13307-cardiovascular-benefits-and-safety-of-sotagliflozin-in-type-22026-10-06 https://evidence-hub.com/study/13308-efficacy-and-safety-of-sglt2-inhibitors-and-glp-1-receptor-agonists2026-10-06 https://evidence-hub.com/study/13309-cardiovascular-benefits-of-sodium-glucose-cotransporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/13310-pharmacological-management-of-type-2-diabetes-what-s-new-in-20172026-10-06 https://evidence-hub.com/study/13311-diabetology-as-an-interdisciplinary-challenge2026-10-06 https://evidence-hub.com/study/13312-is-there-any-robust-evidence-showing-that-sglt2-inhibitor-predisposes2026-10-06 https://evidence-hub.com/study/13313-heart-failure-and-type-2-diabetes-from-cardiovascular-outcome-trials2026-10-06 https://evidence-hub.com/study/13314-effect-of-sodium-glucose-cotransporter-2-inhibitors-on-endothelial2026-10-04 https://evidence-hub.com/study/13315-optimizing-management-of-glycaemia2026-10-06 https://evidence-hub.com/study/13316-the-safety-of-dpp-4-inhibitor-and-sglt2-inhibitor-combination2026-10-06 https://evidence-hub.com/study/13317-sodium-glucose-cotransporter-2-inhibition-for-the-reduction-of2026-10-06 https://evidence-hub.com/study/13318-comparative-efficacy-and-safety-of-antidiabetic-drug-regimens-added2026-10-06 https://evidence-hub.com/study/13319-impact-of-sodium-glucose-cotransporter-2-inhibitors-on-heart-failure2026-10-06 https://evidence-hub.com/study/13320-diabetes-mellitus-arterial-stiffness-and-cardiovascular-disease2026-10-06 https://evidence-hub.com/study/13321-sodium-glucose-cotransporter-2-inhibitors-sglt2i-in-kidney-transplant2026-10-06 https://evidence-hub.com/study/13322-overview-of-sodium-glucose-co-transporter-2-sglt2-inhibitors-for-the2026-10-06 https://evidence-hub.com/study/13323-the-effect-of-sodium-glucose-cotransporter-type-2-inhibitors-on-left2026-10-06 https://evidence-hub.com/study/13324-current-updates-in-the-pharmacotherapy-of-heart-failure-with-a2026-10-06 https://evidence-hub.com/study/13325-advances-in-glp-1-treatment-focus-on-oral-semaglutide2026-10-06 https://evidence-hub.com/study/13326-antihyperglycemic-agents-and-cardiovascular-outcomes-recent-insights2026-10-06 https://evidence-hub.com/study/13327-sodium-glucose-cotransporter-2-inhibition-for-the-reduction-of2026-10-06 https://evidence-hub.com/study/13328-strategies-for-diabetes-management-using-newer-oral-combination2026-10-06 https://evidence-hub.com/study/13329-the-short-and-sweet-on-sodium-glucose-cotransporter-inhibitors-and2026-10-06 https://evidence-hub.com/study/13330-mineral-and-electrolyte-disorders-with-sglt2i-therapy2026-10-06 https://evidence-hub.com/study/13331-efficacy-of-sodium-glucose-2-transporter-inhibitors-in-heart-failure2026-10-06 https://evidence-hub.com/study/13332-the-role-of-sodium-glucose-cotransporter-2-inhibitors-in-the2026-10-06 https://evidence-hub.com/study/13333-comparative-pharmacological-and-pharmaceutical-perspectives-on2026-10-06 https://evidence-hub.com/study/13334-sglt2-inhibitors-in-type-2-diabetes-mellitus-and-heart-failure-a2026-10-06 https://evidence-hub.com/study/13335-the-heart-failure-burden-of-type-2-diabetes-mellitus-a-review-of2026-10-06 https://evidence-hub.com/study/13336-clinical-pharmacology-of-sglt-2-inhibitors-in-heart-failure2026-10-06 https://evidence-hub.com/study/13337-aldh2-enzyme-deficiency-in-diabetic-cardiomyopathy2026-10-06 https://evidence-hub.com/study/13338-sodium-glucose-cotransporter-2-inhibitors-in-the-management-of-heart2026-10-06 https://evidence-hub.com/study/13339-cardiovascular-and-renal-outcomes-with-sodium-glucose-co-transporter2026-10-06 https://evidence-hub.com/study/13340-an-evaluation-of-empagliflozin-and-it-s-applicability-to-hypertension2026-10-06 https://evidence-hub.com/study/13341-nonproteinuric-progressive-diabetic-kidney-disease2026-10-06 https://evidence-hub.com/study/13342-new-therapies-for-the-treatment-of-heart-failure-with-preserved2026-10-06 https://evidence-hub.com/study/13344-a-review-of-the-current-literature-regarding-sodium-glucose2026-10-06 https://evidence-hub.com/study/13345-effects-of-sodium-glucose-cotransporter-2-inhibitors-on-left2026-10-06 https://evidence-hub.com/study/13346-comparative-effects-of-heart-failure-medications-on-cardiac2026-10-06 https://evidence-hub.com/study/13347-the-potential-roles-of-oral-hypoglycemic-agents-to-modulate2026-10-08 https://evidence-hub.com/study/13348-comparative-clinical-outcomes-and-safety-of-finerenone-sglt22026-10-06 https://evidence-hub.com/study/13349-continuous-infusion-and-sequential-nephron-blockade-versus-bolus2026-10-06 https://evidence-hub.com/study/13351-potential-mechanisms-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/13352-effect-of-sodium-glucose-cotransporter-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/13353-cardiovascular-drug-access-in-australia-and-new-zealand-new-pbs-and2026-10-06 https://evidence-hub.com/study/13354-evaluation-of-the-therapeutic-effect-of-new-hypoglycemic-drugs-on2026-10-06 https://evidence-hub.com/study/13355-repurposing-heart-failure-therapies-in-pulmonary-arterial2026-10-08 https://evidence-hub.com/study/13356-sglt2-inhibitors-in-alzheimer-s-disease-biochemical-insights-and2026-10-06 https://evidence-hub.com/study/13357-sglt2-inhibitors-between-benefits-and-euglycemic-ketoacidosis-a2026-10-06 https://evidence-hub.com/study/13358-late-ina-as-a-therapeutic-target-new-strategies-computational2026-10-06 https://evidence-hub.com/study/13359-metabolic-dysfunction-associated-steatotic-liver-disease-and2026-10-06 https://evidence-hub.com/study/13360-association-between-metabolic-dysfunction-associated-steatotic-liver2026-10-06 https://evidence-hub.com/study/13361-sodium-glucose-cotransporter-2-inhibitors-in-type-2-diabetes-from2026-10-06 https://evidence-hub.com/study/13362-irisin-upregulation-as-a-contributory-mechanism-for-the-therapeutic2026-10-06 https://evidence-hub.com/study/13363-the-effects-of-new-antidiabetic-drugs-on-the-course-of-peripheral2026-10-06 https://evidence-hub.com/study/13364-mechanisms-and-therapeutic-potential-of-sodium-glucose-cotransporter2026-10-06 https://evidence-hub.com/study/13365-expanding-the-scope-of-sglt-inhibitors-in-underrepresented-cardiac2026-10-06 https://evidence-hub.com/study/13366-current-understanding-of-sodium-glucose-transporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/13367-from-molecules-to-the-clinic-pathophysiology-of-sodium-glucose2026-10-19 https://evidence-hub.com/study/13368-sglt2-inhibitors-as-a-novel-therapeutic-strategy-in-siadh-induced2026-10-06 https://evidence-hub.com/study/13369-advances-in-targeted-treatment-of-ferroptosis-in-diabetic-kidney2026-10-06 https://evidence-hub.com/study/13370-sodium-glucose-cotransporter-2-inhibitors-in-mood-disorders-a2026-10-06 https://evidence-hub.com/study/13371-sglt2-inhibitors-in-cardiovascular-kidney-metabolic-syndrome-drugs2026-10-06 https://evidence-hub.com/study/13372-repurposed-drugs-and-cardiovascular-morbidity-a-cost-effectiveness2026-10-06 https://evidence-hub.com/study/13373-economic-evaluation-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/13374-integrated-management-strategies-for-hypertension-and-diabetes-in2026-10-06 https://evidence-hub.com/study/13375-sglt2-inhibitors-as-modulators-of-mitochondrial-ion-transport-and-er2026-10-06 https://evidence-hub.com/study/13376-effectiveness-of-sglt2-inhibitors-in-type-2-diabetes-a-systematic2026-10-06 https://evidence-hub.com/study/13377-cardiac-troponin-elevation-beyond-type-1-myocardial-infarction-a2026-10-06 https://evidence-hub.com/study/13378-sodium-glucose-cotransporter-2-inhibitors-versus-dipeptidyl-peptidase2026-10-06 https://evidence-hub.com/study/13379-food-drug-interactions-of-novel-drugs-used-in-cardiologic-and2026-10-06 https://evidence-hub.com/study/13380-which-aldosterone-antagonist-choosing-between-sprionolactone-and-the2026-10-06 https://evidence-hub.com/study/13381-sodium-glucose-cotransporter-2-inhibitors-in-anthracycline-treated2026-10-06 https://evidence-hub.com/study/13382-nephrology-what-you-may-have-missed-in-20252026-10-06 https://evidence-hub.com/study/13383-role-of-sodium-glucose-transport-protein-2-inhibitors-in-renal2026-10-06 https://evidence-hub.com/study/13384-plain-language-summary-of-a-publication-the-effects-of-vicadrostat2026-10-06 https://evidence-hub.com/study/13385-angiogenesis-and-inflammation-in-the-retinopathy-risk-of-insulin-and2026-10-06 https://evidence-hub.com/study/13386-cardiovascular-safety-of-empagliflozin-versus-dipeptidyl-peptidase-42026-10-04 https://evidence-hub.com/study/13388-sglt-2-receptor-inhibitors-for-treating-patients-with-type-2-diabetes2026-10-04 https://evidence-hub.com/study/13390-comparative-efficacy-of-sodium-glucose-cotransporter-2-inhibitors2026-10-04 https://evidence-hub.com/study/13392-sglt2-inhibitors-and-risk-of-cancer-in-type-2-diabetes-a-systematic2026-10-01 https://evidence-hub.com/study/13393-sodium-glucose-cotransporter-2-inhibitors-for-treatment-of2026-10-01 https://evidence-hub.com/study/13394-efficacy-of-sglt2-inhibitors-in-glycemic-control-weight-loss-and2026-10-04 https://evidence-hub.com/study/13395-use-of-sodium-glucose-cotransporter-2-inhibitors-in-clinical-practice2026-10-01 https://evidence-hub.com/study/13396-association-of-sglt2-inhibitors-with-arrhythmias-and-sudden-cardiac2026-09-27 https://evidence-hub.com/study/13397-effects-of-sodium-glucose-cotransporter-2-inhibitors-on-serum-uric2026-10-01 https://evidence-hub.com/study/13398-comparative-cardiovascular-outcomes-of-sglt2-inhibitors-in-type-22026-10-04 https://evidence-hub.com/study/13399-adverse-events-associated-with-sodium-glucose-co-transporter-22026-10-01 https://evidence-hub.com/study/13403-safety-of-four-sglt2-inhibitors-in-three-chronic-diseases-a-meta2026-10-01 https://evidence-hub.com/study/13404-effect-of-sodium-glucose-cotransporter-2-inhibitors-on-cardiac2026-09-27 https://evidence-hub.com/study/13405-the-association-of-sodium-glucose-cotransporter-2-inhibitors-with2026-10-01 https://evidence-hub.com/study/13406-semaglutide-for-the-treatment-of-type-2-diabetes-mellitus-a2026-09-27 https://evidence-hub.com/study/13408-sglt-2-inhibitors-in-patients-with-heart-failure-a-comprehensive-meta2026-10-13 https://evidence-hub.com/study/13409-sodium-glucose-cotransporter-2-inhibitors-and-fracture-risk-in2026-09-27 https://evidence-hub.com/study/13410-ertugliflozin-compared-to-other-anti-hyperglycemic-agents-as2026-10-04 https://evidence-hub.com/study/13411-a-narrative-review-of-diabetic-kidney-disease-previous-and-current2026-10-01 https://evidence-hub.com/study/13412-hemodynamic-effects-of-sglt2-inhibitors-in-patients-with-and-without2026-10-01 https://evidence-hub.com/study/13413-exposure-response-modelling-for-empagliflozin-a-sodium-glucose2026-10-06 https://evidence-hub.com/study/13414-proteomic-signatures-and-blood-adenosine-triphosphate-levels-as2026-10-06 https://evidence-hub.com/study/13415-comparison-of-efficacy-and-safety-of-empagliflozin-vs-linagliptin2026-10-06 https://evidence-hub.com/study/13416-impact-of-empagliflozin-add-on-therapy-on-quality-of-life-in-patients2026-10-06 https://evidence-hub.com/study/13417-effectiveness-and-safety-of-empagliflozin-in-routine-care-patients2026-10-06 https://evidence-hub.com/study/13418-consistent-effects-of-empagliflozin-on-cardiovascular-and-kidney2026-09-29 https://evidence-hub.com/study/13419-rationale-and-design-of-the-emperial-preserved-and-emperial-reduced2026-10-06 https://evidence-hub.com/study/13420-safety-and-efficacy-of-empagliflozin-and-diuretic-use-in-patients2026-10-06 https://evidence-hub.com/study/13421-comparative-healthcare-resource-utilization-and-costs-of2026-10-06 https://evidence-hub.com/study/13422-empagliflozin-s-role-in-reducing-ventricular-repolarization2026-10-06 https://evidence-hub.com/study/13424-evaluating-the-efficacy-and-safety-of-empagliflozin-addition-to2026-10-06 https://evidence-hub.com/study/13425-empagliflozin-in-the-treatment-of-type-2-diabetes-evidence-to-date2026-10-04 https://evidence-hub.com/study/13426-sex-species-and-tissue-specific-metabolism-of-empagliflozin-in-male2026-10-06 https://evidence-hub.com/study/13427-empagliflozin-attenuates-hyperuricemia-by-upregulation-of-abcg2-via2026-10-01 https://evidence-hub.com/study/13428-clinical-parameters-affecting-the-therapeutic-efficacy-of2026-10-06 https://evidence-hub.com/study/13430-empagliflozin-linagliptin-single-tablet-combination-first-in-class2026-10-06 https://evidence-hub.com/study/13431-empagliflozin-in-heart-failure-with-predicted-preserved-versus2026-09-29 https://evidence-hub.com/study/13432-changes-in-plasma-and-urine-metabolites-associated-with-empagliflozin2026-10-06 https://evidence-hub.com/study/13433-an-sglt2-inhibitor-modulates-shh-expression-by-activating-ampk-to2026-09-27 https://evidence-hub.com/study/13434-safety-and-effectiveness-of-empagliflozin-in-japanese-patients-with2026-10-06 https://evidence-hub.com/study/13435-metabolic-consequences-of-acute-and-chronic-empagliflozin2026-10-04 https://evidence-hub.com/study/13436-effect-of-empagliflozin-and-dapagliflozin-on-ambulatory-arterial2026-10-06 https://evidence-hub.com/study/13437-safety-and-effectiveness-of-empagliflozin-and-linagliptin-fixed-dose2026-10-06 https://evidence-hub.com/study/13438-pharmacokinetics-safety-and-bioequivalence-of-two-empagliflozin2026-10-06 https://evidence-hub.com/study/13439-in-ckd-empagliflozin-reduced-kidney-disease-progression-at-a-median-22026-10-06 https://evidence-hub.com/study/13440-empagliflozin-in-patients-with-type-2-diabetes-mellitus-and-chronic2026-10-06 https://evidence-hub.com/study/13441-the-role-of-glucagon-in-the-acute-therapeutic-effects-of-sglt22026-10-06 https://evidence-hub.com/study/13442-cardio-renal-metabolic-modeling-in-asia-pacific-projections-of2026-10-06 https://evidence-hub.com/study/13443-early-sglt2-inhibitor-use-is-associated-with-improved-left-atrial2026-10-06 https://evidence-hub.com/study/13444-are-the-favorable-cardiovascular-outcomes-of-empagliflozin-treatment2026-09-29 https://evidence-hub.com/study/13445-improvements-of-myocardial-strain-and-work-in-diabetes-patients-with2026-10-06 https://evidence-hub.com/study/13446-the-sglt2-inhibitor-empagliflozin-attenuates-atherosclerosis2026-10-06 https://evidence-hub.com/study/13447-empa-reg-outcome-the-cardiologist-s-point-of-view2026-09-29 https://evidence-hub.com/study/13448-empagliflozin-influences-blood-viscosity-and-wall-shear-stress-in2026-10-06 https://evidence-hub.com/study/13449-comparison-of-the-effects-of-empagliflozin-and-sitagliptin-as-add-on2026-10-04 https://evidence-hub.com/study/13450-real-world-eligibility-and-cost-effectiveness-analysis-of2026-10-06 https://evidence-hub.com/study/13451-effect-of-empagliflozin-on-sphingolipid-catabolism-in-diabetic-and2026-10-06 https://evidence-hub.com/study/13452-highly-selective-sodium-glucose-co-transporter-type-2-inhibitor2026-10-06 https://evidence-hub.com/study/13453-impact-of-empagliflozin-on-cardiac-function-and-biomarkers-of-heart2026-10-06 https://evidence-hub.com/study/13454-complex-positive-effects-of-sglt-2-inhibitor-empagliflozin-in-the2026-10-06 https://evidence-hub.com/study/13455-empagliflozin-a-sodium-glucose-cotransporter-2-inhibitor-ameliorates2026-09-27 https://evidence-hub.com/study/13456-relative-bioavailability-of-an-empagliflozin-25-mg-linagliptin-5-mg2026-10-06 https://evidence-hub.com/study/13457-a-novel-self-nanomicellizing-system-of-empagliflozin-for-oral2026-10-06 https://evidence-hub.com/study/13458-usefulness-of-empagliflozin-versus-liraglutide-for-prevention-of2026-10-06 https://evidence-hub.com/study/13459-sglt2-inhibitors-and-cardiovascular-risk-lessons-learned-from-the2026-10-01 https://evidence-hub.com/study/13460-synthesis-and-characterization-of-mip-ghost-approach-for-selective2026-10-06 https://evidence-hub.com/study/13461-sodium-glucose-cotransporter-2-inhibitors-for-prevention-of-heart2026-10-06 https://evidence-hub.com/study/13462-effects-of-semaglutide-and-empagliflozin-on-inflammatory-markers-in2026-10-06 https://evidence-hub.com/study/13463-the-effect-of-empagliflozin-on-index-of-cardio-electrophysiological2026-10-06 https://evidence-hub.com/study/13464-the-effect-of-empagliflozin-on-p-wave-peak-time-and-other-p-wave2026-10-06 https://evidence-hub.com/study/13465-real-world-comparative-effectiveness-of-canagliflozin-versus2026-10-06 https://evidence-hub.com/study/13466-empagliflozin-primus-inter-pares-among-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/13467-sglt-2-inhibitors-reduce-glucose-absorption-from-peritoneal-dialysis2026-10-06 https://evidence-hub.com/study/13468-comparative-effectiveness-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/13469-shifts-in-kdigo-ckd-risk-groups-with-empagliflozin-kidney-protection2026-10-06 https://evidence-hub.com/study/13470-empagliflozin-treatment-effects-across-categories-of-baseline-hba1c2026-10-04 https://evidence-hub.com/study/13471-plain-language-summary-of-the-emperor-preserved-study-looking-at-the2026-10-06 https://evidence-hub.com/study/13472-cubosomal-functionalized-block-copolymer-platform-for-dual-delivery2026-10-06 https://evidence-hub.com/study/13473-empagliflozin-does-not-reverse-lipotoxicity-induced-impairment-in2026-10-06 https://evidence-hub.com/study/13474-protecting-cardiomyocytes-from-hypoxia-reoxygenation-injury2026-10-06 https://evidence-hub.com/study/13475-rationale-and-design-of-the-effects-of-empagliflozin-on-left2026-10-06 https://evidence-hub.com/study/13476-effect-of-empagliflozin-on-weight-in-patients-with-prediabetes-and2026-10-06 https://evidence-hub.com/study/13477-empagliflozin-inhibits-increased-na-influx-in-atrial-cardiomyocytes2026-10-06 https://evidence-hub.com/study/13478-clinical-study-of-metabolic-parameters-leptin-and-the-sglt2-inhibitor2026-10-06 https://evidence-hub.com/study/13479-effects-of-empagliflozin-on-collagen-biomarkers-in-patients-with2026-10-06 https://evidence-hub.com/study/13480-cost-effectiveness-of-empagliflozin-in-combination-with-standard-care2026-10-06 https://evidence-hub.com/study/13481-empagliflozin-reduces-interleukin-6-levels-in-patients-with-heart2026-10-04 https://evidence-hub.com/study/13482-adding-empagliflozin-to-sitagliptin-plus-metformin-vs-adding2026-10-04 https://evidence-hub.com/study/13483-dapagliflozin-versus-empagliflozin-in-patients-with-chronic-kidney2026-10-06 https://evidence-hub.com/study/13485-multinational-cost-effectiveness-analysis-of-empagliflozin-for-heart2026-10-06 https://evidence-hub.com/study/13486-empagliflozin-improves-insulin-sensitivity-in-patients-with-recent2026-10-06 https://evidence-hub.com/study/13487-empagliflozin-improves-the-microrna-signature-of-endothelial2026-10-04 https://evidence-hub.com/study/13488-empagliflozin-improves-outcomes-in-patients-with-heart-failure-and2026-10-01 https://evidence-hub.com/study/13489-empagliflozin-in-patients-post-myocardial-infarction-rationale-and2026-10-01 https://evidence-hub.com/study/13490-cost-effectiveness-of-empagliflozin-in-patients-with-heart-failure2026-10-06 https://evidence-hub.com/study/13491-safety-of-empagliflozin-in-patients-with-type-2-diabetes-and-chronic2026-10-06 https://evidence-hub.com/study/13492-metabolic-intestinal-and-cardiovascular-effects-of-sotagliflozin2026-10-06 https://evidence-hub.com/study/13493-effects-of-empagliflozin-on-markers-of-calcium-and-phosphate2026-10-06 https://evidence-hub.com/study/13494-effect-of-sglt-2-inhibitor-empagliflozin-on-blood-pressure-reduction2026-10-06 https://evidence-hub.com/study/13495-the-sglt2-inhibitor-empagliflozin-reduces-tissue-sodium-content-in2026-10-06 https://evidence-hub.com/study/13496-effect-of-empagliflozin-versus-linagliptin-on-body-composition-in2026-10-06 https://evidence-hub.com/study/13497-cost-utility-analysis-of-empagliflozin-in-heart-failure-patients-with2026-10-06 https://evidence-hub.com/study/13498-favorable-outcome-of-empagliflozin-treatment-in-two-pediatric2026-10-06 https://evidence-hub.com/study/13500-empagliflozin-reduces-myocardial-extracellular-volume-in-patients2026-10-01 https://evidence-hub.com/study/13501-heart-failure-outcomes-according-to-heart-rate-and-effects-of2026-10-06 https://evidence-hub.com/study/13502-cost-effectiveness-of-empagliflozin-in-patients-with-heart-failure2026-10-06 https://evidence-hub.com/study/13503-cost-effectiveness-of-adding-empagliflozin-to-standard-treatment-for2026-10-06 https://evidence-hub.com/study/13504-effect-of-empagliflozin-on-coronary-microvascular-function-in2026-10-06 https://evidence-hub.com/study/13505-effects-of-26-weeks-of-treatment-with-empagliflozin-versus2026-10-06 https://evidence-hub.com/study/13506-safety-and-effectiveness-of-empagliflozin-in-japanese-patients-with2026-10-06 https://evidence-hub.com/study/13507-efficacy-and-safety-of-empagliflozin-in-patients-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13508-empagliflozin-suppresses-urinary-mitochondrial-dna-copy-numbers-and2026-10-06 https://evidence-hub.com/study/13509-effect-of-empagliflozin-on-exercise-ability-and-symptoms-in-heart2026-09-27 https://evidence-hub.com/study/13510-empagliflozin-and-kidney-function-decline-in-patients-with-type-22026-10-01 https://evidence-hub.com/study/13511-empagliflozin-reduces-body-weight-and-indices-of-adipose-distribution2026-10-01 https://evidence-hub.com/study/13513-a-p-hase-iib-randomized-placebo-controlled-study-of-the-sglt22026-09-27 https://evidence-hub.com/study/13514-efficacy-and-safety-of-empagliflozin-in-older-patients-in-the-empa2026-10-01 https://evidence-hub.com/study/13515-the-sglt2-inhibitor-empagliflozin-ameliorates-the-inflammatory2026-10-04 https://evidence-hub.com/study/13516-empagliflozin-and-cerebrovascular-events-in-patients-with-type-22026-10-01 https://evidence-hub.com/study/13517-empagliflozin-as-adjunct-to-insulin-in-patients-with-type-1-diabetes2026-10-01 https://evidence-hub.com/study/13518-effects-of-the-selective-sodium-glucose-cotransporter-2-inhibitor2026-10-01 https://evidence-hub.com/study/13519-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-multiple2026-10-04 https://evidence-hub.com/study/13520-evaluation-of-the-effects-of-sodium-glucose-co-transporter-22026-10-01 https://evidence-hub.com/study/13521-empagliflozin-as-add-on-therapy-to-pioglitazone-with-or-without2026-10-04 https://evidence-hub.com/study/13523-dapagliflozin-in-patients-with-chronic-kidney-disease2026-10-01 https://evidence-hub.com/study/13525-semaglutide-and-cardiovascular-outcomes-in-patients-with-type-22026-10-01 https://evidence-hub.com/study/13526-the-effect-of-empagliflozin-on-muscle-sympathetic-nerve-activity-in2026-09-27 https://evidence-hub.com/study/13528-empagliflozin-and-cardiovascular-outcomes-in-asian-patients-with-type2026-10-01 https://evidence-hub.com/study/13529-empagliflozin-on-top-of-metformin-treatment-improves-arterial2026-10-08 https://evidence-hub.com/study/13530-efficacy-of-empagliflozin-on-heart-failure-and-renal-outcomes-in2026-10-01 https://evidence-hub.com/study/13531-effect-of-empagliflozin-on-ketone-bodies-in-patients-with-stable2026-10-01 https://evidence-hub.com/study/13532-anti-inflammatory-effects-of-empagliflozin-in-patients-with-type-22026-10-04 https://evidence-hub.com/study/13533-empagliflozin-as-add-on-therapy-in-patients-with-type-2-diabetes2026-10-04 https://evidence-hub.com/study/13534-sodium-glucose-cotransporter-2-inhibitors-for-diabetic-neuropathy-a2026-10-08 https://evidence-hub.com/study/13535-pre-pci-sglt2-inhibitors-and-contrast-induced-nephropathy-in-acute2026-10-06 https://evidence-hub.com/study/13536-treatment-of-left-ventricular-dysfunction-during-cancer-therapy-a2026-10-06 https://evidence-hub.com/study/13537-stacked-ensemble-learning-and-in-silico-profiling-reveal-dual-dpp-iv2026-10-06 https://evidence-hub.com/study/13538-effects-of-sodium-glucose-cotransporter-2-inhibitors-on-body-weight2026-10-06 https://evidence-hub.com/study/13539-multi-dimensional-roles-of-sodium-glucose-cotransporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/13540-bibliometric-analysis-of-sglt2-inhibitor-treatment-for-diabetic2026-10-06 https://evidence-hub.com/study/13541-orphan-gpcrs-in-diabetes-mellitus-metabolic-control-inflammation-and2026-10-06 https://evidence-hub.com/study/13542-impact-of-opuntia-ficus-indica-juice-and-empagliflozin-on-glycemic2026-10-04 https://evidence-hub.com/study/13543-update-on-the-efficacy-and-safety-of-sodium-glucose-co-transporter-22026-10-08 https://evidence-hub.com/study/13544-kidney-heart-crosstalk-the-extracellular-vesicles-connection2026-10-06 https://evidence-hub.com/study/13545-beyond-safety-adverse-events-and-unanticipated-advantages-of-sglt22026-10-06 https://evidence-hub.com/study/13546-cardiac-remodelling-in-type-2-diabetes-pathophysiological-mechanisms2026-10-08 https://evidence-hub.com/study/13547-repurposing-fda-approved-drugs-and-natural-compounds-to-inhibit-the2026-10-06 https://evidence-hub.com/study/13548-evaluating-the-potential-of-metabolic-drugs-in-obstructive-sleep2026-10-06 https://evidence-hub.com/study/13549-sglt2-inhibitors-to-slow-chronic-kidney-disease-progression-a-review2026-10-06 https://evidence-hub.com/study/13550-docking-based-classification-of-sglt2-inhibitors2026-10-06 https://evidence-hub.com/study/13551-euglycemic-diabetic-ketoacidosis-and-its-prevention-in-elective2026-10-06 https://evidence-hub.com/study/13552-newer-glucose-lowering-drugs-reduce-the-risk-of-late-onset-seizure2026-10-06 https://evidence-hub.com/study/13553-comparative-efficacy-of-multiple-drugs-for-non-alcoholic-fatty-liver2026-10-06 https://evidence-hub.com/study/13554-sodium-glucose-transporter-2-inhibitors-sglt2i-and-myocardial2026-10-06 https://evidence-hub.com/study/13555-a-systematic-review-of-gut-microbiota-diversity-a-key-player-in-the2026-10-06 https://evidence-hub.com/study/13556-adverse-drug-events-in-cost-effectiveness-models-of-pharmacological2026-10-06 https://evidence-hub.com/study/13557-metabolic-crosstalk-in-diabetic-kidney-disease-synergistic-effects-of2026-10-06 https://evidence-hub.com/study/13558-integrative-gene-metabolite-network-analysis-of-glp-1-receptor2026-10-06 https://evidence-hub.com/study/13559-comparative-efficacy-and-safety-of-cardio-renoprotective2026-10-06 https://evidence-hub.com/study/13560-targeting-the-gut-microbiome-for-type-2-diabetes-management-a-scoping2026-10-08 https://evidence-hub.com/study/13561-sglt2-inhibitor-dapagliflozin-treats-heart-failure-with-preserved2026-10-06 https://evidence-hub.com/study/13562-persade-a-database-of-personalized-adverse-drug-events-and-their2026-10-06 https://evidence-hub.com/study/13563-sglt2-inhibitors-versus-glp-1-receptor-agonists-for-major-adverse2026-10-06 https://evidence-hub.com/study/13564-divergent-renal-benefits-of-sodium-glucose-cotransporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/13565-mechanism-guided-pharmacotherapy-for-cardiometabolic-multimorbidity2026-10-06 https://evidence-hub.com/study/13566-pathophysiological-basis-of-the-cardiological-benefits-of-sglt-22026-10-06 https://evidence-hub.com/study/13567-the-use-of-empagliflozin-post-myocardial-infarction2026-10-06 https://evidence-hub.com/study/13568-the-trem2-paradox-in-fibrosis-a-unified-mechanism-for-opposite2026-10-06 https://evidence-hub.com/study/13569-exploring-the-comparative-cardiovascular-death-benefits-of-sodium2026-10-06 https://evidence-hub.com/study/13570-impact-of-sglt2-inhibition-on-markers-of-reverse-cardiac-remodelling2026-10-06 https://evidence-hub.com/study/13571-the-effects-of-non-insulin-anti-diabetic-medications-on-the-diabetic2026-10-06 https://evidence-hub.com/study/13572-mechanistic-role-of-disulfidptosis-in-type-2-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/13573-safety-of-drugs-in-breastfeeding-women-with-ckd2026-10-06 https://evidence-hub.com/study/13574-heart-failure-in-the-molecular-era-redefining-our-understanding-of2026-10-06 https://evidence-hub.com/study/13575-plant-derived-natural-products-in-neurological-and-psychiatric2026-10-06 https://evidence-hub.com/study/13576-an-integrated-text-mining-approach-for-discovering-pharmacological2026-10-06 https://evidence-hub.com/study/13577-sglt-2-inhibitors-enhance-the-effect-of-metformin-to-ameliorate2026-10-08 https://evidence-hub.com/study/13578-heart-failure-and-all-cause-hospitalizations-in-patients-with-heart2026-10-06 https://evidence-hub.com/study/13579-mechanism-of-substrate-recognition-and-release-of-human-sglt22026-10-06 https://evidence-hub.com/study/13580-sexual-dimorphism-and-menopausal-transition-a-narrative-review-of-the2026-10-06 https://evidence-hub.com/study/13581-the-role-of-arni-in-enhancing-outcomes-of-cardiac-resynchronization2026-10-06 https://evidence-hub.com/study/13582-safety-and-effectiveness-of-empagliflozin-according-to-body-mass2026-10-06 https://evidence-hub.com/study/13583-risk-of-bone-fracture-by-using-dipeptidyl-peptidase-4-inhibitors2026-10-06 https://evidence-hub.com/study/13584-translating-basic-science-to-clinical-applications-a-narrative-review2026-10-10 https://evidence-hub.com/study/13585-sglt2-inhibitors-attenuate-endothelial-to-mesenchymal-transition-and2026-10-06 https://evidence-hub.com/study/13586-ketone-bodies-after-cardiac-arrest-a-narrative-review-and-the2026-10-06 https://evidence-hub.com/study/13587-comparison-of-glp-1-receptor-agonists-sglt-2-inhibitors-and-dpp-42026-10-06 https://evidence-hub.com/study/13588-sodium-glucose-co-transporter-2-inhibitors-for-the-prevention-of2026-10-06 https://evidence-hub.com/study/13589-sodium-glucose-cotransporter-2-sglt2-inhibitors-and-fracture-risk-in2026-10-06 https://evidence-hub.com/study/13590-effects-of-sodium-glucose-cotransporter-1-and-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/13591-effects-of-reducing-blood-pressure-on-cardiovascular-outcomes-and2026-10-01 https://evidence-hub.com/study/13592-peripheral-artery-disease-and-amputations-with-sodium-glucose-co2026-10-06 https://evidence-hub.com/study/13593-genito-urinary-infectious-adverse-events-related-to-sodium-glucose2026-10-06 https://evidence-hub.com/study/13594-conducting-and-interpreting-results-of-network-meta-analyses-in-type2026-10-06 https://evidence-hub.com/study/13595-high-dose-sodium-glucose-co-transporter-2-inhibitors-are-superior-in2026-10-06 https://evidence-hub.com/study/13596-effect-of-glp-1-receptor-agonists-on-post-ablation-atrial2026-10-06 https://evidence-hub.com/study/13597-efficacy-of-sglt2-inhibitors-glp-1-receptor-agonists-and-aerobic2026-10-06 https://evidence-hub.com/study/13598-cardiovascular-and-renal-outcomes-of-combined-sglt2-inhibitors-and2026-10-06 https://evidence-hub.com/study/13599-efficacy-and-safety-of-sglt2-inhibitors-in-pediatric-patients-and2026-10-06 https://evidence-hub.com/study/13600-sglt2-inhibitors-among-patients-with-heart-failure-with-preserved2026-10-06 https://evidence-hub.com/study/13601-sodium-glucose-cotransporter-2-inhibitors-and-outcomes-in2026-10-06 https://evidence-hub.com/study/13602-cardiovascular-outcomes-and-safety-of-sglt2-inhibitors-in-chronic2026-10-06 https://evidence-hub.com/study/13603-sglt-2-inhibitors-and-prevention-of-contrast-induced-nephropathy-in2026-10-06 https://evidence-hub.com/study/13604-comparative-efficacy-and-safety-of-sglt2is-and-ns-mras-in-patients2026-10-06 https://evidence-hub.com/study/13605-first-line-treatment-with-sodium-glucose-cotransporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/13606-abrupt-decline-in-estimated-glomerular-filtration-rate-after2026-10-06 https://evidence-hub.com/study/13607-sodium-glucose-co-transporter-protein-2-sglt2-inhibitors-for-people2026-10-12 https://evidence-hub.com/study/13608-impact-of-anemia-on-clinical-outcomes-in-patients-with-acute-heart2026-10-06 https://evidence-hub.com/study/13609-the-cardiovascular-effects-of-sglt2-inhibitors-ras-inhibitors-and-arn2026-10-06 https://evidence-hub.com/study/13610-sglt-2-inhibitors-improve-cardiovascular-and-renal-outcomes-in2026-10-06 https://evidence-hub.com/study/13611-racial-ethnic-and-regional-differences-in-the-effect-of-sodium2026-10-06 https://evidence-hub.com/study/13612-effects-of-sglt-2-inhibitors-on-vascular-endothelial-function-and2026-10-06 https://evidence-hub.com/study/13613-network-meta-analysis-on-the-effects-of-finerenone-versus-sglt22026-10-06 https://evidence-hub.com/study/13614-the-effect-of-semaglutide-on-blood-pressure-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/13615-relative-frequency-of-urinary-tract-infections-in-patients-affected2026-10-06 https://evidence-hub.com/study/13616-effects-of-first-line-antidiabetic-drugs-on-the-improvement-of2026-10-06 https://evidence-hub.com/study/13617-association-between-the-beta-blockers-calcium-channel-blockers-all2026-10-08 https://evidence-hub.com/study/13618-sodium-glucose-co-transporter-2-inhibitors-in-heart-failure-with2026-10-06 https://evidence-hub.com/study/13619-anti-diabetic-agents-and-the-risks-of-dementia-in-patients-with-type2026-10-06 https://evidence-hub.com/study/13620-effect-of-sodium-glucose-cotransporter-2-inhibitors-on-aldosterone2026-10-06 https://evidence-hub.com/study/13621-effects-of-sglt2-inhibitors-on-haematocrit-and-haemoglobin-levels-and2026-10-06 https://evidence-hub.com/study/13622-a-meta-analysis-of-the-effect-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/13623-sodium-glucose-cotransporter-2-inhibitors-in-heart-failure-an-updated2026-10-06 https://evidence-hub.com/study/13624-cognitive-protection-of-incretin-based-therapies-in-patients-with2026-10-06 https://evidence-hub.com/study/13625-sodium-glucose-cotransporter-type-2-inhibitors-improve-cardiorenal2026-10-06 https://evidence-hub.com/study/13626-effects-of-sglt2-inhibitors-on-cardiovascular-outcomes-in-patients2026-10-06 https://evidence-hub.com/study/13627-sodium-glucose-cotransporter-2-inhibitors-as-an-add-on-therapy-to2026-10-06 https://evidence-hub.com/study/13628-immunosuppressive-therapy-for-iga-nephropathy-in-children2026-10-08 https://evidence-hub.com/study/13629-effects-of-sodium-glucose-cotransporter-2-inhibitors-on-non-alcoholic2026-10-06 https://evidence-hub.com/study/13630-sodium-glucose-cotransporter-inhibitors-as-add-on-therapy-in-addition2026-10-06 https://evidence-hub.com/study/13631-sodium-glucose-cotransporter-2-inhibitors-reduce-the-risk-of-heart2026-10-06 https://evidence-hub.com/study/13632-effect-of-pharmacological-treatment-on-outcomes-of-heart-failure-with2026-10-06 https://evidence-hub.com/study/13633-can-glucose-lowering-medications-improve-outcomes-in-non-diabetic2026-10-06 https://evidence-hub.com/study/13634-safety-assessment-of-glucose-lowering-drugs-and-importance-of2026-10-06 https://evidence-hub.com/study/13635-comparative-cardiovascular-outcomes-of-novel-drugs-as-an-addition-to2026-10-06 https://evidence-hub.com/study/13636-recent-applications-of-quantitative-systems-pharmacology-and-machine2026-10-06 https://evidence-hub.com/study/13637-noninsulin-based-antihyperglycemic-medications-in-patients-with2026-10-06 https://evidence-hub.com/study/13638-metformin-for-preventing-the-progression-of-chronic-kidney-disease2026-10-06 https://evidence-hub.com/study/13639-systematic-review-and-meta-analysis-for-prevention-of-cardiovascular2026-10-06 https://evidence-hub.com/study/13640-cardiovascular-outcomes-associated-with-sglt-2-inhibitors-versus2026-10-06 https://evidence-hub.com/study/13641-effect-of-ramadan-fasting-in-patients-with-type-2-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/13642-dipeptidyl-peptidase-4-inhibitors-glucagon-like-peptide-1-receptor2026-10-06 https://evidence-hub.com/study/13643-effects-of-glucagon-like-peptide-1-receptor-agonists-and-sodium2026-10-06 https://evidence-hub.com/study/13644-sglt2-inhibitors-and-atrial-fibrillation-in-type-2-diabetes-a2026-10-06 https://evidence-hub.com/study/13645-cardiovascular-and-renal-outcomes-with-sglt-2-inhibitors-versus-glp-12026-10-06 https://evidence-hub.com/study/13646-effects-of-sodium-glucose-cotransporter-2-inhibitors-in-addition-to2026-10-06 https://evidence-hub.com/study/13647-glucose-lowering-agents-for-treating-pre-existing-and-new-onset2026-10-06 https://evidence-hub.com/study/13649-a-network-meta-analysis-of-the-efficacy-and-safety-of-empagliflozin2026-10-06 https://evidence-hub.com/study/13650-evaluation-and-comparison-of-efficacy-and-safety-of-tirzepatide2026-10-06 https://evidence-hub.com/study/13651-selective-sodium-glucose-cotransporter-2-inhibitors-in-the2026-10-06 https://evidence-hub.com/study/13652-effect-of-sodium-glucose-cotransporter-2-inhibitor-sglt2-i-in2026-10-06 https://evidence-hub.com/study/13654-cost-utility-analysis-of-empagliflozin-compared-with-dapagliflozin-in2026-10-06 https://evidence-hub.com/study/13655-comparative-safety-of-different-recommended-doses-of-sodium-glucose2026-10-04 https://evidence-hub.com/study/13658-comparative-efficacy-and-safety-of-sodium-glucose-cotransporter-22026-10-10 https://evidence-hub.com/study/13659-sglt2-inhibitors-and-risk-reduction-for-mortality-in-high-risk2026-10-06 https://evidence-hub.com/study/13660-dose-dependent-effects-of-sglt2-inhibitors-on-circadian-blood2026-10-06 https://evidence-hub.com/study/13661-a-network-meta-analysis-of-safety-and-efficacy-of-sodium-glucose2026-10-06 https://evidence-hub.com/study/13662-association-between-sodium-glucose-cotransporter-2-inhibitors-and2026-10-01 https://evidence-hub.com/study/13663-260-efficacy-of-sglt2-inhibitors-in-patients-with-and-without-heart2026-10-06 https://evidence-hub.com/study/13664-comparing-the-clinical-outcomes-across-different-sodium-glucose2026-10-06 https://evidence-hub.com/study/13665-the-effect-of-sodium-glucose-cotransporter-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/13666-the-effects-of-sodium-glucose-co-transporter-sglt-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/13667-risk-of-diabetic-ketoacidosis-caused-by-sodium-glucose-cotransporter2026-10-06 https://evidence-hub.com/study/13668-diabetes-treatment-in-the-elderly-incorporating-geriatrics-technology2026-10-06 https://evidence-hub.com/study/13669-long-term-efficacy-of-gliflozins-versus-gliptins-for-type-2-diabetes2026-10-04 https://evidence-hub.com/study/13670-relative-efficacy-of-sacubitril-valsartan-vericiguat-and-sglt22026-10-06 https://evidence-hub.com/study/13671-cardiovascular-mortality-of-oral-antidiabetic-drugs-approved-before2026-10-06 https://evidence-hub.com/study/13672-systematic-review-of-ocular-and-circulatory-cytokines-linking2026-10-06 https://evidence-hub.com/study/13673-mechanisms-of-sglt-inhibitor-action-and-physiological-mediators2026-10-06 https://evidence-hub.com/study/13674-genomic-insights-about-the-effect-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/13675-anti-inflammatory-effect-of-semaglutide-updated-systematic-review-and2026-10-06 https://evidence-hub.com/study/13676-interplay-between-frailty-and-cardiometabolic-disorders-from2026-10-06 https://evidence-hub.com/study/13677-glucose-lowering-and-the-risk-of-cardiovascular-events-with2026-10-06 https://evidence-hub.com/study/13678-recurrent-urinary-tract-infections-and-type-2-diabetes-mellitus-a2026-10-13 https://evidence-hub.com/study/13679-the-effects-of-subcutaneous-tirzepatide-on-obesity-and-overweight-a2026-10-06 https://evidence-hub.com/study/13680-economic-evaluation-of-adding-dapagliflozin-to-standard-care-in-the2026-10-06 https://evidence-hub.com/study/13681-utilization-of-pharmacokinetic-pharmacodynamic-modeling-in2026-10-06 https://evidence-hub.com/study/13682-prognostic-models-for-patients-suffering-a-heart-failure-with-a2026-10-06 https://evidence-hub.com/study/13683-sodium-glucose-cotransporter-2-inhibitor-effects-on-heart-failure2026-10-06 https://evidence-hub.com/study/13684-sglt2-inhibitors-in-patients-with-type-2-diabetes-with-non-alcoholic2026-10-06 https://evidence-hub.com/study/13686-the-effects-of-sodium-glucose-cotransporter-2-inhibitors-on-steatosis2026-10-04 https://evidence-hub.com/study/13687-abstract-14100-which-sodium-glucose-cotransporter-2-inhibitors-agent2026-10-06 https://evidence-hub.com/study/13688-cost-effectiveness-analysis-and-medication-use-for-gangrene-treatment2026-10-06 https://evidence-hub.com/study/13689-effectiveness-of-sglt2-inhibitors-in-improving-functional-capacity2026-10-06 https://evidence-hub.com/study/13690-effects-and-safety-of-sglt2-inhibitors-compared-to-placebo-in2026-10-01 https://evidence-hub.com/study/13691-sglt2-inhibition-with-empagliflozin-increases-circulating-provascular2026-10-06 https://evidence-hub.com/study/13692-albuminuria-lowering-effect-of-adding-semaglutide-on-top-of2026-10-06 https://evidence-hub.com/study/13695-efficacy-and-safety-of-empagliflozin-twice-daily-versus-once-daily-in2026-10-04 https://evidence-hub.com/study/13697-glucometabolic-control-of-once-weekly-dulaglutide-switched-from-dpp42026-10-06 https://evidence-hub.com/study/13698-effect-of-metformin-and-empagliflozin-on-myocardial-function-in2026-10-04 https://evidence-hub.com/study/13699-evaluating-the-limited-impact-of-therapy-with-empagliflozin-on2026-10-06 https://evidence-hub.com/study/13700-1140-p-empagliflozin-attenuates-fasting-and-postprandial2026-10-06 https://evidence-hub.com/study/13701-empagliflozin-does-not-change-cardiac-index-nor-systemic-vascular2026-10-06 https://evidence-hub.com/study/13702-empagliflozin-improves-left-ventricular-ejection-fraction-and-end2026-10-06 https://evidence-hub.com/study/13703-effect-of-sglt2-inhibition-on-glucosuria-during-a-hyperglycemic-clamp2026-10-06 https://evidence-hub.com/study/13704-empagliflozin-confers-reno-protection-in-acute-myocardial-infarction2026-10-06 https://evidence-hub.com/study/13705-comparison-of-empagliflozin-and-vildagliptin-for-efficacy-and-safety2026-10-06 https://evidence-hub.com/study/13706-effects-of-empagliflozin-on-markers-of-liver-steatosis-and-fibrosis2026-10-06 https://evidence-hub.com/study/13707-pharmacokinetics-and-pharmacodynamics-of-twice-daily-and-once-daily2026-10-06 https://evidence-hub.com/study/13708-empagliflozin-improves-cardiorespiratory-fitness-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13709-eligibility-for-dapagliflozin-and-empagliflozin-in-a-real-world-heart2026-10-06 https://evidence-hub.com/study/13710-impact-of-empagliflozin-in-heart-failure-with-reduced-ejection2026-10-06 https://evidence-hub.com/study/13711-empagliflozin-increases-plasma-levels-of-citrulline-histidine-and2026-10-06 https://evidence-hub.com/study/13712-comparison-between-the-effect-of-empagliflozin-and-pioglitazone-added2026-10-04 https://evidence-hub.com/study/13713-a-prospective-randomized-study-comparing-effects-of-empagliflozin-to2026-10-06 https://evidence-hub.com/study/13714-agonist-antibody-to-guanylate-cyclase-receptor-npr1-regulates2026-10-10 https://evidence-hub.com/study/13715-evaluating-the-effects-of-empagliflozin-in-preventing-myocardial2026-10-06 https://evidence-hub.com/study/13717-gliflozins-in-practice-real-life-use-of-dapagliflozin-and2026-10-06 https://evidence-hub.com/study/13718-empagliflozin-in-patients-hospitalized-for-acute-decompensated-heart2026-10-06 https://evidence-hub.com/study/13720-effects-of-empagliflozin-in-patients-with-heart-failure-and-preserved2026-10-06 https://evidence-hub.com/study/13721-comment-on-clinical-benefits-of-empagliflozin-in-very-old-patients2026-09-27 https://evidence-hub.com/study/13722-comparison-of-the-clinical-effect-of-empagliflozin-on-glycemic-and2026-10-04 https://evidence-hub.com/study/13723-sodium-glucose-cotransporters-as-potential-therapeutic-targets-in2026-10-06 https://evidence-hub.com/study/13725-the-impact-of-empagliflozin-on-renal-function-and-kidney-injury2026-10-06 https://evidence-hub.com/study/13726-cost-effectiveness-analysis-of-empagliflozin-for-treatment-of2026-10-06 https://evidence-hub.com/study/13727-the-efficacy-of-empagliflozin-in-combination-with-pioglitazone-on-the2026-10-06 https://evidence-hub.com/study/13728-vascular-disease-burden-outcomes-and-benefits-with-empagliflozin-in2026-10-06 https://evidence-hub.com/study/13729-highlights-of-cardiovascular-disease-prevention-studies-presented-at2026-10-06 https://evidence-hub.com/study/13730-the-effect-of-sodium-glucose-co-transporter-2-sglt2-inhibitors-on2026-10-06 https://evidence-hub.com/study/13731-glp-1-receptor-agonists-beyond-glycemic-control-integrated-cardio2026-10-06 https://evidence-hub.com/study/13732-novel-therapeutics-for-type-2-diabetes-mellitus-a-look-at-the-past2026-10-06 https://evidence-hub.com/study/13733-novel-antidiabetic-agents-and-their-effects-on-lipid-profile-a-single2026-10-06 https://evidence-hub.com/study/13734-cardiorenal-benefits-of-finerenone-protecting-kidney-and-heart2026-10-06 https://evidence-hub.com/study/13735-effects-of-sodium-glucose-co-transporter-2-inhibitors-on-vascular2026-10-06 https://evidence-hub.com/study/13736-therapeutic-potential-of-traditional-chinese-medicine-for2026-10-06 https://evidence-hub.com/study/13737-role-of-inflammatory-biomarkers-in-peripheral-arterial-disease-a2026-10-06 https://evidence-hub.com/study/13738-implications-of-sglt-inhibition-on-redox-signalling-in-atrial2026-10-06 https://evidence-hub.com/study/13739-finerenone-in-heart-failure-a-novel-therapeutic-approach2026-10-06 https://evidence-hub.com/study/13740-geroprotective-effects-of-drugs-modulating-metabolic-pathways2026-10-08 https://evidence-hub.com/study/13741-time-in-range-a-new-gold-standard-in-type-2-diabetes-research2026-10-06 https://evidence-hub.com/study/13742-meta-analysis-of-the-effects-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/13743-clinical-rationale-behind-glucose-sparing-strategies-in-peritoneal2026-10-06 https://evidence-hub.com/study/13744-advances-in-clinical-cardiology-2024-a-summary-of-key-clinical-trials2026-10-06 https://evidence-hub.com/study/13745-no-cytotoxic-and-inflammatory-effects-of-empagliflozin-and2026-10-01 https://evidence-hub.com/study/13746-efficacy-and-safety-of-sglt2-inhibitors-in-heart-failure-systematic2026-10-06 https://evidence-hub.com/study/13747-inpatient-hypoglycemia-the-challenge-remains2026-10-06 https://evidence-hub.com/study/13748-sotagliflozin-vs-dapagliflozin-a-systematic-review-comparing2026-10-06 https://evidence-hub.com/study/13749-association-of-hyponatremia-with-bone-mineral-density-and-fractures-a2026-10-06 https://evidence-hub.com/study/13750-sodium-glucose-cotransporter-2-inhibitors-in-combination-with-other2026-10-06 https://evidence-hub.com/study/13751-advances-in-device-based-treatment-of-heart-failure-with-preserved2026-10-06 https://evidence-hub.com/study/13752-effect-of-sodium-glucose-cotransporter-2-inhibitors-on-cardiac2026-10-06 https://evidence-hub.com/study/13753-sglt2-inhibitors-or-glp-1-receptor-agonists-as-second-line-therapy-in2026-10-06 https://evidence-hub.com/study/13754-effects-of-antihypertensives-lipid-modifying-drugs-glycaemic-control2026-10-06 https://evidence-hub.com/study/13755-management-of-metabolic-associated-fatty-liver-disease-the2026-10-06 https://evidence-hub.com/study/13756-effects-of-sglt2-inhibitors-on-utis-and-genital-infections-in-type-22026-10-06 https://evidence-hub.com/study/13757-prevention-of-atherothrombotic-events-in-patients-with-diabetes2026-10-06 https://evidence-hub.com/study/13758-the-aggressive-diabetic-kidney-disease-in-youth-onset-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13759-perioperative-management-of-patients-taking-glucagon-like-peptide-12026-10-06 https://evidence-hub.com/study/13760-device-based-solutions-to-improve-cardiac-physiology-and-hemodynamics2026-10-06 https://evidence-hub.com/study/13761-insulin-and-glucose-lowering-agents-for-treating-people-with-diabetes2026-10-06 https://evidence-hub.com/study/13762-type-2-diabetes-mellitus-and-osteoarthritis2026-10-06 https://evidence-hub.com/study/13763-interventions-to-improve-adherence-to-lipid-lowering-medication2026-10-06 https://evidence-hub.com/study/13764-metformin-monotherapy-for-adults-with-type-2-diabetes-mellitus2026-10-08 https://evidence-hub.com/study/13765-metformin-for-prevention-or-delay-of-type-2-diabetes-mellitus-and-its2026-10-06 https://evidence-hub.com/study/13766-effect-of-sglt-2-inhibitors-on-arrhythmia-events-insight-from-an2026-10-06 https://evidence-hub.com/study/13767-single-cell-transcriptomic-analysis-of-sglt2-expression-supports-an2026-10-06 https://evidence-hub.com/study/13768-effect-of-dapagliflozin-on-cardiovascular-outcomes-according-to2026-10-06 https://evidence-hub.com/study/13769-comparative-value-of-dapagliflozin-vs-empagliflozin-in-patients-with2026-10-06 https://evidence-hub.com/study/13770-comparison-of-ventricular-tachyarrhythmias-in-hf-patients-on2026-10-06 https://evidence-hub.com/study/13771-metabolic-and-lipoprotein-changes-in-type-2-diabetes-patients-treated2026-10-06 https://evidence-hub.com/study/13772-effects-of-combination-therapy-with-empagliflozin-and-metformin-on2026-10-04 https://evidence-hub.com/study/13773-effects-of-empagliflozin-on-biomarkers-of-renal-injury-fibrosis-and2026-10-06 https://evidence-hub.com/study/13774-left-ventricular-mass-predicts-cardiac-reverse-remodelling-in2026-10-06 https://evidence-hub.com/study/13775-cost-effectiveness-of-adding-empagliflozin-to-the-standard-of-care2026-10-06 https://evidence-hub.com/study/13776-effect-of-empagliflozin-on-intrarenal-blood-flow-parameters-in2026-10-06 https://evidence-hub.com/study/13777-celestia-cost-effectiveness-analysis-of-empagliflozin-versus2026-10-06 https://evidence-hub.com/study/13778-abstract-16990-empagliflozin-therapy-is-associated-with-improved-left2026-10-06 https://evidence-hub.com/study/13779-empagliflozin-in-patients-with-acute-heart-failure-and-diuretic2026-10-06 https://evidence-hub.com/study/13780-effect-of-empagliflozin-in-patients-with-type-2-diabetes-during2026-10-06 https://evidence-hub.com/study/13781-cost-effectiveness-of-empagliflozin-in-addition-to-metformin-in2026-10-04 https://evidence-hub.com/study/13782-assessment-of-empagliflozin-add-on-therapy-to-metformin-and2026-10-06 https://evidence-hub.com/study/13783-abstract-12880-left-ventricular-mass-predicts-cardiac-reverse2026-10-06 https://evidence-hub.com/study/13784-comparison-of-adverse-kidney-outcomes-with-empagliflozin-and2026-10-06 https://evidence-hub.com/study/13785-risk-of-lower-extremity-amputations-in-patients-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13786-comparative-risk-of-glaucoma-in-patients-using-sodium-glucose2026-10-06 https://evidence-hub.com/study/13787-impact-of-breakthrough-trials-on-prescription-trends-of-sodium2026-10-06 https://evidence-hub.com/study/13788-evaluation-of-salivary-acetylcholinesterase-and-pseudocholinesterase2026-10-06 https://evidence-hub.com/study/13789-risk-factors-for-clostridium-difficile-infection-in-surgical-patients2026-10-06 https://evidence-hub.com/study/13790-radiographic-bone-loss-and-the-risk-of-medication-related2026-10-06 https://evidence-hub.com/study/13791-patient-and-ward-related-risk-factors-in-a-multi-ward-nosocomial2026-10-06 https://evidence-hub.com/study/13792-comparison-of-safety-and-efficacy-of-dapagliflozin-and-empagliflozin2026-10-06 https://evidence-hub.com/study/13793-in-hospital-transfer-is-a-risk-factor-for-invasive-filamentous-fungal2026-10-06 https://evidence-hub.com/study/13794-comparing-effect-of-sitagliptin-versus-empagliflozin-as-add-on2026-10-04 https://evidence-hub.com/study/13795-usefulness-of-empagliflozin-versus-oral-semaglutide-for-prevention-of2026-10-06 https://evidence-hub.com/study/13796-case-control-study-evaluating-risk-factors-for-sars-cov-2-outbreak2026-10-06 https://evidence-hub.com/study/13797-use-of-oral-empagliflozin-to-obtain-optimal-blood-sugar-levels-for2026-10-06 https://evidence-hub.com/study/13800-the-evaluation-of-clinical-factors-affecting-oral-health-impacts-on2026-10-06 https://evidence-hub.com/study/13801-physical-function-and-association-with-cognitive-function-in-patients2026-10-06 https://evidence-hub.com/study/13802-association-of-acidic-urine-ph-with-impaired-renal-function-in2026-10-06 https://evidence-hub.com/study/13803-first-and-second-covid-19-waves-in-brazil-a-cross-sectional-study-of2026-10-10 https://evidence-hub.com/study/13804-association-between-globulin-and-diabetic-nephropathy-in-type22026-10-06 https://evidence-hub.com/study/13805-prevalence-of-sars-cov-2-antibodies-in-a-large-nationwide-sample-of2026-10-10 https://evidence-hub.com/study/13806-depression-anxiety-and-stress-among-patients-with-covid-19-a-cross2026-10-06 https://evidence-hub.com/study/13807-association-between-management-human-resources-and-care-provided-to2026-10-06 https://evidence-hub.com/study/13808-treatment-adherence-among-patients-with-hypertension-findings-from-a2026-10-06 https://evidence-hub.com/study/13810-risk-factors-for-sars-cov-2-among-patients-in-the-oxford-royal2026-10-06 https://evidence-hub.com/study/13811-the-relationship-between-resilience-anxiety-and-depression-among2026-10-06 https://evidence-hub.com/study/13812-public-views-on-obesity-bariatric-surgery-and-bariatric-surgery2026-10-06 https://evidence-hub.com/study/13813-quality-of-life-in-patients-with-papillary-thyroid-microcarcinoma2026-10-06 https://evidence-hub.com/study/13814-a-cross-sectional-study-of-502-patients-found-a-diffuse-hyperechoic2026-10-06 https://evidence-hub.com/study/13815-beneficial-effect-of-mediterranean-diet-on-disease-activity-and2026-10-06 https://evidence-hub.com/study/13816-association-of-vitamin-d-in-patients-with-periodontitis-a-cross2026-10-06 https://evidence-hub.com/study/13817-association-between-vitamin-d-status-and-diabetic-complications-in2026-10-06 https://evidence-hub.com/study/13818-magnitude-and-factors-associated-with-preoperative-anxiety-among2026-10-06 https://evidence-hub.com/study/13819-clinical-profile-and-prevalence-of-conjunctivitis-in-mild-covid-192026-10-06 https://evidence-hub.com/study/13820-nutritional-status-of-tuberculosis-patients-a-comparative-cross2026-10-06 https://evidence-hub.com/study/13821-quality-of-life-and-its-predictors-among-patients-with-chronic-kidney2026-10-06 https://evidence-hub.com/study/13822-the-relationship-between-the-gut-microbiome-and-mild-cognitive2026-10-06 https://evidence-hub.com/study/13823-tooth-grinding-in-older-adults-a-retrospective-cross-sectional-study2026-10-06 https://evidence-hub.com/study/13824-mandibular-bone-imaging-assessment-in-individuals-with-rheumatoid2026-10-06 https://evidence-hub.com/study/13825-prevalence-of-self-stigma-and-its-association-with-self-esteem-among2026-10-06 https://evidence-hub.com/study/13826-impact-of-adherence-to-antiepileptic-medications-on-quality-of-life2026-10-06 https://evidence-hub.com/study/13827-prevalence-and-determinants-of-poor-glycaemic-control-a-cross2026-10-06 https://evidence-hub.com/study/13828-smell-and-taste-disorders-during-covid-19-outbreak-cross-sectional2026-10-06 https://evidence-hub.com/study/13829-impact-of-satisfaction-with-physician-patient-communication-on-self2026-10-10 https://evidence-hub.com/study/13830-association-between-the-triglyceride-glucose-index-and-diabetic2026-10-06 https://evidence-hub.com/study/13831-prevalence-of-anxiety-depression-and-stress-in-patients-with-multiple2026-10-06 https://evidence-hub.com/study/13832-analgesic-effects-of-indomethacin-spray-on-drug-induced-oral2026-10-06 https://evidence-hub.com/study/13833-assessment-of-nutritional-status-in-the-maintenance-of-haemodialysis2026-10-06 https://evidence-hub.com/study/13834-association-of-ultrasound-derived-metrics-of-the-quadriceps-muscle2026-10-12 https://evidence-hub.com/study/13835-psychologic-stress-and-disease-activity-in-patients-with-inflammatory2026-10-06 https://evidence-hub.com/study/13836-depression-and-anxiety-in-patients-with-different-rare-chronic2026-10-06 https://evidence-hub.com/study/13838-type-d-personality-is-associated-with-poor-quality-of-life-social2026-10-06 https://evidence-hub.com/study/13839-prevalence-of-peri-implant-diseases-among-an-italian-population-of2026-10-06 https://evidence-hub.com/study/13840-prevalence-of-diabetic-foot-ulcer-and-associated-factors-among-adult2026-10-06 https://evidence-hub.com/study/13841-relationships-among-medication-adherence-lifestyle-modification-and2026-10-06 https://evidence-hub.com/study/13842-prevalence-severity-and-factors-associated-with-peripheral-neuropathy2026-10-06 https://evidence-hub.com/study/13843-prevalence-of-malnutrition-in-hospitalized-patients-a-multicenter2026-10-06 https://evidence-hub.com/study/13845-use-of-digital-health-technology-in-heart-failure-and-diabetes-a2026-10-06 https://evidence-hub.com/study/13846-executive-summary-from-expert-consensus-on-effectiveness-and-safety2026-10-06 https://evidence-hub.com/study/13847-toxicity-of-psychotropic-drugs-in-patients-with-covid-19-a-systematic2026-10-06 https://evidence-hub.com/study/13848-sacubitril-valsartan-in-heart-failure-efficacy-and-safety-in-and2026-10-06 https://evidence-hub.com/study/13849-management-of-diabetes-in-candidates-for-liver-transplantation-and-in2026-10-06 https://evidence-hub.com/study/13850-an-update-on-drug-drug-interactions-in-older-adults-living-with-human2026-10-08 https://evidence-hub.com/study/13851-medical-management-of-metabolic-and-cardiovascular-complications2026-10-06 https://evidence-hub.com/study/13852-cardiac-fibromas-in-adult-patients-a-case-series-focusing-on2026-10-06 https://evidence-hub.com/study/13853-the-effects-of-a-brief-mindfulness-based-intervention-on-pain2026-10-06 https://evidence-hub.com/study/13854-case-series-of-successful-intravenous-immunoglobulin-ivig-treatment2026-10-06 https://evidence-hub.com/study/13855-real-world-evidence-for-subcutaneous-infliximab-ct-p13-sc-treatment2026-10-13 https://evidence-hub.com/study/13856-understanding-pneumomediastinum-as-a-complication-in-patients-with2026-10-13 https://evidence-hub.com/study/13857-covid-19-presentation-in-patients-with-sickle-cell-disease-a-case2026-10-06 https://evidence-hub.com/study/13858-transcutaneous-electrical-diaphragmatic-stimulation-reduces-the2026-10-06 https://evidence-hub.com/study/13859-st-segment-elevation-in-patients-presenting-with-covid-19-case-series2026-10-06 https://evidence-hub.com/study/13860-a-longitudinal-case-series-of-im-ketamine-for-patients-with-severe2026-10-13 https://evidence-hub.com/study/13861-transcatheter-aortic-valve-replacement-same-day-discharge-for2026-10-06 https://evidence-hub.com/study/13862-cerebrovascular-disease-in-patients-with-covid-19-a-review-of-the2026-10-06 https://evidence-hub.com/study/13863-transcatheter-treatment-of-severe-aortic-stenosis-in-patients-with2026-10-06 https://evidence-hub.com/study/13864-a-case-series-of-adult-patients-diagnosed-with-iga-vasculitis2026-10-06 https://evidence-hub.com/study/13865-long-term-visual-field-changes-after-femtosecond-laser-assisted2026-10-06 https://evidence-hub.com/study/13866-spontaneous-pneumomediastinum-and-pneumothorax-in-nonintubated-covid2026-10-06 https://evidence-hub.com/study/13867-malignant-proliferating-trichilemmal-tumors-arising-in-patients-with2026-10-06 https://evidence-hub.com/study/13868-the-use-of-self-assembling-peptides-purastat-for-hemostasis-in2026-10-06 https://evidence-hub.com/study/13869-patterns-of-immunotherapy-induced-pneumonitis-in-patients-with-non2026-10-06 https://evidence-hub.com/study/13870-pembrolizumab-induced-adrenal-insufficiency-in-patients-with2026-10-06 https://evidence-hub.com/study/13871-clinical-profile-of-covid-19-patients-presenting-with-uveitis-a-short2026-10-06 https://evidence-hub.com/study/13872-elective-checkpoint-inhibitor-discontinuation-in-metastatic-solid2026-10-06 https://evidence-hub.com/study/13873-case-series-bacillary-layer-detachment-associated-with-acute-central2026-10-06 https://evidence-hub.com/study/13874-clinical-outcomes-of-post-renal-transplant-patients-with-covid-192026-10-06 https://evidence-hub.com/study/13875-increase-of-lung-function-usage-bronchoscopy-in-covid-19-patients2026-10-06 https://evidence-hub.com/study/13876-therapeutic-approach-for-severe-covid-19-and-immunocompromised2026-10-06 https://evidence-hub.com/study/13877-disruption-of-ingrown-epithelium-via-nd-yag-laser-or-dieyag-a2026-10-06 https://evidence-hub.com/study/13878-docetaxel-induced-interstitial-lung-disease-among-patients-with2026-10-06 https://evidence-hub.com/study/13879-who-nose-is-it-the-angiotensin-receptor-neprilysin-inhibitor-a-case2026-10-06 https://evidence-hub.com/study/13880-effects-of-mixed-technology-co2-and-ga-as-laser-in-patients-with2026-10-06 https://evidence-hub.com/study/13881-heart-block-in-patients-with-coronavirus-disease-2019-a-case-series2026-10-06 https://evidence-hub.com/study/13882-a-case-series-of-patients-coinfected-with-influenza-and-covid-192026-10-06 https://evidence-hub.com/study/13883-the-use-of-indocyanine-green-fluorescent-in-patients-with-abdominal2026-10-06 https://evidence-hub.com/study/13884-mucopolysaccharidosis-mps-review-of-the-literature-and-case-series-of2026-10-06 https://evidence-hub.com/study/13885-als-like-disorder-in-three-hiv-positive-patients-case-series2026-10-06 https://evidence-hub.com/study/13886-case-series-rare-cases-of-thyroid-storm-in-covid-19-patients2026-10-06 https://evidence-hub.com/study/13887-nontuberculous-mycobacterial-lung-infections-in-patients-with-eating2026-10-06 https://evidence-hub.com/study/13888-a-case-series-of-morbid-copd-exacerbations-during-immune-checkpoint2026-10-06 https://evidence-hub.com/study/13889-acute-pulmonary-embolism-and-systemic-thrombolysis-in-the-era-of2026-10-06 https://evidence-hub.com/study/13890-clinical-and-microbiological-characteristics-of-reactive-infectious2026-10-06 https://evidence-hub.com/study/13891-use-of-cytosorb-therapy-to-treat-critically-ill-coronavirus-disease2026-10-06 https://evidence-hub.com/study/13892-takotsubo-cardiomyopathy-in-elderly-female-trauma-patients-a-case2026-10-06 https://evidence-hub.com/study/13893-living-donor-liver-transplantation-for-combined-hepatocellular2026-10-06 https://evidence-hub.com/study/13894-case-series-on-initial-responses-to-intravitreal-brolucizumab-in2026-10-06 https://evidence-hub.com/study/13895-pericardial-effusion-in-patients-with-covid-19-case-series2026-10-06 https://evidence-hub.com/study/13896-spectacle-independence-in-patients-with-prior-radial-keratotomy2026-10-06 https://evidence-hub.com/study/13897-clinical-case-series-of-decrease-in-shear-wave-elastography-values-in2026-10-06 https://evidence-hub.com/study/13898-mechanical-circulatory-support-and-intravascular-lithotripsy-in-high2026-10-06 https://evidence-hub.com/study/13899-simultaneous-occurrence-of-follicular-and-papillary-thyroid2026-10-06 https://evidence-hub.com/study/13900-clinically-suspected-myocarditis-in-covid-19-patients-case-series-and2026-10-06 https://evidence-hub.com/study/13901-juvenile-and-adult-vulvar-pemphigoid-an-under-recognized-entity-case2026-10-06 https://evidence-hub.com/study/13902-treatment-of-medication-related-osteonecrosis-of-the-jaws-without2026-10-06 https://evidence-hub.com/study/13903-paradoxical-depressive-response-to-intranasal-esketamine-in-treatment2026-10-06 https://evidence-hub.com/study/13904-use-of-leflunomide-as-an-antiviral-agent-with-everolimus-for-bk-virus2026-10-06 https://evidence-hub.com/study/13905-endoscopic-treatment-of-greater-trochanteric-pain-syndrome-a-case2026-10-06 https://evidence-hub.com/study/13906-utilization-of-intra-aortic-balloon-pump-to-allow-mitraclip-procedure2026-10-06 https://evidence-hub.com/study/13907-sodium-glucose-cotransporter-2-inhibitors-for-mesenchymal-epithelial2026-10-06 https://evidence-hub.com/study/13908-challenges-in-the-diagnosis-of-euglycemic-diabetic-ketoacidosis-in-a2026-10-06 https://evidence-hub.com/study/13909-tubulointerstitial-nephritis-after-using-a-sodium-glucose2026-10-06 https://evidence-hub.com/study/13910-insulin-pen-administration-efficacy-and-safety-in-an-older-patient2026-10-06 https://evidence-hub.com/study/13911-sodium-glucose-cotransporter-2-inhibitors-induced-eu-glycemic2026-10-06 https://evidence-hub.com/study/13912-retrospective-review-of-sglt2-inhibitor-exposures-reported-to-132026-10-06 https://evidence-hub.com/study/13913-a-case-of-euglycemic-diabetic-ketoacidosis-due-to-empagliflozin-use2026-10-06 https://evidence-hub.com/study/13914-sglt2-inhibitors-associated-pancreatitis-signal-identification2026-10-06 https://evidence-hub.com/study/13915-add-on-multidrug-treatment-based-on-quadruple-therapy-successfully2026-10-06 https://evidence-hub.com/study/13916-valproate-intoxication-in-a-patient-with-bipolar-i-disorder-due-to2026-10-06 https://evidence-hub.com/study/13917-a-case-of-septic-shock-due-to-serratia-marcescens-pyelonephritis-and2026-10-06 https://evidence-hub.com/study/13918-bittersweet-infective-complications-of-drug-induced-glycosuria-in2026-10-06 https://evidence-hub.com/study/13919-euglycemic-diabetic-ketoacidosis-associated-with-sodium-glucose2026-10-06 https://evidence-hub.com/study/13920-unique-presentation-of-asymptomatic-bacteriuria-vertebral2026-10-06 https://evidence-hub.com/study/13921-euglycaemic-diabetic-ketoacidosis-in-a-patient-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13922-exploring-the-impact-of-sodium-glucose-cotransporter-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/13923-euglycaemic-diabetic-ketoacidosis-in-a-43-year-old-woman-with-type-22026-10-06 https://evidence-hub.com/study/13924-severe-atypical-ketoacidosis-due-to-sglt2-inhibitor-therapy-two-case2026-10-06 https://evidence-hub.com/study/13925-efficacy-and-safety-of-sglt2-inhibitors-in-the-treatment-of-maturity2026-10-06 https://evidence-hub.com/study/13926-ketogenic-diet-as-a-trigger-for-diabetic-euglycaemic-ketoacidosis-in2026-10-06 https://evidence-hub.com/study/13927-live-birth-after-vitrification-of-oocytes-from-capacitation-in-vitro2026-10-06 https://evidence-hub.com/study/13928-case-report-additional-variants-induced-sudden-cardiac-death-among2026-10-06 https://evidence-hub.com/study/13929-2449-treatment-of-chronic-hypomagnesemia-with-sglt2-inhibitor-in-a2026-10-06 https://evidence-hub.com/study/13930-euglycemic-diabetic-ketoacidosis-in-type-2-diabetes-mellitus-patients2026-10-06 https://evidence-hub.com/study/13931-hidden-risk-of-euglycemic-diabetic-ketoacidosis-with-sodium-glucose2026-10-06 https://evidence-hub.com/study/13932-unmasking-type-1-diabetes-mellitus-following-an-episode-of-euglycemic2026-10-06 https://evidence-hub.com/study/13933-emphysematous-kidney-related-to-the-use-of-empagliflozin-in-a2026-10-06 https://evidence-hub.com/study/13934-effect-of-sodium-glucose-co-transporter-2-inhibitor-empagliflozin-on2026-10-06 https://evidence-hub.com/study/13935-euglycemic-diabetic-ketoacidosis-triggered-by-sepsis-in-a-patient-on2026-10-06 https://evidence-hub.com/study/13936-the-deadly-combination-of-a-keto-diet-and-sglt-2-inhibitors-a-case-of2026-10-06 https://evidence-hub.com/study/13937-empagliflozin-induced-acute-pancreatitis-and-euglycemic-diabetic2026-10-06 https://evidence-hub.com/study/13938-myopathy-secondary-to-empagliflozin-therapy-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13939-euglycemic-ketoacidosis-complicating-empagliflozin-therapy-in-a2026-10-06 https://evidence-hub.com/study/13940-p0580acute-interstitial-nephritis-related-to-empagliflozin2026-10-06 https://evidence-hub.com/study/13941-a-case-of-diabetic-ketoacidosis-in-a-patient-on-an-sglt2-inhibitor2026-10-06 https://evidence-hub.com/study/13942-use-of-sglt2-inhibition-in-the-management-of-hyponatremia-in-a2026-10-06 https://evidence-hub.com/study/13943-fournier-s-gangrene-and-sodium-glucose-co-transporter-2-inhibitors-a2026-10-06 https://evidence-hub.com/study/13944-combined-lactic-acidosis-and-ketoacidosis-in-a-female-diabetic2026-10-06 https://evidence-hub.com/study/13945-peri-procedural-ketoacidosis-risk-with-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/13946-sglt2-inhibitors-and-perioperative-euglycemic-diabetic-ketoacidosis2026-10-06 https://evidence-hub.com/study/13948-rapid-onset-diabetic-ketoacidosis-secondary-to-nivolumab-therapy2026-10-06 https://evidence-hub.com/study/13949-odp130-zoledronate-induced-acute-tubular-necrosis-with-baseline2026-10-06 https://evidence-hub.com/study/13950-bitter-sweet-fournier-s-gangrene-and-sglt2-inhibitors2026-10-06 https://evidence-hub.com/study/13951-mitochondrial-diabetes-treated-with-a-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/13952-patient-not-adequately-controlled-with-insulin-therapy-and2026-10-06 https://evidence-hub.com/study/13953-differing-efficacy-of-dapagliflozin-versus-empagliflozin-on-the-risk2026-10-06 https://evidence-hub.com/study/13954-effect-of-newly-approved-medications-sacubitril-valsartan2026-10-06 https://evidence-hub.com/study/13955-syndrome-of-inappropriate-antidiuresis-from-pathophysiology-to2026-10-06 https://evidence-hub.com/study/13956-renoprotective-effects-of-sodium-glucose-cotransporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/13957-cardiovascular-outcomes-of-new-medications-for-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13958-sodium-glucose-cotransporter-2-inhibitors-in-the-treatment-of2026-09-29 https://evidence-hub.com/study/13959-risks-associated-with-sglt2-inhibitors-an-overview2026-10-06 https://evidence-hub.com/study/13960-redox-driven-cardioprotective-effects-of-sodium-glucose-co2026-10-06 https://evidence-hub.com/study/13961-the-beneficial-hemodynamic-actions-of-sglt-2-inhibitors-beyond-the2026-10-06 https://evidence-hub.com/study/13962-mitochondria-mediated-cardiovascular-benefits-of-sodium-glucose-co2026-10-06 https://evidence-hub.com/study/13963-sglt-2-inhibitor-use-in-heart-failure-a-review-for-nurses2026-10-06 https://evidence-hub.com/study/13964-cardiovascular-protection-in-type-2-diabetes-insights-from-recent2026-10-06 https://evidence-hub.com/study/13965-positioning-sglt2-inhibitors-incretin-based-therapies-in-the2026-10-06 https://evidence-hub.com/study/13966-sglt2-inhibitors-and-metformin-dual-antihyperglycemic-therapy-and-the2026-10-06 https://evidence-hub.com/study/13967-ramping-glucosuria-for-management-of-type-2-diabetes-mellitus-an2026-10-06 https://evidence-hub.com/study/13968-empagliflozin-diabetes-and-outcomes2026-10-06 https://evidence-hub.com/study/13969-pleiotropic-effects-of-sglt2-inhibitors-a-focus-on-macrophage2026-10-06 https://evidence-hub.com/study/13970-canagliflozin-and-amputation-risk-evidence-so-far2026-10-06 https://evidence-hub.com/study/13971-impact-of-sglt-inhibitors-on-multiple-organ-defects-in-diabetes2026-10-06 https://evidence-hub.com/study/13972-emerging-roles-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/13973-sodium-glucose-co-transporter-2-inhibitors-in-heart-failure-with2026-10-06 https://evidence-hub.com/study/13974-pharmacological-aspects-of-the-safety-of-gliflozins2026-10-06 https://evidence-hub.com/study/13975-the-empa-reg-outcome-study-critical-appraisal-and-potential-clinical2026-10-01 https://evidence-hub.com/study/13976-novel-therapeutic-approaches-in-diabetes2026-09-27 https://evidence-hub.com/study/13977-advancing-pharmacotherapy-for-diabetic-foot-ulcers2026-10-06 https://evidence-hub.com/study/13978-cardiovascular-safety-of-therapies-for-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13979-sglt2-inhibition-efficacy-and-safety-in-type-2-diabetes-treatment2026-10-06 https://evidence-hub.com/study/13980-news-in-diabetology-20162026-10-06 https://evidence-hub.com/study/13981-cardiovascular-outcomes-with-the-use-of-sodium-glucose-cotransporter2026-10-06 https://evidence-hub.com/study/13982-the-use-of-sodium-glucose-cotransporter-2-inhibitors-in-patients-with2026-10-06 https://evidence-hub.com/study/13983-empagliflozin-in-the-treatment-of-heart-failure2026-10-06 https://evidence-hub.com/study/13984-cardiovascular-protection-with-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/13985-sglt2-inhibitors-their-potential-reduction-in-blood-pressure2026-10-06 https://evidence-hub.com/study/13986-impact-of-empa-reg-outcome-on-the-management-of-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13987-exploring-the-therapeutic-potential-of-sglt-2-inhibitors-in-managing2026-10-06 https://evidence-hub.com/study/13988-empagliflozin-linagliptin-a-review-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/13989-a-year-in-heart-failure-an-update-of-recent-findings2026-10-06 https://evidence-hub.com/study/13990-the-new-hope-study-and-emerging-therapies-for-difficult-to-control2026-10-06 https://evidence-hub.com/study/13991-antihypertensive-and-renal-mechanisms-of-sglt2-sodium-glucose-linked2026-10-06 https://evidence-hub.com/study/13992-management-of-diabetes-mellitus-in-patients-undergoing-liver2026-10-06 https://evidence-hub.com/study/13993-bolstering-your-armamentarium-with-sglt2-inhibitors2026-10-06 https://evidence-hub.com/study/13994-sglt-inhibitors-in-management-of-diabetes2026-10-06 https://evidence-hub.com/study/13995-empagliflozin-a-new-treatment-option-for-patients-with-type-22026-10-06 https://evidence-hub.com/study/13996-sglt2-inhibitors-and-cardioprotection-a-matter-of-debate-and-multiple2026-10-06 https://evidence-hub.com/study/13997-update-on-cardiovascular-effects-of-older-and-newer-anti-diabetic2026-10-06 https://evidence-hub.com/study/13998-the-cardiovascular-phenotype-impact-on-choice-of-glucose-lowering2026-10-06 https://evidence-hub.com/study/13999-novel-therapeutic-options-in-patients-with-type-2-diabetes-and-high2026-10-06 https://evidence-hub.com/study/14000-sglt2-inhibitors-a-review-of-their-antidiabetic-and-cardioprotective2026-10-06 https://evidence-hub.com/study/14001-effects-of-sglt2-inhibitors-on-cardiac-structure-and-function2026-10-06 https://evidence-hub.com/study/14002-functional-and-clinical-importance-of-sglt2-inhibitors-in-frailty2026-10-06 https://evidence-hub.com/study/14003-effects-of-covid-19-on-the-nervous-system2026-10-06 https://evidence-hub.com/study/14004-new-drugs-for-the-treatment-of-chronic-heart-failure-with-a-reduced2026-10-06 https://evidence-hub.com/study/14005-the-potential-role-and-rationale-for-treatment-of-heart-failure-with2026-10-06 https://evidence-hub.com/study/14006-updates-on-cardiovascular-outcome-trials-in-diabetes2026-10-06 https://evidence-hub.com/study/14007-metabolic-and-hemodynamic-effects-of-sodium-dependent-glucose2026-10-06 https://evidence-hub.com/study/14008-sodium-glucose-cotransporter-2-inhibitors-sglt2i-their-role-in2026-10-06 https://evidence-hub.com/study/14009-a-safety-evaluation-of-empagliflozin-plus-linagliptin-for-treating2026-10-06 https://evidence-hub.com/study/14010-sodium-glucose-co-transporter-2-inhibitors-in-patients-with-chronic2026-10-06 https://evidence-hub.com/study/14011-the-mechanisms-and-therapeutic-potential-of-sglt2-inhibitors-in2026-10-06 https://evidence-hub.com/study/14012-the-effect-of-sglt2-inhibitors-on-cardiovascular-events-and-renal2026-10-06 https://evidence-hub.com/study/14013-empagliflozin-for-the-treatment-of-type-2-diabetes2026-10-06 https://evidence-hub.com/study/14014-sglt-2-inhibitors-ideal-remedy-for-cardioprotection-in-diabetes2026-10-06 https://evidence-hub.com/study/14015-new-possibility-in-the-oral-glucose-lowering-treatment-of-type-22026-10-06 https://evidence-hub.com/study/14016-use-of-sglt-2-inhibitors-in-the-treatment-of-type-2-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/14017-sodium-glucose-cotransporter-2-inhibitors-in-patients-with-non2026-10-06 https://evidence-hub.com/study/14018-new-hypoglycemic-agents-and-the-kidney-what-do-the-major-trials-tell2026-10-06 https://evidence-hub.com/study/14019-a-comprehensive-review-of-the-pharmacodynamics-of-the-sglt2-inhibitor2026-10-01 https://evidence-hub.com/study/14020-camkii-and-glut1-in-heart-failure-and-the-role-of-gliflozins2026-10-06 https://evidence-hub.com/study/14021-leptin-cardiovascular-diseases-and-type-2-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/14022-a-safety-evaluation-of-empagliflozin-for-the-treatment-of-type-22026-10-06 https://evidence-hub.com/study/14023-paradigm-shift-in-heart-failure-treatment-are-cardiologists-ready-to2026-10-06 https://evidence-hub.com/study/14024-novel-antidiabetic-drugs-and-cardiovascular-risk-primum-non-nocere2026-10-06 https://evidence-hub.com/study/14025-the-evolving-landscape-of-pulmonary-hypertension-treatment-from2026-10-06 https://evidence-hub.com/study/14026-the-oxidative-stress-paradigm-in-arbovirus-infections-mechanisms-and2026-10-06 https://evidence-hub.com/study/14027-a-clinical-review-of-the-connections-between-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/14028-myocardial-fibrosis-and-glycolysis-a-bibliometric-study-and2026-10-06 https://evidence-hub.com/study/14029-autologous-cell-therapy-for-chronic-limb-threatening-ischemia-towards2026-10-06 https://evidence-hub.com/study/14030-narrative-review-investigating-the-nephroprotective-mechanisms-of2026-10-06 https://evidence-hub.com/study/14031-physiological-conditions-bioactive-ingredients-and-drugs-stimulating2026-10-08 https://evidence-hub.com/study/14032-the-changes-of-cardiac-energy-metabolism-with-sodium-glucose2026-10-06 https://evidence-hub.com/study/14033-dapagliflozin-across-the-range-of-ejection-fraction-in-patients-with2026-10-01 https://evidence-hub.com/study/14034-effect-of-sglt2-inhibitors-on-cardiovascular-renal-and-safety2026-10-01 https://evidence-hub.com/study/14035-lower-extremity-arterial-disease-in-patients-with-diabetes-a2026-10-01 https://evidence-hub.com/study/14036-sodium-glucose-cotransporter-2-inhibition-for-the-prevention-of2026-10-01 https://evidence-hub.com/study/14037-efficacy-and-safety-of-sglt-2-inhibitors-for-treatment-of-diabetes2026-10-01 https://evidence-hub.com/study/14038-cardiovascular-effects-of-dapagliflozin-in-patients-with-type-22026-09-27 https://evidence-hub.com/study/14040-prevalence-of-cardiovascular-disease-in-type-2-diabetes-a-systematic2026-10-01 https://evidence-hub.com/study/14041-sodium-glucose-cotransporter-protein-2-sglt-2-inhibitors-and-glucagon2026-10-01 https://evidence-hub.com/study/14042-the-effects-of-cardioprotective-antidiabetic-therapy-on-microbiota-in2026-10-04 https://evidence-hub.com/study/14043-association-of-sglt2-inhibitors-with-cardiovascular-kidney-and-safety2026-10-01 https://evidence-hub.com/study/14044-sglt2-inhibitors-decrease-cardiovascular-death-and-heart-failure2026-10-01 https://evidence-hub.com/study/14046-efficacy-and-safety-of-the-glucagon-like-peptide-1-receptor-agonist2026-09-27 https://evidence-hub.com/study/14049-effects-of-sglt2-inhibitors-on-stroke-and-its-subtypes-in-patients2026-10-01 https://evidence-hub.com/study/14050-dapagliflozin-binds-specifically-to-sodium-glucose-cotransporter-2-in2026-10-06 https://evidence-hub.com/study/14051-a-validated-lc-ms-ms-method-for-the-determination-of-canagliflozin-a2026-10-06 https://evidence-hub.com/study/14052-differential-sex-dependent-susceptibility-to-diastolic-dysfunction2026-10-06 https://evidence-hub.com/study/14053-empagliflozin-attenuates-cardiac-microvascular-ischemia-reperfusion2026-10-01 https://evidence-hub.com/study/14054-empagliflozin-plays-vasoprotective-role-in-spontaneously-hypertensive2026-10-06 https://evidence-hub.com/study/14055-empagliflozin-protects-against-heart-failure-with-preserved-ejection2026-10-06 https://evidence-hub.com/study/14056-empagliflozin-protects-mice-against-diet-induced-obesity-insulin2026-10-06 https://evidence-hub.com/study/14057-mitochondria-targeted-liposomes-boost-thermogenesis-for-adipose2026-10-06 https://evidence-hub.com/study/14058-empagliflozin-mitigates-type-2-diabetes-associated-peripheral2026-10-04 https://evidence-hub.com/study/14059-empagliflozin-alleviates-hepatic-steatosis-and-oxidative-stress-via2026-10-06 https://evidence-hub.com/study/14060-using-the-intravesical-delivery-route-to-target-the-kidney2026-10-06 https://evidence-hub.com/study/14061-effects-of-npy-2-receptor-antagonists-semaglutide-pyy3-36-and2026-10-06 https://evidence-hub.com/study/14062-empagliflozin-downregulates-amp-activated-protein-kinase-o2026-10-06 https://evidence-hub.com/study/14063-empagliflozin-enhances-metabolic-efficiency-and-improves-left2026-10-06 https://evidence-hub.com/study/14064-sglt2-inhibition-mediates-protection-from-diabetic-kidney-disease-by2026-10-01 https://evidence-hub.com/study/14065-unraveling-the-potential-of-empagliflozin-to-counteract-1-22026-10-06 https://evidence-hub.com/study/14066-a-high-sugar-diet-induced-animal-model-for-insulin-resistance2026-10-06 https://evidence-hub.com/study/14067-empagliflozin-an-inhibitor-of-sodium-glucose-cotransporter-2-exerts2026-10-04 https://evidence-hub.com/study/14068-initiating-empagliflozin-and-sacubitril-valsartan-early-after-acute2026-10-06 https://evidence-hub.com/study/14069-pre-ischaemic-empagliflozin-treatment-attenuates-blood-brain-barrier2026-10-06 https://evidence-hub.com/study/14070-regression-of-diabetic-nephropathy-by-treatment-with-empagliflozin-in2026-10-06 https://evidence-hub.com/study/14071-empagliflozin-targets-mfn1-and-opa1-to-attenuate-microglia-mediated2026-10-04 https://evidence-hub.com/study/14072-glucose-lowering-by-sglt2-inhibitor-empagliflozin-accelerates2026-10-01 https://evidence-hub.com/study/14073-empagliflozin-alleviates-left-ventricle-hypertrophy-in-high-fat-fed2026-10-06 https://evidence-hub.com/study/14074-empagliflozin-rescues-pro-arrhythmic-and-ca2-homeostatic-effects-of2026-10-06 https://evidence-hub.com/study/14075-renoprotective-effects-of-empagliflozin-in-high-fat-diet-induced2026-10-06 https://evidence-hub.com/study/14076-characterization-of-14-3-3-isoforms-expressed-in-the-echinococcus2026-10-06 https://evidence-hub.com/study/14077-empagliflozin-prevent-high-glucose-stimulation-inducing-apoptosis-and2026-10-06 https://evidence-hub.com/study/14078-multiparametric-cardiac-magnetic-resonance-identifies-macrophage2026-10-06 https://evidence-hub.com/study/14079-alterations-of-myocardial-ketone-metabolism-in-heart-failure-with2026-10-06 https://evidence-hub.com/study/14080-empagliflozin-improves-cardiac-mitochondrial-function-and-survival2026-10-06 https://evidence-hub.com/study/14081-sodium-glucose-transporter-2-inhibitor-protects-against-heart-failure2026-10-06 https://evidence-hub.com/study/14082-blockade-of-cannabinoid-cb1-receptors-potentiates-the-anti-fibrotic2026-10-06 https://evidence-hub.com/study/14083-novel-cardioprotective-mechanism-for-empagliflozin-in-nondiabetic2026-10-06 https://evidence-hub.com/study/14084-empaglifozin-mitigates-nafld-in-high-fat-fed-mice-by-alleviating2026-10-06 https://evidence-hub.com/study/14085-empagliflozin-relaxes-resistance-mesenteric-arteries-by-stimulating2026-10-06 https://evidence-hub.com/study/14086-cardioprotective-effects-of-short-term-empagliflozin-treatment-in-db2026-10-06 https://evidence-hub.com/study/14087-biochemical-and-histopathological-evidence-for-beneficial-effects-of2026-10-06 https://evidence-hub.com/study/14088-agomelatine-and-empagliflozin-synergistically-protect-against2026-10-06 https://evidence-hub.com/study/14089-empagliflozin-attenuates-ischemia-and-reperfusion-injury-through-lkb12026-10-06 https://evidence-hub.com/study/14090-empagliflozin-reduces-vascular-damage-and-cognitive-impairment-in-a2026-10-04 https://evidence-hub.com/study/14091-capryol-ethyl-oleate-self-microemulsifying-system-for-improved2026-10-06 https://evidence-hub.com/study/14092-empagliflozin-and-naringenin-mitigate-cisplatin-induced-testicular2026-10-06 https://evidence-hub.com/study/14093-pharmacological-increases-in-circulating-ketones-fail-to-alleviate2026-10-06 https://evidence-hub.com/study/14094-targeting-oxidative-stress-proinflammatory-cytokines-apoptosis-and2026-10-06 https://evidence-hub.com/study/14095-the-sglt2-inhibitor-empagliflozin-negatively-regulates-il-17-il-232026-09-27 https://evidence-hub.com/study/14096-empagliflozin-ameliorates-bleomycin-induced-pulmonary-fibrosis-in2026-10-06 https://evidence-hub.com/study/14097-empagliflozin-preserves-skeletal-muscle-function-in-a-hfpef-rat-model2026-10-01 https://evidence-hub.com/study/14098-ameliorative-effect-of-empagliflozin-and-linagliptin-on-cisplatin2026-10-06 https://evidence-hub.com/study/14099-empagliflozin-as-a-potential-therapy-for-pcos-restoring-hormonal2026-10-06 https://evidence-hub.com/study/14100-empagliflozin-decreases-ageing-associated-arterial-stiffening-and2026-10-06 https://evidence-hub.com/study/14101-empagliflozin-restores-cardiac-metabolism-and-suppresses-immune2026-10-06 https://evidence-hub.com/study/14102-metabolomics-study-reveals-the-alteration-of-fatty-acid-oxidation-in2026-10-06 https://evidence-hub.com/study/14103-empagliflozin-attenuates-ferroptosis-in-acute-myocardial-infarction2026-10-06 https://evidence-hub.com/study/14104-acute-effects-of-empagliflozin-on-open-loop-baroreflex-function-and2026-10-06 https://evidence-hub.com/study/14105-empagliflozin-alleviates-diabetes-induced-cognitive-impairments-by2026-10-06 https://evidence-hub.com/study/14106-two-hit-mouse-model-of-heart-failure-with-preserved-ejection-fraction2026-10-06 https://evidence-hub.com/study/14107-empagliflozin-improves-cardiac-function-in-rats-with-chronic-heart2026-10-06 https://evidence-hub.com/study/14108-canagliflozin-inhibits-electrogenic-na-transport-in-mouse-cortical2026-10-06 https://evidence-hub.com/study/14109-empagliflozin-alleviates-the-development-of-autoimmune-myocarditis2026-10-06 https://evidence-hub.com/study/14110-nascent-shifts-in-renal-cellular-metabolism-structure-and-function2026-10-06 https://evidence-hub.com/study/14111-empagliflozin-mitigates-methotrexate-induced-hepatotoxicity-targeting2026-10-06 https://evidence-hub.com/study/14112-anti-inflammatory-properties-of-the-sglt2-inhibitor-empagliflozin-in2026-10-01 https://evidence-hub.com/study/14113-empagliflozin-slows-down-natural-kidney-senescence-via-six1-wnt4-nf-b2026-10-06 https://evidence-hub.com/study/14114-a-metabonomics-based-renoprotective-mechanism-analysis-of2026-10-06 https://evidence-hub.com/study/14115-empagliflozin-improves-cardiac-function-in-heart-failure-with-reduced2026-10-06 https://evidence-hub.com/study/14116-empagliflozin-reduces-left-ventricular-mass-increase-and-improves2026-10-06 https://evidence-hub.com/study/14117-sglt2-i-improves-markers-of-islet-endothelial-cell-function-in-db-db2026-10-06 https://evidence-hub.com/study/14118-protective-effects-of-empagliflozin-on-methotrexate-induced2026-10-06 https://evidence-hub.com/study/14119-empagliflozin-beyond-antidiabetic-effect-amelioration-of2026-10-06 https://evidence-hub.com/study/14120-empagliflozin-pretreated-mesenchymal-stem-cell-derived-small2026-10-06 https://evidence-hub.com/study/14121-empagliflozin-inhibits-neuronal-ferroptosis-induced-by-oxygen-glucose2026-10-06 https://evidence-hub.com/study/14122-empagliflozin-significantly-prevents-the-doxorubicin-induced-acute2026-10-06 https://evidence-hub.com/study/14123-metformin-empagliflozin-and-their-combination-modulate-ex-vivo2026-10-08 https://evidence-hub.com/study/14124-empagliflozin-mitigates-ponatinib-induced-cardiotoxicity-by-restoring2026-10-06 https://evidence-hub.com/study/14125-empagliflozin-improves-metabolism-and-prevents-myocardial-and2026-10-06 https://evidence-hub.com/study/14126-mechanism-of-jiming-powder-in-ameliorating-heart-failure-with2026-10-06 https://evidence-hub.com/study/14127-combining-sodium-glucose-co-transporter-2-inhibitor-with-mesenchymal2026-10-06 https://evidence-hub.com/study/14128-empagliflozin-inhibits-cadmium-induced-hepatic-cell-apoptosis-through2026-10-06 https://evidence-hub.com/study/14129-crucial-role-for-sensory-nerves-and-na-h-exchanger-inhibition-in2026-10-06 https://evidence-hub.com/study/14130-the-impact-of-aircraft-noise-exposure-on-the-efficacy-of2026-10-04 https://evidence-hub.com/study/14131-sglt2-inhibitor-empagliflozin-prevents-anthracycline-induced2026-10-09 https://evidence-hub.com/study/14132-sglt2i-therapy-prevents-anthracycline-induced-cardiotoxicity-in-a2026-10-06 https://evidence-hub.com/study/14136-effect-of-sodium-glucose-cotransporter-2-inhibitor-empagliflozin-and2026-10-04 https://evidence-hub.com/study/14137-the-influence-of-empagliflozin-on-the-expression-of-mitochondrial2026-10-06 https://evidence-hub.com/study/14138-p0101inhibition-of-tumor-necrosis-factor-alpha-enhanced-antifibrotic2026-10-06 https://evidence-hub.com/study/14139-993-the-molecular-effects-of-sglt2i-empagliflozin-on-klotho-and2026-10-06 https://evidence-hub.com/study/14140-lack-of-evidence-for-improved-adrenoceptor-mediated-papillary-muscle2026-10-06 https://evidence-hub.com/study/14141-therapeutic-effects-of-lisinopril-and-empagliflozin-in-a-mouse-model2026-10-04 https://evidence-hub.com/study/14142-elucidation-of-glomerular-hemodynamic-changes-by-sglt-2-inhibitors2026-10-06 https://evidence-hub.com/study/14143-the-molecular-effect-of-empagliflozin-sglt2i-on-the-autophagy-pathway2026-10-06 https://evidence-hub.com/study/14144-the-effects-of-low-dose-empagliflozin-on-cardiac-function-in-a-rat2026-10-01 https://evidence-hub.com/study/14145-the-potential-neuroprotective-effect-of-empagliflozin-against2026-10-06 https://evidence-hub.com/study/14146-innovative-insights-into-the-effects-of-a-high-sucrose-diet-on2026-10-06 https://evidence-hub.com/study/14147-intranasal-empagliflozin-modulates-synaptic-plasticity-in-migraine2026-10-06 https://evidence-hub.com/study/14148-effect-of-metformin-and-empagliflozin-on-adiponectin-and-leptin2026-10-04 https://evidence-hub.com/study/14149-empagliflozin-attenuates-epithelial-to-mesenchymal-transition-through2026-10-06 https://evidence-hub.com/study/14150-empagliflozin-mitigates-depression-like-behavior-in-diabetic-mice-via2026-10-08 https://evidence-hub.com/study/14151-interference-with-the-ampk-mtor-nlrp3-signaling-and-the-il-23-il-172026-10-08 https://evidence-hub.com/study/14152-empagliflozin-an-sglt2-inhibitor-reduced-the-mortality-rate-after2026-10-01 https://evidence-hub.com/study/14154-empagliflozin-a-novel-potent-and-selective-sglt-2-inhibitor-improves2026-09-27 https://evidence-hub.com/study/14155-abstract-4139791-a-short-version-of-hfd-l-name-mouse-model-enabling2026-10-06 https://evidence-hub.com/study/14156-effects-of-empagliflozin-on-salt-sensitive-hypertension-and-renal2026-10-06 https://evidence-hub.com/study/14157-long-term-treatment-with-empagliflozin-attenuates-renal-damage-in2026-10-06 https://evidence-hub.com/study/14158-abstract-wed092-embracing-the-complex-pathophysiology-of-heart2026-10-06 https://evidence-hub.com/study/14160-1071-the-effect-and-mechanism-of-sglt2-inhibitor-on-improving2026-10-06 https://evidence-hub.com/study/14161-a32-empaglifozin-improves-gastrointestinal-inflammation-in-a-mouse2026-10-06 https://evidence-hub.com/study/14162-diabetes-and-excess-aldosterone-promote-heart-failure-with-preserved2026-10-06 https://evidence-hub.com/study/14163-translational-prediction-of-first-in-human-pharmacokinetics-and2026-10-06 https://evidence-hub.com/study/14164-empagliflozin-targeting-stat3-akt-nrf2-axis-promoting-diabetic-wound2026-10-06 https://evidence-hub.com/study/14165-feeding-time-dependent-changes-in-the-preventive-effect-of2026-10-06 https://evidence-hub.com/study/14166-a272-effects-of-empagliflozin-on-chemically-induced-colitis-in-a2026-10-06 https://evidence-hub.com/study/14167-1299-the-sglt2-inhibitor-canagliflozin-but-not-dapagliflozin-or2026-10-06 https://evidence-hub.com/study/14168-combined-empagliflozin-and-sacubitril-valsartan-therapy-additively2026-10-06 https://evidence-hub.com/study/14169-empagliflozin-halts-nlrp3-inflammasome-mediated-neurodegeneration-in2026-10-06 https://evidence-hub.com/study/14170-dual-empagliflozin-and-sacubitril-valsartan-therapy-improves-ex-vivo2026-10-06 https://evidence-hub.com/study/14171-empagliflozin-in-combination-with-trandolapril-but-not-with-triple2026-10-06 https://evidence-hub.com/study/14172-empagliflozin-attenuates-post-injury-myocardial-remodeling-in-a-rat2026-10-06 https://evidence-hub.com/study/14173-empagliflozin-attenuates-cardiac-fibrosis-via-suppression-of-tlr2-nf2026-10-06 https://evidence-hub.com/study/14174-effects-of-empagliflozin-on-a-model-of-chronic-depression-and-brain2026-10-06 https://evidence-hub.com/study/14175-empagliflozin-promotes-structural-and-functional-recovery-through2026-10-06 https://evidence-hub.com/study/14176-empagliflozin-attenuates-cardiac-dysfunction-in-rat-model-of2026-10-06 https://evidence-hub.com/study/14177-effects-of-finerenone-combined-with-empagliflozin-in-a-model-of2026-10-01 https://evidence-hub.com/study/14178-in-a-prediabetic-model-empagliflozin-improves-hepatic-lipid2026-10-04 https://evidence-hub.com/study/14179-effect-of-sacubitril-valsartan-and-empagliflozin-on-systemic2026-10-06 https://evidence-hub.com/study/14180-empagliflozin-improves-metabolic-and-hepatic-outcomes-in-a-non2026-10-01 https://evidence-hub.com/study/14181-antihypertensive-and-metabolic-effects-of-empagliflozin-in-ren-22026-10-06 https://evidence-hub.com/study/14182-empagliflozin-ameliorates-symptoms-of-diabetes-and-renal-tubular2026-10-06 https://evidence-hub.com/study/14183-empagliflozin-attenuates-renal-fibrosis-through-the-dsba-l-cassting2026-10-06 https://evidence-hub.com/study/14184-neuroprotective-effects-of-empagliflozin-against-scopolamine-induced2026-10-06 https://evidence-hub.com/study/14185-effects-of-empagliflozin-and-target-organ-damage-in-a-novel-rodent2026-10-04 https://evidence-hub.com/study/14187-empagliflozin-improves-left-ventricular-diastolic-dysfunction-in-a2026-10-06 https://evidence-hub.com/study/14188-effects-of-empagliflozin-on-gonadal-functions-of-hyperglycemic-male2026-10-04 https://evidence-hub.com/study/14189-empagliflozin-and-pirfenidone-confer-renoprotection-through2026-10-06 https://evidence-hub.com/study/14190-empagliflozin-reduces-renal-calcium-oxalate-deposition-in2026-10-06 https://evidence-hub.com/study/14191-empagliflozin-protects-against-indomethacin-plus-pyloric-ligation2026-10-06 https://evidence-hub.com/study/14192-cardioprotective-effects-of-empagliflozin-in-cardiac-volume-overload2026-10-06 https://evidence-hub.com/study/14193-empagliflozin-an-sglt2-inhibitor-alone-or-in-combination-with2026-10-04 https://evidence-hub.com/study/14194-empagliflozin-attenuates-global-cerebral-ischemic-injury-after2026-10-06 https://evidence-hub.com/study/14196-sglt2-inhibition-with-empagliflozin-improves-coronary-microvascular2026-10-01 https://evidence-hub.com/study/14197-empagliflozin-inhibits-na-h-exchanger-activity-in-human-atrial2026-10-04 https://evidence-hub.com/study/14199-renal-hemodynamic-effect-of-sodium-glucose-cotransporter-2-inhibition2026-10-01 https://evidence-hub.com/study/14200-load-independent-effects-of-empagliflozin-contribute-to-improved2026-10-01 https://evidence-hub.com/study/14201-empagliflozin-improves-diastolic-function-in-a-nondiabetic-rodent2026-10-01 https://evidence-hub.com/study/14202-the-sodium-glucose-co-transporter-2-inhibitor-empagliflozin2026-10-01 https://evidence-hub.com/study/14203-empagliflozin-normalizes-the-size-and-number-of-mitochondria-and2026-10-01 https://evidence-hub.com/study/14205-empagliflozin-limits-myocardial-infarction-in-vivo-and-cell-death-in2026-10-04 https://evidence-hub.com/study/14206-empagliflozin-improved-systolic-blood-pressure-endothelial2026-10-01 https://evidence-hub.com/study/14207-effect-of-canagliflozin-on-renal-threshold-for-glucose-glycemia-and2026-10-01 https://evidence-hub.com/study/14208-once-daily-administration-of-the-sglt2-inhibitor-empagliflozin2026-10-04 https://evidence-hub.com/study/14209-early-administration-of-empagliflozin-preserved-heart-function-in2026-10-01 https://evidence-hub.com/study/14210-empagliflozin-inhibits-excessive-autophagy-through-the-ampk-gsk32026-10-04 https://evidence-hub.com/study/14211-unraveling-the-molecular-mechanism-of-action-of-empagliflozin-in2026-10-01 https://evidence-hub.com/study/14212-empagliflozin-prevents-cardiomyopathy-via-sgc-cgmp-pkg-pathway-in2026-10-01 https://evidence-hub.com/study/14213-empagliflozin-reduces-podocyte-lipotoxicity-in-experimental-alport2026-10-04 https://evidence-hub.com/study/14215-empagliflozin-is-associated-with-improvements-in-liver-enzymes2026-10-04 https://evidence-hub.com/study/14216-anti-inflammatory-effects-of-empagliflozin-and-gemigliptin-on-lps2026-10-01 https://evidence-hub.com/study/14217-delayed-ischaemic-contracture-onset-by-empagliflozin-associates-with2026-09-27 https://evidence-hub.com/study/14218-empagliflozin-protects-the-heart-against-ischemia-reperfusion-induced2026-10-01 https://evidence-hub.com/study/14220-liraglutide-and-cardiovascular-outcomes-in-type-2-diabetes2026-10-01 https://evidence-hub.com/study/14221-off-target-effects-of-sodium-glucose-co-transporter-2-blockers2026-10-01 https://evidence-hub.com/study/14222-empagliflozin-reduces-renal-hyperfiltration-in-response-to2026-10-04 https://evidence-hub.com/study/14223-the-effects-of-empagliflozin-an-sglt2-inhibitor-on-pancreatic-cell2026-10-04 https://evidence-hub.com/study/14224-empagliflozin-maintains-capillarization-and-improves-cardiac-function2026-10-01 https://evidence-hub.com/study/14225-empagliflozin-and-liraglutide-differentially-modulate-cardiac2026-10-04 https://evidence-hub.com/study/14227-empagliflozin-alleviates-atherosclerosis-progression-by-inhibiting2026-10-04 https://evidence-hub.com/study/14228-direct-blood-pressure-independent-anti-fibrotic-effects-by-the2026-10-01 https://evidence-hub.com/study/14229-empagliflozin-modulates-renal-sympathetic-and-heart-rate-baroreflexes2026-10-01 https://evidence-hub.com/study/14230-supplemented-gegen-qinlian-decoction-formula-attenuates-podocyte2026-10-06 https://evidence-hub.com/study/14231-empagliflozin-and-the-diabetic-kidney-pathophysiological-concepts-and2026-10-06 https://evidence-hub.com/study/14232-empagliflozin-alleviates-iron-accumulation-and-ferroptosis-to2026-10-06 https://evidence-hub.com/study/14233-effects-of-empagliflozin-on-vascular-and-skeletal-mineralization-in2026-10-06 https://evidence-hub.com/study/14234-empagliflozin-supplementation-in-cardioplegic-solution-improves-donor2026-10-06 https://evidence-hub.com/study/14235-empagliflozin-alleviates-myocardial-i-r-injury-and-cardiomyocyte2026-09-27 https://evidence-hub.com/study/14236-empagliflozin-attenuates-trastuzumab-induced-cardiotoxicity-through2026-09-27 https://evidence-hub.com/study/14237-empagliflozin-alleviates-ethanol-induced-cardiomyocyte-injury-through2026-10-06 https://evidence-hub.com/study/14238-empagliflozin-alleviates-obesity-related-cardiac-dysfunction-via-the2026-10-06 https://evidence-hub.com/study/14239-oral-empagliflozin-loaded-tri-layer-core-sheath-fibers-fabricated2026-10-04 https://evidence-hub.com/study/14240-empagliflozin-protected-kidney-function-in-ckd-rat-through2026-10-06 https://evidence-hub.com/study/14241-effects-of-empagliflozin-and-dapagliflozin-in-alleviating-cardiac2026-10-01 https://evidence-hub.com/study/14242-angiotensin-ii-induced-redox-sensitive-sglt1-and-2-expression2026-10-06 https://evidence-hub.com/study/14243-empagliflozin-mitigates-high-glucose-disrupted-mitochondrial2026-10-06 https://evidence-hub.com/study/14244-canagliflozin-promotes-osteoblastic-mc3t3-e1-differentiation-via-ampk2026-10-06 https://evidence-hub.com/study/14245-investigation-into-the-role-of-anti-diabetic-agents-in-cachexia2026-10-06 https://evidence-hub.com/study/14246-concomitant-inhibition-of-tlr-4-and-sglt2-by-phloretin-and2026-10-06 https://evidence-hub.com/study/14247-empagliflozin-inhibits-macrophage-inflammation-through-ampk-signaling2026-09-27 https://evidence-hub.com/study/14248-comparison-of-the-effects-of-empagliflozin-and-sotagliflozin-on-a2026-10-04 https://evidence-hub.com/study/14249-empagliflozin-protects-diabetic-pancreatic-tissue-from-damage-by2026-10-01 https://evidence-hub.com/study/14250-empagliflozin-inhibits-neointimal-hyperplasia-through-attenuating2026-10-06 https://evidence-hub.com/study/14251-empagliflozin-containing-chitosan-alginate-nanoparticles-in2026-09-27 https://evidence-hub.com/study/14252-direct-cardiac-actions-of-the-sodium-glucose-co-transporter-22026-10-01 https://evidence-hub.com/study/14253-the-sglt2-inhibitor-empagliflozin-exerts-neuroprotective-effect2026-10-06 https://evidence-hub.com/study/14254-a-simple-but-novel-glycymicelle-ophthalmic-solution-based-on-two2026-09-27 https://evidence-hub.com/study/14255-a-predominant-oxidative-renal-metabolite-of-empagliflozin-in-male2026-10-06 https://evidence-hub.com/study/14256-novel-sodium-hydrogen-exchanger-1-inhibitors-with-diphenyl-ketone2026-10-06 https://evidence-hub.com/study/14257-sglt2-inhibitor-downregulated-oxidative-stress-via-activating-ampk2026-10-06 https://evidence-hub.com/study/14258-empagliflozin-pretreated-bmsc-exosomes-attenuate-myocardial-ischemia2026-10-06 https://evidence-hub.com/study/14260-adipose-derived-proinflammatory-visfatin-promotes-vascular2026-10-06 https://evidence-hub.com/study/14261-psoralen-attenuates-skeletal-muscle-atrophy-in-mice-with-heart2026-10-06 https://evidence-hub.com/study/14262-placental-transfer-characteristics-and-functional-impact-of-sglt22026-10-06 https://evidence-hub.com/study/14263-common-and-distinct-effects-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/14264-effect-of-empagliflozin-on-human-primary-cardiomyocytes-in-a2026-10-06 https://evidence-hub.com/study/14265-the-sodium-glucose-co-transporter-2-inhibitor-empagliflozin2026-10-06 https://evidence-hub.com/study/14266-empagliflozin-preserves-cardiomyocyte-structural-homeostasis-via-the2026-10-06 https://evidence-hub.com/study/14267-heart-saver-comprehensive-investigation-of-redox-proteomic-and-thiol2026-10-06 https://evidence-hub.com/study/14268-sglt2-inhibitors-and-curcumin-co-loaded-liposomal-formulations-as2026-10-06 https://evidence-hub.com/study/14269-empagliflozin-attenuates-renal-damage-in-diabetic-nephropathy-by2026-10-06 https://evidence-hub.com/study/14270-empagliflozin-promotes-skin-flap-survival-by-activating-ampk2026-10-06 https://evidence-hub.com/study/14271-the-effect-of-empagliflozin-on-circulating-endothelial-progenitor2026-10-06 https://evidence-hub.com/study/14272-empagliflozin-attenuating-renal-interstitial-fibrosis-in-diabetic2026-10-06 https://evidence-hub.com/study/14273-mutagenic-and-genotoxic-in-silico-qsar-prediction-of-dimer-impurity2026-09-27 https://evidence-hub.com/study/14274-a-comparative-in-vitro-study-on-the-effect-of-sglt2-inhibitors-on2026-10-06 https://evidence-hub.com/study/14275-preliminary-investigation-of-the-molecular-mechanism-of-empagliflozin2026-10-06 https://evidence-hub.com/study/14276-insulin-resistance-diabetes-and-schizophrenia-potential-shared2026-10-06 https://evidence-hub.com/study/14277-the-sodium-glucose-co-transporter-2-sglt2-inhibitor-empagliflozin2026-10-06 https://evidence-hub.com/study/14278-in-silico-discovery-of-potential-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/14279-differential-in-vitro-effects-of-sglt2-inhibitors-on-mitochondrial2026-10-06 https://evidence-hub.com/study/14280-sglt2-inhibition-reverts-urinary-peptide-changes-associated-with2026-10-01 https://evidence-hub.com/study/14281-angiotensin-ii-induced-upregulation-of-sglt1-and-2-contributes-to2026-10-06 https://evidence-hub.com/study/14282-metabolic-aspects-of-anthracycline-cardiotoxicity2026-10-06 https://evidence-hub.com/study/14283-empagliflozin-regulates-the-adipor1-p-ampk-p-acc-pathway-to-alleviate2026-10-01 https://evidence-hub.com/study/14284-effects-of-secretome-from-fat-tissues-on-ion-currents-of2026-10-06 https://evidence-hub.com/study/14285-empagliflozin-protects-against-proximal-renal-tubular-cell-injury2026-10-06 https://evidence-hub.com/study/14286-empagliflozin-reduces-high-glucose-induced-oxidative-stress-and-mir2026-10-06 https://evidence-hub.com/study/14287-in-silico-repurposing-of-clinically-approved-drugs-as-potential-braf2026-10-04 https://evidence-hub.com/study/14288-comparing-the-long-term-effectiveness-of-sodium-glucose-cotransporter2026-10-06 https://evidence-hub.com/study/14289-neuroprotective-potential-of-sodium-glucose-cotransporter-2-sglt22026-10-08 https://evidence-hub.com/study/14290-colchicine-and-major-adverse-cardiovascular-events-in-patients-with2026-10-06 https://evidence-hub.com/study/14291-network-pharmacology-and-molecular-docking-based-investigation-of2026-10-04 https://evidence-hub.com/study/14292-renal-and-cardiovascular-effects-of-sglt2-inhibitors-among2026-10-06 https://evidence-hub.com/study/14293-investigating-the-research-trajectory-and-future-trends-in-type-22026-10-08 https://evidence-hub.com/study/14294-use-of-glp-1-receptor-agonists-and-sglt2-inhibitors-among-patients2026-10-08 https://evidence-hub.com/study/14295-the-effect-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-on2026-10-06 https://evidence-hub.com/study/14296-comparing-efficacy-and-safety-of-different-aldosterone-synthase2026-10-06 https://evidence-hub.com/study/14297-sodium-glucose-transporter-2-inhibitors-safety-and-efficacy-in2026-10-06 https://evidence-hub.com/study/14298-discovery-of-potent-and-highly-selective-sodium-dependent-glucose2026-10-06 https://evidence-hub.com/study/14299-effect-of-blood-pressure-control-on-cardiovascular-events-in-patients2026-10-06 https://evidence-hub.com/study/14300-effect-of-sglt-2-inhibitors-on-liver-fibrosis-progression-in-patients2026-10-06 https://evidence-hub.com/study/14301-sodium-glucose-cotransporter-2-inhibitors-in-valvular-heart-disease2026-10-06 https://evidence-hub.com/study/14302-postoperative-complications-of-coronary-artery-bypass-grafting-a2026-10-06 https://evidence-hub.com/study/14303-long-standing-giant-right-sided-inguinal-hernia-containing-the-right2026-10-06 https://evidence-hub.com/study/14304-effects-of-exercises-based-on-acsm-recommendations-on-patients-with2026-10-06 https://evidence-hub.com/study/14305-comparative-efficacy-of-sglt2-inhibitors-in-masld-bayesian-network2026-10-06 https://evidence-hub.com/study/14306-computational-discovery-of-novel-sglt2-inhibitors-from-eight-selected2026-10-06 https://evidence-hub.com/study/14307-assembly-of-hetero-aryl-sulfilimines-via-copper-catalyzed2026-10-06 https://evidence-hub.com/study/14308-comparing-glucagon-like-peptide-1-receptor-agonists-to-sodium-glucose2026-10-06 https://evidence-hub.com/study/14309-adiponectin-signaling-dysfunction-and-pro-inflammation-in2026-10-06 https://evidence-hub.com/study/14310-effects-of-sglt2-inhibitors-on-clinical-outcomes-symptoms-functional2026-10-06 https://evidence-hub.com/study/14311-evaluating-the-overall-renal-outcomes-of-sodium-glucose-cotransporter2026-10-06 https://evidence-hub.com/study/14312-metabolic-syndrome-and-periodontitis-from-shared-mechanisms-to2026-10-06 https://evidence-hub.com/study/14313-large-language-model-enhanced-framework-for-systematic-reviews-and2026-10-06 https://evidence-hub.com/study/14314-safety-and-efficacy-of-sglt2-inhibitors-in-heart-failure-patients2026-10-06 https://evidence-hub.com/study/14315-cardiovascular-outcomes-of-sglt-2-inhibitors-subtypes-in-type-22026-10-06 https://evidence-hub.com/study/14316-insulin-versus-established-glp-1-receptor-agonists-dpp-4-inhibitors2026-10-06 https://evidence-hub.com/study/14317-the-effectiveness-of-sodium-glucose-cotransporter-2-sglt2-inhibitors2026-10-06 https://evidence-hub.com/study/14318-non-st-segment-elevation-myocardial-infarction-nstemi-in-a-high-risk2026-10-06 https://evidence-hub.com/study/14319-cell-target-specific-anti-inflammatory-effect-of-empagliflozin-in2026-10-01 https://evidence-hub.com/study/14321-evaluating-the-alpha-glucosidase-and-alpha-amylase-inhibiting-the2026-10-06 https://evidence-hub.com/study/14322-psychological-activity-study-and-in-vitro-interaction-of-azithromycin2026-10-06 https://evidence-hub.com/study/14324-discerning-computational-in-vitro-and-in-vivo-investigations-of-self2026-10-05 https://evidence-hub.com/study/14325-in-vitro-cytotoxic-genotoxic-embryotoxic-and-oxidative-damage2026-10-06 https://evidence-hub.com/study/14327-safety-assessment-of-the-sglt2-inhibitors-empagliflozin-dapagliflozin2026-10-04 https://evidence-hub.com/study/14328-empagliflozin-attenuates-intestinal-inflammation-through-suppression2026-10-04 https://evidence-hub.com/study/14329-linagliptin-and-empagliflozin-inhibit-microtubule-affinity-regulatory2026-10-04 https://evidence-hub.com/study/14330-in-vitro-evaluation-of-the-anti-inflammatory-potential-of2026-10-06 https://evidence-hub.com/study/14331-empagliflozin-and-doxorubicin-synergistically-inhibit-the-survival-of2026-10-01 https://evidence-hub.com/study/14333-comprehensive-in-vitro-in-vivo-and-stability-evaluation-of-optimized2026-10-04 https://evidence-hub.com/study/14334-empagliflozin-alleviates-hepatic-steatosis-by-activating-the-ampk2026-10-04 https://evidence-hub.com/study/14335-an-in-vitro-and-in-silico-anticancer-study-of-fda-approved2026-10-01 https://evidence-hub.com/study/14338-quality-by-design-approach-to-formulate-empagliflozin-loaded-chitosan2026-09-27 https://evidence-hub.com/study/14340-effects-of-ticagrelor-empagliflozin-and-tamoxifen-against2026-09-27 https://evidence-hub.com/study/14341-development-and-validation-of-rp-hplc-method-for-estimation-of2026-10-01 https://evidence-hub.com/study/14343-unraveling-ppar-nuclear-receptor-agonists-via-a-drug-repurposing2026-10-06 https://evidence-hub.com/study/14344-comparative-efficacy-of-canagliflozin-versus-empagliflozin-on2026-09-27 https://evidence-hub.com/study/14345-identifying-novel-aryl-hydrocarbon-receptor-ahr-modulators-from2026-10-01 https://evidence-hub.com/study/14347-development-and-validation-of-a-dissolution-test-for-empagliflozin-in2026-10-04 https://evidence-hub.com/study/14348-a-human-engineered-heart-tissue-derived-lipotoxic-diabetic2026-10-06 https://evidence-hub.com/study/14349-a-comparison-of-electrospinning-and-pressurized-gyration-production2026-10-06 https://evidence-hub.com/study/14350-empagliflozin-ameliorates-rsl3-induced-ferroptosis-in-vascular2026-10-06 https://evidence-hub.com/study/14351-platelet-mitochondria-dual-targeted-nanocarriers-for-enhanced2026-10-06 https://evidence-hub.com/study/14352-design-formulation-development-and-characterization-of-empagliflozin2026-10-06 https://evidence-hub.com/study/14353-empagliflozin-significantly-reduces-the-capacity-of-sera-to-induce2026-10-06 https://evidence-hub.com/study/14354-formulation-evaluation-of-empagliflozin-tablet-in-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/14355-esrra-modulation-by-empagliflozin-mitigates-diabetic-tubular-injury2026-10-06 https://evidence-hub.com/study/14356-empagliflozin-attenuates-radiation-induced-hematopoietic-damage-via2026-10-06 https://evidence-hub.com/study/14357-exploring-the-phytoconstituents-differential-pharmacology-and2026-10-06 https://evidence-hub.com/study/14358-effect-of-empagliflozin-on-no-reflow-in-patients-with-st-elevation2026-10-06 https://evidence-hub.com/study/14359-development-and-characterization-of-fast-dissolving-tablets-for2026-10-06 https://evidence-hub.com/study/14360-empagliflozin-alleviates-atherosclerotic-calcification-by-inhibiting2026-10-04 https://evidence-hub.com/study/14361-empagliflozin-alleviates-doxorubicin-induced-cardiotoxicity-by2026-10-01 https://evidence-hub.com/study/14362-empagliflozin-improves-renal-injury-of-diabetic-nephropathy2026-10-06 https://evidence-hub.com/study/14363-empagliflozin-mitigates-doxorubicin-induced-nephrotoxicity-by2026-10-06 https://evidence-hub.com/study/14364-design-expert-software-assisted-development-and-evaluation-of2026-10-04 https://evidence-hub.com/study/14365-formulation-and-evaluation-of-metformin-hydrochloride-sustained2026-10-04 https://evidence-hub.com/study/14366-empagliflozin-modulates-biofilm-formation-and-virulence-associated2026-10-06 https://evidence-hub.com/study/14367-empagliflozin-restores-the-colonic-mucous-barrier-by-an-ampk-sox42026-10-06 https://evidence-hub.com/study/14368-empagliflozin-alleviates-osteoarthritis-progression-by-attenuating2026-10-06 https://evidence-hub.com/study/14369-comparative-study-of-dissolution-kinetics-and-permeability-of-a2026-10-06 https://evidence-hub.com/study/14370-analysis-of-allele-specific-expression-highlights-novel-participants2026-10-06 https://evidence-hub.com/study/14371-empagliflozin-pretreated-mesenchymal-stem-cell-derived-extracellular2026-10-06 https://evidence-hub.com/study/14372-cell-line-specific-modulation-of-colorectal-cancer-cell-behavior2026-10-04 https://evidence-hub.com/study/14374-design-and-characterization-of-oral-mucoadhesive-buccal-films-of2026-10-06 https://evidence-hub.com/study/14376-empagliflozin-and-dapagliflozin-reduce-ros-generation-and-restore-no2026-09-27 https://evidence-hub.com/study/14377-effects-of-sglt2-inhibition-in-human-kidney-proximal-tubular-cells2026-10-01 https://evidence-hub.com/study/14378-effect-of-empagliflozin-on-tacrolimus-induced-pancreas-islet2026-09-27 https://evidence-hub.com/study/14379-empagliflozin-reduces-the-senescence-of-cardiac-stromal-cells-and2026-10-01 https://evidence-hub.com/study/14380-empagliflozin-inhibits-hepatic-gluconeogenesis-and-increases-glycogen2026-10-04 https://evidence-hub.com/study/14381-combined-treatment-with-dpp-4-inhibitor-linagliptin-and-sglt22026-10-01 https://evidence-hub.com/study/14382-empagliflozin-prevents-from-early-cardiac-injury-post-myocardial2026-09-27 https://evidence-hub.com/study/14383-empagliflozin-ameliorates-free-fatty-acid-induced-lipotoxicity-in2026-09-27 https://evidence-hub.com/study/14384-empagliflozin-ammeliorates-high-glucose-induced-cardiac-dysfuntion-in2026-10-01 https://evidence-hub.com/study/14385-sglt-2-sodium-glucose-cotransporter-2-inhibition-reduces-ang-ii2026-10-01 https://evidence-hub.com/study/14386-cardioprotective-mechanism-of-sglt2-inhibitor-against-myocardial2026-10-04 https://evidence-hub.com/study/14387-empagliflozin-ameliorates-diabetic-cardiomyopathy-via-attenuating2026-10-04 https://evidence-hub.com/study/14388-in-vitro-and-in-vivo-evidence-that-quercetin-protects-against2026-10-01 https://evidence-hub.com/study/14389-empagliflozin-adjunct-with-metformin-for-the-inhibition-of2026-10-04 https://evidence-hub.com/study/14390-empagliflozin-prevents-neointima-formation-by-impairing-smooth-muscle2026-09-27 https://evidence-hub.com/study/14391-empagliflozin-enhances-autophagy-mitochondrial-biogenesis-and2026-10-01 https://evidence-hub.com/study/14392-new-insights-into-the-role-of-empagliflozin-on-diabetic-renal-tubular2026-10-04 https://evidence-hub.com/study/14393-sodium-glucose-cotransporter-2-inhibitor-empagliflozin-ameliorates2026-10-01 https://evidence-hub.com/study/14394-empagliflozin-protects-hk-2-cells-from-high-glucose-mediated-injuries2026-10-01 https://evidence-hub.com/study/14395-empagliflozin-a-new-sodium-glucose-co-transporter-2-sglt2-inhibitor2026-10-04 https://evidence-hub.com/study/14396-empagliflozin-targets-nf-b-signaling-through-ptgs2-and-tlr4-in2026-10-08 https://evidence-hub.com/study/14397-computational-structural-studies-of-sglt2-related-polypharmacy2026-10-06 https://evidence-hub.com/study/14398-empagliflozin-targeted-the-immune-related-gene-pik3ca-in-type-22026-10-06 https://evidence-hub.com/study/14399-reverse-translational-approach-to-clarify-the-strong-potency-of2026-10-06 https://evidence-hub.com/study/14400-repurposing-of-empagliflozin-as-cardioprotective-drug-an-in-silico2026-09-27 https://evidence-hub.com/study/14401-exploring-the-neuropharmacological-potential-of-empagliflozin-on2026-10-06 https://evidence-hub.com/study/14402-rna-seq-transcriptomic-landscape-profiling-of-spontaneously2026-10-01 https://evidence-hub.com/study/14403-combined-experimental-computational-aspects-for-the-molecular2026-10-06 https://evidence-hub.com/study/14404-repurposing-the-inhibitors-of-mmp-9-and-sglt-2-against-ubiquitin2026-10-06 https://evidence-hub.com/study/14405-development-of-an-hplc-uv-method-to-assay-empagliflozin-tablets-and2026-09-27 https://evidence-hub.com/study/14406-empagliflozin-ameliorates-diabetic-cardiomyopathy-by-inhibiting2026-10-06 https://evidence-hub.com/study/14407-empagliflozin-and-dapagliflozin-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/14408-cost-effectiveness-analysis-of-six-non-insulin-agents-for-type-22026-10-06 https://evidence-hub.com/study/14409-consensus-virtual-screening-and-ex-vivo-evaluation-of-novel-jak22026-10-06 https://evidence-hub.com/study/14410-repurposing-fda-approved-drugs-as-nlrp3-inhibitors-against2026-10-06 https://evidence-hub.com/study/14411-identification-of-phytocompounds-as-potent-inhibitors-of-sodium2026-10-06 https://evidence-hub.com/study/14412-empagliflozin-validation-of-stability-indicating-lc-method-and-in2026-09-27 https://evidence-hub.com/study/14413-decoding-empagliflozin-s-molecular-mechanism-of-action-in-heart2026-10-01 https://evidence-hub.com/study/14414-targeting-skeletal-muscle-in-duchenne-muscular-dystrophy-integrating2026-10-01 https://evidence-hub.com/study/14415-empagliflozin-improves-pressure-overload-induced-cardiac-hypertrophy2026-10-06 https://evidence-hub.com/study/14416-in-silico-screening-and-identification-of-glycomimetic-as-potential2026-09-27 https://evidence-hub.com/study/14417-identification-of-key-genes-increasing-susceptibility-to-atrial2026-10-06 https://evidence-hub.com/study/14418-guideline-directed-medical-therapy-induced-nephrotoxicity-in-hfref2026-10-06 https://evidence-hub.com/study/14419-empagliflozin-exhibits-hepatoprotective-effects-against-bile-duct2026-10-06 https://evidence-hub.com/study/14420-pharmacological-analysis-of-empagliflozin-acting-through-the-camkii2026-10-06 https://evidence-hub.com/study/14421-separation-of-achiral-anti-diabetic-drugs-using-sub-supercritical2026-10-06 https://evidence-hub.com/study/14422-binding-properties-of-sodium-glucose-co-transporter-2-inhibitor2026-10-06 https://evidence-hub.com/study/14423-empagliflozin-restores-electrocontractile-function-in-cardiomyocytes2026-10-06 https://evidence-hub.com/study/14424-morin-enhances-the-renoprotective-effects-of-empagliflozin-in2026-10-06 https://evidence-hub.com/study/14425-novel-sglt2-inhibitors-with-endothelial-protective-potential-a2026-10-06 https://evidence-hub.com/study/14426-the-sodium-glucose-cotransporter-2-inhibitor-empagliflozin-is-a2026-10-06 https://evidence-hub.com/study/14427-sglt2i-delays-c-myc-induced-hcc-progression-via-targeting-mtor2026-10-06 https://evidence-hub.com/study/14428-hplc-dad-technique-for-the-quantification-of-a-recently-approved-anti2026-10-06 https://evidence-hub.com/study/14429-identification-of-key-genes-biological-functions-and-pathways-of2026-10-06 https://evidence-hub.com/study/14430-empagliflozin-induces-apoptotic-signaling-pathway-in-embryonic2026-10-01 https://evidence-hub.com/study/14431-susceptibility-to-serious-skin-and-subcutaneous-tissue-disorders-and2026-10-01 https://evidence-hub.com/study/14432-lassbio-1986-as-a-multifunctional-antidiabetic-lead-sglt1-2-docking2026-10-08 https://evidence-hub.com/study/14433-investigating-the-therapeutic-mechanisms-of-shen-ling-bai-zhu-san-in2026-10-08 https://evidence-hub.com/study/14434-caffeic-acid-phenethyl-ester-protects-renal-tubular-epithelial-cells2026-10-06 https://evidence-hub.com/study/14435-synthesis-of-sglt2-inhibitor-o-glucoside-derivatives-for-enhancing2026-10-06 https://evidence-hub.com/study/14436-in-silico-analysis-of-rutin-and-morin-against-diabetes-associated2026-10-06 https://evidence-hub.com/study/14437-multi-cellular-network-model-predicts-alterations-in-glomerular2026-10-06 https://evidence-hub.com/study/14438-neomangiferin-a-naturally-occurring-mangiferin-congener-inhibits2026-10-01 https://evidence-hub.com/study/14439-computer-aided-drug-repurposing-discovery-for-hepatitis-b-capsid2026-10-06 https://evidence-hub.com/study/14440-molecular-docking-and-in-silico-predictive-analysis-of-potential-herb2026-10-04 https://evidence-hub.com/study/14441-in-silico-discovery-of-potential-sodium-glucose-cotransporter-2-sglt2026-10-01 https://evidence-hub.com/study/14442-studi-in-silico-senyawa-daun-salam-sebagai-antidiabetes-melalui2026-10-06 https://evidence-hub.com/study/14443-in-silico-study-of-acetogenin-compounds-from-soursop-annona-muricata2026-10-06 https://evidence-hub.com/study/14444-abstract-3503-new-generation-drug-development-from-in-silico2026-10-06 https://evidence-hub.com/study/14445-abstract-wed094-empagliflozin-preserves-heart-function-and-reshapes2026-10-06 https://evidence-hub.com/study/14446-141-or-cardioprotective-effect-of-empagliflozin-and-modification-of2026-10-06 https://evidence-hub.com/study/14447-molecular-docking-study-of-bioactive-compounds-in-senggugu2026-10-06 https://evidence-hub.com/study/14448-unveiling-the-synergistic-multi-target-antidiabetic-mechanism-of2026-10-06 https://evidence-hub.com/study/14449-in-silico-pharmacokinetic-bioactivity-and-toxicity-evaluation-of-some2026-10-04 https://evidence-hub.com/study/14450-safety-and-effectiveness-of-empagliflozin-in-korean-patients-with2026-10-06 https://evidence-hub.com/study/14451-comparison-of-cardiovascular-and-renal-outcomes-between-dapagliflozin2026-10-01 https://evidence-hub.com/study/14454-randomized-clinical-trial-replication-using-real-world-data-for2026-10-06 https://evidence-hub.com/study/14456-empagliflozin-ameliorates-atherosclerosis-via-regulating-the2026-10-01 https://evidence-hub.com/study/14457-empagliflozin-a-potential-anticancer-drug2026-10-04 https://evidence-hub.com/study/14458-empagliflozin-and-hfref2026-10-01 https://evidence-hub.com/study/14459-empagliflozin-prevents-oxidative-stress-in-human-coronary-artery2026-10-01 https://evidence-hub.com/study/14460-robust-antiviral-activity-of-commonly-prescribed-antidepressants2026-10-01 https://evidence-hub.com/study/14461-class-effects-of-sglt2-inhibitors-in-mouse-cardiomyocytes-and-hearts2026-10-01 https://evidence-hub.com/study/14462-design-and-synthesis-of-new-quinoxaline-derivatives-as-potential2026-10-01 https://evidence-hub.com/study/14463-in-silico-simulated-prototype-patients-using-tpms-technology-to-study2026-10-01 https://evidence-hub.com/study/14464-finding-new-molecular-targets-of-familiar-natural-products-using-in2026-10-01 https://evidence-hub.com/study/14465-identification-and-mechanism-elucidation-of-medicative-diet-for-food2026-10-01 https://evidence-hub.com/study/14466-in-silico-drug-repurposing-study-predicts-the-combination-of2026-10-01 https://evidence-hub.com/study/14467-chemical-and-biological-review-of-endophytic-fungi-associated-with2026-10-01 https://evidence-hub.com/study/14468-drug-induced-diabetes-type-2-in-silico-study-involving-class-b-gpcrs2026-10-04 https://evidence-hub.com/study/14469-development-of-canagliflozin-nanocrystals-sublingual-tablets-in-the2026-10-08 https://evidence-hub.com/study/14470-methods-to-develop-an-in-silico-clinical-trial-computational-head-to2026-10-01 https://evidence-hub.com/study/14471-in-silico-approaches-for-drug-repurposing-in-oncology-a-scoping-review2026-10-04 https://evidence-hub.com/study/14472-prognosis-and-personalized-in-silico-prediction-of-treatment-efficacy2026-10-01 https://evidence-hub.com/study/14473-in-silico-screening-and-identification-of-antidiabetic-inhibitors2026-10-01 https://evidence-hub.com/study/14474-in-silico-deconjugation-of-glucuronide-conjugates-enhances-tandem2026-10-01 https://evidence-hub.com/study/14475-metformin-empagliflozin-and-their-combination-modulate-ex-vivo2026-10-04 https://evidence-hub.com/study/14476-molecular-docking-and-dynamics-simulation-revealed-the-potential2026-10-01 https://evidence-hub.com/study/14477-canagliflozin-reduces-inflammation-and-fibrosis-biomarkers-a2026-10-01 https://evidence-hub.com/study/14478-empagliflozin-in-heart-failure-with-preserved-ejection-fraction2026-10-01 https://evidence-hub.com/study/14479-sglt2-inhibitor-ameliorates-endothelial-dysfunction-associated-with2026-10-01 https://evidence-hub.com/study/14480-standardized-chromatographic-and-computational-approaches-for2026-10-04 https://evidence-hub.com/study/14481-toxicological-assessment-of-sglt2-inhibitors-metabolites-using-in2026-10-01 https://evidence-hub.com/study/14482-stability-indicating-rp-hplc-method-development-for-the-determination2026-10-04 https://evidence-hub.com/study/14483-cardiovascular-care-with-digital-twin-technology-in-the-era-of2026-10-01 https://evidence-hub.com/study/14484-in-silico-prediction-of-optimal-multifactorial-intervention-in2026-10-01 https://evidence-hub.com/study/14485-epidemiology-and-treatment-of-acute-and-chronic-heart-failure2026-10-01 https://evidence-hub.com/study/14486-empagliflozin-loaded-nanomicelles-responsive-to-reactive-oxygen2026-09-27 https://evidence-hub.com/study/14487-9-pharmacologic-approaches-to-glycemic-treatment-standards-of-care-in2026-10-01 https://evidence-hub.com/study/14488-in-silico-studies-for-the-identification-of-potential-sglt2-inhibitors2026-10-04 https://evidence-hub.com/study/14489-strategy-advancements-in-placental-pharmacokinetics-from-in-vitro2026-10-10 https://evidence-hub.com/study/14490-cumulative-effects-of-vicadrostat-and-empagliflozin-on-albuminuria-in2026-10-01 https://evidence-hub.com/study/14491-a-sensitive-ultra-performance-liquid-chromatography-tandem-mass2026-10-04 https://evidence-hub.com/study/14492-diabetic-vascular-diseases-molecular-mechanisms-and-therapeutic2026-10-04 https://evidence-hub.com/study/14493-multicentric-assessment-of-empagliflozin-sitagliptin-and2026-10-04 https://evidence-hub.com/study/14494-exploring-the-bioactivity-potential-of-prunus-spinosa-antioxidant2026-10-01 https://evidence-hub.com/study/14495-empagliflozin-promotes-autophagy-and-apoptosis-in-a549-lung-cancer2026-10-04 https://evidence-hub.com/study/14496-empagliflozin-inhibits-oscc-proliferation-and-migration-by2026-10-04 https://evidence-hub.com/study/14497-in-vivo-and-in-silico-studies-on-the-potential-role-of-garden-cress2026-10-01 https://evidence-hub.com/study/14499-the-combination-empagliflozin-metformin-attenuates-the-progression-of2026-10-04 https://evidence-hub.com/study/14500-a-drug-repositioning-approach-antidiabetic-empagliflozin-may-be-a2026-10-01 https://evidence-hub.com/study/14501-empagliflozin-inhibits-proximal-tubule-nhe3-activity-preserves-gfr2026-10-01 https://evidence-hub.com/study/14502-pelargonium-graveolens-attenuates-rotenone-induced-parkinson-s2026-10-01 https://evidence-hub.com/study/14503-pik3r1-mutations-in-individuals-with-insulin-resistance-or-growth2026-10-01 https://evidence-hub.com/study/14504-investigation-of-cytotoxic-effects-of-empagliflozin-on-caco-2-lncap2026-10-01 https://evidence-hub.com/study/14505-effects-of-empagliflozin-and-metformin-on-biofilm-formation-and2026-10-13 https://evidence-hub.com/study/14506-deepdrug-as-an-expert-guided-and-ai-driven-drug-repurposing2026-10-01 https://evidence-hub.com/study/14508-6-shogaol-abrogates-parkinson-s-disease-in-rotenone-induced-rodents2026-10-01 https://evidence-hub.com/study/14509-anticoagulants-as-potential-sars-cov-2-mpro-inhibitors-for-covid-192026-10-01 https://evidence-hub.com/study/14510-canagliflozin-impairs-blood-reperfusion-of-ischaemic-lower-limb2026-10-04 https://evidence-hub.com/study/14511-sedem-tool-driven-full-factorial-design-for-osmotic-drug-delivery-of2026-10-01 https://evidence-hub.com/study/14512-will-sglt2-inhibitors-be-effective-and-safe-in-patients-with-severe2026-09-27 https://evidence-hub.com/study/14513-in-silico-prediction-of-optimal-multifactorial-intervention-in-ckd2026-10-01 https://evidence-hub.com/study/14516-comparison-of-the-effects-of-empagliflozin-and-sotagliflozin-on-a2026-10-04 https://evidence-hub.com/study/14518-comprehensive-forced-degradation-and-degradation-kinetics-of2026-09-27 https://evidence-hub.com/study/14519-consensus-recommendations-for-the-use-of-automated-insulin-delivery2026-10-01 https://evidence-hub.com/study/14520-eco-friendly-second-derivative-synchronous-fluorescence-method-for2026-10-06 https://evidence-hub.com/study/14521-architecting-novel-multilayer-nanosponges-for-co-administration-of2026-10-06 https://evidence-hub.com/study/14522-cost-effectiveness-analysis-of-empagliflozin-in-japan-based-on2026-09-29 https://evidence-hub.com/study/14523-different-effects-of-empagliflozin-on-markers-of-mineral-bone2026-10-06 https://evidence-hub.com/study/14524-empagliflozin-and-left-ventricular-diastolic-function-following-an2026-10-06 https://evidence-hub.com/study/14525-analysis-of-fractures-in-patients-with-type-2-diabetes-treated-with2026-10-06 https://evidence-hub.com/study/14526-eco-friendly-assessed-micellar-fluorimetric-platform-for-concurrent2026-10-06 https://evidence-hub.com/study/14527-determination-of-linagliptin-and-empagliflozin-by-uplc-and-hptlc2026-10-06 https://evidence-hub.com/study/14528-impact-of-empagliflozin-on-cardiac-arrhythmias-and-heart-rate2026-10-06 https://evidence-hub.com/study/14529-rationale-and-design-of-the-empa-tropism-trial-atru-4-are-the-cardiac2026-10-06 https://evidence-hub.com/study/14530-empagliflozin-s-role-in-early-tubular-protection-for-type-2-diabetes2026-10-06 https://evidence-hub.com/study/14531-the-ameliorative-effect-of-empagliflozin-in-vigabatrin-induced2026-10-06 https://evidence-hub.com/study/14532-in-hfref-adding-empagliflozin-to-medical-therapy-reduced-a-composite2026-10-06 https://evidence-hub.com/study/14533-benefits-of-sglt2-inhibitors-beyond-glycemic-control-a-focus-on2026-10-06 https://evidence-hub.com/study/14534-empagliflozin-in-diabetic-cardiomyopathy-elucidating-mechanisms2026-10-06 https://evidence-hub.com/study/14535-empagliflozin-decreases-the-plasma-concentration-of-plasminogen2026-10-01 https://evidence-hub.com/study/14536-new-spectrofluorimetric-analysis-of-empagliflozin-in-its-tablets-and2026-10-06 https://evidence-hub.com/study/14537-a-cost-effectiveness-analysis-of-empagliflozin-for-heart-failure2026-10-06 https://evidence-hub.com/study/14538-cost-effectiveness-of-empagliflozin-compared-with-liraglutide-based2026-10-06 https://evidence-hub.com/study/14539-effects-of-empagliflozin-and-its-combination-with-docetaxel-on-lncap2026-10-06 https://evidence-hub.com/study/14541-cost-effectiveness-of-empagliflozin-compared-with-dapagliflozin-for2026-10-06 https://evidence-hub.com/study/14542-time-to-cardiovascular-benefits-of-empagliflozin-a-post-hoc2026-10-01 https://evidence-hub.com/study/14543-cost-effectiveness-of-empagliflozin-for-the-treatment-of-patients2026-10-06 https://evidence-hub.com/study/14544-long-term-treatment-with-empagliflozin-a-novel-potent-and-selective2026-10-06 https://evidence-hub.com/study/14545-the-sglt2-inhibitor-empagliflozin-mitigates-the-harmful-effects-of2026-10-06 https://evidence-hub.com/study/14546-empagliflozin-treatment-is-associated-with-improved-cell-function-in2026-10-06 https://evidence-hub.com/study/14547-pharmacodynamics-efficacy-and-safety-of-sodium-glucose-co-transporter2026-10-06 https://evidence-hub.com/study/14548-anmco-position-paper-sodium-glucose-co-transporter-2-inhibitors-for2026-10-06 https://evidence-hub.com/study/14549-efficacy-of-nondiuretic-pharmacotherapy-for-improving-the-treatment2026-10-06 https://evidence-hub.com/study/14550-empagliflozin-in-type-1-diabetes2026-10-06 https://evidence-hub.com/study/14551-the-role-of-sglt2-inhibitors-in-managing-type-2-diabetes2026-10-06 https://evidence-hub.com/study/14552-sglt2-inhibitors-for-prevention-and-management-of-cancer-treatment2026-10-06 https://evidence-hub.com/study/14553-the-effects-of-sodium-glucose-cotransporter-2-inhibitors-slgt-2i-on2026-10-06 https://evidence-hub.com/study/14554-combination-treatment-of-sglt2-inhibitors-and-glp-1-receptor-agonists2026-10-06 https://evidence-hub.com/study/14555-impact-of-sodium-glucose-cotransporter-2-inhibitors-on-blood-pressure2026-10-06 https://evidence-hub.com/study/14556-sodium-glucose-cotransporter-2-inhibitors-in-the-treatment-of-type-22026-10-06 https://evidence-hub.com/study/14557-comments-on-current-guidelines-of-type-2-diabetes-mellitus-treatment2026-10-06 https://evidence-hub.com/study/14558-empagliflozin-a-sodium-glucose-cotransporter-2-inhibitor-for2026-10-06 https://evidence-hub.com/study/14559-effect-of-empagliflozin-treatment-on-laboratory-and-clinical-findings2026-10-06 https://evidence-hub.com/study/14560-real-world-initiation-of-newly-funded-empagliflozin-and-dulaglutide2026-10-06 https://evidence-hub.com/study/14561-head-to-head-in-heart-failure-comparative-insights-on-empagliflozin2026-10-06 https://evidence-hub.com/study/14562-a-literatur-review-impact-sglt2-inhibitors-dapagliflozin-and2026-10-06 https://evidence-hub.com/study/14563-cost-utility-analysis-of-empagliflozin-on-chronic-kidney-disease2026-10-06 https://evidence-hub.com/study/14564-roles-of-empagliflozin-in-diabetic-cardiomyopathy-a-review2026-10-06 https://evidence-hub.com/study/14565-characteristics-of-fasting-in-ramadan-in-type-2-diabetes-patients-on2026-10-06 https://evidence-hub.com/study/14566-stability-indicating-method-development-and-validation-of-metoprolol2026-10-06 https://evidence-hub.com/study/14567-dapagliflozin-and-empagliflozin-a-new-perspective-for-patients-with2026-10-06 https://evidence-hub.com/study/14568-empagliflozin-pharmacotherapy-an-updated-overview2026-10-06 https://evidence-hub.com/study/14569-real-world-patient-perspectives-on-glipizide-and-empagliflozin-for2026-10-06 https://evidence-hub.com/study/14570-empagliflozin-a-sodium-glucose-cotransporter-inhibitor-enhancing2026-10-06 https://evidence-hub.com/study/14571-comparative-study-on-efficacy-of-empagliflozin-versus-sitagliptin-as2026-10-04 https://evidence-hub.com/study/14572-the-effect-of-empagliflozin-on-vascular-remodeling-related-to2026-10-06 https://evidence-hub.com/study/14573-metabolic-and-renal-outcomes-of-empagliflozin-among-emirati-patients2026-10-06 https://evidence-hub.com/study/14574-empagliflozin-an-sglt2i-relaxes-coronary-smooth-muscle-at2026-10-06 https://evidence-hub.com/study/14575-empagliflozin-mitigates-tmao-induced-nlrp3-inflammation-and-alters2026-10-06 https://evidence-hub.com/study/14576-evaluating-use-of-empagliflozin-for-diabetes-management-in-veterans2026-10-06 https://evidence-hub.com/study/14577-a-comprehensive-review-on-analytical-methods-for-the-quantification2026-10-06 https://evidence-hub.com/study/14578-evaluation-and-measurement-of-potential-genotoxic-impurities-in2026-10-06 https://evidence-hub.com/study/14579-empagliflozin-treatment-of-cardiotoxicity-a-comprehensive-review-of2026-10-06 https://evidence-hub.com/study/14580-review-on-analytical-methods-for-estimation-of-antidiabetic-drugs2026-10-06 https://evidence-hub.com/study/14581-new-insights-into-the-use-of-empagliflozin-a-comprehensive-review2026-10-06 https://evidence-hub.com/study/14582-current-perspectives-on-analytical-method-validation-of-empagliflozin2026-10-06 https://evidence-hub.com/study/14584-empagliflozin-in-adults-with-chronic-kidney-disease-ckd-current2026-10-06 https://evidence-hub.com/study/14585-pancreatitis-in-a-57-year-old-female-two-weeks-after-initiation-of2026-10-06 https://evidence-hub.com/study/14586-how-does-it-work-unraveling-the-mysteries-by-which-empagliflozin2026-10-06 https://evidence-hub.com/study/14587-effects-of-sodium-glucose-co-transporter-2-sglt2-inhibitors-on-serum2026-10-06 https://evidence-hub.com/study/14588-sodium-glucose-co-transporter-2-inhibitors-in-addition-to-insulin2026-10-06 https://evidence-hub.com/study/14590-effects-of-sodium-glucose-cotransporter-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/14591-comparative-effectiveness-of-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/14592-efficacy-and-safety-of-single-or-double-drug-antidiabetic-regimens-in2026-10-06 https://evidence-hub.com/study/14593-redefining-outcomes-of-ventricular-arrhythmia-for-sglt2-inhibitor2026-10-06 https://evidence-hub.com/study/14594-efficacy-safety-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/14595-comparative-efficacy-and-safety-of-antidiabetic-drug-regimens-added2026-10-06 https://evidence-hub.com/study/14596-risks-of-diabetic-foot-syndrome-and-amputation-associated-with-sodium2026-10-06 https://evidence-hub.com/study/14597-effects-of-sodium-glucose-cotransporter-inhibitor-glucagon-like2026-10-06 https://evidence-hub.com/study/14598-a-systematic-review-of-cost-effectiveness-studies-of-newer-non2026-10-06 https://evidence-hub.com/study/14599-role-of-endogenous-adenine-in-kidney-failure-and-mortality-with2026-10-06 https://evidence-hub.com/study/14600-stress-unmasks-impaired-endocrine-coordination-of-glucose-metabolism2026-10-06 https://evidence-hub.com/study/14601-prediction-of-adverse-events-risk-in-patients-with-comorbid-post2026-10-06 https://evidence-hub.com/study/14602-sglt2-inhibitors-protect-against-diabetic-cardiomyopathy-and-atrial2026-10-01 https://evidence-hub.com/study/14603-crucial-role-for-sodium-hydrogen-exchangers-in-sglt2-inhibitor2026-10-01 https://evidence-hub.com/study/14604-sodium-glucose-co-transporter-2-inhibitors-act-independently-of-sglt22026-10-01 https://evidence-hub.com/study/14605-effects-of-empagliflozin-on-right-ventricular-function-in-heart2026-10-01 https://evidence-hub.com/study/14606-caurel-dynamic-counterfactual-learning-for-precision-drug-repurposing2026-10-06 https://evidence-hub.com/study/14607-two-hit-mouse-model-of-heart-failure-with-preserved-ejection-fraction2026-10-06 https://evidence-hub.com/study/14608-load-dependent-effects-of-sodium-glucose-co-transporter-inhibitors-on2026-10-06 https://evidence-hub.com/study/14609-design-synthesis-and-computational-analysis-of-4-amino-1-2-4-triazol2026-10-06 https://evidence-hub.com/study/14610-disruption-of-rbm20-causes-atrial-electrophysiological-disturbances2026-10-06 https://evidence-hub.com/study/14611-the-intertwined-challenge-a-prospective-assessment-of-empagliflozin2026-10-01 https://evidence-hub.com/study/14612-the-possible-ameliorative-effect-of-empagliflozin-on-testicular2026-10-04 https://evidence-hub.com/study/14613-effects-of-empagliflozin-in-chronic-kidney-disease-on-hemodialysis2026-09-27 https://evidence-hub.com/study/14614-do-sglt2-inhibitors-have-a-place-in-the-oncology-toolbox2026-10-06 https://evidence-hub.com/study/14615-empagliflozin-versus-dapagliflozin-for-kidney-outcomes-in-stage-32026-10-06 https://evidence-hub.com/study/14616-synthesis-and-preclinical-evaluation-of-11c-sotagliflozin-the-first2026-10-06 https://evidence-hub.com/study/14617-empagliflozin-pirfenidone-dual-therapy-improves-cardiac-function-and2026-10-06 https://evidence-hub.com/study/14618-to-investigate-the-effect-of-a-high-fat-diet-on-pharmacokinetics2026-09-27 https://evidence-hub.com/study/14619-inhibition-of-late-ina-prevents-pathological-hyperactivation-of2026-10-06 https://evidence-hub.com/study/14620-insights-into-the-complications-of-sglt-2-inhibitors-in-patients-with2026-10-06 https://evidence-hub.com/study/14621-finerenone-prescriptions-in-the-us-2021-2024-by-physician-specialty2026-10-06 https://evidence-hub.com/study/14622-integrated-analysis-reveals-neuro-immune-pathway-in-the-central2026-10-06 https://evidence-hub.com/study/14623-visfatin-from-adipocyte-accelerates-vascular-calcification-via-tlr42026-10-06 https://evidence-hub.com/study/14624-increased-ketoacidosis-from-co-administration-of-glucose-lowering2026-10-06 https://evidence-hub.com/study/14625-impact-of-comprehensive-metabolic-optimization-on-myocardial2026-10-06 https://evidence-hub.com/study/14626-sglt2-inhibitors-in-diabetic-nephropathy-a-systematic-review-of-sglt22026-10-06 https://evidence-hub.com/study/14627-empagliflozin-in-improving-exercise-tolerance-in-hfpef-study-protocol2026-10-06 https://evidence-hub.com/study/14628-sglt2-inhibitors-rescue-lysosomal-mtorc1-hyperactivity-and-proximal2026-10-06 https://evidence-hub.com/study/14629-employing-the-intravesical-delivery-route-to-target-on-the-kidney2026-10-06 https://evidence-hub.com/study/14630-highly-selective-sglt2-inhibitors-suppress-glucose-uptake-in-alpha2026-10-06 https://evidence-hub.com/study/14631-the-sodium-glucose-cotransporter-2-inhibitor-empagliflozin-is-a2026-10-06 https://evidence-hub.com/study/14632-long-term-effect-of-empagliflozin-and-dapagliflozin-in-patients-with2026-10-06 https://evidence-hub.com/study/14633-empagliflozin-improves-mitochondrial-biogenesis-and-ameliorates2026-10-01 https://evidence-hub.com/study/14634-targeting-metabolic-dysfunction-and-inflammation-with-sotagliflozin2026-10-06 https://evidence-hub.com/study/14635-association-of-hypoglycemic-agents-with-the-risk-of-platinum-based2026-10-06 https://evidence-hub.com/study/14636-long-term-follow-up-of-treatment-comparisons-in-recovery-a-randomised2026-10-06 https://evidence-hub.com/study/14637-use-of-sglt-2-inhibitors-in-pediatric-heart-failure-a-multi-center2026-10-06 https://evidence-hub.com/study/14638-short-term-effects-of-empagliflozin-on-exercise-tolerance-in-type-22026-10-06 https://evidence-hub.com/study/14639-microbes-regulate-glomerular-filtration-rate-in-health-and-chronic2026-10-06 https://evidence-hub.com/study/14640-dicar-jp-regulates-ribosome-migration-a-new-theory-of-mitochondrial2026-10-06 https://evidence-hub.com/study/14641-fecal-microbiome-predicts-treatment-response-after-the-initiation-of2026-09-27 https://evidence-hub.com/study/14642-dapagliflozin-vs-empagliflozin-in-patients-with-chronic-heart-failure2026-09-27 https://evidence-hub.com/study/14643-empagliflozin-alleviates-renal-inflammation-in-sprague-dawley2026-10-06 https://evidence-hub.com/study/14644-pharmacokinetic-interactions-between-donafenib-and-empagliflozin-or2026-10-01 https://evidence-hub.com/study/14645-comparison-of-the-severity-of-urinary-tract-infections-between2026-10-06 https://evidence-hub.com/study/14646-empagliflozin-inhibits-pasmcs-phenotypic-transition-via2026-09-27 https://evidence-hub.com/study/14647-renal-and-systemic-hemodynamic-effects-of-empagliflozin-three2026-10-06 https://evidence-hub.com/study/14648-empagliflozin-enhances-cisplatin-activity-in-chemo-resistant-ej1382026-10-06 https://evidence-hub.com/study/14649-sglt2-inhibition-reduces-cardiac-surgery-associated-acute-kidney2026-09-27 https://evidence-hub.com/study/14650-analysis-of-plasma-proteomic-differences-in-the-effects-of2026-10-01 https://evidence-hub.com/study/14651-empagliflozin-ameliorated-chondrocytes-inflammation-catabolism-and2026-10-01 https://evidence-hub.com/study/14652-deepdrug-an-expert-led-domain-specific-ai-driven-drug-repurposing2026-10-01 https://evidence-hub.com/study/14653-the-sglt2-inhibitors-empagliflozin-alleviate-renal-fibrosis-by2026-10-06 https://evidence-hub.com/study/14654-sympathetic-activation-promotes-sodium-glucose-co-transporter-12026-10-06 https://evidence-hub.com/study/14655-comparison-of-semaglutide-in-combined-with-empagliflozin-versus2026-10-01 https://evidence-hub.com/study/14656-the-sglt2-inhibitor-empagliflozin-promotes-post-stroke-functional2026-09-27 https://evidence-hub.com/study/14657-adverse-event-comparison-between-glucagon-like-peptide-1-receptor2026-10-06 https://evidence-hub.com/study/14658-empagliflozin-attenuates-hfd-stz-induced-liver-fibrosis-in-type-22026-10-06 https://evidence-hub.com/study/14659-empagliflozin-reduces-neointimal-formation-and-vascular-smooth-muscle2026-10-01 https://evidence-hub.com/study/14660-empagliflozin-associated-pancreatitis-in-the-setting-of-hyperglycemic2026-09-27 https://evidence-hub.com/study/14661-sotagliflozin-promotes-anti-oxidant-properties-in-the-kidneys-of-type2026-10-06 https://evidence-hub.com/study/14662-empagliflozin-attenuates-vascular-calcification-in-mice-with-chronic2026-10-01 https://evidence-hub.com/study/14665-improved-inflammatory-bowel-disease-wound-healing-and-normal-of2026-10-01 https://evidence-hub.com/study/14666-empagliflozin-improves-cardiac-function-in-rats-with-chronic-heart2026-10-01 https://evidence-hub.com/study/14667-empagliflozin-induces-the-transcriptional-program-for-nutrient2026-10-01 https://evidence-hub.com/study/14669-the-sglt-2-inhibitor-empagliflozin-improves-myocardial-strain-reduces2026-10-01 https://evidence-hub.com/study/14670-the-sglt2-inhibitor-empagliflozin-attenuates-atherosclerosis2026-10-01 https://evidence-hub.com/study/14671-empagliflozin-ameliorates-leukocyte-endothelium-cell-interactions-and2026-10-01 https://evidence-hub.com/study/14673-empagliflozin-restores-cardiac-metabolic-flexibility-in-diet-induced2026-10-01 https://evidence-hub.com/study/14674-aldehyde-dehydrogenase-2-activator-augments-the-beneficial-effects-of2026-09-27 https://evidence-hub.com/study/14675-the-effects-of-low-dose-empagliflozin-on-cardiac-function-and2026-10-01 https://evidence-hub.com/study/14676-empagliflozin-reduces-arrhythmogenic-effects-in-rat-neonatal-and2026-10-01 https://evidence-hub.com/study/14677-empagliflozin-reduces-renal-lipotoxicity-in-experimental-alport2026-10-04 https://evidence-hub.com/study/14678-empagliflozin-repurposing-for-metabolic-substrate-switching-and2026-09-27 https://evidence-hub.com/study/14679-empagliflozin-induced-diabetes-ketoacidosis-a-review-of-literature2026-10-01 https://evidence-hub.com/study/14681-metabolic-profiling-of-the-emdia-cohort-by-a-scalable-dia-lc-ms2026-09-27 https://evidence-hub.com/study/14682-empagliflozin-protects-atherosclerosis-progression-by-modulating2026-10-01 https://evidence-hub.com/study/14683-sglt2-transcriptomic-expression-atlas-supports-a-kidney-centric-role2026-10-01 https://evidence-hub.com/study/14684-empagliflozin-one-bounded-context-dependent-signal-across-receipts2026-09-27 https://evidence-hub.com/study/14685-effects-of-empagliflozin-in-different-phases-of-diabetes-mellitus2026-10-01 https://evidence-hub.com/study/14687-empagliflozin-associated-postoperative-mixed-metabolic-acidosis-case2026-10-01 https://evidence-hub.com/study/14689-effects-of-a-single-10mg-dose-of-empagliflozin-on-postprandial2026-10-01 https://evidence-hub.com/study/14690-evaluation-of-the-effects-of-empagliflozin-on-acute-lung-injury-in2026-10-01 https://evidence-hub.com/study/14692-metabolic-syndrome-in-patients-with-type-2-diabetes-and2026-10-01 https://evidence-hub.com/study/14695-comparison-of-the-effects-of-empagliflozin-and-glimepiride-on2026-10-01 https://evidence-hub.com/study/14697-a-specific-new-analytical-method-for-determining-linagliptin-in-pure2026-10-01 https://evidence-hub.com/study/14698-comparison-of-the-effects-of-empagliflozin-and-glimepiride-on2026-10-01 https://evidence-hub.com/study/14699-early-sglt2-inhibitor-use-is-associated-with-improved-left-atrial2026-10-01 https://evidence-hub.com/study/14700-sodium-glucose-co-transporter-2-inhibition-with-empagliflozin2026-10-01 https://evidence-hub.com/study/14702-aldehyde-dehydrogenase-2-activator-augments-the-beneficial-effects-of2026-10-01 https://evidence-hub.com/study/14703-an-assessment-of-the-human-sortilin1-protein-network-its-expression2026-10-01 https://evidence-hub.com/study/14705-the-safety-of-sglt-2-inhibitors-in-diabetic-patients-submitted-to2026-10-01 https://evidence-hub.com/study/14707-evaluating-the-effect-of-empagliflozin-on-coronary-no-reflow-in2026-09-27 https://evidence-hub.com/study/14708-a-stability-indicating-rp-hplc-method-validation-for-simultaneous2026-09-27 https://evidence-hub.com/study/14718-advanced-rp-hplc-technique-for-huge-drug-formulations-using2026-09-27 https://evidence-hub.com/study/14719-efficacy-and-safety-of-empagliflozin-combined-with-metformin2026-10-04 https://evidence-hub.com/study/14724-exploration-and-validation-of-an-advanced-reverse-phase-hplc-approach2026-09-27 https://evidence-hub.com/study/14725-renal-protection-a-leading-mechanism-for-cardiovascular-benefit-in2026-10-01 https://evidence-hub.com/study/14726-sglt-2-inhibitors-an-evidence-based-perspective2026-09-27 https://evidence-hub.com/study/14727-diabetes-and-antidiabetic-drugs2026-09-27 https://evidence-hub.com/study/14729-general-practice-management-of-type-2-diabetes-2014-152026-10-01 https://evidence-hub.com/study/14730-el-significado-de-la-autoctonia-aloctonia-tafonomica2026-09-27 https://evidence-hub.com/study/14732-tratamento-farmacologico-da-hiperglicemia-no-dm22026-10-01 https://evidence-hub.com/study/14733-diagnosis-and-management-of-heart-failure2026-10-01 https://evidence-hub.com/study/14735-discovering-distinct-phenotypical-clusters-in-heart-failure-across2026-10-01 https://evidence-hub.com/study/14736-novel-molecules-in-diabetes-melitus-dyslipidemia-and-cardiovascular2026-10-01 https://evidence-hub.com/study/14737-molecular-basis-of-blood-glucose-regulation2026-10-01 https://evidence-hub.com/study/14738-management-of-type-2-diabetes-mellitus2026-10-01 https://evidence-hub.com/study/14739-doenca-renal-do-diabetes2026-10-01 https://evidence-hub.com/study/14741-sodium-glucose-cotransporter-2-inhibitors2026-09-27 https://evidence-hub.com/study/14743-case-28-illusion-of-autoimmune-diabetes2026-09-27 https://evidence-hub.com/study/14744-sglt2-inhibitors-therapy-in-type-2-diabetes-mellitus2026-10-01 https://evidence-hub.com/study/14746-the-management-of-patients-with-heart-failure-and-diabetes2026-09-27 https://evidence-hub.com/study/14747-hochpreisige-arzneimittel-herausforderungen-und-perspektiven-aus2026-10-01 https://evidence-hub.com/study/14748-modafinil-ameliorated-fibromyalgia-syndrome-in-rats-by-modulating2026-10-01 https://evidence-hub.com/study/14749-the-use-of-primary-care-big-data-for-covid-19-research-a-consensus2026-10-01 https://evidence-hub.com/study/14750-glycaemic-control-in-diabetes2026-10-01 https://evidence-hub.com/study/14751-experimental-model-of-cardiotoxicity2026-10-01 https://evidence-hub.com/study/14753-inibidores-do-co-transportador-sodio-glicose-2-isglt2-na2026-10-01 https://evidence-hub.com/study/14754-case-16-a-case-of-euglycemic-diabetic-ketoacidosis-after-initiation2026-09-27 https://evidence-hub.com/study/14755-tratamento-da-hiperglicemia-em-pacientes-com-dm2-e-insuficiencia2026-10-01 https://evidence-hub.com/study/14756-from-a-glycocentric-approach-to-prevention-of-multi-organ-damage-in2026-10-01 https://evidence-hub.com/study/14757-acute-decompensated-heart-failure2026-09-27 https://evidence-hub.com/study/14758-doenca-hepatica-gordurosa-metabolica-dhgm2026-10-01 https://evidence-hub.com/study/14759-new-tubulocentric-insights-for-diabetic-nephropathy-from2026-10-01 https://evidence-hub.com/study/14761-lipidomics-in-biomarker-research2026-10-01 https://evidence-hub.com/study/14764-communicating-about-mortality-in-health-decision-support-what-and-why2026-10-01 https://evidence-hub.com/study/14766-advancements-in-gene-therapy-for-type-2-diabetes-insights-from-crispr2026-10-01 https://evidence-hub.com/study/14768-the-role-of-sglt2i-in-the-prevention-and-treatment-of-heart-failure2026-09-27 https://evidence-hub.com/study/14769-familial-dilated-cardiomyopathy-risk-stratification-for-sudden2026-10-01 https://evidence-hub.com/study/14770-sglt2-inhibitoru-iliskili-euglisemik-diyabetik-ketoasidoz-acil2026-09-27 https://evidence-hub.com/study/14771-role-of-congestion-in-heart-failure-from-bench-to-clinical-practice2026-10-01 https://evidence-hub.com/study/14772-acs-in-special-populations-women-diabetic-and-elderly-patients2026-10-01 https://evidence-hub.com/study/14774-pressure-natriuresis-in-blood-pressure-control2026-10-01 https://evidence-hub.com/study/14775-an-overview-of-the-cardiomyopathies2026-10-01 https://evidence-hub.com/study/14776-phytotherapy-the-science-behind-herbal-remedies-and-their-therapeutic2026-10-01 https://evidence-hub.com/study/14777-euglycemic-ketoacidosis-secondary-due-to-sglt2-inhibitors2026-09-27 https://evidence-hub.com/study/14778-the-interplay-of-pathology-prevention-and-treatment-in-cardio2026-10-01 https://evidence-hub.com/study/14779-drug-related-cystitis-an-overview2026-10-01 https://evidence-hub.com/study/14780-interaction-between-atrial-fibrillation-and-heart-failure-recent2026-10-01 https://evidence-hub.com/study/14783-role-of-new-therapies-in-reducing-mortality-and-major-morbidity-in2026-10-01 https://evidence-hub.com/study/14785-the-role-of-the-kidney-in-glucose-homeostasis2026-10-01 https://evidence-hub.com/study/14786-frontiers-in-clinical-drug-research-diabetes-and-obesity-volume-52026-10-01 https://evidence-hub.com/study/14788-sodyum-glukoz-ko-transporter-2-inhibitorleri-ve-bobrek-koruyucu2026-09-27 https://evidence-hub.com/study/14789-a-importancia-da-abordagem-clinica-e-terapeutica-para-manejo-e2026-10-01 https://evidence-hub.com/study/14791-advanced-treatment-of-refractory-congestive-heart-failure-by2026-10-01 https://evidence-hub.com/study/14792-myocarditis-and-inflammatory-cardiomyopathy2026-10-01 https://evidence-hub.com/study/14794-effectiveness-of-lifestyle-interventions-for-nonalcoholic-fatty-liver2026-10-01 https://evidence-hub.com/study/14795-drug-repurposing-scopes-in-herbal-natural-products-based-drug2026-10-01 https://evidence-hub.com/study/14796-atlas-of-diabetes-mellitus2026-10-01 https://evidence-hub.com/study/14799-a-relacao-estabelecida-entre-os-disturbios-do-sono-e-a-incidencia-de2026-10-01 https://evidence-hub.com/study/14801-pharmacotherapy-of-type-2-diabetes-mellitus2026-10-01 https://evidence-hub.com/study/14802-demographischer-wandel-angemessene-arzneimittelversorgung-einer2026-10-01 https://evidence-hub.com/study/14803-association-of-the-l-prf-technique-in-apicoectomies-of-different2026-10-01 https://evidence-hub.com/study/14804-efeitos-da-entrada-de-genericos-no-mercado-sobre-os-precos-de2026-10-01 https://evidence-hub.com/study/14807-berthold-hocher-reno-protective-effects-of-empagliflozin2026-09-27 https://evidence-hub.com/study/14809-impact-of-empagliflozin-on-the-mode-of-death-of-heart-failure-patients2026-10-06 https://evidence-hub.com/study/14810-proteomic-and-pathway-insights-into-heart-failure-progression-and-the2026-10-06 https://evidence-hub.com/study/14813-diabetic-ketoacidosis-associated-with-empagliflozin-therapy2026-10-06 https://evidence-hub.com/study/14814-data-from-complex-antiarrhythmic-effects-of-empagliflozin-in-non2026-10-06 https://evidence-hub.com/study/14815-metformin-and-empagliflozin-attenuate-visceral-adiposity-after-kidney2026-10-06 https://evidence-hub.com/study/14816-biomarker-profiles-in-heart-failure-patients-with-obesity-being2026-10-06 https://evidence-hub.com/study/14818-effects-of-combined-sacubitril-and-empagliflozin-therapy-on2026-10-06 https://evidence-hub.com/study/14819-to-evaluate-the-neuroprotective-potential-of-empagliflozin-using-the2026-10-06 https://evidence-hub.com/study/14821-resolving-problems-encountered-in-spectrophotometric-analysis-of-a2026-10-04 https://evidence-hub.com/study/14822-re-analyzing-the-empact-mi-trial-a-pairwise-comparison-study-of2026-10-06 https://evidence-hub.com/study/14823-effect-of-empagliflozin-on-neutrophil-and-lymphocyte-counts-and-their2026-10-06 https://evidence-hub.com/study/14825-data-from-empagliflozin-restores-cardiac-function-in-obese-diabetic2026-10-06 https://evidence-hub.com/study/14826-advancing-methods-for-fair-outcome-comparisons-in-clinical-trials2026-10-06 https://evidence-hub.com/study/14827-advancing-methods-for-fair-outcome-comparisons-in-clinical-trials2026-10-06 https://evidence-hub.com/study/14828-assay-of-empagliflozin-tablets-by-a-stability-indicating-micellar2026-09-27 https://evidence-hub.com/study/14829-open-dataset-of-physicochemical-adme-and-clinical-pk-parameters-for2026-10-06 https://evidence-hub.com/study/14830-dataset-related-to-empagliflozin-protects-glomerular-endothelial-cell2026-09-27 https://evidence-hub.com/study/14831-dataset-for-empagliflozin-normalizes-the-size-and-number-of2026-09-27 https://evidence-hub.com/study/14833-initial-decline-in-estimated-glomerular-filtration-rate-after2026-10-06 https://evidence-hub.com/study/14835-risk-factors-for-the-initial-decline-in-estimated-glomerular2026-10-06 https://evidence-hub.com/study/14836-available-datapackage-for-study-empact-mi-a-streamlined-multicentre2026-10-06 https://evidence-hub.com/study/14838-available-datapackage-for-study-a-phase-iii-randomised-double-blind2026-10-06 https://evidence-hub.com/study/14839-available-datapackage-for-study-a-phase-iii-randomised-double-blind2026-10-06 https://evidence-hub.com/study/14847-dataset-for-sodium-glucose-transporter-2-inhibition-has-no2026-09-27 https://evidence-hub.com/study/14848-weight-cycling-in-rats-and-ace-activity-in-tally-ho-mice2026-10-06 https://evidence-hub.com/study/14849-sglt2-inhibitor-canagliflozin-alleviates-high-glucose-induced2026-09-27 https://evidence-hub.com/study/14850-sglt2-inhibition-and-inflammasome-pathway-and-diabetic-nephropathy2026-10-06 https://evidence-hub.com/study/14851-sglt2-inhibitors-in-heart-failure-with-preserved-ejection-fraction2026-10-06 https://evidence-hub.com/study/14852-improving-efficiency-of-win-ratio-analyses-through-covariate2026-10-06 https://evidence-hub.com/study/14853-the-public-repurposing-index-pri-2-0-strategic-enhancement-and2026-10-06 https://evidence-hub.com/study/14854-chronic-heart-failure-chf-and-new-drugs-analytical-review-of-efficacy2026-10-06 https://evidence-hub.com/study/14855-the-importance-of-using-sglt-2-inhibitors-in-heart-failure-an-updated2026-10-01 https://evidence-hub.com/study/14856-empagliflozina-per-al-tractament-de-la-insuficiencia-cardiaca-cronica2026-10-01 https://evidence-hub.com/study/14857-vericiguat-per-al-tractament-de-la-insuficiencia-cardiaca-cronica-amb2026-10-01 https://evidence-hub.com/study/14860-recurrent-pericardial-effusions-following-a-pacemaker-implant-a-case2026-10-01 https://evidence-hub.com/study/14861-effects-of-empagliflozin-on-cardiac-function2026-09-27 https://evidence-hub.com/study/14862-cardiovascular-actions-of-empagliflozin-in-no-deficient-hypertension2026-09-27 https://evidence-hub.com/study/14863-the-role-of-empagliflozin-in-cardiac-fibroblast-mediated2026-10-04 https://evidence-hub.com/study/14864-pleiotrope-effekte-empagliflozins-auf-humanes-und-murines-myokard2026-09-27 https://evidence-hub.com/study/14865-empagliflozins-effect-on-molecular-processes-in-hyperglycemia-and2026-10-01 https://evidence-hub.com/study/14867-empagliflozin-analytical-development-identification-of-degradation2026-09-27 https://evidence-hub.com/study/14868-empagliflozin-to-prevent-worsening-of-left-ventricular-volumes-and2026-10-01 https://evidence-hub.com/study/14871-development-and-validation-of-analytical-methods-for-quality-control2026-09-27 https://evidence-hub.com/study/14873-the-effect-of-empagliflozin-on-left-ventricular-mass-and-myocardial2026-10-01 https://evidence-hub.com/study/14874-influence-of-empagliflozin-on-myocardial-infarction-induced-cardiac2026-09-27 https://evidence-hub.com/study/14876-effect-of-chronic-empagliflozin-and-sacubitril-valsartan2026-09-27 https://evidence-hub.com/study/14877-pleiotropic-effects-of-the-sglt2-inhibitor-empagliflozin-on-the2026-09-27 https://evidence-hub.com/study/14878-management-of-postprandial-hypoglycemia-after-bariatric-surgery2026-09-27 https://evidence-hub.com/study/14879-comparison-of-canagliflozin-dapagliflozin-and-empagliflozin-added-to2026-10-01 https://evidence-hub.com/study/14880-empagliflozin-and-its-effect-on-endothelial-dysfunction-through2026-09-27 https://evidence-hub.com/study/14881-the-effect-of-empagliflozin-on-kidney-injury-markers-in-subjects-with2026-10-01 https://evidence-hub.com/study/14882-study-of-the-cardioprotective-effect-of-empagliflozin-on-acute2026-10-01 https://evidence-hub.com/study/14883-study-of-the-effect-of-empagliflozin-on-an-experimental-murine-model2026-09-27 https://evidence-hub.com/study/14884-effect-of-brief-incubation-of-skeletal-muscle-with-the-sodium-glucose2026-09-27 https://evidence-hub.com/study/14885-behandling-av-post-transplantasjonsdiabetes-mellitus-hos2026-10-01 https://evidence-hub.com/study/14886-measuring-health-related-quality-of-life-among-patients-with-chronic2026-10-01 https://evidence-hub.com/study/14888-cardiometabolic-effects-of-the-sglt2-inhibitor-empagliflozin-in-an2026-09-27 https://evidence-hub.com/study/14891-renoprotection-conferred-by-empagliflozin-in-heart-failure-is2026-09-27 https://evidence-hub.com/study/14892-empagliflozin2026-10-01 https://evidence-hub.com/study/14894-empagliflozin-inhibits-proximal-tubule-nhe3-activity-preserves2026-09-27 https://evidence-hub.com/study/14896-empagliflozin-for-prevention-of-acute-kidney-injury-in-patients-with2026-09-27 https://evidence-hub.com/study/14898-impact-of-empagliflozin-on-endothelial-dysfunction-and-impaired2026-09-27 https://evidence-hub.com/study/14899-cost-utility-analysis-of-sglt2-inhibitors-empagliflozin-dapagliflozin2026-09-27 https://evidence-hub.com/study/14903-novel-interventional-therapies-to-improve-cardiovascular-risk-in2026-09-27 https://evidence-hub.com/study/14904-when-innovations-collide-the-adjunct-use-of-sglt2-inhibitors-or-glp12026-09-27 https://evidence-hub.com/study/14905-cardiac-energy-metabolism-and-the-role-of-sglt2-inhibitors-in-heart2026-09-27 https://evidence-hub.com/study/14906-assessing-the-impact-of-cardioprotective-therapies-on-vascular2026-10-01 https://evidence-hub.com/study/14907-cardiac-reverse-remodeling-as-a-mechanism-for-the-cardioprotective2026-10-01 https://evidence-hub.com/study/14908-sglt2-inhibitors-salty-or-just-sweet2026-09-27 https://evidence-hub.com/study/14909-hypervulnerable-youth-in-a-hypermasculine-world-a-critical-analysis2026-09-27 https://evidence-hub.com/study/14910-prospective-study-on-prescribing-pattern-and-short-term-outcomes-of2026-09-27 https://evidence-hub.com/study/14912-direct-cardiac-and-endothelial-effects-of-sodium-glucose2026-09-27 https://evidence-hub.com/study/14913-sodium-glucose-cotransporter-2-inhibitors-regulate-vascular-cell2026-09-27 https://evidence-hub.com/study/14914-evaluation-of-comparative-efficacy-and-pleiotrophy-of-the-available2026-09-27 https://evidence-hub.com/study/14915-the-effects-of-sodium-glucose-co-transporter-2-inhibition-on-plasma2026-10-01 https://evidence-hub.com/study/14916-analysis-of-adverse-events-associated-with-sglt2-inhibitors-and2026-10-01 https://evidence-hub.com/study/14917-sodium-glucose-cotransporter-2-inhibition-and-renal-function2026-10-01 https://evidence-hub.com/study/14918-novel-monitoring-and-management-strategies-for-hepatic-glycogen2026-10-01 https://evidence-hub.com/study/14919-paving-the-way-for-improved-management-of-heart-failure-with2026-10-01 https://evidence-hub.com/study/14921-no-pain-no-gain-a-resource-based-model-of-work-to-family-conflict-and2026-09-27 https://evidence-hub.com/study/14922-vitamin-d-supplementation-in-heart-failure-confusion-without-a-cause2026-10-01 https://evidence-hub.com/study/14923-evaluation-du-role-des-co-transporteurs-sodium-glucose-sglt1-et-22026-09-27 https://evidence-hub.com/study/14924-modelling-adverse-drug-reactions-using-induced-pluripotent-stem-cell2026-09-27 https://evidence-hub.com/study/14925-analisis-pengaruh-pemasangan-filter-pasif-terhadap-penurunan2026-09-27 https://evidence-hub.com/study/14926-renal-glukosehomeostase-og-hyperglykemi-ved-type-2-diabetes-mellitus2026-10-01 https://evidence-hub.com/study/14927-identifying-the-social-problem-of-rape-on-campus-responses-from2026-09-27 https://evidence-hub.com/study/14928-chronic-kidney-disease-and-peritoneal-dialysis-induced-inflammation2026-09-27 https://evidence-hub.com/study/14929-update-on-the-impact-of-sodium-glucose-cotransporter-inhibitors-in2026-10-01 https://evidence-hub.com/study/149302026-09-27 https://evidence-hub.com/study/14931-family-strengths-perceived-by-university-students-and-government2026-09-27 https://evidence-hub.com/study/14932-pharmacological-assessment-on-hormonal-dysfunction-in-thyroid2026-09-27 https://evidence-hub.com/study/14933-investigation-of-the-effects-of-sodium-glucose-co-transporter-22026-10-01 https://evidence-hub.com/study/14934-precision-medicine-in-type-2-diabetes2026-09-27 https://evidence-hub.com/study/149352026-09-27 https://evidence-hub.com/study/14936-eficacia-de-farmacos-hipoglucemiantes-en-diabetes-mellitus-tipo-2-en2026-09-27 https://evidence-hub.com/study/14937-anti-thrombotic-therapies-targeting-novel-approaches-to-improve-the2026-09-27 https://evidence-hub.com/study/14938-using-multi-parametric-imaging-and-multi-nuclear-cardiac-magnetic2026-09-27 https://evidence-hub.com/study/14939-evaluation-des-krankheitsverlaufs-von-patienten-mit-diabetes-mellitus2026-10-01 https://evidence-hub.com/study/14940-investigation-of-the-effects-of-sodium-glucose-co-transporter2026-10-01 https://evidence-hub.com/study/14941-metabolic-fingerprinting-in-heart-failure2026-09-27 https://evidence-hub.com/study/14942-association-of-glp1r-polymorphisms-with-the-incretin-response-the2026-09-27 https://evidence-hub.com/study/14943-optimisation-de-la-prevention-de-la-mort-subite-chez-les-diabetiques2026-10-01 https://evidence-hub.com/study/14944-o-diabetes-mellitus-induz-alteracoes-epigeneticas-no-gene-slc2a4-em2026-10-01 https://evidence-hub.com/study/14945-new-methods-for-the-site-selective-o-h-and-c-h-functionalization-of2026-09-27 https://evidence-hub.com/study/14946-contribution-of-ketone-oxidation-on-energy-production-in-the-failing2026-09-27 https://evidence-hub.com/study/14947-role-of-lipotoxicity-in-vascular-and-cell-damage-in-type-2-diabetes2026-10-01 https://evidence-hub.com/study/14948-functional-approaches-to-study-renal-and-mitochondrial-toxicity-in2026-10-01 https://evidence-hub.com/study/14949-regulation-of-the-endothelial-cell-glycocalyx-and-its-role-in2026-09-27 https://evidence-hub.com/study/14950-qt-interval-abnormalities-in-sulfonylurea-treated-type-2-diabetes2026-09-27 https://evidence-hub.com/study/14951-flavonoids-and-their-effect-on-sglt-isoforms2026-09-27 https://evidence-hub.com/study/14952-personalized-and-evidence-based-management-of-type-2-diabetes-the2026-09-27 https://evidence-hub.com/study/149542026-09-27 https://evidence-hub.com/study/14955-sodium-glucose-co-transporter-2-inhibitors-and-risk-of-early-breast2026-09-27 https://evidence-hub.com/study/14957-international-comparisons-of-the-quality-and-outcomes-of-integrated2026-10-01 https://evidence-hub.com/study/14958-patienter-med-diabetes-typ-2-och-etablerad-hjart-karlsjukdom-i2026-09-27 https://evidence-hub.com/study/14959-vergleich-der-gesundheitskosten-von-typ-2-diabetikern-bei-der2026-09-27 https://evidence-hub.com/study/14960-considering-returns-on-federal-investment-in-the-negotiated-maximum2026-10-01 https://evidence-hub.com/study/14961-efficacy-of-sodium-glucose-cotransport-2-inhibitors-of-fixed-dose-in2026-10-01 https://evidence-hub.com/study/14963-efficacy-and-safety-of-sodium-glucose-cotransporter-2-sglt22026-10-01 https://evidence-hub.com/study/14964-what-difference-does-a-diagnosis-make-evidence-from-marginal-patients2026-10-01 https://evidence-hub.com/study/14967-pharmaceutical-supply-chain-assessment-for-sri-lanka2026-10-01 https://evidence-hub.com/study/14971-farmacia-luisa-vasconcelos-guimaraes-e-nos-servicos-farmaceuticos-da2026-10-01 https://evidence-hub.com/study/14973-farmacia-sa-da-bandeira-porto-e-servicos-farmaceuticos-do-hospital2026-10-01 https://evidence-hub.com/study/14974-farmacia-das-guardeiras-moreira-da-maia-e-servicos-farmaceuticos-do2026-10-01 https://evidence-hub.com/study/149762026-10-06 https://evidence-hub.com/study/14978-children-and-young-people-with-chronic-health-conditions-in-the2026-10-01 https://evidence-hub.com/study/14979-children-and-young-people-with-chronic-health-conditions-in2026-10-01 https://evidence-hub.com/study/14980-farmacia-fonte-da-moura-porto2026-10-06 https://evidence-hub.com/study/14981-chronic-kidney-disease-in-community-dwelling-adults-aged-50-years-in2026-10-01 https://evidence-hub.com/study/14982-a-bayesian-cost-effectiveness-analysis-of-holobalance-holograms-for2026-10-01 https://evidence-hub.com/study/14983-when-biology-crosses-categories-before-medicine-does2026-10-06 https://evidence-hub.com/study/14984-farmacia-martins-da-costa-maia2026-10-01 https://evidence-hub.com/study/14985-establishment-of-center-for-diagnostic-nanosystems2026-10-01 https://evidence-hub.com/study/14986-farmacia-da-liga-das-associacoes-de-socorro-mutuo-vila-nova-de-gaia-e2026-10-01 https://evidence-hub.com/study/14988-integraal-stikstofonderzoek-implementatie-en-gebruik-van-nitrogenius2026-09-27 https://evidence-hub.com/study/14989-a-minha-farmacia-barcelos-e-servicos-farmaceuticos-do-hospital-santa2026-10-01 https://evidence-hub.com/study/14990-on-the-level-evidence-for-action-on-type-2-diabetes2026-10-01 https://evidence-hub.com/study/14991-implementering-av-nya-lakemedelsrekommendationer-vid-hjartsvikt-siq2026-10-06 https://evidence-hub.com/study/14992-farmacia-d-arrabida-vila-nova-de-gaia-e-servicos-farmaceuticos-da2026-10-06 https://evidence-hub.com/study/14993-farmacia-de-sao-pedro-sao-pedro-da-cova-e-nos-servicos-farmaceuticos2026-10-01 https://evidence-hub.com/study/14994-farmacia-nova-de-famalicao-requiao-e-nos-servicos-farmaceuticos-da2026-10-01 https://evidence-hub.com/study/14995-farmacia-ferreira-da-silva-porto-e-servicos-farmaceuticos-do-hospital2026-10-01 https://evidence-hub.com/study/14996-farmacia-arcozelo-arcozelo-e-servicos-farmaceuticos-do-hospital2026-10-01 https://evidence-hub.com/study/15000-farmacia-gomes-esposende-e-na-shoppers-drug-mart-1537-thornhill2026-10-01 https://evidence-hub.com/study/15001-farmacia-do-viso-senhora-da-hora-e-nos-servicos-farmaceuticos-do2026-10-01 https://evidence-hub.com/study/15002-relatorios-de-estagio-realizado-na-farmacia-confianca-e-no-hospital2026-10-01 https://evidence-hub.com/study/15003-farmacia-lever-vila-nova-de-gaia-e-nos-servicos-farmaceuticos-do2026-10-01 https://evidence-hub.com/study/15004-empa-kidney-expanding-the-range-of-kidney-protection-by-sglt22026-10-06 https://evidence-hub.com/study/15005-emperor-preserved-a-promise-fulfilled2026-10-06 https://evidence-hub.com/study/15006-the-kidney-and-cardiovascular-outcome-trials2026-10-06 https://evidence-hub.com/study/15008-elucidating-the-cardioprotective-mechanisms-of-sodium-glucose2026-10-01 https://evidence-hub.com/study/15009-sglt2-inhibitors-in-non-diabetic-kidney-disease2026-10-06 https://evidence-hub.com/study/15010-sglt-2-inhibitors-and-circulating-progenitor-cells-in-diabetes2026-10-06 https://evidence-hub.com/study/15011-sglt-2-inhibitors-and-regenerative-cell-exhaustion2026-10-06 https://evidence-hub.com/study/15012-early-egfr-decline-after-sglt2i-initiation-knowns-and-unknowns2026-10-06 https://evidence-hub.com/study/15013-cardiovascular-outcomes-with-empagliflozin-news-for-type-2-diabetes2026-10-06 https://evidence-hub.com/study/15014-role-of-sodium-glucose-co-transporter-2-inhibitors-in-the-management2026-10-06 https://evidence-hub.com/study/15015-empagliflozin-s-fuel-hypothesis-not-so-soon2026-10-06 https://evidence-hub.com/study/15016-uncoupling-glucosuria-from-infection-sglt2-inhibition-modulates2026-10-06 https://evidence-hub.com/study/15017-sglt2-inhibitors-for-non-diabetic-kidney-disease-drugs-to-treat-ckd2026-10-06 https://evidence-hub.com/study/15018-reversing-endothelial-dysfunction-with-empagliflozin-to-improve2026-10-06 https://evidence-hub.com/study/15019-trials-and-tribulations-the-challenges-of-clinical-trials-in-children2026-10-06 https://evidence-hub.com/study/15020-sodium-glucose-co-transporter-2-inhibition-as-a-mitochondrial-therapy2026-10-06 https://evidence-hub.com/study/15021-can-we-go-beyond-surrogates2026-10-06 https://evidence-hub.com/study/15022-paradoxical-insights-into-whole-body-metabolic-adaptations-following2026-10-06 https://evidence-hub.com/study/15023-heart-failure-sglt2-inhibitors-and-heart-failure-clinical-implications2026-10-06 https://evidence-hub.com/study/15024-sglt2-inhibitor-empagliflozin-finally-at-the-latter-stage-of2026-10-06 https://evidence-hub.com/study/15025-lessons-from-leader-all-round-leadership2026-10-06 https://evidence-hub.com/study/15026-sglt2-inhibitor-not-a-traditional-diuretic-for-heart-failure2026-10-06 https://evidence-hub.com/study/15027-pleiotropic-effects-of-sglt2-inhibitors-beyond-the-effect-on-glycemic2026-10-06 https://evidence-hub.com/study/15029-sglt2-inhibitors-in-patients-with-cirrhosis-and-diabetes-mellitus-a2026-10-06 https://evidence-hub.com/study/15030-need-for-streamlined-use-of-dpp-4-inhibitors-in-the-treatment-of-type2026-10-06 https://evidence-hub.com/study/15031-a-new-era-in-the-management-of-type-2-diabetes-is-cardioprotection-at2026-10-06 https://evidence-hub.com/study/15032-renin-angiotensin-system-blockers-sglt2-inhibitors-mineralocorticoid2026-10-06 https://evidence-hub.com/study/15033-underutilization-of-sodium-glucose-cotransporter-2-sglt-2-inhibitors2026-10-06 https://evidence-hub.com/study/15034-metabolic-analysis-and-renal-protective-effects-of-linagliptin-and2026-10-04 https://evidence-hub.com/study/15035-empa-s-new-clothes-the-untold-story-of-the-empa-reg-outcome-trial2026-10-01 https://evidence-hub.com/study/15036-empagliflozin-reduces-cardiovascular-events-and-mortality-in-type-22026-10-06 https://evidence-hub.com/study/15038-sitagliptin-and-other-gliptins-why-prescribe-them2026-10-06 https://evidence-hub.com/study/15039-sglt2-inhibitors-interaction-with-other-renoactive-drugs-in-type-22026-10-06 https://evidence-hub.com/study/15040-empagliflozin-added-to-metformin-and-sulfonylurea-therapy-in-patients2026-10-04 https://evidence-hub.com/study/15041-treatment-with-sodium-glucose-cotransporter-2-inhibitors-in-heart2026-10-06 https://evidence-hub.com/study/15042-a-call-for-a-new-paradigm-for-diabetes-care-in-the-era-of-sodium2026-10-06 https://evidence-hub.com/study/15043-commentary-sglt-inhibitors-in-type-1-diabetes-place-in-therapy-and-a2026-10-06 https://evidence-hub.com/study/15044-mortality-reduction-in-empa-reg-outcome-trial-beyond-the-antidiabetes2026-10-01 https://evidence-hub.com/study/15046-sglt-2-inhibition-in-pediatric-ckd-advances-challenges-and2026-10-06 https://evidence-hub.com/study/15048-combination-therapy-for-patients-with-uncontrolled-type-2-diabetes2026-10-04 https://evidence-hub.com/study/15049-lack-of-durable-natriuresis-and-objective-decongestion-following2026-10-06 https://evidence-hub.com/study/15050-sodium-glucose-co-transporter-2-inhibitor-for-diabetes2026-10-06 https://evidence-hub.com/study/15051-diabetes-and-branched-chain-amino-acids-what-is-the-link2026-10-06 https://evidence-hub.com/study/15052-podcast-episode-2-heart-failure-management-in-patients-with-diabetes2026-10-06 https://evidence-hub.com/study/15053-editorial-for-special-issue-molecular-mechanisms-underlying-fatty2026-10-06 https://evidence-hub.com/study/15055-empagliflozin-induced-lipidome-remodeling-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/15057-a-case-of-mitochondrial-diabetes-mellitus-with-successful-therapeutic2026-10-06 https://evidence-hub.com/study/15059-treatment-of-immunoglobulin-a-nephropathy-current-perspective-and2026-10-06 https://evidence-hub.com/study/15060-shedding-light-on-the-effects-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/15061-therapeutic-perspective-on-cardiomyopathy-and-heart-failure-in-older2026-10-06 https://evidence-hub.com/study/15062-right-ventricular-dysfunction-in-type-1-diabetic-cardiomyopathy-an2026-10-06 https://evidence-hub.com/study/15064-cvot-summit-report-2024-new-cardiovascular-kidney-and-metabolic2026-10-06 https://evidence-hub.com/study/15065-diabetes-related-renal-complications-insights-on-the-impact-of2026-10-06 https://evidence-hub.com/study/15066-challenges-in-managing-pediatric-heart-failure-especially-in-resource2026-10-06 https://evidence-hub.com/study/15068-editorial-for-the-ijms-special-issue-on-sglt2-inhibitors-volume-22026-10-06 https://evidence-hub.com/study/15070-sodium-dependent-glucose-transporter-2-inhibitors-transforming2026-10-06 https://evidence-hub.com/study/15071-antidiabetic-combination-therapy-and-cardiovascular-outcomes-an2026-10-06 https://evidence-hub.com/study/15072-sodium-dependent-glucose-transporter-2-inhibitors-improve-heart2026-10-06 https://evidence-hub.com/study/15074-zebrafish-models-in-toxicology-and-disease-studies2026-10-06 https://evidence-hub.com/study/15076-are-sodium-glucose-cotransporter-2-inhibitors-safe-adjunctive-drugs2026-10-06 https://evidence-hub.com/study/15077-comprehensive-impact-of-pparg-mutations-in-familial-partial2026-10-06 https://evidence-hub.com/study/15078-searching-in-the-maze-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/15079-breaking-the-diabetes-depression-cycle-exploring-shared-mechanisms2026-10-06 https://evidence-hub.com/study/15080-advancing-cardiovascular-outcomes-with-dapagliflozin-and-sacubitril2026-10-06 https://evidence-hub.com/study/15081-sglt2-inhibitor-an-emerging-pillar-in-heart-failure-therapeutics2026-10-06 https://evidence-hub.com/study/15082-effects-of-sodium-dependent-glucose-transporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/15084-atherosclerotic-and-cardio-metabolic-diseases-from-molecular-basis-to2026-10-06 https://evidence-hub.com/study/15086-exploration-of-metformin-based-drug-combination-for-mitigating2026-10-06 https://evidence-hub.com/study/15087-sglt2-inhibition-for-outcomes-is-this-the-panacea2026-10-06 https://evidence-hub.com/study/15088-nephrocheck-at-10-addressing-unmet-needs-in-aki-diagnosis-and-risk2026-10-06 https://evidence-hub.com/study/15089-euglycemic-diabetic-ketoacidosis-a-rare-but-serious-side-effect-of2026-10-06 https://evidence-hub.com/study/15090-cvot-summit-2022-report-new-cardiovascular-kidney-and-glycemic2026-10-06 https://evidence-hub.com/study/15091-renoprotective-strategies2026-10-06 https://evidence-hub.com/study/15092-effectiveness-and-mechanisms-of-sodium-dependent-glucose-transporter2026-10-06 https://evidence-hub.com/study/15094-sodium-glucose-co-transporter-2-inhibitors-in-the-treatment-of2026-10-06 https://evidence-hub.com/study/15096-sglt2-inhibitors-statins-or-ace-inhibitors-of-the-21st-century2026-10-06 https://evidence-hub.com/study/15098-heart-failure-with-preserved-ejection-fraction-a-distinct-heart2026-10-06 https://evidence-hub.com/study/15099-access-in-all-areas-a-round-up-of-developments-in-market-access-and2026-10-06 https://evidence-hub.com/study/15100-new-therapies-in-pulmonary-arterial-hypertension-recent-insights2026-10-06 https://evidence-hub.com/study/15101-use-of-the-biomarker-score-in-determining-the-risk-of-heart-failure2026-10-06 https://evidence-hub.com/study/15102-from-screening-to-treatment-the-new-landscape-of-diabetic-kidney2026-10-06 https://evidence-hub.com/study/15103-estimation-of-glomerular-filtration-rate-in-cardiorenal-patients-a2026-10-06 https://evidence-hub.com/study/15104-agent-specific-histopathology-stratified-hematologic-malignancy-risk2026-10-06 https://evidence-hub.com/study/15105-sodium-glucose-co-transporter-2-inhibitors-induced-euglycemic2026-10-06 https://evidence-hub.com/study/15106-gaps-in-modern-heart-failure-and-chronic-kidney-disease-research2026-10-06 https://evidence-hub.com/study/15108-aging-like-fine-wine-mischievous-microbes-and-other-factors2026-10-06 https://evidence-hub.com/study/15110-relook-at-dpp-4-inhibitors-in-the-era-of-sglt-2-inhibitors2026-10-06 https://evidence-hub.com/study/15111-teneligliptin-mitigates-diabetic-cardiomyopathy-through-inflammasome2026-10-06 https://evidence-hub.com/study/15112-macrophage-modulation-with-dipeptidyl-peptidase-4-inhibitors-a-new2026-10-06 https://evidence-hub.com/study/15114-heart-failure-with-reduced-mildly-reduced-or-preserved-left2026-10-06 https://evidence-hub.com/study/15115-cvot-summit-report-2023-new-cardiovascular-kidney-and-metabolic2026-10-06 https://evidence-hub.com/study/15117-mind-the-gap-in-kidney-care-translating-what-we-know-into-what-we-do2026-10-06 https://evidence-hub.com/study/15118-heart-failure-with-preserved-ejection-fraction-and-obstructive-sleep2026-10-06 https://evidence-hub.com/study/15119-report-from-the-cvot-summit-2021-new-cardiovascular-renal-and2026-10-06 https://evidence-hub.com/study/15120-protein-restriction-in-ckd-an-outdated-strategy-in-the-modern-era2026-10-06 https://evidence-hub.com/study/15121-nash-and-systemic-complications-from-basic-to-clinical-research2026-10-06 https://evidence-hub.com/study/15124-the-health-system-in-costa-rica-focus-on-the-management-of-diabetes2026-10-06 https://evidence-hub.com/study/15125-sglt2-inhibitors-and-kidney-outcomes-in-patients-with-chronic-kidney2026-10-01 https://evidence-hub.com/study/15126-glp-1-receptor-agonists-vs-sglt-2-inhibitors-the-gap-seems-to-be2026-10-06 https://evidence-hub.com/study/15127-rising-tide-the-global-surge-of-type-2-diabetes-in-children-and2026-10-06 https://evidence-hub.com/study/15128-cardiology-on-the-cutting-edge-updates-from-the-european-society-of2026-10-06 https://evidence-hub.com/study/15129-mind-the-gap-in-kidney-care-translating-what-we-know-into-what-we-do2026-10-06 https://evidence-hub.com/study/15130-worldwide-inertia-to-the-use-of-cardiorenal-protective-glucose2026-10-06 https://evidence-hub.com/study/15132-report-from-the-cvot-summit-2020-new-cardiovascular-and-renal-outcomes2026-10-06 https://evidence-hub.com/study/15133-the-risk-for-urinary-tract-infections-with-sodium-glucose2026-10-06 https://evidence-hub.com/study/15137-empagliflozin-for-non-diabetic-metabolic-dysfunction-associated2026-10-06 https://evidence-hub.com/study/15149-follow-the-empulse-in-hospital-initiation-of-empagliflozin-for-heart2026-10-06 https://evidence-hub.com/study/15155-two-year-therapeutic-efficacy-and-safety-of-initial-triple2026-10-06 https://evidence-hub.com/study/15165-effects-of-baricitinib-empagliflozin-linagliptin-and-telmisartan-on2026-10-06 https://evidence-hub.com/study/15166-interaction-of-natriuretic-peptide-levels-and-ejection-fraction-on2026-10-06 https://evidence-hub.com/study/15175-empagliflozin-inhibits-cardiac-late-sodium-current-via-ca-calmodulin2026-10-06 https://evidence-hub.com/study/15177-trace-element-equilibrium-in-acute-heart-failure-and-the-effect-of2026-10-06 https://evidence-hub.com/study/15187-the-association-between-anthropometric-indicators-of-obesity-and2026-10-06 https://evidence-hub.com/study/15188-influence-of-endpoint-definitions-on-the-effect-of-empagliflozin-on2026-10-06 https://evidence-hub.com/study/15190-time-to-invest-in-the-future-assessing-the-cost-effectiveness-of2026-10-06 https://evidence-hub.com/study/15191-empagliflozin-and-assessment-of-lower-limb-amputations-in-the-empa2026-09-29 https://evidence-hub.com/study/15197-reply-to-comment-on-clinical-benefits-of-empagliflozin-in-very-old2026-09-27 https://evidence-hub.com/study/15201-empagliflozin-in-heart-failure-with-preserved-and-mildly-reduced2026-10-06 https://evidence-hub.com/study/15204-retinopathy-outcomes-with-empagliflozin-versus-placebo-in-the-empa2026-10-01 https://evidence-hub.com/study/15205-empagliflozin-and-cardiovascular-outcomes-in-patients-with-type-22026-09-29 https://evidence-hub.com/study/15209-empagliflozin-across-the-stages-of-diabetic-heart-disease2026-09-27 https://evidence-hub.com/study/15211-does-the-cardioprotective-effect-of-empagliflozin-involve-inhibition2026-10-01 https://evidence-hub.com/study/15212-empagliflozin-as-an-adjunctive-therapy-for-type-1-diabetes2026-10-01 https://evidence-hub.com/study/15213-possible-mechanism-of-hematocrit-elevation-by-sodium-glucose2026-10-01 https://evidence-hub.com/study/15214-emerging-roles-of-sglt2-inhibitors-in-obesity-and-insulin-resistance2026-10-01 https://evidence-hub.com/study/15217-heart-failure-drug-treatment-the-fantastic-four2026-10-01 https://evidence-hub.com/study/15218-tackling-myocardial-oxidative-stress-with-empagliflozin-are-we-big2026-09-27 https://evidence-hub.com/study/15221-finerenone-with-empagliflozin-in-ckd-with-diabetes-confidence-only-a2026-09-27 https://evidence-hub.com/study/15222-comment-on-mone-et-al-empagliflozin-improves-cognitive-impairment-in2026-10-01 https://evidence-hub.com/study/15224-pathways-to-cardiorenal-complications-in-type-2-diabetes-mellitus-a2026-10-01 https://evidence-hub.com/study/15225-review-dapagliflozin-increases-and-empagliflozin-reduces-adverse2026-09-27 https://evidence-hub.com/study/15227-canagliflozin-and-myocardial-oxidative-stress-sglt1-inhibition-takes2026-10-01 https://evidence-hub.com/study/15228-the-serendipitous-story-of-sglt2-inhibitors-in-heart-failure2026-10-01 https://evidence-hub.com/study/15229-are-the-benefits-of-sglt2-inhibitors-in-heart-failure-and-a-reduced2026-10-01 https://evidence-hub.com/study/15230-more-evidence-for-sglt2-inhibitors-in-heart-failure2026-09-27 https://evidence-hub.com/study/15231-two-tales-one-story2026-10-01 https://evidence-hub.com/study/15233-regression-of-left-ventricular-hypertrophy-with-sglt2-inhibitors2026-09-27 https://evidence-hub.com/study/15234-looking-back-at-look-ahead-through-the-lens-of-recent-diabetes2026-10-01 https://evidence-hub.com/study/15235-sglt2-inhibitors-not-for-hypertension-but-exceedingly-useful-in2026-10-01 https://evidence-hub.com/study/15236-the-ethics-of-conducting-clinical-trials-with-sodium-glucose2026-09-29 https://evidence-hub.com/study/15237-treatment-of-diabetes-and-heart-failure-joint-forces2026-09-27 https://evidence-hub.com/study/15238-plausible-effects-of-sodium-glucose-cotransporter-2-inhibitors-on2026-10-01 https://evidence-hub.com/study/15239-a-call-for-more-complete-reporting-of-cardiovascular-death2026-10-01 https://evidence-hub.com/study/15240-sglt2-inhibitors-reviving-the-sodium-hydrogen-exchanger2026-09-27 https://evidence-hub.com/study/15243-sodium-glucose-cotransporter-2-inhibitors-and-amputation-risk2026-10-01 https://evidence-hub.com/study/15245-victims-of-success-in-failure2026-10-01 https://evidence-hub.com/study/15246-quality-of-life-in-emperor-reduced-emphasizing-what-is-important-to2026-10-01 https://evidence-hub.com/study/15250-reply-aspirin-and-glp-1ras-the-missing-confounders-of-empagliflozin2026-09-27 https://evidence-hub.com/study/15252-letter-to-the-editor-indication-specific-cost-effectiveness-of2026-10-01 https://evidence-hub.com/study/15253-proving-sglt2-inhibitor-mediated-improvement-in-cardiomyocyte2026-10-01 https://evidence-hub.com/study/15254-strategy-for-mitigating-dka-risk-in-patients-with-type-1-diabetes-on2026-10-01 https://evidence-hub.com/study/15255-sodium-glucose-cotransporter-2-inhibitors-in-heart-failure-how2026-09-27 https://evidence-hub.com/study/15258-comment-on-kaul-mitigating-cardiovascular-risk-in-type-2-diabetes2026-10-01 https://evidence-hub.com/study/15259-sglt2-inhibitors-in-heart-failure-targeted-metabolomics-and-energetic2026-10-01 https://evidence-hub.com/study/15261-mechanisms-of-blood-pressure-reduction-with-sodium-glucose-co2026-10-01 https://evidence-hub.com/study/15262-diamonds-in-the-rough2026-10-01 https://evidence-hub.com/study/15263-do-sglt2-inhibitors-increase-the-risk-of-amputation-make-haste-slowly2026-09-27 https://evidence-hub.com/study/15264-glucoraphanin-a-broccoli-sprout-extract-that-ameliorates-obesity2026-10-01 https://evidence-hub.com/study/15265-editorial-the-role-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-01 https://evidence-hub.com/study/15266-authors-reply-acute-cisplatin-nephrotoxicity-sodium-glucose2026-09-27 https://evidence-hub.com/study/15267-sodium-glucose-cotransporter-inhibitors-beyond-glycaemic-control2026-10-01 https://evidence-hub.com/study/15268-decoding-the-effects-of-sglt2-inhibitors-on-cardiac-arrhythmias-in2026-09-27 https://evidence-hub.com/study/15269-dapagliflozin-advanced-chronic-kidney-disease-and-mortality-new2026-10-01 https://evidence-hub.com/study/15270-sglt-receptors-and-myocardial-ischaemia-reperfusion-injury-inhibition2026-10-01 https://evidence-hub.com/study/15272-world-health-organization-guidelines-on-medicines-for-diabetes2026-09-27 https://evidence-hub.com/study/15273-editorial-pharmacoeconomics-in-the-era-of-health-technology2026-10-01 https://evidence-hub.com/study/15276-biomarker-driven-prognostic-model-for-risk-prediction-in-heart2026-10-01 https://evidence-hub.com/study/15278-medication-counselling-with-sodium-glucose-transporter-2-inhibitor2026-09-27 https://evidence-hub.com/study/15281-editorial-worsening-heart-failure-challenges-treatments-future2026-10-01 https://evidence-hub.com/study/15282-left-ventricular-performance-by-work-and-wasted-energy-is-strain-not2026-10-01 https://evidence-hub.com/study/15283-on-the-prognostic-value-of-post-load-glucose-in-patients-with2026-10-01 https://evidence-hub.com/study/15289-clinical-evidence-and-treatment-requirements-related-to-heart-failure2026-09-27 https://evidence-hub.com/study/15290-diabetes-mellitus-an-important-risk-factor-for-peripheral-vascular2026-10-01 https://evidence-hub.com/study/15291-diabetes-and-ischaemic-stroke-a-deadly-association2026-09-27 https://evidence-hub.com/study/15292-role-of-metformin-for-weight-management-in-patients-without-type-22026-10-06 https://evidence-hub.com/study/15293-repurposing-metformin-for-the-treatment-of-gastrointestinal-cancer2026-10-06 https://evidence-hub.com/study/15294-transporters-involved-in-metformin-pharmacokinetics-and-treatment2026-10-06 https://evidence-hub.com/study/15295-metformin-new-applications-for-an-old-drug2026-10-06 https://evidence-hub.com/study/15296-the-role-of-metformin-in-the-cardiokidney-metabolic-patient2026-10-06 https://evidence-hub.com/study/15297-the-direct-targets-of-metformin-in-diabetes-and-beyond2026-10-08 https://evidence-hub.com/study/15298-insight-into-the-molecular-mechanism-of-diabetic-kidney-disease-and2026-10-06 https://evidence-hub.com/study/15299-impact-of-metformin-on-immunological-markers-implication-in-its-anti2026-10-06 https://evidence-hub.com/study/15300-a-global-perspective-on-the-use-occurrence-fate-and-effects-of-anti2026-10-06 https://evidence-hub.com/study/15301-metformin-cancer-and-glucose-metabolism2026-10-08 https://evidence-hub.com/study/15302-the-use-of-metformin-in-the-management-of-polycystic-ovary-syndrome2026-10-06 https://evidence-hub.com/study/15303-effects-of-metformin-delivery-via-biomaterials-on-bone-and-dental2026-10-06 https://evidence-hub.com/study/15304-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials2026-10-06 https://evidence-hub.com/study/15305-pharmacokinetic-and-pharmacodynamic-evaluation-of-sitagliptin-plus2026-10-06 https://evidence-hub.com/study/15306-the-role-of-metformin-in-polycystic-ovary-syndrome-a-systematic-review2026-10-08 https://evidence-hub.com/study/15307-a-risk-benefit-assessment-of-metformin-in-type-2-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/15308-should-we-continue-or-stop-insulin-sensitizing-drugs-during-pregnancy2026-10-06 https://evidence-hub.com/study/15309-metformin-in-colorectal-cancer-epidemiological-evidence-predictive2026-10-06 https://evidence-hub.com/study/15310-is-metformin-safe-in-pregnancy-a-focus-on-offspring-outcomes2026-10-06 https://evidence-hub.com/study/15311-metformin-prevents-the-onset-and-progression-of-intervertebral-disc2026-10-06 https://evidence-hub.com/study/15312-metformin-as-an-anticancer-agent2026-10-08 https://evidence-hub.com/study/15313-effects-of-metformin-treatment-on-blood-leptin-and-ghrelin-levels-in2026-10-06 https://evidence-hub.com/study/15314-update-on-the-therapeutic-role-of-metformin-in-the-management-of2026-10-06 https://evidence-hub.com/study/15315-metformin-a-novel-biological-modifier-of-tumor-response-to-radiation2026-10-06 https://evidence-hub.com/study/15316-novel-targets-of-metformin-in-cardioprotection-beyond-the-effects2026-10-08 https://evidence-hub.com/study/15317-comparison-of-the-effect-between-pioglitazone-and-metformin-in2026-10-08 https://evidence-hub.com/study/15318-metformin-use-and-the-risk-of-colorectal-adenoma-a-systematic-review2026-10-08 https://evidence-hub.com/study/15319-metformin-saxagliptin-for-type-2-diabetes2026-10-06 https://evidence-hub.com/study/15320-potential-benefit-of-metformin-as-treatment-for-colon-cancer-the2026-10-06 https://evidence-hub.com/study/15321-chinese-expert-consensus-on-metformin-in-clinical-practice-2023-update2026-10-06 https://evidence-hub.com/study/15322-impact-of-metformin-on-male-reproduction2026-10-06 https://evidence-hub.com/study/15323-the-cardioprotective-effects-of-metformin2026-10-08 https://evidence-hub.com/study/15324-effectiveness-of-metformin-in-prevention-of-development-of2026-10-06 https://evidence-hub.com/study/15325-use-of-metformin-in-polycystic-ovary-syndrome2026-10-08 https://evidence-hub.com/study/15326-metformin-for-the-treatment-of-polycystic-ovary-syndrome2026-10-06 https://evidence-hub.com/study/15327-metformin-cognitive-function-and-changes-in-the-gut-microbiome2026-10-06 https://evidence-hub.com/study/15328-is-metformin-a-possible-treatment-for-diabetic-neuropathy2026-10-06 https://evidence-hub.com/study/15329-metformin-a-new-era-for-an-old-drug-in-the-treatment-of-immune2026-10-06 https://evidence-hub.com/study/15330-what-every-dentist-should-know-about-metformin-diabetes-and-cancer2026-10-06 https://evidence-hub.com/study/15331-effect-of-metformin-on-biomarkers-of-placental-mediated-disease-a2026-10-08 https://evidence-hub.com/study/15332-therapeutic-concentrations-of-metformin-a-systematic-review2026-10-08 https://evidence-hub.com/study/15333-efficacy-of-metformin-and-topiramate-in-prevention-and-treatment-of2026-10-06 https://evidence-hub.com/study/15334-the-antihyperglycaemic-effect-of-metformin-therapeutic-and-cellular2026-10-08 https://evidence-hub.com/study/15335-acute-renal-failure-lactic-acidosis-and-metformin-two-case-reports2026-10-06 https://evidence-hub.com/study/15336-delaying-renal-aging-metformin-holds-promise-as-a-potential-treatment2026-10-06 https://evidence-hub.com/study/15337-advances-in-research-on-the-anticancer-properties-and-mechanisms-of2026-10-06 https://evidence-hub.com/study/15338-co-occurrence-toxicity-and-biotransformation-pathways-of-metformin2026-10-06 https://evidence-hub.com/study/15339-impact-of-metformin-use-on-risk-and-mortality-of-hepatocellular2026-10-08 https://evidence-hub.com/study/15340-metformin-treatment-and-homocysteine-a-systematic-review-and-meta2026-10-08 https://evidence-hub.com/study/15341-new-perspectives-on-the-molecular-action-of-metformin-in-the-context2026-10-06 https://evidence-hub.com/study/15342-long-term-use-of-metformin-and-alzheimer-s-disease-beneficial-or2026-10-08 https://evidence-hub.com/study/15343-metformin-use-associated-with-reduced-risk-of-dementia-in-patients2026-10-08 https://evidence-hub.com/study/15344-metformin-and-autoimmunity-a-new-deal-of-an-old-drug2026-10-06 https://evidence-hub.com/study/15345-metformin-as-an-adjuvant-treatment-for-cancer-a-systematic-review-and2026-10-08 https://evidence-hub.com/study/15346-metformin-a-promising-radiosensitizer-in-neoadjuvant-rectal-cancer2026-10-08 https://evidence-hub.com/study/15347-metformin-in-pregnancy-for-women-with-type-2-diabetes-a-review2026-10-06 https://evidence-hub.com/study/15348-fatalities-associated-with-failure-to-adjust-drug-dose-in-patients2026-10-06 https://evidence-hub.com/study/15349-metformin-a-new-option-in-cancer-treatment2026-10-06 https://evidence-hub.com/study/15350-pleiotropic-effects-of-metformin-shaping-the-microbiome-to-manage2026-10-08 https://evidence-hub.com/study/15351-metformin-and-prostate-cancer-stem-cells-a-novel-therapeutic-target2026-10-06 https://evidence-hub.com/study/15352-effect-of-metformin-intervention-during-pregnancy-on-the-gestational2026-10-06 https://evidence-hub.com/study/15353-discontinuation-of-metformin-in-the-setting-of-coronary-angiography2026-10-06 https://evidence-hub.com/study/15354-metformin-in-cancer-therapy-a-new-perspective-for-an-old-antidiabetic2026-10-06 https://evidence-hub.com/study/15355-reducing-insulin-resistance-with-metformin-the-evidence-today2026-10-06 https://evidence-hub.com/study/15356-metformin-associated-lactic-acidosis-a-rare-or-very-rare-clinical2026-10-06 https://evidence-hub.com/study/15357-an-overview-of-metformin-in-the-treatment-of-type-2-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/15358-metformin-and-aging-a-review2026-10-08 https://evidence-hub.com/study/15359-association-of-tumor-pathological-response-with-the-use-of-metformin2026-10-06 https://evidence-hub.com/study/15360-time-course-and-dose-effect-of-metformin-on-weight-in-patients-with2026-10-06 https://evidence-hub.com/study/15361-safety-and-efficacy-of-nateglinide-metformin-combination-therapy-in2026-10-06 https://evidence-hub.com/study/15362-recommendations-for-diagnosis-and-management-of-metformin-induced2026-10-06 https://evidence-hub.com/study/15363-should-patients-with-polycystic-ovarian-syndrome-be-treated-with2026-10-06 https://evidence-hub.com/study/15364-metformin-and-insulin-in-chronic-heart-failure-contraindications-not2026-10-06 https://evidence-hub.com/study/15365-comparison-of-different-drugs-as-add-on-treatments-to-metformin-in2026-10-08 https://evidence-hub.com/study/15366-metformin-reduces-autoimmune-antibody-levels-in-patients-with2026-09-30 https://evidence-hub.com/study/15367-effects-of-metformin-on-blood-lipid-profiles-in-nondiabetic-adults-a2026-10-06 https://evidence-hub.com/study/15368-association-of-preadmission-metformin-use-and-mortality-in-patients2026-10-08 https://evidence-hub.com/study/15369-survival-benefit-of-metformin-adjuvant-treatment-for-pancreatic2026-10-06 https://evidence-hub.com/study/15370-a-review-of-the-evidence-for-the-use-of-metformin-in-the-treatment-of2026-10-06 https://evidence-hub.com/study/15371-direct-effects-of-metformin-in-the-endometrium-a-hypothetical2026-10-06 https://evidence-hub.com/study/15372-cost-effectiveness-analysis-of-dapagliflozin-treatment-versus2026-10-06 https://evidence-hub.com/study/15373-metformin-and-cancer-solutions-to-a-real-world-evidence-failure2026-10-06 https://evidence-hub.com/study/15374-metformin-old-friend-new-ways-of-action-implication-of-the-gut2026-10-08 https://evidence-hub.com/study/15375-survival-benefits-of-metformin-for-colorectal-cancer-patients-with2026-10-08 https://evidence-hub.com/study/15376-oral-antidiabetic-drugs-bioavailability-assessment-of-fixed-dose2026-10-06 https://evidence-hub.com/study/15378-gaba-as-an-overlooked-mediator-of-metformin-action-gaba-mediated2026-10-08 https://evidence-hub.com/study/15379-sex-differences-in-the-risk-of-metformin-associated-gastrointestinal2026-10-08 https://evidence-hub.com/study/15380-context-dependent-modulation-of-ferroptosis-by-metformin-mechanisms2026-10-08 https://evidence-hub.com/study/15381-metformin-in-cancer-immunotherapy-knowledge-mapping-of-an-evolving2026-10-08 https://evidence-hub.com/study/15382-pharmacological-treatment-of-polyendocrine-metabolic-ovarian-syndrome2026-10-08 https://evidence-hub.com/study/15383-metformin-at-the-convergence-of-aging-and-longevity2026-10-08 https://evidence-hub.com/study/15384-recent-advances-in-nanomaterial-delivery-systems-to-administer2026-10-08 https://evidence-hub.com/study/15385-deciphering-the-anti-tumor-mechanisms-of-metformin-through2026-10-08 https://evidence-hub.com/study/15386-comparison-of-metformin-combinations-with-other-repurposed-drugs-in2026-10-08 https://evidence-hub.com/study/15387-beyond-diabetes-continuous-glucose-monitoring-as-a-candidate2026-10-08 https://evidence-hub.com/study/15388-pharmacological-intersections-between-type-2-diabetes-and-cancer2026-10-08 https://evidence-hub.com/study/15389-metformin-and-sleep-health-in-older-adults-with-type-2-diabetes2026-10-08 https://evidence-hub.com/study/15390-tumour-hypoxia-in-clinical-oncology-imaging-therapeutic-strategies2026-10-08 https://evidence-hub.com/study/15391-therapeutics-beyond-delivery-repurposed-drugs-and-biologic-pathways2026-10-08 https://evidence-hub.com/study/15392-short-term-intensive-insulin-therapy-as-a-remission-induction2026-10-08 https://evidence-hub.com/study/15393-transporter-gene-variants-influencing-metformin-pharmacokinetics-and2026-10-08 https://evidence-hub.com/study/15394-key-hepatokines-linking-masld-and-type-2-diabetes-from2026-10-08 https://evidence-hub.com/study/15395-multi-target-antitumor-effects-of-natural-products-and-approved-drug2026-10-08 https://evidence-hub.com/study/15396-metabolic-and-anti-inflammatory-effects-of-berberine-rationale-for2026-10-08 https://evidence-hub.com/study/15397-repositioning-tradition-a-narrative-review-and-expert-opinion-on-the2026-10-08 https://evidence-hub.com/study/15398-immunometabolic-interactions-in-gynecologic-cancers-mechanisms2026-10-08 https://evidence-hub.com/study/15399-metformin-a-promising-candidate-for-slowing-the-progression-of2026-10-08 https://evidence-hub.com/study/15400-therapeutic-potential-of-anti-obesity-drugs-in-obesity-associated2026-10-08 https://evidence-hub.com/study/15401-metformin-as-a-metabolic-reprogramming-interface-in-host-pathogen-and2026-10-08 https://evidence-hub.com/study/15402-preclinical-and-limited-clinical-evidence-for-metformin-in-ulcerative2026-10-08 https://evidence-hub.com/study/15403-melasma-when-dermal-photoageing-precedes-melanocyte-ageing2026-10-08 https://evidence-hub.com/study/15404-metformin-as-a-multifaceted-therapeutic-agent-for-gastrointestinal2026-10-08 https://evidence-hub.com/study/15405-beyond-glycemic-control-metformin-s-multi-target-role-in-preventing2026-10-08 https://evidence-hub.com/study/15406-oral-antidiabetic-agents-from-routine-quality-control-to-bioanalysis2026-10-08 https://evidence-hub.com/study/15407-postpartum-glp-1-receptor-agonists-and-sglt-2-therapies-in-women-with2026-10-08 https://evidence-hub.com/study/15408-early-combination-therapy-in-type-2-diabetes-rethinking-initial2026-10-08 https://evidence-hub.com/study/15409-endogenous-biomarkers-to-evaluate-transporter-mediated-drug-drug2026-10-08 https://evidence-hub.com/study/15410-pharmacomicrobiomics-in-metabolic-syndrome-and-type-2-diabetes-the2026-10-08 https://evidence-hub.com/study/15411-the-mtor-ampk-signaling-axis-in-placental-dysfunction-and2026-10-08 https://evidence-hub.com/study/15412-the-central-role-of-il-6-in-the-differential-effects-of-glp-12026-10-08 https://evidence-hub.com/study/15413-innovative-biosensor-platforms-for-the-detection-of-metformin-in2026-10-08 https://evidence-hub.com/study/15414-metformin-associated-gastrointestinal-intolerance-a-narrative-review2026-10-08 https://evidence-hub.com/study/15415-metformin-as-an-innate-immune-modulator-metabolic-and-epigenetic2026-10-08 https://evidence-hub.com/study/15416-redox-active-first-row-transition-metal-complexes-of-metformin2026-10-08 https://evidence-hub.com/study/15417-mitochondrial-fusion-and-fission-in-age-related-cardio-cerebral2026-10-06 https://evidence-hub.com/study/15418-pharmacological-mechanisms-and-clinical-impacts-of-antidiabetic-drugs2026-10-08 https://evidence-hub.com/study/15419-impact-of-metformin-on-healthspan-related-outcomes-and-incidence-of2026-10-08 https://evidence-hub.com/study/15420-insulin-resistance-in-polycystic-ovary-syndrome-mechanistic-insights2026-10-08 https://evidence-hub.com/study/15421-mechanistic-insights-into-metformin-s-neuroprotective-effects-against2026-10-08 https://evidence-hub.com/study/15422-metformin-beyond-glycemic-control-new-mechanistic-insights-and2026-10-08 https://evidence-hub.com/study/15423-metformin-in-prostate-cancer-a-context-dependent-antitumour-strategy2026-10-08 https://evidence-hub.com/study/15424-metformin-in-endometrial-cancer-from-metabolic-regulation-to2026-10-08 https://evidence-hub.com/study/15425-uncovering-the-metabolic-origins-of-polycystic-ovary-syndrome2026-10-08 https://evidence-hub.com/study/15427-metabolic-dysfunction-associated-steatotic-liver-disease-an-update2026-10-08 https://evidence-hub.com/study/15428-glp-1-receptor-agonists-and-fertility-what-is-known-so-far2026-10-08 https://evidence-hub.com/study/15429-controversial-effects-of-metformin-on-human-physiology-and2026-10-18 https://evidence-hub.com/study/15430-the-therapeutic-value-of-antidiabetic-drugs-in-lung-cancer-treatment2026-10-08 https://evidence-hub.com/study/15431-efficacy-and-safety-of-pioglitazone-added-to-metformin-and-sglt22026-10-08 https://evidence-hub.com/study/15432-ampk-therapy-a-little-goes-a-long-way2026-10-08 https://evidence-hub.com/study/15433-metformin-s-disruption-of-gluconeogenesis-in-type-2-diabetes2026-10-08 https://evidence-hub.com/study/15434-metformin-as-a-multi-target-modulator-of-atherosclerosis-integrated2026-10-06 https://evidence-hub.com/study/15435-a-mechanism-based-framework-for-anti-aging-strategies-from-metabolic2026-10-06 https://evidence-hub.com/study/15436-mitochondrial-homeostasis-in-musculoskeletal-diseases-from-pathogenic2026-10-06 https://evidence-hub.com/study/15437-metformin-phytochemical-combination-therapy-in-metabolic-dysfunction2026-10-06 https://evidence-hub.com/study/15438-ampk-orchestrated-metabolic-reprogramming-in-some-flavivirus2026-10-06 https://evidence-hub.com/study/15439-metformin-associated-lactic-acidosis-bridging-pharmacokinetic2026-10-06 https://evidence-hub.com/study/15440-an-eye-on-metformin-applications-and-drug-delivery-strategies-for2026-10-06 https://evidence-hub.com/study/15441-brain-insulin-resistance-as-a-driver-of-proteinopathy-in2026-10-06 https://evidence-hub.com/study/15442-contemporary-type-2-diabetes-guidelines-converging-evidence-diverging2026-10-06 https://evidence-hub.com/study/15443-therapeutics-candidates-and-repurposing-strategies-to-target2026-10-06 https://evidence-hub.com/study/15444-implementing-sglt2-inhibitor-therapy-in-line-with-the-new-nice2026-10-06 https://evidence-hub.com/study/15445-cancer-risk-in-diabetic-patients-treated-with-metformin-a-systematic2026-10-08 https://evidence-hub.com/study/15446-glibenclamide-metformin-and-insulin-for-the-treatment-of-gestational2026-10-08 https://evidence-hub.com/study/15447-metformin-therapy-and-risk-of-cancer-in-patients-with-type-2-diabetes2026-10-08 https://evidence-hub.com/study/15449-metformin-and-cancer-risk-and-mortality-a-systematic-review-and-meta2026-10-08 https://evidence-hub.com/study/15450-impact-of-metformin-on-cardiovascular-disease-a-meta-analysis-of2026-10-08 https://evidence-hub.com/study/15451-metformin-and-lifestyle-modification-in-polycystic-ovary-syndrome2026-10-08 https://evidence-hub.com/study/15453-the-effect-of-metformin-on-blood-pressure-plasma-cholesterol-and2026-10-08 https://evidence-hub.com/study/15454-association-of-metformin-use-with-cancer-incidence-and-mortality-a2026-10-08 https://evidence-hub.com/study/15455-metformin-in-non-alcoholic-fatty-liver-disease-a-systematic-review2026-10-08 https://evidence-hub.com/study/15457-metformin-vs-insulin-in-the-management-of-gestational-diabetes-a-meta2026-10-08 https://evidence-hub.com/study/15458-cancer-risk-associated-with-use-of-metformin-and-sulfonylurea-in-type2026-10-08 https://evidence-hub.com/study/15459-metformin-and-lifestyle-modification-in-polycystic-ovary-syndrome2026-10-08 https://evidence-hub.com/study/15460-reappraisal-of-metformin-efficacy-in-the-treatment-of-type-2-diabetes2026-10-08 https://evidence-hub.com/study/15461-anticancer-activity-of-metformin-a-systematic-review-of-the-literature2026-10-08 https://evidence-hub.com/study/15463-metformin-for-obesity-in-children-and-adolescents-a-systematic-review2026-10-08 https://evidence-hub.com/study/15464-a-systematic-review-of-the-reproductive-system-effects-of-metformin2026-10-08 https://evidence-hub.com/study/15468-metformin-environmental-exposure-a-systematic-review2026-10-08 https://evidence-hub.com/study/15472-metformin-and-reduced-risk-of-hepatocellular-carcinoma-in-diabetic2026-10-08 https://evidence-hub.com/study/15473-glp-1-receptor-agonists-versus-metformin-in-pcos-a-systematic-review2026-10-08 https://evidence-hub.com/study/15474-short-and-long-term-outcomes-of-metformin-compared-with-insulin-alone2026-09-30 https://evidence-hub.com/study/15475-metformin-in-the-prevention-of-hepatocellular-carcinoma-in-diabetic2026-10-08 https://evidence-hub.com/study/15476-metformin-as-treatment-for-overweight-and-obese-adults-a-systematic2026-10-08 https://evidence-hub.com/study/15477-the-gut-microbiome-metformin-and-aging2026-10-08 https://evidence-hub.com/study/15478-metformin-is-associated-with-survival-benefit-in-cancer-patients-with2026-09-30 https://evidence-hub.com/study/15479-effects-of-treatment-with-metformin-on-tsh-levels-a-meta-analysis-of2026-10-08 https://evidence-hub.com/study/15482-efficacy-and-safety-of-metformin-for-obesity-a-systematic-review2026-10-08 https://evidence-hub.com/study/15483-effects-of-metformin-on-head-and-neck-cancer-a-systematic-review2026-10-08 https://evidence-hub.com/study/15484-systematic-review-preventive-and-therapeutic-applications-of2026-10-08 https://evidence-hub.com/study/15485-metformin-use-is-associated-with-better-survival-of-breast-cancer2026-10-08 https://evidence-hub.com/study/15486-metformin-and-prostate-cancer-mortality-a-meta-analysis2026-10-08 https://evidence-hub.com/study/15487-effects-of-metformin-in-obesity-treatment-in-different-populations-a2026-10-08 https://evidence-hub.com/study/15488-reduced-risk-of-lung-cancer-with-metformin-therapy-in-diabetic2026-10-01 https://evidence-hub.com/study/15489-effect-of-preconceptional-metformin-on-abortion-risk-in-polycystic2026-10-06 https://evidence-hub.com/study/15490-metformin-for-treatment-of-fragile-x-syndrome-and-other-neurological2026-10-08 https://evidence-hub.com/study/15491-the-effect-of-metformin-therapy-on-incidence-and-prognosis-in2026-10-08 https://evidence-hub.com/study/15492-metformin-or-oral-contraceptives-for-adolescents-with-polycystic2026-10-08 https://evidence-hub.com/study/15493-the-effect-of-metformin-on-survival-of-patients-with-pancreatic2026-10-08 https://evidence-hub.com/study/15495-therapeutic-potential-of-metformin-in-covid-19-reasoning-for-its2026-09-30 https://evidence-hub.com/study/15496-the-effect-of-metformin-on-polycystic-ovary-syndrome-in-overweight2026-10-06 https://evidence-hub.com/study/15498-a-gene-variant-near-atm-is-significantly-associated-with-metformin2026-10-01 https://evidence-hub.com/study/15499-metformin-improves-overall-survival-of-colorectal-cancer-patients2026-10-08 https://evidence-hub.com/study/15500-preventing-type-2-diabetes-systematic-review-of-studies-of-cost2026-10-01 https://evidence-hub.com/study/15501-association-of-metformin-with-breast-cancer-incidence-and-mortality2026-10-08 https://evidence-hub.com/study/15502-efficacy-and-side-effect-profile-of-different-formulations-of2026-10-01 https://evidence-hub.com/study/15503-metformin-exerts-anti-tumor-effects-via-sonic-hedgehog-signaling2026-10-06 https://evidence-hub.com/study/15504-implementation-and-evaluation-of-the-metformin-first-protocol-for2026-10-06 https://evidence-hub.com/study/15505-metformin-associated-lactic-acidosis-precipitated-by-acute-renal2026-10-06 https://evidence-hub.com/study/15506-what-is-the-phenotype-of-patients-with-gastrointestinal-intolerance2026-10-08 https://evidence-hub.com/study/15507-modified-metformin-as-a-more-potent-anticancer-drug-mitochondrial2026-10-06 https://evidence-hub.com/study/15508-cancer-cachexia-and-diabetes-similarities-in-metabolic-alterations2026-10-06 https://evidence-hub.com/study/15509-avandia-and-avandamet-in-the-treatment-of-patients-with-diabetes2026-10-06 https://evidence-hub.com/study/15510-metformin-s-effect-on-first-year-weight-gain-a-follow-up-study2026-10-08 https://evidence-hub.com/study/15511-metformin-attenuates-ischemia-reperfusion-induced-apoptosis-of2026-10-06 https://evidence-hub.com/study/15512-evaluation-of-the-rs3088442-g-a-slc22a3-gene-polymorphism-and-the2026-10-06 https://evidence-hub.com/study/15513-reversible-lactic-acidosis-in-a-diabetic-on-high-dose-metformin2026-10-06 https://evidence-hub.com/study/15514-what-are-patients-attitudes-towards-generic-drugs-the-example-of2026-10-06 https://evidence-hub.com/study/15515-role-of-metformin-in-gynaecology-and-obstetrics2026-10-08 https://evidence-hub.com/study/15516-diabetes-type-2-in-pediatrics-diagnosis-and-management2026-10-08 https://evidence-hub.com/study/15517-fatal-case-of-metformin-induced-lactic-acidosis-after-urography-in-a2026-10-06 https://evidence-hub.com/study/15518-metformin-associated-lactic-acidosis-myth-or-reality2026-10-06 https://evidence-hub.com/study/15519-high-volume-continuous-venovenous-hemodiafiltration-plus-resin2026-10-06 https://evidence-hub.com/study/15520-photosensitivity-induced-by-metformin-a-report-of-3-cases2026-10-06 https://evidence-hub.com/study/15521-long-term-effects-of-metformin-on-diabetes-prevention-identification2026-10-06 https://evidence-hub.com/study/15522-thyrotropin-suppression-by-metformin2026-10-08 https://evidence-hub.com/study/15523-effect-of-metformin-on-the-risk-of-post-covid-19-condition-among2026-10-06 https://evidence-hub.com/study/15524-cost-utility-study-of-the-combination-of-metformin-with-the-different2026-10-06 https://evidence-hub.com/study/15525-metformin-inhibits-progression-of-head-and-neck-squamous-cell2026-10-06 https://evidence-hub.com/study/15526-metformin-induced-lactic-acidosis-two-new-cases-author-s-transl2026-10-06 https://evidence-hub.com/study/15527-current-status-of-the-treatment-of-type-2-diabetes-mellitus-the2026-10-06 https://evidence-hub.com/study/15528-metabolic-and-hemodynamic-effects-of-combined-treatment-with2026-10-06 https://evidence-hub.com/study/15529-metformin-exerts-anti-obesity-effect-via-gut-microbiome-modulation-in2026-10-06 https://evidence-hub.com/study/15530-impact-of-interleukin-1-antibody-canakinumab-on-glycaemic-indicators2026-10-06 https://evidence-hub.com/study/15531-metformin-efficacy-and-tolerance-according-to-genetic-polymorphisms2026-10-06 https://evidence-hub.com/study/15532-toxicity-of-metformin-pro-or-con-a-future-restriction-to-its2026-10-06 https://evidence-hub.com/study/15533-metformin-role-in-the-treatment-of-type-2-diabetes-in-20082026-10-06 https://evidence-hub.com/study/15534-metformin-associates-lactic-acidosis2026-10-08 https://evidence-hub.com/study/15535-metformin-associated-lactic-acidosis-an-insufficiently-recognised2026-10-08 https://evidence-hub.com/study/15536-clinical-vignette-which-combination-of-oral-glucose-lowering-agents2026-10-06 https://evidence-hub.com/study/15537-therapeutic-approaches-to-improve-blood-glucose-control-in-a-patient2026-10-06 https://evidence-hub.com/study/15538-anti-cancer-activity-of-metformin-new-perspectives-for-an-old-drug2026-10-06 https://evidence-hub.com/study/15539-use-of-metformin-in-diabetic-patients-with-cardiac-disease-benefit2026-10-06 https://evidence-hub.com/study/15540-metformin-new-data-for-an-old-molecule2026-10-06 https://evidence-hub.com/study/15541-lactic-acidosis-and-metformin-implicated-why-better-information-about2026-10-06 https://evidence-hub.com/study/15542-severe-lactic-acidosis-due-to-metformin-therapy-in-a-patient-with2026-10-06 https://evidence-hub.com/study/15543-fatal-autointoxication-with-metformin2026-10-06 https://evidence-hub.com/study/15544-prevention-of-lactic-acidosis-due-to-metformin-intoxication-in2026-10-06 https://evidence-hub.com/study/15545-medication-of-the-month-glucovance-in-type-2-diabetes-a-fixed2026-10-06 https://evidence-hub.com/study/15546-acute-blindness-in-a-patient-with-metformin-associated-lactic-acidosis2026-10-06 https://evidence-hub.com/study/15547-sulphonylurea-derivatives-or-insulin-with-metformin2026-10-06 https://evidence-hub.com/study/15548-targeting-tam-secreted-s100a9-effectively-enhances-the-tumor2026-10-06 https://evidence-hub.com/study/15549-metformin-inhibits-non-small-cell-lung-cancer-via-lncrp11-242d8-12026-10-06 https://evidence-hub.com/study/15550-metformin-associated-lactic-acidosis-in-a-patient-with-normal-renal2026-10-06 https://evidence-hub.com/study/15551-changes-in-protein-expression-due-to-metformin-treatment-and2026-10-06 https://evidence-hub.com/study/15552-the-effect-of-metformin-on-atezolizumab-bevacizumab-treatment-in2026-10-06 https://evidence-hub.com/study/15553-skeletal-muscle-adaptations-to-exercise-are-not-influenced-by2026-10-06 https://evidence-hub.com/study/15554-a-proposal-for-the-locus-of-metformin-s-clinical-action-potentiation2026-10-06 https://evidence-hub.com/study/15555-serum-brain-derived-neurotrophic-factor-is-related-to-platelet2026-10-06 https://evidence-hub.com/study/15556-metformin-may-offer-no-protective-effect-in-men-undergoing-external2026-10-06 https://evidence-hub.com/study/15557-comparison-of-effects-of-gliclazide-metformin-and-pioglitazone2026-10-06 https://evidence-hub.com/study/15558-how-i-treat-with-metformin-a-diabetic-patient-with-moderate-renal2026-10-06 https://evidence-hub.com/study/15559-metformin-efficacious-in-poorly-controlled-diabetes-mellitus-type-22026-10-08 https://evidence-hub.com/study/15560-medication-of-the-month-sitagliptin-metformin-fixed-combination2026-10-06 https://evidence-hub.com/study/15561-the-c-allele-of-atm-rs11212617-does-not-associate-with-metformin2026-10-06 https://evidence-hub.com/study/15562-current-role-of-metformin-in-treatment-of-diabetes-mellitus-type-22026-10-06 https://evidence-hub.com/study/15563-reappraisal-of-metformin-less-restrictions-and-more-potential2026-10-06 https://evidence-hub.com/study/15564-info-meeting-pharmacologic-prevention-of-the-progression-from2026-10-06 https://evidence-hub.com/study/15565-metformin-associated-lactic-acidosis-remains-a-serious-complication2026-10-06 https://evidence-hub.com/study/15566-voluntary-self-poisoning-with-metformin-and-antiretroviral-therapy2026-10-06 https://evidence-hub.com/study/15567-metformin-promotes-mitophagy-in-mononuclear-cells-a-potential-in2026-10-08 https://evidence-hub.com/study/15568-metformin-an-antidiabetic-molecule-with-anti-cancer-properties2026-10-06 https://evidence-hub.com/study/15569-metformin-prevents-baff-activation-of-erk1-2-from-b-cell2026-10-06 https://evidence-hub.com/study/15570-dpp-4-or-sglt2-inhibitor-added-to-metformin-alone-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/15571-vildagliptin-galvus-and-fixed-combination-vildagliptine-metformin2026-10-06 https://evidence-hub.com/study/15572-metformin-related-lactic-acidosis-in-an-85-year-old-woman2026-09-30 https://evidence-hub.com/study/15573-oral-diagnosis-of-vitamin-b12-deficiency-due-to-long-term-metformin2026-10-06 https://evidence-hub.com/study/15574-which-anti-tumour-benefits-to-be-expected-from-metformin2026-10-08 https://evidence-hub.com/study/15575-metformin-associated-lactic-acidosis2026-10-08 https://evidence-hub.com/study/15576-new-perspectives-for-metformin-in-cancer-therapy2026-10-06 https://evidence-hub.com/study/15577-antidiabetic-drugs-and-heart-failure-risk-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/15578-metformin-renal-function-and-lactate-the-metclear-study2026-10-06 https://evidence-hub.com/study/15579-jentadueto-fixed-combination-of-linagliptin-plus-metformin-for-the2026-10-06 https://evidence-hub.com/study/15580-metformin-in-adolescents-and-adults-with-type-1-diabetes-mellitus-not2026-10-06 https://evidence-hub.com/study/15581-indication-of-metformin-in-the-management-of-hormonal-dysfunction2026-10-06 https://evidence-hub.com/study/15582-metformin-as-a-geroprotector2026-10-08 https://evidence-hub.com/study/15583-extended-release-metformin-hydrochloride-single-composition-osmotic2026-10-06 https://evidence-hub.com/study/15584-treatment-of-diabetes-in-pregnancy-with-metformin2026-10-08 https://evidence-hub.com/study/15585-chronic-activation-of-amp-activated-kinase-as-a-strategy-for-slowing2026-10-08 https://evidence-hub.com/study/15586-no-decreased-risk-of-gastrointestinal-cancers-in-users-of-metformin2026-10-06 https://evidence-hub.com/study/15587-metformin-induces-cytotoxicity-by-down-regulating-thymidine2026-10-06 https://evidence-hub.com/study/15588-network-toxicology-driven-repurposing-of-metformin-for-hepatocellular2026-10-08 https://evidence-hub.com/study/15589-effects-of-metformin-on-mitochondrial-health-and-oxidative-stress-in2026-10-08 https://evidence-hub.com/study/15590-mitochondrial-diabetes-mellitus-real-world-insights-from-the-genomit2026-10-08 https://evidence-hub.com/study/15591-probiotics-prebiotics-synbiotics-and-fmt-for-glycemic-control-a2026-10-08 https://evidence-hub.com/study/15592-metformin-alleviates-stress-induced-premature-senescence-of-vascular2026-10-08 https://evidence-hub.com/study/15593-efficacy-and-safety-of-syzygium-cumini-and-related-myrtaceae2026-10-08 https://evidence-hub.com/study/15594-emergency-robotic-assisted-repair-in-an-elderly-patient-with2026-10-08 https://evidence-hub.com/study/15595-efficacy-and-safety-of-semaglutide-for-managing-antipsychotic2026-10-08 https://evidence-hub.com/study/15596-caregivers-experiences-and-perceptions-of-caring-for-children-and2026-10-08 https://evidence-hub.com/study/15597-repurposing-metformin-for-treating-osteoarthritis-via-leveraging-nrf22026-10-08 https://evidence-hub.com/study/15598-citrus-lemon-peel-extract-versus-metformin-in-testosterone-induced2026-10-08 https://evidence-hub.com/study/15599-effect-of-myo-inositol-supplementation-in-polycystic-ovary-syndrome2026-10-08 https://evidence-hub.com/study/15600-from-diabetes-to-dentistry-metformin-targets-mitochondrial-immune2026-10-08 https://evidence-hub.com/study/15601-multiple-therapeutic-applications-of-metformin-moving-beyond-its-anti2026-10-08 https://evidence-hub.com/study/15602-antidiabetic-activity-of-chickpea-albumin-hydrolysate-in2026-10-08 https://evidence-hub.com/study/15603-massive-simple-renal-cyst-causing-colonic-obstruction-the-largest2026-10-08 https://evidence-hub.com/study/15604-structural-basis-of-drug-recognition-by-human-mate1-transporter2026-10-08 https://evidence-hub.com/study/15605-in-vitro-comparative-quality-evaluation-of-different-brands-of2026-10-08 https://evidence-hub.com/study/15606-the-effect-of-olanzapine-on-diabetes-related-index-in-humans-a2026-10-08 https://evidence-hub.com/study/15607-efficacy-and-safety-of-gliclazide-versus-glimepiride-in-t2dm-patients2026-10-08 https://evidence-hub.com/study/15608-the-impact-of-diabetes-on-breast-cancer-development-in-women-an2026-10-08 https://evidence-hub.com/study/15609-beyond-metformin-a-review-of-non-pharmacological-treatments-for2026-10-08 https://evidence-hub.com/study/15610-neurohormonal-immune-dysregulation-in-rosacea-emerging-perspectives2026-10-08 https://evidence-hub.com/study/15611-metformin-a-dual-role-player-in-cancer-treatment-and-prevention-a2026-10-08 https://evidence-hub.com/study/15612-efficacy-and-safety-of-acupuncture-related-therapies-in-improving2026-10-08 https://evidence-hub.com/study/15613-the-divergent-roles-of-tryptophans-w354-and-w217-in-oct1-transport2026-10-08 https://evidence-hub.com/study/15614-metformin-loaded-j-aupps-for-infected-diabetic-wound-treatment2026-10-08 https://evidence-hub.com/study/15615-prevalence-and-types-of-prescribing-errors-made-by-non-medical2026-10-08 https://evidence-hub.com/study/15616-utilizing-multiple-behavioral-endpoints-to-identify-negative-control2026-10-08 https://evidence-hub.com/study/15617-sirt1-activators-as-geroprotective-agents-in-brain-aging-mechanisms2026-10-08 https://evidence-hub.com/study/15618-cardiometabolic-comorbidities-in-copd-focus-on-diabetes-glp-12026-10-08 https://evidence-hub.com/study/15619-general-practice-interventions-to-reduce-cardiovascular-disease-risk2026-10-08 https://evidence-hub.com/study/15620-effects-of-yoga-interventions-on-anti-mullerian-hormone-androgen2026-10-08 https://evidence-hub.com/study/15622-efficacy-of-weight-lowering-agents-on-fat-distribution-a-systematic2026-10-08 https://evidence-hub.com/study/15623-genome-wide-association-studies-in-chronic-venous-disease-a2026-10-08 https://evidence-hub.com/study/15624-natural-bioactive-compounds-in-polycystic-ovary-syndrome-properties2026-10-08 https://evidence-hub.com/study/15625-impact-of-core-circadian-gene-variants-on-glycemic-parameters-and2026-10-08 https://evidence-hub.com/study/15626-effects-of-exercise-on-reproductive-endocrine-hormones-in-adult2026-10-08 https://evidence-hub.com/study/15627-gastroparesis-induced-by-glucagon-like-peptide-1-receptor-agonists-a2026-10-08 https://evidence-hub.com/study/15628-terminalia-bellirica-extract-attenuates-fat-accumulation-through2026-10-08 https://evidence-hub.com/study/15629-paradoxical-anti-diuretic-effects-of-thiazide-and-thiazide-like2026-10-08 https://evidence-hub.com/study/15630-a-combination-of-psidium-guajava-and-seriphium-plumosum-modulates2026-10-08 https://evidence-hub.com/study/15631-from-toxicogenomics-data-to-cumulative-assessment-groups-a-framework2026-10-08 https://evidence-hub.com/study/15632-interventions-to-prevent-antipsychotic-induced-weight-gain-and2026-10-08 https://evidence-hub.com/study/15633-metformin-use-linked-to-decreased-risk-of-pelvic-organ-prolapse2026-10-08 https://evidence-hub.com/study/15634-treatment-preference-for-once-weekly-versus-once-daily-dpp-42026-10-08 https://evidence-hub.com/study/15635-preclinical-rat-models-in-oral-implant-dentistry-a-scoping-review-of2026-10-08 https://evidence-hub.com/study/15636-citrus-peel-xanthophylls-orchestrate-lipid-glucose-inflammation-axis2026-10-08 https://evidence-hub.com/study/15637-hyperandrogenemia-induces-trophoblast-ferroptosis-and-early-pregnancy2026-10-08 https://evidence-hub.com/study/15638-the-top-50-cited-publications-in-the-field-of-vitamin-b12-deficiency2026-10-08 https://evidence-hub.com/study/15639-oxidative-stress-in-bladder-outlet-obstruction-a-narrative-review2026-10-19 https://evidence-hub.com/study/15640-glp-1-receptor-agonists-for-the-prevention-of-new-onset-heart-failure2026-10-06 https://evidence-hub.com/study/15641-evidence-on-pharmacological-agents-for-treating-bony-defects-in2026-10-06 https://evidence-hub.com/study/15642-metformin-modulates-mitochondrial-function-and-mitophagy-in2026-10-08 https://evidence-hub.com/study/15643-metformin-reduces-hepatocellular-carcinoma-incidence-after-successful2026-10-08 https://evidence-hub.com/study/15644-metformin-vs-insulin-in-gestational-diabetes-a-randomized-study2026-10-08 https://evidence-hub.com/study/15645-metformin-therapy-effects-on-the-expression-of-sodium-glucose2026-10-08 https://evidence-hub.com/study/15646-metformin-and-risk-of-mortality-in-patients-hospitalised-with-covid2026-10-08 https://evidence-hub.com/study/15647-efficacy-safety-and-tolerability-of-oral-semaglutide-versus-placebo2026-10-08 https://evidence-hub.com/study/15649-metformin-use-is-associated-with-a-reduced-risk-of-mortality-in2026-10-08 https://evidence-hub.com/study/15650-metformin-current-clinical-applications-in-nondiabetic-patients-with2026-10-08 https://evidence-hub.com/study/15651-metformin-upregulates-mitophagy-in-patients-with-t2dm-a-randomized2026-10-08 https://evidence-hub.com/study/15652-metformin-in-patients-with-and-without-diabetes-a-paradigm-shift-in2026-10-08 https://evidence-hub.com/study/15653-epigenetic-markers-associated-with-metformin-response-and-intolerance2026-10-08 https://evidence-hub.com/study/15654-metformin-and-the-risk-of-dementia-in-type-2-diabetes-patients2026-10-08 https://evidence-hub.com/study/15655-clinical-outcomes-in-non-small-cell-lung-cancer-patients-receiving2026-10-08 https://evidence-hub.com/study/15656-pericoronary-fat-inflammation-and-major-adverse-cardiac-events-mace2026-10-08 https://evidence-hub.com/study/15657-association-of-treatment-with-metformin-vs-sulfonylurea-with-major2026-10-08 https://evidence-hub.com/study/15658-long-term-outcomes-of-progestin-plus-metformin-as-a-fertility-sparing2026-10-08 https://evidence-hub.com/study/15659-post-contrast-acute-kidney-injury-part-2-risk-stratification-role-of2026-10-08 https://evidence-hub.com/study/15660-metformin-induced-reduction-of-cd39-and-cd73-blocks-myeloid-derived2026-10-08 https://evidence-hub.com/study/15661-cardiovascular-and-metabolic-effects-of-metformin-in-patients-with2026-10-08 https://evidence-hub.com/study/15664-treatment-with-metformin-in-twelve-patients-with-lafora-disease2026-10-08 https://evidence-hub.com/study/15665-metformin-and-risk-of-hepatocellular-carcinoma-in-patients-with-type2026-10-08 https://evidence-hub.com/study/15667-a-randomized-phase-ii-study-of-metformin-plus-paclitaxel-carboplatin2026-10-08 https://evidence-hub.com/study/15668-profiles-of-circulating-mirnas-following-metformin-treatment-in2026-10-08 https://evidence-hub.com/study/15669-metformin-use-is-associated-with-longer-progression-free-survival-of2026-10-08 https://evidence-hub.com/study/15670-the-effect-of-metformin-on-culture-conversion-in-tuberculosis2026-10-08 https://evidence-hub.com/study/15671-impact-of-diabetes-insulin-and-metformin-use-on-the-outcome-of2026-10-08 https://evidence-hub.com/study/15673-use-of-metformin-and-survival-of-patients-with-high-grade-glioma2026-10-08 https://evidence-hub.com/study/15674-association-of-metformin-treatment-with-reduced-severity-of-diabetic2026-10-08 https://evidence-hub.com/study/15676-effect-of-metformin-on-kidney-function-in-patients-with-type-22026-10-08 https://evidence-hub.com/study/15677-pharmacokinetics-of-metformin-in-patients-with-gastrointestinal2026-10-08 https://evidence-hub.com/study/15678-metformin-intake-associates-with-better-cognitive-function-in2026-10-08 https://evidence-hub.com/study/15679-efficacy-and-safety-of-dapagliflozin-or-dapagliflozin-plus2026-10-06 https://evidence-hub.com/study/15680-results-of-the-safety-run-in-part-of-the-metal-metformin-in-advanced2026-10-08 https://evidence-hub.com/study/15681-metformin-reduces-the-risk-of-cancer-in-patients-with-type-2-diabetes2026-10-08 https://evidence-hub.com/study/15682-effects-of-metformin-treatment-on-radiotherapy-efficacy-in-patients2026-10-08 https://evidence-hub.com/study/15683-severity-of-gastrointestinal-side-effects-of-metformin-tablet2026-10-08 https://evidence-hub.com/study/15684-sex-dependent-difference-in-the-effect-of-metformin-on-colorectal2026-10-08 https://evidence-hub.com/study/15685-association-between-metformin-use-and-below-the-knee-arterial2026-10-08 https://evidence-hub.com/study/15687-vitamin-b12-deficiency-in-metformin-treated-type-2-diabetes-patients2026-10-08 https://evidence-hub.com/study/15689-metformin-therapy-and-risk-of-colorectal-adenomas-and-colorectal2026-10-08 https://evidence-hub.com/study/15690-metformin-use-and-asthma-outcomes-among-patients-with-concurrent2026-10-08 https://evidence-hub.com/study/15691-comparative-evaluation-of-the-therapeutic-effect-of-metformin2026-10-08 https://evidence-hub.com/study/15692-metformin-reduces-gastric-cancer-risk-in-patients-with-type-22026-10-08 https://evidence-hub.com/study/15693-metformin-improves-survival-in-patients-with-pancreatic-ductal2026-10-08 https://evidence-hub.com/study/15694-cumulative-metformin-use-and-its-impact-on-survival-in-gastric-cancer2026-10-08 https://evidence-hub.com/study/15696-metformin-induces-cell-cycle-arrest-reduced-proliferation-wound2026-10-08 https://evidence-hub.com/study/15697-glucose-control-in-severely-burned-patients-using-metformin2026-10-08 https://evidence-hub.com/study/15699-metformin-in-the-treatment-of-patients-with-non-alcoholic2026-10-08 https://evidence-hub.com/study/15700-effect-of-metformin-and-rosiglitazone-combination-therapy-in-patients2026-10-08 https://evidence-hub.com/study/15701-lactic-acidosis-in-patients-with-diabetes-treated-with-metformin2026-10-08 https://evidence-hub.com/study/15702-thiazolidinediones-metformin-and-outcomes-in-older-patients-with2026-10-08 https://evidence-hub.com/study/15704-increased-risk-of-cognitive-impairment-in-patients-with-diabetes-is2026-10-08 https://evidence-hub.com/study/15705-improved-clinical-outcomes-associated-with-metformin-in-patients-with2026-10-08 https://evidence-hub.com/study/15706-long-term-treatment-with-metformin-in-patients-with-type-2-diabetes2026-10-01 https://evidence-hub.com/study/15707-effects-of-dapagliflozin-on-body-weight-total-fat-mass-and-regional2026-09-30 https://evidence-hub.com/study/15708-risk-factors-of-vitamin-b12-deficiency-in-patients-receiving-metformin2026-10-08 https://evidence-hub.com/study/15709-dapagliflozin-versus-glipizide-as-add-on-therapy-in-patients-with2026-10-01 https://evidence-hub.com/study/15711-comparative-safety-and-effectiveness-of-metformin-in-patients-with2026-10-08 https://evidence-hub.com/study/15712-long-term-effects-of-metformin-on-metabolism-and-microvascular-and2026-09-30 https://evidence-hub.com/study/15713-effect-of-metformin-on-carbohydrate-and-lipoprotein-metabolism-in2026-10-08 https://evidence-hub.com/study/15714-metformin-use-is-associated-with-better-survival-of-diabetic-patients2026-10-08 https://evidence-hub.com/study/15715-twelve-and-52-week-efficacy-of-the-dipeptidyl-peptidase-iv-inhibitor2026-10-01 https://evidence-hub.com/study/15716-effect-of-initial-combination-therapy-with-sitagliptin-a-dipeptidyl2026-10-01 https://evidence-hub.com/study/15717-efficacy-and-safety-of-canagliflozin-compared-with-placebo-and2026-10-01 https://evidence-hub.com/study/15718-effects-of-vildagliptin-on-glucose-control-over-24-weeks-in-patients2026-09-30 https://evidence-hub.com/study/15719-metformin-in-patients-with-non-alcoholic-fatty-liver-disease-a2026-10-08 https://evidence-hub.com/study/15721-efficacy-and-safety-of-the-human-glucagon-like-peptide-1-analog2026-10-01 https://evidence-hub.com/study/15722-effects-of-metformin-versus-glipizide-on-cardiovascular-outcomes-in2026-10-01 https://evidence-hub.com/study/15723-reduced-risk-of-colorectal-cancer-with-metformin-therapy-in-patients2026-10-08 https://evidence-hub.com/study/15724-dapagliflozin-maintains-glycaemic-control-while-reducing-weight-and2026-10-01 https://evidence-hub.com/study/15725-10-year-follow-up-of-intensive-glucose-control-in-type-2-diabetes2026-10-01 https://evidence-hub.com/study/15726-effects-of-rosiglitazone-and-metformin-on-liver-fat-content-hepatic2026-10-01 https://evidence-hub.com/study/15727-efficacy-and-safety-of-the-dipeptidyl-peptidase-4-inhibitor2026-10-01 https://evidence-hub.com/study/15728-efficacy-and-safety-of-the-dipeptidyl-peptidase-4-inhibitor2026-10-01 https://evidence-hub.com/study/15729-effect-of-orlistat-in-overweight-and-obese-patients-with-type-22026-10-08 https://evidence-hub.com/study/15730-metformin-and-reduced-risk-of-hepatocellular-carcinoma-in-diabetic2026-10-08 https://evidence-hub.com/study/15731-vitamin-b-12-status-of-patients-on-long-term-metformin-therapy2026-10-08 https://evidence-hub.com/study/15735-lower-risk-of-cancer-in-patients-on-metformin-in-comparison-with2026-10-08 https://evidence-hub.com/study/15736-the-effects-of-metformin-on-the-survival-of-colorectal-cancer2026-10-08 https://evidence-hub.com/study/15737-metformin-use-and-mortality-in-ambulatory-patients-with-diabetes-and2026-10-08 https://evidence-hub.com/study/15738-efficacy-and-safety-of-sitagliptin-added-to-ongoing-metformin-therapy2026-09-30 https://evidence-hub.com/study/15739-efficacy-and-safety-of-canagliflozin-in-patients-with-type-2-diabetes2026-10-01 https://evidence-hub.com/study/15740-effect-of-repaglinide-addition-to-metformin-monotherapy-on-glycemic2026-09-30 https://evidence-hub.com/study/15741-novel-gut-based-pharmacology-of-metformin-in-patients-with-type-22026-10-08 https://evidence-hub.com/study/15742-high-and-typical-18f-fdg-bowel-uptake-in-patients-treated-with2026-10-08 https://evidence-hub.com/study/15743-canagliflozin-compared-with-sitagliptin-for-patients-with-type-22026-09-30 https://evidence-hub.com/study/15744-continuation-of-metformin-use-after-a-diagnosis-of-cirrhosis2026-10-08 https://evidence-hub.com/study/15745-tsh-lowering-effect-of-metformin-in-type-2-diabetic-patients2026-10-08 https://evidence-hub.com/study/15747-combined-lifestyle-modification-and-metformin-in-obese-patients-with2026-10-06 https://evidence-hub.com/study/15748-metformin-increases-the-ovulatory-rate-and-pregnancy-rate-from2026-10-06 https://evidence-hub.com/study/15749-effect-on-glycemic-control-of-exenatide-synthetic-exendin-4-additive2026-10-01 https://evidence-hub.com/study/15750-effects-of-metformin-in-patients-with-poorly-controlled-insulin2026-09-30 https://evidence-hub.com/study/15751-efficacy-and-safety-of-saxagliptin-in-combination-with-metformin2026-10-08 https://evidence-hub.com/study/15752-metformin-for-weight-loss-in-pediatric-patients-taking-psychotropic2026-10-08 https://evidence-hub.com/study/15754-one-year-treatment-with-exenatide-improves-cell-function-compared2026-09-27 https://evidence-hub.com/study/15755-metformin-plays-a-dual-role-in-min6-pancreatic-cell-function-through2026-10-08 https://evidence-hub.com/study/15756-prenatal-metformin-exposure-in-mice-programs-the-metabolic-phenotype2026-10-06 https://evidence-hub.com/study/15757-metformin-promotes-lipid-droplet-mitochondria-coupling-and-improves2026-10-06 https://evidence-hub.com/study/15758-engineered-radially-aligned-gradient-metformin-eluting-nanofiber2026-10-06 https://evidence-hub.com/study/15759-metformin-alleviates-memory-and-hippocampal-neurogenesis-decline2026-10-06 https://evidence-hub.com/study/15760-metformin-reduces-prion-infection-in-neuronal-cells-by-enhancing2026-10-06 https://evidence-hub.com/study/15761-the-protective-effect-of-metformin-in-scopolamine-induced-learning2026-10-06 https://evidence-hub.com/study/15762-metformin-alleviates-bleomycin-induced-pulmonary-fibrosis-in-rats2026-10-06 https://evidence-hub.com/study/15763-metformin-beta-cell-development-and-novel-processes-following-beta2026-10-06 https://evidence-hub.com/study/15764-role-of-the-antidiabetic-drugs-glibenclamide-and-metformin-on-the2026-10-06 https://evidence-hub.com/study/15765-metformin-decreases-glucose-oxidation-and-increases-the-dependency-of2026-10-06 https://evidence-hub.com/study/15766-organic-cation-transporter-and-multidrug-and-toxin-extrusion-1-co2026-10-06 https://evidence-hub.com/study/15767-metformin-at-environmental-relevant-concentration-induced-glucose2026-10-06 https://evidence-hub.com/study/15768-metformin-pretreatment-rescues-olfactory-memory-associated-with2026-10-06 https://evidence-hub.com/study/15769-metformin-induces-cardioprotection-against-ischaemia-reperfusion2026-10-06 https://evidence-hub.com/study/15770-maternal-metformin-treatment-reprograms-maternal-high-fat-diet2026-10-06 https://evidence-hub.com/study/15771-metformin-promotes-histone-deacetylation-of-optineurin-and-suppresses2026-10-06 https://evidence-hub.com/study/15772-not-only-metformin-but-also-d-allulose-alleviates-metabolic2026-10-06 https://evidence-hub.com/study/15773-metformin-attenuates-cisplatin-induced-genotoxicity-and-apoptosis-in2026-10-06 https://evidence-hub.com/study/15774-hypoglycemic-effect-of-electroacupuncture-at-tianshu-st-25-combined2026-10-06 https://evidence-hub.com/study/15775-molecular-interplay-between-microrna-34a-and-sirtuin1-in2026-10-08 https://evidence-hub.com/study/15776-effect-of-metformin-on-metabolic-improvement-and-gut-microbiota2026-10-08 https://evidence-hub.com/study/15777-does-long-term-metformin-treatment-increase-cardiac-lipoprotein-lipase2026-10-06 https://evidence-hub.com/study/15778-metformin-counters-the-insulin-induced-suppression-of-fatty-acid2026-10-06 https://evidence-hub.com/study/15779-akkermansia-muciniphila-which-is-enriched-in-the-gut-microbiota-by2026-10-06 https://evidence-hub.com/study/15780-pet-micro-nano-plastics-modulate-metformin-albumin-binding-and2026-10-04 https://evidence-hub.com/study/15781-metformin-preserves-insulin-secretion-in-pancreatic-cells-through2026-10-06 https://evidence-hub.com/study/15782-glibenclamide-or-metformin-combined-with-honey-improves-glycemic2026-10-06 https://evidence-hub.com/study/15783-metformin-improves-diabetic-bone-health-by-re-balancing-catabolism2026-10-06 https://evidence-hub.com/study/15784-gender-related-differences-in-the-expression-of-organic-cation2026-10-06 https://evidence-hub.com/study/15785-development-and-characterization-of-ph-responsive-delonix-regia-mucin2026-10-06 https://evidence-hub.com/study/15786-metformin-promotes-isolated-rat-liver-mitochondria-impairment2026-10-06 https://evidence-hub.com/study/15787-preclinical-evaluation-of-pharmacokinetic-pharmacodynamic-rationale2026-10-06 https://evidence-hub.com/study/15788-potentiating-effect-of-metformin-on-insulin-induced-glucose-uptake2026-10-06 https://evidence-hub.com/study/15789-metformin-disrupts-signaling-and-metabolism-in-fetal-hepatocytes2026-10-06 https://evidence-hub.com/study/15790-inhibitory-effect-of-metformin-on-the-development-of-cholesterol2026-10-06 https://evidence-hub.com/study/15791-maternal-metformin-exposure-induces-gut-microbial-shifts-in-non2026-10-06 https://evidence-hub.com/study/15792-effects-of-metformin-on-the-glucose-regulation-lipid-levels-and-gut2026-10-06 https://evidence-hub.com/study/15793-metformin-and-resveratrol-ameliorate-muscle-insulin-resistance2026-10-06 https://evidence-hub.com/study/15794-dual-effects-of-metformin-on-adipogenic-differentiation-of-3t3-l12026-10-06 https://evidence-hub.com/study/15795-metformin-enhances-the-action-of-insulin-on-porcine-granulosa-lutein2026-10-06 https://evidence-hub.com/study/15796-the-effect-of-metformin-on-alveolar-bone-in-ligature-induced2026-10-06 https://evidence-hub.com/study/15797-metformin-alleviates-cryoinjuries-in-porcine-oocytes-by-reducing2026-10-06 https://evidence-hub.com/study/15798-non-nutritive-sweetened-beverages-impair-therapeutic-benefits-of2026-10-06 https://evidence-hub.com/study/15799-effects-of-metformin-on-lipopolysaccharide-induced-depressive-like2026-10-06 https://evidence-hub.com/study/15800-metformin-suppresses-proliferation-and-viability-of-rat2026-10-06 https://evidence-hub.com/study/15801-advanced-onset-of-puberty-after-metformin-therapy-in-swine-with2026-10-06 https://evidence-hub.com/study/15802-metformin-increases-mitochondrial-energy-formation-in-l6-muscle-cell2026-10-06 https://evidence-hub.com/study/15803-investigation-of-the-relationship-between-inflammation-and-microbiota2026-10-06 https://evidence-hub.com/study/15804-metformin-limits-apoptosis-in-primary-rat-cortical-astrocytes2026-10-06 https://evidence-hub.com/study/15805-impact-of-metformin-on-neocortical-development-during-pregnancy2026-10-06 https://evidence-hub.com/study/15806-metformin-attenuates-chronic-lung-allograft-dysfunction-evidence-in2026-10-06 https://evidence-hub.com/study/15807-early-treatment-with-metformin-improves-neurological-outcomes-in2026-10-06 https://evidence-hub.com/study/15808-metformin-improves-cognitive-impairment-in-diabetic-mice-induced-by-a2026-10-06 https://evidence-hub.com/study/15809-metformin-alleviates-altered-erythrocyte-redox-status-during-aging-in2026-10-06 https://evidence-hub.com/study/15810-artocarpus-heterophyllus-l-seed-starch-blended-gellan-gum2026-10-06 https://evidence-hub.com/study/15811-metformin-attenuates-experimental-autoimmune-arthritis-through2026-10-06 https://evidence-hub.com/study/15812-metformin-but-not-exercise-training-increases-insulin-responsiveness2026-10-06 https://evidence-hub.com/study/15813-metformin-inhibits-ganglionic-neurotransmission-in-renal-nerves2026-10-06 https://evidence-hub.com/study/15814-4-hne-induces-cell-death-through-the-vcp-related-ubiquitination2026-10-06 https://evidence-hub.com/study/15815-effect-of-metformin-on-sepsis-associated-acute-lung-injury-and-gut2026-10-06 https://evidence-hub.com/study/15816-metformin-shows-anti-inflammatory-effects-in-murine-macrophages2026-10-06 https://evidence-hub.com/study/15817-metformin-exaggerates-phenylephrine-induced-ampk-phosphorylation2026-10-06 https://evidence-hub.com/study/15818-metformin-and-male-reproduction-effects-on-sertoli-cell-metabolism2026-10-06 https://evidence-hub.com/study/15819-hyperbaric-oxygen-and-metformin-treatment-in-ovarian-torsion2026-10-06 https://evidence-hub.com/study/15820-metformin-loaded-cholesterol-lysine-conjugate-nanoparticles-a-novel2026-10-06 https://evidence-hub.com/study/15821-metformin-activates-amp-activated-protein-kinase-by-promoting2026-10-06 https://evidence-hub.com/study/15822-chronic-embryo-larval-exposure-of-fathead-minnows-to-the2026-10-06 https://evidence-hub.com/study/15823-metformin-decreases-meal-size-and-number-and-increases-c-fos2026-10-06 https://evidence-hub.com/study/15824-the-antidiabetic-effects-of-cysteinyl-metformin-a-newly-synthesized2026-10-06 https://evidence-hub.com/study/15825-metformin-increases-proliferative-activity-and-viability-of2026-10-06 https://evidence-hub.com/study/15826-topical-gel-of-metformin-solid-lipid-nanoparticles-a-hopeful-promise2026-10-06 https://evidence-hub.com/study/15827-effects-of-biguanides-on-the-intermediate-metabolism-of-glucose-in2026-10-06 https://evidence-hub.com/study/15828-metformin-induced-mitophagy-suppresses-auditory-hair-cell-apoptosis2026-10-06 https://evidence-hub.com/study/15829-effect-of-metformin-on-adult-hippocampal-neurogenesis-comparison-with2026-10-06 https://evidence-hub.com/study/15830-preparation-and-characterization-of-metformin-surface-modified2026-10-06 https://evidence-hub.com/study/15831-effects-of-huoxuejiangtang-decoction-alone-or-in-combination-with2026-10-06 https://evidence-hub.com/study/15832-effect-of-hyperoxia-and-metformin-on-vascular-responses-to-vasoactive2026-10-06 https://evidence-hub.com/study/15833-changes-in-hepatic-and-intestinal-cholesterol-regulatory-enzymes-the2026-10-06 https://evidence-hub.com/study/15834-role-of-the-arachnoid-mater-organic-anion-and-cation-transporters-in2026-10-06 https://evidence-hub.com/study/15835-metformin-ameliorates-peripheral-neuropathy-in-diabetic-rats-by2026-10-06 https://evidence-hub.com/study/15836-metformin-attenuates-antipsychotic-induced-metabolic-dysfunctions-in2026-10-06 https://evidence-hub.com/study/15837-a-turn-on-optoacoustic-probe-for-imaging-metformin-induced2026-10-06 https://evidence-hub.com/study/15838-possible-protective-mechanisms-exerted-by-metformin-or-metformin-and2026-10-06 https://evidence-hub.com/study/15839-metformin-alleviates-liver-metabolic-dysfunction-in-polycystic-ovary2026-10-06 https://evidence-hub.com/study/15840-metformin-mediates-protection-against-legionella-pneumonia-through2026-10-06 https://evidence-hub.com/study/15841-the-anti-diabetic-drug-metformin-does-not-affect-bone-mass-in-vivo-or2026-10-06 https://evidence-hub.com/study/15842-acute-treatment-with-metformin-improves-cardiac-function-following2026-10-06 https://evidence-hub.com/study/15843-baicalin-improves-antioxidant-status-of-streptozotocin-induced2026-10-06 https://evidence-hub.com/study/15844-effects-of-swimming-on-the-pharmacokinetics-and-glucose-tolerance-of2026-10-06 https://evidence-hub.com/study/15845-the-effects-of-metformin-on-myocardial-ischemia-and-reperfusion2026-10-06 https://evidence-hub.com/study/15846-metformin-attenuates-plaque-associated-tau-pathology-and-reduces2026-10-06 https://evidence-hub.com/study/15847-metformin-preserves-peripheral-nerve-damage-with-comparable-effects2026-10-06 https://evidence-hub.com/study/15848-combinational-effect-of-curcumin-and-metformin-against-gentamicin2026-10-06 https://evidence-hub.com/study/15849-mitochondrial-complex-i-inhibition-by-metformin-limits-reperfusion2026-10-06 https://evidence-hub.com/study/15850-metformin-alleviates-sphingolipids-dysregulation-and-improves-obesity2026-10-06 https://evidence-hub.com/study/15851-metformin-instigates-cellular-autophagy-to-ameliorate-high-fat-diet2026-10-06 https://evidence-hub.com/study/15852-long-term-combination-therapy-with-metformin-and-oxymetholone-in-a2026-10-06 https://evidence-hub.com/study/15853-metformin-protects-against-insulin-resistance-induced-by-high-uric2026-10-08 https://evidence-hub.com/study/15854-metformin-strongly-affects-gut-microbiome-composition-in-high-fat2026-10-06 https://evidence-hub.com/study/15855-altered-pulmonary-glucose-transport-is-restored-by-metformin2026-10-08 https://evidence-hub.com/study/15856-metformin-preconditioning-augments-cardiac-perfusion-and-performance2026-10-08 https://evidence-hub.com/study/15857-metformin-and-caffeine-s-influence-on-lipid-profile-indices-of2026-10-08 https://evidence-hub.com/study/15858-metformin-restores-cognitive-dysfunction-and-histopathological2026-10-08 https://evidence-hub.com/study/15859-combination-of-metformin-and-sub-therapeutic-dose-of-valproic-acid2026-10-08 https://evidence-hub.com/study/15861-psidium-cattleianum-fruit-extract-prevents-systemic-alterations-in-an2026-10-08 https://evidence-hub.com/study/15862-metformin-accelerates-myelin-recovery-and-ameliorates-behavioral2026-10-08 https://evidence-hub.com/study/15863-metformin-enhances-the-immunomodulatory-potential-of-adipose-derived2026-10-08 https://evidence-hub.com/study/15864-romidepsin-and-metformin-nanomaterials-delivery-on-streptozocin-for2026-10-08 https://evidence-hub.com/study/15865-effects-of-metformin-on-the-weight-of-healthy-and-streptozotocin2026-10-08 https://evidence-hub.com/study/15866-chromium-iii-complexes-of-metformin-dapagliflozin-vildagliptin-and2026-10-08 https://evidence-hub.com/study/15868-effect-of-metformin-on-development-of-tendinopathy-due-to-mechanical2026-10-08 https://evidence-hub.com/study/15870-modulatory-effects-of-rutin-and-vitamin-a-on-hyperglycemia-induced2026-10-08 https://evidence-hub.com/study/15872-ameliorative-and-preventive-effects-of-metformin-nigella-sativa2026-10-08 https://evidence-hub.com/study/15873-reliability-of-metformin-s-protective-effects-against-doxorubicin2026-10-08 https://evidence-hub.com/study/15874-repurposing-caffeine-metformin-and-furosemide-to-target-schizophrenia2026-10-06 https://evidence-hub.com/study/15875-in-vivo-evidence-of-metformin-and-aspirin-antibacterial-activity2026-10-08 https://evidence-hub.com/study/15876-modulation-of-altered-immune-parameters-il-2-and-tnf-in-diabetic2026-10-08 https://evidence-hub.com/study/15877-effect-of-metformin-in-a-novel-experimental-model-of-peripheral2026-10-08 https://evidence-hub.com/study/15878-metformin-improves-memory-via-ampk-mtor-dependent-route-in-a-rat2026-10-08 https://evidence-hub.com/study/15879-metformin-alleviates-reactive-gliosis-and-neurodegeneration-improving2026-10-08 https://evidence-hub.com/study/15880-exaggerated-ventilator-induced-lung-injury-in-an-animal-model-of-type2026-10-08 https://evidence-hub.com/study/15881-potential-of-honey-against-the-onset-of-autoimmune-diabetes-and-its2026-10-08 https://evidence-hub.com/study/15882-effects-of-berberine-on-diabetes-and-cognitive-impairment-in-an2026-10-08 https://evidence-hub.com/study/15883-metformin-inhibits-muscle-atrophy-through-the-pi3k-akt-mtor-pathway2026-10-08 https://evidence-hub.com/study/15884-anticancer-effects-of-metformin-in-experimental-animal-models-of2026-10-13 https://evidence-hub.com/study/15885-enhancement-of-radiation-response-associated-with-metformin-in2026-10-08 https://evidence-hub.com/study/15886-breadfruit-leaves-extract-artocarpus-altilis-effect-on-pancreatic2026-10-08 https://evidence-hub.com/study/15887-ellagic-acid-dose-and-time-dependently-abrogates-d-galactose-induced2026-10-10 https://evidence-hub.com/study/15888-evaluation-of-the-combination-of-metformin-and-rapamycin-in-an-mpp2026-10-08 https://evidence-hub.com/study/15889-resveratrol-regulates-hyperglycemia-induced-modulations-in2026-10-08 https://evidence-hub.com/study/15890-study-the-efficacy-of-herbal-formulation-nisamalaki-in-animal-model2026-10-08 https://evidence-hub.com/study/15891-bioactivity-of-methanolic-extract-of-brassica-juncea-in-animal-model2026-10-08 https://evidence-hub.com/study/15892-effect-of-methanolic-extract-of-phyllanthus-niruri-on-leptin-level-in2026-10-08 https://evidence-hub.com/study/15893-novel-role-of-peroxisome-proliferator-activated-receptor-in-valproic2026-10-08 https://evidence-hub.com/study/15895-metformin-attenuates-alveolar-bone-destruction-in-mice-with-apical2026-10-08 https://evidence-hub.com/study/15896-metformin-attenuates-autoimmune-disease-of-the-neuromotor-system-in2026-10-08 https://evidence-hub.com/study/15897-effect-of-combining-rosiglitazone-with-either-metformin-or-insulin-on2026-10-08 https://evidence-hub.com/study/15898-neuroprotective-effects-of-semaglutide-and-metformin-against-rotenone2026-10-08 https://evidence-hub.com/study/15900-metformin-effects-on-brain-development-following-cranial-irradiation2026-10-08 https://evidence-hub.com/study/15902-molecular-insights-into-parkinson-s-disease-and-type-2-diabetes2026-10-08 https://evidence-hub.com/study/15904-interaction-of-clozapine-with-metformin-in-a-schizophrenia-rat-model2026-10-08 https://evidence-hub.com/study/15905-the-effects-of-metformin-and-sitagliptin-for-polycystic-ovary2026-10-08 https://evidence-hub.com/study/15906-association-of-metformin-administration-after-septic-shock-with-short2026-10-08 https://evidence-hub.com/study/15908-mouse-model-of-metformin-induced-diarrhea2026-10-08 https://evidence-hub.com/study/15909-effect-of-metformin-on-locomotor-function-recovery-in-rat-spinal-cord2026-10-08 https://evidence-hub.com/study/15910-metformin-alleviates-colitis-associated-colorectal-cancer-via2026-10-08 https://evidence-hub.com/study/15911-diverse-applications-of-the-anti-diabetic-drug-metformin-in-treating2026-10-08 https://evidence-hub.com/study/15912-metformin-improves-lipid-metabolism-and-reverses-the-warburg-effect2026-10-08 https://evidence-hub.com/study/15913-divergent-effects-of-metformin-on-an-inflammatory-model-of-parkinson2026-10-08 https://evidence-hub.com/study/15914-metformin-attenuates-pm2-5-induced-oxidative-stress-by-inhibiting-the2026-10-08 https://evidence-hub.com/study/15915-effect-of-applying-1-metformin-on-guided-bone-regeneration-processes2026-10-08 https://evidence-hub.com/study/15916-metformin-alleviates-cerebral-ischemia-reperfusion-injury-aggravated2026-10-08 https://evidence-hub.com/study/15917-metformin-ameliorates-diabetes-induced-hepatic-ultrastructural-damage2026-10-08 https://evidence-hub.com/study/15918-metformin-overcomes-chemoresistance-by-regulating-stemness-via-klf42026-10-08 https://evidence-hub.com/study/15919-revealing-metabolic-and-biochemical-variations-via-1h-nmr2026-10-08 https://evidence-hub.com/study/15920-retinoprotection-by-bgp-15-a-hydroximic-acid-derivative-in-a-type-ii2026-10-08 https://evidence-hub.com/study/15921-metformin-inhibits-cyst-formation-in-a-zebrafish-model-of-polycystin2026-10-08 https://evidence-hub.com/study/15922-enhanced-fatty-acid-oxidation-through-metformin-and-baicalin-as2026-10-08 https://evidence-hub.com/study/15923-influence-of-metformin-on-learning-and-memory-in-experimental-amnesia2026-10-08 https://evidence-hub.com/study/15924-knockout-model-reveals-the-role-of-nischarin-in-mammary-gland2026-10-08 https://evidence-hub.com/study/15925-metformin-improves-ovarian-follicle-dynamics-by-reducing-theca-cell2026-10-08 https://evidence-hub.com/study/15926-metformin-promotes-tau-aggregation-and-exacerbates-abnormal-behavior2026-10-08 https://evidence-hub.com/study/15927-metformin-reverses-impaired-osteogenesis-due-to-hyperglycemia-induced2026-10-08 https://evidence-hub.com/study/15928-effects-of-quercetin-on-polycystic-ovary-syndrome-in-animal-models-a2026-10-13 https://evidence-hub.com/study/15929-the-desert-gerbil-psammomys-obesus-as-a-model-for-metformin-sensitive2026-10-08 https://evidence-hub.com/study/15930-metformin-improves-fibroblast-metabolism-and-ameliorates2026-10-08 https://evidence-hub.com/study/15932-beneficial-effects-of-the-herbal-medicine-zuo-gui-wan-in-a-mice-model2026-10-08 https://evidence-hub.com/study/15933-reduced-lactic-acidosis-risk-with-imeglimin-comparison-with-metformin2026-10-08 https://evidence-hub.com/study/15934-sex-specific-effects-of-maternal-metformin-intervention-during2026-10-08 https://evidence-hub.com/study/15935-repurposing-metformin-for-the-prevention-of-cancer-and-cancer2026-10-08 https://evidence-hub.com/study/15936-effect-of-metformin-on-left-ventricular-mass-and-functional2026-10-08 https://evidence-hub.com/study/15937-effect-of-metformin-in-autistic-btbr-t-itpr3tf-j-mice-administered-a2026-10-08 https://evidence-hub.com/study/15938-the-mtor-signaling-pathway-in-multiple-sclerosis-from-animal-models2026-10-08 https://evidence-hub.com/study/15939-sangyod-rice-extract-attenuates-vascular-inflammation-and-injury-in-a2026-10-08 https://evidence-hub.com/study/15940-metformin-inhibits-pancreatic-cancer-metastasis-caused-by-smad42026-10-08 https://evidence-hub.com/study/15941-the-effect-of-nigella-sativa-oil-and-metformin-on-male-seminal2026-10-08 https://evidence-hub.com/study/15942-metformin-impairs-homing-ability-and-efficacy-of-mesenchymal-stem2026-10-08 https://evidence-hub.com/study/15943-metformin-regulates-astrocyte-reactivity-in-parkinson-s-disease-and2026-10-08 https://evidence-hub.com/study/15944-metformin-attenuates-depressive-like-behaviour-of-methamphetamine2026-10-08 https://evidence-hub.com/study/15945-metformin-inhibits-abdominal-aortic-aneurysm-formation-through-the2026-10-08 https://evidence-hub.com/study/15946-promise-of-metformin-for-preventing-age-related-cognitive-dysfunction2026-10-08 https://evidence-hub.com/study/15947-numb-notch-plk1-signaling-pathway-mediated-hyperglycemic-memory-in2026-10-08 https://evidence-hub.com/study/15948-metformin-augments-anti-inflammatory-and-chondroprotective-properties2026-10-08 https://evidence-hub.com/study/15949-metformin-reverses-hashimoto-s-thyroiditis-by-regulating-key-immune2026-10-08 https://evidence-hub.com/study/15950-metformin-attenuated-the-autoimmune-disease-of-the-central-nervous2026-10-08 https://evidence-hub.com/study/15951-use-and-abuse-of-homa-modeling2026-10-01 https://evidence-hub.com/study/15952-the-effect-of-metformin-in-experimentally-induced-animal-models-of2026-10-08 https://evidence-hub.com/study/15953-the-therapeutic-potential-of-metformin-in-neurodegenerative-diseases2026-10-08 https://evidence-hub.com/study/15954-reporting-animal-research-explanation-and-elaboration-for-the-arrive2026-10-01 https://evidence-hub.com/study/15955-cellular-mechanism-of-action-of-metformin2026-10-08 https://evidence-hub.com/study/15956-metformin-prevents-progression-of-heart-failure-in-dogs2026-10-08 https://evidence-hub.com/study/15957-metformin-and-cancer-doses-mechanisms-and-the-dandelion-and-hormetic2026-10-08 https://evidence-hub.com/study/15960-metformin-improves-cardiac-function-in-a-nondiabetic-rat-model-of2026-10-08 https://evidence-hub.com/study/15961-metformin-directly-acts-on-mitochondria-to-alter-cellular2026-10-01 https://evidence-hub.com/study/15963-metformin-alleviates-human-cellular-aging-by-upregulating-the2026-10-01 https://evidence-hub.com/study/15964-metformin-restores-endothelial-function-in-aorta-of-diabetic-rats2026-10-08 https://evidence-hub.com/study/15965-modulation-of-gut-microbiota-by-berberine-and-metformin-during-the2026-10-01 https://evidence-hub.com/study/15970-metformin-and-ageing-improving-ageing-outcomes-beyond-glycaemic2026-10-08 https://evidence-hub.com/study/15971-sirt3-amp-activated-protein-kinase-activation-by-nitrite-and2026-10-08 https://evidence-hub.com/study/15972-metformin-induces-a-dietary-restriction-like-state-and-the-oxidative2026-10-01 https://evidence-hub.com/study/15973-metformin-multi-faceted-protection-against-cancer2026-10-08 https://evidence-hub.com/study/15974-metformin-promotes-lifespan-through-mitohormesis-via-the2026-10-01 https://evidence-hub.com/study/15975-metformin-a-future-therapy-for-neurodegenerative-diseases-theme-drug2026-10-08 https://evidence-hub.com/study/15976-metformin-inhibits-hmgb1-release-in-lps-treated-raw-264-7-cells-and2026-10-01 https://evidence-hub.com/study/15977-repurposing-metformin-for-cancer-treatment-current-clinical-studies2026-10-08 https://evidence-hub.com/study/15979-liraglutide-vs-insulin-glargine-and-placebo-in-combination-with2026-10-01 https://evidence-hub.com/study/15980-renoprotective-effects-of-metformin2026-10-08 https://evidence-hub.com/study/15981-metformin-slows-down-aging-and-extends-life-span-of-female-shr-mice2026-10-01 https://evidence-hub.com/study/15982-metformin-treatment-reduces-motor-and-neuropsychiatric-phenotypes-in2026-10-08 https://evidence-hub.com/study/15983-improvement-of-cardiac-functions-by-chronic-metformin-treatment-is2026-10-01 https://evidence-hub.com/study/15984-metformin-an-old-drug-with-new-applications2026-10-08 https://evidence-hub.com/study/15986-metformin-induces-unique-biological-and-molecular-responses-in-triple2026-10-01 https://evidence-hub.com/study/15987-metformin-inhibits-melanoma-development-through-autophagy-and2026-10-01 https://evidence-hub.com/study/15988-metformin-induced-mitochondrial-complex-i-inhibition-facts2026-10-01 https://evidence-hub.com/study/15989-glucose-promotes-breast-cancer-aggression-and-reduces-metformin2026-10-01 https://evidence-hub.com/study/15990-in-vivo-imaging-of-human-11-c-metformin-in-peripheral-organs2026-10-01 https://evidence-hub.com/study/15992-mechanisms-underlying-metformin-induced-secretion-of-glucagon-like2026-10-01 https://evidence-hub.com/study/15993-metformin-exerts-an-antitumoral-effect-on-papillary-thyroid-cancer2026-10-06 https://evidence-hub.com/study/15994-antidiabetic-drug-metformin-inhibits-esophageal-adenocarcinoma-cell2026-10-08 https://evidence-hub.com/study/15995-regulation-of-organelle-function-by-metformin2026-10-08 https://evidence-hub.com/study/15996-the-effect-and-mechanism-of-action-of-metformin-on-in-vitro-fadu-cell2026-10-06 https://evidence-hub.com/study/15997-in-vitro-and-in-ovo-evaluation-of-the-potential-hepatoprotective2026-10-08 https://evidence-hub.com/study/15998-use-of-metformin-alone-is-not-associated-with-survival-outcomes-of2026-10-06 https://evidence-hub.com/study/15999-synergy-between-sublethal-doses-of-shikonin-and-metformin-fully2026-10-06 https://evidence-hub.com/study/16000-genome-wide-crispr-screen-identifies-synthetic-lethality-between2026-10-06 https://evidence-hub.com/study/16002-metformin-inhibits-breast-cancer-cell-growth-colony-formation-and2026-10-08 https://evidence-hub.com/study/16003-metformin-and-trametinib-have-synergistic-effects-on-cell-viability2026-10-06 https://evidence-hub.com/study/16004-metformin-inhibits-growth-of-thyroid-carcinoma-cells-suppresses-self2026-10-06 https://evidence-hub.com/study/16005-metformin-displays-anti-myeloma-activity-and-synergistic-effect-with2026-10-08 https://evidence-hub.com/study/16006-inactivated-ampk-2-promotes-the-progression-of-diabetic-brain-damage2026-10-06 https://evidence-hub.com/study/16007-effects-of-metformin-on-the-pi3k-akt-foxo1-pathway-in-anaplastic2026-10-06 https://evidence-hub.com/study/16008-combined-regimen-of-photodynamic-therapy-mediated-by-gallium2026-10-06 https://evidence-hub.com/study/16009-mitochondrial-dysfunction-as-the-cause-of-the-failure-to-precondition2026-10-06 https://evidence-hub.com/study/16011-effects-of-commonly-used-medications-on-bone-tissue-mineralisation-in2026-10-06 https://evidence-hub.com/study/16012-metformin-sensitizes-aml-cells-to-venetoclax-through-endoplasmic2026-10-06 https://evidence-hub.com/study/16013-metabolic-regulation-of-neuronal-plasticity-by-the-energy-sensor-ampk2026-10-06 https://evidence-hub.com/study/16014-plasminogen-activator-inhibitor-1-synthesis-in-the-human-hepatoma2026-10-06 https://evidence-hub.com/study/16015-metformin-and-the-molecular-pathways-of-aging-searching-for-the2026-10-08 https://evidence-hub.com/study/16016-sirolimus-and-metformin-synergistically-inhibits-colon-cancer-in2026-10-08 https://evidence-hub.com/study/16017-metformin-elicits-antitumor-effects-and-downregulates-the-histone2026-10-06 https://evidence-hub.com/study/16018-anti-tumour-effect-of-metformin-in-canine-mammary-gland-tumour-cells2026-10-06 https://evidence-hub.com/study/16019-glucotoxicity-promotes-aberrant-activation-and-mislocalization-of-ras2026-10-06 https://evidence-hub.com/study/16020-desmoplasia-suppression-by-metformin-mediated-ampk-activation2026-10-08 https://evidence-hub.com/study/16021-intratumoral-heterogeneity-of-the-therapeutical-response-to2026-10-08 https://evidence-hub.com/study/16022-mitochondrial-dysfunction-in-breast-cancer-cells-prevents-tumor2026-10-06 https://evidence-hub.com/study/16023-combination-therapy-with-vemurafenib-plx4032-rg7204-and-metformin-in2026-10-06 https://evidence-hub.com/study/16024-establishment-and-characterization-of-a-novel-method-for-evaluating2026-10-06 https://evidence-hub.com/study/16025-the-effects-of-brain-derived-neurotrophic-factor-and-metformin-on-in2026-10-06 https://evidence-hub.com/study/16026-application-of-numerical-convolution-in-in-vivo-in-vitro-correlation2026-10-06 https://evidence-hub.com/study/16027-metformin-inhibited-esophageal-squamous-cell-carcinoma-proliferation2026-10-06 https://evidence-hub.com/study/16028-statistically-controlled-identification-of-differentially-expressed2026-10-06 https://evidence-hub.com/study/16029-age-related-hyperinsulinemia-leads-to-insulin-resistance-in-neurons2026-10-06 https://evidence-hub.com/study/16030-synthesis-and-in-vivo-studies-of-metformin-analogues-for-management2026-10-06 https://evidence-hub.com/study/16031-metformin-induced-ampk-activation-g0-g1-phase-cell-cycle-arrest-and2026-10-06 https://evidence-hub.com/study/16032-metformin-regulates-multiple-signaling-pathways-within-castration2026-10-06 https://evidence-hub.com/study/16033-effect-of-ecdysterone-on-glucose-metabolism-in-vitro2026-10-06 https://evidence-hub.com/study/16034-metformin-increases-pdh-and-suppresses-hif-1-under-hypoxic-conditions2026-10-06 https://evidence-hub.com/study/16035-metformin-stimulates-osteoprotegerin-and-reduces-rankl-expression-in2026-10-06 https://evidence-hub.com/study/16036-anti-proliferative-properties-of-the-novel-hybrid-drug-met-itc2026-10-06 https://evidence-hub.com/study/16037-metformin-reduces-glycometabolism-of-papillary-thyroid-carcinoma-in2026-10-08 https://evidence-hub.com/study/16038-mechanisms-by-which-low-glucose-enhances-the-cytotoxicity-of2026-10-08 https://evidence-hub.com/study/16039-metformin-decreases-hepatocellular-carcinoma-risk-in-a-dose-dependent2026-10-08 https://evidence-hub.com/study/16040-metformin-inhibits-lps-induced-inflammatory-response-in-vsmcs-by2026-10-06 https://evidence-hub.com/study/16041-activation-of-amp-activated-protein-kinase-by-metformin-inhibits2026-10-06 https://evidence-hub.com/study/16042-influence-of-water-soluble-polymers-on-the-in-vitro-performance-of2026-10-06 https://evidence-hub.com/study/16043-short-term-metformin-ingestion-by-healthy-older-adults-improves2026-10-08 https://evidence-hub.com/study/16044-metformin-inhibits-renal-cell-carcinoma-in-vitro-and-in-vivo-xenograft2026-10-08 https://evidence-hub.com/study/16045-amp-activated-protein-kinase-regulates-neuronal-polarization-by2026-10-08 https://evidence-hub.com/study/16046-endoplasmic-reticulum-stress-involved-in-the-course-of-lipogenesis-in2026-10-06 https://evidence-hub.com/study/16047-flaxseed-lignans-enhance-the-cytotoxicity-of-chemotherapeutic-agents2026-10-06 https://evidence-hub.com/study/16048-in-vitro-and-in-vivo-efficacy-of-metformin-against-dengue2026-10-08 https://evidence-hub.com/study/16049-metformin-inhibited-growth-invasion-and-metastasis-of-esophageal2026-10-08 https://evidence-hub.com/study/16050-ezh2-presents-a-therapeutic-target-for-neuroendocrine-tumors-of-the2026-10-06 https://evidence-hub.com/study/16051-anti-cancer-effect-of-metformin-by-suppressing-signaling-pathway-of2026-10-06 https://evidence-hub.com/study/16052-metformin-induces-apoptosis-of-pancreatic-cancer-cells2026-10-06 https://evidence-hub.com/study/16053-the-effect-of-metformin-and-gant61-combinations-on-the2026-10-06 https://evidence-hub.com/study/16054-fam98a-promotes-resistance-to-5-fluorouracil-in-colorectal-cancer-by2026-10-06 https://evidence-hub.com/study/16055-effect-of-metformin-on-viability-morphology-and-ultrastructure-of2026-10-06 https://evidence-hub.com/study/16056-inhibitory-effect-of-metformin-combined-with-gemcitabine-on2026-10-06 https://evidence-hub.com/study/16057-metformin-increases-antitumor-activity-of-mek-inhibitors-through-gli12026-10-06 https://evidence-hub.com/study/16058-metformin-and-proliferation-of-cancer-cell-lines2026-10-06 https://evidence-hub.com/study/16059-metformin-induces-apoptosis-in-hepatocellular-carcinoma-huh-7-cells2026-10-06 https://evidence-hub.com/study/16060-metformin-promotes-the-normalization-of-abnormal-blood-vessels-after2026-10-06 https://evidence-hub.com/study/16061-metformin-attenuates-motility-contraction-and-fibrogenic-response-of2026-10-08 https://evidence-hub.com/study/16062-metformin-and-covid-19-focused-review-of-mechanisms-and-current2026-10-08 https://evidence-hub.com/study/16063-meta-analysis-of-microarray-expression-studies-on-metformin-in-cancer2026-10-06 https://evidence-hub.com/study/16064-treatment-resistance-to-melanoma-therapeutics-on-a-single-cell-level2026-10-06 https://evidence-hub.com/study/16066-evaluation-of-renal-transporter-inhibition-using-creatinine-as-a2026-10-06 https://evidence-hub.com/study/16067-repetitive-fasting-refeeding-enhances-metformin-induced-cxcr6-cd8-t2026-10-06 https://evidence-hub.com/study/16068-metoprolol-decreases-the-plasma-exposure-of-metformin-via-the2026-10-06 https://evidence-hub.com/study/16069-metformin-impairs-systemic-bile-acid-homeostasis-through-regulating2026-10-08 https://evidence-hub.com/study/16070-high-efficacy-of-intravesical-treatment-of-metformin-on-bladder2026-10-06 https://evidence-hub.com/study/16071-metformin-protects-against-lipoapoptosis-and-enhances-glp-1-secretion2026-10-06 https://evidence-hub.com/study/16072-glut1-sglt1-balance-associates-with-high-glucose-buffering-of2026-10-06 https://evidence-hub.com/study/16073-the-antiviral-effect-of-metformin-on-zika-and-dengue-virus-infection2026-10-06 https://evidence-hub.com/study/16074-mechanism-of-metformin-action-in-mcf-7-and-mda-mb-231-human-breast2026-10-06 https://evidence-hub.com/study/16075-amp-activated-protein-kinase-ampk-activity-negatively-regulates2026-10-06 https://evidence-hub.com/study/16076-chemopreventive-effects-of-metformin-on-obesity-associated2026-10-06 https://evidence-hub.com/study/16077-in-vitro-study-of-the-drug-drug-interaction-potential-of-cetagliptin2026-10-08 https://evidence-hub.com/study/16078-combination-of-metformin-and-cold-atmospheric-plasma-induces-glioma2026-10-06 https://evidence-hub.com/study/16079-metformin-induces-a-senescence-associated-gene-signature-in-breast2026-10-06 https://evidence-hub.com/study/16080-metformin-attenuates-ox-ldl-induced-macrophage-senescence-and2026-10-06 https://evidence-hub.com/study/16081-metformin-and-its-nanoformulations-in-cancer-prevention-and-therapy2026-10-08 https://evidence-hub.com/study/16082-pleiotropic-effects-of-metformin-on-the-chemotherapy-response-of-hpv2026-10-06 https://evidence-hub.com/study/16083-addition-of-metformin-to-anti-pd-1-pd-l1-drugs-activates-anti-tumor2026-10-06 https://evidence-hub.com/study/16084-effects-of-metformin-on-fertilisation-of-bovine-oocytes-and-early2026-10-06 https://evidence-hub.com/study/16085-metformin-targets-stat3-to-inhibit-cell-growth-and-induce-apoptosis2026-10-06 https://evidence-hub.com/study/16086-metformin-protects-arpe-19-cells-from-glyoxal-induced-oxidative-stress2026-10-06 https://evidence-hub.com/study/16087-metformin-partially-reverses-the-inhibitory-effect-of-co-culture-with2026-10-06 https://evidence-hub.com/study/16088-the-influence-of-the-choice-of-digestion-enzyme-used-to-prepare-rat2026-10-06 https://evidence-hub.com/study/16089-mul1-e3-ligase-regulates-the-antitumor-effects-of-metformin-in2026-10-06 https://evidence-hub.com/study/16090-a-massive-type-iv-hiatal-hernia-with-gastric-volvulus-and-the2026-10-08 https://evidence-hub.com/study/16091-costs-and-cost-effectiveness-of-type-2-diabetes-management-in-sub2026-10-08 https://evidence-hub.com/study/16092-pharmaceutical-quality-and-cost-effectiveness-of-branded-versus2026-10-08 https://evidence-hub.com/study/16093-therapeutic-potential-of-green-tea-s-epigallocatechin-3-gallate-in2026-10-08 https://evidence-hub.com/study/16094-ros-targeted-nanomotor-therapy-in-oa-cartilage-protection-and-pain2026-10-08 https://evidence-hub.com/study/16095-secondary-analysis-of-california-regional-water-boards-dataset2026-10-08 https://evidence-hub.com/study/16096-the-effectiveness-of-glucagon-like-peptide-1-receptor-agonists-glp2026-10-08 https://evidence-hub.com/study/16097-efficacy-of-metformin-as-an-adjunct-in-periodontitis-a-systematic2026-10-08 https://evidence-hub.com/study/16098-the-association-of-adhd-and-adhd-medication-with-adherence-to2026-10-08 https://evidence-hub.com/study/16099-overlap-of-gestational-diabetes-mellitus-and-pre-eclampsia-a-scoping2026-10-08 https://evidence-hub.com/study/16100-natural-and-synthetic-compounds-swords-for-glioblastoma-therapy-from2026-10-08 https://evidence-hub.com/study/16101-three-dimensional-culture-of-epithelial-cells-on-electrospun2026-10-08 https://evidence-hub.com/study/16102-influence-of-pharmacological-agents-on-orthodontic-tooth-movement-a2026-10-08 https://evidence-hub.com/study/16103-implications-of-adp-ribosylation-factor-like-protein-4c-arl4c-in2026-10-08 https://evidence-hub.com/study/16104-impact-of-glp-1-and-glp-1-gip-receptor-agonists-before-during-and2026-10-08 https://evidence-hub.com/study/16105-in-vitro-bioequivalence-analysis-of-generic-metformin-hydrochloride2026-10-08 https://evidence-hub.com/study/16106-healthy-lifestyle-interventions-for-non-communicable-disease2026-10-08 https://evidence-hub.com/study/16107-the-metabolic-epigenetic-landscape-of-aging-interplay-between-histone2026-10-08 https://evidence-hub.com/study/16108-tumor-membrane-based-delivery-system-encapsulating-metfornin-and-tpp12026-10-08 https://evidence-hub.com/study/16109-garlic-improves-normal-water-and-sodium-handling-in-diabetic-kidneys2026-10-08 https://evidence-hub.com/study/16110-technical-refinements-in-laparoscopic-transabdominal-preperitoneal2026-10-08 https://evidence-hub.com/study/16111-prenatal-and-early-life-exposure-to-microbiome-modulating-medications2026-10-08 https://evidence-hub.com/study/16112-association-between-type-2-diabetes-mellitus-and-sepsis-outcomes-a2026-10-08 https://evidence-hub.com/study/16113-long-covid-a-systematic-review-of-preventive-strategies2026-10-08 https://evidence-hub.com/study/16114-effectiveness-and-safety-of-semaglutide-in-type-1-diabetes-a-danish2026-10-08 https://evidence-hub.com/study/16115-premature-immunosenescence-in-aya-gastrointestinal-cancer-the2026-10-08 https://evidence-hub.com/study/16116-neuropsychiatric-effects-of-glucagon-like-peptide-1-receptor-agonists2026-10-08 https://evidence-hub.com/study/16117-targeted-pd-l1-degradation-with-an-injectable-hydrogel-reverses2026-10-08 https://evidence-hub.com/study/16118-a-bioactive-fraction-of-euphorbia-antiquorum-stem-powder-ameliorates2026-10-08 https://evidence-hub.com/study/16119-ultrasound-assisted-ionic-liquid-extraction-macroporous-resin2026-10-08 https://evidence-hub.com/study/16120-antidiabetic-effects-of-anthocyanins-on-pancreatic-cell-function-a2026-10-08 https://evidence-hub.com/study/16121-strangulated-spigelian-hernia-with-small-bowel-obstruction-requiring2026-10-08 https://evidence-hub.com/study/16122-effect-of-intermittent-fasting-on-weight-loss-in-overweight-and-obese2026-10-08 https://evidence-hub.com/study/16123-metformin-and-beyond-glucose-lowering-therapy-as-a-potential2026-10-04 https://evidence-hub.com/study/16124-exercise-intervention-for-blood-pressure-reduction-in-diabetic2026-10-06 https://evidence-hub.com/study/16125-unveiling-the-role-of-the-pi3k-akt-signaling-pathway-in-follicular2026-10-06 https://evidence-hub.com/study/16126-evaluation-of-betanin-on-key-enzymes-related-to-obesity-diabetes2026-10-08 https://evidence-hub.com/study/16127-targeting-her2-positive-hcc1954-breast-cancer-cells-by-novel-thiazole2026-10-06 https://evidence-hub.com/study/16128-differential-expression-patterns-of-glycolytic-enzymes-and2026-10-08 https://evidence-hub.com/study/16129-alterations-of-endometrial-epithelial-mesenchymal-transition-and-mapk2026-10-08 https://evidence-hub.com/study/16131-metformin-modulates-oxidative-stress-via-activation-of-ampk-nf-b2026-10-08 https://evidence-hub.com/study/16132-a-crispr-knockout-negative-screen-reveals-synergy-between-cdks2026-10-08 https://evidence-hub.com/study/16135-beneficial-effects-of-combination-therapy-of-phloretin-and-metformin2026-10-08 https://evidence-hub.com/study/16137-metformin-in-lung-cancer-review-of-in-vitro-and-in-vivo-animal-studies2026-10-08 https://evidence-hub.com/study/16138-permeability-of-metformin-across-an-in-vitro-blood-brain-barrier2026-10-08 https://evidence-hub.com/study/16139-effect-of-calcium-electroporation-in-combination-with-metformin-in2026-10-08 https://evidence-hub.com/study/16140-biodegradable-gg-cl-poly-nipam-co-aa-o-mwcnt-based-hydrogel-for2026-10-08 https://evidence-hub.com/study/16141-effect-of-high-uric-acid-on-the-disposition-of-metformin-in-vivo-and2026-10-08 https://evidence-hub.com/study/16143-low-glucose-availability-potentiates-the-effects-of-metformin-on2026-10-08 https://evidence-hub.com/study/16144-metformin-prevents-methylglyoxal-induced-apoptosis-by-suppressing2026-10-08 https://evidence-hub.com/study/16145-erythrocyte-glucose-consumption-in-insulin-dependent-diabetes-effect2026-10-08 https://evidence-hub.com/study/16146-metformin-improves-ovarian-cancer-sensitivity-to-paclitaxel-and2026-10-08 https://evidence-hub.com/study/16147-metformin-suppressed-platelet-s-function-in-vitro-possible-relation2026-10-08 https://evidence-hub.com/study/16148-therapeutic-vs-suprapharmacological-metformin-concentrations2026-10-08 https://evidence-hub.com/study/16149-metformin-promotes-in-vitro-maturation-of-oocytes-from-aged-mice-by2026-10-08 https://evidence-hub.com/study/16150-diabetes-medication-metformin-inhibits-osteoclast-formation-and2026-10-08 https://evidence-hub.com/study/16151-synergistic-effects-of-combined-anthocyanin-and-metformin-treatment2026-10-08 https://evidence-hub.com/study/16152-metformin-reduces-macrophage-hif1-dependent-proinflammatory-signaling2026-10-08 https://evidence-hub.com/study/16154-comparative-evaluation-of-floating-and-non-floating-controlled2026-10-08 https://evidence-hub.com/study/16155-metformin-in-gynecological-disorders-pathogenic-insights-and2026-10-08 https://evidence-hub.com/study/16157-in-vitro-evaluation-of-the-cytotoxicity-of-metformin-on-human2026-10-08 https://evidence-hub.com/study/16158-effect-of-losartan-potassium-metformin-hydrochloride-and-simvastatin2026-10-08 https://evidence-hub.com/study/16160-metabolic-targeted-combination-therapy-with-dichloroacetate-and2026-10-08 https://evidence-hub.com/study/16161-metformin-potentiates-the-anticancer-effect-of-everolimus-on-cervical2026-10-08 https://evidence-hub.com/study/16162-hemihydrate-calcium-sulfate-n-hydroxyapatite-combined-with-metformin2026-10-08 https://evidence-hub.com/study/16163-effects-of-metformin-on-sonic-hedgehog-subgroup-medulloblastoma2026-10-08 https://evidence-hub.com/study/16164-assessment-of-in-vitro-tests-as-predictors-of-the-antioxidant-effects2026-10-08 https://evidence-hub.com/study/16165-engineering-a-human-pluripotent-stem-cell-based-in-vitro2026-10-08 https://evidence-hub.com/study/16166-metformin-facilitates-the-proliferation-migration-and-osteogenic2026-10-08 https://evidence-hub.com/study/16167-guar-gum-micro-particles-for-targeted-co-delivery-of-doxorubicin-and2026-10-08 https://evidence-hub.com/study/16168-repression-of-cell-to-matrix-adhesion-by-metformin-chloride-supports2026-10-08 https://evidence-hub.com/study/16169-combining-naringenin-and-metformin-with-doxorubicin-enhances2026-10-08 https://evidence-hub.com/study/16170-metformin-improves-boar-sperm-quality-via-5-amp-activated-protein2026-10-08 https://evidence-hub.com/study/16172-metformin-attenuates-diabetes-induced-tau-hyperphosphorylation-in2026-10-08 https://evidence-hub.com/study/16173-metformin-targets-mitochondrial-glycerophosphate-dehydrogenase-to2026-10-08 https://evidence-hub.com/study/16174-effect-of-metformin-on-lactate-metabolism-in-normal-hepatocytes-under2026-10-08 https://evidence-hub.com/study/16175-effects-of-metformin-on-the-heart-with-ischaemia-reperfusion-injury2026-10-08 https://evidence-hub.com/study/16176-metformin-inhibit-lung-cancer-cell-growth-and-invasion-in-vitro-as2026-10-08 https://evidence-hub.com/study/16177-electrospun-metformin-loaded-polycaprolactone-chitosan-nanofibrous2026-10-08 https://evidence-hub.com/study/16178-in-vitro-and-in-vivo-investigation-of-pla-pcl-scaffold-coated-with2026-10-08 https://evidence-hub.com/study/16179-metformin-attenuates-cadmium-induced-neuronal-apoptosis-in-vitro-via2026-10-08 https://evidence-hub.com/study/16180-metformin-incombination-with-curcumin-inhibits-the-growth-metastasis2026-10-08 https://evidence-hub.com/study/16181-metformin-induces-tpc-1-cell-apoptosis-through-endoplasmic-reticulum2026-10-08 https://evidence-hub.com/study/16182-in-vitro-dissolution-and-in-vivo-bioequivalence-evaluation-of-two2026-10-08 https://evidence-hub.com/study/16183-in-vitro-and-in-vivo-targeting-of-bladder-carcinoma-with-metformin-in2026-10-08 https://evidence-hub.com/study/16184-metformin-targets-brown-adipose-tissue-in-vivo-and-reduces-oxygen2026-10-08 https://evidence-hub.com/study/16185-high-dose-metformin-plus-temozolomide-shows-increased-anti-tumor2026-10-08 https://evidence-hub.com/study/16186-the-impact-of-metformin-and-aspirin-on-t-cell-mediated-inflammation-a2026-10-08 https://evidence-hub.com/study/16187-effect-of-metformin-irinotecan-loaded-poly-lactic-co-glycolic-acid2026-10-08 https://evidence-hub.com/study/16188-metformin-prevents-nephrolithiasis-formation-by-inhibiting-the2026-10-08 https://evidence-hub.com/study/16189-effect-of-metformin-on-ossification-and-inflammation-of-fibroblasts2026-10-08 https://evidence-hub.com/study/16191-metformin-inhibits-ovarian-cancer-growth-and-migration-in-vitro-and2026-10-08 https://evidence-hub.com/study/16192-metformin-improves-in-vivo-and-in-vitro-b-cell-function-in2026-10-08 https://evidence-hub.com/study/16193-combined-treatment-with-metformin-and-2-deoxy-glucose-induces2026-10-08 https://evidence-hub.com/study/16194-mechanistic-in-vitro-studies-confirm-that-inhibition-of-the-renal2026-10-08 https://evidence-hub.com/study/16195-metformin-synergizes-with-rapamycin-to-inhibit-the-growth-of2026-10-08 https://evidence-hub.com/study/16196-metformin-alleviates-inflammatory-response-in-non-alcoholic2026-10-08 https://evidence-hub.com/study/16197-preventive-effect-of-metformin-in-radiation-induced-xerostomia2026-10-08 https://evidence-hub.com/study/16198-biguanides-metformin-and-phenformin-generate-therapeutic-effects-via2026-10-08 https://evidence-hub.com/study/16201-the-antitumor-effects-of-metformin-on-gastric-cancer-in-vitro-and-on2026-10-08 https://evidence-hub.com/study/16203-metformin-suppresses-hypoxia-induced-migration-via-the-hif-1-vegf2026-10-08 https://evidence-hub.com/study/16204-mechanistic-study-of-inhibitory-effects-of-metformin-and-atorvastatin2026-10-08 https://evidence-hub.com/study/16205-in-vitro-bioequivalence-study-between-four-different-marketed2026-10-08 https://evidence-hub.com/study/16206-metformin-synergistic-pemetrexed-suppresses-non-small-cell-lung2026-10-08 https://evidence-hub.com/study/16207-in-vitro-synergistic-effect-of-metformin-and-berberine-on-high2026-10-08 https://evidence-hub.com/study/16208-metformin-attenuates-albumin-induced-alterations-in-renal-tubular2026-10-08 https://evidence-hub.com/study/16209-metformin-enhances-the-cytotoxicity-of-5-aminolevulinic-acid-mediated2026-10-08 https://evidence-hub.com/study/16210-biocompatible-delivery-system-for-metformin-characterization2026-10-08 https://evidence-hub.com/study/16211-in-vitro-and-in-vivo-evaluation-of-alginate-and-alginatechitosan2026-10-08 https://evidence-hub.com/study/16212-metformin-enhanced-in-vitro-radiosensitivity-associates-with-g2-m2026-10-08 https://evidence-hub.com/study/16213-the-influence-of-chitosan-cross-linking-on-the-properties-of-alginate2026-10-08 https://evidence-hub.com/study/16215-research-progress-on-the-use-of-metformin-in-leukemia-treatment2026-10-08 https://evidence-hub.com/study/16216-effect-of-the-anti-diabetic-drug-metformin-in-hepatocellular2026-10-08 https://evidence-hub.com/study/16217-protective-effect-of-metformin-on-toxicity-of-butyric-acid-and2026-10-06 https://evidence-hub.com/study/16218-the-antidiabetic-drug-metformin-inhibits-gastric-cancer-cell2026-10-08 https://evidence-hub.com/study/16219-in-vitro-metformin-anti-neoplastic-activity-in-epithelial-ovarian2026-10-08 https://evidence-hub.com/study/16220-effect-of-metformin-on-bone-marrow-progenitor-cell-differentiation-in2026-10-08 https://evidence-hub.com/study/16222-in-vitro-and-in-vivo-anti-melanoma-action-of-metformin2026-10-08 https://evidence-hub.com/study/16223-metformin-suppresses-retinal-angiogenesis-and-inflammation-in-vitro2026-10-08 https://evidence-hub.com/study/16224-metformin-sensitizes-egfr-tki-resistant-human-lung-cancer-cells-in2026-09-30 https://evidence-hub.com/study/16227-effect-of-metformin-treatment-on-insulin-action-in-diabetic-rats-in2026-10-08 https://evidence-hub.com/study/16228-metformin-inhibits-mitochondrial-permeability-transition-and-cell2026-10-08 https://evidence-hub.com/study/16229-antitumor-effect-of-metformin-in-esophageal-cancer-in-vitro-study2026-10-08 https://evidence-hub.com/study/16230-association-of-metformin-with-lower-atrial-fibrillation-risk-among2026-10-01 https://evidence-hub.com/study/16232-the-antidiabetic-drug-metformin-inhibits-the-proliferation-of-bladder2026-10-08 https://evidence-hub.com/study/16233-in-vitro-and-in-vivo-antitumoral-action-of-metformin-on2026-10-08 https://evidence-hub.com/study/16234-mechanism-of-action-of-metformin-insulin-receptor-and-postreceptor2026-10-08 https://evidence-hub.com/study/16235-in-vitro-and-in-vivo-modulation-of-alternative-splicing-by-the2026-10-08 https://evidence-hub.com/study/16236-cytotoxic-activity-of-metformin-in-vitro-does-not-correlate-with-its2026-10-08 https://evidence-hub.com/study/16237-enhancement-of-diabetic-wound-repair-using-biodegradable-nanofibrous2026-10-08 https://evidence-hub.com/study/16238-metformin-and-temozolomide-act-synergistically-to-inhibit-growth-of2026-10-08 https://evidence-hub.com/study/16240-metformin-protects-cardiomyocyte-from-doxorubicin-induced2026-10-01 https://evidence-hub.com/study/16241-in-vitro-and-in-vivo-effects-of-metformin-on-human-adipose-tissue2026-10-08 https://evidence-hub.com/study/16242-in-vitro-and-in-vivoanti-tumor-effect-of-metformin-as-a-novel2026-10-08 https://evidence-hub.com/study/16243-in-vitro-and-in-vivo-evaluation-of-two-extended-release-preparations2026-10-08 https://evidence-hub.com/study/16244-normalization-of-cd4-t-cell-metabolism-reverses-lupus2026-09-30 https://evidence-hub.com/study/16245-metformin-and-phenethyl-isothiocyanate-combined-treatment-in-vitro-is2026-10-08 https://evidence-hub.com/study/16246-metformin-induces-apoptosis-via-a-mitochondria-mediated-pathway-in2026-10-01 https://evidence-hub.com/study/16247-efficacy-of-pd-1-blockade-is-potentiated-by-metformin-induced2026-09-30 https://evidence-hub.com/study/16248-the-anti-diabetic-drug-metformin-inhibits-pancreatic-cancer-cell2026-10-08 https://evidence-hub.com/study/16249-the-beneficial-effects-of-insulin-and-metformin-on-in-vitro2026-10-08 https://evidence-hub.com/study/16250-metformin-improves-vascular-function-in-insulin-resistant-rats2026-10-08 https://evidence-hub.com/study/16251-possible-role-of-5-amp-activated-protein-kinase-in-the-metformin2026-10-01 https://evidence-hub.com/study/16253-antitumor-effect-of-metformin-on-cholangiocarcinoma-in-vitro-and-in2026-10-08 https://evidence-hub.com/study/16254-design-and-in-vitro-testing-of-a-floatable-gastroretentive-tablet-of2026-10-08 https://evidence-hub.com/study/16256-metformin-and-the-mtor-inhibitor-everolimus-rad001-sensitize-breast2026-09-30 https://evidence-hub.com/study/16258-effects-of-metformin-on-retinoblastoma-growth-in-vitro-and-in-vivo2026-10-08 https://evidence-hub.com/study/16259-metformin-kills-and-radiosensitizes-cancer-cells-and-preferentially2026-10-01 https://evidence-hub.com/study/16261-biguanide-metformin-acts-on-tau-phosphorylation-via-mtor-protein2026-09-30 https://evidence-hub.com/study/16262-metformin-treatment-in-patients-with-polycystic-ovary-syndrome2026-10-08 https://evidence-hub.com/study/16263-metformin-may-alter-the-metabolic-reprogramming-in-cancer-cells-by2026-10-06 https://evidence-hub.com/study/16264-molecular-mechanisms-of-diabetic-periodontitis-identification-of-key2026-10-06 https://evidence-hub.com/study/16265-metformin-improves-chronic-rhinosinusitis-with-depressive-like2026-10-06 https://evidence-hub.com/study/16266-prediction-of-drug-disposition-in-diabetic-patients-by-means-of-a2026-10-06 https://evidence-hub.com/study/16267-placental-transcriptomics-identifies-a-candidate-hla-dqa2-fgl2-immune2026-10-06 https://evidence-hub.com/study/16268-evodiamine-may-inhibit-insulin-resistance-in-type-2-diabetes-through2026-10-06 https://evidence-hub.com/study/16269-investigation-of-metformin-analogues-in-targeting-signaling-molecules2026-10-06 https://evidence-hub.com/study/16270-therapeutic-role-of-gut-microbial-metabolite-indole-propionic-acid-in2026-10-06 https://evidence-hub.com/study/16271-intra-articular-metformin-and-chlorogenic-acid-synergistically2026-10-06 https://evidence-hub.com/study/16272-molecular-insights-into-the-interaction-between-metformin-and2026-10-06 https://evidence-hub.com/study/16273-an-integrated-pharmacological-evaluation-and-gc-ms-ms-guided2026-10-06 https://evidence-hub.com/study/16274-structural-and-energetic-modulation-of-the-raloxifene-stat3-complex2026-10-06 https://evidence-hub.com/study/16275-decoding-the-association-of-polycystic-ovary-syndrome-with-metabolic2026-10-06 https://evidence-hub.com/study/16276-exploring-pulegone-in-type-2-diabetes-treatment-molecular-docking2026-10-06 https://evidence-hub.com/study/16277-efficient-anaerobic-metformin-biodegradation-driven-by-a-cross2026-10-06 https://evidence-hub.com/study/16278-systems-level-analysis-of-13-docosenamide-reveals-its-regulatory-role2026-10-06 https://evidence-hub.com/study/16279-synthesis-biological-evaluation-and-computational-studies-of-phenolic2026-10-06 https://evidence-hub.com/study/16280-metformin-prevents-hyperglycemia-associated-oxidative-stress-induced2026-10-01 https://evidence-hub.com/study/16281-network-pharmacology-study-to-reveal-the-potentiality-of-a-methanol2026-10-06 https://evidence-hub.com/study/16282-genomic-editing-of-metformin-efficacy-associated-genetic-variants-in2026-10-06 https://evidence-hub.com/study/16283-antidiabetic-effects-of-ecklonia-cava-and-dieckol-via-dpp-iv2026-10-06 https://evidence-hub.com/study/16284-slc5a11-mediates-metformin-induced-pd-l1-suppression-to-enhance2026-10-06 https://evidence-hub.com/study/16285-the-autophagy-receptor-ndp52-recruits-the-e3-ligase-asb2-to-mediate2026-10-06 https://evidence-hub.com/study/16286-overlooked-roles-of-pharmaceutical-metabolic-products-in-stimulating2026-10-06 https://evidence-hub.com/study/16287-mulberry-derived-carbon-dots-attenuate-kidney-fibrosis-through-direct2026-10-06 https://evidence-hub.com/study/16288-myricetin-ameliorates-letrozole-induced-pcos-in-female-rats-a2026-10-08 https://evidence-hub.com/study/16289-aqueous-extract-of-alstonia-boonei-de-wild-apocynaceae-improves-bone2026-10-08 https://evidence-hub.com/study/16290-metformin-mediated-modulation-of-gut-microbiota-derived2026-10-08 https://evidence-hub.com/study/16291-integrated-bioinformatics-and-molecular-docking-dentify-ccnb1-cdk12026-10-06 https://evidence-hub.com/study/16292-metabolomics-and-network-pharmacology-analysis-of-yiqi-huazhuo2026-10-06 https://evidence-hub.com/study/16293-selective-copper-ii-removal-using-molecularly-imprinted-alginate2026-10-06 https://evidence-hub.com/study/16294-syringaresinol-from-cinnamomum-cassia-l-j-presl-ameliorates-cognitive2026-10-06 https://evidence-hub.com/study/16295-neuroprotective-role-of-eupalitin-in-streptozotocin-induced-diabetic2026-10-06 https://evidence-hub.com/study/16296-a-self-adhesive-ginsenoside-rk3-metformin-loaded-hydrogel-microneedle2026-10-06 https://evidence-hub.com/study/16297-exogenous-gaba-as-a-natural-epigenetic-modifier-for-managing-glycemic2026-10-06 https://evidence-hub.com/study/16298-nimbolide-a-neem-limonoid-inhibits-angiogenesis-in-breast-cancer-by2026-10-06 https://evidence-hub.com/study/16299-gentiopicroside-alleviates-cardiac-inflammation-and-fibrosis-in-t2dm2026-10-08 https://evidence-hub.com/study/16300-assessment-of-the-nlmixr-r-package-for-population-pharmacokinetic2026-10-06 https://evidence-hub.com/study/16301-molecular-docking-and-mouse-modeling-suggest-cmklr1-and-insr-as2026-10-06 https://evidence-hub.com/study/16302-pharmacokinetics-and-drug-likeness-of-antidiabetic-flavonoids2026-10-08 https://evidence-hub.com/study/16303-hypoglycemic-activity-of-aqueous-extract-of-latex-from-hancornia2026-10-06 https://evidence-hub.com/study/16304-total-glucosides-of-paeony-ameliorates-chemotherapy-induced2026-10-06 https://evidence-hub.com/study/16305-antioxidative-and-anti-inflammatory-effects-of-carvacrol-against2026-10-08 https://evidence-hub.com/study/16306-insulin-and-metformin-are-associated-with-reduced-risk-of-amyotrophic2026-10-08 https://evidence-hub.com/study/16307-scrutiny-of-the-co-cytotoxic-impact-of-metformin-omeprazole-on-the2026-10-06 https://evidence-hub.com/study/16308-hypoglycemic-and-hypolipidemic-effects-of-triterpenoid-standardized2026-10-06 https://evidence-hub.com/study/16309-exploring-metformin-s-therapeutic-potential-for-alzheimer-s-disease2026-10-08 https://evidence-hub.com/study/16310-rubia-cordifolia-linn-isolation-molecular-docking-and-brac1-pkd1-gene2026-10-06 https://evidence-hub.com/study/16311-identification-of-known-flavonoids-of-ficus-carica-l-as-aldose2026-10-06 https://evidence-hub.com/study/16312-comparative-in-vitro-and-in-silico-evaluation-of-the-toxic-effects-of2026-10-08 https://evidence-hub.com/study/16313-metformin-inhibits-the-growth-of-sclc-cells-by-inducing-autophagy-and2026-10-06 https://evidence-hub.com/study/16314-disclosing-the-impact-of-metformin-and-methotrexate-in-adjuvant2026-10-06 https://evidence-hub.com/study/16315-insulinotropic-and-anti-obesity-properties-of-ethno-medicinal-plants2026-10-08 https://evidence-hub.com/study/16316-the-specific-p-glycoprotein-inhibitor-zosuquidar-ly335979-also-weakly2026-10-06 https://evidence-hub.com/study/16317-proteomics-exploration-of-metformin-hydrochloride-for-diabetic-kidney2026-10-06 https://evidence-hub.com/study/16318-rutin-promotes-wound-healing-by-inhibiting-oxidative-stress-and2026-10-06 https://evidence-hub.com/study/16319-does-sildenafil-citrate-affect-the-pharmacokinetics-of-metformin-in2026-10-06 https://evidence-hub.com/study/16320-in-vitro-analysis-of-camellia-sinensis-leaf-extract-against-diabetes2026-10-06 https://evidence-hub.com/study/16321-virtual-screening-adme-prediction-drug-likeness-and-molecular-docking2026-10-06 https://evidence-hub.com/study/16322-activating-transcription-factor-3-is-an-antitumor-gene-synergizing2026-10-06 https://evidence-hub.com/study/16323-nicotinate-curcumin-improves-nash-by-inhibiting-the-akr1b10-acc2026-10-08 https://evidence-hub.com/study/16324-quercetin-and-kaempferol-as-multi-targeting-antidiabetic-agents2026-10-06 https://evidence-hub.com/study/16325-research-into-how-carvacrol-and-metformin-affect-several-human2026-10-08 https://evidence-hub.com/study/16326-occurrence-of-pharmaceutically-active-compounds-in-groundwater-and2026-10-06 https://evidence-hub.com/study/16327-coconut-cocos-nucifera-l-water-improves-glucose-uptake-with2026-10-06 https://evidence-hub.com/study/16328-modulatory-effects-of-extract-of-heinsia-crinita-against-fructose2026-10-06 https://evidence-hub.com/study/16329-virtual-screening-molecular-docking-molecular-dynamics-and-mm-gbsa2026-10-06 https://evidence-hub.com/study/16330-binding-interactions-of-vildagliptin-with-pepsin-a-multi2026-10-08 https://evidence-hub.com/study/16331-effectiveness-and-cost-effectiveness-of-six-glp-1ras-for-treatment-of2026-10-06 https://evidence-hub.com/study/16332-green-synthesis-anti-proliferative-evaluation-docking-and-md2026-10-06 https://evidence-hub.com/study/16333-evaluation-of-pen2-atp6ap1-axis-as-an-antiparasitic-target-for2026-10-08 https://evidence-hub.com/study/16334-virtual-screening-of-foxo3a-activators-from-natural-product-like2026-10-06 https://evidence-hub.com/study/16335-entering-the-sugar-rush-era-revisiting-the-antihyperglycemic2026-10-06 https://evidence-hub.com/study/16336-ecofriendly-appraisal-of-stability-indicating-high-performance2026-10-08 https://evidence-hub.com/study/16337-in-silico-study-of-mangostin-compounds-and-its-derivatives-as2026-10-06 https://evidence-hub.com/study/16338-ndufs3-knockout-cancer-cells-and-molecular-docking-reveal-specificity2026-10-06 https://evidence-hub.com/study/16339-in-silico-investigation-of-the-therapeutic-and-prophylactic-potential2026-10-06 https://evidence-hub.com/study/16340-the-determination-of-the-effect-s-of-solute-carrier-family-22-member2026-10-06 https://evidence-hub.com/study/16341-a-software-interface-for-in-silico-testing-of-type-2-diabetes2026-10-08 https://evidence-hub.com/study/16342-sterculia-tragacantha-lindl-leaf-extract-ameliorates-stz-induced2026-10-08 https://evidence-hub.com/study/16343-evaluation-of-the-inhibitory-potentials-of-selected-compounds-from2026-10-06 https://evidence-hub.com/study/16344-bridelia-ferruginea-benth-euphorbiaceae-mitigates-oxidative-imbalance2026-10-06 https://evidence-hub.com/study/16345-the-use-of-ga-rxode-genetics-algorithms-and-running-simulations-from2026-10-08 https://evidence-hub.com/study/16346-metformin-is-a-pyridoxal-5-phosphate-plp-competitive-inhibitor-of2026-10-08 https://evidence-hub.com/study/16347-the-l125f-mate1-variant-enriched-in-populations-of-amerindian-origin2026-10-06 https://evidence-hub.com/study/16348-meta-assessment-of-metformin-absorption-and-disposition2026-10-08 https://evidence-hub.com/study/16349-phensim-phenotype-simulator2026-10-08 https://evidence-hub.com/study/16351-rapid-identification-of-druggable-targets-and-the-power-of-the2026-10-06 https://evidence-hub.com/study/16352-in-silico-analysis-of-a-potential-antidiabetic-phytochemical-erythrin2026-10-08 https://evidence-hub.com/study/16353-development-of-a-pharmacokinetic-model-of-transplacental-transfer-of2026-10-06 https://evidence-hub.com/study/16354-metformin-suppresses-development-of-the-echinococcus-multilocularis2026-10-08 https://evidence-hub.com/study/16355-anti-diabetic-activity-of-quercetin-extracted-from-phyllanthus2026-10-08 https://evidence-hub.com/study/16356-design-graph-theoretical-analysis-and-in-silico-modeling-of2026-10-06 https://evidence-hub.com/study/16357-kinetic-compatibility-as-a-predictor-of-ptp1b-inhibitor-combination2026-10-08 https://evidence-hub.com/study/16358-integrative-in-silico-profiling-of-major-phytochemicals-from-a2026-10-08 https://evidence-hub.com/study/16359-design-and-in-silico-evaluation-of-thiazole-isoxazole-hybrids-as-ppar2026-10-08 https://evidence-hub.com/study/16360-gc-ms-guided-phytochemical-fingerprinting-and-multi-target2026-10-08 https://evidence-hub.com/study/16361-transcriptomics-guided-discovery-of-interleukin-6-modulators-from2026-10-08 https://evidence-hub.com/study/16362-exploring-the-role-of-the-key-gene-tnfaip3-between-periodontitis-and2026-10-08 https://evidence-hub.com/study/16363-mechanisms-of-anti-aging-effect-of-alpinia-oxyphylla-polysaccharides2026-10-08 https://evidence-hub.com/study/16364-screening-and-validation-of-ltbp1-as-a-key-target-of-oxymatrine-in2026-10-08 https://evidence-hub.com/study/16365-elucidating-the-binding-mechanism-of-caralluma-tuberculata2026-10-08 https://evidence-hub.com/study/16366-identification-of-androgen-receptor-as-a-molecular-docking-target-for2026-10-08 https://evidence-hub.com/study/16367-pegylated-liposomal-metformin-overcomes-pharmacokinetic-barriers-to2026-10-08 https://evidence-hub.com/study/16368-metformin-driven-activation-of-polymorphic-follicle-stimulating2026-10-08 https://evidence-hub.com/study/16369-carboplatin-is-associated-with-changes-in-components-of-the-m6a2026-10-08 https://evidence-hub.com/study/16370-probiotics-synbiotics-and-berberine-in-type-2-diabetes-mellitus-a2026-10-08 https://evidence-hub.com/study/16371-multifaceted-analysis-of-lactobacillus-plantarum-dmr14-reveals2026-10-08 https://evidence-hub.com/study/16372-proteins-and-peptides-studied-in-silico-and-in-vivo-for-the-treatment2026-10-08 https://evidence-hub.com/study/16373-protective-effect-of-fermented-vegetable-compounds-against2026-10-08 https://evidence-hub.com/study/16374-integrated-network-pharmacology-and-bioinformatics-analysis-reveals2026-10-08 https://evidence-hub.com/study/16375-circular-rnas-in-diabetic-foot-ulcers-a-scoping-review-of-clinical2026-10-08 https://evidence-hub.com/study/16376-mechanisms-of-luoshi-neiyi-prescription-lsnyp-in-endometriosis-a2026-10-08 https://evidence-hub.com/study/16377-synthesis-and-glycosidase-inhibiton-of-two-types-of-n-alkylated-12026-10-08 https://evidence-hub.com/study/16378-colorimetric-detection-of-nitrosamines-in-human-serum-albumin-using2026-10-08 https://evidence-hub.com/study/16379-consensus-scoring-guided-virtual-screening-identifies-potent-anti2026-10-08 https://evidence-hub.com/study/16380-unveiling-the-hypoglycemic-potential-of-the-traditional-cuisine-jiao2026-10-08 https://evidence-hub.com/study/16381-integration-of-machine-learning-and-experimental-validation-reveals2026-10-08 https://evidence-hub.com/study/16382-cadmium-induced-apoptosis-via-ros-jnk-pathway-in-chicken-primary2026-10-08 https://evidence-hub.com/study/16383-comprehensive-studies-on-the-regulation-of-type-2-diabetes-by2026-10-08 https://evidence-hub.com/study/16384-pharmacovigilance-signal-detection-and-mutually-exclusive-driver2026-10-08 https://evidence-hub.com/study/16385-identification-and-therapeutic-investigation-of-biomarker-genes2026-10-08 https://evidence-hub.com/study/16386-the-effects-of-ondansetron-on-diabetes-and-high-fat-diet-induced2026-10-08 https://evidence-hub.com/study/16387-metformin-facilitates-osteogenic-differentiation-of-bone-marrow2026-10-08 https://evidence-hub.com/study/16388-impact-of-c18-epimerization-of-indole-and-pyrazole-fused-182026-10-08 https://evidence-hub.com/study/16389-bioactive-fraction-isolated-from-curcuma-angustifolia-rhizome-exerts2026-10-08 https://evidence-hub.com/study/16390-african-walnut-plukenetia-conophora-oil-improves-glucose-uptake-and2026-10-08 https://evidence-hub.com/study/16391-coconut-milk-derived-bioactive-peptides-as-multifunctional-agents2026-10-08 https://evidence-hub.com/study/16392-optimization-of-sweet-potato-ipomoea-batatas-l-chlorogenic-acid2026-10-08 https://evidence-hub.com/study/16393-bilayer-tri-dermal-network-hydrogel-for-sequential-delivery-of-pd2026-10-08 https://evidence-hub.com/study/16394-cholesterol-sulfate-replenishment-rejuvenates-aged-hematopoietic-stem2026-10-08 https://evidence-hub.com/study/16395-diverse-sesquiterpenoids-with-antidiabetic-potency-from-the-fruits-of2026-10-06 https://evidence-hub.com/study/16396-in-silico-study-to-optimize-the-dosage-of-oleuropein-with-metformin2026-10-08 https://evidence-hub.com/study/16397-metformin-loaded-silver-nanoparticles-tailored-with-their-in-vitro-ex2026-10-08 https://evidence-hub.com/study/16398-repurposing-metformin-as-a-potential-anticancer-agent-using-in-silico2026-10-08 https://evidence-hub.com/study/16400-response-to-comparative-in-vitro-and-in-silico-evaluation-of-the2026-10-08 https://evidence-hub.com/study/16401-the-effect-of-metformin-and-hydrochlorothiazide-on-cytochrome-p4502026-10-08 https://evidence-hub.com/study/16402-in-silico-and-in-vitro-assessment-of-an-optimized-qbd-guided2026-10-08 https://evidence-hub.com/study/16403-gdf-15-levels-in-patients-with-polycystic-ovary-syndrome-treated-with2026-10-08 https://evidence-hub.com/study/16404-evaluation-of-suppressor-behavior-of-guanidine-derived-metformin-and2026-10-08 https://evidence-hub.com/study/16405-antidiabetic-antioxidant-and-cytotoxicity-activities-of-ortho-and2026-10-08 https://evidence-hub.com/study/16406-regulation-of-protein-induced-apoptosis-and-autophagy-in-human2026-10-08 https://evidence-hub.com/study/16407-physicochemical-and-pharmacokinetic-studies-of-metformin-for2026-10-08 https://evidence-hub.com/study/16408-pharmacophore-mapping-approach-to-find-anti-cancer-phytochemicals2026-10-08 https://evidence-hub.com/study/16409-a-comprehensive-approach-to-derivatization-elemental-composition2026-10-08 https://evidence-hub.com/study/16410-metformin-attenuates-ptz-induced-seizures-and-cognitive-impairment2026-10-08 https://evidence-hub.com/study/16411-conjugation-of-curcumin-and-metformin-for-improved-pharmacological2026-10-08 https://evidence-hub.com/study/16412-dynamic-in-silico-model-of-type-2-diabetes-treated-with-metformin2026-10-08 https://evidence-hub.com/study/16414-prophylactic-treatment-of-probiotic-and-metformin-mitigates-ethanol2026-10-08 https://evidence-hub.com/study/16416-metformin-mediates-microrna-21-regulated-circulating-matrix2026-10-08 https://evidence-hub.com/study/16418-transdermal-metformin-hydrochloride-loaded-cubic-phases-in-silico2026-10-08 https://evidence-hub.com/study/16419-an-in-silico-modeling-for-the-prediction-of-metformin-interaction2026-10-08 https://evidence-hub.com/study/16420-in-silico-and-in-vitro-synergistic-anticancer-effects-of-the2026-10-08 https://evidence-hub.com/study/16421-babe-2018-in-vitro-and-in-silico-drug-food-interaction-an-evaluation2026-10-08 https://evidence-hub.com/study/16422-potential-consequences-of-screening-of-occupational-silica-dust2026-10-08 https://evidence-hub.com/study/16423-antitumor-activity-of-metformin-in-combination-with-binimetinib2026-10-08 https://evidence-hub.com/study/16424-assessment-of-antihyperglycemic-and-modulatory-effects-of-trans2026-10-08 https://evidence-hub.com/study/16425-investigating-the-inhibitory-aspects-of-metformin-curcumin-co2026-10-08 https://evidence-hub.com/study/16426-ternary-cobalt-ii-nickel-ii-and-copper-ii-complexes-containing2026-10-08 https://evidence-hub.com/study/16427-transdermal-cubic-phases-of-metformin-hydrochloride-in-silico-and-in2026-10-08 https://evidence-hub.com/study/16428-interaction-of-rs316019-variants-of-slc22a2-with-metformin-and-other2026-10-08 https://evidence-hub.com/study/16429-molecular-mechanism-of-metformin-associated-lactic-acidosis-mala-an2026-10-08 https://evidence-hub.com/study/16431-unlocking-the-therapeutic-potential-of-catharanthus-roseus-leaves-via2026-10-08 https://evidence-hub.com/study/16432-in-silico-drug-likeness-admet-toxicity-profiling-of-clinically2026-10-08 https://evidence-hub.com/study/16433-in-silico-assessment-of-potential-geroprotectors-from-separate2026-10-08 https://evidence-hub.com/study/16434-mangosteen-peel-garcinia-mangostana-compounds-as-mtnr1b-modulators2026-10-08 https://evidence-hub.com/study/16435-investigating-the-potential-effect-of-l-citrulline-on-pi3k-signaling2026-10-08 https://evidence-hub.com/study/16436-in-silico-and-in-vivo-studies-of-hypoglycemic-activity-of-novel2026-10-08 https://evidence-hub.com/study/16437-in-silico-prediction-of-phytoconstituents-from-manilkara-hexandra-for2026-10-08 https://evidence-hub.com/study/16438-literatur-review-peran-analisis-in-silico-dalam-eksplorasi-senyawa2026-10-08 https://evidence-hub.com/study/16439-in-silico-analysis-of-the-interaction-between-stevia-compounds-and2026-10-08 https://evidence-hub.com/study/16440-antidiabetic-activities-of-aerial-part-of-asparagus-racemosus-willd2026-10-08 https://evidence-hub.com/study/16441-green-approach-for-the-synthesis-of-zinc-oxide-nanoparticles-from2026-10-08 https://evidence-hub.com/study/16442-genetic-overlap-between-sarcoidosis-and-lung-cancer-a-combined-in2026-10-08 https://evidence-hub.com/study/16443-in-silico-and-in-vitro-evidence-on-the-anti-diabetic-effect-of2026-10-08 https://evidence-hub.com/study/16444-antioxidant-alpha-amylase-inhibitory-and-hypoglycemic-activity-of2026-10-08 https://evidence-hub.com/study/16445-phytochemical-analysis-and-bioactive-potential-of-annona-squamosa2026-10-08 https://evidence-hub.com/study/16446-phytochemicals-composition-and-bioactivities-of-fagopyrum-esculentum2026-10-08 https://evidence-hub.com/study/16447-antioxidant-and-antidiabetic-potential-of-ormocarpum-cochinchinense2026-10-08 https://evidence-hub.com/study/16448-pyrazine-and-furan-derivative-activity-prediction-on-type-2-diabetic2026-10-08 https://evidence-hub.com/study/16449-an-in-vitro-in-silico-in-vivo-approach-in-biopharmaceutical-drug2026-10-08 https://evidence-hub.com/study/16450-identifying-anti-diabetic-potential-of-alpha-amylase-inhibitors-in2026-10-08 https://evidence-hub.com/study/16451-identification-of-potential-dpp-4-inhibitors-from-bryophyllum2026-10-08 https://evidence-hub.com/study/16452-in-silico-analysis-activity-of-active-compounds-in-passiflora-foetida2026-10-08 https://evidence-hub.com/study/16453-antidiabetic-potency-of-glimepiride-and-naringin-an-in-silico-and-in2026-10-08 https://evidence-hub.com/study/16454-biochemical-effects-and-theoretical-study-of-a-metformin-in-the-carp2026-10-08 https://evidence-hub.com/study/16455-in-silico-screening-of-a-phytochemical-naringin-isolated-from-citrus2026-10-08 https://evidence-hub.com/study/16456-in-silico-characterization-of-a-novel-bioactive-compound-derived-from2026-10-08 https://evidence-hub.com/study/16457-assessment-of-interaction-of-human-oct-1-3-proteins-and-metformin2026-10-08 https://evidence-hub.com/study/16458-analysis-of-antidiabetic-activity-of-squalene-via-in-silico-and-in2026-10-08 https://evidence-hub.com/study/16459-neuroprotective-effects-of-terpenoids-against-streptozotocin2026-10-08 https://evidence-hub.com/study/16460-role-of-human-organic-cation-transporter-1-oct-1-slc22a1-in2026-10-08 https://evidence-hub.com/study/16461-the-exploration-of-the-antidiabetic-potentialities-of-bottle-gourd2026-10-08 https://evidence-hub.com/study/16463-evaluation-of-the-therapeutic-potentials-of-extract-fractions-of2026-10-08 https://evidence-hub.com/study/16464-identification-of-starvation-mimetic-bioactive-phytocomponent-from2026-10-08 https://evidence-hub.com/study/16465-integrated-in-silico-approach-discovery-of-caryophyllene-from-piper2026-10-08 https://evidence-hub.com/study/16466-rational-design-in-silico-studies-synthesis-and-biological-evaluation2026-10-08 https://evidence-hub.com/study/16467-in-silico-evaluation-oof-bioactive-compounds-from-amorphophallus2026-10-08 https://evidence-hub.com/study/16468-insight-into-the-hypoglycemic-effects-of-pinus-nigra-arn-bark2026-10-08 https://evidence-hub.com/study/16469-in-silico-prediction-of-ezhip-post-translational-modification-sites2026-10-08 https://evidence-hub.com/study/16470-in-vitro-and-in-vivo-antidiabetic-activity-isolation-of-flavonoids2026-10-08 https://evidence-hub.com/study/16471-bio-assisted-synthesis-of-reduced-graphene-oxide-nanosheets-from2026-10-08 https://evidence-hub.com/study/16472-isolation-and-spectral-characterisation-of-bioactives-from-sea-weed2026-10-08 https://evidence-hub.com/study/16473-in-silico-prediction-of-phytoconstituents-from-manilkara-hexandra-for2026-10-08 https://evidence-hub.com/study/16474-kajian-kajian-in-silico-aktivitas-ekstrak-daun-mangga-mangifera2026-10-08 https://evidence-hub.com/study/16475-in-silico-modulation-of-diabetes-melitus-through-bioactive-compounds2026-10-08 https://evidence-hub.com/study/16476-in-silico-prioritization-of-indonesian-medicinal-plant-compounds2026-10-08 https://evidence-hub.com/study/16477-lc-ms-ms-metabolite-profiling-and-in-vivo-antidiabetic-antilipidemic2026-10-06 https://evidence-hub.com/study/16478-in-silico-evaluation-of-camellia-sinensis-phytochemicals-for2026-10-06 https://evidence-hub.com/study/16480-endophenotype-based-in-silico-network-medicine-discovery-combined2026-10-10 https://evidence-hub.com/study/16482-proton-pump-inhibitors-inhibit-metformin-uptake-by-organic-cation2026-10-08 https://evidence-hub.com/study/16483-metformin-is-a-direct-sirt1-activating-compound-computational2026-10-08 https://evidence-hub.com/study/16484-metformin-impairs-glucose-consumption-and-survival-in-calu-1-cells-by2026-10-08 https://evidence-hub.com/study/16485-emerging-wastewater-contaminant-metformin-causes-intersex-and-reduced2026-10-08 https://evidence-hub.com/study/16486-transcription-factor-nrf2-as-a-therapeutic-target-for-chronic2026-10-08 https://evidence-hub.com/study/16487-pre-clinical-effects-of-metformin-and-aspirin-on-the-cell-lines-of2026-10-08 https://evidence-hub.com/study/16488-metformin-inhibits-human-breast-cancer-cell-growth-by-promoting2026-10-08 https://evidence-hub.com/study/16489-the-relationship-between-the-gut-microbiome-and-metformin-as-a-key2026-10-08 https://evidence-hub.com/study/16490-in-silico-repurposing-of-antipsychotic-drugs-for-alzheimer-s-disease2026-10-01 https://evidence-hub.com/study/16491-metformin-directly-targets-the-h3k27me3-demethylase-kdm6a-utx2026-10-08 https://evidence-hub.com/study/16492-metformin-increases-glucose-uptake-and-acts-renoprotectively-by2026-10-08 https://evidence-hub.com/study/16493-selective-interactions-of-zein-microspheres-with-different-class-of2026-10-08 https://evidence-hub.com/study/16494-in-silico-approaches-to-identify-polyphenol-compounds-as-glucosidase2026-10-01 https://evidence-hub.com/study/16495-in-silico-modeling-based-identification-of-glucose-transporter-42026-10-08 https://evidence-hub.com/study/16497-the-anti-diabetic-drug-metformin-reduces-bace1-protein-level-by2026-10-01 https://evidence-hub.com/study/16498-metformin-an-anti-diabetic-drug-to-target-leukemia2026-10-08 https://evidence-hub.com/study/16499-in-vitro-and-in-silico-strategies-to-identify-oatp1b1-inhibitors-and2026-10-10 https://evidence-hub.com/study/16500-an-experimentally-defined-hypoxia-gene-signature-in-glioblastoma-and2026-10-08 https://evidence-hub.com/study/16501-metformin-as-host-directed-therapy-for-tb-treatment-scoping-review2026-10-01 https://evidence-hub.com/study/16502-in-silico-network-pharmacology-and-in-vivo-analysis-of-berberine2026-10-01 https://evidence-hub.com/study/16503-exploring-the-transcriptome-of-ciliated-cells-using-in-silico2026-10-01 https://evidence-hub.com/study/16504-metformin-as-a-potential-combination-therapy-with-existing-front-line2026-10-01 https://evidence-hub.com/study/16505-activation-of-the-atf2-creb-pgc-1-pathway-by-metformin-leads-to2026-10-01 https://evidence-hub.com/study/16506-metformin-induced-ablation-of-microrna-21-5p-releases-sestrin-1-and2026-10-01 https://evidence-hub.com/study/16507-in-vitro-and-in-silico-studies-of-silver-nanoparticles-agnps-from2026-10-01 https://evidence-hub.com/study/16508-in-silico-studies-physicochemical-properties-drug-score-toxicity2026-09-30 https://evidence-hub.com/study/16509-discovery-of-drug-omics-associations-in-type-2-diabetes-with2026-10-01 https://evidence-hub.com/study/16510-large-scale-in-silico-identification-of-drugs-exerting-sex-specific2026-10-08 https://evidence-hub.com/study/16511-salsalate-but-not-metformin-or-canagliflozin-slows-kidney-cyst-growth2026-10-01 https://evidence-hub.com/study/16512-near-infrared-light-activatable-hydrogels-for-metformin-delivery2026-09-30 https://evidence-hub.com/study/16513-plant-derived-bioactive-compounds-their-anti-cancer-effects-and-in2026-10-01 https://evidence-hub.com/study/16514-understanding-the-representative-gut-microbiota-dysbiosis-in2026-10-01 https://evidence-hub.com/study/16515-repurposing-of-existing-drugs-for-the-bacterial-infections-an-in2026-10-08 https://evidence-hub.com/study/16516-metformin-exhibits-preventive-and-therapeutic-efficacy-against2026-10-01 https://evidence-hub.com/study/16517-in-vivo-and-in-silico-assessment-of-diabetes-ameliorating2026-10-01 https://evidence-hub.com/study/16518-discovery-of-a-ni2-dependent-heterohexameric-metformin-hydrolase2026-10-08 https://evidence-hub.com/study/16519-metabolic-therapies-inhibit-tumor-growth-in-vivo-and-in-silico2026-10-08 https://evidence-hub.com/study/16520-metformin-from-diabetes-to-cancer-unveiling-molecular-mechanisms-and2026-10-01 https://evidence-hub.com/study/16521-in-search-for-geroprotectors-in-silico-screening-and-in-vitro2026-10-01 https://evidence-hub.com/study/16522-stevioside-attenuates-insulin-resistance-in-skeletal-muscle-by2026-10-01 https://evidence-hub.com/study/16523-transcriptomics-based-network-medicine-approach-identifies-metformin2026-10-01 https://evidence-hub.com/study/16525-significant-impact-of-time-of-day-variation-on-metformin2026-10-08 https://evidence-hub.com/study/16526-repurposing-anti-diabetic-drugs-to-cripple-quorum-sensing-in2026-10-08 https://evidence-hub.com/study/16527-a-gene-signature-based-approach-identifies-mtor-as-a-regulator-of-p732026-10-08 https://evidence-hub.com/study/16528-rational-in-silico-design-of-molecularly-imprinted-polymers-current2026-10-05 https://evidence-hub.com/study/16532-repurposing-metformin-for-vascular-disease2026-10-08 https://evidence-hub.com/study/16533-metformin-associated-gut-microbiota-remodeling-correlates-with2026-10-08 https://evidence-hub.com/study/16534-methyl-succinate-antagonises-biguanide-induced-ampk-activation-and2026-10-06 https://evidence-hub.com/study/16535-l-lactic-acid-enhances-type-i-interferon-immune-response-and-inhibits2026-10-08 https://evidence-hub.com/study/16536-metformin-ameliorates-doxorubicin-induced-cardiotoxicity-targeting2026-10-08 https://evidence-hub.com/study/16537-effect-of-the-combination-of-metformin-and-fenofibrate-on-glucose2026-10-06 https://evidence-hub.com/study/16538-metformin-s-effect-on-male-rats-experiencing-cmf-induced-neurotoxicity2026-10-06 https://evidence-hub.com/study/16539-the-nephroprotective-effect-of-metformin-with-cisplatin-in-bladder2026-10-06 https://evidence-hub.com/study/16540-design-of-a-cluster-randomized-trial-of-the-effectiveness-and-cost2026-10-06 https://evidence-hub.com/study/16541-low-glucose-enhanced-metformin-s-inhibitory-effect-on-pancreatic2026-10-06 https://evidence-hub.com/study/16542-normalizing-glucose-levels-reconfigures-the-mammary-tumor-immune-and2026-10-06 https://evidence-hub.com/study/16543-metformin-lowers-risk-of-hearing-loss-and-mortality-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/16544-combining-sitagliptin-metformin-with-a-functional-fiber-delays2026-10-06 https://evidence-hub.com/study/16545-metformin-causes-g1-phase-arrest-via-down-regulation-of-mir-221-and2026-10-06 https://evidence-hub.com/study/16546-glucose-deprivation-increases-thyroid-cancer-cells-sensitivity-to2026-10-08 https://evidence-hub.com/study/16547-single-cell-and-spatial-transcriptomics-reveal-mtor-driven-cellular2026-10-06 https://evidence-hub.com/study/16548-cancer-precision-prevention-trial-of-metformin-in-adults-with-li2026-10-06 https://evidence-hub.com/study/16549-effects-of-metformin-treatment-against-endometrial-cancer-cells2026-10-08 https://evidence-hub.com/study/16550-hypoxia-and-hyperglycaemia-determine-why-some-endometrial-tumours2026-10-08 https://evidence-hub.com/study/16551-obligatory-role-of-ampk-activation-and-antioxidant-defense-pathway-in2026-10-06 https://evidence-hub.com/study/16552-metformin-counteracts-lipid-accumulation-and-cell-proliferation-in2026-10-06 https://evidence-hub.com/study/16553-obesity-specific-improvement-of-lung-cancer-outcomes-and2026-10-08 https://evidence-hub.com/study/16554-metformin-treatment-attenuates-brain-inflammation-and-rescues-pacap2026-10-06 https://evidence-hub.com/study/16555-current-biochemical-studies-of-nonalcoholic-fatty-liver-disease-and2026-10-06 https://evidence-hub.com/study/16556-metformin-blocks-myc-protein-synthesis-in-colorectal-cancer-via-mtor2026-10-06 https://evidence-hub.com/study/16557-impact-of-baseline-bmi-on-glycemic-control-and-weight-change-with2026-10-06 https://evidence-hub.com/study/16558-metformin-induced-proprotein-convertase-subtilisin-kexin-type-92026-10-06 https://evidence-hub.com/study/16559-acute-vasorelaxant-effects-of-metformin-and-attenuation-by2026-10-06 https://evidence-hub.com/study/16560-inhibition-of-ezh2-enhances-the-antitumor-efficacy-of-metformin-in2026-10-08 https://evidence-hub.com/study/16561-metformin-alleviates-type-2-diabetes-related-depressive-like2026-10-06 https://evidence-hub.com/study/16563-metformin-based-nanomedicines-for-reprogramming-tumor-immune2026-10-06 https://evidence-hub.com/study/16564-metformin-use-in-women-with-polycystic-ovary-syndrome-pcos2026-10-06 https://evidence-hub.com/study/16565-neuroprotective-effects-of-metformin-through-the-modulation-of2026-10-06 https://evidence-hub.com/study/16566-overview-of-metformin-and-neurodegeneration-a-comprehensive-review2026-10-06 https://evidence-hub.com/study/16567-modulation-of-m1-and-m2-macrophage-polarization-by-metformin2026-10-06 https://evidence-hub.com/study/16568-understanding-the-action-mechanisms-of-metformin-in-the2026-10-06 https://evidence-hub.com/study/16569-metformin-as-anticancer-agent-and-adjuvant-in-cancer-combination2026-10-06 https://evidence-hub.com/study/16570-examining-the-clinical-relevance-of-metformin-as-an-antioxidant2026-10-06 https://evidence-hub.com/study/16571-targeting-cancer-and-immune-cell-metabolism-with-the-complex-i2026-10-06 https://evidence-hub.com/study/16572-view-on-metformin-antidiabetic-and-pleiotropic-effects2026-10-06 https://evidence-hub.com/study/16573-metformin-and-breast-cancer-current-findings-and-future-perspectives2026-10-06 https://evidence-hub.com/study/16574-metformin-as-an-emerging-pollutant-in-the-aquatic-environment2026-10-06 https://evidence-hub.com/study/16575-advances-in-the-mechanism-of-metformin-with-wide-ranging-effects-on2026-10-06 https://evidence-hub.com/study/16576-the-anti-inflammatory-effect-of-metformin-the-molecular-targets2026-10-08 https://evidence-hub.com/study/16577-role-of-metformin-in-polycystic-ovary-syndrome-pcos-related2026-10-06 https://evidence-hub.com/study/16578-metformin-in-aging-and-aging-related-diseases-clinical-applications2026-10-06 https://evidence-hub.com/study/16579-the-role-and-mechanism-of-metformin-in-inflammatory-diseases2026-10-06 https://evidence-hub.com/study/16580-anti-obesity-effects-of-metformin-a-scoping-review-evaluating-the2026-10-06 https://evidence-hub.com/study/16581-molecular-mechanisms-of-action-of-metformin-latest-advances-and2026-10-06 https://evidence-hub.com/study/16582-metformin-and-its-immune-mediated-effects-in-various-diseases2026-10-06 https://evidence-hub.com/study/16583-the-impact-of-metformin-on-tumor-infiltrated-immune-cells-preclinical2026-10-06 https://evidence-hub.com/study/16584-metformin-beyond-an-anti-diabetic-agent-a-comprehensive-and2026-10-06 https://evidence-hub.com/study/16585-promising-use-of-metformin-in-treating-neurological-disorders2026-10-06 https://evidence-hub.com/study/16586-new-insights-on-the-potential-anti-epileptic-effect-of-metformin2026-10-06 https://evidence-hub.com/study/16587-efficacy-and-safety-of-metformin-during-pregnancy-an-update2026-10-06 https://evidence-hub.com/study/16588-action-mechanism-of-metformin-and-its-application-in-hematological2026-10-08 https://evidence-hub.com/study/16590-a-review-of-the-impact-of-pharmacogenetics-and-metabolomics-on-the2026-10-06 https://evidence-hub.com/study/16591-review-of-the-case-reports-on-metformin-sulfonylurea-and2026-10-06 https://evidence-hub.com/study/16592-protective-effects-of-metformin-in-various-cardiovascular-diseases2026-10-06 https://evidence-hub.com/study/16593-the-role-of-ampk-dependent-pathways-in-cellular-and-molecular2026-10-06 https://evidence-hub.com/study/16594-metformin-activation-of-5-amp-activated-protein-kinase-and-its2026-10-06 https://evidence-hub.com/study/16595-metformin-in-the-prevention-of-alzheimer-s-disease-and-alzheimer-s2026-10-06 https://evidence-hub.com/study/16596-metformin-a-biological-and-synthetic-overview2026-10-08 https://evidence-hub.com/study/16597-the-differential-effect-of-metformin-on-osteocytes-osteoblasts-and2026-10-08 https://evidence-hub.com/study/16598-the-emerging-role-of-metformin-in-the-treatment-of-hepatocellular2026-10-04 https://evidence-hub.com/study/16599-actions-of-metformin-in-the-brain-a-new-perspective-of-metformin2026-10-06 https://evidence-hub.com/study/16600-metformin-in-therapeutic-applications-in-human-diseases-its-mechanism2026-10-06 https://evidence-hub.com/study/16601-deciphering-the-roles-of-metformin-in-alzheimer-s-disease-a-snapshot2026-10-04 https://evidence-hub.com/study/16602-metformin-induced-vitamin-b12-deficiency-can-cause-or-worsen-distal2026-10-08 https://evidence-hub.com/study/16604-exploring-the-pharmacological-potential-of-metformin-for2026-10-06 https://evidence-hub.com/study/16605-metformin-contamination-in-global-waters-biotic-and-abiotic2026-10-06 https://evidence-hub.com/study/16606-metabolic-action-of-metformin2026-10-06 https://evidence-hub.com/study/16608-impact-of-metformin-therapy-on-serum-visfatin-levels-in-polycystic2026-10-06 https://evidence-hub.com/study/16609-metformin-use-asthma-outcomes-in-patients-with-concurrent-diabetes2026-10-06 https://evidence-hub.com/study/16610-enhancing-the-efficacy-of-metformin-in-neoadjuvant-therapy-for-breast2026-10-06 https://evidence-hub.com/study/16611-angiogenesis-outcomes-of-metformin-utilization-in-diabetes-mellitus-a2026-10-08 https://evidence-hub.com/study/16612-metabolomic-profiles-of-metformin-in-breast-cancer-survivors-a-pooled2026-10-06 https://evidence-hub.com/study/16613-the-effect-of-metformin-usage-on-survival-outcomes-for-hepatocellular2026-10-06 https://evidence-hub.com/study/16614-comparison-of-insulin-metformin-and-glyburide-on-perinatal2026-10-06 https://evidence-hub.com/study/16615-metformin-induces-significant-reduction-of-body-weight-total2026-10-06 https://evidence-hub.com/study/16616-insulin-sensitising-drugs-metformin-rosiglitazone-pioglitazone-d2026-10-08 https://evidence-hub.com/study/16617-metformin-for-women-who-are-overweight-or-obese-during-pregnancy-for2026-10-06 https://evidence-hub.com/study/16618-metformin-a-potentially-effective-drug-for-gestational-diabetes2026-10-06 https://evidence-hub.com/study/16622-effects-of-metformin-on-blood-pressure-in-nondiabetic-patients-a-meta2026-10-08 https://evidence-hub.com/study/16623-metformin-is-associated-with-survival-benefit-in-pancreatic-cancer2026-10-06 https://evidence-hub.com/study/16626-effect-of-metformin-on-exercise-capacity-a-meta-analysis2026-10-08 https://evidence-hub.com/study/16627-locally-delivered-metformin-as-adjunct-to-scaling-and-root-planing-in2026-10-08 https://evidence-hub.com/study/16628-the-effects-of-metformin-on-simple-obesity-a-meta-analysis2026-10-08 https://evidence-hub.com/study/16629-a-systematic-review-and-meta-analysis-of-the-protective-effects-of2026-10-08 https://evidence-hub.com/study/16630-the-impact-of-metformin-use-on-survival-in-kidney-cancer-patients2026-10-06 https://evidence-hub.com/study/16632-metformin-asian-ethnicity-and-risk-of-prostate-cancer-in-type-22026-10-06 https://evidence-hub.com/study/16633-combination-therapy-of-metformin-plus-dipeptidyl-peptidase-42026-10-06 https://evidence-hub.com/study/16635-metformin-and-cognitive-performance-in-patients-with-type-2-diabetes2026-10-08 https://evidence-hub.com/study/16636-metformin-induced-vitamin-b12-deficiency-among-type-2-diabetes2026-10-06 https://evidence-hub.com/study/16637-effect-of-statins-combined-or-not-combined-with-metformin-on2026-10-08 https://evidence-hub.com/study/16638-metformin-and-colorectal-cancer-a-systematic-review2026-10-08 https://evidence-hub.com/study/16639-systematic-review-and-meta-analysis-of-vildagliptin-for-treatment-of2026-10-06 https://evidence-hub.com/study/16640-prevalence-and-risk-factors-of-osteoporotic-fracture-among-the2026-10-08 https://evidence-hub.com/study/16641-effect-of-metformin-on-adiponectin-in-pcos-a-meta-analysis-and-a2026-10-08 https://evidence-hub.com/study/16642-metformin-in-polycystic-ovary-syndrome2026-10-08 https://evidence-hub.com/study/16643-oral-metformin-for-treating-dermatological-diseases-a-systematic2026-10-08 https://evidence-hub.com/study/16644-evaluation-of-preeclampsia-results-after-use-of-metformin-in2026-10-08 https://evidence-hub.com/study/16645-efficacy-and-safety-of-once-weekly-glucagon-like-peptide-1-receptor2026-10-06 https://evidence-hub.com/study/16646-metformin-as-a-radiosensitiser-for-pelvic-malignancy-a-systematic2026-10-08 https://evidence-hub.com/study/16647-effects-of-glp1ras-on-pregnancy-rate-and-menstrual-cyclicity-in-women2026-10-06 https://evidence-hub.com/study/16648-sex-specific-differences-in-diabetes-prevention-a-systematic-review2026-10-06 https://evidence-hub.com/study/16649-the-impact-of-metformin-use-with-survival-outcomes-in-urologic2026-10-06 https://evidence-hub.com/study/16650-investigating-the-pro-cognitive-and-anti-depressant-efficacy-of2026-10-06 https://evidence-hub.com/study/16651-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials2026-10-06 https://evidence-hub.com/study/16652-suppressive-effects-of-metformin-on-colorectal-adenoma-incidence-and2026-10-06 https://evidence-hub.com/study/16653-protective-effects-of-metformin-statins-and-anti-inflammatory-drugs2026-10-06 https://evidence-hub.com/study/16654-a-systematic-review-of-metformin-to-limit-weight-gain-with-atypical2026-10-06 https://evidence-hub.com/study/16655-effectiveness-of-inositol-metformin-and-their-combination-in-women2026-10-06 https://evidence-hub.com/study/16656-bibliometric-analysis-of-metformin-as-an-immunomodulator-2013-20242026-10-06 https://evidence-hub.com/study/16657-long-versus-short-course-treatment-with-metformin-and-clomiphene2026-10-06 https://evidence-hub.com/study/16658-metformin-and-heart-failure-related-outcomes-in-patients-with-or2026-10-06 https://evidence-hub.com/study/16659-adjunctive-metformin-for-antipsychotic-induced-hyperprolactinemia-a2026-10-08 https://evidence-hub.com/study/16660-extensive-therapeutic-effects-underlying-molecular-mechanisms-and2026-10-06 https://evidence-hub.com/study/16661-bibliometrics-and-visual-analysis-of-metformin-and-gut-microbiota2026-10-06 https://evidence-hub.com/study/16662-the-effects-of-metformin-administration-on-liver-enzymes-and-body2026-10-06 https://evidence-hub.com/study/16663-metformin-as-an-adjunct-treatment-to-temozolomide-for-high-grade2026-10-08 https://evidence-hub.com/study/16664-efficacy-of-adjunctive-local-periodontal-treatment-for-type-22026-10-06 https://evidence-hub.com/study/16665-interventions-for-preventing-the-progression-of-autosomal-dominant2026-10-06 https://evidence-hub.com/study/16666-pharmacologic-therapy-of-diabetes-and-overall-cancer-risk-and2026-10-06 https://evidence-hub.com/study/16667-comparative-efficacy-and-safety-of-glucose-lowering-drugs-in-children2026-10-06 https://evidence-hub.com/study/16668-use-of-repurposed-drugs-in-the-treatment-of-epithelial-ovarian-cancer2026-10-06 https://evidence-hub.com/study/16669-comparative-efficacy-safety-and-cost-utility-of-dpp-4-inhibitors-and2026-10-06 https://evidence-hub.com/study/16670-economic-evaluation-of-type-2-diabetes-mellitus-interventions-in-low2026-10-06 https://evidence-hub.com/study/16671-repositioning-of-diabetes-treatments-for-depressive-symptoms-a2026-10-06 https://evidence-hub.com/study/16672-dipeptidyl-peptidase-4-dpp-4-inhibitor-and-mortality-in-coronavirus2026-10-06 https://evidence-hub.com/study/16673-interventions-for-hirsutism-excluding-laser-and-photoepilation2026-10-06 https://evidence-hub.com/study/16674-interventions-for-latent-autoimmune-diabetes-lada-in-adults2026-10-06 https://evidence-hub.com/study/16675-efficacy-and-safety-of-metformin-in-pregnant-women-with-polycystic2026-10-06 https://evidence-hub.com/study/16676-combined-metformin-clomiphene-in-clomiphene-resistant-polycystic2026-10-06 https://evidence-hub.com/study/16677-association-of-preadmission-metformin-use-and-prognosis-in-patients2026-10-01 https://evidence-hub.com/study/16678-vascular-and-metabolic-effects-of-metformin-added-to-insulin-therapy2026-10-06 https://evidence-hub.com/study/16679-the-effects-of-metformin-on-ovarian-cancer-a-systematic-review2026-10-08 https://evidence-hub.com/study/16680-the-evolving-role-of-targeted-metformin-administration-for-the2026-10-06 https://evidence-hub.com/study/16681-reductive-death-is-averted-by-an-ancient-metabolic-switch2026-10-06 https://evidence-hub.com/study/16682-common-genetic-variants-near-slc2a2-and-glycemic-response-to2026-10-06 https://evidence-hub.com/study/16683-metformin-impairs-intestinal-fructose-metabolism2026-10-01 https://evidence-hub.com/study/16684-non-enzymatic-rna-glycation-is-a-metabolic-sensor-of-cellular-stress2026-10-06 https://evidence-hub.com/study/16685-micrornas-associated-with-metformin-treatment-in-the-diabetes2026-10-08 https://evidence-hub.com/study/16686-breast-adipose-tissue-derived-extracellular-vesicles-from-women-with2026-10-06 https://evidence-hub.com/study/16687-real-world-type-2-diabetes-second-line-treatment-allocation-among2026-10-06 https://evidence-hub.com/study/16688-human-ipsc-derived-salivary-gland-organoids-model-diabetic-salivary2026-10-06 https://evidence-hub.com/study/16689-sars-cov-2-infection-causes-dopaminergic-neuron-senescence2026-10-06 https://evidence-hub.com/study/16690-repeat-associated-non-aug-translation-as-a-common-mechanism-for-the2026-10-06 https://evidence-hub.com/study/16691-metformin-on-the-presence-of-covid-19-symptoms-over-6-months-the2026-10-01 https://evidence-hub.com/study/16692-metformin-impairs-trophoblast-metabolism-and-differentiation-in-dose2026-10-01 https://evidence-hub.com/study/16693-metformin-inhibits-mitochondrial-complex-i-in-intestinal-epithelium2026-10-01 https://evidence-hub.com/study/16694-the-effect-of-type-2-diabetes-genetic-predisposition-on-non2026-10-06 https://evidence-hub.com/study/16695-lac-phe-mediates-the-anti-obesity-effect-of-metformin2026-10-01 https://evidence-hub.com/study/16696-metformin-use-is-associated-with-reduced-mortality-in-a-diverse2026-10-01 https://evidence-hub.com/study/16697-metformin-enhances-antibody-mediated-recognition-of-hiv-infected-cd42026-10-06 https://evidence-hub.com/study/16698-an-accelerated-human-in-vitro-aging-model-mimicsin-vivo-aging-and2026-10-06 https://evidence-hub.com/study/16699-metformin-reduces-sars-cov-2-in-a-phase-3-randomized-placebo2026-10-01 https://evidence-hub.com/study/16700-integration-of-artificial-intelligence-and-high-content-screening2026-10-06 https://evidence-hub.com/study/16701-loss-of-endothelial-glucocorticoid-receptor-accelerates-organ2026-10-06 https://evidence-hub.com/study/16702-prediabetes-phenotype-clusters-in-the-diabetes-prevention-program2026-10-08 https://evidence-hub.com/study/16703-high-dose-of-metformin-decreases-susceptibility-to-occlusive-arterial2026-10-06 https://evidence-hub.com/study/16704-quantitative-contributions-of-hepatic-and-renal-organic-cation2026-10-01 https://evidence-hub.com/study/16705-risk-of-suicidal-ideation-and-behaviors-depression-and-anxiety-with2026-10-06 https://evidence-hub.com/study/16706-hetnet-connectivity-search-provides-rapid-insights-into-how-two2026-10-06 https://evidence-hub.com/study/16707-transitions-in-density-pressure-and-effective-temperature-drive2026-10-06 https://evidence-hub.com/study/16708-molecular-basis-of-polyspecific-drug-binding-and-transport-by-oct12026-10-06 https://evidence-hub.com/study/16709-leveraging-large-scale-biobank-ehrs-to-enhance-pharmacogenetics-of2026-10-06 https://evidence-hub.com/study/16710-comparative-safety-of-second-line-antihyperglycemic-agents-in-older2026-10-06 https://evidence-hub.com/study/16711-start-diabetes-prevention-a-multi-level-strategy-for-primary-care2026-10-06 https://evidence-hub.com/study/16712-in-vitro-modeling-of-nutritional-and-mitochondria-targeted-therapies2026-10-06 https://evidence-hub.com/study/16713-metformin-on-time-to-sustained-recovery-in-adults-with-covid-19-the2026-10-01 https://evidence-hub.com/study/16714-oxidative-stress-is-a-shared-characteristic-of-me-cfs-and-long-covid2026-10-06 https://evidence-hub.com/study/16715-transport-of-metformin-metabolites-by-guanidinium-exporters-of-the2026-10-06 https://evidence-hub.com/study/16716-safety-and-efficacy-of-metformin-for-idiopathic-intracranial2026-10-06 https://evidence-hub.com/study/16717-metformin-does-not-attenuate-angiotensin-ii-induced-aortic-aneurysms2026-10-06 https://evidence-hub.com/study/16718-immunoregulatory-effect-of-metformin-in-monocytes-exposed-to-sars-cov2026-10-06 https://evidence-hub.com/study/16719-a-systematic-review-and-meta-analysis-of-participant-characteristics2026-10-06 https://evidence-hub.com/study/16720-metformin-reduces-the-clonal-fitness-of-dnmt3a-r878h-hematopoietic2026-10-01 https://evidence-hub.com/study/16721-outpatient-treatment-of-covid-19-with-metformin-ivermectin-and2026-10-01 https://evidence-hub.com/study/16722-pro-longevity-compounds-extend-caenorhabditis-elegans-male-lifespan2026-10-06 https://evidence-hub.com/study/16723-metformin-treatment-results-in-distinctive-skeletal-muscle2026-10-06 https://evidence-hub.com/study/16724-osteoblast-intrinsic-defect-in-glucose-metabolism-impairs-bone2026-10-06 https://evidence-hub.com/study/16725-changes-in-the-type-2-diabetes-gut-mycobiome-associate-with-metformin2026-10-06 https://evidence-hub.com/study/16726-enhancing-car-t-cell-metabolism-to-overcome-hypoxic-conditions-in-the2026-10-06 https://evidence-hub.com/study/16727-post-covid-impairment-of-memory-t-cell-responses-to-community2026-10-06 https://evidence-hub.com/study/16728-metabolic-medications-modify-prostate-cancer-progression-through2026-10-06 https://evidence-hub.com/study/16729-inpatient-use-of-metformin-and-acarbose-is-associated-with-reduced2026-10-01 https://evidence-hub.com/study/16730-hif-1-inactivation-empowers-hif-2-to-drive-hypoxia-adaptation-in2026-10-06 https://evidence-hub.com/study/16731-leveraging-generative-ai-to-prioritize-drug-repurposing-candidates2026-10-06 https://evidence-hub.com/study/16732-non-alcoholic-fatty-liver-disease-nafld-and-risk-of-hospitalization2026-10-06 https://evidence-hub.com/study/16733-drug-repositioning-candidates-identified-using-in-silico-quasi2026-10-06 https://evidence-hub.com/study/16734-temporal-dysregulation-of-pparg-prkag2-co-expression-in-gray-matter2026-10-06 https://evidence-hub.com/study/16735-galectin-3-mediates-vascular-dysfunction-in-obesity-by-regulating2026-10-06 https://evidence-hub.com/study/16736-long-term-combination-therapy-with-metformin-and-oxymetholone-in-a2026-10-06 https://evidence-hub.com/study/16737-data-dependent-and-independent-acquisition-lipidomics-analysis2026-10-01 https://evidence-hub.com/study/16738-3d-bioprinted-fat-myocardium-model-unravels-the-role-of-adipocyte2026-10-06 https://evidence-hub.com/study/16739-unraveling-ampk-and-bet-regulation-of-immune-checkpoint-biology2026-10-06 https://evidence-hub.com/study/16740-effect-of-discussing-personalized-estimates-of-diabetes-risk-for2026-10-06 https://evidence-hub.com/study/16741-mitigation-of-stress-induced-structural-remodeling-and-functional2026-10-06 https://evidence-hub.com/study/16742-associations-of-antihypertensive-medication-consumption-and-drug-drug2026-10-06 https://evidence-hub.com/study/16743-ce-lab-a-microfluidic-platform-for-the-study-of-life-history-traits2026-10-06 https://evidence-hub.com/study/16744-gprc6a-is-a-potential-therapeutic-target-for-metformin-regulation-of2026-10-06 https://evidence-hub.com/study/16745-comparative-effectiveness-of-second-line-antihyperglycemic-agents-for2026-10-06 https://evidence-hub.com/study/16746-diabetes-telemedicine-mediterranean-diet-diatelemed-study-study2026-10-06 https://evidence-hub.com/study/16747-a-novel-drosophila-model-to-investigate-adipose-tissue-macrophage2026-10-06 https://evidence-hub.com/study/16748-chronic-alcohol-intake-elicits-distinct-multi-omic-profiles-in-the2026-10-06 https://evidence-hub.com/study/16749-metformin-reduces-the-risk-of-poor-treatment-outcomes-among2026-10-06 https://evidence-hub.com/study/16750-the-combined-treatment-with-ketogenic-diet-and-metformin-slows-tumor2026-10-01 https://evidence-hub.com/study/16751-improvement-in-insulin-sensitivity-prevents-decline-in-glucose-uptake2026-10-06 https://evidence-hub.com/study/16752-estimating-the-risk-based-value-of-the-diabetes-prevention-program2026-10-06 https://evidence-hub.com/study/16753-targeting-the-menopause-transition-with-metformin-improves-breast2026-10-06 https://evidence-hub.com/study/16754-access-to-essential-medicines-for-diabetes-care-availability-price2026-10-06 https://evidence-hub.com/study/16755-shared-genetics-between-breast-cancer-and-predisposing-diseases2026-10-06 https://evidence-hub.com/study/16756-when-nudges-don-t-budge-a-mixed-methods-study-of-why-ehr-based2026-10-08 https://evidence-hub.com/study/16757-host-genetic-liability-for-severe-covid-19-overlaps-with-alcohol2026-10-06 https://evidence-hub.com/study/16758-functional-primary-human-3d-skeletal-muscle-models-enable-exercise2026-10-06 https://evidence-hub.com/study/16759-synergistic-amelioration-of-endocrine-dysregulation-by-vernonia2026-10-06 https://evidence-hub.com/study/16760-oxidative-stress-and-its-relation-to-oncogenesis2026-10-06 https://evidence-hub.com/study/16761-the-microbiome-as-a-pharmacologic-variable-defining-when-microbial2026-10-06 https://evidence-hub.com/study/16762-hospitalization-in-adults-aged-75-years-and-older-with-type-22026-10-06 https://evidence-hub.com/study/16763-a-systems-pharmacology-model-of-ageing-identifies-optimal-combination2026-10-06 https://evidence-hub.com/study/16764-quercetin-attenuates-high-fat-high-sugar-diet-induced-metabolic2026-10-06 https://evidence-hub.com/study/16765-progressive-functional-recovery-following-a-rehabilitation-plateau-in2026-10-06 https://evidence-hub.com/study/16766-creating-a-cohort-of-women-with-incident-diabetes-and-a-background-of2026-10-06 https://evidence-hub.com/study/16767-metformin-a-hopeful-promise-in-aging-research2026-10-01 https://evidence-hub.com/study/16768-ampk-regulation-of-raptor-and-tsc2-mediate-metformin-effects-on2026-10-01 https://evidence-hub.com/study/16769-fatal-toxicity-of-chloroquine-or-hydroxychloroquine-with-metformin-in2026-10-01 https://evidence-hub.com/study/16770-metformin-in-pregnancy-mechanisms-and-clinical-applications2026-10-06 https://evidence-hub.com/study/16772-metformin-in-antiviral-therapy-evidence-and-perspectives2026-10-08 https://evidence-hub.com/study/16773-the-gdf15-gfral-pathway-is-dispensable-for-the-effects-of-metformin2026-10-01 https://evidence-hub.com/study/16774-metformin-induces-apoptosis-and-alters-cellular-responses-to2026-10-01 https://evidence-hub.com/study/16775-metformin-suppresses-sars-cov-2-in-cell-culture2026-10-01 https://evidence-hub.com/study/16776-gut-microbiome-activity-predicts-risk-of-type-2-diabetes-and2026-10-01 https://evidence-hub.com/study/16777-targeting-endometrial-cancer-stem-cell-activity-with-metformin-is2026-10-01 https://evidence-hub.com/study/16778-the-nampt-inhibitor-fk866-increases-metformin-sensitivity-in2026-10-01 https://evidence-hub.com/study/16779-frontiers-in-anti-cancer-drug-discovery-challenges-and-perspectives2026-10-01 https://evidence-hub.com/study/16781-carnitine-palmitoyltransferase-1c-promotes-cell-survival-and-tumor2026-10-01 https://evidence-hub.com/study/16782-late-life-metformin-treatment-limits-cell-survival-and-shortens2026-10-01 https://evidence-hub.com/study/16783-metformin-hydrochloride-plga-nanoparticles-in-diabetic-rats-in-a2026-10-01 https://evidence-hub.com/study/16784-uterine-progesterone-signaling-is-a-target-for-metformin-therapy-in2026-10-01 https://evidence-hub.com/study/16786-drug-repurposing-of-metformin-for-alzheimer-s-disease-combining2026-10-01 https://evidence-hub.com/study/16787-metformin-improves-glycemia-independently-of-skeletal-muscle-ampk-via2026-09-27 https://evidence-hub.com/study/16788-metformin-as-an-accessible-caloric-restriction-mimetic-in-helminth2026-09-27 https://evidence-hub.com/study/16789-gdf15-and-the-beneficial-actions-of-metformin-in-pre-diabetes2026-10-01 https://evidence-hub.com/study/16790-impact-of-metformin-treatment-during-pregnancy-on-maternal-outcomes-a2026-10-01 https://evidence-hub.com/study/16791-potential-of-sustained-release-microparticles-of-metformin-in2026-10-01 https://evidence-hub.com/study/16792-metformin-rescues-muscle-function-in-bag3-myofibrillar-myopathy-models2026-09-27 https://evidence-hub.com/study/16793-metformin-therapy-changes-gut-microbiota-alpha-diversity-in-covid-192026-10-01 https://evidence-hub.com/study/16794-effect-of-metformin-on-the-epigenetic-age-of-peripheral-blood-in2026-10-01 https://evidence-hub.com/study/16796-metformin-strongly-affects-gut-microbiome-composition-in-high-fat2026-10-01 https://evidence-hub.com/study/16797-ampk-activation-by-metformin-promotes-survival-of-dormant-er-breast2026-10-01 https://evidence-hub.com/study/16798-impact-of-gut-microbiota-and-scfas-in-pcos-pathogenesis-and-metformin2026-10-01 https://evidence-hub.com/study/16799-morning-exercise-and-pre-breakfast-metformin-interact-to-reduce2026-10-01 https://evidence-hub.com/study/16800-evaluating-the-antihyperalgesic-potential-of-sildenafil-metformin2026-10-01 https://evidence-hub.com/study/16801-simultaneous-determination-of-metformin-and-glibenclamide-by-rp-hplc2026-10-01 https://evidence-hub.com/study/16802-glycemic-control-and-neonatal-outcomes-in-women-with-gestational2026-10-01 https://evidence-hub.com/study/16803-metformin-is-associated-with-favorable-outcomes-in-patients-with2026-10-01 https://evidence-hub.com/study/16806-metformin-increases-tauroursodeoxycholic-acid-levels-to-improve2026-10-01 https://evidence-hub.com/study/16807-evaluating-the-efficacy-and-mechanism-of-metformin-targets-on2026-09-27 https://evidence-hub.com/study/16808-metformin-induces-ferroptosis-byinhibiting-ufmylation-of-slc7a11-in2026-10-01 https://evidence-hub.com/study/16809-analysis-of-crowdsourced-metformin-tablets-from-individuals-reveals2026-10-01 https://evidence-hub.com/study/16810-braf-controls-the-effects-of-metformin-on-neuroblast-cell-divisions2026-10-08 https://evidence-hub.com/study/16813-metformin-suppresses-monocyte-immunometabolic-activation-by-sars-cov2026-10-01 https://evidence-hub.com/study/16815-metformin-improves-cognition-of-aged-mice-by-promoting-cerebral2026-10-01 https://evidence-hub.com/study/16816-if-metformin-inhibited-the-mitochondrial-glycerol-phosphate2026-10-01 https://evidence-hub.com/study/16817-development-and-validation-of-stability-indicating-hptlc-method-for2026-10-01 https://evidence-hub.com/study/16819-comparative-effect-of-metformin-versus-sulfonylureas-with-dementia2026-10-01 https://evidence-hub.com/study/16820-metformin-exerts-an-antitumor-effect-by-inhibiting-bladder-cancer2026-10-01 https://evidence-hub.com/study/16821-biofilm-growth-of-pseudomonas-aeruginosa-tgc04-exposed-to-metformin2026-10-01 https://evidence-hub.com/study/16823-a-broadly-accessible-liquid-chromatography-method-for-quantification2026-10-01 https://evidence-hub.com/study/16825-the-dual-therapeutic-effect-of-metformin-nuclei-based-drugs-modified2026-10-01 https://evidence-hub.com/study/16826-metformin-inhibits-the-growth-of-pancreatic-cancer-cells-by-inducing2026-10-01 https://evidence-hub.com/study/16829-metformin-regulates-bone-marrow-stromal-cells-to-accelerate-bone2026-10-01 https://evidence-hub.com/study/16830-effects-of-testosterone-and-metformin-on-the-glycanage-index-of2026-10-01 https://evidence-hub.com/study/16831-neuroinflammation-links-covid-19-and-fragile-x-syndrome-role-of-mmp-92026-10-01 https://evidence-hub.com/study/16832-metformin-versus-sulphonylureas-for-new-onset-atrial-fibrillation-and2026-10-01 https://evidence-hub.com/study/16834-exploring-the-next-generation-of-metformin-derivatives-and-their2026-10-01 https://evidence-hub.com/study/16835-metformin-protects-trabecular-meshwork-against-oxidative-injury-via2026-10-01 https://evidence-hub.com/study/16836-metformin-in-nucleus-accumbens-core-reduces-cue-induced-cocaine2026-10-01 https://evidence-hub.com/study/16837-metformin-acts-directly-in-the-brain-to-slow-features-of2026-10-01 https://evidence-hub.com/study/16838-metformin-use-is-associated-with-lower-risks-of-dementia-anxiety-and2026-10-01 https://evidence-hub.com/study/16839-metformin-therapy-and-breast-cancer-incidence-in-the-hail-region2026-10-01 https://evidence-hub.com/study/16840-metformin-therapy-and-breast-cancer-incidence-in-the-hail-region2026-10-01 https://evidence-hub.com/study/16841-the-relationship-between-the-use-of-metformin-and-the-risk-of2026-10-01 https://evidence-hub.com/study/16843-l-ergothioneine-and-metformin-alleviates-liver-injury-in-experimental2026-10-01 https://evidence-hub.com/study/16845-curating-electronic-health-record-data-to-assess-causal-inference2026-10-06 https://evidence-hub.com/study/16849-prescription-drug-costs2026-10-06 https://evidence-hub.com/study/16852-metformin-the-gold-standard-a-scientific-handbook2026-09-27 https://evidence-hub.com/study/16855-metformin-and-pancreatic-cancer-metabolism2026-10-01 https://evidence-hub.com/study/16856-mechanisms-of-action-of-metformin2026-09-27 https://evidence-hub.com/study/16857-clinical-pharmacokinetics-of-metformin2026-09-27 https://evidence-hub.com/study/16858-metformin-pharmacology-and-drug-interactions2026-09-27 https://evidence-hub.com/study/16860-metformin-indications-dosage-adverse-reactions-and-contraindications2026-10-01 https://evidence-hub.com/study/16861-new-insight-into-metformin-mechanism-of-action-and-clinical2026-10-01 https://evidence-hub.com/study/16869-metformin-pros-and-cons2026-10-01 https://evidence-hub.com/study/16870-metformin-activity-against-breast-cancer-mechanistic-differences-by2026-10-01 https://evidence-hub.com/study/16878-copper-zinc-and-magnesium-in-non-insulin-dependent-diabetes-mellitus2026-10-01 https://evidence-hub.com/study/16879-using-ehr-linked-biobank-data-to-study-metformin-pharmacogenomics2026-09-27 https://evidence-hub.com/study/16882-metformin-and-its-benefits-in-improving-gut-microbiota-disturbances2026-10-01 https://evidence-hub.com/study/16887-preventive-and-neo-adjuvant-therapeutic-effects-of-metformin-on-cancer2026-10-01 https://evidence-hub.com/study/16891-metformin-in-health-issues-and-reproductive-system2026-10-01 https://evidence-hub.com/study/16894-metformin-modulates-the-mechanisms-of-ageing2026-10-01 https://evidence-hub.com/study/16897-repurposing-metformin-for-lung-cancer-management2026-10-01 https://evidence-hub.com/study/16899-potential-protective-effects-of-metformin-on-ocular-complications-in2026-10-01 https://evidence-hub.com/study/16900-where-and-how-in-the-mtor-pathway-inhibitors-fight-aging-rapamycin2026-10-01 https://evidence-hub.com/study/16905-therapeutic-potential-of-metformin-in-diabetes-mellitus-related2026-10-01 https://evidence-hub.com/study/16906-metformin-for-tuberculosis-infection2026-09-27 https://evidence-hub.com/study/16907-repurposing-of-metformin-as-a-multifaceted-and-multitasking2026-10-01 https://evidence-hub.com/study/16911-combined-effect-of-metformin-and-statin2026-10-01 https://evidence-hub.com/study/16912-metformin-in-cervical-cancer-metabolic-reprogramming2026-10-01 https://evidence-hub.com/study/16913-antitumoral-effects-of-metformin-in-ovarian-cancer2026-10-01 https://evidence-hub.com/study/16914-metformin-and-its-implication-in-cancer-therapy2026-10-01 https://evidence-hub.com/study/16915-metformin-in-non-diabetic-conditions-an-overview2026-10-01 https://evidence-hub.com/study/16916-peptide-hormones-metformin-and-new-wave-practices-and-research2026-09-27 https://evidence-hub.com/study/16922-metformin-a-small-molecule-with-multi-targets-and-diverse-therapeutic2026-10-01 https://evidence-hub.com/study/16925-a-pharmacodynamic-study-of-sirolimus-and-metformin-in-patients-with2026-09-27 https://evidence-hub.com/study/16928-treatment-of-insulin-resistance-in-youth-the-role-of-metformin2026-09-27 https://evidence-hub.com/study/16934-gestational-diabetes-mellitus2026-09-27 https://evidence-hub.com/study/16939-pcr-primer-design-for-detection-of-snps-in-slc22a1-rs683369-encoding2026-09-27 https://evidence-hub.com/study/16940-non-insulin-antidiabetic-therapy-in-cardiac-patients-current-problems2026-09-27 https://evidence-hub.com/study/16942-case-1-suspected-maturity-onset-diabetes-of-the-young-mody-5-mody2026-09-27 https://evidence-hub.com/study/16948-in-vitro-drug-interactions-study-of-lisinopril-with-metformin2026-10-08 https://evidence-hub.com/study/16955-fibroblasts-rescue-oral-squamous-cancer-cell-from-metformin-induced2026-09-27 https://evidence-hub.com/study/16956-metadata-record-for-the-article-effect-of-metformin-versus-placebo-on2026-09-27 https://evidence-hub.com/study/16958-effects-of-metformin-pioglitazone-and-aqueous-extract-of-delonix2026-09-27 https://evidence-hub.com/study/16961-metformin-associated-lactic-acidosis2026-09-27 https://evidence-hub.com/study/16964-repurposing-of-metformin-for-the-prevention-and-treatment-of2026-09-27 https://evidence-hub.com/study/16968-interventions-to-improve-cardiovascular-risk-factors-in-people-with2026-09-27 https://evidence-hub.com/study/16972-metabolic-changes-in-cancer-cells-after-metformin-treatment2026-09-27 https://evidence-hub.com/study/16979-efficacy-in-controlling-glycaemia-with-victoza-liraglutide-as-add-on2026-10-06 https://evidence-hub.com/study/16980-available-datapackage-for-study-a-phase-3-double-blind-randomized2026-10-06 https://evidence-hub.com/study/16981-effects-of-exercise-and-metformin-on-the-prevention-of-glucose2026-09-27 https://evidence-hub.com/study/16982-database-of-metformin-versus-insulin-in-pregnancy-a-randomized2026-10-06 https://evidence-hub.com/study/16983-metformin-driven-metabolic-reprogramming-as-a-therapeutic-strategy-in2026-10-06 https://evidence-hub.com/study/16984-metformin-inhibits-proliferation-and-migration-of-glioblastoma-cells2026-09-27 https://evidence-hub.com/study/16986-uncovering-antiobesity-related-hypertension-targets-and-mechanisms-of2026-10-08 https://evidence-hub.com/study/16989-physical-exercise-and-metformin-in-the-prevention-of-pre-eclampsia2026-09-27 https://evidence-hub.com/study/16991-available-datapackage-for-study-efficacy-in-controlling-glycaemia2026-10-06 https://evidence-hub.com/study/16992-metformin-rescues-muscle-function-in-bag3-myofibrillar-myopathy-models2026-09-27 https://evidence-hub.com/study/16995-metformin-promotes-susceptibility-to-experimental-leishmania2026-09-27 https://evidence-hub.com/study/16998-metformin-rescues-muscle-function-in-bag3-myofibrillar-myopathy-models2026-09-27 https://evidence-hub.com/study/16999-effectiveness-of-metformin-in-the-prevention-of-gestational-diabetes2026-09-27 https://evidence-hub.com/study/17000-metformin-rescues-muscle-function-in-bag3-myofibrillar-myopathy-models2026-09-27 https://evidence-hub.com/study/17001-stingless-bee-propolis-metformin-and-their-combination-alleviate2026-09-27 https://evidence-hub.com/study/17002-vildagliptin-compared-to-gliclazide-in-combination-with-metformin-in2026-10-06 https://evidence-hub.com/study/17005-dataset-related-to-article-metformin-and-everolimus-a-promising2026-09-27 https://evidence-hub.com/study/17006-the-mechanism-of-drug-interactions-of-a-selected-antiarrhythmic-drug2026-10-08 https://evidence-hub.com/study/17008-factors-associated-with-the-need-for-insulin-as-a-complementary2026-09-27 https://evidence-hub.com/study/17011-ccne1-is-a-potential-target-of-metformin-for-tumor-suppression-of2026-09-27 https://evidence-hub.com/study/17012-physical-exercise-and-metformin-in-gestational-obesity-and-prevention2026-09-27 https://evidence-hub.com/study/17014-the-impact-of-metformin-on-survival-outcomes-in-patients-with2026-10-06 https://evidence-hub.com/study/17015-dataset-related-to-article-a-novel-insight-into-the-anticancer2026-09-27 https://evidence-hub.com/study/17018-evaluation-of-preeclampsia-results-after-use-of-metformin-in2026-09-27 https://evidence-hub.com/study/17021-efficacy-and-safety-of-semaglutide-versus-dulaglutide-as-add-on-to2026-10-06 https://evidence-hub.com/study/17024-effect-of-diacerein-as-an-add-on-to-metformin-in-patients-with-type-22026-09-27 https://evidence-hub.com/study/17025-efficacy-and-safety-of-vildagliptin-compared-to-metformin-in-drug2026-10-06 https://evidence-hub.com/study/17026-efficacy-and-safety-of-semaglutide-versus-canagliflozin-as-add-on-to2026-10-06 https://evidence-hub.com/study/17029-metformin-and-liraglutide-ameliorate-high-glucose-induced-oxidative2026-10-01 https://evidence-hub.com/study/17030-formulation-and-in-vitro-evaluation-of-bilayer-floating-tablets-of2026-09-27 https://evidence-hub.com/study/17032-effect-of-metformin-on-breast-cancer-metabolism2026-09-27 https://evidence-hub.com/study/17033-the-ecotoxicological-effects-of-metformin-and-its-metabolite2026-10-01 https://evidence-hub.com/study/17034-the-investigation-of-the-effects-of-metformin-in-thyroid-cancer2026-10-01 https://evidence-hub.com/study/17035-compare-the-safety-and-efficacy-of-glimepiride-metformin-with2026-09-27 https://evidence-hub.com/study/17036-the-effects-of-metformin-on-pancreatic-cancer-metabolism2026-09-27 https://evidence-hub.com/study/17037-dicarbonyl-protein-adduction-plasminogen-as-a-target-and-metformin-as2026-09-27 https://evidence-hub.com/study/17038-metformin-use-and-the-hepatic-and-renal-toxicity2026-09-27 https://evidence-hub.com/study/17039-a-comparison-of-the-effectiveness-of-two-homoeopathic-dosage-forms-of2026-10-01 https://evidence-hub.com/study/17040-the-role-of-metformin-in-obesity-driven-endometrial-cancer2026-10-01 https://evidence-hub.com/study/17041-therapeutic-modulation-of-cancer-metabolism-with-dichloroacetate-and2026-10-01 https://evidence-hub.com/study/17042-beneficial-effects-of-metformin-in-diet-induced-obesity-associated2026-10-01 https://evidence-hub.com/study/17043-bedeutung-von-metformin-als-kausaler-faktor-einer-metformin2026-10-01 https://evidence-hub.com/study/17044-reduction-of-obesity-associated-breast-cancer-risk-in-a-phase-ii2026-09-27 https://evidence-hub.com/study/17045-efficacy-and-safety-of-probiotics-as-an-add-on-therapy-to-metformin2026-09-27 https://evidence-hub.com/study/17047-modulatory-effects-of-metformin-on-mutagenicity-and-epithelial-tumor2026-09-27 https://evidence-hub.com/study/17048-uptake-organ-distribution-and-physiological-effects-of-an-anti2026-10-01 https://evidence-hub.com/study/17050-repurposing-medicines-for-the-adjuvant-treatment-of-cancer-an2026-09-27 https://evidence-hub.com/study/17051-formulation-evaluation-and-optimization-of-metformin-hydrochloride2026-09-27 https://evidence-hub.com/study/17052-analysis-of-the-effects-of-metformin-administered-alone-or-in2026-09-27 https://evidence-hub.com/study/17054-simultaneous-estimation-of-repaglinide-and-metformin-hydrochloride-in2026-09-27 https://evidence-hub.com/study/17055-metformin-attenuates-hepatic-mitochondrial-dysfunction-and-oxidative2026-10-01 https://evidence-hub.com/study/17056-metformin-and-preservation-of-left-ventricular-function2026-09-27 https://evidence-hub.com/study/17057-orodispersible-tablets-containing-taste-masked-lipid-pellets-with2026-09-27 https://evidence-hub.com/study/17058-comparison-of-the-therapeutic-effect-of-melatonin-metformin-and2026-09-27 https://evidence-hub.com/study/17059-preparation-characterization-and-in-vitro-evaluation-of-metformin2026-09-27 https://evidence-hub.com/study/17060-hubungan-lama-penggunaan-metformin-terhadap-indeks-eritrosit-pada2026-09-27 https://evidence-hub.com/study/17061-metformin-improves-glucose-effectiveness-not-insulin-sensitivity2026-09-27 https://evidence-hub.com/study/17065-the-effect-of-genetic-polymorphism-on-therapeutic-response-of2026-09-27 https://evidence-hub.com/study/17066-analisis-efektivitas-biaya-pengobatan-pasien-diabetes-tipe-2-dengan2026-09-27 https://evidence-hub.com/study/17067-the-prevalence-and-treatment-of-metformin-associated-vitamin-b122026-09-27 https://evidence-hub.com/study/17069-metformin-prevents-peritoneal-dissemination-via-immune-suppressive2026-10-01 https://evidence-hub.com/study/17070-a-rapid-rp-hplc-method-development-and-validation-for-the2026-09-27 https://evidence-hub.com/study/17071-perbandingan-efek-hipoglikemik-bekatul-beras-hitam-dengan-metformin2026-09-27 https://evidence-hub.com/study/17072-study-of-metformin-effects-and-involvement-of-the-mtor-signaling2026-09-27 https://evidence-hub.com/study/17073-a-randomized-open-labelled-single-centered-study-of-metformin-in2026-09-27 https://evidence-hub.com/study/17074-analisis-efektivitas-biaya-antidiabetes-oral-metformin-dan-glimepirid2026-09-27 https://evidence-hub.com/study/17076-a-comparison-of-the-efficacy-of-syzygium-jambolanum-java-plum-6ch-and2026-10-01 https://evidence-hub.com/study/17078-phytoextraction-of-metformin2026-09-27 https://evidence-hub.com/study/17079-pengaruh-ekstrak-herba-anting-anting-acalypha-australis-l-terhadap2026-09-27 https://evidence-hub.com/study/17080-phytoextraction-of-metformin-and-guanylurea2026-09-27 https://evidence-hub.com/study/17081-obesity-and-metformin-in-pregnancy2026-09-27 https://evidence-hub.com/study/17083-metformin-in-gestational-diabetes-mellitus2026-10-01 https://evidence-hub.com/study/17084-preclinical-testing-of-potential-therapeutics-for-amyotrophic-lateral2026-10-01 https://evidence-hub.com/study/17085-metformin-mechanistic-and-cardiovascular-effects2026-10-01 https://evidence-hub.com/study/17086-the-effects-of-metformin-on-the-gastrointestinal-tract2026-09-27 https://evidence-hub.com/study/17087-the-effects-of-metformin-on-the-vascular-system2026-09-27 https://evidence-hub.com/study/17088-metformins-effekt-pa-endometriecancer2026-09-27 https://evidence-hub.com/study/17089-metformin-metabolomics-and-inflammation-in-gestational-diabetes2026-10-01 https://evidence-hub.com/study/17090-the-use-of-metformin-in-patients-with-renal-impairment2026-10-01 https://evidence-hub.com/study/17091-grape-fruit-juice-improves-glycemic-index-and-up-regulates-expression2026-10-01 https://evidence-hub.com/study/17092-diabetes-metformin-and-gastric-adenocarcinoma2026-09-27 https://evidence-hub.com/study/17093-metformin-action-on-nuclear-transport2026-09-27 https://evidence-hub.com/study/17094-intensive-care-of-patient-with-metformin-intoxication2026-09-27 https://evidence-hub.com/study/17095-molecular-impact-of-metformin-on-hepatocellular-metabolism2026-09-27 https://evidence-hub.com/study/17096-antibacterial-properties-of-the-diabetic-drug-metformin2026-10-01 https://evidence-hub.com/study/17097-understanding-the-role-of-metformin-in-alzheimer-s-disease2026-09-27 https://evidence-hub.com/study/17098-the-effect-of-ampk-activation-on-alzheimer-s-like-symptoms-in-app-mice2026-10-01 https://evidence-hub.com/study/17099-the-pharmacologic-and-biologic-roles-of-transporters-for-metformin2026-10-08 https://evidence-hub.com/study/17100-metformin-from-antidiabetic-to-cancer-therapeutic2026-09-27 https://evidence-hub.com/study/17101-metformin-glucotoxicity-and-islet-dysfunction2026-10-01 https://evidence-hub.com/study/17102-effects-of-surfactant-systems-on-metformin-transport2026-09-27 https://evidence-hub.com/study/17103-predictors-of-cancer-cell-response-to-metformin2026-09-27 https://evidence-hub.com/study/17104-metformin-aspirin-and-colorectal-cancer-outcomes2026-09-27 https://evidence-hub.com/study/17105-metformin-and-prostate-cancer-among-diabetic-men2026-10-01 https://evidence-hub.com/study/17106-the-effect-of-obesity-and-metformin-on-influenza-vaccine-response2026-09-27 https://evidence-hub.com/study/17107-acute-metabolic-effects-of-metformin-during-critical-illness2026-10-01 https://evidence-hub.com/study/17108-influence-of-metformin-on-t-cell-mrna-expression2026-09-27 https://evidence-hub.com/study/17109-the-effects-of-metformin-on-obesity-induced-diabetic-retinas2026-09-27 https://evidence-hub.com/study/17111-metformin-and-guanylurea-in-aquatic-environments-an-overview-and2026-10-01 https://evidence-hub.com/study/17112-the-effect-of-diet-exercise-and-metformin-on-the-progression-of2026-10-01 https://evidence-hub.com/study/17113-the-antitumor-effect-of-metformin-on-esophageal-squamous-cell2026-10-01 https://evidence-hub.com/study/17114-synthesis-and-characterisation-of-calcium-citrate-nanoparticles-for2026-09-27 https://evidence-hub.com/study/17115-usage-of-metformin-in-patients-with-type-2-diabetes-mellitus2026-10-01 https://evidence-hub.com/study/17116-the-role-of-organic-cation-transporters-in-the-pharmacokinetics-and2026-10-08 https://evidence-hub.com/study/17117-pentoxifylline-metformin2026-09-27 https://evidence-hub.com/study/17118-drug-drug-interactions-ddi-and-pharmacodynamic-effects-of-metformin2026-09-27 https://evidence-hub.com/study/17119-metabolic-assessment-of-metformin-treatment-in-colon-cancer-cells2026-09-27 https://evidence-hub.com/study/17120-metformin-zur-prophylaxe-der-antipsychotika-induzierten2026-09-27 https://evidence-hub.com/study/17121-enhanced-degradation-of-epidermal-growth-factor-receptor-by-metformin2026-09-27 https://evidence-hub.com/study/17122-effects-of-metformin-on-contractility-of-isolated-rat-thoracic-aorta2026-09-27 https://evidence-hub.com/study/17123-the-effects-of-metformin-on-metabolism-and-cardiovascular-disease-in2026-09-27 https://evidence-hub.com/study/17124-the-effect-of-metformin-on-inflammatory-and-fibrotic-responses-in2026-09-27 https://evidence-hub.com/study/17125-otoprotection-of-metformin-in-radiation-induced-sensorineural-hearing2026-09-27 https://evidence-hub.com/study/17126-metformin-in-the-horse-pharmacokinetic-modeling-detection-methods-and2026-10-01 https://evidence-hub.com/study/17129-effect-of-new-anti-diabetic-medications-in-combination-with-metformin2026-09-27 https://evidence-hub.com/study/17130-metformin-for-weight-gain-in-youth-on-atypical-antipsychotics2026-10-06 https://evidence-hub.com/study/17131-the-clinical-effectiveness-and-cost-effectiveness-of-rosiglitazone2026-10-01 https://evidence-hub.com/study/17132-metformin-a-versatile-therapeutic-agent-in-various-diseases-and2026-09-27 https://evidence-hub.com/study/17135-topical-metformin-30-gel-in-the-treatment-of-acne-vulgaris-a-split2026-10-01 https://evidence-hub.com/study/17136-the-effect-of-metformin-on-gastric-cancer-in-patients-with-type-22026-10-01 https://evidence-hub.com/study/17140-clinical-efficacy-comparison-of-metformin-and-myo-inositol-in-the2026-10-06 https://evidence-hub.com/study/17142-reconnaissance-of-pharmaceutical-chemicals-in-urban-streams-of-the2026-09-27 https://evidence-hub.com/study/17146-creek-and-quarry-water-quality-at-pipestone-national-monument-and2026-10-01 https://evidence-hub.com/study/17149-metformin-liraglutide-orlistat-and-phentermine-for-childhood-obesity2026-10-01 https://evidence-hub.com/study/17150-a-new-therapeutic-strategy-for-autosomal-dominant-polycystic-kidney2026-09-27 https://evidence-hub.com/study/17155-the-effect-of-traditional-chinese-medicine-combined-with-metformin2026-10-01 https://evidence-hub.com/study/17158-educational-mock-type-ii-drug-master-file-dmf-for-metformin2026-10-06 https://evidence-hub.com/study/17160-investigating-the-prevalence-and-causes-of-prescribing-errors-in2026-10-01 https://evidence-hub.com/study/17161-production-of-drinking-water-from-surface-water-analysis-of-the2026-10-01 https://evidence-hub.com/study/17163-transcan-iii-verbund-klinische-studie-zur-wirkung-von-aspirin-und2026-10-06 https://evidence-hub.com/study/17165-effekt-av-tiltak-for-barn-og-unge-med-overvekt-eller-fedme2026-10-01 https://evidence-hub.com/study/17166-report-of-the-australian-and-new-zealand-neonatal-network-20012026-10-01 https://evidence-hub.com/study/17167-pharmaceutical-use-following-generic-entry-paying-less-and-buying-less2026-10-01 https://evidence-hub.com/study/17168-validation-of-the-cdc-rti-diabetes-cost-effectiveness-model2026-10-01 https://evidence-hub.com/study/17169-racial-concordance-and-the-quality-of-medical-care-evidence-from-the2026-10-01 https://evidence-hub.com/study/17171-the-health-costs-of-cost-sharing2026-10-01 https://evidence-hub.com/study/17172-polypharmacy-in-adults-over-50-in-ireland-opportunities-for-cost2026-10-01 https://evidence-hub.com/study/17173-phase-ii-6-month-cyclic-progesterone-spironolactone-pilot-therapy2026-09-27 https://evidence-hub.com/study/17175-patient-responses-to-incentives-in-consumer-directed-health-plans2026-10-01 https://evidence-hub.com/study/17176-how-does-cost-sharing-affect-drug-purchases-insurance-regimes-in-the2026-10-01 https://evidence-hub.com/study/17177-medicijnresten-en-waterkwaliteit-een-update2026-10-01 https://evidence-hub.com/study/17179-marginal-effects-in-multivariate-probit-and-kindred-discrete-and2026-10-01 https://evidence-hub.com/study/17181-ampk2026-10-01 https://evidence-hub.com/study/17182-olanzapine-induced-weight-gain-can-akkermansia-muciniphila-help2026-10-06 https://evidence-hub.com/study/17183-does-entry-remedy-collusion-evidence-from-the-generic-prescription2026-10-01 https://evidence-hub.com/study/17184-nanochip-based-precision-medicine-targeting-cellular-ageing2026-09-27 https://evidence-hub.com/study/17185-multi-drug-loaded-gastric-floating-microcapsules2026-09-27 https://evidence-hub.com/study/17186-the-roots-of-health-inequality-and-the-value-of-intra-family-expertise2026-10-01 https://evidence-hub.com/study/17187-treatment-of-irritability-in-asd-risperidone-and-aripiprazole2026-10-06 https://evidence-hub.com/study/17189-trimaster-statistical-analysis-plan2026-09-27 https://evidence-hub.com/study/17190-microtubule-control-of-metabolism-in-prostate-cancer2026-09-27 https://evidence-hub.com/study/17191-simplifying-and-improving-the-performance-of-risk-adjustment-systems2026-10-01 https://evidence-hub.com/study/17193-national-hospital-ambulatory-medical-care-survey-2019-national2026-10-01 https://evidence-hub.com/study/17194-comparison-friction-experimental-evidence-from-medicare-drug-plans2026-10-01 https://evidence-hub.com/study/17195-cd442026-10-01 https://evidence-hub.com/study/17196-overcoming-autophagy-to-induce-apoptosis-in-castration-resistant2026-09-27 https://evidence-hub.com/study/17197-antidepressant-use-during-pregnancy-and-the-risk-for-gestational2026-10-06 https://evidence-hub.com/study/17198-milieuafwegingen-in-de-geneesmiddelvoorziening2026-10-01 https://evidence-hub.com/study/17200-modeling-and-control-of-the-cobelli-model-as-a-personalized2026-10-01 https://evidence-hub.com/study/17201-antipsychotic-induced-weight-gain-prevention-and-management2026-10-06 https://evidence-hub.com/study/17202-is-aripiprazole-really-metabolically-safer-than-olanzapine2026-10-06 https://evidence-hub.com/study/17203-behandlung-von-reizbarkeit-bei-ass-risperidon-und-aripiprazol2026-10-06 https://evidence-hub.com/study/17204-gebelik-s-ras-nda-antidepresan-kullan-m-ve-gestasyonel-diyabet-riski2026-10-06 https://evidence-hub.com/study/17205-antidiabetic-medications-and-the-risk-of-prostate-cancer-in-patients2026-10-01 https://evidence-hub.com/study/17206-aripiprazol-gercekten-olanzapinden-metabolik-ac-dan-daha-guvenli-mi2026-10-06 https://evidence-hub.com/study/17207-integrate-new-schizophrenia-treatment-guidelines2026-10-06 https://evidence-hub.com/study/17208-antidepressivaeinsatz-in-der-schwangerschaft-und-das-risiko-eines2026-10-06 https://evidence-hub.com/study/17209-quality-of-health-care-in-the-lao-people-s-democratic-republic2026-10-01 https://evidence-hub.com/study/17210-antipsikotiklere-bagl-kilo-al-m-onleme-ve-yonetim2026-10-06 https://evidence-hub.com/study/17211-managing-cardiac-and-metabolic-adverse-effects-of-clozapine2026-10-06 https://evidence-hub.com/study/17212-what-drove-first-year-premiums-in-stand-alone-medicare-drug-plans2026-10-01 https://evidence-hub.com/study/17213-antipsychotika-induzierte-gewichtszunahme-pravention-und-management2026-10-06 https://evidence-hub.com/study/17214-antipsychotic-induced-weight-gain-best-management-strategies2026-10-06 https://evidence-hub.com/study/17216-ist-aripiprazol-wirklich-metabolisch-vertraglicher-als-olanzapin2026-10-06 https://evidence-hub.com/study/17217-integrate-neue-behandlungsleitlinien-fur-schizophrenie2026-10-06 https://evidence-hub.com/study/17218-diabetic-gastroparesis2026-10-06 https://evidence-hub.com/study/17219-targeted-therapy-on-the-screen-do-we-hit-the-target2026-10-06 https://evidence-hub.com/study/17220-meds-modify-microbiome-mediating-their-effects2026-10-06 https://evidence-hub.com/study/17221-time-to-exercise-boosting-exercise-performance-via-ampk-signaling2026-10-06 https://evidence-hub.com/study/17222-interventions-for-hirsutism2026-10-06 https://evidence-hub.com/study/17223-next-steps-in-mechanisms-of-inflammaging2026-10-06 https://evidence-hub.com/study/17224-mitochondrial-biogenesis-pharmacological-approaches2026-10-06 https://evidence-hub.com/study/17225-sepsis-associated-liver-injury-mechanisms-and-potential-therapeutic2026-10-06 https://evidence-hub.com/study/17226-a-gut-feeling-for-metformin2026-10-06 https://evidence-hub.com/study/17227-metformin-administration-protects-against-deltoid-tendon-damage2026-10-06 https://evidence-hub.com/study/17228-unusual-extreme-leukocytosis-in-metformin-overdose2026-10-06 https://evidence-hub.com/study/17229-clinical-effects-of-antidiabetic-drugs-on-psoriasis-the-perspective2026-10-06 https://evidence-hub.com/study/17231-metformin-treating-the-cause-of-fanconi-anemia2026-10-06 https://evidence-hub.com/study/17232-metformin-joins-forces-with-microbes2026-10-06 https://evidence-hub.com/study/17233-fructose-1-6-bisphosphatase-getting-the-message-across2026-10-06 https://evidence-hub.com/study/17234-scientific-and-ethical-issues-in-add-on-designs-for-antidiabetic-drugs2026-10-06 https://evidence-hub.com/study/17235-metformin-microbes-and-aging2026-10-06 https://evidence-hub.com/study/17236-opcs-on-a-diet-a-youthful-serving-of-remyelination2026-10-06 https://evidence-hub.com/study/17237-metformin-an-old-dog-with-a-new-trick2026-10-06 https://evidence-hub.com/study/17238-metformin-diamonds-are-forever2026-10-06 https://evidence-hub.com/study/17239-copper-boosts-pro-inflammatory-state-of-macrophages2026-10-06 https://evidence-hub.com/study/17241-metformin-therapy-for-the-reproductive-and-metabolic-consequences-of2026-10-06 https://evidence-hub.com/study/17242-response-to-insulin-degludec-and-insulin-glargine-300-u-ml-which-of2026-10-06 https://evidence-hub.com/study/17243-an-acid-test-for-metformin2026-10-08 https://evidence-hub.com/study/17244-the-abcd-s-of-5-adenosine-monophosphate-activated-protein-kinase-and2026-10-06 https://evidence-hub.com/study/17245-does-the-oncology-community-have-a-rejection-bias-when-it-comes-to2026-10-06 https://evidence-hub.com/study/17249-metformin-abrogates-age-associated-ovarian-fibrosis2026-10-06 https://evidence-hub.com/study/17250-sacred-codes-preservation-permutation-and-expression2026-10-06 https://evidence-hub.com/study/17253-pioglitazone-a-valuable-component-of-combination-therapy-for-type-22026-10-06 https://evidence-hub.com/study/17254-do-sodium-glucose-cotransporter-2-inhibitors-affect-renal2026-10-06 https://evidence-hub.com/study/17255-tuning-room-temperature-injectability-of-gelatin-based-hydrogels-via2026-10-06 https://evidence-hub.com/study/17256-editorial-hepatocellular-carcinoma-in-type-2-diabetes-more-than-meets2026-10-06 https://evidence-hub.com/study/17257-metformin-is-synthetically-lethal-with-glucose-withdrawal-in-cancer2026-10-08 https://evidence-hub.com/study/17259-opposing-effects-of-antidiabetic-interventions-on-malignant-growth2026-10-06 https://evidence-hub.com/study/17260-metformin-action-in-the-gut-insight-provided-by-18f-fdg-pet-imaging2026-10-06 https://evidence-hub.com/study/17261-enhancing-metformin-efficacy-with-cholecalciferol-and-taurine-in2026-10-01 https://evidence-hub.com/study/17262-new-use-for-an-old-drug-metformin-and-atrial-fibrillation2026-10-06 https://evidence-hub.com/study/17263-renaissance-of-metformin2026-10-06 https://evidence-hub.com/study/17264-smr-transporters-meet-the-challenge-of-metformin-metabolites2026-10-06 https://evidence-hub.com/study/17265-mechanisms-of-metformin-action-in-and-out-of-the-gut2026-10-06 https://evidence-hub.com/study/17266-prediabetes-and-atrial-fibrillation-risk-stratification-phenotyping2026-10-06 https://evidence-hub.com/study/17267-metformin-in-the-treatment-of-infertility-in-polycystic-ovarian2026-10-01 https://evidence-hub.com/study/17268-metformin-for-high-altitude-performance2026-10-06 https://evidence-hub.com/study/17269-long-term-effects-of-metformin-use-in-gestational-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/17270-chemoprevention-meets-glucose-control2026-10-06 https://evidence-hub.com/study/17271-dexamethasone-reduces-androgen-levels-in-metformin-treated-patients2026-10-06 https://evidence-hub.com/study/17272-metformin-restraining-nucleocytoplasmic-shuttling-to-fight-cancer-and2026-10-06 https://evidence-hub.com/study/17273-cd4-t-cells-at-the-center-of-inflammaging2026-10-06 https://evidence-hub.com/study/17274-tameing-adpkd-with-metformin-safe-and-effective2026-10-06 https://evidence-hub.com/study/17275-amelioration-of-aminoglycoside-nephrotoxicity-requires-protection-of2026-10-06 https://evidence-hub.com/study/17277-can-we-prevent-premature-luteinization-in-ivf-cycles2026-10-06 https://evidence-hub.com/study/17278-succinate-and-the-shortcut-to-the-cure-of-metformin-induced-lactic2026-10-06 https://evidence-hub.com/study/17279-art-interrupted-insights-into-art-free-hiv-remission2026-10-06 https://evidence-hub.com/study/17281-metformin-arterial-contrast-and-acute-kidney-injury2026-10-08 https://evidence-hub.com/study/17282-eradicate-tumor-progression-with-metformin2026-10-06 https://evidence-hub.com/study/17283-metabolic-regulation-by-the-intestinal-metformin-ampk-axis2026-10-06 https://evidence-hub.com/study/17284-anagliptin-and-sitagliptin-as-add-ons-to-metformin-for-patients-with2026-10-06 https://evidence-hub.com/study/17285-is-time-ready-for-combination-therapy-at-diagnosis-of-type-2-diabetes2026-10-06 https://evidence-hub.com/study/17286-reduction-of-depression-in-diabetes-a-new-pleiotropic-action-of2026-10-06 https://evidence-hub.com/study/17287-the-real-world-effect-of-anti-hyperglycemic-drugs-on-the-development2026-10-06 https://evidence-hub.com/study/17288-impact-of-metformin-on-advanced-pancreatic-cancer-survival-too-little2026-10-06 https://evidence-hub.com/study/17289-confounding-effects-of-metformin-on-the-human-gut-microbiome-in-type2026-10-06 https://evidence-hub.com/study/17290-metformin-and-cancer-licence-to-heal2026-10-06 https://evidence-hub.com/study/17291-metformin-versus-sglt-2-inhibitors-how-low-can-we-go2026-10-06 https://evidence-hub.com/study/17292-metformin-inhibits-melanoma-cell-metastasis-by-suppressing-the-mir2026-10-06 https://evidence-hub.com/study/17293-metformin-overdose-time-to-move-on2026-10-06 https://evidence-hub.com/study/17294-metformin-insulin-breast-cancer-and-more2026-10-06 https://evidence-hub.com/study/17295-recurrent-pregnancy-loss-novel-insights-and-future-directions2026-10-06 https://evidence-hub.com/study/17296-repurposing-metformin-as-therapy-for-prostate-cancer-within-the2026-10-01 https://evidence-hub.com/study/17297-teaching-an-old-drug-new-tricks2026-10-06 https://evidence-hub.com/study/17298-the-charcot-neuroarthropathy-as-onset-of-type-2-diabetes-a-diagnostic2026-10-06 https://evidence-hub.com/study/17299-an-engineered-enzyme-that-targets-circulating-lactate-to-alleviate2026-10-06 https://evidence-hub.com/study/17300-forty-four-years-of-the-uk-prospective-diabetes-study-legacy-effect2026-10-06 https://evidence-hub.com/study/17302-cancer-and-aging-more-puzzles-more-promises2026-10-06 https://evidence-hub.com/study/17303-the-150-most-important-questions-in-cancer-research-and-clinical2026-10-06 https://evidence-hub.com/study/17304-the-metabolic-syndrome-is-dead-these-reports-are-an-exaggeration2026-10-06 https://evidence-hub.com/study/17305-effect-of-glucose-tolerance-factor-gtf-on-lipid-profile-blood-glucose2026-10-06 https://evidence-hub.com/study/17306-effect-of-sitagliptin-versus-glibenclamide-on-glycemic-markers-lipid2026-10-06 https://evidence-hub.com/study/17307-lowering-homocysteine-levels-may-prevent-cardiovascular-impairments2026-10-06 https://evidence-hub.com/study/17308-metformin-an-old-drug-with-new-potential2026-10-01 https://evidence-hub.com/study/17309-ovulation-disorders-part-ii-anovulation-associated-with-normal2026-10-06 https://evidence-hub.com/study/17310-family-physicians-are-complex-care-physicians-and-quality-of-care2026-10-06 https://evidence-hub.com/study/17311-limitations-and-suggestions-for-type-2-diabetes-mellitus-and2026-10-06 https://evidence-hub.com/study/17312-reduced-progression-of-monoclonal-gammopathy-of-undetermined2026-10-06 https://evidence-hub.com/study/17313-beyond-weight-loss-glucagon-like-peptide-1-receptor-agonists-and2026-10-06 https://evidence-hub.com/study/17314-comment-on-risk-factors-associated-with-prediabetes-to-diabetes2026-10-06 https://evidence-hub.com/study/17315-advancing-physical-therapy-integrating-biomechanics-neuroscience-and2026-10-06 https://evidence-hub.com/study/17316-sglt2-inhibitors-are-associated-with-suppression-of-the-sema3a-nrp12026-10-06 https://evidence-hub.com/study/17317-letter-to-the-editor-endocrine-determinants-of-diabetic-ketoacidosis2026-10-06 https://evidence-hub.com/study/17319-knowledge-engine-wisdom-system-aligning-generative-ai-with-the2026-10-06 https://evidence-hub.com/study/17321-vitamins-and-human-health-3rd-edition-editorial2026-10-06 https://evidence-hub.com/study/17322-pharmacokinetics-and-drug-interactions2026-10-19 https://evidence-hub.com/study/17323-covid-19-and-metabolic-health-lessons-from-a-global-pandemic2026-10-06 https://evidence-hub.com/study/17324-unveiling-the-gut-kidney-dialogue-in-diabetic-kidney-disease2026-10-06 https://evidence-hub.com/study/17327-a-cardiometabolic-perspective-on-post-exertional-malaise-in-myalgic2026-10-06 https://evidence-hub.com/study/17329-ai-in-drug-repurposing-for-cancer-therapies2026-10-06 https://evidence-hub.com/study/17331-natural-products-in-diabetes-mellitus-2nd-edition2026-10-06 https://evidence-hub.com/study/17333-emerging-and-off-label-uses-of-glucagon-like-peptide-1-receptor2026-10-06 https://evidence-hub.com/study/17335-more-than-just-numbers-the-expanding-burden-of-non-communicable2026-10-06 https://evidence-hub.com/study/17336-from-molecules-to-medicine-deciphering-obesity-and-lipid-metabolism2026-10-06 https://evidence-hub.com/study/17337-the-liver-left-behind-glp-1-receptor-agonists-and-the-prospect-of2026-10-06 https://evidence-hub.com/study/17338-type-5-diabetes-as-a-growing-malnutrition-driven-health-crisis-in-low2026-10-06 https://evidence-hub.com/study/17339-neuroinflammation-driven-glymphatic-dysfunction-implications-for2026-10-06 https://evidence-hub.com/study/17341-design-and-evaluation-of-substituted-tryptamines-for-nonpsychedelic2026-10-06 https://evidence-hub.com/study/17342-new-advances-in-cardiovascular-drugs-in-memory-of-professor-akira-endo2026-10-06 https://evidence-hub.com/study/17343-special-issue-molecular-background-of-obesity-and-its-impact-on2026-10-06 https://evidence-hub.com/study/17345-beyond-egfr-critical-appraisal-of-mannitol-use-in-nephron-sparing2026-10-06 https://evidence-hub.com/study/17346-latest-findings-challenge-behavioural-approaches-to-the-management-of2026-10-06 https://evidence-hub.com/study/17347-editorial-of-topic-issue-chromatography-mass-spectrometry-analysis-in2026-10-06 https://evidence-hub.com/study/17348-zhejiang-university-index-predicts-metabolic-dysfunction-associated2026-10-06 https://evidence-hub.com/study/17349-examining-experiences-with-menstruation-and-glycemic-variability2026-10-06 https://evidence-hub.com/study/17352-early-gestational-diabetes-mellitus-a-need-for-better-understanding2026-10-06 https://evidence-hub.com/study/17354-plantamajoside-mitigates-endoplasmic-reticulum-stress-mediated2026-10-06 https://evidence-hub.com/study/17355-bridging-medical-specialities-in-the-management-of-polycystic-ovary2026-10-06 https://evidence-hub.com/study/17356-the-induction-effect-of-hydroxyurea-and-metformin-on-fetal-globin-in2026-10-06 https://evidence-hub.com/study/17357-potentially-novel-surrogate-biomarker-for-diagnosing-insulin2026-10-06 https://evidence-hub.com/study/17358-managing-drug-interactions-with-enzalutamide-in-patients-with2026-10-06 https://evidence-hub.com/study/17359-drug-induced-liver-injury-from-high-dose-intravenous2026-10-06 https://evidence-hub.com/study/17362-implications-of-bioactive-compounds-in-lifelong-disorders2026-10-06 https://evidence-hub.com/study/17363-special-issue-diabetes-comorbidities-therapeutics-and-insights-2nd2026-10-06 https://evidence-hub.com/study/17364-rheb1-as-a-novel-cell-regulator-connecting-mtorc1-ampk-and-notch12026-10-06 https://evidence-hub.com/study/17365-various-classification-methods-for-diabetes-mellitus-in-the2026-10-06 https://evidence-hub.com/study/17368-improve-2025-the-3rd-international-meeting-on-pathway-related-obesity2026-10-06 https://evidence-hub.com/study/17369-impact-of-poorly-controlled-type-ii-diabetes-mellitus-on2026-10-06 https://evidence-hub.com/study/17370-glucagon-like-peptide-1-receptor-agonists-for-arthritis-and2026-10-06 https://evidence-hub.com/study/17371-a-rebrand-for-proteasome-inhibition-in-solid-tumors-via-continuous2026-10-06 https://evidence-hub.com/study/17372-mitochondrial-regulation-of-stem-cell-osteogenic-differentiation-a2026-10-06 https://evidence-hub.com/study/17374-problem-resources-and-goals-oriented-progo-approach-in-psychiatry2026-10-06 https://evidence-hub.com/study/17375-medical-students-and-clinicians-perceptions-of-social-media-direct-to2026-10-06 https://evidence-hub.com/study/17376-clinical-management-of-lipid-metabolism-abnormalities-induced-by2026-10-06 https://evidence-hub.com/study/17377-adiposity-in-chinese-people-with-type-1-diabetes2026-10-06 https://evidence-hub.com/study/17378-unveiling-the-crucial-nexus-mitochondrial-quality-control-as-a2026-10-06 https://evidence-hub.com/study/17380-the-present-and-future-of-antiarrhythmic-drugs2026-10-06 https://evidence-hub.com/study/17381-inflammation-and-hypoalbuminemia-mediate-the-association-between-ckd2026-10-06 https://evidence-hub.com/study/17382-targeting-ras-homolog-enriched-in-brain-1-to-restore-cell-mass-and2026-10-06 https://evidence-hub.com/study/17383-gut-microbiota-an-overlooked-target-in-dyslipidemia-management2026-10-06 https://evidence-hub.com/study/17384-care-of-diabetes-and-the-sacrifice-of-evidence-based-medicine-and2026-10-06 https://evidence-hub.com/study/17386-advances-in-pharmaceutical-science-in-electrochemotherapy-a-tribute2026-10-06 https://evidence-hub.com/study/17387-insulin-resistance-with-associated-hyperinsulinemia-as-a-cause-of-the2026-10-06 https://evidence-hub.com/study/17388-the-international-evidence-based-guidelines-for-the-assessment-and2026-10-06 https://evidence-hub.com/study/17389-cell-dedifferentiation-in-type-2-diabetes-interplay-of-metabolic2026-10-06 https://evidence-hub.com/study/17390-amp-activated-protein-kinases-in-health-and-disease2026-10-06 https://evidence-hub.com/study/17391-premixed-insulin-advantages-disadvantages-and-future2026-10-06 https://evidence-hub.com/study/17392-impacts-of-tirzepatide-on-older-patients-with-diminished-cell2026-10-06 https://evidence-hub.com/study/17393-sars-cov-2-vaccination-can-only-be-held-responsible-for-thrombotic2026-10-06 https://evidence-hub.com/study/17402-safety-and-antitumor-activity-of-metformin-plus-lanreotide-in2026-10-06 https://evidence-hub.com/study/17404-about-metformin-and-its-action-on-the-mitochondrial-respiratory-chain2026-10-06 https://evidence-hub.com/study/17405-the-promising-therapeutic-effects-of-metformin-on-metabolic2026-10-06 https://evidence-hub.com/study/17407-cardiovascular-outcomes-in-patients-initiating-first-line-treatment2026-10-06 https://evidence-hub.com/study/17408-metformin-targets-clusterin-to-control-lipogenesis-and-inhibit-the2026-10-06 https://evidence-hub.com/study/17410-metformin-therapy-in-covid-19-inhibition-of-netosis2026-10-06 https://evidence-hub.com/study/17411-effects-of-liraglutide-on-cardiovascular-outcomes-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/17412-a-proposed-mechanism-for-the-possible-therapeutic-potential-of2026-10-06 https://evidence-hub.com/study/17414-a-comment-on-metformin-and-covid-19-with-regard-to-metformin-use-is2026-10-06 https://evidence-hub.com/study/17415-addition-of-metformin-to-non-small-cell-lung-cancer-patients-with-or2026-10-06 https://evidence-hub.com/study/17416-mortality-risk-with-preadmission-metformin-use-in-patients-with-covid2026-10-06 https://evidence-hub.com/study/17417-the-potential-role-for-metformin-in-the-prevention-and-treatment-of2026-10-06 https://evidence-hub.com/study/17419-editorial-new-lights-through-old-windows-metformin-and-derivatives-as2026-10-01 https://evidence-hub.com/study/17420-metformin-in-covid-19-clinical-trials-are-needed-to-prove-its-benefits2026-10-06 https://evidence-hub.com/study/17421-metformin-should-be-used-to-treat-prediabetes-in-selected-individuals2026-10-06 https://evidence-hub.com/study/17424-metformin-and-covid-19-a-novel-deal-of-an-old-drug2026-10-06 https://evidence-hub.com/study/17426-metformin-versus-placebo-in-obese-pregnant-women-without-diabetes2026-10-06 https://evidence-hub.com/study/17429-treatment-options-following-metformin-in-primary-prevention2026-10-01 https://evidence-hub.com/study/17430-metformin-use-amid-coronavirus-disease-2019-pandemic2026-10-06 https://evidence-hub.com/study/17431-harnessing-the-soil-reshaping-the-tumor-microenvironment-towards-an2026-10-06 https://evidence-hub.com/study/17432-randomized-controlled-trial-comparing-hydroxychloroquine-with2026-10-06 https://evidence-hub.com/study/17435-an-update-to-the-article-efficacy-and-side-effect-profile-of2026-10-06 https://evidence-hub.com/study/17437-metformin-in-acute-respiratory-distress-syndrome-an-opinion2026-10-06 https://evidence-hub.com/study/17438-use-of-metformin-and-cardiovascular-effects-of-new-classes-of-glucose2026-10-06 https://evidence-hub.com/study/17441-metformin-preserves-peripheral-nerve-damage-with-comparable-effects2026-10-06 https://evidence-hub.com/study/17442-initiation-of-metformin-in-melas-patient-a-dangerous-combination2026-10-06 https://evidence-hub.com/study/17443-metformin-rosiglitazone-or-both-for-obese-women-with-polycystic-ovary2026-10-06 https://evidence-hub.com/study/17444-effect-of-cost-and-formulation-on-persistence-and-adherence-to2026-10-06 https://evidence-hub.com/study/17445-reduced-prevalence-of-latent-tb-infection-in-diabetes-patients-using2026-10-06 https://evidence-hub.com/study/17447-metformin-might-inhibit-virus-through-increasing-insulin-sensitivity2026-10-06 https://evidence-hub.com/study/17448-comment-on-samara-et-al-metformin-use-is-associated-with-slowed2026-10-06 https://evidence-hub.com/study/17449-pharmacodynamics-and-pharmacokinetics-of-extended-release-metformin2026-10-06 https://evidence-hub.com/study/17450-high-accumulation-of-metformin-in-colonic-tissue-of-subjects-with2026-10-06 https://evidence-hub.com/study/17452-comment-on-kwon-et-al-the-long-term-effects-of-metformin-on-patients2026-10-01 https://evidence-hub.com/study/17453-the-effect-of-metformin-on-the-risk-of-recurrent-nonmelanoma-skin2026-10-06 https://evidence-hub.com/study/17458-response-to-comment-on-samara-et-al-metformin-use-is-associated-with2026-10-06 https://evidence-hub.com/study/17460-the-effects-of-the-metformin-on-inhibition-of-uva-induced-expression2026-10-06 https://evidence-hub.com/study/17461-understanding-the-association-between-metformin-plasma-concentrations2026-10-06 https://evidence-hub.com/study/17463-the-fda-metformin-label-change-and-racial-and-sex-disparities-in2026-10-06 https://evidence-hub.com/study/17467-association-between-metformin-use-prior-to-admission-and-lower2026-10-06 https://evidence-hub.com/study/17468-response-by-bergmark-et-al-to-letter-regarding-article-metformin-use2026-10-06 https://evidence-hub.com/study/17470-cardioprotective-effect-of-metformin-against-doxorubicin2026-10-06 https://evidence-hub.com/study/17471-commentary-lactate-induced-glucose-output-is-unchanged-by-metformin2026-10-01 https://evidence-hub.com/study/17472-contraindications-to-the-use-of-metformin2026-10-08 https://evidence-hub.com/study/17474-glioblastoma-stem-cells-a-new-target-for-metformin-and-arsenic2026-09-27 https://evidence-hub.com/study/17475-metformin-and-heart-failure-never-say-never-again2026-10-08 https://evidence-hub.com/study/17476-metformin-reduces-trib3-expression-and-restores-autophagy-flux-an2026-10-01 https://evidence-hub.com/study/17477-comment-on-today-study-group-effects-of-metformin-metformin-plus2026-09-27 https://evidence-hub.com/study/17480-metformin-inhibits-rankl-and-sensitizes-cancer-stem-cells-to-denosumab2026-10-01 https://evidence-hub.com/study/17481-metformin-not-only-per-os2026-10-01 https://evidence-hub.com/study/17482-metformin-improves-diabetic-kidney-disease2026-09-27 https://evidence-hub.com/study/17483-metformin-use-in-patients-with-historical-contraindications2026-09-27 https://evidence-hub.com/study/17485-metformin-and-the-promise-of-geroprotection2026-09-27 https://evidence-hub.com/study/17486-repurposing-metformin-for-covid-19-complications-in-patients-with2026-09-27 https://evidence-hub.com/study/17487-prevention-of-cv-outcomes-in-antihyperglycaemic-drug-naive-patients2026-10-01 https://evidence-hub.com/study/17488-reader-response-association-of-prestroke-metformin-use-stroke2026-09-27 https://evidence-hub.com/study/17489-metformin-again-atheroprotection-mediated-by-macrophage-ampk-and-atf12026-10-01 https://evidence-hub.com/study/17494-comment-on-association-of-b12-deficiency-and-clinical-neuropathy-with2026-09-27 https://evidence-hub.com/study/17496-metformin-pioneering-a-path-forward-in-knee-osteoarthritis-care2026-10-01 https://evidence-hub.com/study/17497-safety-of-metformin-use-during-the-first-trimester2026-09-27 https://evidence-hub.com/study/17500-re-statistical-interpretation-error-in-metformin-trial-article2026-09-27 https://evidence-hub.com/study/17502-expanding-the-evidence-for-managing-metformin-poisoning-to-support2026-09-30 https://evidence-hub.com/study/17504-impact-of-diabetes-and-metformin-use-on-prostate-cancer2026-09-27 https://evidence-hub.com/study/17505-re-reduced-risk-of-lung-cancer-with-metformin-therapy-in-diabetic2026-09-27 https://evidence-hub.com/study/17508-an-oncologist-s-perspective-on-metformin-use-and-acute-lymphoblastic2026-10-01 https://evidence-hub.com/study/17511-review-metformin-does-not-increase-risk-for-lactic-acidosis-in-type-22026-09-27 https://evidence-hub.com/study/17512-comment-on-xu-et-al-effects-of-metformin-on-metabolite-profiles-and2026-09-27 https://evidence-hub.com/study/17513-a-pharmacist-s-perspective-on-metformin-use-and-cancer-outcomes2026-09-27 https://evidence-hub.com/study/17519-reply-metformin-in-therapy-naive-patients-with-polycystic-ovary2026-10-06 https://evidence-hub.com/study/17521-editorial-emerging-horizons-of-metformin-exploring-recent-advances2026-10-01 https://evidence-hub.com/study/17524-comment-on-suissa-and-azoulay-metformin-and-the-risk-of-cancer-time2026-10-01 https://evidence-hub.com/study/17525-commentary-metformin-use-is-associated-with-reduced-gastric-cancer2026-09-27 https://evidence-hub.com/study/17527-re-effect-of-metformin-and-rosiglitazone-in-a-prepubertal-boy-with2026-09-27 https://evidence-hub.com/study/17528-metformin-reduced-diabetes-related-end-points-and-all-cause-mortality2026-09-27 https://evidence-hub.com/study/17529-should-pharmacokinetic-safety-challenges-prevent-metformin-use-in2026-10-01 https://evidence-hub.com/study/17530-comment-on-nachum-et-al-glyburide-versus-metformin-and-their2026-09-27 https://evidence-hub.com/study/17531-comment-on-rowan-et-al-metformin-in-gestational-diabetes-the2026-10-01 https://evidence-hub.com/study/17537-in-type-2-diabetes-early-metformin-plus-vildagliptin-reduced2026-09-27 https://evidence-hub.com/study/17538-type-2-diabetes-patients-at-high-risk-for-cardiovascular-events-time2026-09-27 https://evidence-hub.com/study/17541-comment-on-the-pharmacokinetics-of-metformin-in-patients-receiving2026-10-01 https://evidence-hub.com/study/17543-response-to-diet-and-metformin-in-women-with-idiopathic-intracranial2026-09-27 https://evidence-hub.com/study/17548-commentary-metformin-use-is-associated-with-reduced-gastric-cancer2026-10-01 https://evidence-hub.com/study/17550-insulin-secretagogues-were-associated-with-increased-mortality2026-09-27 https://evidence-hub.com/study/17552-re-metformin-use-and-gastric-cancer-risk-in-diabetic-patients-after2026-10-01 https://evidence-hub.com/study/17553-comment-on-genuth-should-sulfonylureas-remain-an-acceptable-first2026-09-27 https://evidence-hub.com/study/17554-adding-metformin-to-insulin-did-not-improve-a-composite-of2026-09-27 https://evidence-hub.com/study/17556-targeting-renal-glucose-reabsorption-to-treat-hyperglycaemia-the2026-10-06 https://evidence-hub.com/study/17557-implications-of-the-empa-reg-trial-for-clinical-care-and-research2026-09-29 https://evidence-hub.com/study/17558-therapeutic-advances-in-diabetic-kidney-disease-30-years-of-evidence2026-10-06 https://evidence-hub.com/study/17559-empa-reg-outcome-the-endocrinologist-s-point-of-view2026-09-29 https://evidence-hub.com/study/17560-36th-international-symposium-on-intensive-care-and-emergency-medicine2026-10-08 https://evidence-hub.com/study/17561-cardiovascular-protection-with-anti-hyperglycemic-agents2026-10-08 https://evidence-hub.com/study/17562-blood-pressure-reduction-in-diabetes-lessons-from-accord-sprint-and2026-09-29 https://evidence-hub.com/study/17563-effects-of-reducing-blood-pressure-on-renal-outcomes-in-patients-with2026-10-01 https://evidence-hub.com/study/17564-sglt2-inhibition-and-cardiovascular-events-why-did-empa-reg-outcomes2026-10-01 https://evidence-hub.com/study/17565-mitigating-cardiovascular-risk-in-type-2-diabetes-with-antidiabetes2026-10-01 https://evidence-hub.com/study/17566-reappraisal-of-the-diuretic-effect-of-empagliflozin-in-the-empa-reg2026-09-29 https://evidence-hub.com/study/17567-renal-physiology-of-glucose-handling-and-therapeutic-implications2026-10-06 https://evidence-hub.com/study/17568-renoprotective-effects-of-sodium-glucose-cotransporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/17569-direct-cardiovascular-impact-of-sglt2-inhibitors-mechanisms-and2026-10-06 https://evidence-hub.com/study/17570-a-comparison-of-individuals-with-diabetes-and-empa-reg-trial2026-10-06 https://evidence-hub.com/study/17571-new-antihyperglycemic-drugs-and-heart-failure-synopsis-of-basic-and2026-10-06 https://evidence-hub.com/study/17572-cardiovascular-and-renal-protection-of-patients-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/17573-mechanisms-of-protective-effects-of-sglt2-inhibitors-in2026-10-06 https://evidence-hub.com/study/17574-which-is-the-main-molecular-target-responsible-for-the-cardiovascular2026-09-29 https://evidence-hub.com/study/17575-closing-the-knowledge-gap-on-cardiovascular-disease-in-type-22026-10-06 https://evidence-hub.com/study/17576-cardiovascular-and-renal-outcomes-of-newer-anti-diabetic-medications2026-10-06 https://evidence-hub.com/study/17577-sglt2-inhibitors-and-cardiovascular-outcomes-do-they-differ-or-there2026-10-01 https://evidence-hub.com/study/17578-combination-of-empagliflozin-and-metformin-therapy-a-consideration-of2026-10-04 https://evidence-hub.com/study/17579-oral-glucose-lowering-drugs-and-cardiovascular-outcomes-from-the2026-10-06 https://evidence-hub.com/study/17580-cardiovascular-outcomes-and-safety-with-antidiabetic-drugs2026-10-06 https://evidence-hub.com/study/17581-minireview-are-sglt2-inhibitors-heart-savers-in-diabetes2026-10-06 https://evidence-hub.com/study/17582-mechanisms-linking-empagliflozin-to-cardiovascular-and-renal2026-10-06 https://evidence-hub.com/study/17583-cardio-renal-protection-with-empagliflozin2026-10-06 https://evidence-hub.com/study/17584-potential-mechanisms-responsible-for-cardioprotective-effects-of2026-10-06 https://evidence-hub.com/study/17585-outcome-studies-on-sglt-2-inhibitors2026-10-06 https://evidence-hub.com/study/17586-sodium-glucose-co-transporter-2-inhibitors-and-heart-failure2026-10-06 https://evidence-hub.com/study/17587-finerenone-and-empagliflozin-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/17588-empa-reg-and-other-cardiovascular-outcome-trials-of-glucose-lowering2026-10-01 https://evidence-hub.com/study/17589-multi-organ-protective-effects-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/17590-use-of-diuretics-and-outcomes-in-patients-with-type-2-diabetes2026-10-01 https://evidence-hub.com/study/17591-spotlight-on-antidiabetic-agents-with-cardiovascular-or2026-10-06 https://evidence-hub.com/study/17592-cardiovascular-outcomes-trial-data-from-empa-reg-outcome-carolina-and2026-10-06 https://evidence-hub.com/study/17593-diabetes-and-cardiovascular-disease-from-new-mechanisms-to-new2026-10-06 https://evidence-hub.com/study/17594-glucose-lowering-therapy-in-type-2-diabetes-new-hope-after-the-empa2026-10-06 https://evidence-hub.com/study/17595-sodium-glucose-cotransporter-2-sglt2-inhibitors-and-cardiovascular2026-10-06 https://evidence-hub.com/study/17596-updates-in-pharmacotherapy-of-heart-failure-with-reduced-ejection2026-10-06 https://evidence-hub.com/study/17597-sodium-glucose-cotransporter-2-inhibitors-mechanisms-of-action-in2026-10-06 https://evidence-hub.com/study/17598-a-story-of-serendipities-from-phlorizin-to-gliflozins2026-10-06 https://evidence-hub.com/study/17599-effect-of-empagliflozin-on-total-myocardial-infarction-events-by-type2026-10-06 https://evidence-hub.com/study/17600-cardiovascular-protection-by-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/17601-cardiovascular-effects-of-new-oral-glucose-lowering-agents-dpp-4-and2026-10-06 https://evidence-hub.com/study/17602-impact-of-empagliflozin-on-first-and-recurrent-events-leading-to-or2026-10-06 https://evidence-hub.com/study/17603-mediators-of-the-improvement-in-heart-failure-outcomes-with2026-10-01 https://evidence-hub.com/study/17604-effects-of-empagliflozin-on-insulin-initiation-or-intensification-in2026-10-01 https://evidence-hub.com/study/17605-early-benefits-of-empagliflozin-in-patients-with-or-without-heart2026-10-01 https://evidence-hub.com/study/17606-cost-effectiveness-of-empagliflozin-in-the-uk-in-an-empa-reg-outcome2026-10-01 https://evidence-hub.com/study/17607-effect-of-empagliflozin-on-cardiorenal-outcomes-and-mortality2026-10-01 https://evidence-hub.com/study/17608-the-impact-of-empagliflozin-on-obstructive-sleep-apnea-and2026-10-01 https://evidence-hub.com/study/17609-relationship-between-hypoglycaemia-cardiovascular-outcomes-and2026-10-01 https://evidence-hub.com/study/17610-focus-on-empagliflozin-post-hoc-analyses-of-the-cardiovascular2026-10-06 https://evidence-hub.com/study/17611-empa-reg-outcome-the-nephrologist-s-point-of-view2026-09-29 https://evidence-hub.com/study/17612-cost-effectiveness-analysis-of-empagliflozin-treatment-in-people-with2026-10-01 https://evidence-hub.com/study/17613-an-exploration-of-the-heterogeneity-in-effects-of-sglt2-inhibition-on2026-10-01 https://evidence-hub.com/study/17614-estimating-the-number-of-preventable-cardiovascular-disease-events-in2026-10-06 https://evidence-hub.com/study/17615-empa-reg-outcome-trial-what-does-it-mean2026-10-06 https://evidence-hub.com/study/17616-can-the-cardiovascular-risk-reductions-observed-with-empagliflozin-in2026-10-01 https://evidence-hub.com/study/17617-cardiovascular-and-renal-protection-with-sglt2-inhibitors-from-empa2026-10-06 https://evidence-hub.com/study/17618-direct-effects-of-empagliflozin-on-extracellular-matrix-remodelling2026-09-29 https://evidence-hub.com/study/17619-vascular-legacy-hope-advances-to-empa-reg-and-leader-a-surprising2026-10-06 https://evidence-hub.com/study/17620-following-the-results-of-the-empa-reg-outcome-trial-with2026-10-01 https://evidence-hub.com/study/17621-cv-protection-in-the-empa-reg-outcome-trial-a-thrifty-substrate2026-10-01 https://evidence-hub.com/study/17622-economic-modelling-of-costs-associated-with-outcomes-reported-for2026-10-06 https://evidence-hub.com/study/17623-clinical-evidence-of-cardioprotective-effects-of-sglt2-inhibitors2026-10-06 https://evidence-hub.com/study/17624-correction-to-comparison-of-adipose-distribution-indices-with-gold2026-10-06 https://evidence-hub.com/study/17625-clinical-implications-of-cardiovascular-outcome-trials-in-type-22026-09-29 https://evidence-hub.com/study/17626-implications-of-acute-change-in-estimated-glomerular-filtration-rate2026-10-06 https://evidence-hub.com/study/17627-can-a-shift-in-fuel-energetics-explain-the-beneficial-cardiorenal2026-10-01 https://evidence-hub.com/study/17628-analysis-from-the-empa-reg-outcome-trial-indicates-empagliflozin-may2026-10-01 https://evidence-hub.com/study/17629-putting-empa-reg-into-practice-a-data-driven-intervention2026-10-06 https://evidence-hub.com/study/17630-resolution-of-an-online-meeting-of-the-volga-federal-district-experts2026-10-06 https://evidence-hub.com/study/17632-journey-from-empa-reg-to-carmelina-to-emperor-preserved-empagliflozin2026-10-06 https://evidence-hub.com/study/17635-response-to-comment-on-neeland-et-al-the-impact-of-empagliflozin-on2026-10-06 https://evidence-hub.com/study/17636-declare-timi-58-trial-in-the-context-of-empa-reg-outcome-and-canvas2026-10-01 https://evidence-hub.com/study/17637-28-or-how-early-after-treatment-initiation-are-the-cv-benefits-of2026-10-06 https://evidence-hub.com/study/17638-bladder-cancer-in-the-empa-reg-outcome-trial2026-10-01 https://evidence-hub.com/study/17640-cost-effectiveness-analysis-of-empagliflozin-in-the-treatment-of2026-10-01 https://evidence-hub.com/study/17643-319-or-effects-of-empagliflozin-on-markers-of-liver-steatosis-and2026-10-06 https://evidence-hub.com/study/17644-p2629early-benefits-of-empagliflozin-in-patients-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/17647-randomized-double-blind-placebo-controlled-parallel-group-prospective2026-09-29 https://evidence-hub.com/study/17648-effects-of-sglt-2-inhibitor-on-myocardial-perfusion-function-and2026-09-29 https://evidence-hub.com/study/17651-sglt2-inhibitors-through-the-windows-of-empa-reg-and-canvas-trials-a2026-10-01 https://evidence-hub.com/study/17652-the-empa-reg-study-what-has-it-told-us-a-diabetologist-s-perspective2026-10-01 https://evidence-hub.com/study/17656-comparison-of-adipose-distribution-indices-with-gold-standard-body2026-10-01 https://evidence-hub.com/study/17657-empa-reg-outcome-cardiovascular-outcome-trials-in-diabetes-come-of-age2026-09-29 https://evidence-hub.com/study/17658-diabetes-medications-with-cardiovascular-protection-in-the-wake-of2026-10-01 https://evidence-hub.com/study/17659-empa-reg-outcome-empagliflozin-reduces-mortality-in-patients-with2026-09-29 https://evidence-hub.com/study/17661-lower-limb-amputations-protection-with-glp-1-receptor-agonists-rather2026-10-06 https://evidence-hub.com/study/17662-could-metformin-modulate-cardiovascular-outcomes-differently-with-dpp2026-10-06 https://evidence-hub.com/study/17663-effects-of-sodium-glucose-cotransporter-type-2-inhibitors-on-heart2026-10-06 https://evidence-hub.com/study/17664-the-safety-outcomes-of-sodium-glucose-cotransporter-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/17665-surrogate-cardiovascular-outcomes-with-sodium-glucose-co-transporter2026-10-06 https://evidence-hub.com/study/17666-generalizability-of-sodium-glucose-co-transporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/17667-efficacy-of-sglt2-inhibitors-across-different-definitions-of-heart2026-10-06 https://evidence-hub.com/study/17668-kidney-outcomes-using-a-sustained-40-decline-in-egfr-a-meta-analysis2026-10-06 https://evidence-hub.com/study/17669-sglt2-inhibitors-and-kidney-outcomes-by-glomerular-filtration-rate2026-10-08 https://evidence-hub.com/study/17670-the-potential-of-precision-diabetology-for-type-2-diabetes-treatment2026-10-06 https://evidence-hub.com/study/17671-effects-of-sodium-glucose-cotransporter-2-inhibitors-by-diabetes2026-10-06 https://evidence-hub.com/study/17672-effect-of-sodium-glucose-cotransporter-2-inhibitors-on-all-cause2026-10-06 https://evidence-hub.com/study/17673-evidence-based-recommendations-for-the-use-of-continuous-glucose2026-10-06 https://evidence-hub.com/study/17674-absolute-treatment-effects-of-novel-antidiabetic-drugs-on-a-composite2026-10-06 https://evidence-hub.com/study/17675-sodium-glucose-cotransporter-2-inhibitors-and-major-adverse2026-10-06 https://evidence-hub.com/study/17676-cardioprotective-glucose-lowering-agents-and-dementia-risk-a2026-10-06 https://evidence-hub.com/study/17677-glucagon-like-peptide-1-receptor-agonists-for-prevention-of-heart2026-10-06 https://evidence-hub.com/study/17678-impact-of-sodium-glucose-cotransporter-2-inhibitors-in-patients-with2026-10-06 https://evidence-hub.com/study/17679-impact-of-sodium-glucose-co-transporter-2-inhibitors-on-renal2026-10-06 https://evidence-hub.com/study/17680-cardiovascular-and-renal-benefits-of-novel-diabetes-drugs-by-baseline2026-10-06 https://evidence-hub.com/study/17681-effect-of-pharmacological-selectivity-of-sglt2-inhibitors-on2026-10-06 https://evidence-hub.com/study/17682-potential-mediators-for-treatment-effects-of-novel-diabetes2026-10-06 https://evidence-hub.com/study/17683-absolute-treatment-effects-for-the-primary-outcome-and-all-cause2026-10-06 https://evidence-hub.com/study/17684-comparative-cardiovascular-effectiveness-of-glucagon-like-peptide-12026-10-06 https://evidence-hub.com/study/17685-ethnic-variations-in-cardiovascular-and-renal-outcomes-from-newer2026-10-06 https://evidence-hub.com/study/17686-influence-of-glucagon-like-peptide-1-receptor-agonists-on-renal2026-10-06 https://evidence-hub.com/study/17687-effect-of-sodium-glucose-cotransporter-2-inhibitors-on-the-rate-of2026-10-06 https://evidence-hub.com/study/17688-the-effect-of-sodium-glucose-cotransporter-2-inhibitors-in-patients2026-10-06 https://evidence-hub.com/study/17689-effects-of-sodium-glucose-cotransporter-2-inhibitors-in-patients-with2026-10-06 https://evidence-hub.com/study/17690-clinical-efficacy-of-sglt2-inhibitors-with-different-sglt1-sglt22026-10-06 https://evidence-hub.com/study/17691-early-initiation-of-sglt2-inhibitors-in-acute-myocardial-infarction2026-10-06 https://evidence-hub.com/study/17692-the-efficacy-and-safety-of-sglt2-inhibitors-in-diabetes-kidney2026-10-06 https://evidence-hub.com/study/17693-cardiovascular-therapy-benefits-of-novel-antidiabetic-drugs-in2026-10-06 https://evidence-hub.com/study/17694-meta-analysis-of-the-efficacy-and-safety-of-sglt-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/17695-assessing-the-benefit-risk-profile-of-newer-glucose-lowering-drugs-a2026-10-06 https://evidence-hub.com/study/17696-larger-effect-size-in-composite-kidney-outcomes-than-in-major2026-10-06 https://evidence-hub.com/study/17697-impact-of-diabetes-on-the-effects-of-sodium-glucose-co-transporter-22026-10-17 https://evidence-hub.com/study/17698-association-of-sodium-glucose-cotransporter-2-inhibitors-with2026-10-06 https://evidence-hub.com/study/17699-meta-analysed-numbers-needed-to-treat-of-novel-antidiabetic-drugs-for2026-10-06 https://evidence-hub.com/study/17700-association-of-sglt2-inhibitors-with-cardiovascular-and-kidney2026-10-06 https://evidence-hub.com/study/17701-sodium-glucose-cotransporter-2-inhibitor-for-renal-function2026-10-06 https://evidence-hub.com/study/17702-effect-of-sodium-glucose-cotransporter-2-inhibitors-on-blood-pressure2026-10-06 https://evidence-hub.com/study/17703-benefits-and-harms-of-sodium-glucose-co-transporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/17704-sodium-glucose-co-transporter-inhibitors-and-atrial-fibrillation-a2026-10-06 https://evidence-hub.com/study/17705-comparison-of-efficacy-and-safety-of-three-novel-hypoglycemic-agents2026-10-06 https://evidence-hub.com/study/17706-improvement-of-glycemic-control-and-reduction-of-major-cardiovascular2026-10-06 https://evidence-hub.com/study/17707-comparison-of-cardiovascular-outcomes-of-new-antihyperglycemic-agents2026-10-06 https://evidence-hub.com/study/17708-the-effect-of-dpp-4-inhibitors-glp-1-receptor-agonists-and-sglt-22026-10-06 https://evidence-hub.com/study/17709-association-of-sodium-glucose-cotransporter-2-inhibitors-with2026-10-06 https://evidence-hub.com/study/17710-effects-of-sglt2-inhibitors-on-cardiovascular-and-renal-outcomes-in2026-10-06 https://evidence-hub.com/study/17711-efficacy-of-antihyperglycemic-therapies-on-cardiovascular-and-heart2026-10-06 https://evidence-hub.com/study/17712-sodium-glucose-cotransporter-2-inhibitors-sglt2i-and-cardiac2026-10-06 https://evidence-hub.com/study/17713-characteristics-predicting-the-efficacy-of-sglt-2-inhibitors-versus2026-10-06 https://evidence-hub.com/study/17715-m18-three-year-cardiovascular-outcome-of-sglt-2-inhibitor-in-patient2026-10-06 https://evidence-hub.com/study/17716-m3-cardiovascular-outcome-of-sglt-2-inhibitor-in-patient-with-type-22026-10-06 https://evidence-hub.com/study/17717-the-association-between-baseline-insulin-treatment-and-cardiovascular2026-10-06 https://evidence-hub.com/study/17718-p20-a-comparison-of-the-cardiovascular-effects-of-empagliflozin-and2026-10-06 https://evidence-hub.com/study/17719-genito-urinary-infection-and-urinary-tract-infection-in-patients-with2026-10-08 https://evidence-hub.com/study/17720-evaluating-the-efficacy-of-sglt2-inhibitors-in-preventing-diabetic2026-10-06 https://evidence-hub.com/study/17721-1267-impact-of-diabetes-albuminuria-acute-egfr-dip-and-disease2026-10-06 https://evidence-hub.com/study/17722-is-it-effective-sglt2-inhibitors-for-every-af-patients2026-10-06 https://evidence-hub.com/study/17723-the-cost-effectiveness-of-empagliflozin-versus-liraglutide-treatment2026-10-06 https://evidence-hub.com/study/17726-p2482sex-based-differences-in-cardioprotective-role-of-sglt-22026-10-06 https://evidence-hub.com/study/17727-left-bundle-branch-area-pacing-versus-right-ventricular-pacing-in2026-10-06 https://evidence-hub.com/study/17728-risk-factors-for-the-development-of-knee-osteoarthritis-across-the2026-10-06 https://evidence-hub.com/study/17729-the-efficacy-of-reg-proteins-as-a-diagnostic-biomarker-for-pancreatic2026-10-06 https://evidence-hub.com/study/17730-validity-of-nutrition-screening-tools-for-risk-of-malnutrition-among2026-10-08 https://evidence-hub.com/study/17731-abstract-14849-lifetime-benefit-of-empagliflozin-in-extending2026-10-06 https://evidence-hub.com/study/17732-1128-p-empagliflozin-and-obstructive-sleep-apnea-osa-exploratory2026-10-06 https://evidence-hub.com/study/17733-10-year-level-trends-and-socio-demographic-disparities-of-obesity2026-10-06 https://evidence-hub.com/study/17734-abstract-14961-external-applicability-of-reduce-it-in-a-large2026-10-06 https://evidence-hub.com/study/17735-comparison-between-the-open-and-the-laparoscopic-approach-in-the2026-10-06 https://evidence-hub.com/study/17736-19-lb-consistent-cardiovascular-cv-benefits-from-empagliflozin-across2026-10-06 https://evidence-hub.com/study/17737-the-association-between-uric-acid-levels-and-cardiorenal-outcomes-and2026-10-06 https://evidence-hub.com/study/17738-the-influence-of-microvascular-disease-on-cardiovascular-events-in2026-10-06 https://evidence-hub.com/study/17739-the-association-between-polyvascular-disease-and-cardiovascular2026-10-06 https://evidence-hub.com/study/17740-empa-reg-outcome-eligibility-and-preventable-cardiovascular-events-in2026-10-06 https://evidence-hub.com/study/17741-reducing-self-stigma-in-psychosis-a-systematic-review-and-meta2026-10-06 https://evidence-hub.com/study/17742-the-impact-of-primary-headaches-on-disability-outcomes-a-literature2026-10-06 https://evidence-hub.com/study/17743-meta-analysis-shows-no-consistent-evidence-for-senescence-in2026-10-06 https://evidence-hub.com/study/17744-effects-of-intrauterine-exposure-to-sars-cov-2-on-infants-development2026-10-06 https://evidence-hub.com/study/17745-selective-internal-radiation-therapy-using-y-90-resin-microspheres2026-10-06 https://evidence-hub.com/study/17746-a-systematic-review-and-meta-analysis-of-90-cohort-studies-of-social2026-10-06 https://evidence-hub.com/study/17747-knowledge-attitudes-and-practice-of-dentists-on-minimal-intervention2026-10-06 https://evidence-hub.com/study/17748-comparison-of-the-electromyography-activity-during-exercises-with2026-10-06 https://evidence-hub.com/study/17749-maternal-age-is-related-to-offspring-dna-methylation-a-meta-analysis2026-10-08 https://evidence-hub.com/study/17750-comparison-of-seven-popular-structured-dietary-programmes-and-risk-of2026-10-06 https://evidence-hub.com/study/17751-global-prevalence-of-asymptomatic-dengue-infections-a-systematic2026-10-06 https://evidence-hub.com/study/17752-association-between-cannabis-use-and-symptom-dimensions-in2026-10-06 https://evidence-hub.com/study/17753-direct-16s-18s-rrna-gene-pcr-followed-by-sanger-sequencing-as-a2026-10-06 https://evidence-hub.com/study/17757-comparison-between-frail-and-non-frail-older-adults-gut-microbiota-a2026-10-06 https://evidence-hub.com/study/17758-seroprevalence-and-associated-risk-factors-of-ovine-neosporosis2026-10-06 https://evidence-hub.com/study/17759-association-between-sarcopenia-falls-and-cognitive-impairment-in2026-10-06 https://evidence-hub.com/study/17760-cardiovascular-effectiveness-and-safety-of-antidiabetic-drugs-in2026-10-06 https://evidence-hub.com/study/17761-role-and-mechanisms-of-sglt-2-inhibitors-in-the-treatment-of-diabetic2026-10-06 https://evidence-hub.com/study/17762-risk-of-hypovolemia-associated-with-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/17763-effect-of-sglt-2-inhibitors-on-prognosis-in-diabetic-patients-with2026-10-06 https://evidence-hub.com/study/17764-non-inferiority-and-clinical-superiority-of-glucagon-like-peptide-12026-10-06 https://evidence-hub.com/study/17765-cardiovascular-outcomes-in-patients-treated-with-sodium-glucose2026-10-06 https://evidence-hub.com/study/17766-cardiovascular-outcome-in-patients-treated-with-sglt2-inhibitors-for2026-10-06 https://evidence-hub.com/study/17767-the-effects-of-dapagliflozin-in-patients-with-heart-failure2026-10-06 https://evidence-hub.com/study/17768-heart-failure-protection-by-sglt2-inhibitors-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/17769-association-of-sodium-glucose-cotransporter-2-inhibitors-with2026-10-06 https://evidence-hub.com/study/17770-association-of-sodium-glucose-cotransporter-2-inhibitors-sglt2i-with2026-10-06 https://evidence-hub.com/study/17771-the-impacts-of-new-antidiabetic-drugs-on-the-risk-of-ischemic-and2026-10-06 https://evidence-hub.com/study/17772-sglt2-inhibitors-in-diabetic-patients-with-cardiovascular-disease-or2026-10-06 https://evidence-hub.com/study/17773-comparative-efficacy-of-once-weekly-semaglutide-versus-sglt-22026-10-06 https://evidence-hub.com/study/17774-clinical-benefit-of-sodium-glucose-transport-protein-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/17775-sglt-2-inhibitors-a-systematic-review-of-their-extra-glycaemic2026-10-06 https://evidence-hub.com/study/17776-diabetic-cardiomyopathy-distinct-clinical-entity-or-manifestation-of2026-10-06 https://evidence-hub.com/study/17777-clinical-implementation-of-artificial-intelligence-scribes-in-health2026-10-06 https://evidence-hub.com/study/17779-working-conditions-and-mental-health-of-migrants-and-refugees-in2026-10-06 https://evidence-hub.com/study/17780-maternal-emotional-and-behavioral-regulation-dysregulation-and2026-10-06 https://evidence-hub.com/study/17781-home-visiting-parenting-programs-to-improve-mother-infant2026-10-06 https://evidence-hub.com/study/17783-therapeutic-effect-of-dietary-ingredients-on-cellular-senescence-in2026-10-06 https://evidence-hub.com/study/17784-disease-burden-estimates-in-economic-evaluation-studies-of2026-10-06 https://evidence-hub.com/study/17785-leveraging-multisectoral-approach-to-understand-the-determinants-of2026-10-06 https://evidence-hub.com/study/17786-multifaceted-interventions-inclusive-of-medication-optimization-for2026-10-06 https://evidence-hub.com/study/17787-adherence-enhancing-interventions-for-pharmacological-and-oxygen2026-10-06 https://evidence-hub.com/study/17788-peer-support-interventions-in-patients-with-kidney-failure-a2026-10-06 https://evidence-hub.com/study/17789-incidence-of-guillain-barre-syndrome-in-the-world-between-1985-and2026-10-06 https://evidence-hub.com/study/17790-the-incidence-of-fractures-in-children-under-two-years-of-age-a2026-10-06 https://evidence-hub.com/study/17791-a-role-of-nlrp3-and-mmp9-in-migraine-progression-a-systematic-review2026-10-04 https://evidence-hub.com/study/17792-prevalence-of-metabolic-syndrome-and-associated-factors-in-primary2026-10-06 https://evidence-hub.com/study/17793-correlation-between-diabetes-prevalence-and-icu-hospital-stay-across2026-10-06 https://evidence-hub.com/study/17794-barriers-to-high-school-and-university-students-physical-activity-a2026-10-06 https://evidence-hub.com/study/17795-mediterranean-diet-for-primary-and-secondary-prevention-of2026-10-06 https://evidence-hub.com/study/17796-effectiveness-of-computer-based-interventions-for-community-dwelling2026-10-08 https://evidence-hub.com/study/17797-administrative-professionals-quality-of-life-in-educational2026-10-06 https://evidence-hub.com/study/17798-positive-psychological-well-being-and-clinical-characteristics-in-ibs2026-10-06 https://evidence-hub.com/study/17799-quality-of-life-after-bariatric-surgery-a-systematic-review2026-10-06 https://evidence-hub.com/study/17800-does-regular-engagement-with-arts-and-creative-activities-improve2026-10-06 https://evidence-hub.com/study/17801-disease-burden-estimates-in-economic-evaluation-studies-of2026-10-06 https://evidence-hub.com/study/17802-relationship-between-emotional-eating-consumption-of-hyperpalatable2026-10-06 https://evidence-hub.com/study/17803-identifying-nursing-home-residents-with-unmet-palliative-care-needs-a2026-10-06 https://evidence-hub.com/study/17805-the-effect-of-virtual-reality-on-cognitive-affective-and-psychomotor2026-10-06 https://evidence-hub.com/study/17806-probiotics-for-the-treatment-of-depression-and-anxiety-a-systematic2026-10-06 https://evidence-hub.com/study/17807-the-performance-of-large-language-models-in-dentomaxillofacial2026-10-06 https://evidence-hub.com/study/17808-the-prevalence-of-excessive-exercise-in-eating-disorders-a-systematic2026-10-13 https://evidence-hub.com/study/17809-effects-of-radiofrequency-electromagnetic-field-exposure-on-cancer-in2026-10-06 https://evidence-hub.com/study/17810-artificial-intelligence-assisted-capsule-endoscopy-versus2026-10-06 https://evidence-hub.com/study/17811-the-role-of-micrornas-in-modulating-sars-cov-2-infection-in-human2026-10-06 https://evidence-hub.com/study/17812-social-media-use-and-roles-of-self-objectification-self-compassion2026-10-06 https://evidence-hub.com/study/17813-the-results-and-the-meaning-of-empa-reg-outcome-and-leader-studies2026-10-06 https://evidence-hub.com/study/17814-3d-printed-hydroxyapatite-scaffolds-for-bone-tissue-engineering-a2026-10-06 https://evidence-hub.com/study/17815-chronotype-and-synchrony-effects-in-human-cognitive-performance-a2026-10-06 https://evidence-hub.com/study/17816-the-comparative-efficacy-and-safety-of-sweet-solutions-to-reduce2026-10-06 https://evidence-hub.com/study/17817-maternal-history-of-childhood-adversities-and-later-negative2026-10-06 https://evidence-hub.com/study/17818-intake-of-legumes-and-cardiovascular-disease-a-systematic-review-and2026-10-06 https://evidence-hub.com/study/17820-risk-factors-for-hiv-infection-among-adolescents-and-the-youth-a2026-10-06 https://evidence-hub.com/study/17822-types-prevalence-and-gender-differences-of-childhood-trauma-in-first2026-10-06 https://evidence-hub.com/study/17823-harnessing-artificial-intelligence-for-predicting-breast-cancer2026-10-06 https://evidence-hub.com/study/17824-cognitive-behavioral-therapy-for-managing-depressive-and-anxiety2026-10-06 https://evidence-hub.com/study/17825-vocabulary-interventions-for-children-with-developmental-language2026-10-06 https://evidence-hub.com/study/17826-adherence-enhancing-interventions-for-pharmacological-and-oxygen2026-10-06 https://evidence-hub.com/study/17827-towards-the-automation-of-systematic-reviews-using-natural-language2026-10-06 https://evidence-hub.com/study/17828-the-impact-of-weight-loss-interventions-on-disordered-eating-symptoms2026-10-06 https://evidence-hub.com/study/17829-effectiveness-of-photobiomodulation-therapy-in-radiation-dermatitis-a2026-10-06 https://evidence-hub.com/study/17830-axillary-pathologic-complete-response-after-neoadjuvant-systemic2026-10-06 https://evidence-hub.com/study/17831-multisystem-inflammatory-syndrome-mis-c-a-systematic-review-and-meta2026-10-06 https://evidence-hub.com/study/17832-the-prevalence-of-mental-health-conditions-among-high-school-and2026-10-06 https://evidence-hub.com/study/17833-effectiveness-of-complementary-therapies-for-the-management-of2026-10-06 https://evidence-hub.com/study/17835-interventions-to-prevent-potentially-avoidable-hospitalizations-a2026-10-06 https://evidence-hub.com/study/17836-perspectives-of-ozone-induced-neuropathology-and-memory-decline-in2026-10-06 https://evidence-hub.com/study/17837-impact-of-social-protection-programs-on-adults-diagnosed-with2026-10-06 https://evidence-hub.com/study/17838-imaging-of-cancer-of-unknown-primary-a-systematic-literature-review2026-10-06 https://evidence-hub.com/study/17839-empa-reg-outcome-trial-and-canagliflozin-cardiovascular-assessment2026-10-06 https://evidence-hub.com/study/17840-eligibility-of-outpatients-with-chronic-heart-failure-for-sodium2026-10-06 https://evidence-hub.com/study/17841-sotagliflozin-and-kidney-outcomes-kidney-function-and-albuminuria-in2026-10-06 https://evidence-hub.com/study/17842-empagliflozin-as-add-on-to-metformin-in-people-with-type-2-diabetes2026-10-04 https://evidence-hub.com/study/17843-why-do-sglt2-inhibitors-reduce-heart-failure-hospitalization-a2026-10-06 https://evidence-hub.com/study/17844-dapagliflozin-effects-on-haematocrit-red-blood-cell-count-and2026-10-06 https://evidence-hub.com/study/17845-are-the-cardiovascular-and-kidney-benefits-of-empagliflozin2026-10-06 https://evidence-hub.com/study/17846-research-into-the-effect-of-sglt2-inhibition-on-left-ventricular2026-10-06 https://evidence-hub.com/study/17847-rationale-and-design-of-a-multicenter-placebo-controlled-double-blind2026-10-06 https://evidence-hub.com/study/17848-rationale-design-and-baseline-characteristics-of-a-4-year-208-week2026-10-04 https://evidence-hub.com/study/17849-does-dapagliflozin-regress-left-ventricular-hypertrophy-in-patients2026-10-06 https://evidence-hub.com/study/17850-a-four-week-treatment-with-dapagliflozin-is-associated-with-a2026-10-06 https://evidence-hub.com/study/17851-effects-of-dapagliflozin-on-cardiovascular-outcomes-in-patients-with2026-10-06 https://evidence-hub.com/study/17852-dapagliflozin-does-not-impair-microvascular-hemorheology-in-type-22026-10-06 https://evidence-hub.com/study/17853-long-term-safety-and-efficacy-of-sglt2-inhibitor-use-in-older-east2026-10-06 https://evidence-hub.com/study/17854-effects-of-sglt2-inhibition-on-insulin-use-in-ckd-and-type-2-diabetes2026-10-06 https://evidence-hub.com/study/17855-is-gfr-decline-induced-by-sglt2-inhibitor-of-clinical-importance2026-10-06 https://evidence-hub.com/study/17856-effect-of-ertugliflozin-on-left-ventricular-function-in-type-22026-10-19 https://evidence-hub.com/study/17857-ertugliflozin-and-incident-obstructive-sleep-apnea-an-analysis-from2026-10-06 https://evidence-hub.com/study/17858-impact-of-changes-in-conventional-risk-factors-induced-by-once-weekly2026-10-06 https://evidence-hub.com/study/17859-effect-of-intensive-lifestyle-intervention-on-cardiovascular-risk2026-10-06 https://evidence-hub.com/study/17860-canagliflozin-reduces-oral-loop-diuretic-intensification-in-patients2026-10-06 https://evidence-hub.com/study/17861-unveiling-the-benefits-of-vitamin-d3-with-sglt-2-inhibitors-for2026-10-06 https://evidence-hub.com/study/17862-impact-of-dapagliflozin-treatment-on-renal-function-and-diuretics-use2026-10-06 https://evidence-hub.com/study/17863-dapagliflozin-reduces-systemic-inflammation-in-patients-with-type-22026-10-06 https://evidence-hub.com/study/17864-rate-and-risk-factors-of-kidney-function-decline-among-south-asians2026-10-06 https://evidence-hub.com/study/17865-development-of-a-novel-machine-learning-method-for-estimation-of-life2026-10-06 https://evidence-hub.com/study/17866-long-term-weight-loss-and-cardiorenal-outcomes-by-baseline-bmi-in-the2026-10-06 https://evidence-hub.com/study/17867-effect-of-sglt2-inhibitors-on-stroke-and-atrial-fibrillation-in2026-10-06 https://evidence-hub.com/study/17868-decline-in-estimated-glomerular-filtration-rate-after-dapagliflozin2026-10-06 https://evidence-hub.com/study/17869-effects-of-empagliflozin-on-myocardial-flow-reserve-in-patients-with2026-10-06 https://evidence-hub.com/study/17870-the-cost-effectiveness-of-dapagliflozin-in-treating-high-risk2026-10-06 https://evidence-hub.com/study/17871-empagliflozin-decreases-remnant-like-particle-cholesterol-in-type-22026-10-06 https://evidence-hub.com/study/17872-dapagliflozin-and-prevention-of-kidney-disease-among-patients-with2026-10-06 https://evidence-hub.com/study/17874-canagliflozin-and-stroke-in-type-2-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/17875-obstructive-sleep-apnoe-and-cardiovascular-heart-failure-and2026-10-06 https://evidence-hub.com/study/17877-empagliflozin-does-not-change-cardiac-index-nor-systemic-vascular2026-10-06 https://evidence-hub.com/study/17878-empagliflozin-leads-to-a-rapid-and-sustained-improvement-of-left2026-10-06 https://evidence-hub.com/study/17879-comparisons-of-sodium-glucose-cotransporter-2-inhibitors-induced2026-10-06 https://evidence-hub.com/study/17880-polycythemia-sglt2-inhibitors-and-associated-outcomes-across-the2026-10-06 https://evidence-hub.com/study/17881-individuals-with-chronic-kidney-disease-qualifying-for-sglt-22026-10-06 https://evidence-hub.com/study/17882-the-effects-and-the-mechanisms-of-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/17883-sodium-glucose-cotransporter-2-inhibitors-an-additional-management2026-10-06 https://evidence-hub.com/study/17885-an-age-of-sodium-glucose-cotransporter-2-inhibitor-priority-are-we2026-10-06 https://evidence-hub.com/study/17890-immune-and-metabolic-effects-of-african-heritage-diets-versus-western2026-10-13 https://evidence-hub.com/study/17891-effects-of-a-mat-pilates-based-exercise-program-for-low-back-pain-in2026-10-06 https://evidence-hub.com/study/17892-effect-of-a-seven-strain-probiotic-on-dietary-intake-inflammatory2026-10-06 https://evidence-hub.com/study/17893-effects-of-remote-exercise-on-physical-function-in-pre-frail-older2026-10-06 https://evidence-hub.com/study/17894-randomized-double-blind-placebo-pl-controlled-phase-iii-trial-of2026-10-06 https://evidence-hub.com/study/17895-open-label-randomized-controlled-crossover-trial-on-the-effect-of2026-10-13 https://evidence-hub.com/study/17896-efficacy-of-intra-articular-hypertonic-dextrose-prolotherapy-for-knee2026-10-06 https://evidence-hub.com/study/17897-abstract-14959-effect-of-empagliflozin-on-total-events-of-myocardial2026-10-06 https://evidence-hub.com/study/17898-effects-of-a-group-mindfulness-based-cognitive-programme-on2026-10-06 https://evidence-hub.com/study/17899-mindful-eating-for-reducing-emotional-eating-in-patients-with2026-10-06 https://evidence-hub.com/study/17900-abstract-14960-empagliflozin-reduces-the-total-burden-of2026-10-06 https://evidence-hub.com/study/17901-laparoscopic-magnetic-sphincter-augmentation-versus-double-dose2026-10-06 https://evidence-hub.com/study/17902-topical-imiquimod-compared-with-conization-to-treat-cervical-high2026-10-06 https://evidence-hub.com/study/17903-dynamic-interactive-social-cognition-training-in-virtual-reality2026-10-06 https://evidence-hub.com/study/17905-effects-of-transcranial-direct-current-stimulation-on-knee2026-10-06 https://evidence-hub.com/study/17907-improvements-in-liver-enzymes-with-empagliflozin-in-the-empa-reg2026-10-06 https://evidence-hub.com/study/17908-increased-physical-activity-reduces-sleep-disturbances-in-asthma-a2026-10-06 https://evidence-hub.com/study/17909-improving-lung-function-in-severe-heterogenous-emphysema-with-the2026-10-06 https://evidence-hub.com/study/17910-843-the-palm-consortium-a-multicenter-multioutbreak-randomized2026-10-06 https://evidence-hub.com/study/17911-the-impact-of-an-exercise-program-on-quality-of-life-in-older-breast2026-10-06 https://evidence-hub.com/study/17913-a-pilot-feasibility-randomized-controlled-trial-on-combining-mind2026-10-06 https://evidence-hub.com/study/17914-the-effect-of-early-treatment-with-ivermectin-on-viral-load-symptoms2026-10-06 https://evidence-hub.com/study/17915-reboot-online-a-randomized-controlled-trial-comparing-an-online2026-10-06 https://evidence-hub.com/study/17916-is-only-one-cognitive-technique-also-effective-results-from-a2026-10-06 https://evidence-hub.com/study/17918-effects-of-improved-water-sanitation-and-hygiene-and-improved2026-10-06 https://evidence-hub.com/study/17919-randomized-controlled-trial-of-a-4-week-mindfulness-intervention2026-10-06 https://evidence-hub.com/study/17920-the-sarcopenia-and-physical-frailty-in-older-people-multi-component2026-10-06 https://evidence-hub.com/study/17921-rasagiline-for-amyotrophic-lateral-sclerosis-a-randomized-controlled2026-10-06 https://evidence-hub.com/study/17922-effect-of-a-glucagon-receptor-antibody-remd-477-in-type-1-diabetes-a2026-10-06 https://evidence-hub.com/study/17923-cannabidiol-for-covid-19-patients-with-mild-to-moderate-symptoms2026-10-06 https://evidence-hub.com/study/17924-design-recruitment-and-baseline-characteristics-of-the-empa-kidney2026-10-06 https://evidence-hub.com/study/17925-design-and-rationale-of-the-empa-vision-trial-investigating-the2026-10-06 https://evidence-hub.com/study/17926-effect-of-dapagliflozin-on-the-initial-estimated-glomerular2026-10-06 https://evidence-hub.com/study/17927-rationale-design-and-baseline-characteristics-of-the-effect-of2026-10-06 https://evidence-hub.com/study/17928-design-of-a-randomised-controlled-trial-of-the-effects-of2026-10-06 https://evidence-hub.com/study/17929-investigating-the-roles-of-hyperglycaemia-hyperinsulinaemia-and2026-10-06 https://evidence-hub.com/study/17930-initial-egfr-changes-with-ertugliflozin-and-associations-with2026-10-06 https://evidence-hub.com/study/17931-evaluation-of-the-effect-of-sodium-glucose-co-transporter-22026-10-06 https://evidence-hub.com/study/17932-the-effect-of-luseogliflozin-and-alpha-glucosidase-inhibitor-on-heart2026-10-06 https://evidence-hub.com/study/17933-a-trial-to-evaluate-the-effect-of-the-sodium-glucose-co-transporter-22026-10-12 https://evidence-hub.com/study/17934-effects-of-the-dual-sodium-glucose-linked-transporter-inhibitor2026-10-06 https://evidence-hub.com/study/17935-empagliflozin-as-adjunct-to-insulin-in-japanese-participants-with2026-10-06 https://evidence-hub.com/study/17936-change-in-albuminuria-and-gfr-slope-as-joint-surrogate-end-points-for2026-10-06 https://evidence-hub.com/study/17937-sodium-glucose-co-transporter-2-inhibition-in-patients-hospitalized2026-10-06 https://evidence-hub.com/study/17938-impact-of-empagliflozin-on-subclinical-left-ventricular-dysfunctions2026-10-06 https://evidence-hub.com/study/17939-efficacy-and-safety-of-canagliflozin-as-add-on-therapy-to-a-glucagon2026-10-06 https://evidence-hub.com/study/17940-effects-of-switching-from-a-dipeptidyl-peptidase-4-inhibitor-to2026-10-06 https://evidence-hub.com/study/17941-dapagliflozin-reduces-uric-acid-concentration-an-independent2026-10-06 https://evidence-hub.com/study/17942-rationale-and-design-of-an-investigator-initiated-multicenter2026-10-06 https://evidence-hub.com/study/17943-dapagliflozin-versus-saxagliptin-as-add-on-therapy-in-patients-with2026-10-08 https://evidence-hub.com/study/17944-impact-of-dapagliflozin-on-left-ventricular-diastolic-function-of2026-10-06 https://evidence-hub.com/study/17945-microvascular-and-cardiovascular-outcomes-according-to-renal-function2026-10-06 https://evidence-hub.com/study/17946-safety-of-liraglutide-in-type-2-diabetes-and-chronic-kidney-disease2026-10-06 https://evidence-hub.com/study/17947-basal-insulin-secretion-capacity-predicts-the-initial-response-and2026-10-06 https://evidence-hub.com/study/17948-factors-affecting-canagliflozin-induced-transient-urine-volume2026-10-06 https://evidence-hub.com/study/17949-efficacy-and-safety-of-canagliflozin-in-patients-with-type-2-diabetes2026-10-06 https://evidence-hub.com/study/17950-effects-of-canagliflozin-a-sodium-glucose-co-transporter-2-inhibitor2026-10-06 https://evidence-hub.com/study/17951-renal-effects-of-a-sodium-glucose-cotransporter-2-inhibitor2026-10-06 https://evidence-hub.com/study/17952-efficacy-and-safety-of-ipragliflozin-and-metformin-for-visceral-fat2026-10-06 https://evidence-hub.com/study/17953-sglt-2-inhibition-with-dapagliflozin-reduces-tissue-sodium-content-a2026-10-06 https://evidence-hub.com/study/17954-effect-of-2-clinical-decision-support-strategies-on-chronic-kidney2026-10-06 https://evidence-hub.com/study/17955-effects-of-the-sglt2-inhibitor-dapagliflozin-on-hdl-cholesterol2026-10-06 https://evidence-hub.com/study/17956-luseogliflozin-reduces-epicardial-fat-accumulation-in-patients-with2026-10-06 https://evidence-hub.com/study/17957-improved-home-bp-profile-with-dapagliflozin-is-associated-with2026-10-06 https://evidence-hub.com/study/17958-pharmacokinetic-and-pharmacodynamic-profile-of-the-sodium-glucose-co2026-10-06 https://evidence-hub.com/study/17959-effects-of-baseline-blood-pressure-and-low-density-lipoprotein2026-10-06 https://evidence-hub.com/study/17960-rationale-design-and-baseline-characteristics-of-the-cardiovascular2026-10-06 https://evidence-hub.com/study/17961-leader-4-blood-pressure-control-in-patients-with-type-2-diabetes-and2026-10-06 https://evidence-hub.com/study/17962-efficacy-and-safety-of-monotherapy-with-the-novel-sodium-glucose2026-10-06 https://evidence-hub.com/study/17964-248-or-empagliflozin-and-cardiorenal-outcomes-in-patients-with2026-10-06 https://evidence-hub.com/study/17965-the-interim-experts-council-resolution-on-the-empa-reg-outcome-trial2026-10-06 https://evidence-hub.com/study/17967-bmi-variability-and-cardiovascular-outcomes-within-clinical-trial-and2026-10-06 https://evidence-hub.com/study/17969-1-effect-of-empagliflozin-on-cardiovascular-death-in-subgroups-by-age2026-10-06 https://evidence-hub.com/study/17970-relevance-of-positive-cardiovascular-outcome-trial-results-in2026-10-06 https://evidence-hub.com/study/17971-sodium-glucose-cotransporter-2-inhibition-in-heart-failure-potential2026-10-06 https://evidence-hub.com/study/17972-empagliflozin-and-heart-failure-position-paper-of-the-experts-on-the2026-10-06 https://evidence-hub.com/study/17973-transposition-of-cardiovascular-outcome-trial-effects-to-the-real2026-10-06 https://evidence-hub.com/study/17974-sodium-glucose-co-transporter-2-inhibitors-and-cardiovascular-event2026-10-06 https://evidence-hub.com/study/17975-the-empagliflozin-comparative-effectiveness-and-safety-emprise-study2026-10-06 https://evidence-hub.com/study/17976-continued-efforts-to-translate-diabetes-cardiovascular-outcome-trials2026-10-06 https://evidence-hub.com/study/17977-using-the-bravo-risk-engine-to-predict-cardiovascular-outcomes-in2026-10-06 https://evidence-hub.com/study/17978-time-constant-absolute-effect-measures-for-time-to-event-outcomes2026-10-06 https://evidence-hub.com/study/17980-sglt2-inhibitors-cardiovascular-and-renoprotective-outcomes-in-type-22026-10-06 https://evidence-hub.com/study/17981-clinical-influence-of-sodium-glucose-cotransporter-2-sglt2-inhibitors2026-10-06 https://evidence-hub.com/study/17982-translating-recent-results-from-the-cardiovascular-outcomes-trials2026-10-06 https://evidence-hub.com/study/17983-increased-hematocrit-during-sodium-glucose-cotransporter-2-inhibitor2026-10-06 https://evidence-hub.com/study/17984-sodium-glucose-co-transporter-2-sglt2-inhibitors-comparing-trial-and2026-10-06 https://evidence-hub.com/study/17985-clinical-relevance-of-recent-outcome-trials-with-antidiabetic-drugs2026-10-06 https://evidence-hub.com/study/17986-class-effects-of-sglt2-inhibitors-on-cardiorenal-outcomes2026-10-06 https://evidence-hub.com/study/17988-use-of-empagliflozin-as-an-adjuvant-treatment-for-obstructive-sleep2026-10-06 https://evidence-hub.com/study/17989-gliflozins-from-antidiabetic-drugs-to-cornerstone-in-heart-failure2026-10-06 https://evidence-hub.com/study/17990-population-diversity-of-cardiovascular-outcome-trials-and-real-world2026-10-06 https://evidence-hub.com/study/17994-sodium-glucose-cotransporter-2-inhibitors-are-potential-therapeutic2026-10-06 https://evidence-hub.com/study/17995-prediction-of-the-effects-of-empagliflozin-on-cardiovascular-and2026-10-06 https://evidence-hub.com/study/17996-abstract-332-racial-differences-in-prescribing-of-sodium-glucose2026-10-06 https://evidence-hub.com/study/17998-focusing-on-sodium-glucose-cotransporter-2-and-the-sympathetic2026-10-06 https://evidence-hub.com/study/18000-sodium-glucose-co-transporter-2-inhibitors-in-severe-estimated2026-10-06 https://evidence-hub.com/study/18001-dapagliflozin-as-an-adjunct-to-insulin-improves-glycemic-control2026-10-06 https://evidence-hub.com/study/18002-cardiorenal-protection-in-type-2-diabetes-a-systematic-review2026-10-06 https://evidence-hub.com/study/18003-effects-of-sglt2-inhibitors-across-the-spectrum-of-albuminuria-in2026-10-06 https://evidence-hub.com/study/18004-sweet-relief-exploring-mechanisms-and-therapeutic-approaches-of2026-10-06 https://evidence-hub.com/study/18005-clinical-effects-of-sodium-glucose-cotransporter-2-inhibitors2026-10-06 https://evidence-hub.com/study/18006-sodium-glucose-cotransporter-2-inhibitors-and-acute-kidney-injury2026-10-06 https://evidence-hub.com/study/18007-hitting-the-sweet-spot-a-review-of-sglt2i-in-cardiovascular-medicine2026-10-06 https://evidence-hub.com/study/18008-diabetes-mellitus-and-chronic-kidney-disease-the-future-is-being2026-10-06 https://evidence-hub.com/study/18009-novel-cardiometabolic-medications-in-the-cardiovascular-kidney2026-10-06 https://evidence-hub.com/study/18010-real-world-risk-factors-and-clinical-implications-of-early-estimated2026-10-06 https://evidence-hub.com/study/18011-sodium-glucose-cotransporter-2-inhibitors-and-arrhythmias-a-meta2026-10-06 https://evidence-hub.com/study/18012-beyond-glycemic-control-roles-for-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/18013-sodium-glucose-cotransporter-2-inhibitors-in-diabetic-kidney-disease2026-10-06 https://evidence-hub.com/study/18014-risk-management-of-cardiovascular-disease-in-older-patients-with2026-10-06 https://evidence-hub.com/study/18015-sodium-glucose-cotransporter-2-inhibitors-in-diabetes-and-beyond2026-10-06 https://evidence-hub.com/study/18016-expanding-the-use-of-sglt2-inhibitors-in-t2d-patients-across-clinical2026-10-06 https://evidence-hub.com/study/18017-effect-of-sglt2-inhibitors-on-atrial-fibrillation-in-patients-with2026-10-06 https://evidence-hub.com/study/18018-impact-of-sodium-glucose-transport-protein-2-sglt2-inhibitors-on-the2026-10-06 https://evidence-hub.com/study/18019-a-comparison-of-sglt2-or-dpp-4-inhibitor-monotherapy-vs-placebo-for2026-10-06 https://evidence-hub.com/study/18020-plausible-prediction-of-renoprotective-effects-of-sodium-glucose2026-10-06 https://evidence-hub.com/study/18021-effect-of-empagliflozin-on-whole-body-cardiac-and-renal-sympathetic2026-10-06 https://evidence-hub.com/study/18022-how-to-enhance-cardiorenal-benefits-in-patients-with-chronic-heart2026-10-06 https://evidence-hub.com/study/18023-a-systematic-review-and-meta-analysis-of-sodium-glucose-cotransporter2026-10-06 https://evidence-hub.com/study/18024-the-role-of-sglt2-inhibitors-across-all-stages-of-heart-failure-and2026-10-06 https://evidence-hub.com/study/18025-from-evidence-to-action-advancing-timely-implementation-of-triple2026-10-06 https://evidence-hub.com/study/18026-diabetic-kidney-disease-from-pathophysiology-to-regression-of2026-10-06 https://evidence-hub.com/study/18027-real-world-kidney-and-glycaemic-outcomes-following-semaglutide2026-10-06 https://evidence-hub.com/study/18028-cardiovascular-outcomes-and-safety-assessment-of-sglt2i-on-heart2026-10-06 https://evidence-hub.com/study/18029-challenges-and-opportunities-in-the-management-of-type-2-diabetes-in2026-10-06 https://evidence-hub.com/study/18030-sglt2-inhibitors-and-glp-1-receptor-agonists-in-pad-a-state-of-the2026-10-06 https://evidence-hub.com/study/18031-obesity-and-heart-failure-introducing-the-theme2026-10-06 https://evidence-hub.com/study/18032-triple-therapy-of-ras-inhibitors-dapagliflozin-and-finerenone-in2026-10-06 https://evidence-hub.com/study/18033-nephroprotective-mechanisms-of-sglt2i-beyond-the-glucose-lowering2026-10-06 https://evidence-hub.com/study/18034-the-role-of-sodium-glucose-co-transporter-2-inhibitors-in-frail-older2026-10-06 https://evidence-hub.com/study/18035-sodium-glucose-co-transporter-2-inhibitors-and-cardiovascular-event2026-10-06 https://evidence-hub.com/study/18036-metabolic-inflammation-as-a-common-thread-in-cardio-endocrine2026-10-06 https://evidence-hub.com/study/18037-drug-development-in-pediatric-chronic-kidney-disease-a-review-of2026-10-06 https://evidence-hub.com/study/18038-unveiling-the-podocyte-protective-effect-of-sodium-glucose2026-10-06 https://evidence-hub.com/study/18039-sodium-glucose-co-transporter-2-inhibitors-sglt2i-for-pediatric2026-10-06 https://evidence-hub.com/study/18040-comprehensive-review-of-sglt2-inhibitors-efficacy-through-their2026-10-06 https://evidence-hub.com/study/18041-modern-antidiabetic-therapy-by-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/18042-impact-of-sglt-2-inhibitors-on-biomarkers-of-heart-failure2026-10-06 https://evidence-hub.com/study/18043-effect-of-sglt2-inhibitors-on-heart-failure-outcomes-in-patients-with2026-10-06 https://evidence-hub.com/study/18045-the-impact-of-psychosocial-safety-climate-on-the-intervention-effect2026-10-06 https://evidence-hub.com/study/18046-structured-nurse-led-picu-liberation-bundle-abcdef-discussion-during2026-10-06 https://evidence-hub.com/study/18048-the-palliative-care-needs-of-patients-with-multiple-sclerosis2026-10-06 https://evidence-hub.com/study/18049-deeprna-reg-a-deep-learning-based-approach-for-comparative-analysis2026-10-06 https://evidence-hub.com/study/18050-microbiology-testing-capacity-and-antimicrobial-drug-resistance-in2026-10-06 https://evidence-hub.com/study/18051-series-cardiovascular-outcome-trials-for-diabetes-drugs-empagliflozin2026-10-06 https://evidence-hub.com/study/18052-lb005kidney-implications-of-the-initial-egfr-response-to-sglt22026-10-06 https://evidence-hub.com/study/18053-effect-of-sotagliflozin-on-major-adverse-cardiovascular-events-a2026-10-13 https://evidence-hub.com/study/18054-1144-p-patient-phenotypes-and-sglt2-inhibition-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/18055-impact-of-polyvascular-disease-and-renal-dysfunction-on2026-10-06 https://evidence-hub.com/study/18056-empagliflozin-is-associated-with-a-lower-risk-of-post-acute-heart2026-10-06 https://evidence-hub.com/study/18057-1225-p-the-association-between-long-term-glucose-variability-gv2026-10-06 https://evidence-hub.com/study/18059-development-of-a-clinical-prediction-rule-for-treatment-success-with2026-10-06 https://evidence-hub.com/study/18060-tranexamic-acid-for-the-prevention-of-blood-loss-after-cesarean-among2026-10-06 https://evidence-hub.com/study/18061-tranexamic-acid-for-the-prevention-of-blood-loss-after-cesarean-among2026-10-06 https://evidence-hub.com/study/18062-sedation-and-ventilator-weaning-bundle-and-time-to-extubation-in2026-10-13 https://evidence-hub.com/study/18063-comparison-of-urinary-incontinence-based-on-pelvic-floor-and2026-10-06 https://evidence-hub.com/study/18064-associations-between-nighttime-or-weekend-deliveries-and-adverse2026-10-06 https://evidence-hub.com/study/18065-a-restrictive-versus-a-liberal-transfusion-strategy-in-patients-with2026-10-06 https://evidence-hub.com/study/18066-ibudilast-attenuates-the-association-between-pain-intensity-and-heavy2026-10-06 https://evidence-hub.com/study/18067-general-vs-nongeneral-anesthesia-for-endovascular-thrombectomy-in2026-10-06 https://evidence-hub.com/study/18068-clinical-psychosocial-and-structural-factors-associated-with-the2026-10-06 https://evidence-hub.com/study/18069-acupuncture-improves-functional-limitations-for-cancer-patients-with2026-10-06 https://evidence-hub.com/study/18071-1418-phase-ii-dose-selection-randomised-controlled-trial-of-asi-bi2026-10-06 https://evidence-hub.com/study/18072-the-relevance-of-geriatric-assessments-on-the-association-between2026-10-06 https://evidence-hub.com/study/18073-effects-of-neck-exercise-and-health-promotion-on-headache-outcomes-in2026-10-06 https://evidence-hub.com/study/18074-159-lb-relationship-between-hypoglycaemia-hypo-outcomes-and2026-10-06 https://evidence-hub.com/study/18075-measuring-reliable-internet-connectivity-among-families-with-children2026-10-06 https://evidence-hub.com/study/18076-results-and-outcome-reporting-in-clinicaltrials-gov-what-makes-it2026-10-06 https://evidence-hub.com/study/18077-weight-gain-stopping-switch-rules-for-antiretroviral-clinical-trials2026-10-06 https://evidence-hub.com/study/18078-leukotriene-receptor-antagonists-and-5-lipoxygenase-inhibitors-in2026-10-06 https://evidence-hub.com/study/18079-new-possibilities-in-clinical-use-of-angiotensin-ii-receptor2026-10-06 https://evidence-hub.com/study/18080-angiotensin-converting-enzyme-inhibition-in-myocardial-infarction2026-10-06 https://evidence-hub.com/study/18081-effect-of-psychoprophylaxis-lamaze-preparation-on-labor-and-delivery2026-10-06 https://evidence-hub.com/study/18082-cerebral-complications-of-hypertension-in-the-elderly2026-10-06 https://evidence-hub.com/study/18083-lack-of-symptomatic-and-long-term-hemodynamic-effects-of-prazosin-in2026-10-06 https://evidence-hub.com/study/18084-the-efficacy-of-sotalol-in-suppressing-ventricular-ectopic-beats2026-10-06 https://evidence-hub.com/study/18085-methodology-of-clinical-studies-dealing-with-the-treatment-of2026-10-06 https://evidence-hub.com/study/18086-non-peptidic-prenyltransferase-inhibitors-diverse-structural-classes2026-10-06 https://evidence-hub.com/study/18087-application-of-epothilones-in-breast-cancer-therapy2026-10-06 https://evidence-hub.com/study/18088-the-efficacy-of-intranasal-antihistamines-in-the-treatment-of2026-10-06 https://evidence-hub.com/study/18089-use-of-propranolol-to-control-rate-pressure-product-during-cardiac2026-10-06 https://evidence-hub.com/study/18090-an-analysis-of-the-role-of-ige-in-intolerance-to-aspirin-and2026-10-06 https://evidence-hub.com/study/18091-the-clinical-development-of-mupirocin2026-10-06 https://evidence-hub.com/study/18092-graphing-and-reporting-heterogeneous-treatment-effects-through2026-10-06 https://evidence-hub.com/study/18093-therapy-of-left-ventricular-dysfunction-implications-of-recent2026-10-06 https://evidence-hub.com/study/18094-antihypertensive-drugs-adverse-reactions-and-metabolic-effects-in2026-10-06 https://evidence-hub.com/study/18095-design-and-endpoints-of-clinical-trials-in-hepatocellular-carcinoma2026-10-01 https://evidence-hub.com/study/18096-statistical-considerations-in-clinical-trial-design-of2026-10-06 https://evidence-hub.com/study/18097-a-lay-patient-navigation-training-curriculum-targeting-disparities-in2026-10-06 https://evidence-hub.com/study/18098-rabies-specific-igm-and-igg-antibody-response-in-persons-immunized2026-10-06 https://evidence-hub.com/study/18099-metastatic-melanoma-scientific-rationale-for-sorafenib-treatment-and2026-10-06 https://evidence-hub.com/study/18100-distribution-of-postpartum-blood-loss-modeling-estimation-and2026-10-06 https://evidence-hub.com/study/18101-structure-based-design-of-11-hsd1-inhibitors2026-10-06 https://evidence-hub.com/study/18102-global-landscape-analysis-of-antibody-drug-conjugate-clinical-trials2026-10-06 https://evidence-hub.com/study/18103-clinical-trial-experience-around-the-globe-focus-on-calcium-channel2026-10-06 https://evidence-hub.com/study/18104-interferons-in-the-treatment-of-genital-human-papillomavirus2026-10-06 https://evidence-hub.com/study/18105-prospective-evaluation-of-patients-with-early-intermediate-stage2026-10-06 https://evidence-hub.com/study/18106-biomarkers-in-t-cell-therapy-clinical-trials2026-10-06 https://evidence-hub.com/study/18107-annual-bleeding-rates-pitfalls-of-clinical-trial-outcomes-in2026-10-06 https://evidence-hub.com/study/18108-comparative-effects-of-lipid-lowering-therapies2026-10-06 https://evidence-hub.com/study/18109-difficult-laryngoscopy-incidence-and-predictors-in-patients2026-10-06 https://evidence-hub.com/study/18110-review-recent-clinical-trials-in-epigenetic-therapy2026-10-06 https://evidence-hub.com/study/18111-sequential-conditional-probability-ratio-tests-for-normalized-test2026-10-06 https://evidence-hub.com/study/18112-drug-development-eu-paediatric-legislation-the-european-medicines2026-10-06 https://evidence-hub.com/study/18113-optimal-promising-zone-designs2026-10-06 https://evidence-hub.com/study/18114-single-dose-amoxycillin-in-the-treatment-of-bacteriuria-in-pregnancy2026-10-06 https://evidence-hub.com/study/18115-novel-strategies-for-the-treatment-of-covid-192026-10-06 https://evidence-hub.com/study/18116-ranking-the-efficacy-of-drugs-a-question-of-class-it-is-difficult-to2026-10-06 https://evidence-hub.com/study/18117-hi3-3-a-model-assisted-dose-finding-design-borrowing-historical-data2026-10-06 https://evidence-hub.com/study/18118-how-and-why-study-designs-affect-the-nature-and-validity-of-study2026-10-06 https://evidence-hub.com/study/18119-validity-and-reliability-of-the-nyha-classes-for-measuring-research2026-10-06 https://evidence-hub.com/study/18120-clinical-performance-and-utility-a-microsimulation-model-to-inform2026-10-06 https://evidence-hub.com/study/18121-tirbanibulin-1-ointment-clinical-trial-and-real-world-evidence-on2026-10-06 https://evidence-hub.com/study/18122-antiangiogenic-agents-for-the-treatment-of-glioblastoma2026-10-06 https://evidence-hub.com/study/18123-factors-influencing-participation-of-psychiatry-inpatients-in2026-10-06 https://evidence-hub.com/study/18124-safety-of-antileukotriene-agents-in-asthma-management2026-10-06 https://evidence-hub.com/study/18125-powerful-short-cuts-for-multiple-testing-procedures-with-special2026-10-06 https://evidence-hub.com/study/18126-controlling-false-discovery-proportion-in-identification-of-drug2026-10-06 https://evidence-hub.com/study/18127-novel-combinations-in-the-treatment-of-hypertension2026-10-06 https://evidence-hub.com/study/18128-principles-of-dose-finding-studies-in-cancer-a-comparison-of-trial2026-10-06 https://evidence-hub.com/study/18129-ethical-assessment-of-clinical-asthma-trials-including-children2026-10-06 https://evidence-hub.com/study/18130-dual-topoisomerase-i-ii-inhibitors-in-cancer-therapy2026-10-06 https://evidence-hub.com/study/18131-treatment-of-risk-factors-to-prevent-stroke2026-10-06 https://evidence-hub.com/study/18132-nitrosoureas-a-reappraisal-of-clinical-trials2026-10-06 https://evidence-hub.com/study/18133-diazabicyclooctanes-dbos-a-potent-new-class-of-non-lactam-lactamase2026-10-06 https://evidence-hub.com/study/18134-the-clinical-trial-landscape-in-oncology-and-connectivity-of-somatic2026-10-06 https://evidence-hub.com/study/18135-omapatrilat-for-the-management-of-heart-failure-and-hypertension2026-10-06 https://evidence-hub.com/study/18136-an-update-on-dapagliflozin-for-chronic-kidney-disease2026-10-06 https://evidence-hub.com/study/18137-which-drug-should-be-used-to-treat-patients-with-uncomplicated2026-10-06 https://evidence-hub.com/study/18138-characteristics-of-ongoing-clinical-trials-of-psychogenic-substances2026-10-06 https://evidence-hub.com/study/18139-efficacy-and-indications-of-ursodeoxycholic-acid-treatment-for2026-10-06 https://evidence-hub.com/study/18140-description-of-subgroup-reporting-in-clinical-trials-of-chronic2026-10-06 https://evidence-hub.com/study/18141-use-of-pseudomonas-immunoglobulin-in-ventilated-patients-at-an2026-10-06 https://evidence-hub.com/study/18142-selection-of-patients-with-melanoma-brain-metastases-for-aggressive2026-10-06 https://evidence-hub.com/study/18143-a-review-of-statistical-designs-for-improving-the-efficiency-of-phase2026-10-06 https://evidence-hub.com/study/18144-glycoprotein-iib-iiia-platelet-receptor-inhibitors-a-new-dimension-in2026-10-06 https://evidence-hub.com/study/18145-geographical-randomization-and-social-exploitation-in-clinical2026-10-06 https://evidence-hub.com/study/18146-role-of-glycoprotein-iib-iiia-inhibitors-in-the-management-of-acute2026-10-06 https://evidence-hub.com/study/18147-developing-antitussives-the-ideal-clinical-trial2026-10-06 https://evidence-hub.com/study/18148-future-directions-in-lipid-therapies2026-10-06 https://evidence-hub.com/study/18149-a-systematic-review-of-in-hospital-worsening-heart-failure-as-an2026-10-06 https://evidence-hub.com/study/18150-the-two-sample-problem-with-induced-dependent-censorship2026-10-06 https://evidence-hub.com/study/18151-use-of-pseudomonas-immunoglobulin-in-artificially-respirated-patients2026-10-06 https://evidence-hub.com/study/18152-lessons-from-antiarrhythmic-trials-involving-class-iii-antiarrhythmic2026-10-06 https://evidence-hub.com/study/18153-composite-endpoints-including-patient-reported-outcomes-in-rare2026-10-06 https://evidence-hub.com/study/18154-what-can-post-market-registries-tell-us-about-the-use-of-cardiac2026-10-06 https://evidence-hub.com/study/18155-effects-of-isoptin-and-obsidan-on-the-coronary-blood-flow-and-tactics2026-10-06 https://evidence-hub.com/study/18156-measures-of-clinical-malaria-in-field-trials-of-interventions-against2026-10-06 https://evidence-hub.com/study/18157-cluster-randomised-trials2026-10-06 https://evidence-hub.com/study/18158-arterial-hypertension-and-stroke-prevention-an-update2026-10-06 https://evidence-hub.com/study/18159-recruitment-of-childhood-leukaemia-patients-to-clinical-trials-in2026-10-06 https://evidence-hub.com/study/18160-sample-sizes-based-on-the-log-rank-statistic-in-complex-clinical2026-10-06 https://evidence-hub.com/study/18161-enalapril-an-update-of-its-pharmacological-properties-and-therapeutic2026-10-06 https://evidence-hub.com/study/18162-indole-therapeutics-latest-fda-updates-ongoing-trials-and-future2026-10-06 https://evidence-hub.com/study/18163-a-framework-for-standardising-toxicity-management-guidelines-in2026-10-06 https://evidence-hub.com/study/18164-new-vinca-alkaloids-and-related-compounds2026-10-06 https://evidence-hub.com/study/18165-a-hierarchical-testing-approach-for-detecting-safety-signals-in2026-10-06 https://evidence-hub.com/study/18166-can-pregnancy-be-a-placebo-effect-terminology-designs-and-conclusions2026-10-06 https://evidence-hub.com/study/18167-treatment-of-patients-with-exercise-induced-angina-pectoris-with2026-10-06 https://evidence-hub.com/study/18168-antimitochondrial-agents-a-new-class-of-anticancer-agents2026-10-06 https://evidence-hub.com/study/18169-design-and-study-similarities-and-contrasts-the-veterans2026-10-06 https://evidence-hub.com/study/18170-prognostic-factors-influencing-cisplatin-induced-emesis-definition2026-10-06 https://evidence-hub.com/study/18171-pharmacology-of-aging-and-cancer-how-useful-are-pharmacokinetic-tests2026-10-06 https://evidence-hub.com/study/18172-the-ketogenic-diet-update-on-recent-clinical-trials2026-10-06 https://evidence-hub.com/study/18173-therapeutic-drug-monitoring-in-pregnant-patients2026-10-06 https://evidence-hub.com/study/18174-computer-simulation-of-a-clinical-trial-as-an-aid-to-teaching-the2026-10-06 https://evidence-hub.com/study/18175-effect-of-closed-loop-stimulation-versus-accelerometer-on-outcomes2026-10-06 https://evidence-hub.com/study/18176-strength-training-intervention-with-creatine-whey-protein2026-10-06 https://evidence-hub.com/study/18177-bioplastic-food-packaging-and-the-young-women-s-exposome-body-burden2026-10-06 https://evidence-hub.com/study/18178-prospective-evaluation-of-a-deep-learning-model-for-classifying2026-10-06 https://evidence-hub.com/study/18179-dualattentionnet-a-lightweight-dual-attention-framework-for-robust2026-10-06 https://evidence-hub.com/study/18180-short-term-antiproteinuric-effects-of-disease-modifying-therapies-for2026-10-06 https://evidence-hub.com/study/18181-ai-enhanced-case-based-learning-for-clinical-reasoning-in2026-10-06 https://evidence-hub.com/study/18182-history-structured-forecasting-of-rewarded-give-up-behavior-in-a2026-10-06 https://evidence-hub.com/study/18183-escalate-or-switch-treating-the-post-titration-glp-1-non-responder-a2026-10-06 https://evidence-hub.com/study/18184-in-a-sham-controlled-at-home-study-sleeping-on-a-temperature2026-10-06 https://evidence-hub.com/study/18185-cost-effectiveness-of-ivonescimab-plus-chemotherapy-versus2026-10-06 https://evidence-hub.com/study/18186-synergistic-interactions-of-midlife-multimorbidity-on-dementia-a2026-10-06 https://evidence-hub.com/study/18187-acute-neurophysiological-effects-of-transcutaneous-auricular-vagus2026-10-06 https://evidence-hub.com/study/18188-physiotherapy-educational-intervention-for-occipital-positional2026-10-06 https://evidence-hub.com/study/18189-merit-mechanism-driven-model-predicts-drug-outcomes-and-nominates2026-10-06 https://evidence-hub.com/study/18190-sacubitril-valsartan-versus-valsartan-in-elderly-patients-with-acute2026-10-06 https://evidence-hub.com/study/18191-initial-biomechanical-response-to-different-attachment-configurations2026-10-06 https://evidence-hub.com/study/18192-impact-of-flipped-classroom-combined-with-mini-cex-formative2026-10-06 https://evidence-hub.com/study/18193-evaluation-and-demonstration-of-a-new-tuberculosis-diagnostic-tool2026-10-06 https://evidence-hub.com/study/18194-integrating-basic-science-teachers-and-clinicians-in-problem-based2026-10-06 https://evidence-hub.com/study/18195-a-context-conditional-audit-of-trial-pairing-dependent-neural-gain-in2026-10-06 https://evidence-hub.com/study/18196-ileal-bile-acid-transporter-inhibitors-in-paediatric-cholestatic2026-10-06 https://evidence-hub.com/study/18197-preload-versus-co-load-of-ringer-s-lactate-to-prevent-hypotension2026-10-06 https://evidence-hub.com/study/18198-triptans-and-lasmiditan-are-safe-and-effective-in-patients-with2026-10-06 https://evidence-hub.com/study/18199-postbiotics-in-psychiatry-can-microbial-metabolites-replace-live2026-10-06 https://evidence-hub.com/study/18200-clinical-and-microbiological-outcomes-of-implant-supported-hybrid2026-10-06 https://evidence-hub.com/study/18201-enhancing-guideline-directed-medical-therapy-at-discharge-through2026-10-06 https://evidence-hub.com/study/18202-the-magnitude-of-early-hepatitis-b-rna-and-dna-declines-directly2026-10-06 https://evidence-hub.com/study/18203-mobile-phone-use-digital-engagement-patterns-and-neurofunctional2026-10-06 https://evidence-hub.com/study/18204-a-stochastic-physiology-based-digital-twin-model-of-hemostasis-and2026-10-06 https://evidence-hub.com/study/18205-colchicine-as-a-repurposed-nlrp3-inflammasome-inhibitor-in2026-10-06 https://evidence-hub.com/study/18206-behavioural-insights-for-public-health-engagement-a-four-arm-school2026-10-06 https://evidence-hub.com/study/18207-pharmacokinetic-study-of-sal0140-tablets-in-patients-with-varying2026-10-06 https://evidence-hub.com/study/18208-a-school-based-behavioural-change-intervention-study-protocol-for2026-10-06 https://evidence-hub.com/study/18209-subject-calibrated-attention-state-classification-during-digital2026-10-06 https://evidence-hub.com/study/18210-target-trial-emulation-for-a-two-arm-parallel-stratified-pragmatic2026-10-06 https://evidence-hub.com/study/18211-ilico-study-safety-and-effectiveness-assessment-of-icover-balloon2026-10-06 https://evidence-hub.com/study/18212-effect-of-tango-versus-exercise-on-chemotherapy-induced-neuropathy2026-10-06 https://evidence-hub.com/study/18213-analysis-of-personality-traits-and-feedback-on-video-based-flipped2026-10-06 https://evidence-hub.com/study/18214-supervised-contrastive-learning-based-digital-biomarker-discovery-for2026-10-06 https://evidence-hub.com/study/18215-the-impact-of-vr-sketching-simulations-on-the-assessment-of-scale-and2026-10-06 https://evidence-hub.com/study/18216-effect-of-functional-movement-screen-informed-corrective-training-on2026-10-06 https://evidence-hub.com/study/18217-conduction-system-pacing-vs-biventricular-pacing-for-cardiac2026-10-06 https://evidence-hub.com/study/18218-talking-with-the-book-not-just-at-children-a-cluster-randomized-trial2026-10-06 https://evidence-hub.com/study/18219-effectiveness-of-rmssd-based-adaptive-music-therapy-skitii-in2026-10-06 https://evidence-hub.com/study/18220-differential-cortical-effects-of-synaptic-versus-extrasynaptic-gabaa2026-10-06 https://evidence-hub.com/study/18221-sociodemographic-predictors-of-consent-a-protocol-and-statistical2026-10-06 https://evidence-hub.com/study/18222-toward-uncertainty-aware-clinical-decision-support-for-treatment2026-10-06 https://evidence-hub.com/study/18223-use-of-tacrolimus-and-voclosporin-as-induction-therapy-in-lupus2026-10-06 https://evidence-hub.com/study/18224-impact-of-subgroup-classificuation-accuracy-on-detecting2026-10-06 https://evidence-hub.com/study/18225-dual-mechanism-benefits-of-mixed-reality-in-motor-imagery-bcis2026-10-06 https://evidence-hub.com/study/18226-machine-learning-versus-self-supervised-transfer-learning-for-30-day2026-10-06 https://evidence-hub.com/study/18227-scalable-mqtt-based-communication-architecture-for-distributed2026-10-06 https://evidence-hub.com/study/18228-automating-clinical-trial-outcome-identification-and-misreporting2026-10-06 https://evidence-hub.com/study/18229-artificial-intelligence-for-icu-mortality-prediction-comparative2026-10-06 https://evidence-hub.com/study/18230-reducing-placebo-response-in-clinical-trials-of-agitation-in2026-10-06 https://evidence-hub.com/study/18231-glucagon-like-peptide-1-receptor-agonists-in-the-real-world-are2026-10-06 https://evidence-hub.com/study/18232-effect-of-respiratory-phenotype-on-extrapulmonary-organ-dysfunction2026-10-06 https://evidence-hub.com/study/18233-maxilla-vs-mandible-a-multi-dimensional-risk-scoring-system-for2026-10-06 https://evidence-hub.com/study/18234-association-between-behavioral-phenotypes-and-paid-subscription-and2026-10-06 https://evidence-hub.com/study/18235-clinical-evaluation-of-marginal-integrity-of-tempered-and-non2026-10-06 https://evidence-hub.com/study/18236-breaking-penalty-plateaus-with-quantum-inspired-improved-particle2026-10-06 https://evidence-hub.com/study/18237-development-and-preliminary-evaluation-of-a-cdio-based2026-10-06 https://evidence-hub.com/study/18238-multi-ancestry-mhc-pqtl-mapping-reveals-disease-linked-hla-protein2026-10-06 https://evidence-hub.com/study/18239-vaccine-adjuvants-recapitulate-the-early-innate-response-to-live2026-10-06 https://evidence-hub.com/study/18240-endogenous-incretin-secretagogue-compositions-as-a-mechanistic-class2026-10-06 https://evidence-hub.com/study/18241-active-voxel-selection-for-small-sample-fmri-decoding-dataset2026-10-06 https://evidence-hub.com/study/18242-characterizing-tuberculosis-medication-side-effects-using-video2026-10-06 https://evidence-hub.com/study/18243-causally-inspired-meta-representation-learning-framework-for2026-10-06 https://evidence-hub.com/study/18244-identifying-risk-factors-for-adverse-cancer-related-fatigue2026-10-06 https://evidence-hub.com/study/18245-cost-effectiveness-of-seizure-detection-devices-for-high-risk-night2026-10-06 https://evidence-hub.com/study/18246-efficacy-and-safety-of-cardiac-rehabilitation-augmented-with-whole2026-10-06 https://evidence-hub.com/study/18247-clinical-performance-of-a-universal-adhesive-applied-with-different2026-10-06 https://evidence-hub.com/study/18248-development-and-validation-of-a-machine-learning-model-integrating2026-10-06 https://evidence-hub.com/study/18249-personalised-approach-to-hypertension-treatment-rationale-and-design2026-10-06 https://evidence-hub.com/study/18250-identifying-high-need-patient-profiles-that-respond-to-intensive-care2026-10-06 https://evidence-hub.com/study/18251-regimen-stratified-bayesian-model-based-meta-analysis-of-targeted2026-10-06 https://evidence-hub.com/study/18252-application-of-a-medication-adherence-management-program-based-on-the2026-10-06 https://evidence-hub.com/study/18253-identification-of-collagen-features-predictive-of-recurrence2026-10-06 https://evidence-hub.com/study/18254-lessons-from-the-beat-trial-implications-for-inhaled-treprostinil2026-10-06 https://evidence-hub.com/study/18255-multimodal-wearable-system-for-objective-assessment-of-dynamic2026-10-06 https://evidence-hub.com/study/18256-amyloid-beta-targeting-monoclonal-antibodies-in-early-alzheimer-s2026-10-06 https://evidence-hub.com/study/18257-peroxisome-proliferator-activated-receptor-in-liver-disease2026-10-06 https://evidence-hub.com/study/18258-shift-qa-target-calibrated-accept-or-review-quality-assurance-for2026-10-06 https://evidence-hub.com/study/18259-more-rapid-influenza-virus-elimination-on-baloxavir-versus2026-10-06 https://evidence-hub.com/study/18260-analgesic-equivalence-of-nsaids-and-a-weak-opioid-in-acute2026-10-06 https://evidence-hub.com/study/18261-three-dimensional-echocardiography-derived-right-atrioventricular2026-10-06 https://evidence-hub.com/study/18262-efficacy-and-safety-of-henagliflozin-in-chinese-adults-with-type-22026-10-06 https://evidence-hub.com/study/18263-a-latent-profiles-analysis-of-feminist-identity-among-clinical-nurses2026-10-06 https://evidence-hub.com/study/18264-cross-response-to-cgrp-monoclonal-antibodies-in-a-real-world-setting2026-10-06 https://evidence-hub.com/study/18265-interpretable-machine-learning-predicts-hepatic-fat-response-to-a2026-10-06 https://evidence-hub.com/study/18266-threats-to-validity-of-the-pesto-perispinal-etanercept-stroke-trial-a2026-10-06 https://evidence-hub.com/study/18267-polygenic-and-familial-contributions-to-antidepressant-continuation2026-10-06 https://evidence-hub.com/study/18268-do-all-individuals-with-type-2-diabetes-mellitus-prefer2026-10-06 https://evidence-hub.com/study/18269-longitudinal-response-patterns-to-a-combined-motor-cognitive2026-10-06 https://evidence-hub.com/study/18270-t-cell-engagers-targeting-bcma-gprc5d-or-fcrh5-in-relapsed-refractory2026-10-06 https://evidence-hub.com/study/18271-aficamten-reduces-eligibility-for-septal-reduction-therapy-in2026-10-06 https://evidence-hub.com/study/18272-dose-finding-experimental-medicine-evaluation-of-sodium-valproate-for2026-10-06 https://evidence-hub.com/study/18274-treatment-of-advanced-gastrointestinal-cancer-with-genetically2026-10-01 https://evidence-hub.com/study/18276-semaglutide-in-hfpef-across-obesity-class-and-by-body-weight2026-10-01 https://evidence-hub.com/study/18277-endoscopic-sleeve-gastroplasty-for-treatment-of-class-1-and-2-obesity2026-09-27 https://evidence-hub.com/study/18278-cost-effectiveness-of-ultrasound-guided-foam-sclerotherapy-endovenous2026-10-01 https://evidence-hub.com/study/18280-ai-tutoring-outperforms-in-class-active-learning-an-rct-introducing-a2026-10-06 https://evidence-hub.com/study/18281-gastrointestinal-toxicity-with-celecoxib-vs-nonsteroidal-anti2026-10-16 https://evidence-hub.com/study/18283-effect-of-laparoscopic-vs-open-distal-gastrectomy-on-3-year-disease2026-10-06 https://evidence-hub.com/study/18284-dapagliflozin-and-new-york-heart-association-functional-class-in2026-10-06 https://evidence-hub.com/study/18286-nbtxr3-a-first-in-class-radioenhancer-hafnium-oxide-nanoparticle-plus2026-10-01 https://evidence-hub.com/study/18287-fostering-holistic-development-with-a-designed-multisport2026-10-06 https://evidence-hub.com/study/18288-phase-3-trial-of-sotatercept-for-treatment-of-pulmonary-arterial2026-10-06 https://evidence-hub.com/study/18289-systemic-interferon-increases-mhc-class-i-expression-and-t-cell2026-10-01 https://evidence-hub.com/study/18290-pulsed-field-ablation-for-the-treatment-of-atrial-fibrillation-pulsed2026-10-06 https://evidence-hub.com/study/18295-the-master-observational-trial-a-new-class-of-master-protocol-to2026-10-06 https://evidence-hub.com/study/18296-a-phase-ib-ii-trial-of-the-first-in-class-anti-cxcr4-antibody2026-10-06 https://evidence-hub.com/study/18297-effect-of-blood-pressure-lowering-and-antihypertensive-drug-class-on2026-09-27 https://evidence-hub.com/study/18298-abstract-ct141-phase-1-trial-of-mov18-a-first-in-class-ige-antibody2026-10-06 https://evidence-hub.com/study/18300-glucagon-like-peptide-1-class-drugs-show-clear-protective-effects-in2026-10-06 https://evidence-hub.com/study/18301-first-in-human-first-in-class-phase-i-trial-of-the-anti-cd47-antibody2026-10-01 https://evidence-hub.com/study/18302-identifying-clinical-subtypes-in-sepsis-survivors-with-different-one2026-10-06 https://evidence-hub.com/study/18303-randomized-trial-of-left-bundle-branch-vs-biventricular-pacing-for2026-10-06 https://evidence-hub.com/study/18304-mavacamten-for-treatment-of-symptomatic-obstructive-hypertrophic2026-10-01 https://evidence-hub.com/study/18305-diagnosis-and-treatment-protocol-for-novel-coronavirus-pneumonia2026-10-06 https://evidence-hub.com/study/18306-early-class-iii-protraction-facemask-treatment-reduces-the-need-for2026-10-01 https://evidence-hub.com/study/18308-percutaneous-gastrostomy-device-for-the-treatment-of-class-ii-and2026-10-19 https://evidence-hub.com/study/18309-ablation-versus-drug-therapy-for-atrial-fibrillation-in-heart-failure2026-10-06 https://evidence-hub.com/study/18310-haemodynamic-guided-management-of-heart-failure-guide-hf-a-randomised2026-10-06 https://evidence-hub.com/study/18312-refining-adjuvant-treatment-in-endometrial-cancer-based-on-molecular2026-10-06 https://evidence-hub.com/study/18314-a-randomized-placebo-controlled-trial-of-natalizumab-for-relapsing2026-10-13 https://evidence-hub.com/study/18315-efficacy-of-telemedical-interventional-management-in-patients-with2026-10-06 https://evidence-hub.com/study/18319-individualised-cognitive-functional-therapy-compared-with-a-combined2026-10-06 https://evidence-hub.com/study/18320-efficacy-and-safety-of-dapagliflozin-according-to-frailty-in-patients2026-10-06 https://evidence-hub.com/study/18321-dapagliflozin-for-heart-failure-according-to-body-mass-index-the2026-10-06 https://evidence-hub.com/study/18324-cognitive-training-for-children-with-adhd-a-randomized-controlled2026-10-06 https://evidence-hub.com/study/18325-class-wide-function-related-intervention-teams-cw-fit-efficacy-trial2026-10-06 https://evidence-hub.com/study/18327-randomized-trial-of-metoprolol-in-patients-with-obstructive2026-10-06 https://evidence-hub.com/study/18329-talimogene-laherparepvec-moving-from-first-in-class-to-best-in-class2026-10-06 https://evidence-hub.com/study/18330-phase-2-trial-of-rituximab-in-acetylcholine-receptor-antibody2026-10-06 https://evidence-hub.com/study/18332-talimogene-laherparepvec-first-in-class-oncolytic-virotherapy2026-10-06 https://evidence-hub.com/study/18335-results-of-the-predictors-of-response-to-crt-prospect-trial2026-10-01 https://evidence-hub.com/study/18336-proof-of-concept-clinical-trial-of-etokimab-shows-a-key-role-for-il2026-10-06 https://evidence-hub.com/study/18337-latent-class-analysis-of-ards-subphenotypes-a-secondary-analysis-of2026-10-06 https://evidence-hub.com/study/18338-a-randomized-trial-of-the-angiotensin-receptor-blocker-valsartan-in2026-10-01 https://evidence-hub.com/study/18340-interpretable-deep-neural-networks-for-single-trial-eeg-classification2026-10-06 https://evidence-hub.com/study/18341-a-randomized-controlled-trial-to-evaluate-the-safety-and-efficacy-of2026-10-13 https://evidence-hub.com/study/18344-clinical-trials-progression-speed-differentiating-features-and2026-10-01 https://evidence-hub.com/study/18347-long-term-follow-up-results-of-a-randomized-drug-abuse-prevention2026-09-27 https://evidence-hub.com/study/18351-combined-cardiac-resynchronization-and-implantable-cardioversion2026-09-27 https://evidence-hub.com/study/18356-a-randomized-controlled-trial-of-the-use-of-pulmonary-artery2026-10-01 https://evidence-hub.com/study/18359-exon-skipping-a-first-in-class-strategy-for-duchenne-muscular2026-10-06 https://evidence-hub.com/study/18364-discovery-and-clinical-introduction-of-first-in-class-imipridone2026-10-06 https://evidence-hub.com/study/18366-how-attention-influences-perceptual-decision-making-single-trial-eeg2026-10-06 https://evidence-hub.com/study/18367-treatment-of-class-iii-multiple-gingival-recessions-a-randomized2026-09-27 https://evidence-hub.com/study/18369-testing-the-mechanism-of-action-of-computerized-cognitive-training-in2026-09-27 https://evidence-hub.com/study/18370-the-clinical-trial-of-difference-between-formaderm-lidocaine-and2026-09-27 https://evidence-hub.com/study/18371-three-dimensional-bone-regeneration-using-custom-made-meshes-with-and2026-09-27 https://evidence-hub.com/study/18372-proof-of-concept-study-of-alendronate-for-asthma2026-09-27 https://evidence-hub.com/study/18373-a-randomized-controlled-trial-of-bronchodilator-delivery-by-vibrating2026-09-27 https://evidence-hub.com/study/18374-feasibility-study-of-early-outpatient-review-and-early-cardiac2026-09-27 https://evidence-hub.com/study/18375-a-phase-ii-iii-multicenter-partially-randomized-open-label-trial2026-09-27 https://evidence-hub.com/study/18376-a-randomized-double-blind-placebo-controlled-prospective-multicenter2026-09-27 https://evidence-hub.com/study/18377-effectiveness-and-uptake-of-a-transdiagnostic-emotion-regulation2026-09-27 https://evidence-hub.com/study/18378-community-partnered-medical-nutrition-intervention-for-native2026-09-27 https://evidence-hub.com/study/18379-an-exploratory-double-blind-randomized-vehicle-controlled-paired2026-09-27 https://evidence-hub.com/study/18380-effects-of-dhea-in-pulmonary-hypertension2026-09-27 https://evidence-hub.com/study/18381-phase-1-open-label-dose-escalation-trial-of-intracoronary-infusion-of2026-09-27 https://evidence-hub.com/study/18382-a-randomized-phase-ii-study-for-tertiary-prevention-of-squamocellular2026-09-27 https://evidence-hub.com/study/18383-evaluation-of-the-accuracy-of-full-digital-workflow-for-guided2026-09-27 https://evidence-hub.com/study/18384-pilot-study-to-evaluate-the-anti-tumor-effect-of-durvalumab-medi47362026-09-27 https://evidence-hub.com/study/18385-mindfulness-and-cardiometabolic-health-for-spanish-speaking-latina2026-09-27 https://evidence-hub.com/study/18386-effects-of-ongoing-movement-based-mindfulness-training-for-children2026-09-27 https://evidence-hub.com/study/18387-a-randomized-double-blind-placebo-controlled-phase-1-clinical-trial2026-09-27 https://evidence-hub.com/study/18388-a-multidimensional-health-perspective-analysis-of-the-effects-of-yoga2026-09-27 https://evidence-hub.com/study/18389-a-dose-ranging-trial-of-mart-1-gp100-tyrosinase-ny-eso-1-peptide2026-09-27 https://evidence-hub.com/study/18390-online-or-face-to-face-treatment-for-insomnia-a-wait-list-controlled2026-09-27 https://evidence-hub.com/study/18391-the-impact-of-virtual-reality-on-pain-perception-and-patients2026-09-27 https://evidence-hub.com/study/18392-a-randomized-trial-of-thyroxine-therapy-for-subclinical2026-09-27 https://evidence-hub.com/study/18393-effects-of-exergame-and-gross-motor-cognitive-training-on-executive2026-09-27 https://evidence-hub.com/study/18394-clinical-trial-of-the-viability-of-lab-and-bifidobacteria-from2026-09-27 https://evidence-hub.com/study/18395-clinical-performances-of-3-different-tooth-colored-restorative2026-09-27 https://evidence-hub.com/study/18396-tai-chi-mind-body-therapy-for-fibromyalgia-a-pilot-single-blind2026-09-27 https://evidence-hub.com/study/18397-bump-on-the-ball-impact-of-a-prenatal-exercise-education-program-on2026-09-27 https://evidence-hub.com/study/18398-phase-i-study-to-assess-the-tolerability-and-efficacy-of-selinexor2026-09-27 https://evidence-hub.com/study/18399-the-opus-young-study-the-efficacy-of-early-intervention-service2026-09-27 https://evidence-hub.com/study/18400-a-randomised-double-blind-double-dummy-placebo-controlled-parallel2026-09-27 https://evidence-hub.com/study/18401-cognitive-behaviour-therapy-with-mindfulness-course-for-building2026-09-27 https://evidence-hub.com/study/18402-randomized-trial-of-aerobic-exercise-training-on-cognitive-and2026-09-27 https://evidence-hub.com/study/18403-evaluating-impact-of-near-infrared-autofluorescence-niraf-detection2026-09-27 https://evidence-hub.com/study/18404-prospective-randomized-trial-comparing-triple-site-ventricular2026-09-27 https://evidence-hub.com/study/18405-effects-of-different-interventions-using-boxing-taekwondo-and-elastic2026-09-27 https://evidence-hub.com/study/18406-linking-churches-with-parks-to-increase-physical-activity-among2026-09-27 https://evidence-hub.com/study/18407-evaluation-of-periodontal-health-and-patient-satisfaction-of-cad-cam2026-09-27 https://evidence-hub.com/study/18408-tai-chi-for-relieving-aromatase-inhibitor-induced-arthralgia-in2026-09-27 https://evidence-hub.com/study/18409-a-phase-i-open-label-randomised-balanced-single-dose-two-period-two2026-09-27 https://evidence-hub.com/study/18410-comparative-evaluation-of-rhpdgf-bb-with-modified-coronally-advanced2026-09-27 https://evidence-hub.com/study/18411-a-randomized-double-blind-placebo-controlled-phase-2-trial-of2026-09-27 https://evidence-hub.com/study/18412-national-taipei-university-of-nursing-and-health-sciences2026-09-27 https://evidence-hub.com/study/18413-a-patient-centered-strategy-for-improving-diabetes-prevention-in2026-09-27 https://evidence-hub.com/study/18414-detection-of-thyroid-cancer-and-central-lymph-node-metastases-using2026-09-27 https://evidence-hub.com/study/18415-a-hybrid-effectiveness-implementation-trial-of-a-school-based2026-09-27 https://evidence-hub.com/study/18416-a-24-week-randomized-placebo-controlled-double-blind-multi-center2026-09-27 https://evidence-hub.com/study/18417-a-phase-1-2-trial-of-intracoronary-administration-of-mydicar-aav12026-09-27 https://evidence-hub.com/study/18418-a-randomized-double-blind-study-of-the-safety-and-efficacy-of2026-09-27 https://evidence-hub.com/study/18419-structure-learning-training-and-cognitive-flexibility2026-09-27 https://evidence-hub.com/study/18420-evaluation-of-the-planet-nutrition-program-on-obesity-parameters-in2026-09-27 https://evidence-hub.com/study/18421-prospective-randomized-single-blind-controlled-trial-of-topical2026-09-27 https://evidence-hub.com/study/18422-stress-reduction-in-the-prevention-of-left-ventricular-hypertrophy-a2026-09-27 https://evidence-hub.com/study/18423-comparing-smoking-cessation-interventions-among-underserved-patients2026-09-27 https://evidence-hub.com/study/18424-application-of-livespo-navax-in-the-treatment-support-of-acute2026-09-27 https://evidence-hub.com/study/18425-an-open-label-dose-escalation-study-to-evaluate-safety-tolerability2026-09-27 https://evidence-hub.com/study/18426-the-effects-of-a-biomechanical-based-tai-chi-intervention-program-on2026-09-27 https://evidence-hub.com/study/18427-effect-of-bilateral-distalization-of-upper-first-molars-in-a-group-of2026-09-27 https://evidence-hub.com/study/18428-phase-i-ii-study-of-immunization-with-mhc-class-i-matched-allogeneic2026-09-27 https://evidence-hub.com/study/18429-a-phase-ii-study-to-assess-immunosuppression-with-sirolimus-combined2026-09-27 https://evidence-hub.com/study/18430-effectiveness-of-gamification-with-a-narrative-adapted-to-the-player2026-09-27 https://evidence-hub.com/study/18431-harmonizing-optimal-strategy-for-treatment-of-coronary-artery2026-09-27 https://evidence-hub.com/study/18432-better-adherence-to-therapeutic-lifestyle-change-efforts-battle-trial2026-09-27 https://evidence-hub.com/study/18433-photobiomodulation-therapy-for-idiopathic-facial-paralysis2026-09-27 https://evidence-hub.com/study/18434-effects-of-a-physical-activity-promotion-program-on-body-composition2026-09-27 https://evidence-hub.com/study/18435-investigating-the-effect-of-cognitive-training-with-and-without2026-09-27 https://evidence-hub.com/study/18436-randomized-trial-of-rivaroxaban-xarelto-and-apixaban-eliquis-for-the2026-09-27 https://evidence-hub.com/study/18437-minnesota-medicaid-incentives-to-prevent-chronic-disease2026-09-27 https://evidence-hub.com/study/18438-wiihome-amps-a-pilot-randomized-controlled-trial-to-investigate-the2026-09-27 https://evidence-hub.com/study/18439-h2-physical-education-promoting-cardiometabolic-health-by-2-high2026-09-27 https://evidence-hub.com/study/18440-enhanced-efficacy-of-early-orthopedic-intervention-with-rapid2026-09-27 https://evidence-hub.com/study/18441-a-randomized-placebo-controlled-clinical-trial-assessing-the-efficacy2026-09-27 https://evidence-hub.com/study/18442-radiographic-analysis-of-skeletal-and-dentoalveolar-changes-following2026-09-27 https://evidence-hub.com/study/18443-enhanced-safety-surveillance-of-gsk-s-quadrivalent-seasonal-influenza2026-09-27 https://evidence-hub.com/study/18444-yoga-to-prevent-mobility-limitations-in-older-adults-a-pilot2026-09-27 https://evidence-hub.com/study/18445-pelvic-floor-muscle-training-included-in-general-fitness-classes-is2026-09-29 https://evidence-hub.com/study/18446-evaluation-of-the-skeletal-dental-and-soft-tissue-changes-after-en2026-09-27 https://evidence-hub.com/study/18447-a-double-blind-placebo-controlled-pilot-investigation-of-the-safety2026-09-27 https://evidence-hub.com/study/18448-the-effects-of-single-dose-rifampin-on-pharmacokinetics-of2026-09-27 https://evidence-hub.com/study/18449-effect-of-the-community-based-sims-programme-on-preschool-children-s2026-09-27 https://evidence-hub.com/study/18450-stereotactic-laser-ablation-for-temporal-lobe-epilepsy2026-09-27 https://evidence-hub.com/study/18451-intravenous-thrombolysis-with-recombinant-human-tnk-tissue-type2026-09-27 https://evidence-hub.com/study/18452-concentrated-growth-factor-membrane-versus-subepithelial-connective2026-09-27 https://evidence-hub.com/study/18453-an-open-label-single-arm-clinical-trial-to-evaluate-the2026-09-27 https://evidence-hub.com/study/18454-first-or-second-class-compression-hosiery-after-endovenous-laser-with2026-09-27 https://evidence-hub.com/study/18455-quartettm-bad-oeynhausen-trial2026-09-27 https://evidence-hub.com/study/18456-a-pilot-clinical-trial-to-assess-the-effect-of-transfemoral-socket2026-09-27 https://evidence-hub.com/study/18457-a-cluster-randomized-trial-to-assess-a-sexual-assault-prevention2026-09-27 https://evidence-hub.com/study/18458-a-phase-iib-multicenter-randomized-double-blind-placebo-controlled2026-10-10 https://evidence-hub.com/study/18459-co-administration-of-smectite-gel-with-live-probiotic-strains-on2026-09-27 https://evidence-hub.com/study/18460-anxiety-among-children-adaptation-and-effectiveness-of-the-program2026-09-27 https://evidence-hub.com/study/18461-yoga-for-persistent-fatigue-in-the-survivors-of-bone-marrow2026-09-27 https://evidence-hub.com/study/18462-a-prospective-observational-study-to-evaluate-predictors-of-clinical2026-09-27 https://evidence-hub.com/study/18463-adapting-the-us-based-clinic-community-model-of-child-obesity2026-09-27 https://evidence-hub.com/study/18464-a-phase-3-multicenter-trial-evaluating-the-efficacy-and-safety-of-ugn2026-09-27 https://evidence-hub.com/study/18465-pioneering-video-based-neurocritical-care-education-in-palestine-a2026-09-27 https://evidence-hub.com/study/18466-a-phase-1-study-of-abemaciclib-and-niraparib-as-neoadjuvant-therapy2026-09-27 https://evidence-hub.com/study/18467-the-cochrane-collaboration-s-tool-for-assessing-risk-of-bias-in2026-10-01 https://evidence-hub.com/study/18472-spirit-2013-explanation-and-elaboration-guidance-for-protocols-of2026-10-01 https://evidence-hub.com/study/18473-physical-activity-for-osteoarthritis-management-a-randomized2026-09-27 https://evidence-hub.com/study/18474-consort-2010-explanation-and-elaboration-updated-guidelines-for2026-10-01 https://evidence-hub.com/study/18475-a-randomized-trial-of-intensive-versus-standard-blood-pressure-control2026-10-01 https://evidence-hub.com/study/18479-a-class-of-designs-for-sequential-clinical-trials2026-09-27 https://evidence-hub.com/study/18480-the-druggable-genome-evaluation-of-drug-targets-in-clinical-trials2026-09-27 https://evidence-hub.com/study/18481-recursive-partitioning-analysis-rpa-of-prognostic-factors-in-three2026-09-27 https://evidence-hub.com/study/18483-fremanezumab-versus-placebo-for-migraine-prevention-in-patients-with2026-10-04 https://evidence-hub.com/study/18484-use-of-blood-pressure-lowering-drugs-in-the-prevention-of2026-10-05 https://evidence-hub.com/study/18485-cardiovascular-outcomes-in-trials-of-new-antidiabetic-drug-classes-a2026-10-01 https://evidence-hub.com/study/18486-implications-of-recent-clinical-trials-for-the-national-cholesterol2026-10-01 https://evidence-hub.com/study/18488-headgear-versus-function-regulator-in-the-early-treatment-of-class-ii2026-10-01 https://evidence-hub.com/study/18489-singing-classes-for-chronic-obstructive-pulmonary-disease-a2026-10-01 https://evidence-hub.com/study/18493-consort-2010-statement-extension-to-cluster-randomised-trials2026-10-01 https://evidence-hub.com/study/18494-angiotensin-neprilysin-inhibition-versus-enalapril-in-heart-failure2026-10-01 https://evidence-hub.com/study/18495-a-randomized-trial-of-bevacizumab-for-newly-diagnosed-glioblastoma2026-10-01 https://evidence-hub.com/study/18496-overview-of-randomized-trials-of-angiotensin-converting-enzyme2026-09-27 https://evidence-hub.com/study/18497-trastuzumab-plus-adjuvant-chemotherapy-for-operable-her2-positive2026-10-01 https://evidence-hub.com/study/18498-phase-i-dose-escalation-trial-of-pt2385-a-first-in-class-hypoxia2026-10-01 https://evidence-hub.com/study/18499-a-randomized-controlled-trial-of-continuous-labor-support-for-middle2026-09-27 https://evidence-hub.com/study/18501-genomic-classification-and-prognosis-in-acute-myeloid-leukemia2026-10-01 https://evidence-hub.com/study/18502-cardiovascular-risk-associated-with-celecoxib-in-a-clinical-trial-for2026-10-01 https://evidence-hub.com/study/18503-twenty-year-follow-up-of-a-randomized-trial-comparing-total2026-10-01 https://evidence-hub.com/study/18504-industry-foundation-classes-for-project-management-a-trial2026-09-27 https://evidence-hub.com/study/18505-pharmacological-treatment-of-migraine-drug-classes-mechanisms-of2026-10-01 https://evidence-hub.com/study/18506-phase-i-trial-of-first-in-class-atr-inhibitor-m6620-vx-970-as2026-09-27 https://evidence-hub.com/study/18507-a-randomized-trial-of-an-n-methyl-d-aspartate-antagonist-in-treatment2026-10-01 https://evidence-hub.com/study/18509-modular-multiplication-without-trial-division2026-09-27 https://evidence-hub.com/study/18510-response-of-patients-in-classes-iii-and-iv-of-cardiomyopathy-to2026-09-27 https://evidence-hub.com/study/18511-phase-3-trial-of-177-lu-dotatate-for-midgut-neuroendocrine-tumors2026-10-01 https://evidence-hub.com/study/18512-the-interplay-of-product-class-knowledge-and-trial-experience-in2026-09-27 https://evidence-hub.com/study/18513-supplementation-of-a-home-based-exercise-programme-with-a-class-based2026-10-01 https://evidence-hub.com/study/18514-pembrolizumab-in-patients-with-advanced-hepatocellular-carcinoma2026-09-27 https://evidence-hub.com/study/18515-pharmacological-interventions-for-somatoform-disorders-in-adults2026-09-27 https://evidence-hub.com/study/18516-the-effect-of-spironolactone-on-morbidity-and-mortality-in-patients2026-10-01 https://evidence-hub.com/study/18517-atezolizumab-in-patients-with-locally-advanced-and-metastatic2026-10-01 https://evidence-hub.com/study/18518-prophylactic-implantation-of-a-defibrillator-in-patients-with2026-10-01 https://evidence-hub.com/study/18519-unprecedented-selectivity-and-structural-determinants-of-a-new-class2026-09-27 https://evidence-hub.com/study/18520-is-early-class-iii-protraction-facemask-treatment-effective-a2026-09-27 https://evidence-hub.com/study/18523-aptamers-an-emerging-class-of-therapeutics2026-09-27 https://evidence-hub.com/study/18524-a-first-in-class-first-in-human-phase-i-trial-of-p28-a-non-hdm22026-10-01 https://evidence-hub.com/study/18525-development-of-pd-1-and-pd-l1-inhibitors-as-a-form-of-cancer2026-10-01 https://evidence-hub.com/study/18526-selective-averaging-of-rapidly-presented-individual-trials-using-fmri2026-09-27 https://evidence-hub.com/study/18527-community-based-yoga-classes-for-type-2-diabetes-an-exploratory2026-10-01 https://evidence-hub.com/study/18531-exploring-heterogeneity-in-clinical-trials-with-latent-class-analysis2026-10-01 https://evidence-hub.com/study/18532-randomized-trial-of-thymectomy-in-myasthenia-gravis2026-10-01 https://evidence-hub.com/study/18533-prompt-compression-in-production-task-orchestration-a-pre-registered2026-10-01 https://evidence-hub.com/study/18534-garbage-collection-makes-rust-easier-to-use-a-randomized-controlled2026-10-06 https://evidence-hub.com/study/18535-generating-the-right-evidence-at-the-right-time-principles-of-a-new2026-10-01 https://evidence-hub.com/study/18536-robust-integration-of-external-control-data-in-randomized-trials2026-10-01 https://evidence-hub.com/study/18537-bayesian-uncertainty-directed-trial-designs2026-10-01 https://evidence-hub.com/study/18538-intra-class-correlation-coefficient-ignorable-clustered-randomized2026-10-01 https://evidence-hub.com/study/18539-confidence-intervals-for-adaptive-trial-designs-i-a-methodological2026-10-01 https://evidence-hub.com/study/18540-admissibility-of-completely-randomized-trials-a-large-deviation2026-10-01 https://evidence-hub.com/study/18541-learning-signal-representations-for-eeg-cross-subject-channel2026-10-01 https://evidence-hub.com/study/18542-an-adaptive-design-for-optimizing-treatment-assignment-in-randomized2026-10-01 https://evidence-hub.com/study/18543-implementing-advanced-trial-wave-functions-in-fermion-quantum-monte2026-10-08 https://evidence-hub.com/study/18544-on-the-complexity-of-trial-and-error2026-10-01 https://evidence-hub.com/study/18545-trialview-an-ai-powered-visual-analytics-system-for-temporal-event2026-10-01 https://evidence-hub.com/study/18546-familywise-error-control-in-multi-armed-response-adaptive-trials2026-10-06 https://evidence-hub.com/study/18547-automating-the-compilation-of-potential-core-outcomes-for-clinical2026-10-01 https://evidence-hub.com/study/18548-evaluating-the-impact-of-outcome-delay-on-the-efficiency-of-two-arm2026-10-06 https://evidence-hub.com/study/18549-on-the-complexity-of-trial-and-error-for-constraint-satisfaction2026-10-01 https://evidence-hub.com/study/18550-handling-covariates-in-the-design-of-clinical-trials2026-10-06 https://evidence-hub.com/study/18551-modeling-synergism-in-early-phase-cancer-trials-with-drug-combination2026-10-01 https://evidence-hub.com/study/18552-an-integrated-and-coherent-framework-for-point-estimation-and2026-10-01 https://evidence-hub.com/study/18553-transporting-trial-evidence-under-posterior-drift-and-possible-hidden2026-10-01 https://evidence-hub.com/study/18554-optimal-study-designs-for-cluster-randomised-trials-an-overview-of2026-10-01 https://evidence-hub.com/study/18555-validating-gan-biobert-a-methodology-for-assessing-reporting-trends2026-10-01 https://evidence-hub.com/study/18556-robust-designs-for-prospective-randomized-trials-surveying-sensitive2026-10-01 https://evidence-hub.com/study/18557-efficient-response-adaptive-randomization-for-multi-arm-trials-with2026-10-01 https://evidence-hub.com/study/18558-trial-wave-functions-molecular-states-and-ro-vibrational-spectra-in2026-10-01 https://evidence-hub.com/study/18559-borrowing-of-information-across-patient-subgroups-in-a-basket-trial2026-10-06 https://evidence-hub.com/study/18560-increasing-the-efficiency-of-randomized-trial-estimates-via-linear2026-10-01 https://evidence-hub.com/study/18561-automated-detection-of-dosing-errors-in-clinical-trial-narratives-a2026-10-01 https://evidence-hub.com/study/18562-model-robust-inference-for-clinical-trials-that-improve-precision-by2026-10-01 https://evidence-hub.com/study/18563-leveraging-external-controls-in-clinical-trials-estimands-estimation2026-10-01 https://evidence-hub.com/study/18564-bayesian-decision-optimal-interval-designs-for-phase-i-clinical-trials2026-10-01 https://evidence-hub.com/study/18565-visualizing-adverse-events-in-clinical-trials-using-correspondence2026-10-01 https://evidence-hub.com/study/18566-sibyl-autoresearch-autonomous-research-needs-self-evolving-trial-and2026-10-01 https://evidence-hub.com/study/18567-leveraging-contact-network-structure-in-the-design-of-cluster2026-10-06 https://evidence-hub.com/study/18568-trial-and-error-mathematics-dialectical-systems-and-completions-of2026-10-01 https://evidence-hub.com/study/18569-toolcompass-guiding-tool-trialing-not-suppressing-it2026-10-01 https://evidence-hub.com/study/18570-performance-analysis-of-trial-and-error-algorithms2026-10-01 https://evidence-hub.com/study/18571-lowest-landau-level-stress-tensor-and-structure-factor-of-trial2026-10-01 https://evidence-hub.com/study/18572-investigating-primary-care-indications-to-improve-electronic-health2026-10-01 https://evidence-hub.com/study/18573-robust-wald-type-tests-under-random-censoring-with-applications-to2026-10-01 https://evidence-hub.com/study/18574-enhancing-statistical-validity-and-power-in-hybrid-controlled-trials2026-10-01 https://evidence-hub.com/study/18575-semeval-2023-task-7-multi-evidence-natural-language-inference-for2026-10-01 https://evidence-hub.com/study/18576-a-web-based-application-leveraging-geospatial-information-to-automate2026-10-01 https://evidence-hub.com/study/18577-doubly-robust-estimators-of-the-restricted-mean-time-in-favor2026-10-01 https://evidence-hub.com/study/18578-learning-clinical-trial-strategy-offline-policy-training-for-decision2026-10-01 https://evidence-hub.com/study/18579-a-modified-weighted-log-rank-test-for-confirmatory-trials-with-a-high2026-10-06 https://evidence-hub.com/study/18580-an-ipcw-adjusted-win-statistics-approach-in-clinical-trials2026-10-01 https://evidence-hub.com/study/18581-propensity-score-weighting-for-covariate-adjustment-in-randomized2026-10-01 https://evidence-hub.com/study/18582-a-novel-statistical-test-for-treatment-differences-in-clinical-trials2026-10-01 https://evidence-hub.com/study/18583-object-classification-from-randomized-eeg-trials2026-10-01 https://evidence-hub.com/study/18584-tensor-network-trial-states-for-chiral-topological-phases-in-two2026-10-06 https://evidence-hub.com/study/18585-trial-wavefunctions-for-1-2-1-2-quantum-hall-bilayers2026-10-06 https://evidence-hub.com/study/18586-optical-data-transmission-field-trial-44tb-s-with-a-49ghz-kerr2026-10-06 https://evidence-hub.com/study/18587-solving-general-utility-markov-decision-processes-in-the-single-trial2026-10-01 https://evidence-hub.com/study/18588-teaching-transformers-to-solve-combinatorial-problems-through2026-10-01 https://evidence-hub.com/study/18589-development-evaluation-and-multicenter-clinical-trial-application-of2026-10-01 https://evidence-hub.com/study/18590-the-number-of-trials-matters-in-infinite-horizon-general-utility2026-10-01 https://evidence-hub.com/study/18591-sample-size-determination-for-win-statistics-in-cluster-randomized2026-10-01 https://evidence-hub.com/study/18592-unbiased-and-efficient-estimation-of-causal-treatment-effects-in2026-10-01 https://evidence-hub.com/study/18593-a-tutorial-on-conducting-sample-size-and-power-calculations-for2026-10-06 https://evidence-hub.com/study/18594-evaluating-the-ability-of-large-language-models-to-identify-adherence2026-10-01 https://evidence-hub.com/study/18595-response-adaptive-randomization-in-clinical-trials-from-myths-to2026-10-01 https://evidence-hub.com/study/18596-targeted-data-fusion-for-region-specific-survival-effects-in-the-amp2026-10-01 https://evidence-hub.com/study/18597-doubly-robust-estimation-and-sensitivity-analysis-with-outcomes2026-10-01 https://evidence-hub.com/study/18598-learning-exemplar-representations-in-single-trial-eeg-category2026-10-01 https://evidence-hub.com/study/18599-possible-contexts-of-use-for-in-silico-trials-methodologies-a2026-10-06 https://evidence-hub.com/study/18600-general-solutions-for-some-classes-of-interacting-two-field-kinks2026-10-06 https://evidence-hub.com/study/18601-anpp-the-adapted-normalized-power-prior-for-borrowing-information2026-10-01 https://evidence-hub.com/study/18602-stratification-trees-for-adaptive-randomization-in-randomized2026-10-01 https://evidence-hub.com/study/18603-muce-bayesian-hierarchical-modeling-for-the-design-and-analysis-of2026-10-06 https://evidence-hub.com/study/18604-bernoulli-trials-of-fixed-parity-random-and-randomly-oriented-graphs2026-10-01 https://evidence-hub.com/study/18605-sl-2-variational-schemes-for-solving-one-class-of-quantum-nonlinear2026-10-01 https://evidence-hub.com/study/18606-mapping-the-exploitation-surface-a-10-000-trial-taxonomy-of-what2026-10-01 https://evidence-hub.com/study/18607-bridging-probabilistic-llms-and-deterministic-statistical-validation2026-10-01 https://evidence-hub.com/study/18608-solitary-waves-and-compactons-in-a-class-of-generalized-korteweg2026-10-06 https://evidence-hub.com/study/18609-inference-on-a-new-class-of-sample-average-treatment-effects2026-10-01 https://evidence-hub.com/study/18610-doubly-robust-estimators-for-generalizing-treatment-effects-on2026-10-01 https://evidence-hub.com/study/18611-a-class-of-exactly-solvable-models-to-illustrate-supersymmetry-and2026-10-01 https://evidence-hub.com/study/18612-incorporation-of-eye-tracking-and-gaze-feedback-to-characterize-and2026-10-01 https://evidence-hub.com/study/18613-c-gap-class-aware-and-online-prompting-improves-vision-language2026-10-01 https://evidence-hub.com/study/18614-a-nonlinear-sl-2-dynamics-and-new-quasiclassical-solutions-for-a2026-10-01 https://evidence-hub.com/study/18615-enhancing-accuracy-and-robustness-through-adversarial-training-in2026-10-01 https://evidence-hub.com/study/18616-mitigating-domain-drift-in-multi-species-segmentation-with-dinov2-a2026-09-27 https://evidence-hub.com/study/18617-a-bayesian-predictive-framework-for-adaptive-interim-analysis-timing2026-10-01 https://evidence-hub.com/study/18618-survey-of-the-didemnins-a-class-of-depsipeptide-natural-products-with2026-10-01 https://evidence-hub.com/study/18619-a-class-of-two-sample-nonparametric-statistics-for-binary-and-time-to2026-10-06 https://evidence-hub.com/study/18620-constrained-markov-decision-processes-for-response-adaptive2026-10-01 https://evidence-hub.com/study/18621-class-imbalance-corrections-failed-to-enhance-discrimination-model2026-10-01 https://evidence-hub.com/study/18622-a-quiet-failure-in-calibrated-virtual-screening-marginal-conformal2026-10-01 https://evidence-hub.com/study/18623-a-class-of-computational-methods-to-reduce-selection-bias-when2026-10-06 https://evidence-hub.com/study/18624-fixed-effects-models-for-causal-inference-in-longitudinal-cluster2026-10-01 https://evidence-hub.com/study/18625-slo-guard-crash-aware-budget-consistent-autotuning-for-slo2026-10-01 https://evidence-hub.com/study/18626-stochastic-estimations-of-a-total-number-of-classes-for-the2026-10-06 https://evidence-hub.com/study/18627-crocs-clustering-and-retrieval-of-cardiac-signals-based-on-patient2026-10-01 https://evidence-hub.com/study/18628-testing-for-treatment-effect-in-covariate-adaptive-randomized2026-10-06 https://evidence-hub.com/study/18629-causal-mediation-in-cluster-randomized-trials-with-multiple-mediators2026-10-01 https://evidence-hub.com/study/18630-evidence-records-for-public-record-changes-definitional-class2026-10-01 https://evidence-hub.com/study/18631-latent-class-model-with-application-to-speaker-diarization2026-10-01 https://evidence-hub.com/study/18632-role-of-sglt2-inhibitors-gliflozins-in-heart-failure2026-10-06 https://evidence-hub.com/study/18633-eligibility-and-preventive-potential-for-new-evidence-based2026-10-06 https://evidence-hub.com/study/18634-cardiovascular-disease-prevalence-in-type-2-diabetes-an-analysis-of-a2026-10-06 https://evidence-hub.com/study/18635-glp-1-receptor-agonists-and-heart-failure-in-diabetes2026-10-06 https://evidence-hub.com/study/18636-antidiabetic-agents-and-risk-of-atrial-fibrillation-flutter-a2026-10-06 https://evidence-hub.com/study/18637-effects-of-empagliflozin-treatment-on-cardiac-function-and-structure2026-10-06 https://evidence-hub.com/study/18638-incidence-of-adverse-cardiovascular-events-in-type-2-diabetes2026-10-06 https://evidence-hub.com/study/18639-external-applicability-of-sglt2-inhibitor-cardiovascular-outcome2026-10-06 https://evidence-hub.com/study/18640-lower-risk-of-death-with-sglt2-inhibitors-in-observational-studies2026-10-06 https://evidence-hub.com/study/18641-92-eligibility-and-reimbursement-of-sglt2-inhibitors-in-a-heart2026-10-06 https://evidence-hub.com/study/18642-1054-impact-of-slgt2-inhibitors-in-kidney-transplant-patients-a2026-10-06 https://evidence-hub.com/study/18643-cost-effectiveness-of-sglt2-inhibitors-in-a-real-world-population-a2026-10-06 https://evidence-hub.com/study/18644-cardiovascular-disease-in-patients-with-type-2-diabetes-and-in2026-10-06 https://evidence-hub.com/study/18645-peripheral-arterial-stiffness-increases-the-risk-of-progression-of2026-10-06 https://evidence-hub.com/study/18646-implementation-of-empagliflozin-in-patients-with-diabetes-mellitus2026-10-06 https://evidence-hub.com/study/18647-cohort-profile-the-swiss-cerebral-palsy-registry-swiss-cp-reg-cohort2026-10-06 https://evidence-hub.com/study/18648-cohort-profile-the-swiss-cerebral-palsy-registry-swiss-cp-reg-cohort2026-10-06 https://evidence-hub.com/study/18650-is-an-increase-in-serum-magnesium-one-of-the-causes-of-cardiovascular2026-10-06 https://evidence-hub.com/study/18653-post-covid-19-syndrome-in-outpatients-a-cohort-study2026-10-13 https://evidence-hub.com/study/18657-risk-factors-for-coronavirus-disease-2019-covid-19-death-in-a2026-10-16 https://evidence-hub.com/study/18659-sarcopenia-is-associated-with-decreased-gray-matter-volume-in-the2026-10-06 https://evidence-hub.com/study/18660-baseline-viral-load-and-on-treatment-hepatocellular-carcinoma-risk-in2026-10-06 https://evidence-hub.com/study/18661-a-methodology-for-assessing-deployment-trauma-and-its-consequences-in2026-10-06 https://evidence-hub.com/study/18663-factors-influencing-primary-and-secondary-implant-stability-a2026-10-06 https://evidence-hub.com/study/18664-blockers-in-hypertension-studies-and-meta-analyses-over-the-years2026-10-06 https://evidence-hub.com/study/18665-treatment-of-ssri-resistant-depression-a-meta-analysis-comparing2026-10-06 https://evidence-hub.com/study/18666-efficacy-of-ace-inhibitors-in-chronic-heart-failure-with-preserved2026-10-06 https://evidence-hub.com/study/18667-root-coverage-by-coronally-advanced-flap-with-connective-tissue-graft2026-10-06 https://evidence-hub.com/study/18668-antidepressants-for-treating-depression-in-dementia2026-10-06 https://evidence-hub.com/study/18669-long-term-proton-pump-inhibitor-ppi-use-and-the-development-of2026-10-13 https://evidence-hub.com/study/18670-comparative-effectiveness-of-vasopressin-steroids-and-epinephrine2026-10-06 https://evidence-hub.com/study/18671-anakinra-for-rheumatoid-arthritis2026-10-06 https://evidence-hub.com/study/18672-effects-of-akt-inhibitors-for-pik3ca-akt1-pten-altered-advanced-or2026-10-06 https://evidence-hub.com/study/18673-immunosuppressive-treatment-for-idiopathic-membranous-nephropathy-in2026-10-06 https://evidence-hub.com/study/18674-are-proton-pump-inhibitors-superior-to-h2-receptor-antagonists-within2026-10-06 https://evidence-hub.com/study/18675-izalontamab-brengitecan-iza-bren-bl-b01d1-a-first-in-class-egfr-her32026-10-06 https://evidence-hub.com/study/18676-the-effectiveness-and-relative-effectiveness-of-intravenous-inotropic2026-10-06 https://evidence-hub.com/study/18677-the-efficacy-of-cardiac-myosin-inhibitors-versus-placebo-in-patients2026-10-06 https://evidence-hub.com/study/18678-predicting-appropriate-shocks-in-patients-with-heart-failure-patient2026-10-06 https://evidence-hub.com/study/18679-antidepressants-for-the-treatment-of-depression-in-people-with-cancer2026-10-06 https://evidence-hub.com/study/18680-targeted-therapy-for-solid-tumors-and-risk-of-hypertension-a-meta2026-10-06 https://evidence-hub.com/study/18681-erythropoiesis-stimulating-agents-for-anaemia-in-chronic-heart2026-10-06 https://evidence-hub.com/study/18682-efavirenz-based-regimens-in-antiretroviral-naive-hiv-infected2026-10-06 https://evidence-hub.com/study/18683-antidepressants-for-depression-in-parkinson-s-disease-systematic2026-10-06 https://evidence-hub.com/study/18684-efficacy-of-duloxetine-versus-alternative-oral-therapies-an-indirect2026-10-06 https://evidence-hub.com/study/18685-land-based-exercise-for-osteoarthritis-of-the-knee-a-metaanalysis-of2026-10-06 https://evidence-hub.com/study/18686-incident-diabetes-in-clinical-trials-of-antihypertensive-drugs-a2026-10-06 https://evidence-hub.com/study/18687-predicting-benefit-from-adjuvant-therapy-with-corticosteroids-in2026-10-06 https://evidence-hub.com/study/18688-transmyocardial-laser-revascularization-versus-medical-therapy-for2026-10-06 https://evidence-hub.com/study/18689-efficacy-and-safety-of-perampanel-in-epilepsy-a-systematic-review-and2026-10-06 https://evidence-hub.com/study/18690-janus-kinase-inhibitors-versus-tumor-necrosis-factor-inhibitors-in2026-10-06 https://evidence-hub.com/study/18691-context-effects-and-behaviour-change-techniques-in-randomised-trials2026-10-06 https://evidence-hub.com/study/18692-assessment-botulinum-neurotoxin-in-the-treatment-of-autonomic2026-10-06 https://evidence-hub.com/study/18693-a-systematic-review-and-mixed-treatment-comparison-of-the-efficacy-of2026-10-06 https://evidence-hub.com/study/18694-pharmacological-treatment-for-gestational-diabetes-mellitus-a2026-10-06 https://evidence-hub.com/study/18695-incentives-for-preventing-smoking-in-children-and-adolescents2026-10-06 https://evidence-hub.com/study/18696-mtor-inhibitors-a-new-era-for-metastatic-luminal-her2-negative-breast2026-10-06 https://evidence-hub.com/study/18697-antibiotic-prophylaxis-in-men-undergoing-transurethral-resection-of2026-10-06 https://evidence-hub.com/study/18698-cardiac-resynchronization-therapy-in-patients-with-minimal-heart2026-10-06 https://evidence-hub.com/study/18699-antidepressants-for-people-with-epilepsy-and-depression2026-10-06 https://evidence-hub.com/study/18700-indirect-treatment-comparisons-of-ibrutinib-versus-physician-s-choice2026-10-06 https://evidence-hub.com/study/18701-effect-of-age-on-hypnotics-efficacy-and-safety-in-insomnia-a2026-10-06 https://evidence-hub.com/study/18702-glucocorticoid-supplementation-during-ovarian-stimulation-for-ivf-or2026-10-06 https://evidence-hub.com/study/18703-comparative-efficacy-and-safety-of-transcatheter-edge-to-edge-repair2026-10-06 https://evidence-hub.com/study/18704-group-exercise-for-balance-in-people-with-parkinson-s-disease-a2026-10-06 https://evidence-hub.com/study/18705-a-non-cephalometric-three-dimensional-appraisal-of-soft-tissue2026-10-06 https://evidence-hub.com/study/18706-pharmacotherapy-and-immunotherapy-of-allergic-rhinitis-induced-by2026-10-06 https://evidence-hub.com/study/18707-effects-of-antihistamines-in-adult-asthma-a-meta-analysis-of-clinical2026-10-06 https://evidence-hub.com/study/18708-do-antimicrobial-mass-medications-work-a-systematic-review-and-meta2026-10-06 https://evidence-hub.com/study/18709-bile-acids-for-liver-transplanted-patients2026-10-06 https://evidence-hub.com/study/18710-short-term-efficacy-reliably-predicts-long-term-clinical-benefit-in2026-10-06 https://evidence-hub.com/study/18711-cardiotoxicity-of-newer-her2-directed-therapies-in-breast-cancer-a2026-10-06 https://evidence-hub.com/study/18712-treatment-of-class-ii-molar-furcation-involvement-meta-analyses-of2026-10-06 https://evidence-hub.com/study/18713-a-systematic-review-and-meta-analysis-of-randomized-trials-on-the2026-10-06 https://evidence-hub.com/study/18714-does-a-change-in-angiotensin-ii-formation-caused-by-antihypertensive2026-10-06 https://evidence-hub.com/study/18715-pharmacologic-modulation-of-circadian-rhythms-for-delirium-prevention2026-10-06 https://evidence-hub.com/study/18716-efficacy-and-safety-of-adjunctive-serotonin-dopamine-activity2026-10-06 https://evidence-hub.com/study/18717-cftr-modulator-monotherapy-for-people-with-cystic-fibrosis-with-class2026-10-06 https://evidence-hub.com/study/18718-dipeptidyl-peptidase-4-inhibitors-and-pancreatitis-risk-a-meta2026-10-06 https://evidence-hub.com/study/18719-do-bioactive-materials-show-greater-retention-rates-in-restoring2026-10-06 https://evidence-hub.com/study/18720-meta-analysis-of-the-effectiveness-of-esomeprazole-in2026-10-13 https://evidence-hub.com/study/18721-torsemide-versus-furosemide-in-the-treatment-of-heart-failure-a2026-10-06 https://evidence-hub.com/study/18722-honey-vs-pharmacological-treatment-for-acute-cough-in-children-a2026-10-08 https://evidence-hub.com/study/18723-botulinum-toxins-for-the-prevention-of-migraine-in-adults2026-10-06 https://evidence-hub.com/study/18724-impact-of-exercise-rehabilitation-on-exercise-capacity-and-quality-of2026-10-06 https://evidence-hub.com/study/18725-bridging-olaparib-capsule-and-tablet-formulations-using-population2026-10-06 https://evidence-hub.com/study/18726-efficacy-of-pharmacotherapy-against-core-traits-of-borderline2026-10-06 https://evidence-hub.com/study/18727-efficacy-and-safety-of-glp-1-receptor-agonists-for-adolescents-and2026-10-06 https://evidence-hub.com/study/18728-selective-serotonin-reuptake-inhibitors-and-benzodiazepines-in-panic2026-10-06 https://evidence-hub.com/study/18729-novel-oral-anticoagulants-in-atrial-fibrillation-a-meta-analysis-of2026-10-06 https://evidence-hub.com/study/18730-risk-of-bone-fractures-associated-with-glucagon-like-peptide-12026-10-06 https://evidence-hub.com/study/18731-treatment-effects-of-removable-functional-appliances-in-pre-pubertal2026-10-06 https://evidence-hub.com/study/18732-efficacy-of-topical-antifungal-drugs-in-different-dermatomycoses-a2026-10-06 https://evidence-hub.com/study/18733-efficacy-safety-and-comparison-of-sonic-hedgehog-inhibitors-in-basal2026-10-06 https://evidence-hub.com/study/18734-contemporary-femoropopliteal-stents-reporting-gaps-of-randomized2026-10-06 https://evidence-hub.com/study/18735-clinical-effects-of-beta-adrenergic-blockade-in-chronic-heart-failure2026-10-06 https://evidence-hub.com/study/18736-pharmacological-interventions-for-prevention-or-treatment-of2026-10-06 https://evidence-hub.com/study/18737-nsaids-for-prophylaxis-for-heterotopic-ossification-after-total-hip2026-10-06 https://evidence-hub.com/study/18738-a-review-regarding-the-article-supervised-exercise-training-in-heart2026-10-06 https://evidence-hub.com/study/18739-orthodontic-treatment-for-prominent-upper-front-teeth-in-children2026-10-06 https://evidence-hub.com/study/18740-incorporating-parp-inhibitors-in-primary-and-recurrent-ovarian-cancer2026-10-06 https://evidence-hub.com/study/18741-efficacy-and-safety-of-imipenem-cilastatin-relebactam-imi-cs-rel-a2026-10-06 https://evidence-hub.com/study/18742-renin-inhibitors-versus-angiotensin-receptor-blockers-for-primary2026-10-06 https://evidence-hub.com/study/18743-a-nomogram-to-estimate-the-proportion-of-patients-at-hemoglobin-a1c2026-10-06 https://evidence-hub.com/study/18744-cardiovascular-effects-of-dipeptidyl-peptidase-4-inhibitor-in2026-10-06 https://evidence-hub.com/study/18745-the-validity-of-left-ventricular-mass-as-a-surrogate-end-point-for2026-10-06 https://evidence-hub.com/study/18746-the-impact-of-cell-therapy-on-cardiovascular-outcomes-in-patients2026-10-06 https://evidence-hub.com/study/18747-safety-and-efficacy-of-thrombectomy-in-patients-undergoing-primary2026-10-06 https://evidence-hub.com/study/18748-oral-antidiabetic-drugs-and-regression-from-prediabetes-to2026-10-06 https://evidence-hub.com/study/18749-venous-thromboembolism-risk-with-jak-inhibitors-a-meta-analysis2026-10-06 https://evidence-hub.com/study/18750-effects-of-glucose-lowering-medications-on-intrapancreatic-fat2026-10-06 https://evidence-hub.com/study/18751-corticosteroids-for-patients-with-acute-respiratory-distress-syndrome2026-10-06 https://evidence-hub.com/study/18752-cardiovascular-prevention-and-blood-pressure-reduction-a-quantitative2026-10-06 https://evidence-hub.com/study/18753-can-medications-be-safely-withdrawn-in-patients-with-stable-chronic2026-10-06 https://evidence-hub.com/study/18754-remission-dropouts-and-adverse-drug-reaction-rates-in-major2026-10-06 https://evidence-hub.com/study/18755-association-between-follow-up-mean-blood-pressure-and-blood-pressure2026-10-06 https://evidence-hub.com/study/18756-quadruple-versus-triple-combination-antiretroviral-therapies-for2026-10-06 https://evidence-hub.com/study/18757-assessment-of-the-impact-of-fibrates-and-diet-on-survival-and-their2026-10-06 https://evidence-hub.com/study/18758-classes-of-antihypertensive-agents-and-mortality-in-hypertensive2026-10-06 https://evidence-hub.com/study/18759-a-meta-analytical-approach-to-the-efficacy-of-antihypertensive-drugs2026-10-06 https://evidence-hub.com/study/18760-drug-therapy-for-the-management-of-cancer-related-fatigue2026-10-06 https://evidence-hub.com/study/18761-comparative-efficacy-and-safety-of-il-17-and-il-23-inhibitors-for2026-10-06 https://evidence-hub.com/study/18762-testosterone-replacement-therapy-in-hypogonadal-male-patients-with2026-10-06 https://evidence-hub.com/study/18763-impact-of-bmi-on-response-to-janus-kinase-inhibitors-in-rheumatoid2026-10-06 https://evidence-hub.com/study/18764-anti-inflammatory-agents-after-hip-and-shoulder-arthroplasty-a2026-10-06 https://evidence-hub.com/study/18765-igm-enriched-immunoglobulin-as-adjunctive-therapy-in-adult-sepsis-and2026-10-06 https://evidence-hub.com/study/18766-oteseconazole-for-acute-and-recurrent-vulvovaginal-candidiasis-a2026-10-06 https://evidence-hub.com/study/18767-five-year-survival-after-minimally-invasive-versus-open-gastrectomy-a2026-10-06 https://evidence-hub.com/study/18768-relapse-trajectories-and-antipsychotic-discontinuation-in2026-10-06 https://evidence-hub.com/study/18769-unmetabolized-folic-acid-biology-epidemiology-and-clinical2026-10-06 https://evidence-hub.com/study/18770-conduction-system-vs-biventricular-pacing-in-heart-failure-with2026-10-06 https://evidence-hub.com/study/18771-prophylactic-mesh-reinforcement-at-emergency-midline-laparotomy-a2026-10-06 https://evidence-hub.com/study/18772-effects-of-antidepressant-administration-on-physical-performance-and2026-10-06 https://evidence-hub.com/study/18773-placebo-referenced-class-level-treatment-effects-on-chronic-kidney2026-10-06 https://evidence-hub.com/study/18774-efficacy-and-safety-of-baff-april-pathway-inhibitors-versus-placebo2026-10-06 https://evidence-hub.com/study/18775-comparative-efficacy-of-aldosterone-related-sodium-retention-pathway2026-10-06 https://evidence-hub.com/study/18776-dose-stratified-lipid-lowering-efficacy-and-safety-of-oral-pcsk92026-10-06 https://evidence-hub.com/study/18777-comparison-of-the-efficacy-and-safety-of-myasthenia-gravis-treatments2026-10-06 https://evidence-hub.com/study/18778-efficacy-safety-and-certainty-of-evidence-for-selective-d1-d52026-10-06 https://evidence-hub.com/study/18779-jak-inhibitors-in-inflammatory-skin-diseases-a-15-427-patient2026-10-06 https://evidence-hub.com/study/18780-characterization-of-the-safety-profile-of-the-triple-monoamine2026-10-06 https://evidence-hub.com/study/18781-age-and-treatment-efficacy-in-myasthenia-gravis-a-systematic-review2026-10-06 https://evidence-hub.com/study/18782-a-dual-level-bayesian-network-meta-analysis-of-first-line2026-10-06 https://evidence-hub.com/study/18783-pharmacological-lipid-lowering-therapies-for-primary-and-secondary2026-10-06 https://evidence-hub.com/study/18784-methods-of-incisor-inclination-control-during-the-non-accelerated2026-10-06 https://evidence-hub.com/study/18785-cardiovascular-efficacy-of-glp-1-receptor-agonists-by-kidney-function2026-10-06 https://evidence-hub.com/study/18786-efficacy-and-safety-of-tubeless-hybrid-closed-loop-systems-in-type-12026-10-06 https://evidence-hub.com/study/18787-pharmacological-and-clinical-heterogeneity-of-anti-amyloid-monoclonal2026-10-06 https://evidence-hub.com/study/18788-infection-risk-associated-with-talquetamab-in-relapsed-refractory2026-10-06 https://evidence-hub.com/study/18789-drug-approvals-in-crowded-drug-classes-potentially-reflect-efficacy2026-10-06 https://evidence-hub.com/study/18790-conduction-system-pacing-vs-biventricular-pacing-for-cardiac2026-10-06 https://evidence-hub.com/study/18791-il-17-ligand-targeting-inhibitors-in-psoriatic-arthritis-a-focused2026-10-06 https://evidence-hub.com/study/18792-burden-and-risk-of-depression-in-patients-receiving-semaglutide-a2026-10-06 https://evidence-hub.com/study/18793-a-meta-analysis-of-the-long-term-effects-of-antihypertensive-therapy2026-10-06 https://evidence-hub.com/study/18794-optimal-serum-potassium-concentrations-in-heart-failure-an-individual2026-10-06 https://evidence-hub.com/study/18795-comparative-effects-of-emerging-lp-a-lowering-agents-and-pcsk92026-10-06 https://evidence-hub.com/study/18796-potassium-competitive-acid-blockers-in-gastroesophageal-reflux2026-10-20 https://evidence-hub.com/study/18797-pharmacologic-management-of-sleep-bruxism-in-adults-a-systematic2026-10-06 https://evidence-hub.com/study/18798-novel-nonsteroidal-topical-therapies-for-pediatric-atopic-dermatitis2026-10-06 https://evidence-hub.com/study/18799-weight-regain-trajectories-after-discontinuation-of-semaglutide-or2026-10-06 https://evidence-hub.com/study/18800-efficacy-and-safety-of-ion-channel-modulators-in-painful-diabetic2026-10-06 https://evidence-hub.com/study/18801-tuberculosis-related-outcomes-in-dermatologic-patients-receiving2026-10-06 https://evidence-hub.com/study/18802-efficacy-and-safety-of-bispecific-antibodies-versus-other-antitumor2026-10-06 https://evidence-hub.com/study/18803-early-analgesia-for-the-management-of-acute-pancreatitis-a-systematic2026-10-06 https://evidence-hub.com/study/18804-pharmacotherapy-for-post-traumatic-stress-disorder-ptsd2026-10-06 https://evidence-hub.com/study/18805-venous-thromboembolism-with-modern-glucose-lowering-agents-in2026-10-06 https://evidence-hub.com/study/18806-erythropoiesis-stimulating-agents-to-reduce-heart-failure2026-10-06 https://evidence-hub.com/study/18807-pooled-safety-profiles-of-bispecific-antibodies-targeting-pd-1-ctla-42026-10-06 https://evidence-hub.com/study/18808-pulsed-field-ablation-vs-thermal-ablation-for-pulmonary-vein2026-10-06 https://evidence-hub.com/study/18809-comparative-impact-of-clear-aligners-and-traditional-fixed-appliances2026-10-06 https://evidence-hub.com/study/18810-isolated-physical-activity-programs-during-pregnancy-and-postpartum2026-10-06 https://evidence-hub.com/study/18811-the-optimal-therapeutic-window-for-nonbioartificial-liver-support-in2026-10-06 https://evidence-hub.com/study/18812-a-review-of-clinical-trial-and-meta-analyses-of-bp-treatment2026-10-06 https://evidence-hub.com/study/18813-the-impact-of-glp-1-based-therapies-on-cardiovascular-outcomes-in2026-10-06 https://evidence-hub.com/study/18814-weight-loss-comorbidity-and-complications-after-single-anastomosis2026-10-06 https://evidence-hub.com/study/18815-updating-the-mash-pharmacotherapy-landscape-a-network-meta-analysis2026-10-06 https://evidence-hub.com/study/18816-efficacy-of-subgingival-irrigation-with-chemical-agents-as-adjuvants2026-10-06 https://evidence-hub.com/study/18817-effect-of-glucagon-like-peptide-1-receptor-agonists-on-body-weight2026-10-06 https://evidence-hub.com/study/18818-left-atrial-appendage-closure-versus-medical-therapy-in-atrial2026-10-06 https://evidence-hub.com/study/18819-perioperative-continuous-vs-interrupted-oral-anticoagulation-in-tavr2026-10-06 https://evidence-hub.com/study/18820-adjuvant-aspirin-for-colorectal-cancer-with-pik3ca-mutated-and-cox-22026-10-06 https://evidence-hub.com/study/18821-glucagon-like-peptide-1-receptor-agonists-and-advanced-liver-outcomes2026-10-06 https://evidence-hub.com/study/18822-reshaping-the-battlefield-reprogramming-the-melanoma-tumour2026-10-08 https://evidence-hub.com/study/18823-mineralocorticoid-receptor-antagonists-and-mortality-in-hypertension2026-10-06 https://evidence-hub.com/study/18824-efficacy-and-safety-of-glp-1-receptor-agonists-on-combined2026-10-06 https://evidence-hub.com/study/18825-comparative-efficacy-of-prevention-strategies-for-oral-mucositis-in2026-10-06 https://evidence-hub.com/study/18826-endogenous-sex-steroid-hormones-sex-hormone-binding-globulin-and-risk2026-10-06 https://evidence-hub.com/study/18827-longitudinal-changes-in-the-relative-toxicity-of-fda-approved2026-10-06 https://evidence-hub.com/study/18828-estimated-glomerular-filtration-rate-change-and-heart-failure-events2026-10-06 https://evidence-hub.com/study/18829-use-of-sedative-hypnotic-drugs-and-the-risk-of-developing-alzheimer-s2026-10-06 https://evidence-hub.com/study/18830-comparative-efficacy-of-tirzepatide-and-glucagon-like-peptide-12026-10-06 https://evidence-hub.com/study/18831-comparative-efficacy-and-safety-of-inhaled-maintenance-therapy2026-10-06 https://evidence-hub.com/study/18832-global-landscape-for-pulmonary-fibrosis-treatment-a-data-driven2026-10-06 https://evidence-hub.com/study/18833-mortality-in-octogenarian-patients-with-transthyretin-amyloidosis2026-10-06 https://evidence-hub.com/study/18834-nurse-led-nutritional-interventions-in-nursing-care-for-malnourished2026-10-08 https://evidence-hub.com/study/18835-adverse-effects-and-treatment-discontinuation-of-blood-pressure2026-10-06 https://evidence-hub.com/study/18836-targeting-neuroinflammation-in-adult-ischemic-stroke-direct2026-10-06 https://evidence-hub.com/study/18837-risk-factors-for-sudden-cardiac-death-in-heart-failure-a-systematic2026-10-06 https://evidence-hub.com/study/18838-preventing-pancreatic-fistula-following-pancreatectomy-meta-analysis2026-10-06 https://evidence-hub.com/study/18839-impact-of-female-underrepresentation-in-trials-investigating-long2026-10-06 https://evidence-hub.com/study/18840-permanent-vs-temporary-embolic-agents-in-genicular-artery2026-10-06 https://evidence-hub.com/study/18841-ocular-gene-therapy-targeting-retinal-angiogenesis-and-vascular2026-10-06 https://evidence-hub.com/study/18842-long-term-use-of-dual-orexin-receptor-antagonists-for-the-treatment2026-10-08 https://evidence-hub.com/study/18843-effects-of-biologic-and-targeted-synthetic-disease-modifying2026-10-06 https://evidence-hub.com/study/18844-the-quantitative-haemodynamic-effect-of-levosimendan-dobutamine-and2026-10-06 https://evidence-hub.com/study/18845-telmisartan-based-monotherapy-and-combination-regimens-for-blood2026-10-06 https://evidence-hub.com/study/18846-digital-health-technology-for-improving-physical-function-in-adults2026-10-06 https://evidence-hub.com/study/18847-first-line-treatment-for-transplant-ineligible-newly-diagnosed2026-10-06 https://evidence-hub.com/study/18848-pharmacologic-and-nutritional-therapies-in-idiopathic-male2026-10-06 https://evidence-hub.com/study/18849-skeletally-anchored-forsus-fatigue-resistant-device-for-correction-of2026-10-06 https://evidence-hub.com/study/18850-impact-of-physical-training-programs-on-physical-fitness-in-people2026-10-06 https://evidence-hub.com/study/18851-multivariate-network-meta-analysis-incorporating-class-effects2026-10-06 https://evidence-hub.com/study/18852-pharmacist-and-nurse-led-medical-optimization-in-heart-failure-a2026-10-06 https://evidence-hub.com/study/18853-cardiovascular-and-microvascular-outcomes-of-glucagon-like-peptide-12026-10-06 https://evidence-hub.com/study/18854-comparative-effects-of-sodium-glucose-cotransporter-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/18855-research-review-the-most-effective-parenting-program-content-for2026-10-06 https://evidence-hub.com/study/18856-individual-differences-in-response-to-antidepressants-a-meta-analysis2026-10-06 https://evidence-hub.com/study/18857-effect-of-hysteroscopic-metroplasty-on-reproductive-outcomes-in-women2026-10-06 https://evidence-hub.com/study/18859-the-effectiveness-of-cs-reducer-for-the-treatment-of-refractory2026-10-06 https://evidence-hub.com/study/18860-individual-differences-in-response-to-antidepressants-a-meta-analysis2026-10-06 https://evidence-hub.com/study/18861-effect-of-sodium-glucose-cotransport-2-inhibitors-on-blood-pressure2026-10-06 https://evidence-hub.com/study/18862-the-impact-of-financial-incentives-on-physical-activity-a-systematic2026-10-06 https://evidence-hub.com/study/18863-efficacy-and-safety-of-echinocandins-for-the-treatment-of-invasive2026-10-06 https://evidence-hub.com/study/18867-risk-of-cancer-with-angiotensin-receptor-blockers-increases-with2026-10-06 https://evidence-hub.com/study/18872-ceftaroline-fosamil-versus-ceftriaxone-for-the-treatment-of-community2026-10-06 https://evidence-hub.com/study/18873-abstract-11595-predicting-appropriate-shocks-in-patients-with-heart2026-10-06 https://evidence-hub.com/study/18874-clinical-effectiveness-of-direct-anterior-restorations-a-meta-analysis2026-10-06 https://evidence-hub.com/study/18876-effectiveness-and-safety-of-poly-adp-ribose-polymerase-inhibitors-in2026-10-06 https://evidence-hub.com/study/18877-atypical-antipsychotic-augmentation-in-ssri-treatment-refractory2026-10-06 https://evidence-hub.com/study/18878-meta-analysis-of-prevention-of-surgical-site-infections-following2026-10-06 https://evidence-hub.com/study/18882-less-is-more-in-antidepressant-clinical-trials-a-meta-analysis-of-the2026-10-06 https://evidence-hub.com/study/18883-angiotensin-converting-enzyme-inhibitors-reduce-mortality-in2026-10-06 https://evidence-hub.com/study/18886-use-of-fibrates-and-cancer-risk-a-systematic-review-and-meta-analysis2026-10-06 https://evidence-hub.com/study/18887-efficacy-comparison-of-trimetazidine-with-therapeutic-alternatives-in2026-10-06 https://evidence-hub.com/study/18888-adverse-effects-of-cyclooxygenase-2-inhibitors-on-renal-and2026-09-27 https://evidence-hub.com/study/18891-meta-analysis-of-antiarrhythmic-drug-trials2026-10-06 https://evidence-hub.com/study/18898-anti-anginal-drugs-systematic-review-and-clinical-implications2026-10-06 https://evidence-hub.com/study/18902-methods-for-synthesizing-findings-on-moderation-effects-across2026-10-06 https://evidence-hub.com/study/18904-acellular-dermal-matrix-and-subepithelial-connective-tissue-grafts2026-10-06 https://evidence-hub.com/study/18907-variability-in-running-economy-of-kenyan-world-class-and-european2026-10-06 https://evidence-hub.com/study/18908-effect-of-age-sex-and-morbidity-count-on-trial-attrition-meta2026-10-06 https://evidence-hub.com/study/18909-dental-and-skeletal-effects-of-herbst-appliance-forsus-fatigue2026-10-06 https://evidence-hub.com/study/18910-effect-of-lipid-lowering-therapies-on-c-reactive-protein-levels-a2026-10-10 https://evidence-hub.com/study/18911-a-systematic-review-and-network-meta-analysis-of-psychological2026-10-06 https://evidence-hub.com/study/18912-a-meta-analysis-of-efficacy-and-safety-data-from-head-to-head-first2026-10-06 https://evidence-hub.com/study/18913-comparative-effectiveness-and-safety-of-statins-as-a-class-and-of2026-10-06 https://evidence-hub.com/study/18914-an-investigation-of-antihypertensive-class-dementia-and-cognitive2026-10-06 https://evidence-hub.com/study/18915-atrial-fibrillation-ablation-in-heart-failure-with-reduced-vs2026-10-06 https://evidence-hub.com/study/18916-do-patients-with-different-craniofacial-patterns-have-differences-in2026-10-06 https://evidence-hub.com/study/18917-procedural-outcomes-with-femoral-radial-distal-radial-and-ulnar2026-10-06 https://evidence-hub.com/study/18918-efficacy-of-danshen-class-injection-in-the-treatment-of-acute2026-10-06 https://evidence-hub.com/study/18919-effect-of-removable-functional-appliances-on-mandibular-length-in2026-10-06 https://evidence-hub.com/study/18921-blood-pressure-lowering-efficacy-of-antihypertensive-drugs-and-their2026-10-06 https://evidence-hub.com/study/18922-efficacy-of-gut-brain-neuromodulators-in-irritable-bowel-syndrome-an2026-10-06 https://evidence-hub.com/study/18923-benefits-and-harms-of-drug-treatment-for-type-2-diabetes-systematic2026-10-06 https://evidence-hub.com/study/18924-clinical-performance-of-glass-ionomer-cement-and-composite-resin-in2026-10-06 https://evidence-hub.com/study/18925-the-era-of-parp-inhibitors-in-ovarian-cancer-class-action-or-not-a2026-10-06 https://evidence-hub.com/study/18928-comparative-effectiveness-of-glp-1-receptor-agonists-on-glycaemic2026-10-06 https://evidence-hub.com/study/18929-the-impact-of-antidepressant-dose-and-class-on-treatment-response-in2026-10-06 https://evidence-hub.com/study/18930-comparative-effects-of-11-antipsychotics-on-weight-gain-and-metabolic2026-10-06 https://evidence-hub.com/study/18931-risk-of-herpes-zoster-associated-with-jak-inhibitors-in-immune2026-10-10 https://evidence-hub.com/study/18932-risk-of-major-adverse-cardiovascular-events-in-immune-mediated2026-10-06 https://evidence-hub.com/study/18933-agreement-between-self-reported-illicit-drug-use-and-biological2026-10-06 https://evidence-hub.com/study/18934-the-effect-of-blood-pressure-lowering-medications-on-the-prevention2026-10-08 https://evidence-hub.com/study/18938-screen-time-increases-overweight-and-obesity-risk-among-adolescents-a2026-10-06 https://evidence-hub.com/study/18939-biologic-agents-licensed-for-severe-asthma-a-systematic-review-and2026-10-06 https://evidence-hub.com/study/18940-effects-of-exergames-on-student-physical-education-learning-in-the2026-10-06 https://evidence-hub.com/study/18941-pharmacological-therapy-in-the-management-of-temporomandibular2026-10-06 https://evidence-hub.com/study/18942-pharmacological-treatments-for-psychotic-depression-a-systematic2026-10-06 https://evidence-hub.com/study/18943-hepatitis-b-virus-reactivation-associated-with-new-classes-of2026-10-06 https://evidence-hub.com/study/18944-exposure-to-who-aware-antibiotics-and-isolation-of-multi-drug2026-10-06 https://evidence-hub.com/study/18945-arbuscular-mycorrhizal-fungi-mediated-enhanced-biomass-root2026-10-06 https://evidence-hub.com/study/18946-serms-ethnicity-and-clinical-trials-opportunities-and-challenges2026-10-06 https://evidence-hub.com/study/18947-postmarketing-surveillance-curriculum-for-the-clinical-pharmacologist2026-10-06 https://evidence-hub.com/study/18948-cox-2-inhibitors-a-class-act-or-just-vigorously-promoted2026-10-06 https://evidence-hub.com/study/18949-clinical-trials-of-behavioural-interventions-with-heterogeneous2026-10-06 https://evidence-hub.com/study/18950-master-protocol-trial-design-for-efficient-and-rational-evaluation-of2026-10-06 https://evidence-hub.com/study/18951-cannabinoids-for-the-treatment-of-pain-an-update-on-recent-clinical2026-10-06 https://evidence-hub.com/study/18952-discrete-choice-experiment-dce-to-quantify-the-influence-of-trial2026-10-06 https://evidence-hub.com/study/18953-personality-trait-dimensions-and-the-pharmacological-treatment-of2026-10-06 https://evidence-hub.com/study/18954-the-future-of-clinical-trials-in-inflammatory-bowel-disease2026-10-06 https://evidence-hub.com/study/18955-oral-hypoglycemic-agents-and-the-heart-failure-conundrum-lessons-from2026-10-06 https://evidence-hub.com/study/18956-the-changing-landscape-of-heart-failure-drug-clinical-trials-in-china2026-10-06 https://evidence-hub.com/study/18957-bayesian-borrowing-with-multiple-heterogeneous-historical-studies2026-10-06 https://evidence-hub.com/study/18958-tradeoff-based-optimization-criteria-in-clinical-trials-with-multiple2026-10-06 https://evidence-hub.com/study/18959-thiazide-diuretics-in-the-treatment-of-hypertension-an-update2026-10-06 https://evidence-hub.com/study/18960-homophily-and-co-occurrence-patterns-shape-randomized-trials-agendas2026-10-06 https://evidence-hub.com/study/18961-overview-of-microbicides-for-the-prevention-of-human-immunodeficiency2026-10-06 https://evidence-hub.com/study/18962-a-protected-class-an-unprotected-condition-and-a-biomarker-a-method2026-10-06 https://evidence-hub.com/study/18963-organization-and-analysis-of-safety-data-using-a-multivariate-approach2026-10-06 https://evidence-hub.com/study/18964-adaptive-design-for-staggered-start-clinical-trial2026-10-06 https://evidence-hub.com/study/18965-effect-of-long-term-prophylactic-treatment-on-survival-after2026-10-06 https://evidence-hub.com/study/18966-phase-i-first-in-class-trial-of-mcarh109-a-g-protein-coupled-receptor2026-10-06 https://evidence-hub.com/study/18967-transcatheter-edge-to-edge-repair-for-severe-isolated-tricuspid2026-10-06 https://evidence-hub.com/study/18968-iph4102-a-first-in-class-anti-kir3dl2-monoclonal-antibody-in-patients2026-10-06 https://evidence-hub.com/study/18969-long-term-weight-loss-effects-of-semaglutide-in-obesity-without2026-10-06 https://evidence-hub.com/study/18970-remote-haemodynamic-monitoring-of-pulmonary-artery-pressures-in2026-10-06 https://evidence-hub.com/study/18971-mavacamten-in-patients-with-hypertrophic-cardiomyopathy-referred-for2026-10-06 https://evidence-hub.com/study/18972-nivolumab-versus-sorafenib-in-advanced-hepatocellular-carcinoma2026-10-06 https://evidence-hub.com/study/18973-ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular2026-10-06 https://evidence-hub.com/study/18974-efficacy-and-safety-of-voclosporin-versus-placebo-for-lupus-nephritis2026-10-06 https://evidence-hub.com/study/18975-tazemetostat-for-patients-with-relapsed-or-refractory-follicular2026-10-06 https://evidence-hub.com/study/18976-safety-and-efficacy-of-the-dragonfly-system-for-transcatheter-valve2026-10-06 https://evidence-hub.com/study/18977-phase-ii-randomised-trial-of-type-i-interferon-inhibitor-anifrolumab2026-10-06 https://evidence-hub.com/study/18978-reduction-of-dietary-sodium-to-less-than-100-mmol-in-heart-failure2026-10-10 https://evidence-hub.com/study/18979-safety-tolerability-and-efficacy-of-up-titration-of-guideline2026-10-19 https://evidence-hub.com/study/18980-dapagliflozin-effects-on-biomarkers-symptoms-and-functional-status-in2026-10-06 https://evidence-hub.com/study/18981-mavacamten-for-treatment-of-symptomatic-obstructive-hypertrophic2026-10-06 https://evidence-hub.com/study/18982-effect-of-treatment-with-sacubitril-valsartan-in-patients-with2026-10-06 https://evidence-hub.com/study/18983-morbidity-and-mortality-of-laparoscopic-vs-open-total-gastrectomy-for2026-10-06 https://evidence-hub.com/study/18984-effect-of-digoxin-vs-bisoprolol-for-heart-rate-control-in-atrial2026-10-06 https://evidence-hub.com/study/18985-mtl-cebpa-a-small-activating-rna-therapeutic-upregulating-c-ebp-in2026-10-06 https://evidence-hub.com/study/18987-first-in-class-erk1-2-inhibitor-ulixertinib-bvd-523-in-patients-with2026-10-06 https://evidence-hub.com/study/18988-macitentan-for-the-treatment-of-portopulmonary-hypertension-portico-a2026-10-06 https://evidence-hub.com/study/18990-calcium-upregulation-by-percutaneous-administration-of-gene-therapy2026-10-06 https://evidence-hub.com/study/18991-a-randomized-controlled-trial-evaluating-general-endotracheal2026-10-06 https://evidence-hub.com/study/18992-treatment-of-advanced-gastrointestinal-cancer-with-genetically2026-10-06 https://evidence-hub.com/study/18993-baseline-characteristics-of-patients-with-hf-with-mildly-reduced-and2026-10-06 https://evidence-hub.com/study/18994-phase-i-ii-trial-testing-safety-and-immunogenicity-of-the2026-10-06 https://evidence-hub.com/study/18995-phase-ib-trial-with-birabresib-a-small-molecule-inhibitor-of2026-10-06 https://evidence-hub.com/study/18996-effect-of-neladenoson-bialanate-on-exercise-capacity-among-patients2026-10-12 https://evidence-hub.com/study/18997-phase-i-ii-multicenter-trial-of-a-novel-therapeutic-cancer-vaccine2026-10-06 https://evidence-hub.com/study/19001-intraaortic-balloon-pump-in-cardiogenic-shock-complicating-acute2026-10-06 https://evidence-hub.com/study/19003-phase-ii-trial-of-the-pi3-kinase-inhibitor-buparlisib-bkm-120-with-or2026-10-06 https://evidence-hub.com/study/19004-six-subphenotypes-in-septic-shock-latent-class-analysis-of-the2026-10-06 https://evidence-hub.com/study/19009-improved-survival-with-adjuvant-cyclooxygenase-2-inhibition-in-pik3ca2026-10-06 https://evidence-hub.com/study/19010-non-steroidal-anti-inflammatory-drug-nsaid-therapy-in-patients-with2026-10-06 https://evidence-hub.com/study/19011-challenges-and-opportunities-for-celecoxib-repurposing2026-10-01 https://evidence-hub.com/study/19012-cardiovascular-anti-inflammatory-drugs-repurposed-for-treating-or2026-10-06 https://evidence-hub.com/study/19013-cyclooxygenase-2-inhibitors2026-10-06 https://evidence-hub.com/study/19014-aspirin-and-other-non-steroidal-anti-inflammatory-drugs-for-the2026-10-06 https://evidence-hub.com/study/19015-cyclooxygenase-2-inhibitors-a-painful-lesson2026-10-06 https://evidence-hub.com/study/19016-relative-thromboembolic-risks-associated-with-cox-2-inhibitors2026-10-06 https://evidence-hub.com/study/19017-risk-of-cardiovascular-events-and-celecoxib-a-systematic-review-and2026-10-01 https://evidence-hub.com/study/19018-clinical-recommendations-for-augmentation-agents-in-obsessive2026-10-06 https://evidence-hub.com/study/19019-polypharmacology-of-carbonic-anhydrase-inhibitors-and-activators2026-10-06 https://evidence-hub.com/study/19020-cox-2-inhibitors-today-and-tomorrow2026-10-06 https://evidence-hub.com/study/19021-multi-and-polypharmacology-of-carbonic-anhydrase-inhibitors2026-10-06 https://evidence-hub.com/study/19022-cardiovascular-effects-of-cyclooxygenase-2-inhibitors2026-10-06 https://evidence-hub.com/study/19023-celecoxib-and-cardiovascular-risks2026-10-06 https://evidence-hub.com/study/19024-pharmacology-and-cellular-molecular-mechanisms-of-action-of-aspirin2026-10-06 https://evidence-hub.com/study/19025-selective-cox-2-inhibitors-as-anticancer-agents-a-patent-review-20182026-10-06 https://evidence-hub.com/study/19026-cox-2-selective-inhibitors-and-heart-health2026-10-06 https://evidence-hub.com/study/19027-gastrointestinal-safety-of-coxibs-and-outcomes-studies-what-s-the2026-10-06 https://evidence-hub.com/study/19028-outcomes-studies-of-the-gastrointestinal-safety-of-cyclooxygenase-22026-10-06 https://evidence-hub.com/study/19029-drug-interaction-considerations-in-the-therapeutic-use-of-carbonic2026-09-27 https://evidence-hub.com/study/19030-are-all-oral-cox-2-selective-inhibitors-the-same-a-consideration-of2026-10-01 https://evidence-hub.com/study/19031-review-article-nsaids-gastroprotection-and-cyclo-oxygenase-ii2026-09-27 https://evidence-hub.com/study/19032-cox-2-specific-inhibitors-the-emergence-of-a-new-class-of-analgesic2026-10-06 https://evidence-hub.com/study/19033-problems-of-cardiovascular-toxicity-of-coxibs-and-non-selective-nsa2026-10-06 https://evidence-hub.com/study/19034-clinically-relevant-anti-inflammatory-agents-for-chemoprevention-of2026-10-01 https://evidence-hub.com/study/19035-the-double-edged-sword-of-cox-2-selective-nsaids2026-10-01 https://evidence-hub.com/study/19036-systematic-review-and-meta-analysis-of-studies-in-which-burrowing2026-10-06 https://evidence-hub.com/study/19037-cox-2-specific-inhibitors-and-the-kidney-effect-on-hypertension-and2026-10-06 https://evidence-hub.com/study/19038-prostaglandin-e2-as-a-therapeutic-target-in-bladder-cancer-from-basic2026-10-06 https://evidence-hub.com/study/19039-evaluating-adverse-events-reported-for-non-steroidal-anti2026-10-06 https://evidence-hub.com/study/19040-clinical-pharmacology-of-selective-cox-2-inhibitors2026-10-06 https://evidence-hub.com/study/19041-cox-2-inhibitors-and-the-cardiovascular-system2026-10-06 https://evidence-hub.com/study/19042-the-efficacy-of-chemopreventive-agents-on-the-incidence-of-colorectal2026-10-06 https://evidence-hub.com/study/19043-cyclooxygenase-1-and-2-molecular-targets-for-cervical-neoplasia2026-10-06 https://evidence-hub.com/study/19044-cyclooxygenase-2-inhibitors-what-went-wrong2026-10-06 https://evidence-hub.com/study/19045-selective-cyclooxygenase-2-inhibitors-for-the-treatment-of-arthritis2026-10-06 https://evidence-hub.com/study/19046-dual-blockade-of-ep2-and-ep4-signaling-is-required-for-optimal-immune2026-10-06 https://evidence-hub.com/study/19047-an-evidence-based-evaluation-of-the-gastrointestinal-safety-of-coxibs2026-09-27 https://evidence-hub.com/study/19048-efficacy-and-safety-of-co-crystal-of-tramadol-celecoxib-ctc-in-acute2026-10-06 https://evidence-hub.com/study/19049-medications-for-the-prevention-of-pruritus-in-women-undergoing2026-10-06 https://evidence-hub.com/study/19050-cyclooxygenase-inhibition-between-the-devil-and-the-deep-blue-sea2026-10-06 https://evidence-hub.com/study/19051-drug-repurposing-in-pediatric-brain-tumors-posterior-fossa-ependymoma2026-10-06 https://evidence-hub.com/study/19052-genetic-polymorphism-of-the-human-cytochrome-p450-2c9-gene-and-its2026-10-06 https://evidence-hub.com/study/19053-single-dose-and-steady-state-pharmacokinetics-of-celecoxib-in-children2026-10-06 https://evidence-hub.com/study/19054-cox-2-inhibitors-a-story-of-greed-deception-and-death2026-10-06 https://evidence-hub.com/study/19055-nonsteroidal-anti-inflammatory-drugs-confusion-controversy-and-dental2026-10-06 https://evidence-hub.com/study/19056-chemoprevention-for-barrett-s-esophagus-trial-design-and-outcome2026-10-06 https://evidence-hub.com/study/19057-efficacy-and-tolerability-of-nonprescription-ibuprofen-versus2026-09-27 https://evidence-hub.com/study/19058-selective-cyclooxygenase-2-cox-2-inhibitors-and-potential-risk-of2026-10-06 https://evidence-hub.com/study/19059-risk-of-cardiovascular-events-associated-with-selective-cox-22026-09-27 https://evidence-hub.com/study/19060-effectiveness-and-tolerance-of-anti-inflammatory-drugs-add-on-therapy2026-10-06 https://evidence-hub.com/study/19061-what-do-we-know-about-the-cardiovascular-toxicity-of-the-nsaids2026-10-06 https://evidence-hub.com/study/19062-monocyte-cyclooxygenase-2-activity-a-new-therapeutic-target-for2026-10-06 https://evidence-hub.com/study/19063-gastrointestinal-safety-of-selective-cox-2-inhibitors2026-10-06 https://evidence-hub.com/study/19064-angiogenesis-inhibitors-under-study-for-the-treatment-of-lung-cancer2026-10-06 https://evidence-hub.com/study/19065-cox-2-selective-inhibitors-in-the-treatment-of-arthritis2026-10-06 https://evidence-hub.com/study/19066-current-perspective-on-the-cardiovascular-effects-of-coxibs2026-10-06 https://evidence-hub.com/study/19067-celecoxib-tramadol-co-crystal-in-patients-with-moderate-to-severe2026-10-06 https://evidence-hub.com/study/19068-clinical-pharmacology-of-lumiracoxib-a-second-generation2026-10-06 https://evidence-hub.com/study/19069-drug-insight-cyclo-oxygenase-2-inhibitors-and-cardiovascular-risk2026-10-06 https://evidence-hub.com/study/19070-non-steroidal-anti-inflammatory-drugs-nsaids-and-other-anti2026-10-06 https://evidence-hub.com/study/19071-comparative-pain-reduction-of-oral-non-steroidal-anti-inflammatory2026-10-01 https://evidence-hub.com/study/19072-celecoxib-tramadol-co-crystal-a-randomized-4-way-crossover2026-10-06 https://evidence-hub.com/study/19074-cardiovascular-hazard-of-selective-cox-2-inhibitors-myth-or-reality2026-10-06 https://evidence-hub.com/study/19075-selective-cox-2-inhibitors-eicosanoid-synthesis-and-clinical-outcomes2026-10-06 https://evidence-hub.com/study/19076-a-phase-1-trial-of-human-telomerase-reverse-transcriptase-htert2026-10-06 https://evidence-hub.com/study/19077-selective-cox-2-inhibitors-and-gastrointestinal-mucosal-injury2026-10-06 https://evidence-hub.com/study/19078-the-coxibs-and-traditional-nonsteroidal-anti-inflammatory-drugs-a2026-10-06 https://evidence-hub.com/study/19079-is-cox-2-a-collateral-target-in-cancer-prevention2026-10-06 https://evidence-hub.com/study/19080-clinical-switching-strategies-of-various-antidepressants-to2026-10-06 https://evidence-hub.com/study/19081-use-of-first-and-second-generation-cyclooxygenase-2-selective2026-10-01 https://evidence-hub.com/study/19082-cardiorenal-effects-of-celecoxib-as-compared-with-the-nonsteroidal2026-10-06 https://evidence-hub.com/study/19083-are-there-any-differences-in-the-cardiovascular-tolerance-between2026-10-06 https://evidence-hub.com/study/19084-selective-cox-2-inhibitors-and-risk-of-thromboembolic-events2026-10-06 https://evidence-hub.com/study/19085-non-conventional-pharmacological-agents-for-the-treatment-of-bipolar2026-10-06 https://evidence-hub.com/study/19086-selecting-new-drugs-for-pain-control-evidence-based-decisions-or2026-10-06 https://evidence-hub.com/study/19087-targeting-angiogenesis-a-review-of-angiogenesis-inhibitors-in-the2026-10-06 https://evidence-hub.com/study/19088-non-antidepressant-pharmacological-treatment-of-obsessive-compulsive2026-10-06 https://evidence-hub.com/study/19089-investigation-of-the-predictive-validity-of-laser-eps-in-normal-uvb2026-10-06 https://evidence-hub.com/study/19090-celecoxib-up-regulates-the-expression-of-the-zeta-chain-of-t-cell2026-10-06 https://evidence-hub.com/study/19091-ulcers-helicobacter-pylori-infection-platelets-and-gastrointestinal2026-10-06 https://evidence-hub.com/study/19092-cox-inhibitors-relieve-the-immunosuppressive-effect-of-tumor-cells2026-10-06 https://evidence-hub.com/study/19093-pharmacokinetics-of-tramadol-and-celecoxib-in-japanese-and-caucasian2026-10-06 https://evidence-hub.com/study/19094-cox-2-inhibition-and-thrombotic-tendency-a-need-for-surveillance2026-10-06 https://evidence-hub.com/study/19095-deep-learning-assisted-colonoscopy-images-for-prediction-of-mismatch2026-10-06 https://evidence-hub.com/study/19096-postoperative-nonsteroidal-anti-inflammatory-drug-prophylaxis-for2026-10-06 https://evidence-hub.com/study/19097-nsaids-and-cox-2-inhibitors-what-can-we-learn-from-large-outcomes2026-10-06 https://evidence-hub.com/study/19098-assessment-of-comparative-pain-relief-and-tolerability-of-ski306x2026-09-27 https://evidence-hub.com/study/19099-what-have-we-learned-from-the-large-outcomes-trials-of-cox-22026-10-06 https://evidence-hub.com/study/19100-pharmacokinetic-drug-interactions-of-the-selective-androgen-receptor2026-10-06 https://evidence-hub.com/study/19101-cardiovascular-thrombotic-events-in-arthritis-trials-of-the2026-09-27 https://evidence-hub.com/study/19102-phase-i-pilot-study-of-a-novel-celecoxib-containing-paste-for-local2026-10-06 https://evidence-hub.com/study/19103-efficacy-and-safety-of-celecoxib-combined-with-jintiange-capsules-for2026-10-06 https://evidence-hub.com/study/19104-effects-of-chronic-pain-medications-on-cardiovascular-health-a2026-10-06 https://evidence-hub.com/study/19105-comparison-of-transdermal-and-oral-anti-inflammatory-drugs-on2026-10-06 https://evidence-hub.com/study/19106-heterotopic-ossification-following-total-hip-arthroplasty-a2026-10-06 https://evidence-hub.com/study/19107-randomised-phase-iii-trials-of-cancer-prevention-drugs-a-systematic2026-10-06 https://evidence-hub.com/study/19108-comparison-of-the-efficacy-and-safety-of-acetaminophen-versus-nsaids2026-10-06 https://evidence-hub.com/study/19109-pragmatic-evaluation-of-prescription-glucosamine-sulfate-pgs-in-knee2026-10-06 https://evidence-hub.com/study/19110-standard-rescue-medication-adjustments-produce-biased-estimates-of2026-10-06 https://evidence-hub.com/study/19111-acute-migraine-treatments-in-patients-above-age-652026-10-06 https://evidence-hub.com/study/19112-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of2026-10-06 https://evidence-hub.com/study/19113-synergistic-inhibition-of-colorectal-cancer-growth-by-combined-pi3k2026-10-06 https://evidence-hub.com/study/19114-preventive-and-therapeutic-interventions-for-anticancer-drug-induced2026-10-06 https://evidence-hub.com/study/19115-cyclooxygenases-in-pancreatic-ductal-adenocarcinoma-are-they2026-10-06 https://evidence-hub.com/study/19116-discovering-repurposable-drugs-for-alzheimer-s-disease-and-related2026-10-06 https://evidence-hub.com/study/19117-toward-personalized-nsaid-therapy-in-osteoarthritis-the-right-patient2026-10-06 https://evidence-hub.com/study/19118-efficacy-and-safety-of-low-dose-celecoxib-in-patients-with-mild-to2026-10-06 https://evidence-hub.com/study/19119-chemotherapy-related-hand-foot-syndrome-and-hand-foot-skin-reaction-a2026-10-06 https://evidence-hub.com/study/19120-degree-of-cyclooxygenase-2-inhibition-modulates-blood-pressure2026-10-06 https://evidence-hub.com/study/19121-novel-therapeutic-strategies-for-osteoarthritis-from-mechanistic2026-10-06 https://evidence-hub.com/study/19122-depression-of-tryptophan-may-contribute-to-adverse-effects-of-naproxen2026-10-06 https://evidence-hub.com/study/19123-analgesic-efficacy-of-meloxicam-vs-ibuprofen-on-pain-after-third2026-10-06 https://evidence-hub.com/study/19124-protective-effects-of-natural-products-functional-foods-and2026-10-06 https://evidence-hub.com/study/19125-celecoxib-in-oncology-targeting-the-cox-2-pge2-axis-to-reprogram-the2026-10-06 https://evidence-hub.com/study/19126-systemic-therapies-for-desmoid-tumors-a-review-of-past-present-and2026-10-06 https://evidence-hub.com/study/19127-preoperative-nonopioid-analgesia-reduces-postoperative-opioid2026-10-06 https://evidence-hub.com/study/19128-trends-in-celecoxib-prescribing-a-single-institution-16-month-review2026-10-06 https://evidence-hub.com/study/19129-biology-and-evolving-management-of-resectable-dmmr-msi-h-cancers2026-10-06 https://evidence-hub.com/study/19130-the-effect-of-anti-inflammatory-drugs-on-the-incidence-of-colorectal2026-10-06 https://evidence-hub.com/study/19131-systematic-review-and-meta-analysis-of-analgesic-treatment-options-in2026-10-06 https://evidence-hub.com/study/19132-pharmacotherapy-for-bladder-spasm-and-irritative-lower-urinary-tract2026-10-06 https://evidence-hub.com/study/19133-adverse-effects-and-perceived-benefits-of-medications-in-children2026-10-08 https://evidence-hub.com/study/19134-recent-advances-in-thiazole-based-derivatives-targeting-diverse-anti2026-10-06 https://evidence-hub.com/study/19135-evaluation-of-potential-drug-drug-interactions-polypharmacy-and2026-10-06 https://evidence-hub.com/study/19136-a-triple-blinded-randomized-controlled-trial-comparing-hydromorphone2026-10-06 https://evidence-hub.com/study/19137-comparative-efficacy-of-interventions-for-the-prevention-and2026-10-08 https://evidence-hub.com/study/19138-zastaprazan-a-novel-potassium-competitive-acid-blocker-for-acid2026-10-20 https://evidence-hub.com/study/19139-non-pharmacological-complementary-and-alternative-therapies-for-knee2026-10-06 https://evidence-hub.com/study/19140-predicting-amyotrophic-lateral-sclerosis-mortality-with-machine2026-10-06 https://evidence-hub.com/study/19141-nonsteroidal-anti-inflammatory-drugs-and-risk-of-gastrointestinal2026-10-06 https://evidence-hub.com/study/19142-liposomal-bupivacaine-after-reduction-mammaplasty-is-it-worth-the2026-10-06 https://evidence-hub.com/study/19143-postoperative-pain-management-strategies-without-regional-analgesia2026-10-06 https://evidence-hub.com/study/19144-nutritional-interventions-in-cancer-management-a-comprehensive2026-10-06 https://evidence-hub.com/study/19145-rethinking-als-current-understanding-and-emerging-therapeutic2026-10-06 https://evidence-hub.com/study/19146-second-stage-knee-pain-is-not-increased-after-staged-bilateral-total2026-10-06 https://evidence-hub.com/study/19147-artificial-intelligence-for-precision-oncology-from-phenotyping-and2026-10-06 https://evidence-hub.com/study/19148-a-narrative-review-do-systemic-drugs-used-in-the-treatment-of2026-10-06 https://evidence-hub.com/study/19149-three-privileged-scaffolds-one-pipeline-chalcones-pyrazolines-and2026-10-06 https://evidence-hub.com/study/19150-postoperative-oral-corticosteroids-for-pain-management-and-recovery2026-10-06 https://evidence-hub.com/study/19151-a-phase-ii-study-evaluating-the-preventive-effect-of-topical2026-10-06 https://evidence-hub.com/study/19152-effectiveness-and-safety-of-pretreatment-analgesics-and-anti2026-10-06 https://evidence-hub.com/study/19153-targeting-cancer-cell-energy-metabolism-in-colorectal-cancer2026-10-06 https://evidence-hub.com/study/19154-neuroprotective-effects-of-the-nonsteroidal-anti-inflammatory-drug2026-10-06 https://evidence-hub.com/study/19155-fu-s-subcutaneous-needling-assisted-conservative-treatment-for-distal2026-10-06 https://evidence-hub.com/study/19156-therapeutic-repurposing-of-old-drugs-to-modulate-the-tumor-immune2026-10-19 https://evidence-hub.com/study/19157-pharmacologic-pain-management-strategies-for-reducing-postoperative2026-10-06 https://evidence-hub.com/study/19158-neoadjuvant-immunotherapy-in-mismatch-repair-proficient-colon-cancers2026-10-06 https://evidence-hub.com/study/19159-low-dose-nivolumab-with-neoadjuvant-chemotherapy-and-oral-metronomic2026-10-06 https://evidence-hub.com/study/19160-tnf-inhibitor-etanercept-improves-cerebrovascular-function-in-elderly2026-10-06 https://evidence-hub.com/study/19161-pharmacogenomic-stratification-for-oncology-drug-repurposing-an2026-10-06 https://evidence-hub.com/study/19162-beyond-pain-relief-the-thrombosis-threat-of-celecoxib2026-10-06 https://evidence-hub.com/study/19163-effectiveness-of-gabapentinoids-in-orthopedic-surgeries-a-systematic2026-10-06 https://evidence-hub.com/study/19164-do-nonsteroidal-anti-inflammatory-drugs-increase-the-risk-of-atrial2026-10-06 https://evidence-hub.com/study/19165-myeloid-derived-suppressor-cells-and-radiotherapy-regulation-and2026-10-06 https://evidence-hub.com/study/19166-identification-of-drug-related-cardiovascular-risks-a-comprehensive2026-10-06 https://evidence-hub.com/study/19167-prophylactic-effects-of-non-steroidal-anti-inflammatory-drugs-on2026-10-06 https://evidence-hub.com/study/19168-anti-oxidative-stress-therapies-reduce-chemotherapy-induced2026-10-06 https://evidence-hub.com/study/19169-inflammation-and-carcinogenesis-molecular-targets-and-small-molecule2026-10-06 https://evidence-hub.com/study/19170-review-of-structural-modification-and-development-of-novel-tramadol2026-10-06 https://evidence-hub.com/study/19171-comparison-of-a-fixed-dose-combination-of-celecoxib-pg201-layla2026-10-06 https://evidence-hub.com/study/19172-adjusted-indirect-and-mixed-comparisons-of-drug-therapy-for2026-10-06 https://evidence-hub.com/study/19173-temporal-trend-in-selective-cyclooxygenase-2-inhibitors-sales-in2026-10-06 https://evidence-hub.com/study/19174-combination-immunotherapy-for-colorectal-cancer-clinical-applications2026-10-06 https://evidence-hub.com/study/19175-navigating-chronic-pain-in-patients-with-cirrhosis-unique-analgesic2026-10-06 https://evidence-hub.com/study/19176-polymer-microneedles-for-localized-drug-delivery-in-musculoskeletal2026-10-06 https://evidence-hub.com/study/19177-medical-treatment-of-autism-spectrum-disorder-in-children-current2026-10-18 https://evidence-hub.com/study/19178-design-of-experiments-leads-to-scalable-analgesic-near-infrared2026-10-06 https://evidence-hub.com/study/19179-safety-and-efficacy-of-chemoprevention-for-familial-adenomatous2026-10-06 https://evidence-hub.com/study/19180-a-systematic-review-and-meta-analysis-of-the-effect-of-acupuncture2026-10-06 https://evidence-hub.com/study/19181-evaluating-the-association-between-migraine-treatments-and-tinnitus2026-10-06 https://evidence-hub.com/study/19182-combinatorial-delivery-of-low-dose-radiotherapy-and-immunotherapy-to2026-10-06 https://evidence-hub.com/study/19183-exploration-of-purine-metabolism-related-genes-in-the-development-of2026-10-06 https://evidence-hub.com/study/19184-estimating-costs-of-market-exclusivity-extensions-for-4-top-selling2026-10-06 https://evidence-hub.com/study/19185-adjuvant-aspirin-treatment-in-pik3ca-mutated-colon-cancer-patients2026-10-06 https://evidence-hub.com/study/19186-impact-on-analgesia-diaphragmatic-function-and-recovery-between2026-10-06 https://evidence-hub.com/study/19187-cost-effectiveness-of-monotherapy-versus-polypharmacy-in2026-10-06 https://evidence-hub.com/study/19188-chemopreventive-strategies-for-sporadic-colorectal-cancer-a-narrative2026-10-06 https://evidence-hub.com/study/19189-dexmedetomidine-ketamine-based-multimodal-general-anesthesia-with2026-10-06 https://evidence-hub.com/study/19190-efficacy-and-safety-of-esketamine-in-total-hip-and-knee-arthroplasty2026-10-06 https://evidence-hub.com/study/19191-anti-inflammatory-therapies-to-prevent-cardiovascular-events2026-10-06 https://evidence-hub.com/study/19192-evaluating-the-efficacy-of-lower-level-transversus-abdominis-plane2026-10-06 https://evidence-hub.com/study/19193-effects-of-general-anesthesia-versus-spinal-anesthesia-on-early2026-10-06 https://evidence-hub.com/study/19194-gout-therapy-updated2026-10-06 https://evidence-hub.com/study/19195-navigating-the-post-opioid-era-a-focus-on-non-opioid-perioperative2026-10-06 https://evidence-hub.com/study/19196-comparative-efficacy-and-safety-of-imrecoxib-versus-celecoxib-a2026-10-06 https://evidence-hub.com/study/19197-ubc4-a-repurposed-drug-regimen-for-adjunctive-use-during-bladder2026-10-06 https://evidence-hub.com/study/19199-new-long-term-insights-from-the-adenoma-prevention-with-celecoxib2026-09-27 https://evidence-hub.com/study/19200-the-cost-effectiveness-of-celecoxib-vs-diclofenac-in-the-treatment-of2026-10-01 https://evidence-hub.com/study/19201-celecoxib-versus-ibuprofen-in-the-prevention-of-heterotopic2026-10-06 https://evidence-hub.com/study/19202-comparison-of-the-effectiveness-and-tolerability-of-lidocaine-patch-52026-10-06 https://evidence-hub.com/study/19203-the-celecoxib-derivative-ar-12-has-broad-spectrum-antifungal-activity2026-10-01 https://evidence-hub.com/study/19213-are-selective-cox-2-inhibitors-superior-to-traditional-nsaids2026-10-06 https://evidence-hub.com/study/19215-are-selective-cox-2-inhibitors-superior-to-traditional-non-steroidal2026-10-01 https://evidence-hub.com/study/19233-phase-1-study-of-high-dose-dfmo-celecoxib-cyclophosphamide-and2026-10-06 https://evidence-hub.com/study/19234-co-crystal-of-tramadol-celecoxib-versus-tramadol-or-placebo-for-acute2026-10-06 https://evidence-hub.com/study/19235-inflammation-stratified-augmentation-of-vortioxetine-with-celecoxib2026-10-06 https://evidence-hub.com/study/19237-neoadjuvant-pd-1-blockade-with-toripalimab-with-or-without-celecoxib2026-10-06 https://evidence-hub.com/study/19238-effect-of-celecoxib-vs-placebo-added-to-standard-adjuvant-therapy-on2026-10-01 https://evidence-hub.com/study/19239-high-dose-celecoxib-for-pain-after-pediatric-tonsillectomy-a2026-10-06 https://evidence-hub.com/study/19241-short-term-celecoxib-celebrex-adjuvant-therapy-a-clinical-trial-study2026-10-06 https://evidence-hub.com/study/19243-effects-of-add-on-celecoxib-treatment-on-patients-with-schizophrenia2026-10-06 https://evidence-hub.com/study/19245-efficacy-of-sertraline-plus-placebo-or-add-on-celecoxib-in-major2026-10-06 https://evidence-hub.com/study/19246-phase-ii-trial-of-adjuvant-dendritic-cell-vaccine-in-combination-with2026-10-06 https://evidence-hub.com/study/19247-from-celecoxib-to-a-novel-class-of-phosphodiesterase-5-inhibitors2026-10-06 https://evidence-hub.com/study/19248-minocycline-and-celecoxib-as-adjunctive-treatments-for-bipolar2026-10-06 https://evidence-hub.com/study/19249-efficacy-of-the-addition-of-celecoxib-to-selective-serotonin-reuptake2026-10-06 https://evidence-hub.com/study/19250-translocator-protein-distribution-volume-predicts-reduction-of2026-10-06 https://evidence-hub.com/study/19251-postoperative-intravenous-parecoxib-sodium-followed-by-oral-celecoxib2026-10-06 https://evidence-hub.com/study/19252-evaluation-of-the-efficacy-of-celecoxib-and-ibuprofen-on2026-10-06 https://evidence-hub.com/study/19253-celecoxib-with-neoadjuvant-chemotherapy-for-breast-cancer-might2026-10-06 https://evidence-hub.com/study/19254-clinical-comparison-of-platelet-rich-plasma-injection-and-daily2026-10-06 https://evidence-hub.com/study/19255-transdermal-buprenorphine-patch-versus-oral-celecoxib-for-pain2026-10-06 https://evidence-hub.com/study/19256-short-term-effects-of-early-postoperative-celecoxib-administration2026-10-06 https://evidence-hub.com/study/19258-prognostic-and-predictive-role-of-circulating-tumor-dna-ctdna-in2026-10-06 https://evidence-hub.com/study/19259-boxit-a-randomised-phase-iii-placebo-controlled-trial-evaluating-the2026-10-06 https://evidence-hub.com/study/19260-randomized-trial-of-oral-cyclophosphamide-versus-oral2026-10-06 https://evidence-hub.com/study/19263-differential-blood-pressure-effects-of-ibuprofen-naproxen-and2026-10-06 https://evidence-hub.com/study/19264-pharmaceutical-grade-chondroitin-sulfate-is-as-effective-as-celecoxib2026-10-01 https://evidence-hub.com/study/19266-comparative-analgesic-efficacy-and-tolerability-of-celecoxib-and2026-10-06 https://evidence-hub.com/study/19267-adding-celecoxib-with-or-without-zoledronic-acid-for-hormone-naive2026-10-06 https://evidence-hub.com/study/19269-preemptive-analgesia-in-total-knee-arthroplasty-comparing-the-effects2026-10-06 https://evidence-hub.com/study/19270-efficacy-of-celecoxib-versus-ibuprofen-for-the-treatment-of-patients2026-10-06 https://evidence-hub.com/study/19272-co-crystal-of-tramadol-celecoxib-in-patients-with-moderate-to-severe2026-10-06 https://evidence-hub.com/study/19273-anti-inflammatory-treatment-of-depression-study-protocol-for-a2026-10-06 https://evidence-hub.com/study/19274-cerebral-mechanism-of-celecoxib-for-treating-knee-pain-study-protocol2026-10-06 https://evidence-hub.com/study/19277-single-dose-pharmacokinetics-of-co-crystal-of-tramadol-celecoxib2026-10-10 https://evidence-hub.com/study/19278-gastrointestinal-gi-randomized-event-and-safety-open-label-nsaid2026-09-27 https://evidence-hub.com/study/19279-a-13-week-multicenter-randomized-double-blind-double-dummy-placebo2026-09-27 https://evidence-hub.com/study/19280-a-prospective-randomized-double-blinded-active-comparator-non2026-09-27 https://evidence-hub.com/study/19281-the-use-of-celecoxib-celebrex-c-in-post-operative-pain-control-after2026-09-27 https://evidence-hub.com/study/19282-phase-i-clinical-trial-assessing-the-combination-of-chemokine2026-09-27 https://evidence-hub.com/study/19283-double-blind-triple-dummy-parallel-group-randomized-six-month-study2026-09-27 https://evidence-hub.com/study/19284-synthesis-and-biological-evaluation-of-the-1-5-diarylpyrazole-class2026-09-27 https://evidence-hub.com/study/19285-cardiovascular-safety-of-celecoxib-naproxen-or-ibuprofen-for-arthritis2026-10-01 https://evidence-hub.com/study/19286-celecoxib-versus-diclofenac-and-omeprazole-in-reducing-the-risk-of2026-10-01 https://evidence-hub.com/study/19287-risk-of-hospitalization-for-myocardial-infarction-among-users-of2026-09-27 https://evidence-hub.com/study/19288-efficacy-tolerability-and-upper-gastrointestinal-safety-of-celecoxib2026-10-01 https://evidence-hub.com/study/19290-comparison-of-thromboembolic-events-in-patients-treated-with2026-09-27 https://evidence-hub.com/study/19291-chemoprevention-of-nonmelanoma-skin-cancer-with-celecoxib-a2026-10-01 https://evidence-hub.com/study/19292-five-year-efficacy-and-safety-analysis-of-the-adenoma-prevention-with2026-10-01 https://evidence-hub.com/study/19293-celecoxib-for-osteoarthritis2026-10-01 https://evidence-hub.com/study/19294-tolerability-and-adverse-events-in-clinical-trials-of-celecoxib-in2026-10-01 https://evidence-hub.com/study/19295-celecoxib-a-specific-cox-2-inhibitor-with-anticancer-properties2026-10-01 https://evidence-hub.com/study/19297-single-dose-oral-celecoxib-for-acute-postoperative-pain-in-adults2026-10-01 https://evidence-hub.com/study/19298-eicosanoid-modulation-in-advanced-lung-cancer-cyclooxygenase-22026-10-01 https://evidence-hub.com/study/19299-randomized-trial-of-switching-from-prescribed-non-selective-non2026-10-01 https://evidence-hub.com/study/19301-cyclooxygenase-2-selective-non-steroidal-anti-inflammatory-drugs2026-10-01 https://evidence-hub.com/study/19302-history-and-progress-of-hypotheses-and-clinical-trials-for-alzheimer2026-10-01 https://evidence-hub.com/study/19303-celecoxib-a-selective-cyclooxygenase-2-inhibitor-for-the-treatment-of2026-10-01 https://evidence-hub.com/study/19305-effects-of-celecoxib-on-ambulatory-blood-pressure-in-hypertensive2026-10-01 https://evidence-hub.com/study/19306-s-adenosyl-methionine-same-versus-celecoxib-for-the-treatment-of2026-10-01 https://evidence-hub.com/study/19307-glucosamine-chondroitin-sulfate-and-the-two-in-combination-for2026-10-01 https://evidence-hub.com/study/19308-perioperative-celecoxib-administration-for-pain-management-after2026-10-01 https://evidence-hub.com/study/19309-pregabalin-celecoxib-and-their-combination-for-treatment-of-chronic2026-10-01 https://evidence-hub.com/study/19310-celecoxib-in-breast-cancer-prevention-and-therapy2026-10-01 https://evidence-hub.com/study/19311-cardiovascular-safety-of-non-steroidal-anti-inflammatory-drugs2026-10-01 https://evidence-hub.com/study/19312-effects-of-non-steroidal-anti-inflammatory-drug-treatments-on2026-10-01 https://evidence-hub.com/study/19313-celecoxib-considerations-regarding-its-potential-disease-modifying2026-10-01 https://evidence-hub.com/study/19314-dimethyl-celecoxib-dmc-a-derivative-of-celecoxib-that-lacks2026-10-01 https://evidence-hub.com/study/19315-celecoxib-for-rheumatoid-arthritis2026-10-01 https://evidence-hub.com/study/19316-efficacy-and-tolerability-of-celecoxib-in-the-treatment-of-acute2026-10-01 https://evidence-hub.com/study/19317-antitumor-properties-of-dimethyl-celecoxib-a-derivative-of-celecoxib2026-09-27 https://evidence-hub.com/study/19318-celecoxib-compared-with-sustained-release-paracetamol-for2026-10-06 https://evidence-hub.com/study/19319-co-crystal-of-tramadol-hydrochloride-celecoxib-ctc-a-novel-api-api-co2026-10-01 https://evidence-hub.com/study/19320-polymeric-nanoparticles-for-increased-oral-bioavailability-and-rapid2026-10-01 https://evidence-hub.com/study/19321-trial-publication-after-registration-in-clinicaltrials-gov-a-cross2026-10-01 https://evidence-hub.com/study/19322-antidepressant-activity-of-anti-cytokine-treatment-a-systematic2026-10-01 https://evidence-hub.com/study/19323-effects-of-celecoxib-and-naproxen-on-renal-function-in-nonazotemic2026-10-01 https://evidence-hub.com/study/19324-mechanism-of-dissolution-enhancement-and-bioavailability-of-poorly2026-10-01 https://evidence-hub.com/study/19327-downregulation-of-survivin-expression-and-concomitant-induction-of2026-10-01 https://evidence-hub.com/study/19328-haemoglobin-decreases-in-nsaid-users-over-time-an-analysis-of-two2026-10-01 https://evidence-hub.com/study/19329-combination-of-atorvastatin-and-celecoxib-synergistically-induces2026-10-01 https://evidence-hub.com/study/19330-cholestatic-hepatitis-in-association-with-celecoxib2026-10-01 https://evidence-hub.com/study/19331-cardiovascular-and-cerebrovascular-events-in-the-randomized2026-10-01 https://evidence-hub.com/study/19332-effects-of-celecoxib-on-blood-loss-pain-and-recovery-of-function2026-10-01 https://evidence-hub.com/study/19334-synergistic-effects-of-celecoxib-and-bupropion-in-a-model-of-chronic2026-10-01 https://evidence-hub.com/study/19335-celecoxib-a-cyclooxygenase-2-inhibitor-reduces-neointimal-hyperplasia2026-10-01 https://evidence-hub.com/study/19336-a-randomised-controlled-phase-ii-trial-of-pre-operative-celecoxib2026-10-01 https://evidence-hub.com/study/19337-celecoxib-for-mood-disorders-a-systematic-review-and-meta-analysis-of2026-10-01 https://evidence-hub.com/study/19338-role-of-inflammation-in-cognitive-impairment-results-of-observational2026-10-01 https://evidence-hub.com/study/19339-cyclooxygenase-2-dependent-and-independent-effects-of-celecoxib-in2026-10-01 https://evidence-hub.com/study/19340-celecoxib-analogues-disrupt-akt-signaling-which-is-commonly-activated2026-10-01 https://evidence-hub.com/study/19342-united-kingdom-back-pain-exercise-and-manipulation-uk-beam-randomised2026-10-01 https://evidence-hub.com/study/19344-the-risk-of-cardiovascular-thrombotic-events-with-selective2026-09-27 https://evidence-hub.com/study/19345-the-selective-cox-2-inhibitor-celecoxib-modulates-sphingolipid2026-10-01 https://evidence-hub.com/study/19346-celecoxib-enhances-radiosensitivity-of-hypoxic-glioblastoma-cells2026-10-01 https://evidence-hub.com/study/19347-ethosomal-nanocarriers-the-impact-of-constituents-and-formulation2026-10-01 https://evidence-hub.com/study/19348-hepatotoxicity-of-nonsteroidal-anti-inflammatory-drugs-a-systematic2026-10-01 https://evidence-hub.com/study/19349-effects-of-celecoxib-on-major-prostaglandins-in-asthma2026-10-01 https://evidence-hub.com/study/19350-trial-watch-tlr3-agonists-in-cancer-therapy2026-10-01 https://evidence-hub.com/study/19351-relationship-between-selective-cyclooxygenase-2-inhibitors-and-acute2026-10-01 https://evidence-hub.com/study/19352-differences-between-clinical-trials-and-postmarketing-use2026-10-01 https://evidence-hub.com/study/19353-cusp9-treatment-protocol-for-recurrent-glioblastoma-aprepitant2026-10-01 https://evidence-hub.com/study/19354-the-cyclo-oxygenase-2-inhibitor-celecoxib-perturbs-intracellular2026-10-01 https://evidence-hub.com/study/19355-patient-level-pooled-analysis-of-adjudicated-gastrointestinal2026-10-01 https://evidence-hub.com/study/19357-statins-as-potential-disease-modifying-therapy-of-parkinson-s-disease2026-10-06 https://evidence-hub.com/study/19358-mandibular-class-ii-furcation-defect-treatment-effects-of-the2026-10-06 https://evidence-hub.com/study/19359-reducing-the-risk-of-stroke-in-elderly-patients-with-hypertension-a2026-10-06 https://evidence-hub.com/study/19360-a-systematic-review-of-tacrolimus-ointment-compared-with2026-10-06 https://evidence-hub.com/study/19361-effectiveness-of-cardiac-resynchronization-therapy-in-mild-congestive2026-10-06 https://evidence-hub.com/study/19362-impact-of-baseline-hiv-1-rna-levels-on-initial-highly-active2026-10-06 https://evidence-hub.com/study/19363-effectiveness-of-multipoint-cardiac-resynchronizing-therapy-in-heart2026-10-06 https://evidence-hub.com/study/19364-intraocular-pressure-lowering-efficacy-and-ocular-safety-of-rho2026-10-06 https://evidence-hub.com/study/19365-blood-pressure-lowering-efficacy-of-beta-1-selective-beta-blockers2026-10-06 https://evidence-hub.com/study/19366-assessment-botulinum-neurotoxin-for-the-treatment-of-spasticity-an2026-10-06 https://evidence-hub.com/study/19367-exercise-training-for-systolic-heart-failure-cochrane-systematic2026-10-06 https://evidence-hub.com/study/19368-autologous-bone-marrow-stem-cell-transplantation-in-critical-limb2026-10-06 https://evidence-hub.com/study/19369-evidence-based-cognitive-rehabilitation-updated-review-of-the2026-10-06 https://evidence-hub.com/study/19370-medical-expulsive-therapy-in-urolithiasis-a-mixed-treatment2026-10-06 https://evidence-hub.com/study/19371-pharmacological-interventions-for-hypertension-in-children2026-10-06 https://evidence-hub.com/study/19372-interventions-for-preventing-high-altitude-illness-part-1-commonly2026-10-10 https://evidence-hub.com/study/19373-efficacy-and-safety-of-parp-inhibitors-in-the-treatment-of-advanced2026-10-06 https://evidence-hub.com/study/19374-effects-of-ad5fgf-4-in-patients-with-angina-an-analysis-of-pooled2026-10-06 https://evidence-hub.com/study/19375-difference-in-blood-pressure-response-to-ace-inhibitor-monotherapy2026-10-06 https://evidence-hub.com/study/19376-drug-treatment-for-panic-disorder-with-or-without-agoraphobia2026-10-06 https://evidence-hub.com/study/19377-blood-pressure-control-and-primary-prevention-of-stroke-summary-of2026-10-06 https://evidence-hub.com/study/19378-first-line-drugs-for-hypertension2026-10-06 https://evidence-hub.com/study/19379-first-line-drugs-for-hypertension2026-10-06 https://evidence-hub.com/study/19380-a-systematic-review-of-placebo-controlled-randomized-clinical-trials2026-10-06 https://evidence-hub.com/study/19381-adjuvant-hyperbaric-oxygen-therapy-in-the-management-of-crush-injury2026-10-06 https://evidence-hub.com/study/19382-effect-of-herbst-treatment-on-temporomandibular-joint-morphology-a2026-10-06 https://evidence-hub.com/study/19383-interventions-for-deliberately-altering-blood-pressure-in-acute-stroke2026-10-06 https://evidence-hub.com/study/19384-branched-chain-amino-acids-for-people-with-hepatic-encephalopathy2026-10-06 https://evidence-hub.com/study/19385-can-subepithelial-connective-tissue-grafts-be-considered-the-gold2026-10-06 https://evidence-hub.com/study/19386-conflicting-results-between-randomized-trials-and-observational2026-10-06 https://evidence-hub.com/study/19387-meta-analysis-on-drug-and-device-therapy-of-new-york-heart2026-10-06 https://evidence-hub.com/study/19388-paediatric-safety-of-azithromycin-worldwide-experience2026-10-06 https://evidence-hub.com/study/19389-evidence-based-assessment-of-tooth-colored-restorations-in-proximal2026-10-06 https://evidence-hub.com/study/19390-effect-of-lipid-lowering-therapies-on-lipoprotein-a-levels-a2026-10-06 https://evidence-hub.com/study/19391-risk-of-major-adverse-cardiovascular-events-and-stroke-associated2026-10-06 https://evidence-hub.com/study/19392-a-historical-cohort-of-temporal-lobe-surgery-for-medically-refractory2026-10-06 https://evidence-hub.com/study/19393-medications-for-adults-with-type-2-diabetes-a-living-systematic2026-10-06 https://evidence-hub.com/study/19394-risk-for-cancer-with-glucagon-like-peptide-1-receptor-agonists-and2026-10-06 https://evidence-hub.com/study/19395-the-effectiveness-of-sodium-glucose-co-transporter-2-inhibitors-on2026-10-06 https://evidence-hub.com/study/19396-conduction-system-pacing-versus-biventricular-pacing-in-heart-failure2026-10-06 https://evidence-hub.com/study/19397-efficacy-of-modern-therapies-for-heart-failure-with-reduced-ejection2026-10-06 https://evidence-hub.com/study/19398-risk-of-diabetic-ketoacidosis-associated-with-sodium-glucose2026-10-06 https://evidence-hub.com/study/19399-influence-of-blood-pressure-reduction-on-pulse-wave-velocity-in2026-10-06 https://evidence-hub.com/study/19400-clinical-effectiveness-of-different-types-of-bone-anchored-maxillary2026-10-06 https://evidence-hub.com/study/19401-complete-root-coverage-in-the-treatment-of-miller-class-iii-or-rt22026-10-06 https://evidence-hub.com/study/19402-efficacy-and-safety-of-cardioprotective-drugs-in-chemotherapy-induced2026-10-06 https://evidence-hub.com/study/19403-efficacy-of-peritoneal-dialysis-in-patients-with-refractory2026-10-06 https://evidence-hub.com/study/19404-improved-outcomes-of-conduction-system-pacing-in-heart-failure-with2026-10-06 https://evidence-hub.com/study/19406-incidence-of-infections-in-patients-with-psoriatic-arthritis-and2026-10-06 https://evidence-hub.com/study/19407-imeglimin-a-novel-first-in-class-blood-glucose-lowering-agent-a2026-10-06 https://evidence-hub.com/study/19408-characterizing-class-specific-exposure-viral-load-suppression2026-10-06 https://evidence-hub.com/study/19409-insights-into-the-cardiovascular-benefits-of-taurine-a-systematic2026-10-06 https://evidence-hub.com/study/19410-comparative-effects-of-glucose-lowering-agents-on-endothelial2026-10-06 https://evidence-hub.com/study/19411-medical-therapies-for-prevention-and-treatment-of-inflammatory-pouch2026-10-06 https://evidence-hub.com/study/19412-comparative-efficacy-of-thr-agonists-fgf-21-analogues-glp-1r-agonists2026-10-06 https://evidence-hub.com/study/19413-rhythm-vs-rate-control-strategy-for-atrial-fibrillation-a-meta2026-10-06 https://evidence-hub.com/study/19414-the-effectiveness-of-alternating-rapid-maxillary-expansion-and2026-10-06 https://evidence-hub.com/study/19415-hypoglycemic-agents-and-bone-health-an-umbrella-systematic-review-of2026-10-06 https://evidence-hub.com/study/19418-sodium-restriction-in-patients-with-heart-failure-a-systematic-review2026-10-06 https://evidence-hub.com/study/19419-efficacy-and-safety-of-atogepant-a-small-molecule-cgrp-receptor2026-10-06 https://evidence-hub.com/study/19420-blood-pressure-lowering-and-risk-of-new-onset-type-2-diabetes-an2026-10-06 https://evidence-hub.com/study/19421-antihypertensive-treatment-and-risk-of-cancer-an-individual2026-10-06 https://evidence-hub.com/study/19422-efficacy-of-personalized-psychological-interventions-a-systematic2026-10-06 https://evidence-hub.com/study/19423-efficacy-of-psychotropic-medications-on-suicide-and-self-injury-a2026-10-06 https://evidence-hub.com/study/19424-systematic-review-and-meta-analysis-of-studies-assessing-the2026-10-06 https://evidence-hub.com/study/19425-comparative-efficacy-and-tolerability-of-pharmacological2026-10-06 https://evidence-hub.com/study/19426-efficacy-of-pulmonary-artery-pressure-monitoring-in-patients-with2026-10-06 https://evidence-hub.com/study/19428-the-effect-of-renin-angiotensin-aldosterone-system-inhibitors-on2026-10-06 https://evidence-hub.com/study/19429-topical-treatments-for-atopic-dermatitis-eczema-systematic-review-and2026-10-06 https://evidence-hub.com/study/19430-efficacy-and-safety-of-copanlisib-in-relapsed-refractory-b-cell-non2026-10-06 https://evidence-hub.com/study/19431-revisiting-monoamine-oxidase-inhibitors-for-the-treatment-of2026-10-06 https://evidence-hub.com/study/19433-the-comparative-effectiveness-and-safety-of-insomnia-drugs-a2026-10-06 https://evidence-hub.com/study/19434-sex-related-differences-in-patient-characteristics-and-efficacy-and2026-10-06 https://evidence-hub.com/study/19435-pharmacotherapy-for-dravet-syndrome-a-systematic-review-and-network2026-10-06 https://evidence-hub.com/study/19436-glucagon-like-peptide-1-based-incretin-agonists-in-obesity-related2026-10-06 https://evidence-hub.com/study/19437-beta-blocker-therapy-in-patients-with-copd-a-systematic-literature2026-10-06 https://evidence-hub.com/study/19438-distalization-of-maxillary-molars-using-temporary-skeletal-anchorage2026-10-06 https://evidence-hub.com/study/19439-mavacamten-treatment-for-hypertrophic-cardiomyopathy-a-systematic2026-10-06 https://evidence-hub.com/study/19440-left-bundle-branch-area-pacing-vs-biventricular-pacing-for-cardiac2026-10-06 https://evidence-hub.com/study/19441-comparative-efficacy-and-safety-of-adjunctive-drugs-to-levodopa-for2026-10-06 https://evidence-hub.com/study/19442-weight-and-metabolic-outcomes-in-naive-hiv-patients-treated-with2026-10-06 https://evidence-hub.com/study/19443-effects-of-lifestyle-interventions-that-include-a-physical-activity2026-10-06 https://evidence-hub.com/study/19444-comparison-of-the-effects-of-glucagon-like-peptide-receptor-agonists2026-10-06 https://evidence-hub.com/study/19445-network-meta-analysis-comparing-relatively-selective-cox-2-inhibitors2026-10-06 https://evidence-hub.com/study/19446-adverse-events-of-oral-analgesics-after-third-molar-extraction-a2026-10-06 https://evidence-hub.com/study/19447-systemic-therapy-in-the-treatment-of-recurrent-or-refractory2026-10-06 https://evidence-hub.com/study/19448-effect-of-anti-inflammatory-treatment-on-depressive-symptom-severity2026-10-06 https://evidence-hub.com/study/19449-effectiveness-of-exercise-therapy-for-osteoarthritis-an-overview-of2026-10-06 https://evidence-hub.com/study/19450-pre-emptive-analgesia-for-periodontal-and-implant-related-surgery-a2026-10-06 https://evidence-hub.com/study/19451-prognostic-significance-of-kras-nras-braf-and-pik3ca-mutations-in2026-10-06 https://evidence-hub.com/study/19452-liposomal-bupivacaine-versus-conventional-anesthetics-in-adductor2026-10-06 https://evidence-hub.com/study/19453-comparative-effects-of-drug-interventions-for-the-acute-management-of2026-10-06 https://evidence-hub.com/study/19454-a-network-meta-analysis-of-optimal-strategies-for-preventing-post2026-10-10 https://evidence-hub.com/study/19455-colchicine-for-the-primary-prevention-of-cardiovascular-events2026-10-06 https://evidence-hub.com/study/19456-comparative-efficacy-and-safety-of-different-pharmacological2026-10-06 https://evidence-hub.com/study/19457-a-meta-analysis-exploring-the-efficacy-of-neuropathic-pain-medication2026-10-06 https://evidence-hub.com/study/19458-selective-versus-non-selective-nsaids-as-prophylaxis-for-heterotopic2026-10-06 https://evidence-hub.com/study/19459-treatment-of-gouty-arthritis-with-traditional-chinese-medicine2026-10-06 https://evidence-hub.com/study/19460-non-steroidal-anti-inflammatory-drugs-for-treating-symptomatic2026-10-13 https://evidence-hub.com/study/19461-cardiovascular-safety-of-celecoxib-in-rheumatoid-arthritis-and2026-10-06 https://evidence-hub.com/study/19462-clinical-efficacy-evaluation-and-potential-mechanism-prediction-on2026-10-06 https://evidence-hub.com/study/19463-multimethod-quantitative-benefit-risk-assessment-of-treatments-for2026-10-06 https://evidence-hub.com/study/19464-perioperative-nsaids-and-long-term-outcomes-after-cancer-surgery-a2026-10-06 https://evidence-hub.com/study/19465-efficacy-and-safety-of-duhuo-jisheng-decoction-in-rheumatoid2026-10-06 https://evidence-hub.com/study/19466-use-of-corticoids-and-non-steroidal-anti-inflammatories-in-the2026-10-06 https://evidence-hub.com/study/19467-systematic-review-and-network-meta-analysis-on-the-efficacy-and2026-10-06 https://evidence-hub.com/study/19468-exploring-the-complex-relationship-between-gut-microbiota-and-risk-of2026-10-06 https://evidence-hub.com/study/19469-effects-of-microecological-regulators-on-rheumatoid-arthritis-a2026-10-06 https://evidence-hub.com/study/19470-safety-of-cyclooxygenase-2-inhibitors-in-osteoarthritis-outcomes-of-a2026-10-06 https://evidence-hub.com/study/19471-pharmacological-interventions-for-the-prevention-of-bleeding-in2026-10-06 https://evidence-hub.com/study/19472-cardiovascular-safety-of-nsaids-additional-insights-after-precision2026-10-06 https://evidence-hub.com/study/19473-duration-of-symptom-relief-and-early-trajectory-of-adverse-events-for2026-10-06 https://evidence-hub.com/study/19474-topical-azole-treatments-for-otomycosis2026-10-06 https://evidence-hub.com/study/19475-comparative-efficacy-and-tolerability-of-adjunctive-pharmacotherapies2026-10-06 https://evidence-hub.com/study/19476-update-on-the-role-of-pharmaceutical-grade-chondroitin-sulfate-in-the2026-10-06 https://evidence-hub.com/study/19477-high-molecular-weight-intraarticular-hyaluronic-acid-for-the2026-10-06 https://evidence-hub.com/study/19478-symptomatic-efficacy-of-pharmacological-treatments-for-knee2026-10-06 https://evidence-hub.com/study/19479-helicobacter-pylori-eradication-for-the-prevention-of-gastric2026-10-20 https://evidence-hub.com/study/19480-pharmacological-agents-for-prevention-of-pruritus-in-women-undergoing2026-10-06 https://evidence-hub.com/study/19481-association-of-pharmacological-treatments-with-long-term-pain-control2026-10-06 https://evidence-hub.com/study/19482-tocolytics-for-delaying-preterm-birth-a-network-meta-analysis-09242026-10-06 https://evidence-hub.com/study/19483-exercise-for-cancer-cachexia-in-adults2026-10-06 https://evidence-hub.com/study/19484-adverse-events-of-immune-checkpoint-inhibitors-for-patients-with2026-10-06 https://evidence-hub.com/study/19485-efficacy-of-different-interventions-for-the-treatment-of-postherpetic2026-10-06 https://evidence-hub.com/study/19486-antibiotics-for-secondary-prevention-of-coronary-heart-disease2026-10-06 https://evidence-hub.com/study/19487-a-genomic-exploration-identifies-mechanisms-that-may-explain-adverse2026-10-06 https://evidence-hub.com/study/19488-circulating-tumor-dna-imaging-and-carcinoembryonic-antigen-comparison2026-10-08 https://evidence-hub.com/study/19489-non-steroidal-anti-inflammatory-drugs-for-acute-low-back-pain2026-10-06 https://evidence-hub.com/study/19490-potentiating-the-effects-of-radiotherapy-in-rectal-cancer-the-role-of2026-10-06 https://evidence-hub.com/study/19491-prediction-of-differentially-expressed-micrornas-in-blood-as2026-10-06 https://evidence-hub.com/study/19492-paracetamol-versus-placebo-for-knee-and-hip-osteoarthritis2026-10-06 https://evidence-hub.com/study/19493-the-prognostic-value-of-pi3k-mutational-status-in-breast-cancer-a2026-10-06 https://evidence-hub.com/study/19494-non-steroidal-anti-inflammatory-drugs-nsaids-for-axial2026-10-06 https://evidence-hub.com/study/19495-oral-non-steroidal-anti-inflammatory-drugs-versus-other-oral2026-10-06 https://evidence-hub.com/study/19496-drug-treatment-for-spinal-muscular-atrophy-types-ii-and-iii2026-10-06 https://evidence-hub.com/study/19497-relative-benefit-risk-comparing-diclofenac-to-other-traditional-non2026-10-06 https://evidence-hub.com/study/19498-exercise-therapy-for-chronic-low-back-pain2026-10-06 https://evidence-hub.com/study/19499-bisphosphonates-or-rank-ligand-inhibitors-for-men-with-prostate2026-10-06 https://evidence-hub.com/study/19500-single-dose-oral-analgesics-for-acute-postoperative-pain-in-adults-an2026-10-06 https://evidence-hub.com/study/19501-biased-safety-reporting-in-blinded-randomized-clinical-trials-meta2026-10-06 https://evidence-hub.com/study/19502-the-efficacy-of-duloxetine-non-steroidal-anti-inflammatory-drugs-and2026-10-06 https://evidence-hub.com/study/19503-helicobacter-pylori-eradication-for-the-prevention-of-gastric2026-10-13 https://evidence-hub.com/study/19504-cannabinoids-the-endocannabinoid-system-and-pain-a-review-of2026-10-06 https://evidence-hub.com/study/19505-safety-of-symptomatic-slow-acting-drugs-for-osteoarthritis-outcomes2026-10-06 https://evidence-hub.com/study/19506-use-of-non-steroidal-anti-inflammatory-drugs-that-elevate2026-10-06 https://evidence-hub.com/study/19507-aspirin-steroidal-and-non-steroidal-anti-inflammatory-drugs-for-the2026-10-06 https://evidence-hub.com/study/19508-nonsteroidal-anti-inflammatory-drugs-and-risk-of-incident-heart2026-10-06 https://evidence-hub.com/study/19509-helicobacter-pylori-eradication-therapy-to-prevent-gastric-cancer-in2026-10-06 https://evidence-hub.com/study/19510-alpha-blockers-after-shock-wave-lithotripsy-for-renal-or-ureteral2026-10-06 https://evidence-hub.com/study/19511-single-dose-oral-celecoxib-for-acute-postoperative-pain-in-adults2026-10-06 https://evidence-hub.com/study/19512-nonsteroidal-anti-inflammatory-drugs-for-dysmenorrhoea2026-10-06 https://evidence-hub.com/study/19513-is-local-infiltration-analgesia-superior-to-peripheral-nerve-blockade2026-10-06 https://evidence-hub.com/study/19514-topical-nsaids-for-chronic-musculoskeletal-pain-in-adults2026-10-06 https://evidence-hub.com/study/19515-canadian-network-for-mood-and-anxiety-treatments-canmat-2016-clinical2026-10-10 https://evidence-hub.com/study/19516-single-dose-oral-analgesics-for-acute-postoperative-pain-in-adults2026-10-06 https://evidence-hub.com/study/19517-selective-noradrenaline-reuptake-inhibitors-for-schizophrenia2026-10-06 https://evidence-hub.com/study/19518-tocolytic-therapy-for-preterm-delivery-systematic-review-and-network2026-10-06 https://evidence-hub.com/study/19519-cyclo-oxygenase-cox-inhibitors-for-treating-preterm-labour2026-10-06 https://evidence-hub.com/study/19520-single-dose-oral-etoricoxib-for-acute-postoperative-pain-in-adults2026-10-06 https://evidence-hub.com/study/19521-different-treatment-regimens-of-magnesium-sulphate-for-tocolysis-in2026-10-06 https://evidence-hub.com/study/19522-pharmacological-interventions-for-acute-pancreatitis2026-10-06 https://evidence-hub.com/study/19523-efficacy-and-safety-of-celecoxib-in-schizophrenia-a-systematic-review2026-10-06 https://evidence-hub.com/study/19524-efficacy-and-safety-of-celecoxib-and-a-korean-sysadoa-joins-for-the2026-10-06 https://evidence-hub.com/study/19525-assessing-the-efficacy-of-celecoxib-after-tonsillectomy-and-or2026-10-06 https://evidence-hub.com/study/19526-efficacy-and-safety-of-celecoxib-on-the-incidence-of-recurrent2026-10-06 https://evidence-hub.com/study/19527-the-efficacy-and-safety-of-celecoxib-in-addition-to-standard-cancer2026-10-06 https://evidence-hub.com/study/19528-effect-of-celecoxib-on-improving-depression-a-systematic-review-and2026-10-06 https://evidence-hub.com/study/19529-efficacy-of-inflammation-based-stratification-for-add-on-celecoxib-or2026-10-06 https://evidence-hub.com/study/19530-renal-effects-of-selective-cyclooxygenase-2-inhibitor-anti2026-10-06 https://evidence-hub.com/study/19531-effectiveness-of-combined-pregabalin-and-celecoxib-for-treatment-of2026-10-06 https://evidence-hub.com/study/19532-the-efficacy-and-safety-of-celecoxib-for-pain-management-after-total2026-10-06 https://evidence-hub.com/study/19533-systematic-review-and-network-meta-analysis-of-different-non2026-10-06 https://evidence-hub.com/study/19534-meta-analysis-comparing-celecoxib-with-diclofenac-sodium-in-patients2026-10-06 https://evidence-hub.com/study/19535-chemotherapy-induced-hand-foot-syndrome-comparative-efficacy-and2026-10-06 https://evidence-hub.com/study/19536-efficacy-of-celecoxib-adjunct-treatment-on-bipolar-disorder2026-10-06 https://evidence-hub.com/study/19537-correction-tolerability-and-adverse-events-in-clinical-trials-of2026-10-06 https://evidence-hub.com/study/19539-efficacy-and-safety-of-transdermal-buprenorphine-for-acute2026-10-06 https://evidence-hub.com/study/19540-anti-inflammatory-pharmacotherapy-for-depressive-disorders-a-network2026-10-06 https://evidence-hub.com/study/19541-is-there-a-benefit-of-addition-docetaxel-abiraterone-celecoxib-or2026-10-06 https://evidence-hub.com/study/19543-selective-cox-2-inhibitors-do-not-increase-gastrointestinal-reactions2026-10-06 https://evidence-hub.com/study/19545-systematic-review-and-meta-analysis-of-the-benefit-of-celecoxib-in2026-10-06 https://evidence-hub.com/study/19546-effects-of-aspirin-and-non-aspirin-nonsteroidal-anti-inflammatory2026-10-06 https://evidence-hub.com/study/19547-non-opioid-analgesics-for-postoperative-pain-management-following2026-10-06 https://evidence-hub.com/study/19549-effectiveness-and-priority-of-irradiation-and-six-nsaids-in2026-10-06 https://evidence-hub.com/study/19550-what-is-the-optimal-systemic-treatment-of-men-with-metastatic-hormone2026-10-06 https://evidence-hub.com/study/19552-pharmacological-prevention-strategy-for-capecitabine-induced-hand2026-10-06 https://evidence-hub.com/study/19553-tolerance-to-coxibs-in-patients-with-intolerance-to-non-steroidal2026-10-06 https://evidence-hub.com/study/19554-efficacy-and-safety-of-manufactured-chinese-herbal-formula-for2026-10-06 https://evidence-hub.com/study/19555-anti-oxidative-stress-therapies-prevent-severe-chemotherapy-induced2026-10-06 https://evidence-hub.com/study/19556-the-antitumoral-effect-of-statins-in-pancreatic-ductal-adenocarcinoma2026-10-06 https://evidence-hub.com/study/19557-metabolic-regulation-and-immunosuppressive-functions-of-lipid2026-10-06 https://evidence-hub.com/study/19558-comparison-of-tanezumab-and-non-steroidal-anti-inflammatory-drugs-in2026-10-06 https://evidence-hub.com/study/19559-depressive-disorders-systematic-review-of-approved-psychiatric2026-10-02 https://evidence-hub.com/study/19560-biomarkers-in-als-trials-from-discovery-to-clinical-utility2026-10-06 https://evidence-hub.com/study/19561-the-role-of-omega-3-polyunsaturated-fatty-acids-in-modulating2026-10-06 https://evidence-hub.com/study/19562-multimodal-microglial-and-kynurenine-pathway-alterations-across-the2026-10-06 https://evidence-hub.com/study/19563-chemoprevention-of-gastrointestinal-cancers-an-umbrella-review-of2026-10-06 https://evidence-hub.com/study/19564-effects-of-drug-administration-on-postoperative-pain-in-orthognathic2026-10-06 https://evidence-hub.com/study/19565-new-strategies-in-comprehensive-melanoma-treatment-applications2026-10-06 https://evidence-hub.com/study/19566-a-bibliometric-analysis-and-systematic-review-of-drug-repurposing2026-10-10 https://evidence-hub.com/study/19567-preemptive-use-of-anti-inflammatories-and-analgesics-in-oral-surgery2026-10-06 https://evidence-hub.com/study/19568-repurposing-neurological-drugs-for-brain-cancer-therapeutics-a2026-10-06 https://evidence-hub.com/study/19569-non-steroidal-anti-inflammatory-drugs-for-treatment-of-cancer2026-10-06 https://evidence-hub.com/study/19570-identification-of-cardiotoxicity-related-to-non-small-cell-lung2026-10-06 https://evidence-hub.com/study/19571-nanomaterials-targeting-ferroptosis-for-osteoarthritis-treatment-a2026-10-06 https://evidence-hub.com/study/19572-efficacy-of-mirabegron-for-ureteral-stones-a-systematic-review-with2026-10-19 https://evidence-hub.com/study/19573-looking-at-nsaids-from-a-historical-perspective-and-their-current2026-10-06 https://evidence-hub.com/study/19574-antidepressant-effects-of-nsaids-in-rodent-models-of-depression-a2026-10-06 https://evidence-hub.com/study/19575-a-comprehensive-overview-of-the-molecular-features-and-therapeutic2026-10-06 https://evidence-hub.com/study/19576-a-systematic-review-of-immune-cell-roles-in-breast-cancer2026-10-06 https://evidence-hub.com/study/19577-efficacy-and-safety-of-iguratimod-in-the-treatment-of-rheumatic-and2026-10-06 https://evidence-hub.com/study/19578-investigational-drugs-for-the-treatment-of-depression-part-12026-10-06 https://evidence-hub.com/study/19579-long-term-use-of-muscle-relaxant-medications-for-chronic-pain-a2026-10-06 https://evidence-hub.com/study/19580-combining-various-acupuncture-therapies-with-multimodal-analgesia-to2026-10-06 https://evidence-hub.com/study/19581-intelligent-structure-prediction-and-visualization-analysis-of-non2026-10-06 https://evidence-hub.com/study/19582-pharmaco-psychiatry-and-gut-microbiome-a-systematic-review-of-effects2026-10-06 https://evidence-hub.com/study/19583-adjunctive-agents-to-antipsychotics-in-schizophrenia-a-systematic2026-10-06 https://evidence-hub.com/study/19584-non-steroidal-anti-inflammatory-drugs-for-acute-gout2026-10-06 https://evidence-hub.com/study/19585-brazilian-research-consortium-on-obsessive-compulsive-spectrum2026-10-06 https://evidence-hub.com/study/19586-interventions-for-managing-oral-submucous-fibrosis2026-10-06 https://evidence-hub.com/study/19587-nonsteroidal-anti-inflammatory-drugs-in-acute-viral-respiratory-tract2026-10-06 https://evidence-hub.com/study/19588-cost-effectiveness-of-pharmacogenetic-testing-for-drugs-with-clinical2026-10-06 https://evidence-hub.com/study/19589-inexpensive-systemic-inflammatory-biomarkers-in-ovarian-cancer-an2026-10-06 https://evidence-hub.com/study/19590-pharmacological-intervention-for-irritability-aggression-and-self2026-10-13 https://evidence-hub.com/study/19591-er-stress-as-a-trigger-of-upr-and-er-phagy-in-cancer-growth-and-spread2026-10-06 https://evidence-hub.com/study/19592-immune-cell-proinflammatory-microenvironment-and-androgen-related2026-10-06 https://evidence-hub.com/study/19593-anti-inflammatory-therapy-for-preventing-stroke-and-other-vascular2026-10-06 https://evidence-hub.com/study/19594-histamine-receptors-and-covid-192026-10-01 https://evidence-hub.com/study/19595-systematic-review-of-phase-i-ii-trials-enrolling-refractory-and2026-10-06 https://evidence-hub.com/study/19596-deficiency-in-the-treatment-description-of-mtor-inhibitor-resistance2026-10-06 https://evidence-hub.com/study/19597-influence-of-microbiota-on-nsaid-enteropathy-a-systematic-review-of2026-10-06 https://evidence-hub.com/study/19598-the-promising-ability-of-humulus-lupulus-l-iso-acids-vs-diabetes2026-10-06 https://evidence-hub.com/study/19599-antidepressants-for-hip-and-knee-osteoarthritis2026-10-06 https://evidence-hub.com/study/19600-adjunctive-therapies-in-addition-to-land-based-exercise-therapy-for2026-10-06 https://evidence-hub.com/study/19601-emerging-role-of-artificial-intelligence-in-therapeutics-for-covid-192026-10-06 https://evidence-hub.com/study/19602-blood-biomarkers-of-glioma-in-response-assessment-including2026-10-06 https://evidence-hub.com/study/19603-exercise-as-adjunctive-therapy-for-systemic-lupus-erythematosus2026-10-06 https://evidence-hub.com/study/19604-same-day-discharge-sdd-vs-standard-enhanced-recovery-after-surgery2026-10-06 https://evidence-hub.com/study/19605-composition-and-regulation-of-the-immune-microenvironment-of-salivary2026-10-06 https://evidence-hub.com/study/19606-micrornas-in-the-anticancer-effects-of-celecoxib-a-systematic-review2026-10-06 https://evidence-hub.com/study/19607-hematological-toxicity-of-parp-inhibitors-in-solid-tumors-a2026-10-13 https://evidence-hub.com/study/19608-current-evidence-on-celecoxib-safety-in-the-management-of-chronic2026-10-06 https://evidence-hub.com/study/19609-chemoprophylaxis-for-heterotrophic-ossification-following-hip2026-10-06 https://evidence-hub.com/study/19610-analgesic-efficacy-of-cox-2-inhibitors-in-periodontal-surgery-a2026-10-06 https://evidence-hub.com/study/19611-sex-race-and-bmi-in-clinical-trials-of-medications-for-obesity-over2026-10-06 https://evidence-hub.com/study/19612-the-effect-of-weight-loss-through-lifestyle-interventions-in-patients2026-10-06 https://evidence-hub.com/study/19613-a-systematic-review-of-the-impacts-of-oral-tetracycline-class2026-10-06 https://evidence-hub.com/study/19614-pharmacokinetic-interactions-and-clinical-implications-of-ppis-and2026-10-20 https://evidence-hub.com/study/19615-efficacy-and-safety-of-percutaneous-intramyocardial-septal2026-10-06 https://evidence-hub.com/study/19616-lipid-profile-changes-induced-by-glucagon-like-peptide-1-receptor2026-10-06 https://evidence-hub.com/study/19618-direct-acting-antivirals-for-chronic-hepatitis-c-infection-a-protocol2026-10-06 https://evidence-hub.com/study/19619-anti-inflammatory-treatment-efficacy-in-major-depressive-disorder-a2026-10-06 https://evidence-hub.com/study/19620-evaluating-the-efficacy-of-interatrial-shunt-devices-in-heart-failure2026-10-06 https://evidence-hub.com/study/19621-efficacy-of-biologic-agents-in-patients-with-comorbid-asthma-and2026-10-06 https://evidence-hub.com/study/19622-the-clinical-performance-of-bulk-fill-versus-the-incremental-layered2026-10-06 https://evidence-hub.com/study/19623-a-systematic-review-of-trials-currently-investigating-therapeutic2026-10-06 https://evidence-hub.com/study/19624-ketogenic-interventions-in-mild-cognitive-impairment-alzheimer-s2026-10-06 https://evidence-hub.com/study/19625-effectiveness-of-prefabricated-myofunctional-appliances-in-the2026-10-06 https://evidence-hub.com/study/19626-the-safety-and-efficacy-of-glucosamine-and-or-chondroitin-in-humans-a2026-10-06 https://evidence-hub.com/study/19627-quarter-dose-quadruple-combination-therapy-for-initial-treatment-of2026-10-06 https://evidence-hub.com/study/19628-the-role-of-celecoxib-for-colorectal-cancer-treatment-a-systematic2026-10-06 https://evidence-hub.com/study/19629-a-systematic-review-of-mobile-device-use-in-the-primary-school2026-10-06 https://evidence-hub.com/study/19630-oxygen-ozone-therapy-for-the-treatment-of-knee-osteoarthritis-a2026-10-06 https://evidence-hub.com/study/19631-efficacy-and-safety-of-parp-inhibitors-in-the-treatment-of-brca2026-10-06 https://evidence-hub.com/study/19632-the-effect-of-chin-cup-therapy-in-class-iii-malocclusion-a-systematic2026-10-06 https://evidence-hub.com/study/19634-nonsteroidal-anti-inflammatory-drugs-and-their-neuroprotective-role2026-10-06 https://evidence-hub.com/study/19635-revisiting-the-association-between-sodium-glucose-cotransporter-22026-10-06 https://evidence-hub.com/study/19636-the-impact-of-glp1-agonists-on-bone-metabolism-a-systematic-review2026-10-06 https://evidence-hub.com/study/19638-a-systematic-review-of-functional-outcomes-in-cancer-rehabilitation2026-10-06 https://evidence-hub.com/study/19643-team-based-learning-vs-lecture-based-learning-in-nursing-a-systematic2026-10-06 https://evidence-hub.com/study/19645-glucagon-like-peptide-1-glp-1-receptor-agonists-as-a-protective2026-10-06 https://evidence-hub.com/study/19646-real-world-effectiveness-and-safety-of-sacubitril-valsartan-in-heart2026-10-06 https://evidence-hub.com/study/19647-efficacy-of-benzodiazepines-or-antihistamines-for-patients-with-acute2026-10-06 https://evidence-hub.com/study/19648-preoperative-treatment-with-a-non-steroidal-anti-inflammatory-drug2026-10-06 https://evidence-hub.com/study/19649-the-effect-of-food-on-tramadol-and-celecoxib-bioavailability2026-10-06 https://evidence-hub.com/study/19650-pharmacokinetic-interactions-of-the-oral-renin-inhibitor-aliskiren2026-10-06 https://evidence-hub.com/study/19651-effects-of-cox-inhibition-on-blood-pressure-and-kidney-function-in2026-10-06 https://evidence-hub.com/study/19652-comparison-of-gastroduodenal-ulcer-incidence-in-healthy-japanese2026-10-06 https://evidence-hub.com/study/19653-predictors-of-response-to-cyclo-oxygenase-2-inhibitors-in2026-10-06 https://evidence-hub.com/study/19654-postoperative-analgesia-after-laparoscopic-cholecystectomy-comparison2026-10-06 https://evidence-hub.com/study/19655-effect-of-perioperative-multistrain-probiotics-on-the-ct-callus2026-10-08 https://evidence-hub.com/study/19656-effect-of-parecoxib-on-postoperative-anxiety-and-cognitive-function2026-10-06 https://evidence-hub.com/study/19657-increasing-dose-of-esketamine-for-supplemental-analgesia-after2026-10-06 https://evidence-hub.com/study/19658-esketamine-as-an-adjuvant-to-ropivacaine-in-genicular-nerve-and-ipack2026-10-06 https://evidence-hub.com/study/19659-liposomal-bupivacaine-versus-ropivacaine-for-surgical-site2026-10-06 https://evidence-hub.com/study/19660-polmacoxib-2mg-in-patients-with-mild-to-moderate-idiopathic2026-10-06 https://evidence-hub.com/study/19661-association-of-non-steroidal-anti-inflammatory-medications-and2026-10-06 https://evidence-hub.com/study/19662-effects-of-acute-selective-cyclooxygenase-2-inhibition-on-skeletal2026-10-06 https://evidence-hub.com/study/19663-pericapsular-nerve-group-block-with-periarticular-injection-for-pain2026-10-06 https://evidence-hub.com/study/19664-probiotics-ameliorate-h-pylori-associated-gastric-catenin-and-cox-22026-10-06 https://evidence-hub.com/study/19665-a-randomized-controlled-trial-of-intraoperative-ketamine-for-acute2026-10-06 https://evidence-hub.com/study/19666-comparison-of-the-effect-of-treatment-with-nsaids-added-to-anti-tnf2026-10-06 https://evidence-hub.com/study/19667-efficacy-and-safety-of-fasinumab-in-an-nsaid-controlled-study-in2026-10-06 https://evidence-hub.com/study/19668-s-ketamine-reduces-the-risk-of-rebound-pain-in-patients-following2026-10-06 https://evidence-hub.com/study/19669-the-efficacy-of-liposomal-bupivacaine-in-parasacral-ischial-plane2026-10-06 https://evidence-hub.com/study/19670-platform-study-of-circulating-tumor-dna-directed-adjuvant2026-10-06 https://evidence-hub.com/study/19671-efficacy-of-aceclofenac-and-ilaprazole-combination-therapy-versus2026-10-06 https://evidence-hub.com/study/19672-inhibition-of-p38-mapk-increases-short-term-astrocyte-reactivity-the2026-10-06 https://evidence-hub.com/study/19673-comparing-the-efficacy-and-safety-of-fexuprazan-and-lansoprazole-for2026-10-19 https://evidence-hub.com/study/19674-the-effect-of-butyrylated-starch-on-bowel-polyps-in-familial2026-10-06 https://evidence-hub.com/study/19675-pharmacokinetic-interactions-between-fexuprazan-a-potassium2026-10-19 https://evidence-hub.com/study/19676-novel-subtypes-of-severe-covid-19-respiratory-failure-based-on2026-10-06 https://evidence-hub.com/study/19677-blood-conserving-and-therapeutic-efficacy-of-intravenous-tranexamic2026-10-06 https://evidence-hub.com/study/19678-observation-of-the-therapeutic-effect-of-auricular-bean-pressing-on2026-10-06 https://evidence-hub.com/study/19679-the-translocator-protein-18kda-ligand-etifoxine-in-the-treatment-of2026-10-06 https://evidence-hub.com/study/19680-precision-medicine-for-preventing-alzheimer-s-disease-analysis-of-the2026-10-06 https://evidence-hub.com/study/19681-the-effect-of-ultrasound-guided-intercostal-nerve-block-on2026-10-06 https://evidence-hub.com/study/19682-efficacy-and-safety-of-ibuprofen-gargle-for-postoperative-pain-after2026-10-06 https://evidence-hub.com/study/19683-comparison-of-post-operative-bleeding-incidence-in-laser2026-10-06 https://evidence-hub.com/study/19684-efficacy-and-safety-of-single-dose-dfn-15-for-treatment-of-acute2026-10-06 https://evidence-hub.com/study/19685-intra-articular-autologous-conditioned-serum-and-triamcinolone2026-10-06 https://evidence-hub.com/study/19686-a-new-cocktail-formula-with-diprospan-of-local-infiltration-analgesia2026-10-06 https://evidence-hub.com/study/19687-effect-of-systematic-exercise-rehabilitation-on-patients-with-knee2026-10-06 https://evidence-hub.com/study/19688-dexmedetomidine-combined-with-femoral-nerve-block-provides-effective2026-10-06 https://evidence-hub.com/study/19689-efficacy-and-safety-of-s-flurbiprofen-plaster-in-knee-osteoarthritis2026-10-06 https://evidence-hub.com/study/19690-the-efficacy-of-eye-movement-desensitization-and-reprocessing-in2026-10-06 https://evidence-hub.com/study/19692-a-comparative-study-of-the-efficacy-of-naxozol-compared-to-celecoxib2026-10-06 https://evidence-hub.com/study/19693-efficacy-of-serratiopeptidase-after-impacted-third-molar-surgery-a2026-10-06 https://evidence-hub.com/study/19694-influence-of-ozonized-water-on-pain-oedema-and-trismus-during2026-10-06 https://evidence-hub.com/study/19695-effect-of-intraperitoneal-local-anesthesia-on-enhanced-recovery2026-10-06 https://evidence-hub.com/study/19696-multi-centre-prospective-randomised-controlled-clinical-trial-to2026-10-06 https://evidence-hub.com/study/19697-effect-of-a-structured-teaching-module-including-intensive2026-10-06 https://evidence-hub.com/study/19698-sustained-release-lidocaine-sheet-for-pain-following-tooth-extraction2026-10-06 https://evidence-hub.com/study/19699-celecoxib-use-and-circulating-oxylipins-in-a-colon-polyp-prevention2026-10-06 https://evidence-hub.com/study/19700-a-phase-i-study-to-evaluate-the-safety-tolerability-pharmacodynamic2026-10-06 https://evidence-hub.com/study/19701-celecoxib-versus-diclofenac-for-the-treatment-of-ankylosing2026-10-06 https://evidence-hub.com/study/19702-adjunctive-use-of-celecoxib-with-anti-tuberculosis-drugs-evaluation2026-10-06 https://evidence-hub.com/study/19703-a-randomized-multicenter-phase-iii-trial-to-evaluate-the-efficacy-and2026-10-06 https://evidence-hub.com/study/19704-pharmacokinetics-of-multiple-doses-of-co-crystal-of-tramadol2026-10-10 https://evidence-hub.com/study/19705-randomised-clinical-study-oral-aspirin-325-mg-daily-vs-placebo-alters2026-10-06 https://evidence-hub.com/study/19706-a-randomised-double-blind-placebo-controlled-trial-of-megestrol2026-10-06 https://evidence-hub.com/study/19707-gabapentin-does-not-appear-to-improve-postoperative-pain-and-sleep2026-10-06 https://evidence-hub.com/study/19708-epidural-morphine-improves-postoperative-analgesia-in-patients-after2026-10-06 https://evidence-hub.com/study/19709-pharmacokinetics-of-dfn-15-a-novel-oral-solution-of-celecoxib-versus2026-10-06 https://evidence-hub.com/study/19710-a-randomized-phase-ii-feasibility-trial-of-a-multimodal-intervention2026-10-06 https://evidence-hub.com/study/19711-evaluation-of-intravenous-parecoxib-infusion-pump-of-patient2026-10-06 https://evidence-hub.com/study/19712-randomized-placebo-controlled-trial-of-the-effects-of-aspirin-on2026-10-06 https://evidence-hub.com/study/19713-clinical-risk-factors-associated-with-radiographic-osteoarthritis2026-10-06 https://evidence-hub.com/study/19714-study-protocol-comparison-of-the-effect-of-treatment-with2026-10-06 https://evidence-hub.com/study/19715-chondroitin-sulfate-efficacy-versus-celecoxib-on-knee-osteoarthritis2026-10-06 https://evidence-hub.com/study/19716-a-proof-of-concept-phase-2-clinical-trial-of-the-gastrointestinal2026-10-06 https://evidence-hub.com/study/19717-penehyclidine-for-prevention-of-postoperative-nausea-and-vomiting2026-10-06 https://evidence-hub.com/study/19718-augmentation-therapy-with-minocycline-in-treatment-resistant2026-10-06 https://evidence-hub.com/study/19719-a-comparison-of-adductor-canal-block-and-femoral-nerve-block-after2026-10-06 https://evidence-hub.com/study/19720-evaluation-of-clinically-relevant-drug-drug-interactions-and2026-10-06 https://evidence-hub.com/study/19721-efficacy-of-wira-in-the-treatment-of-sacroiliitis-in-male-patients2026-10-06 https://evidence-hub.com/study/19722-comparison-of-the-efficacy-and-safety-profiles-of-a-pelubiprofen2026-10-06 https://evidence-hub.com/study/19723-celecoxib-pharmacogenetics-and-pediatric-adenotonsillectomy-a-double2026-10-06 https://evidence-hub.com/study/19724-nonsteroidal-anti-inflammatory-drugs-vs-cognitive-behavioral-therapy2026-10-06 https://evidence-hub.com/study/19725-efficacy-and-safety-of-different-aceclofenac-treatments-for-chronic2026-10-06 https://evidence-hub.com/study/19726-regular-aspirin-use-and-gene-expression-profiles-in-prostate-cancer2026-10-06 https://evidence-hub.com/study/19727-the-efficacy-tolerability-and-joint-safety-of-fasinumab-in2026-10-06 https://evidence-hub.com/study/19728-comparative-clinical-effectiveness-of-nonsurgical-treatment-methods2026-10-06 https://evidence-hub.com/study/19729-human-leukocyte-antigen-complex-and-other-immunogenetic-and-clinical2026-10-06 https://evidence-hub.com/study/19730-ursodeoxycholic-acid-counteracts-celecoxib-in-reduction-of-duodenal2026-10-06 https://evidence-hub.com/study/19731-randomized-double-blind-placebo-controlled-trial-of-celecoxib-for2026-10-06 https://evidence-hub.com/study/19732-clinical-trial-of-vadadustat-in-patients-with-anemia-secondary-to2026-10-06 https://evidence-hub.com/study/19733-topical-diclofenac-for-prevention-of-capecitabine-associated-hand2026-10-06 https://evidence-hub.com/study/19736-minocycline-and-celecoxib-as-adjunctive-treatments-for-bipolar2026-10-06 https://evidence-hub.com/study/19739-positive-preemptive-analgesia-effectiveness-of-pregabalin-combined2026-10-06 https://evidence-hub.com/study/19740-effects-of-postoperative-administration-of-celecoxib-on-pain2026-10-06 https://evidence-hub.com/study/19743-the-effectiveness-of-tuina-in-relieving-pain-negative-emotions-and2026-10-06 https://evidence-hub.com/study/19747-a-randomized-double-blind-placebo-controlled-trial-of-celecoxib2026-10-06 https://evidence-hub.com/study/19749-prevention-of-severe-acute-pancreatitis-with-cyclooxygenase-22026-10-06 https://evidence-hub.com/study/19753-an-intensive-perioperative-regimen-of-pregabalin-and-celecoxib2026-10-06 https://evidence-hub.com/study/19758-celecoxib-or-naproxen-treatment-does-not-benefit-depressive-symptoms2026-10-06 https://evidence-hub.com/study/19760-efficacy-and-safety-of-adalimumab-by-intra-articular-injection-for2026-10-06 https://evidence-hub.com/study/19761-a-randomized-controlled-trial-of-celecoxib-to-prevent-recurrence-of2026-10-06 https://evidence-hub.com/study/19764-enhanced-recovery-after-elective-craniotomy-a-randomized-controlled2026-10-06 https://evidence-hub.com/study/19767-combination-of-gabapentin-and-celecoxib-for-analgesia-after-major2026-10-06 https://evidence-hub.com/study/19777-comparing-etoricoxib-and-celecoxib-for-preemptive-analgesia-for-acute2026-10-06 https://evidence-hub.com/study/19783-children-s-international-polyposis-chip-study-a-randomized-double2026-10-06 https://evidence-hub.com/study/19786-continued-treatment-with-tirzepatide-for-maintenance-of-weight2026-10-06 https://evidence-hub.com/study/19788-microplastics-in-our-waters-insights-from-a-configurative-systematic2026-10-01 https://evidence-hub.com/study/19789-microplastics-in-drinking-water-a-review-of-sources-removal-detection2026-10-06 https://evidence-hub.com/study/19790-microplastics-in-drinking-water-distribution-systems-occurrence2026-10-06 https://evidence-hub.com/study/19791-investigation-of-heavy-metals-adsorbed-on-microplastics-in-drinking2026-10-06 https://evidence-hub.com/study/19792-purifying-or-polluting-tracing-membrane-based-microplastics-release2026-10-06 https://evidence-hub.com/study/19793-identification-and-occurrence-of-microplastics-in-drinking-water2026-10-06 https://evidence-hub.com/study/19794-activation-of-gut-metabolite-acsl4-lpcat3-by-microplastics-in2026-10-06 https://evidence-hub.com/study/19795-tracking-microplastics-at-the-source-a-comparative-study-of2026-10-06 https://evidence-hub.com/study/19796-microplastics-in-freshwaters-and-drinking-water-critical-review-and2026-10-01 https://evidence-hub.com/study/19797-implementation-plan-to-monitor-microplastics-in-surface-and-drinking2026-10-06 https://evidence-hub.com/study/19798-tire-based-microplastics-composition-detection-and-impacts-of2026-10-06 https://evidence-hub.com/study/19799-occurrence-and-fate-of-microplastics-from-a-water-source-to-two2026-10-06 https://evidence-hub.com/study/19800-microplastics-in-drinking-water-a-review-on-methods-occurrence2026-09-27 https://evidence-hub.com/study/19801-a-systematic-review-on-the-presence-of-microplastics-in-drinking2026-10-01 https://evidence-hub.com/study/19803-microplastics-in-drinking-water-quantitative-analysis-of2026-10-06 https://evidence-hub.com/study/19804-biofilm-induced-microplastics-and-microbial-metabolites-release-from2026-10-06 https://evidence-hub.com/study/19805-environmental-microplastics-as-vectors-of-non-polar-organic2026-10-06 https://evidence-hub.com/study/19806-advancements-and-regulatory-situation-in-microplastics-removal-from2026-10-06 https://evidence-hub.com/study/19807-mapping-microplastics-in-humans-analysis-of-polymer-types-and-shapes2026-10-01 https://evidence-hub.com/study/19808-contamination-morphological-and-chemical-characterization-and-hazard2026-10-06 https://evidence-hub.com/study/19809-aging-of-drinking-water-transmission-pipes-during-long-term-operation2026-10-06 https://evidence-hub.com/study/19810-insights-into-human-exposure-to-microplastics-through-drinking-water2026-10-06 https://evidence-hub.com/study/19811-exploring-correlations-between-microplastics-microorganisms-and-water2026-10-06 https://evidence-hub.com/study/19813-transport-behavior-and-human-exposure-of-microplastics-in-rural2026-10-06 https://evidence-hub.com/study/19814-release-of-microplastics-from-polymeric-ultrafiltration-membrane2026-10-06 https://evidence-hub.com/study/19815-occurrence-and-characterization-of-microplastics-in-bottled-drinking2026-10-06 https://evidence-hub.com/study/19816-evaluating-the-potential-of-daily-intake-of-polystyrene-microplastics2026-10-06 https://evidence-hub.com/study/19817-routine-method-for-the-analysis-of-microplastics-in-natural-and2026-10-06 https://evidence-hub.com/study/19818-pathways-and-risks-of-pesticides-microplastics-and-emerging2026-10-01 https://evidence-hub.com/study/19819-the-risk-exposure-of-microplastics-on-bottled-drinking-water-for2026-10-06 https://evidence-hub.com/study/19820-physicochemical-and-statistical-analysis-of-water-and-microplastics2026-10-06 https://evidence-hub.com/study/19821-microplastics-in-treatment-units-and-water-recirculation-systems-of2026-10-06 https://evidence-hub.com/study/19822-novel-materials-for-the-removal-of-microplastics-and-nanoplastics-in2026-10-06 https://evidence-hub.com/study/19823-microplastics-in-drinking-water-and-food-a-threat-to-human-health2026-10-06 https://evidence-hub.com/study/19824-efficient-and-scalable-detection-of-microplastics-in-drinking-water2026-10-06 https://evidence-hub.com/study/19825-tracking-microplastics-in-a-drinking-water-supply-system-proximity-to2026-10-06 https://evidence-hub.com/study/19826-addressing-microplastics-in-drinking-water-in-the-global-plastics2026-10-06 https://evidence-hub.com/study/19828-microplastics-and-nanoplastics-in-drinking-water-and-beverages2026-10-06 https://evidence-hub.com/study/19829-microplastics-and-non-natural-cellulosic-particles-in-spanish-bottled2026-10-06 https://evidence-hub.com/study/19830-identification-of-microplastics-and-their-removal-efficiency-in2026-10-06 https://evidence-hub.com/study/19831-microplastics-in-drinking-water2026-09-27 https://evidence-hub.com/study/19832-microplastics-and-nitrogenous-disinfection-byproducts-in-drinking2026-10-06 https://evidence-hub.com/study/19834-standardization-of-ftir-based-methodologies-for-microplastics2026-09-27 https://evidence-hub.com/study/19835-mass-concentration-and-removal-characteristics-of-microplastics-and2026-10-01 https://evidence-hub.com/study/19836-polyamide-6-microplastics-as-carriers-led-to-changes-in-the-fate-of2026-10-06 https://evidence-hub.com/study/19837-occurrence-and-risk-of-microplastics-and-hexabromocyclododecane-in2026-10-06 https://evidence-hub.com/study/19838-drinking-boiled-tap-water-reduces-human-intake-of-nanoplastics-and2026-09-27 https://evidence-hub.com/study/19839-smartphone-microscopic-method-for-imaging-and-quantification-of2026-10-06 https://evidence-hub.com/study/19840-impact-of-non-aged-and-uv-aged-microplastics-on-the-formation-of2026-10-06 https://evidence-hub.com/study/19845-microplastics-in-urban-water-cycles-looking-for-a-more-scientific2026-10-06 https://evidence-hub.com/study/19849-cu-fate-driven-by-colloidal-polystyrene-microplastics-with-pipe-scale2026-10-06 https://evidence-hub.com/study/19850-development-of-an-accreditation-process-for-analytical-methods-to2026-10-06 https://evidence-hub.com/study/19851-tracking-microplastics-contamination-in-drinking-water-supply-chain2026-10-06 https://evidence-hub.com/study/19852-the-detection-and-analysis-of-microplastics-in-a-typical-mountainous2026-10-06 https://evidence-hub.com/study/19853-determination-of-microplastics-in-drinking-water-treatment-plants-and2026-10-06 https://evidence-hub.com/study/19854-occurrence-and-identification-of-microplastics-retained-in-corrosion2026-10-06 https://evidence-hub.com/study/19855-the-effects-of-exposure-to-microplastics-in-drinking-water-on-sperm2026-10-06 https://evidence-hub.com/study/19856-microplastics-in-bottled-water-assessing-drinking-safety-in-nepal2026-10-06 https://evidence-hub.com/study/19858-effects-of-polystyrene-microplastics-on-the-distribution-behaviors2026-10-06 https://evidence-hub.com/study/19859-raman-spectroscopy-laser-induced-breakdown-spectroscopy-libs-and2026-10-06 https://evidence-hub.com/study/19860-laser-induced-spectroscopy-libs-technology-and-environmental-risk2026-10-06 https://evidence-hub.com/study/19861-profile-and-different-approaches-for-size-characterization-of2026-10-06 https://evidence-hub.com/study/19862-occurrence-and-removal-efficiency-of-microplastics-in-four-drinking2026-10-06 https://evidence-hub.com/study/19863-research-advances-in-removal-efficiency-and-mechanism-of2026-10-06 https://evidence-hub.com/study/19864-abundance-and-characteristics-of-microplastics-in-drinking-water2026-09-27 https://evidence-hub.com/study/19865-a-review-of-microplastics-in-table-salt-drinking-water-and-air-direct2026-10-01 https://evidence-hub.com/study/19866-tracing-microplastics-in-rural-drinking-water-in-chongqing-china2026-09-27 https://evidence-hub.com/study/19867-tracking-microplastics-contamination-in-drinking-water-in-zahedan2026-09-27 https://evidence-hub.com/study/19868-contamination-and-removal-efficiency-of-microplastics-and-synthetic2026-10-01 https://evidence-hub.com/study/19869-seasonal-variations-of-microplastics-in-surface-water-and-sediment-in2026-09-27 https://evidence-hub.com/study/19870-first-evidence-of-microplastics-and-their-characterization-in-bottled2026-10-06 https://evidence-hub.com/study/19871-microplastics-and-associated-chemicals-in-drinking-water-a-review-of2026-10-01 https://evidence-hub.com/study/19873-impact-of-chlorine-and-uv-h2o2-on-microplastics-in-drinking-water2026-10-06 https://evidence-hub.com/study/19876-removal-efficiencies-of-microplastics-of-the-three-largest-drinking2026-10-06 https://evidence-hub.com/study/19877-microplastics-and-chemical-leachates-from-plastic-pipes-are2026-10-06 https://evidence-hub.com/study/19878-low-numbers-of-microplastics-detected-in-drinking-water-from-ground2026-10-01 https://evidence-hub.com/study/19879-occurrence-of-microplastics-in-raw-and-treated-drinking-water2026-09-27 https://evidence-hub.com/study/19881-microplastics-attenuation-from-surface-water-to-drinking-water-impact2026-10-06 https://evidence-hub.com/study/19882-longitudinal-and-vertical-distribution-of-microplastics-in-various2026-10-06 https://evidence-hub.com/study/19883-screening-for-microplastics-in-drinking-water-and-its-toxicity2026-10-06 https://evidence-hub.com/study/19884-it-matters-how-we-measure-quantification-of-microplastics-in-drinking2026-10-01 https://evidence-hub.com/study/19885-a-baseline-study-on-the-prevalence-of-microplastics-in-south-african2026-10-06 https://evidence-hub.com/study/19886-do-drinking-water-plants-retain-microplastics-an-exploratory-study2026-10-06 https://evidence-hub.com/study/19887-occurrence-of-microplastics-in-drinking-water-in-south-east-asia-a2026-10-06 https://evidence-hub.com/study/19888-a-randomized-double-blind-controlled-trial-study-on-the-antagonistic2026-09-27 https://evidence-hub.com/study/19889-lactiplantibacillus-plantarum-pd01-supplementation-reduces2026-09-27 https://evidence-hub.com/study/19891-occurrence-and-removal-of-microplastics-in-an-advanced-drinking-water2026-09-27 https://evidence-hub.com/study/19892-microplastics-in-drinking-water2026-10-01 https://evidence-hub.com/study/19893-microplastics-in-drinking-water-treatment-current-knowledge-and2026-09-27 https://evidence-hub.com/study/19894-human-consumption-of-microplastics2026-09-27 https://evidence-hub.com/study/19895-microplastic-contamination-of-drinking-water-a-systematic-review2026-10-01 https://evidence-hub.com/study/19897-microplastics-in-drinking-water-a-review-and-assessment2026-10-01 https://evidence-hub.com/study/19898-removal-of-microplastics-via-drinking-water-treatment-current2026-09-27 https://evidence-hub.com/study/19899-drinking-plastics-quantification-and-qualification-of-microplastics2026-10-01 https://evidence-hub.com/study/19900-fate-of-microplastics-in-the-drinking-water-production2026-09-27 https://evidence-hub.com/study/19901-a-critical-review-of-extraction-and-identification-methods-of2026-10-01 https://evidence-hub.com/study/19902-microplastic-pollution-in-drinking-water2026-10-01 https://evidence-hub.com/study/19903-microplastics-removal-efficiency-of-drinking-water-treatment-plant2026-09-27 https://evidence-hub.com/study/19904-analysis-of-microplastics-in-drinking-water-and-other-clean-water2026-10-01 https://evidence-hub.com/study/19907-microplastics-in-freshwater-systems-a-review-of-the-emerging-threats2026-09-27 https://evidence-hub.com/study/19908-investigation-of-microplastics-contamination-in-drinking-water-of-a2026-10-01 https://evidence-hub.com/study/19909-plasticenta-first-evidence-of-microplastics-in-human-placenta2026-10-01 https://evidence-hub.com/study/19910-occurrence-and-fate-of-microplastics-at-two-different-drinking-water2026-09-27 https://evidence-hub.com/study/19911-microplastic-removal-in-conventional-drinking-water-treatment2026-10-01 https://evidence-hub.com/study/19914-the-occurrence-and-dietary-intake-related-to-the-presence-of2026-09-27 https://evidence-hub.com/study/19915-environmental-source-fate-and-toxicity-of-microplastics2026-09-27 https://evidence-hub.com/study/19918-occurrence-and-removal-of-microplastics-in-wastewater-treatment2026-09-27 https://evidence-hub.com/study/19920-microplastic-contamination-in-human-stools-foods-and-drinking-water2026-10-01 https://evidence-hub.com/study/19921-application-of-gcms-pyrolysis-to-estimate-the-levels-of-microplastics2026-09-27 https://evidence-hub.com/study/19922-microplastics-in-drinking-water-a-macro-issue2026-10-01 https://evidence-hub.com/study/19923-conventional-and-biological-treatment-for-the-removal-of2026-09-27 https://evidence-hub.com/study/19924-chemical-analysis-of-microplastics-and-nanoplastics-challenges2026-10-01 https://evidence-hub.com/study/19926-microplastics-and-nanoplastics-in-aquatic-environments-aggregation2026-10-01 https://evidence-hub.com/study/19928-microplastics-in-seafood-and-the-implications-for-human-health2026-10-01 https://evidence-hub.com/study/19929-microplastics-in-wastewater-and-drinking-water-treatment-plants2026-10-01 https://evidence-hub.com/study/19931-analysis-of-microplastics-in-human-feces-reveals-a-correlation2026-09-27 https://evidence-hub.com/study/19933-occurrence-removal-and-potential-threats-associated-with2026-09-27 https://evidence-hub.com/study/19934-microplastic-concentrations-in-raw-and-drinking-water-in-the-sinos2026-10-01 https://evidence-hub.com/study/19936-unintended-human-ingestion-of-nanoplastics-and-small-microplastics2026-09-27 https://evidence-hub.com/study/19938-screening-of-microplastics-in-water-and-sludge-lines-of-a-drinking2026-10-01 https://evidence-hub.com/study/19939-a-critical-review-on-recent-research-progress-on-microplastic2026-09-27 https://evidence-hub.com/study/19940-visible-light-photocatalytic-degradation-of-polypropylene2026-10-01 https://evidence-hub.com/study/19941-a-review-of-human-exposure-to-microplastics-and-insights-into2026-10-01 https://evidence-hub.com/study/19942-microplastic-contamination-in-karst-groundwater-systems2026-10-01 https://evidence-hub.com/study/19943-occurrence-and-identification-of-microplastics-in-tap-water-from-china2026-09-27 https://evidence-hub.com/study/19945-presence-and-fate-of-microplastics-in-the-water-sources-focus-on-the2026-09-27 https://evidence-hub.com/study/19946-source-migration-and-toxicology-of-microplastics-in-soil2026-10-01 https://evidence-hub.com/study/19947-estimation-of-microplastic-exposure-via-the-composite-sampling-of2026-09-27 https://evidence-hub.com/study/19948-assessing-microplastic-characteristics-in-bottled-drinking-water-and2026-10-01 https://evidence-hub.com/study/19951-a-detailed-review-study-on-potential-effects-of-microplastics-and2026-10-01 https://evidence-hub.com/study/19953-microplastics-a-real-global-threat-for-environment-and-food-safety-a2026-10-01 https://evidence-hub.com/study/19954-microplastics-and-nanoplastics-in-atheromas-and-cardiovascular-events2026-10-01 https://evidence-hub.com/study/19955-microplastics-contamination-in-groundwater-of-a-drinking-water-source2026-09-27 https://evidence-hub.com/study/19956-detection-of-microplastics-in-human-lung-tissue-using-ftir2026-10-01 https://evidence-hub.com/study/19957-what-have-we-known-so-far-about-microplastics-in-drinking-water2026-10-01 https://evidence-hub.com/study/19958-review-of-the-potential-effects-and-remediation-strategies-of2026-09-27 https://evidence-hub.com/study/19959-identification-of-microplastics-in-conventional-drinking-water2026-09-27 https://evidence-hub.com/study/19960-impact-of-microplastics-and-nanoplastics-on-human-health2026-10-01 https://evidence-hub.com/study/19962-microplastic-occurrence-after-conventional-and-nanofiltration2026-09-27 https://evidence-hub.com/study/19965-marine-microplastic-debris-an-emerging-issue-for-food-security-food2026-10-01 https://evidence-hub.com/study/19966-presence-of-microplastics-in-drinking-water-from-different-freshwater2026-10-01 https://evidence-hub.com/study/19967-development-and-application-of-a-health-based-framework-for-informing2026-10-01 https://evidence-hub.com/study/19968-human-exposure-to-microplastics-from-urban-decentralized-pay-to-fetch2026-09-27 https://evidence-hub.com/study/19969-human-health-concerns-regarding-microplastics-in-the-aquatic2026-10-01 https://evidence-hub.com/study/19970-microplastic-removal-from-drinking-water-using-point-of-use-devices2026-10-01 https://evidence-hub.com/study/19971-microplastic-in-drinking-water-a-pilot-study2026-10-01 https://evidence-hub.com/study/19972-microplastics-in-honey-beer-milk-and-refreshments-in-ecuador-as2026-10-01 https://evidence-hub.com/study/19973-analysis-of-microplastic-particles-in-danish-drinking-water2026-09-27 https://evidence-hub.com/study/19977-microplastics-generation-from-pvc-pipes-in-drinking-water2026-10-06 https://evidence-hub.com/study/19978-low-abundance-but-high-microplastic-toxicity-and-potential-ecological2026-10-06 https://evidence-hub.com/study/19979-rice-husk-biochar-filtration-for-microplastic-removal-from-raw-water2026-10-06 https://evidence-hub.com/study/19980-exposure-relevant-microplastic-characteristics-in-drinking-water-and2026-10-06 https://evidence-hub.com/study/19981-microplastics-in-bottled-water-and-human-health-outcomes-a-systematic2026-10-06 https://evidence-hub.com/study/19982-effects-of-microplastic-aging-on-the-adsorption-and-desorption-of2026-10-06 https://evidence-hub.com/study/19983-a-portable-instrument-for-intelligent-analysis-of-low-abundance2026-10-06 https://evidence-hub.com/study/19984-unraveling-health-risk-of-microplastics-in-bottled-water-evidence-of2026-10-06 https://evidence-hub.com/study/19985-integrated-pmf-cfm-source-apportionment-reveals-contrasting2026-10-06 https://evidence-hub.com/study/19986-chlorination-driven-leaching-and-characterization-of-dissolved2026-10-06 https://evidence-hub.com/study/19987-assessing-the-release-of-microplastics-from-reusable-plastic-water2026-10-06 https://evidence-hub.com/study/19988-pathways-to-identifying-the-impacts-of-microplastic-exposure-on2026-10-06 https://evidence-hub.com/study/19989-do-physically-active-people-ingest-more-microplastics-an2026-10-06 https://evidence-hub.com/study/19990-microplastics-in-drinking-water-a-neglected-public-health-risk-in2026-10-06 https://evidence-hub.com/study/19991-microplastic-contamination-in-drinking-water-sources-and-distribution2026-10-06 https://evidence-hub.com/study/19992-microplastic-accumulation-in-fish-and-water-a-case-study-from-a2026-10-06 https://evidence-hub.com/study/19993-microplastics-and-nanoplastics-in-food-dietary-toxicology-beyond2026-10-06 https://evidence-hub.com/study/19994-micro-and-nanoplastics-in-the-environment-analytical-approaches2026-10-06 https://evidence-hub.com/study/19995-microplastics-in-groundwater-an-updated-systematic-review-of2026-10-06 https://evidence-hub.com/study/19996-from-aquatic-pollution-to-drinking-water-exposure-analytical2026-10-06 https://evidence-hub.com/study/19997-an-ultra-sensitive-qcm-based-detecting-platform-for-on-site-and-rapid2026-10-06 https://evidence-hub.com/study/19998-controlled-modification-of-the-hydrophilicity-of-polyethylene2026-10-06 https://evidence-hub.com/study/19999-the-reproductive-toxicity-of-microplastics-from-environmental2026-10-06